Jazz Pharmaceuticals Annual Report 2021

FY2021 Annual Report · Jazz Pharmaceuticals
Loading PDF…
CAMMY
EPIDIOLEX® Patient

JENNIE
XYWAV® Patient

GRACE
EPIDIOLEX® Patient

Jazz Pharmaceuticals plc
Proxy Statement
2021 Annual Report

OSCAR
XYWAV® Patient

(Page Intentionally Left Blank)

continued growth of existing products, commercializing
pipeline products, and products acquired through
strategic corporate development transactions, driven
by our oxybate, Epidiolex® and oncology franchises.

2. Pipeline We aim to achieve at least ﬁve additional novel
product approvals in areas of critical unmet need with
signiﬁcant market opportunity by the end of the decade.
We expect these approvals to come from our current
pipeline, including programs from the GW Pharmaceuticals
(GW) acquisition, and corporate development activities.

3. Operational Excellence With multiple important
product launches underway and continuing to gain
momentum, we are conﬁdent in our ability to effectively
scale our operations and improve our adjusted operating
margin, driving towards our target of achieving a ﬁve
percentage point improvement from 2021 to 2025.

2021 ACCOMPLISHMENTS PROVIDE
SIGNIFICANT MOMENTUM

Looking back at 2021, we executed across the organization
and are well positioned to achieve Vision 2025.

• We realized the ambitious corporate objective of

completing ﬁve key commercial launches through
2020 and 2021. With the launch of Xywav® for idiopathic
hypersomnia (IH) and Rylaze® for acute lymphoblastic
leukemia and lymphoblastic lymphoma in 2021, we
have now accomplished this goal, demonstrating our
signiﬁcant execution capabilities and commitment to
bring important new medicines forward for patients.

• We enhanced our position as a leader in sleep medicine.
We saw market-leading adoption of Xywav in narcolepsy
in 2021, and the beneﬁts of lower-sodium oxybate
continue to resonate with physicians and patients. With
its U.S. Food and Drug Administration (FDA) approval
in August 2021, Xywav became the only FDA-approved
therapy to treat IH, a serious and disruptive sleep
disorder. We were also pleased to receive Orphan Drug
Exclusivity (ODE) for both indications.

• We successfully integrated GW Pharmaceuticals and

increased Epidiolex/Epidyolex® revenues. We completed
the acquisition of GW in May 2021, adding a third high-
growth commercial franchise and diversifying our pipeline
and revenue. The cultures of Jazz and GW proved to be
complementary, and many talented and experienced
members of the legacy GW team have assumed leadership
positions across our combined enterprise.

• We established Zepzelca® as market leader in

second-line SCLC. Over 2021, Zepzelca continued
to gain market share and we rapidly established this
therapy as treatment of choice in second-line small
cell lung cancer (SCLC). A registrational trial in ﬁrst-line
SCLC in combination with Tecentriq® (atezolizumab),
in collaboration with our partner F. Hoffmann-La Roche
Ltd, is ongoing and a Phase 2 basket trial in solid tumors
enrolled its ﬁrst patient in March 2022. Both of these

June 2022

DEAR FELLOW SHAREHOLDERS,

On behalf of Jazz and our Board of Directors, I hope you
and your families are healthy and safe. In this period of global
challenges, I’m incredibly proud that Jazz was once again
able to build on our track record of achieving corporate
milestones, driven by our purpose to innovate to transform
the lives of patients and their families by developing life-
changing medicines for people with serious diseases —
often with limited or no therapeutic options.

As always, key to this success has been our constant
focus on execution and investing in our highest strategic
priorities across our entire organization. Thanks to
the passion, innovation, collaboration and pursuit of
excellence demonstrated by our more than 3,100
dedicated and talented employees around the world, we
helped more patients, achieved record product revenues
and advanced our pipeline in 2021.

VISION 2025 TO DELIVER SUSTAINABLE
GROWTH AND ENHANCED VALUE

Our achievements in 2021, and goals for 2022, combined
with our expanded capabilities and disciplined capital
allocation, have positioned us to deliver long-term sustainable
growth and enhanced value. In January 2022, we introduced
Vision 2025 to help chart our transformation into an
innovative, high-growth global biopharmaceutical leader.

Vision 2025 has three core components:

1. Commercial We were pleased to exceed $3 billion
in annual revenue for the ﬁrst time in 2021, driven by
successful commercial execution. In 2025, we expect
to grow our annual revenue to $5 billion, through the

trials provide the opportunity for us to bring Zepzelca to
additional patients in need.

• We secured rapid FDA approval for Rylaze under the
Real-Time Oncology Review program. We launched
Rylaze approximately 2.5 year after Phase 1 initiation,
demonstrating our ability to advance products from
concept to approval and deliver them to patients. Initial
demand has been strong, reﬂecting the high-quality,
reliable supply for this important treatment option for
patients who are in critical need.

• We have created a robust innovation engine and
expanded our pipeline and capabilities. We have
more than 30 active clinical trials, including both Jazz
and partnered programs, and near-term pipeline
opportunities across neuroscience, oncology and
cannabinoids. Key programs include nabiximols for
multiple sclerosis-related spasticity, suvecaltamide
(JZP385) for essential tremor and JZP150 for post-
traumatic stress disorder.

STRONG FINANCIAL RESULTS

As noted above, in 2021, we achieved our guidance and
exceeded $3 billion in annual revenue for the ﬁrst time.
We also generated nearly $1 billion of adjusted net income.

In addition, we achieved signiﬁcant revenue diversiﬁcation
with approximately 59% of net product sales from products
launched or acquired since 2019, exiting the fourth quarter
of 2021. We have signiﬁcantly and meaningfully diversiﬁed
our business and also remain on track to reach less than
3.5 times net leverage ratio by the end of 2022.

We will remain disciplined in how we invest our signiﬁcant
cash ﬂow in strategic investments to deliver commercial
growth, expand our pipeline and expertise, conduct
opportunistic corporate development and meet our
deleveraging targets. This strategic capital allocation is
expected to both grow and diversify our business.

We believe that positively impacting patients' lives,
investing in our people and our commitment to long-term
sustainability are important to delivering on Vision 2025.

In closing, with our history of strong execution, we are
optimistic about the year ahead, on track to achieve Vision
2025 and focused on growing our productive R&D engine.
This is an exciting time of transformation for Jazz.

Thank you for your continued support as we innovate to
transform the lives of patients and their families. I would
also like to recognize all our employees at Jazz for their
dedication and creativity, allowing us to deliver new
therapeutic options to patients. We look forward to
updating you on our progress as we drive toward our
2022 goals and Vision 2025.

(cid:37)(cid:85)(cid:88)(cid:70)(cid:72) (cid:38)(cid:17) (cid:38)(cid:82)(cid:93)(cid:68)(cid:71)(cid:71)
(cid:38)(cid:75)(cid:68)(cid:76)(cid:85)(cid:83)(cid:72)(cid:85)(cid:86)(cid:82)(cid:81) (cid:68)(cid:81)(cid:71) (cid:38)(cid:75)(cid:76)(cid:72)(cid:73) (cid:40)(cid:91)(cid:72)(cid:70)(cid:88)(cid:87)(cid:76)(cid:89)(cid:72) (cid:50)(cid:396)(cid:70)(cid:72)(cid:85)

(cid:48)(cid:40)(cid:40)(cid:55) (cid:45)(cid:40)(cid:49)(cid:49)(cid:44)(cid:40)(cid:15) (cid:59)(cid:60)(cid:58)(cid:36)(cid:57) (cid:44)(cid:43) (cid:51)(cid:36)(cid:55)(cid:44)(cid:40)(cid:49)(cid:55)

(cid:45)(cid:72)(cid:81)(cid:81)(cid:76)(cid:72) (cid:85)(cid:72)(cid:80)(cid:72)(cid:80)(cid:69)(cid:72)(cid:85)(cid:86) (cid:69)(cid:72)(cid:76)(cid:81)(cid:74) (cid:68)(cid:90)(cid:68)(cid:85)(cid:72) (cid:87)(cid:75)(cid:68)(cid:87) (cid:75)(cid:72)(cid:85) (cid:86)(cid:79)(cid:72)(cid:72)(cid:83)
(cid:81)(cid:72)(cid:72)(cid:71)(cid:86) (cid:90)(cid:72)(cid:85)(cid:72) (cid:71)(cid:76)(cid:393)(cid:72)(cid:85)(cid:72)(cid:81)(cid:87) (cid:68)(cid:87) (cid:68) (cid:92)(cid:82)(cid:88)(cid:81)(cid:74) (cid:68)(cid:74)(cid:72)(cid:17) (cid:54)(cid:75)(cid:72) (cid:90)(cid:82)(cid:88)(cid:79)(cid:71)
(cid:80)(cid:76)(cid:86)(cid:86) (cid:82)(cid:88)(cid:87) (cid:82)(cid:81) (cid:76)(cid:80)(cid:83)(cid:82)(cid:85)(cid:87)(cid:68)(cid:81)(cid:87) (cid:72)(cid:89)(cid:72)(cid:81)(cid:87)(cid:86) (cid:68)(cid:81)(cid:71) (cid:75)(cid:68)(cid:71) (cid:87)(cid:82) (cid:83)(cid:79)(cid:68)(cid:81)
(cid:68)(cid:85)(cid:82)(cid:88)(cid:81)(cid:71) (cid:79)(cid:82)(cid:81)(cid:74) (cid:81)(cid:76)(cid:74)(cid:75)(cid:87)(cid:87)(cid:76)(cid:80)(cid:72) (cid:86)(cid:79)(cid:72)(cid:72)(cid:83) (cid:68)(cid:81)(cid:71) (cid:80)(cid:68)(cid:81)(cid:92) (cid:75)(cid:82)(cid:88)(cid:85)(cid:86) (cid:82)(cid:73)
(cid:81)(cid:68)(cid:83)(cid:86) (cid:71)(cid:88)(cid:85)(cid:76)(cid:81)(cid:74) (cid:87)(cid:75)(cid:72) (cid:71)(cid:68)(cid:92)(cid:17) (cid:54)(cid:75)(cid:72) (cid:85)(cid:72)(cid:70)(cid:82)(cid:74)(cid:81)(cid:76)(cid:93)(cid:72)(cid:71) (cid:75)(cid:72)(cid:85) (cid:86)(cid:79)(cid:72)(cid:72)(cid:83)(cid:76)(cid:81)(cid:74)
(cid:83)(cid:68)(cid:87)(cid:87)(cid:72)(cid:85)(cid:81)(cid:86) (cid:90)(cid:72)(cid:85)(cid:72) (cid:76)(cid:80)(cid:83)(cid:68)(cid:70)(cid:87)(cid:76)(cid:81)(cid:74) (cid:75)(cid:72)(cid:85) (cid:84)(cid:88)(cid:68)(cid:79)(cid:76)(cid:87)(cid:92) (cid:82)(cid:73) (cid:79)(cid:76)(cid:73)(cid:72)(cid:15) (cid:68)(cid:81)(cid:71)
(cid:81)(cid:72)(cid:89)(cid:72)(cid:85) (cid:74)(cid:68)(cid:89)(cid:72) (cid:88)(cid:83) (cid:82)(cid:81) (cid:87)(cid:85)(cid:92)(cid:76)(cid:81)(cid:74) (cid:87)(cid:82) (cid:394)(cid:81)(cid:71) (cid:68)(cid:81)(cid:86)(cid:90)(cid:72)(cid:85)(cid:86)(cid:17) (cid:36)(cid:79)(cid:87)(cid:75)(cid:82)(cid:88)(cid:74)(cid:75)
(cid:45)(cid:72)(cid:81)(cid:81)(cid:76)(cid:72) (cid:85)(cid:72)(cid:70)(cid:72)(cid:76)(cid:89)(cid:72)(cid:71) (cid:86)(cid:72)(cid:89)(cid:72)(cid:85)(cid:68)(cid:79) (cid:71)(cid:76)(cid:393)(cid:72)(cid:85)(cid:72)(cid:81)(cid:87) (cid:71)(cid:76)(cid:68)(cid:74)(cid:81)(cid:82)(cid:86)(cid:72)(cid:86)
(cid:68)(cid:81)(cid:71) (cid:87)(cid:85)(cid:76)(cid:72)(cid:71) (cid:68) (cid:81)(cid:88)(cid:80)(cid:69)(cid:72)(cid:85) (cid:82)(cid:73) (cid:80)(cid:72)(cid:71)(cid:76)(cid:70)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81)(cid:86)(cid:15) (cid:86)(cid:75)(cid:72) (cid:71)(cid:76)(cid:71) (cid:81)(cid:82)(cid:87)
(cid:72)(cid:91)(cid:83)(cid:72)(cid:85)(cid:76)(cid:72)(cid:81)(cid:70)(cid:72) (cid:85)(cid:72)(cid:79)(cid:76)(cid:72)(cid:73) (cid:73)(cid:85)(cid:82)(cid:80) (cid:75)(cid:72)(cid:85) (cid:86)(cid:92)(cid:80)(cid:83)(cid:87)(cid:82)(cid:80)(cid:86)(cid:17) (cid:45)(cid:72)(cid:81)(cid:81)(cid:76)(cid:72)
(cid:69)(cid:72)(cid:74)(cid:68)(cid:81) (cid:87)(cid:82) (cid:76)(cid:81)(cid:87)(cid:72)(cid:85)(cid:81)(cid:68)(cid:79)(cid:76)(cid:93)(cid:72) (cid:81)(cid:72)(cid:74)(cid:68)(cid:87)(cid:76)(cid:89)(cid:72) (cid:87)(cid:75)(cid:82)(cid:88)(cid:74)(cid:75)(cid:87)(cid:86) (cid:68)(cid:81)(cid:71)
(cid:69)(cid:72)(cid:79)(cid:76)(cid:72)(cid:89)(cid:72)(cid:71) (cid:87)(cid:75)(cid:72)(cid:86)(cid:72) (cid:86)(cid:79)(cid:72)(cid:72)(cid:83) (cid:76)(cid:86)(cid:86)(cid:88)(cid:72)(cid:86) (cid:90)(cid:72)(cid:85)(cid:72) (cid:75)(cid:72)(cid:85) (cid:73)(cid:68)(cid:88)(cid:79)(cid:87)(cid:17)

(cid:352)(cid:44)(cid:10)(cid:80) (cid:68)(cid:70)(cid:87)(cid:88)(cid:68)(cid:79)(cid:79)(cid:92) (cid:72)(cid:91)(cid:70)(cid:76)(cid:87)(cid:72)(cid:71) (cid:87)(cid:82) (cid:74)(cid:82) (cid:87)(cid:82) (cid:69)(cid:72)(cid:71) (cid:72)(cid:68)(cid:70)(cid:75) (cid:81)(cid:76)(cid:74)(cid:75)(cid:87)
(cid:81)(cid:82)(cid:90) (cid:348) (cid:90)(cid:75)(cid:68)(cid:87) (cid:88)(cid:86)(cid:72)(cid:71) (cid:87)(cid:82) (cid:394)(cid:79)(cid:79) (cid:80)(cid:72) (cid:90)(cid:76)(cid:87)(cid:75) (cid:71)(cid:85)(cid:72)(cid:68)(cid:71) (cid:76)(cid:86) (cid:81)(cid:82)(cid:90)
(cid:71)(cid:72)(cid:79)(cid:76)(cid:74)(cid:75)(cid:87)(cid:73)(cid:88)(cid:79)(cid:17) (cid:36)(cid:81)(cid:71) (cid:44)(cid:350)(cid:80) (cid:72)(cid:81)(cid:77)(cid:82)(cid:92)(cid:76)(cid:81)(cid:74) (cid:72)(cid:68)(cid:85)(cid:79)(cid:92) (cid:80)(cid:82)(cid:85)(cid:81)(cid:76)(cid:81)(cid:74)(cid:86) (cid:73)(cid:82)(cid:85)
(cid:87)(cid:75)(cid:72) (cid:394)(cid:85)(cid:86)(cid:87) (cid:87)(cid:76)(cid:80)(cid:72) (cid:76)(cid:81) (cid:80)(cid:92) (cid:79)(cid:76)(cid:73)(cid:72)(cid:17)(cid:353) (cid:348) (cid:45)(cid:72)(cid:81)(cid:81)(cid:76)(cid:72)

(cid:44)(cid:81) (cid:36)(cid:88)(cid:74)(cid:88)(cid:86)(cid:87) (cid:21)(cid:19)(cid:21)(cid:20)(cid:15) (cid:45)(cid:72)(cid:81)(cid:81)(cid:76)(cid:72) (cid:86)(cid:68)(cid:90) (cid:68) (cid:86)(cid:79)(cid:72)(cid:72)(cid:83) (cid:86)(cid:83)(cid:72)(cid:70)(cid:76)(cid:68)(cid:79)(cid:76)(cid:86)(cid:87)
(cid:73)(cid:82)(cid:85) (cid:87)(cid:75)(cid:72) (cid:394)(cid:85)(cid:86)(cid:87) (cid:87)(cid:76)(cid:80)(cid:72) (cid:68)(cid:81)(cid:71) (cid:68)(cid:73)(cid:87)(cid:72)(cid:85) (cid:75)(cid:68)(cid:89)(cid:76)(cid:81)(cid:74) (cid:68) (cid:86)(cid:79)(cid:72)(cid:72)(cid:83) (cid:86)(cid:87)(cid:88)(cid:71)(cid:92)(cid:15)
(cid:90)(cid:68)(cid:86) (cid:71)(cid:76)(cid:68)(cid:74)(cid:81)(cid:82)(cid:86)(cid:72)(cid:71) (cid:90)(cid:76)(cid:87)(cid:75) (cid:76)(cid:71)(cid:76)(cid:82)(cid:83)(cid:68)(cid:87)(cid:75)(cid:76)(cid:70) (cid:75)(cid:92)(cid:83)(cid:72)(cid:85)(cid:86)(cid:82)(cid:80)(cid:81)(cid:76)(cid:68)
(cid:11)(cid:44)(cid:43)(cid:12)(cid:17) (cid:45)(cid:72)(cid:81)(cid:81)(cid:76)(cid:72) (cid:69)(cid:72)(cid:74)(cid:68)(cid:81) (cid:87)(cid:68)(cid:78)(cid:76)(cid:81)(cid:74) (cid:59)(cid:92)(cid:90)(cid:68)(cid:89)(cid:112) (cid:11)(cid:70)(cid:68)(cid:79)(cid:70)(cid:76)(cid:88)(cid:80)(cid:15)
(cid:80)(cid:68)(cid:74)(cid:81)(cid:72)(cid:86)(cid:76)(cid:88)(cid:80)(cid:15) (cid:83)(cid:82)(cid:87)(cid:68)(cid:86)(cid:86)(cid:76)(cid:88)(cid:80) (cid:68)(cid:81)(cid:71) (cid:86)(cid:82)(cid:71)(cid:76)(cid:88)(cid:80) (cid:82)(cid:91)(cid:92)(cid:69)(cid:68)(cid:87)(cid:72)(cid:86)(cid:12)(cid:15)
(cid:90)(cid:75)(cid:76)(cid:70)(cid:75) (cid:76)(cid:86) (cid:76)(cid:81)(cid:71)(cid:76)(cid:70)(cid:68)(cid:87)(cid:72)(cid:71) (cid:87)(cid:82) (cid:87)(cid:85)(cid:72)(cid:68)(cid:87) (cid:44)(cid:43)(cid:17) (cid:36)(cid:73)(cid:87)(cid:72)(cid:85) (cid:85)(cid:72)(cid:70)(cid:72)(cid:76)(cid:89)(cid:76)(cid:81)(cid:74) (cid:87)(cid:75)(cid:76)(cid:86)
(cid:71)(cid:76)(cid:68)(cid:74)(cid:81)(cid:82)(cid:86)(cid:76)(cid:86) (cid:68)(cid:81)(cid:71) (cid:87)(cid:85)(cid:72)(cid:68)(cid:87)(cid:80)(cid:72)(cid:81)(cid:87)(cid:15) (cid:86)(cid:75)(cid:72) (cid:75)(cid:68)(cid:86) (cid:69)(cid:72)(cid:72)(cid:81) (cid:68)(cid:69)(cid:79)(cid:72) (cid:87)(cid:82)
(cid:86)(cid:83)(cid:72)(cid:81)(cid:71) (cid:80)(cid:82)(cid:85)(cid:72) (cid:87)(cid:76)(cid:80)(cid:72) (cid:90)(cid:76)(cid:87)(cid:75) (cid:75)(cid:72)(cid:85) (cid:73)(cid:68)(cid:80)(cid:76)(cid:79)(cid:92) (cid:68)(cid:81)(cid:71) (cid:85)(cid:72)(cid:86)(cid:88)(cid:80)(cid:72)
(cid:83)(cid:68)(cid:76)(cid:81)(cid:87)(cid:76)(cid:81)(cid:74)(cid:15) (cid:82)(cid:81)(cid:72) (cid:82)(cid:73) (cid:75)(cid:72)(cid:85) (cid:73)(cid:68)(cid:89)(cid:82)(cid:85)(cid:76)(cid:87)(cid:72) (cid:83)(cid:68)(cid:86)(cid:87)(cid:76)(cid:80)(cid:72)(cid:86)(cid:17)

(cid:59)(cid:92)(cid:90)(cid:68)(cid:89) (cid:76)(cid:86) (cid:76)(cid:81)(cid:71)(cid:76)(cid:70)(cid:68)(cid:87)(cid:72)(cid:71) (cid:87)(cid:82) (cid:87)(cid:85)(cid:72)(cid:68)(cid:87) (cid:68)(cid:71)(cid:88)(cid:79)(cid:87)(cid:86) (cid:90)(cid:76)(cid:87)(cid:75) (cid:76)(cid:71)(cid:76)(cid:82)(cid:83)(cid:68)(cid:87)(cid:75)(cid:76)(cid:70)
(cid:75)(cid:92)(cid:83)(cid:72)(cid:85)(cid:86)(cid:82)(cid:80)(cid:81)(cid:76)(cid:68) (cid:11)(cid:44)(cid:43)(cid:12)(cid:15) (cid:68) (cid:88)(cid:81)(cid:76)(cid:84)(cid:88)(cid:72) (cid:80)(cid:72)(cid:71)(cid:76)(cid:70)(cid:68)(cid:79) (cid:70)(cid:82)(cid:81)(cid:71)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81) (cid:87)(cid:75)(cid:68)(cid:87) (cid:70)(cid:68)(cid:81)
(cid:75)(cid:68)(cid:89)(cid:72) (cid:86)(cid:76)(cid:74)(cid:81)(cid:76)(cid:394)(cid:70)(cid:68)(cid:81)(cid:87) (cid:72)(cid:393)(cid:72)(cid:70)(cid:87)(cid:86) (cid:82)(cid:81) (cid:87)(cid:75)(cid:72) (cid:79)(cid:76)(cid:89)(cid:72)(cid:86) (cid:82)(cid:73) (cid:87)(cid:75)(cid:82)(cid:86)(cid:72) (cid:71)(cid:76)(cid:68)(cid:74)(cid:81)(cid:82)(cid:86)(cid:72)(cid:71)
(cid:90)(cid:76)(cid:87)(cid:75) (cid:87)(cid:75)(cid:72) (cid:70)(cid:82)(cid:81)(cid:71)(cid:76)(cid:87)(cid:76)(cid:82)(cid:81)(cid:17) (cid:44)(cid:43) (cid:76)(cid:86) (cid:68) (cid:81)(cid:72)(cid:88)(cid:85)(cid:82)(cid:79)(cid:82)(cid:74)(cid:76)(cid:70) (cid:86)(cid:79)(cid:72)(cid:72)(cid:83) (cid:71)(cid:76)(cid:86)(cid:82)(cid:85)(cid:71)(cid:72)(cid:85)
(cid:70)(cid:75)(cid:68)(cid:85)(cid:68)(cid:70)(cid:87)(cid:72)(cid:85)(cid:76)(cid:93)(cid:72)(cid:71) (cid:69)(cid:92) (cid:71)(cid:72)(cid:69)(cid:76)(cid:79)(cid:76)(cid:87)(cid:68)(cid:87)(cid:76)(cid:81)(cid:74) (cid:86)(cid:92)(cid:80)(cid:83)(cid:87)(cid:82)(cid:80)(cid:86)(cid:15) (cid:76)(cid:81)(cid:70)(cid:79)(cid:88)(cid:71)(cid:76)(cid:81)(cid:74)
(cid:86)(cid:87)(cid:85)(cid:88)(cid:74)(cid:74)(cid:79)(cid:76)(cid:81)(cid:74) (cid:90)(cid:76)(cid:87)(cid:75) (cid:73)(cid:72)(cid:72)(cid:79)(cid:76)(cid:81)(cid:74) (cid:72)(cid:91)(cid:70)(cid:72)(cid:86)(cid:86)(cid:76)(cid:89)(cid:72)(cid:79)(cid:92) (cid:86)(cid:79)(cid:72)(cid:72)(cid:83)(cid:92) (cid:72)(cid:89)(cid:72)(cid:81) (cid:68)(cid:73)(cid:87)(cid:72)(cid:85) (cid:79)(cid:82)(cid:81)(cid:74)
(cid:83)(cid:72)(cid:85)(cid:76)(cid:82)(cid:71)(cid:86) (cid:82)(cid:73) (cid:86)(cid:79)(cid:72)(cid:72)(cid:83)(cid:15) (cid:86)(cid:79)(cid:72)(cid:72)(cid:83) (cid:76)(cid:81)(cid:72)(cid:85)(cid:87)(cid:76)(cid:68) (cid:82)(cid:85) (cid:87)(cid:75)(cid:72) (cid:73)(cid:72)(cid:72)(cid:79)(cid:76)(cid:81)(cid:74) (cid:82)(cid:73) (cid:86)(cid:72)(cid:89)(cid:72)(cid:85)(cid:72)
(cid:74)(cid:85)(cid:82)(cid:74)(cid:74)(cid:76)(cid:81)(cid:72)(cid:86)(cid:86) (cid:90)(cid:75)(cid:72)(cid:81) (cid:90)(cid:68)(cid:78)(cid:76)(cid:81)(cid:74) (cid:88)(cid:83)(cid:15) (cid:68)(cid:81)(cid:71) (cid:69)(cid:85)(cid:68)(cid:76)(cid:81) (cid:73)(cid:82)(cid:74)(cid:17)

(cid:44)(cid:81) (cid:36)(cid:88)(cid:74)(cid:88)(cid:86)(cid:87) (cid:21)(cid:19)(cid:21)(cid:20)(cid:15) (cid:56)(cid:17)(cid:54)(cid:17) (cid:41)(cid:82)(cid:82)(cid:71) (cid:68)(cid:81)(cid:71) (cid:39)(cid:85)(cid:88)(cid:74) (cid:36)(cid:71)(cid:80)(cid:76)(cid:81)(cid:76)(cid:86)(cid:87)(cid:85)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81) (cid:11)(cid:41)(cid:39)(cid:36)(cid:12)
(cid:68)(cid:83)(cid:83)(cid:85)(cid:82)(cid:89)(cid:72)(cid:71) (cid:59)(cid:92)(cid:90)(cid:68)(cid:89)(cid:112) (cid:11)(cid:70)(cid:68)(cid:79)(cid:70)(cid:76)(cid:88)(cid:80)(cid:15) (cid:80)(cid:68)(cid:74)(cid:81)(cid:72)(cid:86)(cid:76)(cid:88)(cid:80)(cid:15) (cid:83)(cid:82)(cid:87)(cid:68)(cid:86)(cid:86)(cid:76)(cid:88)(cid:80) (cid:68)(cid:81)(cid:71)
(cid:86)(cid:82)(cid:71)(cid:76)(cid:88)(cid:80) (cid:82)(cid:91)(cid:92)(cid:69)(cid:68)(cid:87)(cid:72)(cid:86)(cid:12) (cid:82)(cid:85)(cid:68)(cid:79) (cid:86)(cid:82)(cid:79)(cid:88)(cid:87)(cid:76)(cid:82)(cid:81) (cid:73)(cid:82)(cid:85) (cid:87)(cid:75)(cid:72) (cid:87)(cid:85)(cid:72)(cid:68)(cid:87)(cid:80)(cid:72)(cid:81)(cid:87) (cid:82)(cid:73) (cid:44)(cid:43)(cid:17)
(cid:55)(cid:75)(cid:72) (cid:83)(cid:68)(cid:87)(cid:76)(cid:72)(cid:81)(cid:87) (cid:86)(cid:87)(cid:82)(cid:85)(cid:92) (cid:86)(cid:75)(cid:68)(cid:85)(cid:72)(cid:71) (cid:76)(cid:81) (cid:87)(cid:75)(cid:76)(cid:86) (cid:70)(cid:82)(cid:80)(cid:80)(cid:88)(cid:81)(cid:76)(cid:70)(cid:68)(cid:87)(cid:76)(cid:82)(cid:81) (cid:71)(cid:72)(cid:83)(cid:76)(cid:70)(cid:87)(cid:86)
(cid:68)(cid:81) (cid:76)(cid:81)(cid:71)(cid:76)(cid:89)(cid:76)(cid:71)(cid:88)(cid:68)(cid:79) (cid:83)(cid:68)(cid:87)(cid:76)(cid:72)(cid:81)(cid:87)(cid:350)(cid:86) (cid:85)(cid:72)(cid:86)(cid:83)(cid:82)(cid:81)(cid:86)(cid:72) (cid:87)(cid:82) (cid:82)(cid:88)(cid:85) (cid:80)(cid:72)(cid:71)(cid:76)(cid:70)(cid:76)(cid:81)(cid:72) (cid:68)(cid:81)(cid:71) (cid:76)(cid:86) (cid:81)(cid:82)(cid:87)
(cid:85)(cid:72)(cid:83)(cid:85)(cid:72)(cid:86)(cid:72)(cid:81)(cid:87)(cid:68)(cid:87)(cid:76)(cid:89)(cid:72) (cid:82)(cid:73) (cid:68)(cid:79)(cid:79) (cid:83)(cid:68)(cid:87)(cid:76)(cid:72)(cid:81)(cid:87) (cid:85)(cid:72)(cid:86)(cid:83)(cid:82)(cid:81)(cid:86)(cid:72)(cid:86)(cid:17)

ROBUST AND PRODUCTIVE PIPELINE FOR SUSTAINABLE GROWTH

PRE-CLINICAL

PHASEAA 1

PHASEAA 2

ASE 3

REGULATORYRR

Undisclosed targets
Neuroscience

CombiPlex
Exploratory activities

JZP341
(Long-acting Erwinia
asparaginase)
ALL/LBL

JZP815
Pan-Raf Inhibitor
Program
Raf & Ras mutant tumors

Undisclosed targets
Ras/Raf/MAP kinase
pathway1

Exosome targets
(NRAS and up to 4
others)1
Hematological malignancies/
solid tumors

JZP898 (WTX-613)2
Conditionally activated IFN(cid:302)

Undisclosed targets
Oncology

Undisclosed targets
Cannabinoids

JZP3243
Oxybate extended-release
formulation

Suvecaltamide
(JZP385)
Essential tremor

JZP441 (DSP-0187)2,4
Orexin-2 receptor agonist

JZP1506
PTSD

JZP351 (Vyxeos)
Low Intensity Dosing for
higher risk MDS5

JZP351 + other
approved therapies
• R/RAMLorHMAFailureMDS5
• First-line, ﬁt AML (Phase 1b)
• Low Intensity Therapy for

ﬁrst-line,unﬁtAML(Phase1b)

Additional
Cannabinoids
Neonatal hypoxic-ischemic
encephalopathy

Additional
Cannabinoids
Neuropsychiatry targets

Lurbinectedin
(Zepzelca)
Basket trial: advanced
urothelial cancer, large cell
neuroendocrine tumor of the
lung, HRD+ cancers

JZP351
• HR-MDS (EMSCO)7
• Newly diagnosed older
adults with HR-AML7

JZP351 + venetoclax
de novo or R/R AML5

Additional
Cannabinoids
Autism spectrum disorders

Lurbinectedin1
1L treatment SCLC in
combination with Tecentriq®
(atezolizumab)

JZP458 (Rylaze)8
(recombinant Erwinia
asparaginase)
ALL/LBL

JZP351
• AML or HR-MDS >60yrs

(AML18)7

• Newly diagnosed adults

with standard- and HR-AML
(AMLSG)7

• Newly diagnosed <22 yrs

with AML (COG)7

Cannabidiol
(Epidiolex)3
EMAS

Nabiximols
MS spasticity

Nabiximols3
Spinal cord injury spasticity

Neuroscience

Oncology

Cannabinoids

1. Partnered collaboration; 2. Recently acquired; 3. Planned; 4. Phase 1 trial ongoing in Japan — expect to rapidly advance
development in U.S.; 5. Jazz & MD Anderson Cancer Center collaboration study; 6. JZP150 is a fatty acid amide hydrolase inhibitor
which modulates the endocannabinoid anandamide; 7. Cooperative group study; 8. FDA approval on June 30, 2021; submitted
additional data to support U.S. label update. 1L = ﬁrst line, ALL/LBL = acute lymphoblastic leukemia / lymphoblastic lymphoma, AML
= acute myeloid leukemia, COG = Children’s Oncology Group, HMA = hypomethylating agents, HR = high-risk, HRD+ = homologous
recombinant deﬁcient positive, MDS = myelodysplastic syndromes, MS = multiple sclerosis, PTSD = post-traumatic stress disorder,
R/R = relapsing/refractory, SCLC = small cell lung cancer, SG = study group

STRONG FINANCIAL EXECUTION

TOTAL REVENUES
$ in millions
(audited)

NON-GAAP ADJUSTED NET
INCOME DIULTED SHARE1
(unaudited)

$3,094

$16.23

$16.23

$2,364

$2,162

$13.70

$11.04

$1,891

$1,619

$12.46

$693

NET CASH PROVIDED BY
OPERATING ACTVITIES
$ in millions
(audited)

$900

$799

$776

$779

2017

2018

2019

2020

2021

2017

2018

2019

2020

2021

2017

2018

2019

2020

2021

17.6% 4 YEAR CAGR

10.1% 4 YEAR CAGR

1. Reconciliations of GAAP net income per diluted share to non-GAAP adjusted net income per diluted share can be found on pages 71–72 of the enclosed Proxy
Statement. 2. CAGR = Compound Annual Growth Rate

“Our achievements in
2021 have positioned
us to deliver long-term
sustainable growth
and enhanced value.”

SIGNIFICANT REVENUE DIVERSIFICATION

2015 REVENUE
$1.3 billion

2021 REVENUE
$3.1 billion

Other

72%

41%

OUR LONG-TERM ESG STRATEGY

Integrated ESG Approach

Nominating
and Corporate
Governance
Committee oversees
ESG strategy
and policies

Created a Global
Corporate
Sustainability and
Social Impact Team
in 2021

Performed
ESG materiality
assessment for GW
business following
the acquisition
by Jazz

Aligning strategy
and reporting with
UN SDGs and
SASB standards,
respectively

ENVIRONMENTAL

SOCIAL

GOVERNANCE

• Lead Independent Director with
clearly deﬁned responsibilities

• 11 of 12 directors are independent

• Annual Board and Committee

self-evaluations

• Anti-hedging/pledging/claw back

policies

• Majority vote standard

• Share ownership requirements

• 50% of executive target equity is

performance based

• Long-standing commitment
to sustainable practices in
manufacturing processes

• Extensive rainwater harvesting at
our cannabis growing operations
(utilize or recapture 98%)

• Jazz produces less than 650 kg CO2
(Scope 1 & 2 GHG emissions) per kg
of dried cannabis ﬂower compared to
3,697 kg CO2 per kg of ﬂower from the
average U.S. cannabis cultivation site1

• Use green chemistry principles
in our ﬁrst in-house commercial
production site (Athlone, IRE)

• New buildings meet highest

level of sustainability standards
Building Research Establishment
Environmental Assessment
Methodology (BREEAM)

• Focused on expanding

environmental disclosures

• Increase the diversity of our global
workforce by providing an inclusive
environmenthighlightedbythecreation
of ﬁve unique Employee Resource
Teams (Black, Asian and Paciﬁc
Islander, LGBTQ+, LatinX/Hispanic,
and Women employees + allies)

• Focused on attracting the best talent,
supporting employee well-being
through personal development
practices/tools and enhanced
beneﬁt programs

• Ongoing employee engagement
through interactive forums with
company leadershipand pulse surveys
(~ 80% response rate). Engagement
surveys indicate employees
experience an inclusive culture

• Commitment to improving diversity

in our clinical trial enrollments
and advocating for public policy
initiatives that improve access to
care and health equity metrics

1. https://www.arcgis.com/apps/webappviewer/index.html?id=f47100de3f6b46bb9aebf8dc52d957bf&extent=-18880993.9285%2C2754896.1724%
2C-8069740.6478%2C10092850.8878%2C102100

Commitment to U.N. Sustainable Development Goals

(Page Intentionally Left Blank)

NOTICE OF 2022 ANNUAL GENERAL MEETING
OF SHAREHOLDERS
TO BE HELD ON JULY 28, 2022

Dear Shareholder:

The 2022 annual general meeting of shareholders (the “annual meeting”) of Jazz
Pharmaceuticals plc, a public limited company formed under the laws of Ireland (the “company”),
will be held on Thursday, July 28, 2022, at 9:45 a.m. local time at our corporate headquarters
located at Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland, for the following
purposes:

1.

2.

3.

4.

5.

To elect by separate resolutions each of the four nominees for director named in the
accompanying proxy statement (the “proxy statement”) to hold office until the 2025 annual
meeting of shareholders (Proposal 1).

To ratify, on a non-binding advisory basis, the appointment of KPMG, Dublin, or KPMG, as
the independent auditors of the company for the fiscal year ending December 31, 2022 and
to authorize, in a binding vote, the board of directors, acting through the audit committee, to
determine the independent auditors’ remuneration (Proposal 2).

To approve, on a non-binding advisory basis, the compensation of the company’s named
executive officers, or NEOs, as disclosed in the accompanying proxy statement (Proposal 3).

To grant the board of directors authority under Irish law to allot and issue ordinary shares for
cash without first offering those ordinary shares to existing shareholders pursuant to the
statutory pre-emption right that would otherwise apply (Proposal 4).

To approve any motion to adjourn the annual meeting, or any adjournments thereof, to
another time and place to solicit additional proxies if there are insufficient votes at the time of
the annual meeting to approve Proposal 4 (Proposal 5).

To conduct any other business properly brought before the annual meeting.

Proposals 1, 2, 3 and 5 are ordinary resolutions, requiring the affirmative vote of a majority of the
votes cast (in person or by proxy) at the annual meeting. Proposal 4 is a special resolution,
requiring the approval of not less than 75% of the votes cast (in person or by proxy) at the annual
meeting.

In addition to the above proposals, the annual meeting will also receive and consider the
company’s Irish statutory financial statements for the fiscal year ended December 31, 2021 and
the reports of the directors and auditors thereon. There is no requirement under Irish law that the
Irish statutory financial statements be approved by the shareholders, and no such approval will be
sought at the annual meeting. Under the company’s Memorandum and Articles of Association
(our “articles”), and the Irish Companies Act 2014 (the “2014 Act”), Proposals 1 and 2 are deemed
to be ordinary business, and Proposals 3, 4 and 5 are deemed to be special business.

The record date for the annual meeting is June 1, 2022. Only shareholders of record at the close
of business on that date may vote at the annual meeting or any adjournment or postponement
thereof. The Notice of Internet Availability of Proxy Materials and our proxy materials, which
include this proxy statement, our annual letter to shareholders and our 2021 Annual Report on
Form 10-K, are first being mailed to shareholders on or about June 15, 2022.

A shareholder entitled to attend and vote at the annual meeting is entitled to appoint one or more
proxies to attend, speak and vote instead of him or her at the annual meeting, using the proxy
card provided (or the form of proxy contained in section 184 of the 2014 Act) or using an
electronic proxy card by telephone or via the internet in the manner described in this proxy
statement. A proxy need not be a shareholder of record.

Whether or not you expect to
attend the meeting, please vote as
soon as possible. You may vote
your shares:

y
x
o
r
P

Over the Telephone
1-800-690-6903

Via the Internet
www.proxyvote.com

By Mail
Complete, sign and
return proxy card

In Person
Attend Annual Meeting

If you received a proxy card or
voting instruction card by mail, you
may submit your proxy card or
voting instruction card mailing your
proxy card or voting instruction
card in the envelope provided.
Proxy cards must be received by
July 27, 2022. Electronic proxy
cards submitted via the internet or
by telephone must be received by
11:59 p.m., U.S. Eastern Time, on
July 27, 2022. It may not be
possible to count proxy cards
received after the relevant time
towards voting. Proxy cards
received will be forwarded to the
company’s registered office
electronically before
commencement of the annual
meeting to comply with Irish law.
Even if you have voted by proxy,
you may still vote in person if you
attend the meeting. Please note,
however, that if the record holder of
your ordinary shares is a broker,
bank or other agent, and you wish
to vote at the meeting, you must
obtain a proxy issued in your name
from that record holder.

Important Notice Regarding the Availability of Proxy Materials for the annual meeting of shareholders to be held on July 28, 2022,
at 9:45 a.m. local time at our corporate headquarters located at Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland.

The proxy statement, our letter to shareholders, our Irish statutory financial statements and our 2021 Annual Report on Form 10-K
are available at https://materials.proxyvote.com/G50871.

By order of the board of directors,

/s/ Aislinn Doody
Aislinn Doody, Company Secretary
Dublin, Ireland
June 10, 2022

Potential Impacts of the COVID-19 Pandemic on the Annual General Meeting

The company would like to emphasize that we consider the health of our shareholders, employees and other attendees a top
priority. We are monitoring guidance issued by appropriate governmental health agencies, including the Irish Health Service
Executive, or the HSE, the Irish government, the U.S. Centers for Disease Control and Prevention and the World Health
Organization, collectively, the Health Authorities, and we have implemented, and will continue to implement the measures
advised by the relevant Health Authorities to address health and safety concerns. Information on such measures and on
COVID-19 generally is available on the HSE’s website at https://www.hse.ie/eng/services/news/newsfeatures/covid19-
updates/.

The annual meeting will be held in accordance with HSE and relevant Health Authority guidance.

Should we determine that alternative arrangements are necessitated due to public health recommendations regarding
containment of COVID-19, which may include a change in date or time of the meeting, a change in venue or format of the
meeting we will announce our decision by press release and/or filing with the Securities and Exchange Commission as
additional soliciting materials and also post information on the investor relations page of the company’s website found at https:/
/investor.jazzpharma.com/news. We encourage shareholders to keep up-to-date with, and follow the guidance from the
Government of Ireland and the Department of Health (of Ireland) (as appropriate), as circumstances may change at short
notice. Due to this uncertainty, shareholders are encouraged to vote their shares by proxy in advance at the annual meeting.

y
x
o
r
P

PROPOSAL 2 RATIFY, ON A NON-BINDING
ADVISORY BASIS, THE APPOINTMENT OF
INDEPENDENT AUDITORS AND AUTHORIZE,
IN A BINDING VOTE, THE BOARD OF
DIRECTORS, ACTING THROUGH THE AUDIT
COMMITTEE, TO DETERMINE THE
INDEPENDENT AUDITORS’ REMUNERATION

Independent Registered Public Accounting Firm Fees
and Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pre-Approval Policies and Procedures . . . . . . . . . . . . .
Independence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

PROPOSAL 3 NON-BINDING ADVISORY
VOTE ON EXECUTIVE COMPENSATION

PROPOSAL 4 BOARD AUTHORITY TO ISSUE
SHARES FOR CASH WITHOUT FIRST
OFFERING SHARES TO EXISTING
SHAREHOLDERS

PROPOSAL 5 ADJOURNMENT PROPOSAL

QUESTIONS AND ANSWERS ABOUT THESE
PROXY MATERIALS AND VOTING

OTHER MATTERS

97

97
98
98

99

101

107

108

115

Presentation of Irish Statutory Financial
Statements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
Section 16(a) Beneficial Ownership Reporting
Compliance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
Registered and Principal Executive Offices . . . . . . . . . 115
Shareholder Proposals and Director Nominations for
the 2023 Annual Meeting . . . . . . . . . . . . . . . . . . . . . . . . 115
Householding of Proxy Materials . . . . . . . . . . . . . . . . . . 116
Annual Report on Form 10-K . . . . . . . . . . . . . . . . . . . . . 116
Special Note Regarding Forward-Looking
Statements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
General . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118

TABLE OF CONTENTS

PROXY OVERVIEW

1

Business Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Information About our Board of Directors . . . . . . . . . . . .
Shareholder and Other Stakeholder Engagement . . . . .
ESG Highlights . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Summary of Shareholder Voting Matters and Board
Recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13

1
3
5
8

GENERAL

PROPOSAL 1 ELECTION OF DIRECTORS

CORPORATE GOVERNANCE AND BOARD
MATTERS

17

18

25

Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
Independence of the Board of Directors . . . . . . . . . . . . . 25
Board Leadership Structure . . . . . . . . . . . . . . . . . . . . . . 25
Risk Oversight
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
Meetings of the Board of Directors . . . . . . . . . . . . . . . . . 29
Director Commitments . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Classified Board Structure . . . . . . . . . . . . . . . . . . . . . . . . 30
Information About Board Committees . . . . . . . . . . . . . . . 30
Audit Committee . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31
Report of the Audit Committee of the Board of
Directors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
Compensation Committee . . . . . . . . . . . . . . . . . . . . . . . . 33
Compensation Committee Processes and
Procedures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
Compensation Committee Interlocks and Insider
Participation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
Compensation Consultant Fees . . . . . . . . . . . . . . . . . . . 34
Compensation Committee Report . . . . . . . . . . . . . . . . . . 35
Nominating and Corporate Governance Committee . . . 35
Corporate Governance Strengths . . . . . . . . . . . . . . . . . . 37
Other Corporate Governance Matters . . . . . . . . . . . . . . 38

SECURITY OWNERSHIP OF CERTAIN
BENEFICIAL OWNERS AND MANAGEMENT

EXECUTIVE OFFICERS

EXECUTIVE COMPENSATION

39

41

44

Compensation Discussion and Analysis . . . . . . . . . . . . . 44
Summary of Compensation . . . . . . . . . . . . . . . . . . . . . . . 73
Grants of Plan-Based Awards . . . . . . . . . . . . . . . . . . . . . 75
Description of Compensation Arrangements . . . . . . . . . 76
Outstanding Equity Awards at Fiscal Year-End . . . . . . . 80
Option Exercises and Stock Vested . . . . . . . . . . . . . . . . 82
Potential Payments upon Termination or Change in
Control . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
Pay Ratio Disclosure . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89

DIRECTOR COMPENSATION

CERTAIN RELATIONSHIPS AND RELATED
PARTY TRANSACTIONS

91

95

Index of Frequently Requested Information

Anti-Hedging/Pledging Policy . . . . . . . . . . . . . . . . . .

Auditor Fees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Auditor Tenure . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Board Diversity . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Board Leadership . . . . . . . . . . . . . . . . . . . . . . . . . . .

Board Meeting Attendance . . . . . . . . . . . . . . . . . . . .

Clawback Policy . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Code of Conduct . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Compensation Consultant Fees . . . . . . . . . . . . . . .

Corporate Governance Guidelines . . . . . . . . . . . . .

Director Biographies . . . . . . . . . . . . . . . . . . . . . . . . .

Director Commitments . . . . . . . . . . . . . . . . . . . . . . .

Director Independence . . . . . . . . . . . . . . . . . . . . . . .

Director Qualifications . . . . . . . . . . . . . . . . . . . . . . .

Environmental Sustainability . . . . . . . . . . . . . . . . . .

ESG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Majority Voting for Directors . . . . . . . . . . . . . . . . . . .

Pay Ratio Disclosure . . . . . . . . . . . . . . . . . . . . . . . .

Peer Group Companies . . . . . . . . . . . . . . . . . . . . . .

Performance-Based Equity Awards . . . . . . . . . . . . .

Procedures for Shareholder Proposals and
Director Nominations for the 2023 Annual
Meeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Related Party Transactions . . . . . . . . . . . . . . . . . . .

Risk Oversight . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Severance Benefits . . . . . . . . . . . . . . . . . . . . . . . . . .

Share Ownership Guidelines for Directors . . . . . . .

Share Ownership Guidelines for Executives . . . . .

Shareholder and Other Stakeholder
Engagement

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Shareholder Communications with the Board . . . .

Page

38

97

97

4

25

29

69

28

34

38

19

29

25

19

9

8

18

89

51

55

115

95

27

56

38

38

5

38

2022 NOTICE OF MEETING AND PROXY STATEMENT

PROXY OVERVIEW

This overview highlights certain information contained elsewhere in this proxy statement and does not contain all
of the information that you should consider. You should read the entire proxy statement carefully before voting.
For more complete information regarding our business and 2021 performance, please review our Annual Report
on Form 10-K for the year ended December 31, 2021 that we filed with the Securities and Exchange Commission,
or SEC, on March 1, 2022, which we refer to throughout this proxy statement as the 2021 Annual Report on Form
10-K.

In this proxy statement, unless otherwise indicated or the context otherwise requires, all references to “Jazz
Pharmaceuticals,” “Jazz,” “the company,” “we,” “us” and “our” refer to Jazz Pharmaceuticals plc and its
consolidated subsidiaries, except when the context makes clear that the time period being referenced is prior to
January 18, 2012, in which case such terms are references to Jazz Pharmaceuticals, Inc. and its consolidated
subsidiaries. On January 18, 2012, the businesses of Jazz Pharmaceuticals, Inc. and Azur Pharma Public Limited
Company, or Azur Pharma, were combined in a merger transaction, or the Azur Merger, in connection with which
Azur Pharma was renamed Jazz Pharmaceuticals plc, and we became the parent company of and successor to
Jazz Pharmaceuticals, Inc., with Jazz Pharmaceuticals, Inc. becoming our wholly owned subsidiary.

y
x
o
r
P

Meeting and Voting Information

Time and Date:

9:45 a.m., local time on
Thursday, July 28, 2022

Place:

Our Corporate Headquarters
Fifth Floor, Waterloo Exchange
Waterloo Road Dublin 4, Ireland

In light of the COVID-19 pandemic, we recommend that you vote your shares by proxy in advance of the
meeting. Whether or not you expect to attend the meeting, please vote as soon as possible. Please see
“Questions and Answers About These Proxy Materials and Voting—How do I vote?” beginning on
page 110 below. Please also see “Questions and Answers About These Proxy Materials and Voting—
What are the potential impacts of the COVID-19 pandemic on the annual meeting?” beginning on
page 108 below.

Business Overview

We are a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and
their families. We are dedicated to developing life-changing medicines for people with serious diseases—often
with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product
candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas,
we strive to identify new options for patients by actively exploring small molecules and biologics, and through
innovative delivery technologies and cannabinoid science.

Our strategy for growth is rooted in executing commercial launches and ongoing commercialization initiatives;
advancing robust research and development, or R&D, programs and delivering impactful clinical results;
effectively deploying capital to strengthen the prospects of achieving our short- and long-term goals through
strategic corporate development; and delivering strong financial performance. We focus on patient populations
with high unmet needs. We identify and develop differentiated therapies for these patients that we expect will be
long-lived assets and that we can support with an efficient commercialization model. In addition, we leverage our
efficient, scalable operating model and integrated capabilities across our global infrastructure to effectively reach
patients around the world.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

1

2022 NOTICE OF MEETING AND PROXY STATEMENT

Proxy Overview (continued)

Our lead marketed products are:

Neuroscience

•

•

•

•

Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution, a product approved by
the U.S. Food and Drug Administration, or FDA, in July 2020 and launched in the U.S. in November 2020 for
the treatment of cataplexy or excessive daytime sleepiness, or EDS, in patients with narcolepsy aged seven
years of age and older, and also approved by FDA in August 2021 for the treatment of idiopathic
hypersomnia, or IH, in adults and launched in the U.S. in November 2021. Xywav contains 92% less sodium
than Xyrem®;

Xyrem (sodium oxybate) oral solution, a product approved by FDA and distributed in the U.S. for the
treatment of both cataplexy and EDS in patients seven years of age and older with narcolepsy; Jazz also
markets Xyrem in Canada for the treatment of cataplexy in patients with narcolepsy. Xyrem is also approved
and distributed in the EU, Great Britain and other markets through a licensing agreement;

Epidiolex® (cannabidiol) oral solution, a product approved by FDA and launched in the U.S. in 2018 by
GW Pharmaceuticals plc, or GW, and currently indicated for the treatment of seizures associated with
Lennox-Gastaut syndrome, or LGS, Dravet syndrome, or DS, or tuberous sclerosis complex, or TSC, in
patients one year of age or older; in the EU (where it is marketed as Epidyolex®) and other markets, it is
approved for adjunctive treatment of seizures associated with LGS or DS, in conjunction with clobazam (EU
and Great Britain only), in patients 2 years of age and older and for adjunctive treatment of seizures
associated with TSC in patients 2 years of age and older; and

Sativex® (nabiximols) oral solution, a product approved and marketed in more than 25 markets outside the
U.S. as treatment for symptom improvement in adult patients with moderate to severe spasticity due to
multiple sclerosis, or MS, who have not responded adequately to other anti-spasticity medication and who
demonstrate clinically significant improvement in spasticity-related symptoms during an initial trial of therapy.

Oncology

•

•

•

•

Zepzelca® (lurbinectedin), a product approved by FDA in June 2020 and launched in the U.S. in July 2020
for the treatment of adult patients with metastatic small cell lung cancer, or SCLC, with disease progression
on or after platinum-based chemotherapy; in Canada, Zepzelca was approved in September 2021 for the
treatment of adults with Stage III or metastatic SCLC, who have progressed on or after platinum-containing
therapy;

Rylaze® (recombinant Erwinia asparaginase), a product approved by FDA in June 2021 and launched in
the U.S. in July 2021 for use as a component of a multi-agent chemotherapeutic regimen for the treatment of
acute lymphoblastic leukemia, or ALL, or lymphoblastic lymphoma, or LBL, in adults and pediatric patients
who have developed hypersensitivity to E. coli-derived asparaginase;

Vyxeos® (daunorubicin and cytarabine) liposome for injection, a product approved in the U.S., Canada,
EU, Great Britain, and recently in Switzerland (marketed as Vyxeos® liposomal in the EU and Great Britain)
for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia, or t-AML, or AML
with myelodysplasia-related changes (AML-MRC). An expanded indication was granted in the U.S. for the
treatment of newly diagnosed t-AML or AML-MRC in pediatric patients aged 1 year and older; and

Defitelio® (defibrotide sodium), a product approved in the U.S. and Brazil for the treatment of hepatic veno-
occlusive disease, or VOD, with renal or pulmonary dysfunction following hematopoietic stem cell
transplantation, or HSCT, and in Japan for the treatment of hepatic sinusoidal obstruction syndrome (hepatic-
veno occlusive disease). It is currently approved in the EU, Great Britain and other markets for the treatment
of severe hepatic VOD, also known as sinusoidal obstructive syndrome, or SOS, in HSCT therapy. It is
indicated in adults and pediatric patients over 1 month of age.

Our strategy to create sustainable shareholder value is focused on:

•

2

Strong commercial execution to drive diversified revenue growth and address unmet medical needs of our
patients across our product portfolio, which focuses on neuroscience and oncology medicines;

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Proxy Overview (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

•

•

•

•

•

Expanding and advancing our pipeline to achieve a valuable product portfolio of durable, highly differentiated
programs;

Continuing to build a flexible, efficient, and productive development engine for targeted therapeutic areas to
identify and progress early-, mid- and late-stage assets;

Identifying and acquiring novel product candidates and approved therapies to complement our existing
pipeline and commercial portfolio;

Investing in an efficient, scalable operating model and differentiated capabilities to enable growth; and

Unlocking further value through indication expansion and entry into global markets.

y
x
o
r
P

In 2021, consistent with our strategy, we continued to focus on R&D activities within our neuroscience and
oncology therapeutic areas, such as our expansion into movement disorders and solid tumors, and exploring
adjacent therapeutic areas that could further diversify our portfolio. In addition, in May 2021, we completed our
acquisition of GW Pharmaceuticals plc, or GW, as consistent with our overall business and capital allocation
strategy to expand our neuroscience portfolio and enhance value for our shareholders.

Information About Our Board of Directors

Director Nominees and Continuing Directors
Summary information about our director nominees and continuing directors, including their key skills and
experiences that are relevant to serving on our board, is provided in the charts below. See pages 18 to 31 for
more information.

Our nominating and corporate governance committee examines the experience and expertise of our board as a
whole to ensure alignment between the abilities and contributions of our board and our long-term strategic
priorities by primarily emphasizing expertise in global and U.S. sales and marketing, in product development, in
financial management and in corporate development transactions among other skill sets. All of our directors
exhibit high integrity, collegiality, innovative thinking, sound business judgment and a knowledge of corporate
governance requirements and practices.

Name

2022 Director Nominees

Jennifer E. Cook

Patrick G. Enright

Seamus Mulligan

Norbert G. Riedel, Ph,D,

Continuing Directors

Bruce C. Cozadd

Heather Ann McSharry

Anne O’Riordan

Rick E Winningham

Peter Gray

Kenneth W. O’Keefe

Mark D. Smith

Catherine A. Sohn, Pharm.D.

Age

Director
Since

Principal Position

Independent

Other Current
Public Boards

56

60

61

64

58

60

54

62

67

55

70

69

2020

Director, BridgeBio Pharma, Inc. and Denali
Therapeutics Inc.

2009(1) Managing Director, Longitude Capital

2012

2013

Director, Jazz Pharmaceuticals plc

Executive Chairperson, Aptinyx Inc.

2003(1) Chairperson and Chief Executive Officer, Jazz

Pharmaceuticals plc

2013

2019

Director, International Airlines Group, S.A.

Group Director of Digital, Jardine Matheson Limited

2010(1) Chairperson and Chief Executive Officer,

Theravance Biopharma, Inc.

2013

Chairperson, Teckro, Inc. and Abzena

2004(1) Managing Director, Beecken Petty O’Keefe &

Company

2020

2012

Professor, University of California, San Francisco
and Director, Teladoc Health, Inc. and Phreesia, Inc.

Chairperson, BioEclipse Therapeutics, Inc. and
Director, Axcella Health Inc., Landec Corporation
and Rubius Therapeutics

Yes

Yes

Yes

Yes

No

Yes

Yes

Yes

Yes

Yes

Yes

Yes

2

2

0

3

0

1

0

1

0

0

2

3

(1)

Includes service on the board of directors of Jazz Pharmaceuticals, Inc., our predecessor.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

3

Proxy Overview (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

Director Diversity
Our board is substantially independent and has a mix of relatively newer and longer-tenured directors. The charts
below show board makeup by various characteristics with respect to our director nominees and continuing
directors:

RESIDENCY

GENDER

DIRECTOR DIVERSITY

TENURE

50%

Skills

Total of 12

Government Affairs/Public Policy

Product Development

Industry Experience/Industry
Knowledge/Regulatory/FDA

Accounting/Audit

Risk Oversight and Risk Management

Human Capital Management

Public Company Board and
Committees

Corporate Development

Senior Leadership/CEO

4

2022 Proxy Statement | JAZZ PHARMACEUTICALS

5

5

6

6

7

10

10

10

11

Proxy Overview (continued)

Total Number of Directors

12

Board Diversity Matrix (as of June 1, 2022)

2022 NOTICE OF MEETING AND PROXY STATEMENT

Part I: Gender Identity

Directors

Part II: Demographic Background

African American or Black

White

LGBTQ+

Female

Male

Non-Binary

4

—

4

8

1

7

—

—

—

1

Did Not
Disclose
Gender

—

—

—

y
x
o
r
P

Shareholder and Other Stakeholder Engagement

A priority for our board of directors is soliciting and listening to the views of our shareholders on a variety of topics,
including our business and growth strategy, corporate governance practices, executive compensation matters,
and various other environmental, social and governance (ESG) matters. Discussions with our shareholders have
been productive and informative and have provided valuable feedback to our board of directors to help ensure
that our board’s decisions align with shareholder objectives. The graphic under the section entitled “Executive
Compensation—Compensation Discussion and Analysis—How We Determine Executive Compensation—2021
Advisory Vote on Executive Compensation and Shareholder Engagement” on page 54 below describes our typical
shareholder outreach and engagement cycle.

Leading up to and following our 2021 annual general meeting, we reached out to shareholders who collectively
held approximately 29% of our then-outstanding shares to request meetings, and held meetings with each
shareholder who accepted our request for engagement.

We have taken a number of significant and responsive actions over the past several years to incorporate
feedback received from shareholders, as highlighted in the following table.

Topic

What We Heard

What We Did

Board Refreshment

Shareholders continued to stress the importance of
board refreshment and the role it plays in
enhancing skills and capabilities and increasing
board diversity.

•

We enhanced our demographic board
diversity in both 2019 and 2020. Specifically,
in 2020, we underwent a board refreshment
program and candidate search for new
directors, which provided an opportunity to
enhance the range of skills and capabilities of
the board. As part of that search process, the
nominating and corporate governance
committee asked the search firm it engaged to
provide, and then considered, a set of highly
qualified candidates that included both
women and people from underrepresented
communities. In late 2020, we added two
additional diverse directors, including a
practicing physician and a seasoned
biopharma executive/former CEO.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

5

Proxy Overview (continued)

Topic

Compensation

2022 NOTICE OF MEETING AND PROXY STATEMENT

What We Heard

What We Did

While shareholders provided positive feedback
regarding our pay-for-performance alignment, we
heard a strong preference that our long-term
incentive program include performance-based
equity awards. Shareholders have raised concerns
that our burn rate is higher than some of our peers.
Shareholders disfavor the “evergreen provision” in
our 2011 Equity Incentive Plan.

Shareholders also expressed their desire for our
annual performance bonus plan to have an explicit
cap on payouts to avoid the potential of excessive
payouts not tied to performance and to mitigate
certain risks inherent in incentive plans.

In response to shareholder feedback:

•

•

•

•

•

•

•

Since 2021, approximately 50% of each
executive officer’s target equity compensation
has been in the form of performance-based
equity awards, or PSUs;

Since 2021, stock options have been
eliminated from our long-term incentive
program, and 100% of the awards granted
thereunder have been in the form of restricted
stock units, or RSUs, and PSUs;

The evergreen provision in the 2011 Equity
Incentive Plan expired in January 2022 and
we will not adopt a new one in the future;

Since 2021, payouts under the annual
performance bonus awards have been
capped at 300% of an individual’s target
award;

We selected performance goals for our
executive compensation program that focus
specifically on (i) growing and diversifying our
commercial portfolio and (ii) enhancing the
value of our pipeline to create a meaningful
incentive and reward for successfully driving
transformation and delivery of long-term
sustainable value to shareholders and life-
changing medicines to patients;

Once the aggregate achievement percentage
of the performance goals is determined, that
result is modified, from 75% to 125%, based
on the performance of our stock price relative
to peers, or a relative TSR modifier. We
believe that having a TSR modifier helps
balance the importance of providing
executives clearer line of sight to payout
opportunities using financial/operational
measures with the need to ensure that those
payouts are aligned with shareholders’
experience during the performance period;
and

We also have a policy for recoupment of
incentive compensation, or a clawback policy,
which is designed to mitigate risks generally
associated with incentive compensation and
allow us to recover any erroneously earned
compensation.

In 2020, we conducted a formal materiality
assessment and established clear oversight and
governance around ESG. In 2021, we established
a dedicated Global Corporate Sustainability and
Social Impact (“CSSI”) Team to lead our ESG
program. The CSSI Team, senior management,
and our board are building upon a strong
foundation of environmental stewardship and social
impact initiatives, and our nominating and
corporate governance board committee has
oversight responsibility over ESG policies and
initiatives. We are continually innovating across our
manufacturing sites and supplier networks and

ESG

ESG continues to be a priority for our shareholders
and stakeholders.

6

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Proxy Overview (continued)

Topic

What We Heard

What We Did

2022 NOTICE OF MEETING AND PROXY STATEMENT

have successfully redesigned product packaging,
drug production processes, and facilities
operations to reduce our water and energy use and
waste generation globally. We have also launched
social impact programs that deliver our medicines
to underserved regions and support the civic health
of our communities and developed diversity, equity,
inclusion and belonging (DEIB) commitments to
enhance representation of diverse perspectives
within our organization.

y
x
o
r
P

We also continue to evaluate feedback received from shareholders on other topics, including our classified board
structure, setting climate change targets and reporting on workforce diversity.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

7

2022 NOTICE OF MEETING AND PROXY STATEMENT

Proxy Overview (continued)

ESG Highlights

At Jazz our purpose is to innovate to transform the lives of patients and their families. Our core values—integrity, collaboration, passion,
pursuit of excellence and innovation—define our corporate practices and demonstrate our commitment to improving patients’ lives.

Our values, combined with good corporate governance, environmental stewardship and social responsibility anchor our corporate strategy and
make up key elements of our vision to deliver on our commitment to generate long-term sustainable value for patients, employees,
shareholders, and other stakeholders.

Our board and management are focused on establishing a clear ESG strategic roadmap for the proactive management of ESG risks,
assessments and disclosures. The board oversees ESG matters at both the full board and committee level. The nominating and corporate
governance committee has primary oversight for our ESG strategy. In addition, the compensation and management development committee
works with the full board to oversee human capital management matters, including DEIB. See the section entitled “Corporate Governance and
Board Matters” on page 25 for a further discussion of our board and board committees.

Corporate Sustainability and Social Impact Highlights

Senior management has operational responsibility for ESG matters. As part of our proactive management of ESG factors, in 2021, Jazz
formed the Global Corporate Sustainability and Social Impact (“CSSI”) team to lead our ESG program. The CSSI team and our senior
management regularly brief the board and its committees on ESG matters.

Our ESG program is aligned to our corporate strategy and is organized around four key pillars; planet; patients; community; and people. We
conduct formalized materiality assessments of our business to consider the financial materiality of key ESG metrics and their relation to the
financial and competitive strategy of Jazz. In addition, internal and external stakeholder feedback informs Jazz’s assessment of key ESG
priorities. For each priority topic, we are developing a strategic vision along with an action plan to get us there, including targets, where
applicable. The company plans to publish its first ESG report later this year.

Selected ESG achievements and initiatives under each pillar are highlighted below:

8

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Proxy Overview (continued)

Planet

We seek to operate
our business in an
environmentally
responsible way to
ensure we are
protecting our
people, our
business, our
environment and the
local communities in
which we operate.

We are committed to
reducing our
environmental
impact and to using
sustainable practices
wherever feasible.

U.N. SDG
Alignment

2022 NOTICE OF MEETING AND PROXY STATEMENT

We have implemented environmental sustainability measures across our different manufacturing sites and
throughout our product portfolio, with key activities below:

•

•

•

•

•

•

•

•

Redesigned our Epidiolex packaging to be more sustainable, reducing total energy used, carbon emissions,
water consumption, and waste produced.

We use green chemistry principles in our first in-house commercial production site (Athlone, Ireland)
(green solvent selection, reduced solvent usage, usage of enzyme catalysts in the place of heavy metals).

All electricity used at our Athlone site has been sourced from Moanmore wind farm, (county Clare) since
2019.

The Athlone manufacturing site was built on a greenfield site in an environmentally sensitive area, rich in
flora and fauna. We spend considerable time and resources protecting our local environment including daily
water quality assessment and monitoring.

y
x
o
r
P

Our growing site at Yorkshire Botanicals Limited (YBL) uses electricity generated from wind turbines,
powering over 300 local homes when the power is not needed; additionally at our British Sugar growing
site we have achieved a 30% reduction in the usage of peat with further reductions targeted.

At our Villa Guardia site, we replaced all light points with LEDs saving 103,699 kwh per year of electricity;
we have introduced significant steps to reduce our solvent usage, recovering 500 tonnes of acetone per
year and we introduced a “cleaning in place” system together with new dry screw vacuum pumps in 2018
which allowed us to save more than 18,000m3 of potable water per year.

In addition, our Villa Guardia site has implemented an Environmental Management System since 2007
reporting on water consumption, discharges, atmospheric emissions, energy efficiency, material efficiency
and biodiversity which is publicly available on our website.

Our new buildings meet the highest level of Building Research Establishment Environmental Assessment
Methodology (BREEAM) standards. Our new bulk drug product (BDP) facility at KSP (Building 755) has
been designed in order to achieve the BREEAM ‘very good’ status to encourage environmental, social and
economic sustainability. The design includes planting 2,125 trees, deploying 1,144 solar panels on its roof,
using low energy lighting throughout and utilizing environmentally friendly building materials.

Our 2022 sustainability report will include expanded environmental disclosures, including measures relating to
waste generation, energy and water use, and carbon emissions.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

9

Proxy Overview (continued)

Patients

We are innovating to

develop life-

changing medicines

for patients—often

with limited or no

therapeutic options.

We strive to help

patients get access

to the medications

they need, and we

advocate for policies

that transform the

lives of patients.

U.N. SDG
Alignment

2022 NOTICE OF MEETING AND PROXY STATEMENT

•

•

•

•

•

•

•

•

Expanding patient access to medicines, including through our patient assistance programs, product

donations to global aid organizations and monetary contributions to independent charities. We have been

able to provide greater support and access to our medicines in markets around the world.

Appointed Jazz’s first Vice President of Patient Advocacy in 2022 to drive patient-focused strategies and

embed the patient voice into our decision making.

We are incorporating patient perspectives early in the drug development process and building endpoints

based on their feedback. This includes studying nontraditional metrics like the impact of treatment on

activities of daily living and exploring social/emotional endpoints as reported by patients.

Engaged with patient advocacy organizations and public officials in the state of Kentucky to bring awareness

to Lung Cancer, culminating in a Governor’s Proclamation Event and the passage of the Lung Cancer

Screening and Prevention Program bill.

In partnership with Stand Up To Cancer, we are supporting ethnographic research to help drive

improvements in the treatment of small cell lung cancer for Black patients. This research explores the

attitudes towards small cell lung cancer among Black patients and their caregivers in the United States.

Our pipeline of potential new therapies has expanded 4x since 2015 and we are committed through our

Vision 2025 framework to deliver at least 5 novel product approvals by the end of the decade.

Our launch of Rylaze in 2021 allowed us to move away from supply chain disruptions previously common to

Erwinaze, and to better support ALL and LBL patients. We are also pursuing approval of two-day and

intravenous dosing regimens that will allow patients and providers increased flexibility.

Committed to improving diversity in our clinical trial enrollments, including support of the American Cancer

Society’s Blue-Button Project which will make clinical trial eligibility screening part of routine care that

requires little effort and make trial screening site agnostic. Our hope is to increase overall cancer clinical trial

enrollment with more diverse patients in those trials, better reflecting the U.S. cancer population.

•

Jazz is continuing our commitment to supporting the long-term health outcomes of our sleep medicine

patients, increasing educational funding and advocacy to raise awareness about the benefits of low-sodium

therapies for chronic conditions.

10

2022 Proxy Statement | JAZZ PHARMACEUTICALS

2022 NOTICE OF MEETING AND PROXY STATEMENT

Proxy Overview (continued)

Community

We aim to be an
engaged corporate
citizen globally and
in the specific
communities in
which we work.

We work through
direct philanthropy,
employee
volunteerism and
with partners to
execute key social
good initiatives that
reflect our social
impact goals and
values.

U.N. SDG
Alignment

•

•

•

•

•

•

•

Jazz supports a wide and varied corporate philanthropy program that includes support across our key
strategic therapeutic focus areas.

We empower our employees to help guide decisions on funding and support to charitable organizations,
including our donations to the International Red Cross, UNICEF, and World Central Kitchen.

We believe that greater inclusion of underrepresented groups in the scientific and biopharmaceutical arenas
is a priority and can further address health inequities. We help both individuals and employees through
financial support, mentoring, and internship programs.

Our employee volunteer program, Community Beat, is focused on creating co-worker engagement and
community outreach through coordinated programs and activities throughout the year.

We donated thousands of doses of oncology medication to underserved countries in Africa and South
America.

y
x
o
r
P

Established a Global Volunteer Day to allow all Jazz employees a paid day off to serve in their local
communities.

We support underrepresented communities with limited access to legal services and have established a
program to assist recent childhood and young adult immigrants to the United States as part of the Deferred
Action for Childhood Arrivals (or DACA) Program. Jazz lawyers help prepare renewal applications and we
cover the application fees for those seeking renewals.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

11

2022 NOTICE OF MEETING AND PROXY STATEMENT

Proxy Overview (continued)

People
Jazz is committed
to creating a
company where the
culture embodies
our corporate
purpose to
innovate to
transform the lives
of patients and
reflects our key
goals: (1) be a
great place to work;
and (2) live our
core values of
Integrity,
Collaboration,
Passion,
Innovation, and
Pursuit of
Excellence.

We aim to be the
best experience of
our employees’
careers.

U.N. SDG
Alignment

•

•

•

•

•

•

•

•

•

•

We gather more frequent feedback from our employees on what they value about the workplace experience;
we consistently achieve participation rates of more than 80% in our annual engagement survey and 77% of
employees would recommend Jazz as a good place to work.

As part of our multi-dimensional diversity strategy, Jazz ConcERTos, our employee resource teams, are
self-led teams of employee volunteers with diverse backgrounds who come together to promote innovation
through inclusion and to increase awareness of all dimensions of diversity. In addition, we have six active
affinity forums at Jazz.

Fifty percent of our Executive Committee is diverse in terms of gender, ethnicity and sexual orientation.

Females represent 55% of our global workforce and 43% at the leadership level (employees at executive
director and above).

In the U.S., people of color represent 33% of our U.S. workforce and 20% at the leadership level.

We provide customizable continuous learning opportunities for employees to allow for course-work that
matches career ambitions and strengths with customized development; We have targeted a development
effort to build leadership capabilities within our team of global leaders (80+ top leaders).

We designed a new work model we call Jazz Remix. It’s based upon direct input from employees and
external insights and best practices. Jazz Remix blends the advantages of remote/virtual working and in-
person collaboration. Employees work dynamically from our sites, from home and other locations as
business and personal needs require.

Jazz offers full company participation in our long-term incentive plan providing employees with an ownership
stake.

Jazz provides differentiated global leave and time-off polices including minimum standards for new parent
leave, irrespective of gender or how a family is created, family caregiver leave, and bereavement leave.

We offer an array of mental health, well-being and mindfulness programs including fully covered counseling
sessions for employees and their families.

We are committed to advancing our ESG Strategy, building upon previous third-party materiality assessments and will seek to report against
the upcoming International Sustainability Standards Board (ISSB) consolidated reporting metrics. Our Board, senior management, and CSSI
Team will focus on the Agriculture, Biotechnology and Pharmaceutical ESG standards that apply to our business and maintain our
commitment to operating ethically, sustainably and in alignment with many of the U.N.’s Sustainable Development Goals (SDGs).

12

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Proxy Overview (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

Summary of Shareholder Voting Matters and Board Recommendations

For the reasons set forth below and in the rest of this proxy statement, our board of directors recommends that
you vote your shares “FOR” each of the nominees named below for director to hold office until the 2025 annual
meeting of shareholders and “FOR” each of the other proposals.

Proposal 1 — Election of Directors

The board of directors
recommends a vote “FOR”
each of the named
nominees.

Vote required to elect
each nominee to hold
office until the 2025
annual meeting of
shareholders: Affirmative
vote of a majority of the
votes cast on his or her
election.

For more information, see
Proposal 1 starting on
page 18.

y
x
o
r
P

We are asking our shareholders to vote, by separate resolutions, on the
election of each of Jennifer E. Cook, Patrick G. Enright, Seamus
Mulligan and Norbert G. Riedel, Ph.D. to hold office until the 2025
annual meeting of shareholders. Detailed information about each
nominee’s background and experience can be found beginning on
page 19.

Each of the nominees for director was nominated for election by the
board of directors upon the recommendation of our nominating and
corporate governance committee. Our board of directors believes that
each nominee has the specific experience, qualifications, attributes and
skills to serve as a member of the board of directors and has
demonstrated the ability to devote sufficient time and attention to board
duties and to otherwise fulfill the responsibilities required of directors.
See “Corporate Governance and Board Matters—Director
Commitments” beginning on page 29 for more information.

Proposal 2 — Ratify, on a Non-Binding Advisory Basis, the Appointment of Independent
Auditors and Authorize, in a Binding Vote, the Board of Directors, Acting Through the Audit
Committee, to Determine the Independent Auditors’ Remuneration

The board of directors
recommends a vote “FOR”
this proposal.

Vote required for
approval: Affirmative vote
of a majority of the votes
cast on the proposal.

For more information, see
Proposal 2 starting on
page 97.

Under Irish law, KPMG will be deemed to be reappointed as our
independent auditors for the financial year ending December 31, 2022,
without needing a shareholder vote at the annual meeting. However,
our shareholders are being asked to ratify KPMG’s appointment on a
non-binding advisory basis because we value our shareholders’ views
on the company’s independent auditors. The board of directors and the
audit committee intend to consider the results of this vote in making
determinations in the future regarding the appointment of the
company’s independent auditors.

Our shareholders are also being asked to authorize the board of
directors, acting through the audit committee, to determine KPMG’s
remuneration. This authorization is required by Irish law.

Less than 3% of the total fees that KPMG billed us for services last year
were for services other than audit, audit-related and tax compliance
services.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

13

Proxy Overview (continued)

Proposal 3 — Non-Binding Advisory Vote on Executive Compensation

2022 NOTICE OF MEETING AND PROXY STATEMENT

The board of directors
recommends a vote “FOR”
this proposal.

Vote required for approval:
Affirmative vote of a
majority of the votes cast
on the proposal.

For more information, see
Proposal 3 starting on
page 99.

We are asking our shareholders for advisory approval of our NEOs’
compensation. This non-binding advisory vote is commonly referred to
as a “say-on-pay” vote. Our executive compensation program is aligned
with our business strategy and priorities and encourages executive
officers to work for meaningful shareholder returns consistent with our
pay-for-performance philosophy. Our executive compensation program
focuses on target total direct compensation, combining short-term and
long-term components, cash and equity, and fixed and variable
payments, in the proportions that we believe are the most appropriate
to incentivize and reward our executive officers for achieving our
corporate goals while minimizing incentives for excessive risk-taking or
unethical conduct. Our annual performance bonus awards are not
earned unless pre-determined levels of performance are achieved
against annual corporate objectives approved by our board of directors
at the beginning of the year. Likewise, our stock option awards will not
provide realizable value and our restricted stock unit awards will not
provide increased value unless there is an increase in the value of our
shares, which benefits all shareholders. We also have executive share
ownership guidelines to further support our ownership culture and align
the interests of executive officers and shareholders. Further, in 2021 we
implemented a new performance-based equity program tied to the
achievement of critical multi-year financial and other strategic objectives
as well as relative total shareholder return goals, with performance-
based restricted stock unit awards making up approximately 50% of
each NEO’s target annual equity grant, and time-vested restricted stock
unit awards making up the other approximately 50%. Our 2021 advisory
say-on-pay proposal was approved by approximately 90% of total votes
cast.

Proposal 4 — Board Authority to Issue Shares for Cash Without First Offering Shares to
Existing Shareholders

The board of directors
recommends a vote “FOR”
this proposal.

Vote required for approval:
Affirmative vote of 75% of
the votes cast on the
proposal.

For more information, see
Proposal 4 starting on
page 101.

We are asking our shareholders to grant the board of directors the
pre-emption opt-out authority to allot equity securities for cash for up to
20% of our issued ordinary share capital in the aggregate, for a period
expiring on the date being 18 months from the passing of the resolution
set forth in Proposal 4, unless otherwise varied, renewed or revoked.

Prior to casting your vote on Proposal 4, we strongly urge you to
carefully read the discussion in Proposal 4 beginning on page 101.

In general, unless otherwise authorized by shareholders, before an Irish
public limited company can issue shares for cash (including rights to
subscribe for, convert into or otherwise acquire any shares) to any new
shareholders, it must first offer the shares or rights to existing
shareholders of the company pro-rata to their existing shareholdings.
Under Irish law, the authority to opt-out of this pre-emption right, which
we call the pre-emption opt-out authority, can be granted by
shareholders for a maximum period of five years, at which point it
lapses unless renewed by shareholders. At our 2021 annual general
meeting of shareholders, our proposal to renew our prior unlimited

14

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Proxy Overview (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

y
x
o
r
P

pre-emption opt-out authority for an additional five-year term did not
receive the affirmative vote of at least 75% of the votes cast as required
by the Irish law super majority voting regime for special resolutions. At
an extraordinary general meeting we held in September 2021, or the
2021 EGM, our shareholders approved our current pre-emption opt-out
authority for an 18-month period from the date of the 2021 EGM under
which our directors are authorized to issue new shares for cash, if the
issuance is limited to up to 5% of our issued ordinary share capital, with
the possibility of issuing an additional 5% of our issued ordinary share
capital provided the additional 5% is only to be used for the purposes of
financing (or refinancing, if the refinancing is announced within six
months after the original transaction) a transaction that our board of
directors determines to be an acquisition or a specified capital
investment. Accordingly, the current pre-emption opt-out authority is
due to expire on March 23, 2023.

When we formulated the pre-emption opt-out authority that was
presented at, and approved by, our shareholders at the 2021 EGM, we
followed the market practice for companies whose share capital is listed
on Euronext Dublin because it was critical for us to submit a
pre-emption opt-out authority proposal at the 2021 EGM that we were
certain shareholders would support given the Irish law super majority
voting regime for special resolutions. However, upon further analysis
and following engagement with our shareholders, we believe at this
time that it is in the best interests of the company and our shareholders
to seek approval for a new pre-emption opt-out authority on the terms
set forth in Proposal 4.

Earlier this year, we announced our Vision 2025, which aims to deliver
sustainable growth and enhanced value, driving our continued
transformation to an innovative, high-growth global pharmaceutical
leader, with a focus on commercial execution, pipeline productivity and
operational excellence. In this regard, strategic capital allocation will
continue to be an important driver of our growth.

Granting our board of directors the pre-emption opt-out authority on the
terms set forth in Proposal 4 is vital to the way we intend to advance
our business. As explained in more detail in Proposal 4, we received
feedback from shareholders during engagement efforts both before and
after our 2021 annual general meeting that indicated certain
shareholders preferred limits on our pre-emption opt-out authority. In
light of our strategy for growth and related initiatives and after extensive
consideration, we determined at this time that seeking approval for a
pre-emption out-out authority to issue up to 20% of our issued ordinary
share capital for cash over the next 18 months would likely provide us
with sufficient flexibility to execute on our strategy while also taking into
account shareholder feedback that expressed a preference for some
limits on our pre-emption opt-out authority. We also believe that the
20% limit in Proposal 4 strikes the right balance between protecting
shareholders from excessive dilution resulting from issuances of shares
for cash and providing us with sufficient flexibility to execute on our
strategy for growth.

We will, like all U.S.-incorporated companies listed on Nasdaq, continue
to be subject to the Nasdaq shareholder approval requirements,
including the Nasdaq requirement for shareholder approval for certain

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

15

Proxy Overview (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

acquisitions or private placements when the number of shares to be
issued is or will be equal to or in excess of 20% of the number of our
ordinary shares outstanding before the issuance. Unlike our
U.S.-incorporated peer companies listed on Nasdaq, however, we will
also be limited by the terms of Proposal 4, which imposes an overall
20% limit on our ability to issue shares for cash without shareholder
pre-emption rights for the entirety of the 18-month authorization period
regardless of the type of transaction or financing.

As noted above, our strategy for growth depends in part on our ability to
quickly take advantage of strategic opportunities, including potential
acquisitions and other capital-intensive transactions that we believe
would increase shareholder value. Many of these opportunities are
highly competitive, with multiple parties often offering comparable or
even the same economics. In light of our strategy for growth and
related initiatives and after extensive consideration, we determined at
this time that seeking approval for a pre-emption out-out authority to
issue up to 20% of our issued ordinary share capital for cash over the
next 18 months would likely provide us with sufficient flexibility to
execute on our strategy, including as part of our Vision 2025.

If Proposal 4 is not approved, in each case where we propose to issue
shares for cash consideration after March 23, 2023 and/or beyond the
more restrictive limits of our current pre-emption opt-out authority, we
would first have to offer those shares on the same or more favorable
terms to our existing shareholders pro-rata to their existing
shareholdings in the absence of a new shareholder approval to dis-
apply the pre-emption rights provision to the issuance of those shares.
This could put us at a significant disadvantage vis-a` -vis many of
our peers in competing for acquisitions and similar transactions
(particularly since many of the companies with which we compete
strategically are listed and incorporated in the U.S. and are not
subject to similar pre-emption right restrictions), and might make
it difficult for us to complete such transactions in a timely manner
or at all, potentially limiting our ability to further our strategy for
growth by deploying capital to meet strategic goals that are in the
best interests of our shareholders.

Proposal 5 — Adjournment Proposal

The board of directors
recommends a vote
“FOR” this proposal.

Vote required for
approval: Affirmative vote
of a majority of the votes
cast on the proposal.

For more information, see
Proposal 5 starting on
page 107.

We are asking our shareholders to vote on a proposal to approve any
motion to adjourn the annual meeting, or any adjournments thereof, to
another time and place to solicit additional proxies if there are
insufficient votes at the time of the annual meeting to approve
Proposal 4.

Under Irish law, Proposal 4 is a special resolution, which requires no
less than 75% of the votes of shareholders cast (in person or by proxy)
at a general meeting to be voted “FOR” the proposal in order to be
passed. Given the high vote threshold associated with Proposal 4, we
are seeking your authority to adjourn the meeting to solicit additional
proxies if there are insufficient votes at the time of the annual meeting
to approve Proposal 4.

16

2022 Proxy Statement | JAZZ PHARMACEUTICALS

2022 NOTICE OF MEETING AND PROXY STATEMENT

PROXY STATEMENT
FOR THE 2022 ANNUAL GENERAL MEETING OF SHAREHOLDERS
TO BE HELD ON JULY 28, 2022

y
x
o
r
P

GENERAL

Purpose of this Proxy Statement and Other General Information

Our board of directors is soliciting proxies for use at our 2022 annual general meeting of shareholders, or the
annual meeting. This proxy statement contains important information for you to consider when deciding how to
vote on the matters brought before the annual meeting. Please read it carefully. The Notice of Internet Availability
of Proxy Materials and our proxy materials, which include this proxy statement, our annual letter to shareholders
and our 2021 Annual Report on Form 10-K, are first being mailed to shareholders on or about June 15, 2022. Our
proxy materials are also available online at https://materials.proxyvote.com/G50871. The specific proposals to be
considered and acted upon at the annual meeting are summarized in the accompanying Notice of 2022 Annual
General Meeting of Shareholders. Each proposal is described in more detail in this proxy statement.

This solicitation is made on behalf of our board of directors and all solicitation expenses, including costs of
preparing, assembling and mailing proxy materials and notices, will be borne by us. In addition to these proxy
materials, our directors and employees may also solicit proxies in person, by telephone, or by other means of
communication. Directors and employees will not be paid any additional compensation for soliciting proxies. We
may also reimburse brokerage firms, banks and other agents for the cost of forwarding proxy materials to
beneficial owners. In addition, we have retained Alliance Advisors, a proxy solicitation firm, to assist in the
solicitation of proxies for a fee of approximately $40,000 plus reimbursement of expenses.

Our board of directors has set the close of business on June 1, 2022 as the record date for the annual meeting.
Shareholders of record who owned our ordinary shares on that date are entitled to vote at and attend the annual
meeting. Each ordinary share is entitled to one vote. There were 62,442,548 of our ordinary shares outstanding
and entitled to vote on the record date.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

17

2022 NOTICE OF MEETING AND PROXY STATEMENT

PROPOSAL 1
ELECTION OF DIRECTORS
Our board of directors is divided into three classes, designated Class I, Class II and Class III. The term of the
Class II directors will expire on the date of this annual meeting of shareholders; the term of the Class III directors
will expire on the date of the 2023 annual meeting of shareholders; and the term of the Class I directors will expire
on the date of the 2024 annual meeting of shareholders. At each annual meeting of shareholders, successors to
the directors whose term expires at that annual meeting are put forward for election for a three-year term.
The board of directors currently has 12 members and there are no vacancies. There are currently four directors in
Class II, the class whose term of office expires at this annual meeting, all of whom are standing for election at the
annual meeting: Jennifer E. Cook, Patrick G. Enright, Seamus Mulligan and Norbert G. Riedel, Ph.D. All four
Class II director nominees were nominated for election by the board of directors upon the recommendation of our
nominating and corporate governance committee. Each of Ms. Cook, Mr. Enright, Mr. Mulligan and Dr. Riedel
were previously elected to our board of directors by our shareholders.
In order to be elected as a director at the annual meeting to hold office until the 2025 annual meeting of
shareholders, each nominee must be appointed by an ordinary resolution, meaning each must individually receive
the affirmative vote of a majority of the votes cast by the holders of ordinary shares represented in person or by
proxy at the annual meeting (including any adjournment thereof). Under our articles, if, at any annual meeting of
shareholders, the number of directors is reduced below the minimum prescribed by the board of directors
pursuant to our articles due to the failure of any director nominee to receive the affirmative vote of a majority of
the votes cast, then in those circumstances, the nominee or nominees who receive the highest number of votes in
favor of election will be elected in order to maintain such prescribed minimum number of directors. Each such
director would remain a director (subject to the provisions of the 2014 Act and our articles) only until the
conclusion of the next annual meeting of shareholders unless he or she is re-elected at such time.
If any nominee becomes unavailable for election as a result of an unexpected occurrence, the proxy holders will
vote your proxy for the election of any substitute nominee as may be proposed by the nominating and corporate
governance committee. Each nominee has consented to being named as a nominee in this proxy statement and
has agreed to serve if elected, and we have no reason to believe that any nominee will be unable to serve. If
elected at the annual meeting by the affirmative vote of a majority of the votes cast on his election, each nominee
would serve as a director until the 2025 annual meeting of shareholders and until his successor has been elected
and qualified, or, if sooner, until his death, resignation, retirement, disqualification or removal. It is our policy to
invite directors and nominees for director to attend annual meetings of shareholders. Due to the COVID-19
pandemic, including related travel restrictions, none of our directors attended our 2021 annual meeting of
shareholders in person; however, all of the directors then in office participated in the meeting by video
conference.
Vacancies on the board of directors, including a vacancy that results from an increase in the authorized number of
directors, may be filled only by the affirmative vote of a majority of the directors then in office, provided that a
quorum is present at the relevant board meeting. A director elected by the board of directors to fill a vacancy in a
class will serve for the remainder of the full term of that class and until the director’s successor is elected and
qualified, or, if sooner, until his or her death, resignation, retirement, disqualification or removal. Under our
articles, if the number of directors is increased, directors are apportioned among the classes to maintain the
number of directors in each class as nearly equal as possible, or as the Chairperson of our board may otherwise
direct.
The following includes a brief biography of each nominee for director and each of our other directors whose terms
of office will continue following the annual meeting, including their respective ages, as of June 1, 2022. Each
biography includes information regarding the specific experience, qualifications, attributes or skills that led the
nominating and corporate governance committee and the board of directors to determine that the applicable
nominee or other current director should serve as a member of the board of directors. We evaluate diversity
considerations as well as the experience and expertise of our board as a whole to ensure alignment between the
abilities and contributions of our board and our strategic priorities and long-range plan, emphasizing, among other
things, expertise in global and U.S. sales and marketing, in product development, in financial management and in
corporate development transactions.

18

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Proposal 1 (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

Class II Director Nominees for Election for a Three-Year Term Expiring at the 2025
Annual Meeting

Jennifer E. Cook
Director, BridgeBio Pharma, Inc. and Denali Therapeutics, Inc.

Jennifer E. Cook has served as a member of our board of directors since December 2020. Ms.
Cook serves as a non-executive director on the boards of directors of two other publicly-held
companies, Denali Therapeutics Inc. and BridgeBio Pharma, Inc., both biotechnology
companies. She also serves on the board of directors of Ambys Medicines, Inc., a privately held
biotechnology company. Ms. Cook founded Jennifer Cook Consulting, a consulting company,
and has served as Principal since July 2019. From January 2018 to June 2019, Ms. Cook was
the Chief Executive Officer at GRAIL, Inc., a privately-held early cancer detection diagnostic
company. Prior to that, Ms. Cook worked at Roche Pharmaceuticals/Genentech for 25 years,
where she held a number of senior management positions covering the full lifecycle of product
development and commercialization. From 2010 to 2013, she oversaw Genentech’s U.S.
Immunology and Ophthalmology Business Unit, and from 2013 to 2016, she led Roche’s
European commercial business. She also served as Roche’s Global Head of Clinical
Operations throughout 2017. In 2016, Ms. Cook was recognized as Woman of the Year by the
Healthcare Businesswoman’s Association. Ms. Cook received a B.A. in Human Biology and a
M.S. in Biology from Stanford University and an M.B.A. from the Haas School of Business at
University of California, Berkeley. Ms. Cook brings to our board over 30 years of
biopharmaceutical experience with significant C-suite, global product development and
commercialization expertise, with a focus on transformative growth.

y
x
o
r
P

Director since 2020

Age 56

Key Qualifications and Expertise:
Ms. Cook brings to our board over 30
years of biopharmaceutical experience
with significant C-suite, global product
development and commercialization
expertise, with a focus on transformative
growth.

Committee Assignments:

• Compensation Committee1 since

April 2021. Chair of Compensation
Committee since April 2022.

Other Current Public Company
Boards:

• BridgeBio Pharma, Inc.
• Denali Therapeutics Inc.

Patrick G. Enright
Managing Director, Longitude Capital

Patrick G. Enright has served as a member of our board of directors since the closing of the
Azur Merger in January 2012 and was a director of Jazz Pharmaceuticals, Inc. from 2009 until
the closing of the Azur Merger. Mr. Enright co-founded Longitude Capital, a healthcare venture
capital firm, where he has served as a Managing Director since 2006. Prior to Longitude
Capital, Mr. Enright was a Managing Director of Pequot Ventures where he co-led the life
sciences investment practice. Mr. Enright also has significant life sciences operations
experience including senior executive positions at Valentis, Boehringer Mannheim (acquired by
Roche) and Sandoz (now known as Novartis). Mr. Enright currently serves on the boards of
directors of Aptinyx Inc. and Vera Therapeutics, Inc. as well as several privately held healthcare
companies and the National Venture Capital Association. Mr. Enright previously served on the
boards of directors of over 20 companies, including Aimmune Therapeutics, Inc from 2013 until
its acquisition by Nestlé in 2020 and Vaxcyte, Inc from 2015 to 2020. Mr. Enright received a
B.S. in Biological Sciences from Stanford University and an M.B.A. from the Wharton School of
the University of Pennsylvania. Based on his experience as a venture capital investor focused
on life sciences companies and his past work in the pharmaceutical industry, Mr. Enright brings
to our board of directors over 30 years of operating experience and financial expertise in the life
sciences industry.

Director since 2009*

Age 60

Key Qualifications and Expertise:
Based on his experience as a venture
capital investor focused on life sciences
companies and his past work in the
pharmaceutical industry, Mr. Enright
brings to our board of directors over 30
years of operating experience and
financial expertise in the life sciences
industry.

Committee Assignments:

• Audit Committee
• Compensation Committee

Other Current Public Company
Boards:

• Aptinyx Inc.
• Vera Therapeutics, Inc.

*Includes service on the board of
directors of Jazz Pharmaceuticals, Inc.,
our predecessor.

1

In this proxy statement, we refer to our Compensation & Management Development Committee as the compensation committee.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

19

2022 NOTICE OF MEETING AND PROXY STATEMENT

Proposal 1 (continued)

Seamus Mulligan
Director, Jazz Pharmaceuticals plc

Seamus Mulligan has served as a member of our board of directors since the closing of the
Azur Merger in January 2012. Mr. Mulligan was a founder and principal investor of Azur
Pharma and was Azur Pharma’s Chairperson and Chief Executive Officer as well as being a
member of its board of directors from 2005 until January 2012. Mr. Mulligan also served as our
Chief Business Officer, International Business Development from January 2012 until February
2013. Between 2014 and 2018, Mr. Mulligan served as Chairperson and Chief Executive
Officer of Adapt Pharma Limited or “Adapt Pharma”, a specialty pharmaceutical company,
which was acquired in October 2018 by Emergent BioSolutions Inc., a multinational specialty
biopharmaceutical company. Mr. Mulligan acted as a Consultant to Emergent BioSolutions Inc.
from October 2018 to March 2019, when he was appointed to the board. He resigned from the
board in May 2020. From 2006 to 2017, Mr. Mulligan served as Executive Chairperson of Circ
Pharma Limited and its subsidiaries, a pharmaceutical development stage group. From 1984
until 2004, Mr. Mulligan held various positions with Elan Corporation, plc, a pharmaceutical
company, most recently as Executive Vice President, Business and Corporate Development,
and prior to that position, held the roles of President of Elan Pharmaceutical Technologies, the
drug delivery division of Elan Corporation, plc, Executive Vice President, Pharmaceutical
Operations, Vice President, U.S. Operations and Vice President, Product Development. Mr.
Mulligan served as a member of the board of directors of the U.S. National Pharmaceutical
Council until 2004. Mr. Mulligan holds a B.Sc. (Pharm) and M.Sc. from Trinity College Dublin.
As a founder of Adapt Pharma and Azur Pharma, and a pharmaceutical industry executive, Mr.
Mulligan brings to our board of directors an expertise in business development and over 35
years of experience in the pharmaceutical industry.

Norbert G. Riedel, Ph.D.
Executive Chairperson, Aptinyx Inc.

Norbert G. Riedel, Ph.D., age 64, has served as a member of our board of directors since May
2013 and was appointed chairperson of our compensation committee in August 2013. Dr.
Riedel has served as Executive Chairperson of Aptinyx Inc. since January 2022 and previously
served as Chief Executive Officer from September 2015 to December 2021 and as President
from September 2015 to December 2020. Aptinyx Inc. is a biopharmaceutical company spun
out of its predecessor company, Naurex, Inc., where Dr. Riedel served as Chief Executive
Officer and President from January 2014 to September 2015. From 2001 to 2013, he served as
Corporate Vice President and Chief Scientific Officer of Baxter International Inc., a diversified
healthcare company, where from 1998 to 2001, he also served as President and General
Manager of the recombinant therapeutic proteins business unit and Vice President of Research
and Development of the bioscience business unit. From 1996 to 1998, Dr. Riedel served as
head of worldwide biotechnology and worldwide core research functions at Hoechst-Marion
Roussel, now Sanofi, a global pharmaceutical company. Dr. Riedel served on the board of
directors of Ariad Pharmaceuticals, Inc., an oncology company, from May 2011 until the
company was acquired in February 2017. Dr. Riedel currently serves on the boards of directors
of three other publicly-held companies, Aptinyx Inc., Eton Pharmaceuticals, Inc., a development
stage pharmaceutical company, where he also serves as Chairperson of the board, and
Cerevel Therapeutics Holdings, Inc., a biopharmaceutical company. Dr. Riedel also currently
serves on the board of directors of a non-profit organization, the Illinois Biotechnology Industry
Organization, and is a member of the Austrian Academy of Sciences. Dr. Riedel is an Adjunct
Professor at Boston University School of Medicine and an Adjunct Professor of Medicine at
Northwestern University’s Feinberg School of Medicine. Dr. Riedel holds a Diploma in
biochemistry and a Ph.D. in biochemistry from the University of Frankfurt. Dr. Riedel brings
significant scientific, drug discovery and development, and commercial expertise to our board
of directors with over 20 years of experience in the biotechnology and pharmaceutical
industries.

Director since 2012

Age 61

Key Qualifications and Expertise:
As a founder of Azur Pharma and a
pharmaceutical industry executive,
Mr. Mulligan brings to our board of
directors an expertise in business
development and over 35 years of
experience in the pharmaceutical
industry.

Committee Assignments:

• None*

Other Current Public Company
Boards:

• None

* While Mr. Mulligan is not a member of
any of our three standing committees of
the board, he serves as Chair of our
Transaction Committee.

Director since 2013

Age 64

Key Qualifications and Expertise:
Dr. Riedel brings significant scientific,
drug discovery and development, and
commercial expertise to our board of
directors with over 20 years of experience
in the biotechnology and pharmaceutical
industries.

Committee Assignments:

• Compensation Committee. Chair of
Compensation Committee until April
2022.

• Chair of advisory Science and

Medicine Committee since April
2022.

Other Current Public Company
Boards:

• Aptinyx Inc.
• Cerevel Therapeutics Holdings, Inc.
• Eton Pharmaceuticals, Inc.

The board of directors recommends a vote “FOR” each nominee named above.

20

2022 Proxy Statement | JAZZ PHARMACEUTICALS

2022 NOTICE OF MEETING AND PROXY STATEMENT

Proposal 1 (continued)

Class III Directors Continuing Until the 2023 Annual Meeting

Bruce C. Cozadd
Chairperson and Chief Executive Officer of Jazz Pharmaceuticals plc

Bruce C. Cozadd has served as our Chairperson and Chief Executive Officer since the closing
of the Azur Merger in January 2012, and from October 2019 through March 2020, he served as
our interim principal financial officer. Mr. Cozadd co-founded Jazz Pharmaceuticals, Inc. and
has served as Chairperson and Chief Executive Officer of Jazz Pharmaceuticals, Inc. since
April 2009. From 2003 until 2009, he served as Jazz Pharmaceuticals, Inc.’s Executive
Chairperson and as a member of its board of directors. From 1991 until 2001, he held various
positions with ALZA Corporation, a pharmaceutical company acquired by Johnson & Johnson,
most recently as Executive Vice President and Chief Operating Officer, with responsibility for
research and development, manufacturing and sales and marketing. Previously at ALZA
Corporation, he held the roles of Chief Financial Officer and Vice President, Corporate Planning
and Analysis. Mr. Cozadd serves on the board of Acelyrin, Inc., a clinical stage biotechnology
company. Mr. Cozadd also serves on the board of Biotechnology Innovation Organization, a
biotechnology trade association, where he serves on its Health Section Governing Board. He
also serves on the boards of two non-profit organizations, The Nueva School and SFJAZZ. Mr.
Cozadd previously served on the boards of directors of Cerus Corporation from 2001 to
January 2018 and Threshold Pharmaceuticals, Inc. from 2005 to August 2017. He received a
B.S. from Yale University and an M.B.A. from the Stanford Graduate School of Business. As a
co-founder and our Chief Executive Officer of over 10 years, he brings to our board a deep and
comprehensive knowledge of our business, as well as shareholder-focused insight into
effectively executing the company’s strategy and business plans to maximize shareholder
value.

y
x
o
r
P

Director since 2003*

Age 58

Key Qualifications and Expertise:
As a co-founder and our Chief Executive
Officer of over 10 years, he brings to our
board a deep and comprehensive
knowledge of our business, as well as
shareholder-focused insight into
effectively executing the company’s
strategy and business plans to maximize
shareholder value.

Committee Assignments:

• None

Other Current Public Boards:

• None

* Includes service on the board of
directors of Jazz Pharmaceuticals, Inc.,
our predecessor.

Heather Ann McSharry
Director International Airlines Group, S.A.

Heather Ann McSharry has served as a member of our board of directors since May 2013 and
was appointed as chairperson of our nominating and corporate governance committee in
August 2017. Ms. McSharry has served as a non-executive director on the board of directors of
International Airlines Group, S.A since 2020. From 2006 to 2009, Ms. McSharry was Managing
Director Ireland of Reckitt Benckiser, a multinational health, home and hygiene consumer
products company. From 1989 to 2006, she held various positions at Boots Healthcare, a
leading global consumer healthcare company, most recently as Managing Director of Boots
Healthcare Ireland Limited. Ms. McSharry served on the boards of directors of the Bank of
Ireland from 2007 to 2011, the Industrial Development Agency in Ireland from 2010 to 2014,
Uniphar plc from 2019 to 2020, Greencore Group plc from 2013 to 2021 and CRH plc from
2012 to 2021. Ms. McSharry holds a Bachelor of Commerce and a Master of Business Studies
degree from University College Dublin. Ms. McSharry brings to our board of directors over 30
years of experience in multiple international industries, including healthcare, consumer goods
and financial services, as well as expertise in crisis management, cybersecurity and privacy
issues relevant to our business.

Director since 2013

Age 60

Key Qualifications and Expertise:
Ms. McSharry brings to our board of
directors over 30 years of experience in
multiple international industries, including
healthcare, consumer goods and financial
services, as well as expertise in crisis
management, cybersecurity and privacy
issues relevant to our business.

Committee Assignments:

• Audit Committee
• Nominating & Corporate Governance

Committee (Chair)

Other Current Public Boards:

• International Airlines Group, S.A.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

21

2022 NOTICE OF MEETING AND PROXY STATEMENT

Proposal 1 (continued)

Anne O’Riordan
Group Director of Digital, Jardine Matheson Limited

Anne O’Riordan has served as a member of our board of directors since February 2019. Since
June 2019, Ms. O’Riordan has served as Group Director of Digital of Jardine Matheson Limited,
an Asian conglomerate headquartered in Hong Kong, where she also serves on the board of
directors. From 1990 to March 2019, Ms. O’Riordan held various leadership positions in the life
sciences industry group in each of the operating units of Accenture (formerly Andersen
Consulting) in North America, Europe and Asia Pacific. She most recently served as Global
Industry Senior Managing Director of Accenture’s Life Sciences Business from 2012 to 2019.
Between 2008 and 2012, Ms. O’Riordan led Accenture’s life sciences practice in Asia Pacific,
focusing on strategic client development, market entry and business transformation. Prior to
that, she led Accenture’s European health and life sciences business, working with clients
across Europe on significant regional transformation initiatives. She also spent nine years in
North America working with pharmaceutical and medical products clients. She currently serves
on the board of governors of the American Chamber of Commerce in Hong Kong, or AmCham
Hong Kong, where she serves as the board liaison for the Healthcare Committee and is on the
board of the International Women’s Forum Hong Kong where she serves as the Treasurer. She
is also a long-standing member of the Women’s Foundation and the 30% Club. Ms. O’Riordan
received a B.Sc in Biotechnology from Dublin City University as well as a postgraduate diploma
in Financial Accounting and MIS from the National University of Ireland, Galway. Ms. O’Riordan
brings to our board of directors nearly 30 years of knowledge and leadership experience
advising life sciences and healthcare companies across the globe, with a uniquely diverse
perspective attributable to her geographic residency in Asia. Ms. O’Riordan’s background in
advising life sciences companies with respect to significant global markets provides an
important contribution to our board of director’s mix of backgrounds, experiences and skills.

Rick E Winningham
Chairperson and Chief Executive Officer, Theravance Biopharma, Inc.

Rick E Winningham has served as a member of our board of directors since the closing of the
Azur Merger in January 2012 and was a director of Jazz Pharmaceuticals, Inc. from 2010 until
the closing of the Azur Merger. In May 2014, Mr. Winningham was appointed as Lead
Independent Director of our board of directors. Mr. Winningham has served as Chairperson of
the board of directors of Theravance Biopharma, Inc., a biopharmaceutical company, since July
2013. He has served as Chief Executive Officer of Theravance Biopharma, Inc. since its spin-
off from Innoviva, Inc. in June 2014. From October 2001 to August 2014, Mr. Winningham
served as Chief Executive Officer of Innoviva, Inc., where he also served as Chairperson of the
board of directors from April 2010 to October 2014. From 1997 to 2001, he served as President
of Bristol-Myers Squibb Oncology/Immunology/Oncology Therapeutics Network and, from 2000
to 2001, as President of Global Marketing. Mr. Winningham is a member of Biotechnology
Industry Organization’s board of directors and serves on the Health Section Governing Board
Standing Committee on Reimbursement. He previously served as a member of the board of
directors of Retrotope, Inc., a private biotechnology company focused on cell degeneration,
from February 2021 to January 2022 and OncoMed Pharmaceuticals, Inc. from June 2015 until
the company’s merger with Mereo BioPharma Group plc in April 2019. He also served as a
member of the board of directors of the California Healthcare Institute, or CHI, from November
2011 to March 2015 and served as its Chairperson from January 2014 until CHI merged with
Bay Area Bioscience Association to become the California Life Sciences Association, or CLSA,
in March 2015. Mr. Winningham is on the board of directors of CLSA, and served as its
Chairperson from March 2015 until November 2015. Mr. Winningham holds an M.B.A. from
Texas Christian University and a B.S. from Southern Illinois University. Mr. Winningham’s
experience in senior management positions in the pharmaceutical industry provides significant
industry knowledge and operational and management expertise to our board of directors.

Director since 2019

Age 54

Key Qualifications and Expertise:
Ms. O’Riordan brings to our board of
directors nearly 30 years of knowledge
and leadership experience advising life
sciences and healthcare companies
across the globe, with a uniquely diverse
perspective attributable to her geographic
residency in Asia. Ms. O’Riordan’s
background in advising life sciences
companies with respect to significant
global markets provides an important
contribution to our board of director’s mix
of backgrounds, experiences and skills.

Committee Assignments:

• Audit Committee
• Nominating and Corporate

Governance Committee since April
2022

Other Current Public Boards:

• None

Director since 2010*

Age 62

Key Qualifications and Expertise:
Mr. Winningham’s experience in senior
management positions in the
pharmaceutical industry provides
significant industry knowledge and
operational and management expertise to
our board of directors.

Committee Assignments:

• Nominating & Corporate Governance

Committee

Other Current Public Boards:

• Theravance Biopharma, Inc.

* Includes service on the board of
directors of Jazz Pharmaceuticals, Inc.,
our predecessor.

22

2022 Proxy Statement | JAZZ PHARMACEUTICALS

2022 NOTICE OF MEETING AND PROXY STATEMENT

Proposal 1 (continued)

Class I Directors Continuing Until the 2024 Annual Meeting

Peter Gray
Chairperson, Teckro, Inc. and Abzena

Peter Gray has served as a member of our board of directors since May 2013 and was
appointed as chairperson of our audit committee in April 2014. He is Chairperson of a
privately-held company providing outsourced technology services to the biopharma industry,
Chairperson of a privately-held large molecule development company, and chairs a non-profit
educational establishment. He served as Chairperson of the board of directors of UDG
Healthcare plc, an international provider of healthcare services, from February 2012 to
September 2020. In September 2011, Mr. Gray retired from his position as Chief Executive
Officer of ICON plc, a global provider of outsourced development services to the
pharmaceutical, biotechnology and medical device industries, which he held since November
2002. At ICON plc, Mr. Gray previously served as Group Chief Operating Officer from June
2001 to November 2002 and Chief Financial Officer from June 1997 to June 2001. From
November 1983 to November 1989, Mr. Gray served as senior financial officer at Elan
Corporation plc, a pharmaceutical company. Mr. Gray holds a degree in law from Trinity
College Dublin and qualified as a chartered accountant in 1981. Given his experience as
Chief Executive Officer and Chief Financial Officer of ICON plc, Mr. Gray brings to our board
of directors and audit committee over 30 years of experience in financial and operational
management within the pharmaceutical industry.

Kenneth W. O’Keefe
Managing Director of Beecken Petty O’Keefe & Company

Kenneth W. O’Keefe has served as a member of our board of directors since the closing of
the Azur Merger in January 2012 and was a director of Jazz Pharmaceuticals, Inc. from 2004
until the closing of the Azur Merger. Since January 2018, he has been Managing Director of
Beecken Petty O’Keefe & Company, a private equity firm, which he co-founded. From
November 2015 to January 2018, he was Chief Executive Officer, from January 2011 to
November 2015, he was Managing Partner, and from 1997 to January 2011, he was
Managing Director, of Beecken Petty O’Keefe & Company. He serves on the boards of
several privately-held healthcare companies. He received a B.A. from Northwestern
University and an M.B.A. from the University of Chicago. As a member of Beecken Petty
O’Keefe & Company, Mr. O’Keefe brings to our board of directors’ significant expertise in
accounting and financial matters and in analyzing and evaluating financial statements, as well
as substantial experience managing private equity investments. He serves or has served on
the audit committee of several companies in the healthcare industry. As the former
chairperson and current member of our audit committee, Mr. O’Keefe brings to our board of
directors detailed knowledge of our financial position and financial statements.

Director since 2013

Age 67

Key Qualifications and Expertise:
Given his experience as Chief Executive
Officer and Chief Financial Officer of ICON
plc, Mr. Gray brings to our board of
directors and audit committee over 30
years of experience in financial and
operational management within the
pharmaceutical industry.

y
x
o
r
P

Committee Assignments:

• Audit Committee (Chair)

Other Current Public Boards:

• None

Director since 2004*

Age 55

Key Qualifications and Expertise:
As a member of Beecken Petty O’Keefe &
Company, Mr. O’Keefe brings to our board
of directors significant expertise in
accounting and financial matters and in
analyzing and evaluating financial
statements, as well as substantial
experience managing private equity
investments. He serves or has served on
the audit committee of several companies
in the healthcare industry. As the former
chairperson and current member of our
audit committee, Mr. O’Keefe brings to our
board of directors detailed knowledge of
our financial position and financial
statements.

Committee Assignments:

• Audit Committee

Other Current Public Boards:

• None

*Includes service on the board of directors
of Jazz Pharmaceuticals, Inc., our
predecessor.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

23

Proposal 1 (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

Mark D. Smith, M.D.
Professor, University of California, San Francisco and Director, Teladoc Health, Inc. and
Phreesia, Inc.

Director since 2020

Age 70

Mark D. Smith, M.D. has served as a member of our board of directors since December 2020.
Dr. Smith is a practicing physician and professor of clinical medicine at the University of
California at San Francisco, where he has served since 1994. He also serves as a non-
executive director on the boards of directors of two other publicly-held companies, Teladoc
Health, Inc., a telemedicine and virtual healthcare company, and Phreesia, Inc., a healthcare
software company. Dr. Smith also serves on the board of directors of the Commonwealth
Fund, a private health policy foundation. From 1996 to 2013, Dr. Smith was the founding
President and Chief Executive Officer of the California HealthCare Foundation, an
independent nonprofit philanthropy organization. From 1991 to 1996, he served as Executive
Vice President at the Henry J. Kaiser Family Foundation. Dr. Smith received a B.A. from
Harvard College, an M.D. from the University of North Carolina at Chapel Hill and an M.B.A.
from The Wharton School at the University of Pennsylvania. Dr. Smith brings to our board of
directors an impressive background that marries the worlds of active medical practice and
business development. A practicing physician and professor, Dr. Smith also has experience
working for a variety of health focused companies both public and private. Additionally, Dr.
Smith allocates part of his time for nonprofit organizations and a health policy foundation.

Key Qualifications and Expertise:
Dr. Smith brings to our board of directors
an impressive background that marries the
worlds of active medical practice and
business development. A practicing
physician and professor, Dr. Smith also
has experience working for a variety of
health focused companies both public and
private. Additionally, Dr. Smith allocates
part of his time for nonprofit organizations
and a health policy foundation.

Committee Assignments:

• Nominating & Corporate Governance

Committee since April 2021

Other Current Public Company Boards:

• Phreesia, Inc.
• Teladoc Health, Inc.

Catherine A. Sohn, Pharm.D.
Chairperson, BioEclipse Therapeutics Inc., and Director, Axcella Health Inc., Landec
Corporation and Rubius Therapeutics

Director since 2012

Age 69

Catherine A. Sohn, Pharm.D. has served as a member of our board of directors since July
2012. Dr. Sohn also serves as a non-executive director on the boards of directors of three
other publicly-held companies: Axcella Health Inc., a biotechnology company, Landec
Corporation, a life sciences company, and Rubius Therapeutics, a biotechnology company.
From January 2014 to May 2017, Dr. Sohn served as an independent director on the board of
directors of Neuralstem, Inc., a publicly traded life sciences company. She also serves as
Chairperson of the board of BioEclipse Therapeutics, Inc., a privately-held clinical-stage
biopharmaceutical company. From 1998 to 2010, she was Senior Vice President, Worldwide
Business Development and Strategic Alliances at GlaxoSmithKline Consumer Healthcare
responsible for leading numerous U.S., regional and global partnering deals, and acquisitions.
From 1994 to 1998, she was Vice President, Worldwide Strategic Product Development at
SmithKline Beecham Pharmaceuticals plc in the pharmaceutical division. From 1982 to 1994,
she held a series of positions in Medical Affairs, Pharmaceutical Business Development and
U.S. Product Marketing, including leading the launch of the U.S. Vaccine business and
subsequently the commercialization of the company’s largest neuroscience product at
SmithKline Beecham Pharmaceuticals plc and its predecessor, Smith, Kline & French. Dr.
Sohn holds the position of Adjunct Professor at the University of California, San Francisco.
She received a Doctor of Pharmacy from the University of California, San Francisco, School
of Pharmacy and a Certificate of Professional Development from the Wharton School at the
University of Pennsylvania. Dr. Sohn was named Woman of the Year by the Healthcare
Businesswomen’s Association (2003), Distinguished Alumnus of the Year by the University of
California, San Francisco (2000), the Frank Barnes Mentoring Award from the Licensing
Executive Society, and has completed executive education on Corporate Governance, Audit
and ESG at Harvard Business School and Berkeley Law. Dr. Sohn brings to our board of
directors three decades of product development, strategy, commercial launch and business
development transaction experience in the pharmaceutical industry and a global perspective
that is directly relevant to our company.

Key Qualifications and Expertise:
Dr. Sohn brings to our board of directors
three decades of product development,
strategy, commercial launch and business
development transaction experience in the
pharmaceutical industry and a global
perspective that is directly relevant to our
company.

Committee Assignments:

• Compensation Committee
• Nominating & Corporate Governance

Committee until April 2022

Other Current Public Company Boards:

• Axcella Health Inc.
• Landec Corporation
• Rubius Therapeutics

There are no family relationships among any of our executive officers and directors.

24

2022 Proxy Statement | JAZZ PHARMACEUTICALS

2022 NOTICE OF MEETING AND PROXY STATEMENT

CORPORATE GOVERNANCE AND BOARD MATTERS

Overview

We are committed to exercising good corporate governance practices. In furtherance of this commitment, we
regularly monitor developments in the area of corporate governance and review our processes, policies and
procedures in light of such developments. Key information regarding our corporate governance initiatives can be
found on our website, www.jazzpharmaceuticals.com, including our Corporate Governance Guidelines, Code of
Conduct, and the charters for our audit, compensation and nominating and corporate governance committees.
We believe that our strong corporate governance policies and practices, including the substantial percentage of
independent directors on our board of directors and the robust duties of our Lead Independent Director, empower
our independent directors to effectively oversee our management—including the performance of our Chief
Executive Officer—and provide an effective and appropriately balanced board governance structure. In addition,
we believe that our directors are all actively and constructively engaged in the exercise of their duties and
responsibilities, with each independent director serving on at least one board committee and engaging with
management between board meetings to remain well-informed of our strategy and our business.

y
x
o
r
P

Independence of the Board of Directors

As required under the Nasdaq listing standards, a majority of the members of a listed company’s board of
directors must qualify as “independent,” as affirmatively determined by the board of directors. Our board of
directors consults with counsel to ensure that the board’s determinations are consistent with relevant securities
and other laws and regulations regarding the definition of “independent,” including those set forth in the applicable
Nasdaq listing standards, as in effect from time to time. Consistent with these considerations, after review of all
relevant transactions or relationships between each director, or any of his or her family members, and our
company, our senior management and our independent registered public accounting firm, the board of directors
affirmatively determined that all of our current directors are independent directors within the meaning of the
applicable Nasdaq listing standards, except that Mr. Cozadd, our Chairperson and Chief Executive Officer, is not
independent by virtue of his employment with our company. In addition, our board of directors has determined
that each member of the audit committee, compensation and management development committee (which we
refer to in this proxy statement as the compensation committee) and nominating and corporate governance
committee meets the applicable Nasdaq and SEC rules and regulations regarding “independence” and that each
member is free of any relationship that would impair his or her individual exercise of independent judgment with
regard to the company.

Board Leadership Structure

Mr. Cozadd has served as our Chairperson and Chief Executive Officer since the closing of the Azur Merger in
January 2012. He co-founded Jazz Pharmaceuticals, Inc. in 2003 and served as its Chairperson and Chief
Executive Officer since April 2009 and, prior to that, as Executive Chairperson.

The board of directors believes that the Chief Executive Officer is best suited to serve as our Chairperson
because he is the member of the board of directors who is most familiar with our business as a whole, and the
most capable of identifying and bringing to the attention of the full board of directors the strategic priorities and
key issues facing the company. The board of directors also believes that having Mr. Cozadd in particular in a
combined Chairperson/Chief Executive Officer role helps provide strong, unified leadership for our management
team and optimizes communication with our board of directors. In addition, having previously served for many
years as a director of other publicly-traded and privately-held companies, as well as in executive management
roles, Mr. Cozadd brings both a strategic and operational perspective to this combined position.

In addition to our Chairperson, our Lead Independent Directors plays an important role on the board. Our
Corporate Governance Guidelines require the independent directors to elect a Lead Independent Director when
the roles of Chairperson and Chief Executive Officer are held by the same person. Rick Winningham currently
serves as our Lead Independent Director.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

25

Corporate Governance and Board Matters (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

A critical function of the Lead Independent Director is to help to ensure the effective independent functioning of
the board of directors.

Accordingly, specific roles and responsibilities of the Lead Independent Director, which are detailed in our
Corporate Governance Guidelines, include:

•

•

•

•

•

serving as the principal liaison between the independent directors and the Chairperson;

coordinating the activities of the independent directors, including developing agendas for and presiding at
executive sessions of the independent directors;

advising the Chairperson on board and committee agendas, meeting schedules and information provided to
other board members, including the quality, quantity and timeliness of such information that is necessary or
appropriate for the directors to effectively and responsibly perform their duties;

discussing the results of the Chief Executive Officer’s performance evaluation with the chair of the
compensation committee; and

presiding at all meetings of the board of directors at which the Chairperson is not present.

The Lead Independent Director also has the authority to call meetings of the independent directors of the board of
directors and is available for consultation and communication with significant shareholders. In addition to fulfilling
the basic requirements of his role as Lead Independent Director, Mr. Winningham attends meetings of
committees where he is not a member to remain informed and engaged, communicates with the Chief Executive
Officer on matters involving the company on a regular basis, regularly seeks input from other independent
directors relating to significant developments at the company between regular board meetings, attends certain
meetings at the company involving strategic portfolio and/or scientific reviews, and makes himself available for
direct communication with significant shareholders as necessary.

In addition, our board of directors is currently comprised of 12 directors, of whom 11 are independent. At meetings
of our board of directors, the independent directors regularly convene executive sessions without the presence of
our Chairperson and Chief Executive Officer and other members of management.

26

2022 Proxy Statement | JAZZ PHARMACEUTICALS

2022 NOTICE OF MEETING AND PROXY STATEMENT

Corporate Governance and Board Matters (continued)

Risk Oversight

We believe that our directors provide effective oversight of risk management for our company (including
financial, operational, business, intellectual property, information technology (including cybersecurity) and
reputational risk, governance and compliance), particularly as a result of the work of our committees and the
ongoing dialogue between the full board, our Chairperson and Chief Executive Officer and our active and
engaged Lead Independent Director.

At its meetings, our full board of directors receives reports concerning the management of the relevant risks
from each committee, in addition to reports concerning material risks and concerns or significant updates on
such matters from our Chief Legal Officer, Chief Compliance Officer and other executive officers, as necessary.

y
x
o
r
P

Our audit committee is responsible for overseeing our financial reporting process on
behalf of our board of directors and reviewing with management and our auditors, as
appropriate, our major financial risk exposures and the steps taken by management to
monitor and control these exposures. Our board of directors has also formalized our
audit committee’s role in oversight of risks related to information security, including
cybersecurity. In its oversight role, the audit committee receives quarterly updates on
information security developments, cybersecurity incidents and the steps taken by
management to monitor and mitigate risk exposures in these areas.

Our Compensation and Management Development Committee, or compensation
committee, approves compensation of executive officers and all material compensation
plans for our company and reviews our compensation practices to ensure that they do
not encourage excessive risk taking and provide appropriate incentives for meeting
both short-term and long-term objectives and increasing shareholder value over time.
Our compensation committee also works with our full board of directors to oversee
matters related to diversity, talent, and culture strategy including human capital
programs and policies regarding management development, talent planning, diversity
and inclusion initiatives, and employee engagement, as well as human capital
management, which includes reviewing workforce trends, executive succession plans
and talent risk and maintaining compensation objectives and corporate policies that
appropriately incentivize creating and maintaining a positive workplace and corporate
culture.

Our nominating and corporate governance committee oversees the company’s risk
management other than those concerning the company’s major financial, business or
cybersecurity risk exposures or risks related to our compensation programs and
policies, on behalf of our board of directors. Our nominating and corporate governance
committee maintains oversight over the company’s enterprise risk management
program and also has oversight responsibility over our ESG program and strategy. The
nominating and corporate governance committee has oversight responsibility related to
administration of and certifies to, compliance with the company’s corporate integrity
agreement, or CIA, including compliance with CIA requirements related to training and
disclosures of instances of potential non-compliance with certain federal laws,
regulations, or company policy and meets at least quarterly.

Audit
Committee

Compensation
and
Management
Development
Committee

Nominating
and Corporate
Governance
Committee

Ethical Business Practices

We are committed to conducting our business with integrity and the pursuit of excellence in all that we do. Our
management team and our board of directors are committed to honesty and compliance with all laws, rules,
regulations and corporate policies that apply to our business, and we expect the same commitment from our
employees, consultants, business partners and service providers. In particular, we are committed to acting

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

27

Corporate Governance and Board Matters (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

responsibly, safely and with transparency in our interactions with patients, doctors and other stakeholders in the
healthcare system.

Compliance and Ethics Program – I-CARE. I-CARE is our philosophy that acknowledges it takes more than just
mandated adherence to the law and company policy to create a healthy and ethical corporate culture. The
following elements comprise I-CARE:

•

•

•

•

•

Integrity: Our corporate value of integrity is the foundation of our approach.

Compliance: The elements of an effective compliance program are managed to deter, detect, and respond
appropriately to potential wrongdoing.

Accountability: Every employee plays a role in ensuring our actions live up to the company’s expectations,
and every employee is encouraged to speak up if something looks wrong.

Respect: Respect for our patients, company and each other keep us on the right path.

Ethics: Being lawful is the minimum bar we must meet. Our commitment to patients and other stakeholders
requires a higher ethical standard.

I-CARE strives to create a strong, effective compliance and ethics program by educating and advising our
employees to empower smart risk decisions, advance our value of integrity, and promote operational efficiencies.

We have established various methods of confidential communication for our employees, vendors and others to
report suspected violations of laws, rules, regulations or company policies. Where permitted by local laws,
anonymous reporting is available.

Compliance Committee. The compliance committee is comprised of members of our management team and
oversees the implementation and effectiveness of our compliance program and supports the Chief Compliance
Officer in:

•

Adoption of a system of standards of conduct, policies, procedures, trainings, communications, reporting
mechanisms, monitoring, investigations and internal control system reasonably designed, implemented,
enforced and effective in preventing and detecting violations of applicable laws, rules and regulations;

• Making periodic (at least quarterly) reports regarding compliance matters directly to the nominating and

corporate governance committee of the board of directors;

•

•

Assuring that the individuals responsible for the compliance and ethics program have adequate resources,
authority and competencies to carry out their responsibilities; and

Periodically reviewing the effectiveness of the day-to-day compliance activities engaged in by the company.

Board Compliance. The board of directors reviews and oversees matters related to compliance requirements
and inquires, and reviews our compliance program, including: the performance of the Chief Compliance Officer
and compliance committee; the adequacy of resources dedicated to the compliance function; the identification
and handling of non-compliance; and the overall effectiveness of the compliance program. In addition, the board
meets regularly with the Chief Compliance Officer during executive sessions.

Anti-Corruption Policy. Our global Anti-Corruption Policy applies to all of our employees, directors and officers,
our subsidiaries and affiliates, and third party vendors and other agents acting on our behalf. We are committed to
complying with applicable anti-corruption and anti-bribery laws, including the Foreign Corrupt Practices Act
(FCPA) and the UK Bribery Act (UKBA). The Anti-Corruption Policy is available on our website at
www.jazzpharmaceuticals.com under the section entitled “Ethical Standards” under “Our Purpose.”

Code of Conduct. Our Code of Conduct applies to all of our employees, directors and officers, including our
principal executive officer, principal financial officer, principal accounting officer or controller, or persons
performing similar functions, and those of our subsidiaries. The Code of Conduct is available on our website at
www.jazzpharmaceuticals.com under the section entitled “Ethical Standards” under “Our Purpose.” We intend to
satisfy the disclosure requirements under Item 5.05 of SEC Form 8-K regarding an amendment to, or waiver from,
a provision of our Code of Conduct by posting such information on our website at the website address and
location specified above.

28

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Corporate Governance and Board Matters (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

Political Contributions Guidance. Our Political Contributions Guidance outlines a process intended to ensure all
political contributions (including political action committee contributions) are made with transparency, segregated
from lobby activities, and that both are conducted in accordance with the applicable federal, state, and local
campaign and lobbying laws.

Meetings of the Board of Directors
The board of directors met twelve times and acted by written consent three times during 2021. All directors
attended at least 75% of the aggregate number of meetings of the board of directors and of the committees on
which they served that were held during 2021. As required under applicable Nasdaq listing standards, in 2021, the
independent directors generally met at each regular board meeting in scheduled executive sessions at which only
independent directors were present.

y
x
o
r
P

Director Commitments
Our board of directors believes that all members of the board should have sufficient time and attention to devote
to board duties and to otherwise fulfill the responsibilities required of directors. In assessing whether directors and
nominees for director have sufficient time and attention to devote to board duties, the nominating and corporate
governance committee and our board of directors consider, among other things, whether directors may be
“overboarded,” which refers to the situation where a director serves on an excessive number of boards.

Our board of directors believes that each of our directors, including each of our director nominees, has
demonstrated the ability to devote sufficient time and attention to board duties and to otherwise fulfill the
responsibilities required of directors.

However, we understand that certain institutional investors and proxy advisory firms may have deemed Dr. Riedel
overboarded last year based on his role as CEO at Aptinyx and the number of public company boards on which
he serves. Nevertheless, we have determined none of our directors are currently overboarded. In particular,
Dr. Riedel serves on the boards of directors of three other public companies: Cerevel Therapeutics Inc., Eton
Pharmaceuticals, Inc., and Aptinyx Inc. Our board of directors does not believe that Dr. Riedel’s outside boards or
other commitments limit his ability to devote sufficient time and attention to his duties as a director of Jazz
Pharmaceuticals. Our board of directors believes that Dr. Riedel has demonstrated, and will continue to
demonstrate, his ability to dedicate sufficient time to carry out his board duties effectively as an active member of
our board of directors and believes that it is in the company’s best interest that he continue to serve as a director
for the following reasons:

•

•

•

•

•

•

•

In January 2022, Dr. Riedel transitioned out of his role of President and CEO at Aptinyx and is now Aptinyx’s
Executive Chairperson. His new role at Aptinyx significantly reduces his time commitment at Aptinyx, and
Dr. Riedel will devote only 60% of his working time to the role of executive chairperson at Aptinyx. He is no
longer involved in the day to day running of Aptinyx.

At Jazz, Dr. Riedel is also stepping down as chair of the compensation committee in connection with his
transition into the role as Chair of our newly formed advisory Science and Medicine Committee where he will
leverage his extensive experience.

Dr. Riedel is consistently prepared and has exemplary participation at meetings of our board of directors and
compensation committee, as demonstrated by his insightful questions and comments, and he contributes
significantly to discussions and decision making.

He is also appropriately engaged with management and the other members of our board of directors outside
of meetings of the board of directors and compensation committee including attending certain meetings at the
company involving strategic portfolio, scientific and similar reviews.

Dr. Riedel’s attendance record demonstrates his commitment to our board of directors, participating in 100%
of board meetings and 100% of compensation committee meetings for the past three years.

Dr. Riedel’s experience in senior management positions in the pharmaceutical industry provides significant
industry knowledge and operational and management expertise to our board of directors.

His experience on the boards of directors of other public companies will benefit us by providing him with
insight and experience that enhances his value to our board of directors.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

29

Corporate Governance and Board Matters (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

•

Dr. Riedel has assured our board that his ongoing commitments to Cerevel, Eton and Aptinyx are not
expected to exceed the demands that existed in past years and will continue to not detract from his service on
our board of directors going forward.

Classified Board Structure

Our board of directors is divided into three classes, designated Class I, Class II and Class III. Our nominating and
corporate governance committee has discussed the shareholder feedback received on the topic of our classified
board structure and continues to believe that this structure is appropriate for our company and beneficial to our
shareholders. In particular, the nominating and corporate governance committee believes that the classified board
structure:

•

•

•

promotes stability and continuity, allowing our board and management to remain focused on our long-term
strategy and value generation for our shareholders;

allows for the development of institutional knowledge at the board level, which is particularly important in our
industry, given the multi-year life cycles of our product development programs; and

enhances director independence by decreasing pressures from special interest groups that might have short-
term agendas contrary to the long-term interests of our shareholders.

Moreover, a classified board for an Irish company does not present the same entrenchment risk as for a typical
U.S. company due to the ability of shareholders to refresh the board at any time under Irish law.

Information About Board Committees

The standing committees of the board of directors include an audit committee, the compensation committee, and
a nominating and corporate governance committee. Each of these committees is comprised solely of independent
directors, has a chair and has a written charter approved by the board of directors reflecting applicable standards
and requirements adopted by the SEC and Nasdaq. A copy of the standing committees’ charters can be found on
our website, www.jazzpharmaceuticals.com, in the section titled “About” under the subsection titled “Board of
Directors.”

30

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Corporate Governance and Board Matters (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

The following table provides membership information for 2021 for each of the audit, compensation, and
nominating and corporate governance committees of our board of directors

Name

Jennifer E. Cook

Patrick G. Enright

Peter Gray

Heather Ann McSharry

Kenneth W. O’Keefe

Anne O’Riordan

Norbert G. Riedel, Ph.D.

Mark D. Smith

Catherine A. Sohn, Pharm.D.

Audit

Š
C
Š
Š
Š

Nominating and Corporate
Governance2

Compensation1
Š
Š

y
x
o
r
P

C

Š
Š
Š

C

Š

Rick E Winningham

C = committee chairperson
1

Š = committee member

Jennifer E. Cook was appointed as a member of our compensation committee in April 2021. Paul L. Berns resigned from our board and
compensation committee effective as of our 2021 annual general meeting of shareholders held in July 2021.

2 Mark D. Smith was appointed as a member of our nominating and corporate governance committee in April 2021. Since Elmar Schnee

did not stand for re-election when his term expired at our 2021 annual general meeting of shareholders held in July 2021, his term expired
on the nominating and corporate governance committee in July 2021.

Audit Committee

The audit committee of the board of directors oversees our corporate accounting and financial reporting
processes, our systems of internal control over financial reporting and audits of our financial statements, the
quality and integrity of our financial statements and reports, the qualifications, independence and performance of
the auditors engaged as our independent registered public accounting firm for purposes of preparing or issuing an
audit report or performing audit services and certain enterprise risk issues. Specific responsibilities of the audit
committee include:

•

•

•

•

evaluating the performance of and assessing the qualifications of the independent auditors;

determining and approving the engagement and remuneration of the independent auditors;

determining whether to retain or terminate the existing independent auditors or to appoint and engage new
independent auditors;

determining and approving the engagement of the independent auditors to perform any proposed permissible
non-audit services;

• monitoring the rotation of partners of the independent auditors on our audit engagement team as required by

applicable laws and rules;

•

•

reviewing and advising on the selection and removal of the head of our internal audit function, the activities
and organizational structure of the internal audit function and the results of internal audit activities;

reviewing and approving the internal audit charter at least annually and the annual internal audit plan and
budget;

• meeting to review our annual audited financial statements, our quarterly financial statements and our financial
press releases with management and the independent auditors, including reviewing our disclosures under
“Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our
annual and quarterly reports filed with the SEC;

•

reviewing, overseeing and approving transactions between our company and any related persons;

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

31

Corporate Governance and Board Matters (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

•

•

•

•

conferring with management, the internal audit function and the independent auditors regarding the scope,
adequacy and effectiveness of our internal control over financial reporting;

reviewing with management, the internal audit function and the independent auditors, as appropriate, major
financial risk exposures, including reviewing, evaluating and approving our hedging and other financial risk
management policies, as well as the steps taken by management to monitor and control these exposures;

establishing procedures, when and as required under applicable laws and rules, for the receipt, retention and
treatment of any complaints received by our company regarding accounting, internal accounting controls or
auditing matters and the confidential and anonymous submission by employees of concerns regarding
questionable accounting or auditing matters; and

reviewing with management our information security (including cybersecurity) risk exposures and the steps
taken by management to monitor and mitigate these exposures.

The audit committee was during all of 2021 composed of Mr. Gray, Mr. Enright, Ms. McSharry, Mr. O’Keefe and
Ms. O’Riordan. Our board of directors has determined that each of Mr. Gray, Mr. Enright, Ms. McSharry,
Mr. O’Keefe and Ms. O’Riordan meets the independence requirements of Rule 10A-3 of the Securities Exchange
Act of 1934, as amended, or the Exchange Act, and the Nasdaq listing standards with respect to audit committee
members. Our board of directors has also determined that each of Mr. Gray, Mr. Enright, Ms. McSharry and
Mr. O’Keefe qualifies as an “audit committee financial expert” within the meaning of SEC regulations. In making
this determination, our board of directors considered the overall knowledge, experience and familiarity of each
with accounting matters, analyzing and evaluating financial statements, and, in the case of Mr. O’Keefe,
managing private equity investments, and, in the case of Mr. Enright, managing venture capital investments.
Mr. Gray serves as chair of the audit committee.

The audit committee met four times during 2021 and acted by written consent once during 2021. The audit
committee also had a number of informal discussions and consultations with one another, with our Chief Financial
Officer, our Chief Accounting Officer and our Head of Internal Audit and with Mr. Cozadd during 2021.

Report of the Audit Committee of the Board of Directors(1)

The audit committee has reviewed and discussed the company’s audited financial statements for the fiscal year
ended December 31, 2021 with management of the company. The audit committee has discussed with KPMG,
the independent registered public accounting firm that audited the company’s financial statements for the fiscal
year ended December 31, 2021, the matters required to be discussed by the applicable requirements of the
Public Company Accounting Oversight Board, or PCAOB, and the SEC. The audit committee has also received
the written disclosures and the letter from KPMG required by applicable requirements of the PCAOB regarding
the independent accountants’ communications with the audit committee concerning independence, and has
discussed with KPMG that firm’s independence. Based on the foregoing, the audit committee recommended to
the board of directors that the audited financial statements be included in the 2021 Annual Report on Form 10-K
filed with the SEC.

Respectfully submitted,
The Audit Committee of the Board of Directors

Mr. Peter Gray
Mr. Patrick Enright
Ms. Heather Ann McSharry
Mr. Kenneth W. O’Keefe
Ms. Anne O’Riordan

(1) The material under the heading “Report of the Audit Committee of the Board of Directors” in this proxy statement is not “soliciting

material,” is not deemed “filed” with the SEC and is not to be incorporated by reference in any filing of the company under the Securities
Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and
irrespective of any general incorporation language in any such filing.

32

2022 Proxy Statement | JAZZ PHARMACEUTICALS

2022 NOTICE OF MEETING AND PROXY STATEMENT

Corporate Governance and Board Matters (continued)

Compensation Committee

The compensation committee of the board of directors reviews and oversees our compensation policies, plans
and programs and reviews and generally determines the compensation to be paid to the executive officers and
directors, and prepares and reviews the compensation committee report included in our annual proxy statement.
Specific responsibilities and authority of our compensation committee include:

•

•

•

•

•

•

•

•

•

reviewing, modifying (as needed) and approving overall compensation strategy and policies;

recommending to our board of directors for determination and approval the compensation and other terms of
employment of our Chief Executive Officer and evaluating our Chief Executive Officer’s performance in light of
relevant goals and objectives;

y
x
o
r
P

reviewing and approving the goals and objectives of our other executive officers and determining and
approving the compensation and other terms of employment of these executive officers, as appropriate;

reviewing and recommending to our board of directors the type and amount of compensation to be paid or
awarded to the members of our board of directors;

having the full power and authority of our board of directors regarding the adoption, amendment and
termination of our compensation plans and programs and administering these plans and programs;

having direct responsibility for appointing, and providing compensation and oversight of the work of, any
compensation consultants and other advisors retained by the compensation committee and considering the
independence of each such advisor;

reviewing our practices and policies of employee compensation as they relate to risk management and risk-
taking incentives, to determine whether such compensation policies and practices are reasonably likely to
have a material adverse effect on our company;

periodically reviewing with our Chief Executive Officer the plans for succession to the offices of our executive
officers and making recommendations to our board of directors with respect to the selection of appropriate
individuals to succeed to these positions; and

reviewing and discussing with management our disclosures contained under the caption “Compensation
Discussion and Analysis” in our annual proxy statement.

The compensation committee was composed of five directors during 2021: Ms. Cook, Messrs. Berns and Enright,
Dr. Riedel and Dr. Sohn. Dr. Riedel served as the chair of the compensation committee. Ms. Cook was appointed
as a member of the compensation committee in April 2021 and appointed Chair of the compensation committee in
April 2022. Mr. Berns resigned as a director of Jazz Pharmaceuticals effective as of our 2021 annual general
meeting of shareholders. Each member of the compensation committee meets the independence requirements of
the Nasdaq listing standards with respect to compensation committee members. In determining whether
Mr. Berns, Mr. Enright, Dr. Riedel, Dr. Sohn and Ms. Cook are (or in the case Mr. Berns, was) independent within
the meaning of the Nasdaq listing standards pertaining to compensation committee membership, our board of
directors determined, based on its consideration of factors specifically relevant to determining whether any such
director has a relationship to us that is material to that director’s ability to be independent from management in
connection with the duties of a compensation committee member, that no member of the compensation
committee has (or in the case Mr. Berns, had) a relationship that would impair that member’s ability to make
independent judgments about compensation of our executive officers.

Compensation Committee Processes and Procedures

Our compensation committee meets as often as it determines necessary to carry out its duties and responsibilities
through regularly scheduled meetings and, if necessary, special meetings. The agenda for each compensation
committee meeting is usually developed by members of our human resources department and our Chief
Executive Officer, with input from members of our legal department, and is reviewed and finalized with the chair of
the compensation committee. Members of our human resources and legal departments also attend compensation

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

33

Corporate Governance and Board Matters (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

committee meetings. From time to time, various other members of management and other employees as well as
outside advisors or consultants may be invited by the compensation committee to make presentations, provide
financial or other background information or advice or otherwise participate in the compensation committee
meetings. The compensation committee met six times during 2021.

In making executive compensation determinations (other than for our Chief Executive Officer), the compensation
committee considers recommendations from our Chief Executive Officer. In making his recommendations, our
Chief Executive Officer receives input from our human resources department and from the individuals who
manage or report directly to the other executive officers, and he reviews various third party compensation surveys
and compensation data provided by the independent compensation consultant to the compensation committee,
as described in the section of this proxy statement entitled “Executive Compensation—Compensation Discussion
and Analysis.” While our Chief Executive Officer discusses his recommendations for the other executive officers
with the compensation committee, he does not participate in the deliberations and recommendations to our board
of directors concerning, or our board of directors’ determination of, his own compensation. The charter of the
compensation committee grants the compensation committee full access to all books, records, facilities and
personnel of the company, as well as authority to obtain, at our expense, advice and assistance from
compensation consultants and internal and external legal, accounting or other advisors and consultants and other
external resources that the compensation committee considers necessary or appropriate in the performance of its
duties. In particular, the compensation committee has the authority, in its sole discretion, to retain or obtain, at the
expense of the company, compensation consultants to assist in its evaluation of executive compensation, and is
directly responsible for the appointment, compensation and oversight of the work of its compensation consultants.
The compensation committee engages an independent compensation consultant each year to provide a
competitive compensation assessment with respect to the executive officers to assist the compensation
committee in making annual compensation decisions. Since 2010, Radford, a business area within Aon plc, or
Aon, has been engaged by the compensation committee each year to provide peer company and industry
compensation data and provide the compensation committee with advice regarding executive officers’
compensation, including base salaries, performance-based bonuses and long-term equity compensation, and
similar advice regarding non-employee director compensation.

The charter of the compensation committee provides that the compensation committee may delegate any
responsibility or authority of the compensation committee under its charter to the chair of the committee or to one
or more committee members, including subcommittees, except to the extent inconsistent with any applicable laws
and rules, including the Nasdaq listing standards. Our compensation committee does not, however, delegate any
of its functions to others in determining or recommending executive or director compensation.

For additional information regarding our processes and procedures for the consideration and determination of
executive compensation, including the role of Radford in determining and recommending executive
compensation, see the section of this proxy statement entitled “Executive Compensation—Compensation
Discussion and Analysis.” With respect to director compensation matters, our compensation committee
recommends to our board of directors and our board of directors determines and sets non-employee director
compensation. Our compensation arrangements for our non-employee directors are described under the section
of this proxy statement entitled “Director Compensation.”

Compensation Committee Interlocks and Insider Participation

None of Ms. Cook, Dr. Riedel, Messrs. Berns and Enright or Dr. Sohn was at any time our officer or employee
during 2021. None of our executive officers serve, or in the past fiscal year served, as a member of the board of
directors or the compensation committee of any entity that has one or more of its executive officers serving on our
board of directors or compensation committee.

Compensation Consultant Fees

Since 2010, Aon has been engaged by the compensation committee each year to provide peer company and
industry compensation data and provide the compensation committee with advice regarding executive officers’

34

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Corporate Governance and Board Matters (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

compensation, including base salaries, performance-based bonuses and long-term equity incentives, advice
regarding directors’ compensation as well as other matters under the compensation committee’s charter. In 2021,
the cost of Aon’s consulting services directly related to compensation committee support was approximately
$170,000.

Management also engaged with Aon for various insurance-related products and services, covering director and
officer liability insurance, health and benefits, pension-related services, other insurance brokerage services and
risk services to the business. The aggregate Aon revenue from these additional services in 2021 (not related to
Aon’s compensation committee consulting services) was approximately $8,280,000. Although the compensation
committee was aware of the nature of the services performed by Aon affiliates and the non-executive employee
compensation survey data provided by Aon, the compensation committee did not review and approve such
services, surveys and insurance premiums and policies, as those were reviewed and approved by management in
the ordinary course of business.

y
x
o
r
P

Aon maintains certain policies and practices to protect the independence of the executive compensation
consultants engaged by the compensation committee. In particular, Aon provides an annual update to the
compensation committee on the financial relationship between Aon and the company, and provides written
assurances that, within Aon, the Aon consultants who perform executive compensation services for the
compensation committee have compensation determined separately from Aon’s other lines of business and from
the other services it provides to the company. These safeguards were designed to help ensure that the
compensation committee’s executive compensation consultants continued to fulfill their role in providing
independent, objective advice.

Compensation Committee Report(1)

The compensation committee has reviewed and discussed with management the Compensation Discussion and
Analysis contained herein. Based on this review and discussion, the compensation committee has recommended
to the board of directors that the Compensation Discussion and Analysis be included in our proxy statement for
the 2022 annual general meeting of shareholders and be included in the company’s Annual Report on Form 10-K
we filed with the SEC for the fiscal year ended December 31, 2021.

Respectfully submitted,
The Compensation Committee of the Board of Directors

Ms. Jennifer E. Cook
Mr. Patrick G. Enright
Dr. Norbert G. Riedel
Dr. Catherine A. Sohn

(1) The material under the heading “Compensation Committee Report” in this proxy statement is not “soliciting material,” is not deemed “filed”
with the SEC and is not to be incorporated by reference in any filing of the company under the Securities Act of 1933, as amended, or the
Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation
language in any such filing.

Nominating and Corporate Governance Committee

The nominating and corporate governance committee of our board of directors is responsible for, among other
things:

•

overseeing all aspects of our corporate governance functions on behalf of our board of directors;

• making recommendations to our board of directors regarding corporate governance issues;

•

identifying, reviewing and evaluating candidates to serve on our board of directors, and reviewing and
evaluating incumbent directors;

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

35

Corporate Governance and Board Matters (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

•

•

•

•

•

•

reviewing, evaluating and considering the recommendation for nomination of incumbent members for
reelection to our board of directors and monitoring the size of our board;

recommending director candidates to our board of directors;

overseeing on behalf of our board of directors the company’s compliance with applicable laws and
regulations, other than the financial compliance issues overseen by the audit committee;

overseeing on behalf of our board of directors the company’s risk management matters, other than with
respect to risks that are financial or information security risks (as to which the audit committee has oversight
responsibility on behalf of our board of directors) or risks related to compensation policies (as to which the
compensation committee has oversight responsibility on behalf of our board of directors);

evaluating director nominations and proposals by our shareholders and establishing policies, requirements,
criteria and procedures in furtherance of the foregoing; and

reviewing, discussing and assessing the performance of our board of directors, including committees of our
board of directors, seeking input from all board members, senior management and others.

The nominating and corporate governance committee believes that candidates for director should have certain
minimum qualifications, including the ability to read and understand basic financial statements, being over 21
years of age, and the highest personal integrity and ethics. The nominating and corporate governance committee
also intends to consider such factors as possessing relevant expertise upon which to be able to offer advice and
guidance to management, having sufficient time to devote to our affairs, demonstrated excellence in his or her
field, having the ability to exercise sound business judgment and having the commitment to rigorously represent
the long-term interests of our shareholders. However, the nominating and corporate governance committee
retains the right to modify these qualifications from time to time. Members of the nominating and corporate
governance committee obtain recommendations for potential directors from their and other board members’
contacts in our industry, and we or the nominating and corporate governance committee have in the past and may
from time to time again in the future engage a search firm to assist in identifying potential directors. In this regard,
in 2020, we underwent a board refreshment program and candidate search for new directors. As part of that
search process, the nominating and corporate governance committee asked the search firm it engaged to
provide, and then considered, a set of candidates that included both underrepresented people of color and
different genders. In late 2020, after being considered and recommended by the nominating and corporate
governance committee, we added two additional diverse directors to our board: Dr. Smith and Ms. Cook.

Candidates for director nominees are reviewed in the context of the then current composition of the board of
directors, the operating requirements of the company and the long-term interests of shareholders. In this regard,
we examine the experience and expertise of our board as a whole to ensure alignment between the abilities and
contributions of our board and our strategic priorities and long-range plan, emphasizing, among other things,
expertise in global and U.S. sales and marketing, in product development, in financial management and in
corporate development transactions. In addition, while we do not have specific numerical targets with respect to
board diversity, the nominating and corporate governance committee’s policy is to take into account a broad
range of considerations when assessing director candidates, including individual backgrounds, gender, skill sets,
professional experience, geographic residency and other factors. The nominating and corporate governance
committee assesses the effectiveness of its diversity policy through its periodic evaluation of the composition of
the full board of directors. Recently, in recruiting and nominating candidates for our board of directors, our
nominating and corporate governance committee has focused on increasing diversity overall, including with
respect to gender and geographic residency.

Of the director nominees and the continuing directors, our board of directors has four female directors, four Irish
directors, one of whom is a non-resident, one director that identifies as LBGTQ and one person of color. In the
case of incumbent directors whose terms of office are set to expire, the nominating and corporate governance
committee reviews these directors’ overall service to the company during their terms, including the number of
meetings attended, level of participation, quality of performance and any other relationships and transactions that
might impair the directors’ independence, as well as the results of the board of directors’ self-evaluation, which is
generally conducted annually, to determine whether to recommend them to the board of directors for nomination
for a new term. In the case of new director candidates, the nominating and corporate governance committee also

36

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Corporate Governance and Board Matters (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

determines whether the nominee is “independent” based upon applicable Nasdaq listing standards, applicable
SEC rules and regulations and the advice of counsel, if necessary. The nominating and corporate governance
committee conducts appropriate and necessary inquiries into the backgrounds and qualifications of possible
candidates after considering the function and needs of the board of directors. The nominating and corporate
governance committee meets to discuss and consider the candidates’ qualifications and then selects a nominee
for recommendation to the board of directors.

The nominating and corporate governance committee will consider director candidates recommended by
shareholders on a case-by-case basis, as appropriate. Shareholders wishing to recommend individuals for
consideration by the nominating and corporate governance committee may do so by delivering a written
recommendation to our Company Secretary at Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland
with the candidate’s name, biographical data and qualifications and a document indicating the candidate’s
willingness to serve if elected. The nominating and corporate governance committee does not intend to alter the
manner in which it evaluates candidates based on whether the candidate was recommended by a shareholder or
not.

y
x
o
r
P

To date, the nominating and corporate governance committee has not received any such nominations nor has it
rejected a director nominee from a shareholder or shareholders.

Our nominating and corporate governance committee was composed of the following five directors during 2021:
Ms. McSharry, Dr. Smith, Mr. Schnee, Dr. Sohn and Mr. Winningham. Ms. McSharry serves as chair of the
nominating and corporate governance committee. In April 2021, Dr. Smith was appointed as a member of the
nominating and corporate governance committee, and Mr. Schnee resigned as a director of Jazz Pharmaceuticals
effective as of the 2021 annual general meeting of shareholders. Each member of the nominating and corporate
governance committee meets the independence requirements of the Nasdaq listing standards.

The nominating and corporate governance committee met five times during 2021.

Corporate Governance Strengths
We are committed to exercising good corporate governance practices. We believe that good governance
promotes the long-term interests of our shareholders and strengthens board and management accountability. The
highlights of our corporate governance practices include the following:

• Of our director nominees and continuing directors,

11 out of 12 are independent

•

•

•

•

•

•

•

Regular executive sessions of independent directors

Audit, compensation and nominating and corporate
governance committees are comprised solely of
independent directors

Diverse board in terms of tenure, residency, gender,
ethnicity, sexual orientation, experience and skills

Annual board self-evaluation(1)

Risk oversight by the full board and committees

Board and committees may engage outside advisors
independently of management

Independent compensation consultant reporting
directly to the compensation committee

•

•

•

•

Regular meeting attendance and devote sufficient
time and attention to board duties

Director participation in continuing education and
related reimbursement policy

Lead Independent Director with clearly delineated
duties

Corporate Governance Guidelines

• Majority voting for elections of directors for a

three-year term

•

•

•

•

•

Share ownership guidelines for directors and
executive officers

Anti-hedging/pledging policy

Code of Conduct

Annual advisory approval of executive
compensation

Shareholders may call extraordinary meetings

(1)

In 2021, the nominating and corporate governance committee engaged a third-party advisor to conduct a comprehensive, independent
evaluation that included interviews with each member of the board, including a specific focus on the key capabilities and skills that existed
on the board and where there were opportunities for enhancement.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

37

2022 NOTICE OF MEETING AND PROXY STATEMENT

Corporate Governance and Board Matters (continued)

Other Corporate Governance Matters

Corporate Governance Guidelines. As a part of our board of directors’ commitment to enhancing shareholder
value over the long term, our board of directors has adopted a set of Corporate Governance Guidelines to provide
the framework for the governance of our company and to assist our board of directors in the exercise of its
responsibilities. Our Corporate Governance Guidelines cover, among other topics, board composition, structure
and functioning, director qualifications and board membership criteria, director independence, board and board
committee annual self-evaluations, committees of the board, board access to management and outside advisors,
board share ownership guidelines, and director orientation and education. Our Corporation Governance
Guidelines are available on our website at www.jazzpharmaceuticals.com under the section entitled “About” under
“Board of Directors.”

Anti-Hedging/Pledging Policy. Our insider trading policy prohibits directors, executive officers and other
employees from engaging in speculative trading activities, including hedging transactions or other inherently
speculative transactions with respect to our securities. Our insider trading policy also prohibits directors, executive
officers and other employees from pledging our securities as collateral for any loans.

Share Ownership Guidelines for Directors and Executive Officers. We maintain and periodically review share
ownership guidelines for our non-employee directors, Chief Executive Officer and certain other employees who
serve on our executive committee. More information about our share ownership guidelines can be found under
the sections of this proxy statement entitled “Executive Compensation—Compensation Discussion and Analysis—
Additional Compensation Information—Ownership Guidelines for Executive Officers” and “Director
Compensation—Ownership Guidelines for Directors.”

Shareholder Ability to Call Extraordinary Meetings. Irish law provides that shareholders holding 10% or more
of the total voting rights may at any time request that the directors call an extraordinary general meeting (i.e.,
special meeting). The shareholders who wish to request an extraordinary general meeting must deliver to our
principal executive office a written notice, signed by the shareholders requesting the meeting and stating the
purposes of the meeting. If the directors do not, within 21 days of the date of delivery of the request, proceed to
convene a meeting to be held within two months of that date, those shareholders (or any of them representing
more than half of the total voting rights of all of them) may themselves convene a meeting within a specified
period, but any meeting so convened cannot be held after the expiration of three months from the date of delivery
of the request.

Shareholder Communications with the Board of Directors. Our board of directors believes that shareholders
should have an opportunity to communicate with the board, and efforts have been made to ensure that the views
of shareholders are heard by the board of directors or individual directors, as applicable, and that appropriate
responses are provided to shareholders in a timely manner. We believe that our responsiveness to shareholder
communications to the board of directors has been excellent. Shareholders interested in communicating with the
board of directors or a particular director (including our Chairperson or our Lead Independent Director) may do so
by sending written communication to: Jazz Pharmaceuticals plc, Attention: Company Secretary, Fifth Floor,
Waterloo Exchange, Waterloo Road, Dublin 4, Ireland. Each communication should set forth the name and
address of the shareholder as it appears on our records (and, if the shares are held by a nominee, the name and
address of the beneficial owner of the shares), and the number of our ordinary shares that are owned of record by
the record holder or beneficially by the beneficial owner, as applicable. The Company Secretary will, in his or her
discretion, screen out communications from shareholders that are not related to the duties and responsibilities of
the board of directors. The purpose of this screening is to allow the board of directors to avoid having to consider
irrelevant or inappropriate communications (such as advertisements, solicitations and hostile communications). If
deemed an appropriate communication, the Company Secretary will forward the communication, depending on
the subject matter, to the Chairperson, the Lead Independent Director or the chair of the appropriate committee of
the board of directors.

38

2022 Proxy Statement | JAZZ PHARMACEUTICALS

y
x
o
r
P

2022 NOTICE OF MEETING AND PROXY STATEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
OWNERS AND MANAGEMENT

The following table sets forth certain information regarding the ownership of our ordinary shares as of May 1,
2022 (except as noted) by: (i) each director; (ii) each of the executive officers named in the Summary
Compensation Table under “Executive Compensation” below (referred to throughout this proxy statement as our
NEOs); (iii) all of our executive officers and directors as a group; and (iv) all those known by us to be beneficial
owners of more than five percent of our ordinary shares.

Name and Address of Beneficial Owner(1)

5% Shareholders:
BlackRock, Inc.(3)

55 East 52nd Street
New York, NY 10055

The Vanguard Group(4)
100 Vanguard Blvd.
Malvern, PA 19355
JPMorgan Chase & Co.(5)
383 Madison Avenue
New York, NY 10179

Named Executive Officers and Directors:
Bruce C. Cozadd(6)
Daniel N. Swisher, Jr.(7)
Renée Galá(8)
Robert Iannone, M.D., M.S.C.E(9)
Chris Tovey(10)
Jennifer E. Cook(11)
Patrick G. Enright(12)
Peter Gray(13)
Heather Ann McSharry(14)
Seamus Mulligan(15)
Kenneth W. O’Keefe(16)
Anne O‘Riordan(17)
Norbert G. Riedel, Ph.D.(18)
Mark D. Smith, M.D.(19)
Catherine A. Sohn, Pharm.D.(20)
Rick E Winningham(21)
All directors and executive officers as a group (21 persons)(22)

Beneficial Ownership(2)

Number of Shares

Percentage of
Total

6,450,368

10.4%

5,544,701

3,248,156

902,519
120,972
30,722
52,292
6,330
3,685
35,673
47,456
45,769
1,193,343
55,156
26,135
45,003
3,685
38,166
33,742
2,803,126

8.9%

5.2%

1.4%
*
*
*
*
*
*
*
*
1.9%
*
*
*
*
*
*
4.4%

Less than 1%.

*
(1) Unless otherwise provided in the table above or in the notes below, the address for each of the beneficial owners listed is c/o Fifth Floor,

Waterloo Exchange, Waterloo Road, Dublin 4, Ireland.

(2) This table is based upon information supplied by officers and directors as well as Schedules 13G or 13G/A filed with the SEC by beneficial

owners of more than five percent of our ordinary shares. Unless otherwise indicated in the footnotes to this table and subject to
community property laws where applicable, we believe that each of the shareholders named in this table has sole voting and investment
power with respect to the ordinary shares indicated as beneficially owned. Applicable percentages are based on 62,319,578 ordinary
shares outstanding on May 1, 2022, adjusted as required by rules promulgated by the SEC. The number of shares beneficially owned
includes ordinary shares issuable pursuant to the exercise of stock options that are exercisable and RSUs that will vest within 60 days of
May 1, 2022. Shares issuable pursuant to the exercise of stock options that are exercisable and RSUs that will vest within 60 days of

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

39

Security Ownership of Certain Beneficial Owners and Management (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

May 1, 2022 are deemed to be outstanding and beneficially owned by the person to whom such shares are issuable for the purpose of
computing the percentage ownership of that person, but they are not treated as outstanding for the purpose of computing the percentage
ownership of any other person.

(3) This information is based on a Schedule 13G/A filed with the SEC on January 28, 2022 by BlackRock, Inc., or BlackRock. According to

the Schedule 13G/A, as of December 31, 2021, BlackRock has sole power to vote or direct the vote of 5,840,215 ordinary shares and
sole power to dispose or direct the disposition of 6,450,368 ordinary shares. The Schedule 13G/A also indicates that BlackRock is acting
as a parent holding company for a number of entities that beneficially owned the ordinary shares being reported. The Schedule 13G/A
provides information only as of December 31, 2021 and, consequently, the beneficial ownership of the above-mentioned entity may have
changed between December 31, 2021 and May 1, 2022.

(4) This information is based on a Schedule 13G/A filed with the SEC on February 10, 2022 by The Vanguard Group, or Vanguard. According
to the Schedule 13G/A, as of December 31, 2021, Vanguard has shared power to vote or direct the vote of 56,344 ordinary shares, sole
power to dispose or direct the disposition of 5,414,080 ordinary shares, and shared power to dispose or direct the disposition of 130,621
shares. The Schedule 13G/A provides information only as of December 31, 2021 and, consequently, the beneficial ownership of the
above-mentioned entity may have changed between December 31, 2021 and May 1, 2022.

(5) This information is based on a Schedule 13G filed with the SEC on January 24, 2022 by JPMorgan Chase & Co., or JP Morgan.

According to the Schedule 13G, as of December 31, 2021, JP Morgan has sole power to vote or direct the vote of 3,033,304 ordinary
shares, sole power to dispose or the direct the disposition of 3,246,823 ordinary shares and shared power to dispose or direct the
disposition of 226 shares. The Schedule 13G provides information only as of December 31, 2021 and, consequently, the beneficial
ownership of the above-mentioned entity may have changed between December 31, 2021 and May 1, 2022.

(6)

(7)

(8)

(9)

Includes 669,188 ordinary shares Mr. Cozadd has the right to acquire pursuant to options exercisable within 60 days of May 1, 2022.

Includes 97,499 ordinary shares Mr. Swisher has the right to acquire pursuant to options exercisable within 60 days of May 1, 2022.

Includes 23,343 ordinary shares Ms. Galá has the right to acquire pursuant to options exercisable.

Includes 39,260 ordinary shares Dr. Iannone has the right to acquire pursuant to options exercisable and 3,050 shares Dr. Iannone is
expected to receive pursuant to RSUs scheduled to vest, in each case, within 60 days of May 1, 2022.

(10) Mr. Tovey was appointed our Chief Operating Officer and Managing Director, Europe & International, in May 2021 following the GW
Acquisition. Includes 4,032 ordinary shares Mr. Tovey has the right to acquire pursuant to options exercisable and 2,273 shares
Mr. Tovey is expected to receive pursuant to RSUs scheduled to vest, in each case, within 60 days of May 1, 2022.

(11)

(12)

(13)

(14)

(15)

(16)

(17)

(18)

(19)

(20)

(21)

(22)

Includes 3,238 ordinary shares Ms. Cook has the right to acquire pursuant to options exercisable within 60 days of May 1, 2022.

Includes 15,305 ordinary shares Mr. Enright has the right to acquire pursuant to options exercisable within 60 days of May 1, 2022.

Includes 36,850 ordinary shares Mr. Gray has the right to acquire pursuant to options exercisable within 60 days of May 1, 2022.

Includes 36,850 ordinary shares Ms. McSharry has the right to acquire pursuant to options exercisable within 60 days of May 1, 2022.

Includes 37,850 ordinary shares Mr. Mulligan has the right to acquire pursuant to options exercisable within 60 days of May 1, 2022.

Includes 33,350 ordinary shares Mr. O’Keefe has the right to acquire pursuant to options exercisable within 60 days of May 1, 2022.

Includes 18,670 ordinary shares Ms. O’Riordan has the right to acquire pursuant to options exercisable and 946 shares Ms. O’Riordan is
expected to receive pursuant to RSUs scheduled to vest, in each case, within 60 days of May 1, 2022.

Includes 36,850 ordinary shares Dr. Riedel has the right to acquire pursuant to options exercisable within 60 days of May 1, 2022.

Includes 3,238 ordinary shares Dr. Smith has the right to acquire pursuant to options exercisable within 60 days of May 1, 2022.

Includes 28,850 ordinary shares Dr. Sohn has the right to acquire pursuant to options exercisable within 60 days of May 1, 2022.

Includes 28,850 ordinary shares Mr. Winningham has the right to acquire pursuant to options exercisable within 60 days of May 1, 2022.

Includes 1,247,157 ordinary shares that our executive officers and non-employee directors have the right to acquire pursuant to options
exercisable within 60 days of May 1, 2022 and 15,741 ordinary shares that our executive officers and non-employee directors are
expected to receive pursuant to RSUs scheduled to vest within 60 days of May 1, 2022.

40

2022 Proxy Statement | JAZZ PHARMACEUTICALS

2022 NOTICE OF MEETING AND PROXY STATEMENT

EXECUTIVE OFFICERS

The following table provides information regarding our executive officers as of June 1, 2022.

Name

Bruce C. Cozadd

Daniel N. Swisher, Jr.

Renée Galá

Robert Iannone, M.D., M.S.C.E

Kim Sablich

Christopher Tovey

Patricia Carr

Finbar Larkin, Ph.D.

Neena M. Patil

Samantha Pearce

Age

58

59

50

55

53

56

51

64

47

56

Position

Chairperson and Chief Executive Officer

President

Executive Vice President and Chief Financial Officer

Executive Vice President, Global Head of Research and
Development

Executive Vice President and General Manager, North America

Executive Vice President and Chief Operating Officer and
Managing Director, Europe and International

Senior Vice President, Chief Accounting Officer

Senior Vice President, Technical Operations

Chief Legal Officer and Senior Vice President, Legal and
Corporate Affairs

Senior Vice President, Europe and International

y
x
o
r
P

Bruce C. Cozadd. Biographical information regarding Mr. Cozadd is set forth below under “Proposal 1 Election of
Directors”

Daniel N. Swisher, Jr. was appointed our President as of January 2018 and also served as our Chief Operating
Officer from that date until May 2021. From December 2003 to December 2017, he was Chief Executive Officer
and a member of the board of directors of Sunesis Pharmaceuticals, Inc., a biopharmaceutical company focused
on the development of novel targeted cancer therapeutics in hematologic and solid tumor malignancies. He also
served as Chief Business Officer and Chief Financial Officer of Sunesis from 2001 to 2003. Prior to 2001,
Mr. Swisher served in various management roles, including Senior Vice President of Sales and Marketing, for
ALZA Corporation from 1992 to 2001. He currently serves as Chairperson of the board of directors of Cerus
Corporation, a biomedical products company focused on the field of blood transfusion safety, and as a member of
the board of directors of Corcept Therapeutics Inc., a pharmaceutical company focused on cortisol-modulating
therapeutics to address metabolic and other serious medical conditions. Mr. Swisher received a B.A. from Yale
University and an M.B.A. from the Stanford Graduate School of Business.

Renée Galá was appointed our Executive Vice President and Chief Financial Officer as of March 2020. From
January to June 2019, Ms. Galá served as the Chief Financial Officer of GRAIL, Inc., a private healthcare
company focused on the early detection of cancer. Prior to that, from December 2014 to January 2019, she
served as Senior Vice President and Chief Financial Officer of Theravance Biopharma, Inc., a biopharmaceutical
company, following its spin-out from Innoviva, Inc. Ms. Galá joined Innoviva in 2006 and held various roles in the
finance organization before leading the company’s spin-out transaction. Prior to that, Ms. Galá served in various
roles in global treasury, pharmaceutical sales and corporate strategy/business development at Eli Lilly and
Company, from 2001 to 2006. Before joining Eli Lilly, Ms. Galá spent seven years in the energy industry in
positions focused on corporate finance, project finance, and mergers and acquisitions. Ms. Galá serves on the
board of directors of Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, where she also chairs the
audit committee. Ms. Galá holds a B.S. in Mathematics from Vanderbilt University and an M.B.A. from Columbia
Business School.

Robert Iannone, M.D., M.S.C.E. was appointed our Executive Vice President, Global Head of Research and
Development as of May 2019. He also served as our Chief Medical Officer from December 2019 until October
2021. From April 2018 until May 2019, Dr. Iannone served as Head of Research and Development and Chief
Medical Officer of Immunomedics, Inc., a biopharmaceutical company. Prior to that, from July 2014 to April 2018,

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

41

Executive Officers (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

Dr. Iannone served in the roles of Senior Vice President and Head of Immuno-oncology, Global Medicines
Development and the Global Products Vice President at AstraZeneca plc, a global science-led biopharmaceutical
company. From 2004 to 2014, Dr. Iannone served in management roles at Merck Co., Inc., a global
biopharmaceutical company, culminating in his role as Executive Director and Section Head of Oncology Clinical
Development. From 2001 to 2004, he served as Assistant Professor of Pediatrics and from 2004 to 2012 as
Adjunct Assistant Professor of Pediatrics at the University of Pennsylvania School of Medicine.

Dr. Iannone has been serving on the board of directors of iTeos Therapeutics, Inc., a clinical- stage
biopharmaceutical company, since May 2021, Jounce Therapeutics, Inc., a clinical-stage immunotherapy
company, since January 2020 and on the Cancer Steering Committee of the Foundation for the National Institutes
of Health since 2011. Dr. Iannone received a B.S. from The Catholic University of America, an M.D. from Yale
University and an M.S.C.E. from University of Pennsylvania and completed his residency in Pediatrics and
fellowship in Pediatric Hematology-Oncology at Johns Hopkins University.

Kim Sablich was appointed our Executive Vice President and General Manager, North America, as of June
2020. Ms. Sablich previously served as the Chief Commercial Officer of Myovant Sciences, Inc., a clinical-stage
biopharmaceutical company, from December 2018 to May 2020. Prior to that, she served in various executive
roles at GlaxoSmithKline plc, a multinational pharmaceutical company, including as Vice President, U.S. Primary
Care Marketing from May 2015 to May 2018, as Vice President, Global Medicines Commercialization from July
2013 to May 2015, and as Vice President, U.S. Vaccines Commercial Strategy from October 2010 to June 2013.
Prior to 2010,

Ms. Sablich served in various positions of increasing responsibility at Merck & Company, a global healthcare
company, in its commercial organization across sales, product management, pricing/access, and customer
insights, with a focus on the cardiovascular, respiratory, and vaccines business areas. She serves on the board of
directors of Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on rare
diseases. Ms. Sablich previously served on the board of directors of AllerGenis, LLC, a food allergy diagnostic
solutions company, from April 2018 to April 2021. Ms. Sablich holds a B.A. in Economics from Denison University
and an M.B.A. from The Wharton School of the University of Pennsylvania.

Christopher Tovey was appointed our Executive Vice President and Chief Operating Officer and Managing
Director, Europe & International, in May 2021 following our acquisition of GW Pharmaceuticals, plc, or the GW
Acquisition. At GW Pharmaceuticals, plc, or GW, he served as Chief Operating Officer since joining GW in
October 2012. Prior to joining GW, Mr. Tovey served in multiple roles at UCB Pharmaceuticals from 2006 to 2012,
most recently as Vice President of Global Marketing Operations. Prior to joining UCB, Mr. Tovey served 18 years
at GlaxoSmithKline plc in senior commercial roles in both the European and U.K. organizations. These roles
included Director Commercial Strategy Distribution Europe, Director European Vaccine Therapy, Director
Commercial Development U.K., Director Vaccines Business Unit U.K. and Business Unit Manager Oncology U.K.
Mr. Tovey holds a BSc in marine biology from the University of Liverpool, U.K.

Patricia Carr was appointed our Senior Vice President and Chief Accounting Officer as of August 2021. Ms. Carr
joined Jazz Pharmaceuticals as Vice President, Finance in July 2012 and was appointed Principal Accounting
Officer in August 2019. Prior to that, from September 2011 to July 2012, she served as Vice President, Finance of
Alkermes plc, a global biopharmaceutical company. From June 2002 to September 2011, she served in a number
of roles in Elan Corporation, a neuroscience-based biotechnology company, most recently as Vice President,
Finance. Ms. Carr is a Fellow of the Institute of Chartered Accountants (Ireland) and received a Bachelor of
Commerce from the National University of lreland, Galway.

Finbar Larkin, Ph.D. was appointed our Senior Vice President, Technical Operations as of October 2019 and
served as our Senior Vice President, Pharmaceutical Development & Manufacturing Science from September
2018 until October 2019, our Vice President, Technical Development from February 2014 until August 2018, and
our Executive Director, Technical Operations from April 2013 until February 2014. Prior to that, from September
2009 until March 2013, Dr. Larkin served in management roles at Ipsen Pharma SAS, culminating in his role as
Vice President, Engineering & Senior Specialist. From February 1997 until August 2009, he served as Vice
President and Managing Director at Ipsen Manufacturing Ireland. From 1990 until 1997, he served in various

42

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Executive Officers (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

project and operational management roles at Novartis. Prior to 1990, Dr. Larkin served in various roles in
manufacturing science and technology, human resources and quality & analytical science at Lilly SA. Dr. Larkin
received a B.Sc. and Ph.D. in Chemistry from University College Dublin.

Neena M. Patil was appointed our Senior Vice President and General Counsel as of July 2019, and has served
as our Chief Legal Officer and Senior Vice President, Legal and Corporate Affairs since February 2021. From
September 2018 to July 2019, Ms. Patil served as Senior Vice President, General Counsel and Corporate
Secretary of Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company. Prior to that, from May 2008
to October 2016, Ms. Patil served in management positions at Novo Nordisk Inc., culminating in her role as Vice
President for Legal Affairs and Associate General Counsel. Prior to 2008, she worked for several other global
biopharmaceutical companies including Pfizer, GPC Biotech and Sanofi. Ms. Patil serves on the board of directors
of Teleflex, Inc., a global provider of medical technologies. Ms. Patil also serves on the U.S. Board of Mothers 2
Mothers, a global health care organization operating in Africa. Ms. Patil received a B.A. from Georgetown
University and a J.D. and Master of Health Services Administration from the University of Michigan.

y
x
o
r
P

Samantha Pearce was appointed our Senior Vice President, Europe and International as of March 2020. From
March 2010 to December 2019, Ms. Pearce held various global senior management positions with Celgene
Corporation, most recently as Vice President and General Manager, International Markets. Prior to that, from
August 2002 to March 2010, she served in management positions at AstraZeneca plc, culminating in her role as
Director, Specialist Care. Prior to August 2002, she worked for DuPont Pharmaceuticals. Ms. Pearce received a
B.Sc. from Birmingham University, U.K. and an M.B.A. from Cranfield University, U.K.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

43

2022 NOTICE OF MEETING AND PROXY STATEMENT

EXECUTIVE COMPENSATION
Compensation Discussion and Analysis

The following Compensation Discussion and Analysis
describes the material elements of compensation for
the following individuals who served as our principal
executive officer, principal financial officer and three
other most highly compensated executive officers as
of December 31, 2021. These individuals are our
named executive officers, or NEOs, for 2021.

Bruce C. Cozadd
Chairperson and Chief Executive Officer (CEO)

Daniel N. Swisher, Jr.
President

Renée Galá
Executive Vice President and Chief Financial Officer (CFO)

Robert Iannone
Executive Vice President, Global Head of Research and
Development

Chris Tovey
Executive Vice President and Chief Operating Officer and
Managing Director, Europe and International

TABLE OF CONTENTS

Compensation Discussion and Analysis

Executive Summary . . . . . . . . . . . . . . . . . . . . . . . . . .
2021 Performance Highlights . . . . . . . . . . . . . . . . . .

Key Features of Our Executive Compensation
Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2021 Pay-for-Performance Overview . . . . . . . . . . .
Compensation Philosophy and Objectives . . . . . .
How We Determine Executive Compensation . . . .

Role of Our Compensation Committee and
Executive Officers . . . . . . . . . . . . . . . . . . . . . . . . . . .

Role of the Independent Compensation
Consultant . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Competitive Assessment of Compensation—Peer
Companies and Market Data . . . . . . . . . . . . . . . . . .

Factors Used in Determining Executive
Compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2021 Advisory Vote on Executive Compensation
and Shareholder Engagement

. . . . . . . . . . . . . . . . .

Key Components and Design of Executive
Compensation Program . . . . . . . . . . . . . . . . . . . . . .
Total Direct Compensation . . . . . . . . . . . . . . . . . . . .

Components of Total Direct Compensation . . . . . . .
2021 Performance Bonus Program . . . . . . . . . . . . .
Quantitative Objectives . . . . . . . . . . . . . . . . . . . . . . .

Qualitative Objectives . . . . . . . . . . . . . . . . . . . . . . . .

2021 Compensation Decisions for Our Named
Executive Officers . . . . . . . . . . . . . . . . . . . . . . . . . . .
General Approach . . . . . . . . . . . . . . . . . . . . . . . . . . .

Summary of 2021 Compensation Decisions . . . . . .

Individual NEO Compensation Decisions . . . . . . . .
Additional Compensation Information . . . . . . . . . .
Ownership Guidelines for Executive Officers . . . . .
Change in Control Plan . . . . . . . . . . . . . . . . . . . . . . .
Equity Grant Timing and Equity Plan
Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accounting and Tax Considerations . . . . . . . . . . . . .
Risk Assessment Concerning Compensation
Practices and Policies
Reconciliations of Non-GAAP Financial
Measures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . .

45

45

48

48

49

50

50

50

51

53

53

54

54

55

56

57

60

61

61

61

63

69

69
69

70
70

70

71

44

2022 Proxy Statement | JAZZ PHARMACEUTICALS

2022 NOTICE OF MEETING AND PROXY STATEMENT

Executive Compensation (continued)

Executive Summary

Our Business

We are a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and
their families. We are dedicated to developing and commercializing life-changing medicines for people with
serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines
and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these
therapeutic areas, we strive to identify new options for patients by actively exploring small molecules and
biologics, and through innovative delivery technologies and cannabinoid science.

y
x
o
r
P

Our strategy for growth is rooted in executing commercial launches and ongoing commercialization initiatives;
advancing robust research and development, or R&D, programs and delivering impactful clinical results;
effectively deploying capital to strengthen the prospects of achieving our short- and long-term goals through
strategic corporate development; and delivering strong financial performance. We focus on patient populations
with high unmet needs. We identify and develop differentiated therapies for these patients that we expect will be
long-lived assets and that we can support with an efficient commercialization model. In addition, we leverage our
efficient, scalable operating model and integrated capabilities across our global infrastructure to effectively reach
patients around the world.

Our strategy to create sustainable shareholder value is focused on:

•

•

•

•

•

•

Strong commercial execution to drive diversified revenue growth and address unmet medical needs of our
patients across our product portfolio, which focuses on neuroscience and oncology medicines;

Expanding and advancing our pipeline to achieve a valuable product portfolio of durable, highly differentiated
programs;

Continuing to build a flexible, efficient, and productive development engine for targeted therapeutic areas to
identify and progress early-, mid- and late-stage assets;

Identifying and acquiring novel product candidates and approved therapies to complement our existing
pipeline and commercial portfolio;

Investing in an efficient, scalable operating model and differentiated capabilities to enable growth; and

Unlocking further value through indication expansion and entry into global markets.

In 2021, consistent with our strategy, we continued to focus on R&D activities within our neuroscience and
oncology therapeutic areas, such as our expansion into movement disorders and solid tumors, and exploring
adjacent therapeutic areas that could further diversify our portfolio. In addition, in May 2021, we completed our
acquisition of GW Pharmaceuticals plc, or GW, as consistent with our overall business and capital allocation
strategy to expand our neuroscience portfolio and enhance value for our shareholders.

2021 Performance Highlights

2021 was a transformative year for Jazz, delivering over $3 billion in total revenues for the first time. With the
approvals and launches of Rylaze® for the treatment of acute lymphoblastic leukemia, or ALL, or lymphoblastic
lymphoma, or LBL, in pediatric and adult patients one month and older who have developed hypersensitivity to E.
coli-derived asparaginase and Xywav® for idiopathic hypersomnia, or IH, in 2021, we accomplished our goal to
deliver five product launches through 2020 and 2021. We also acquired and integrated GW which expanded our
commercial portfolio with Epidiolex®, enhanced our R&D capabilities and talent, and added the industry-leading
GW cannabinoid platform. These accomplishments underscore a significant advance in Jazz’s evolution to an
innovative global biopharmaceutical company. We expect these achievements, coupled with our expanded
capabilities and disciplined capital allocation, to drive sustainable growth. In 2022, we remain focused on growing
and diversifying our revenue, investing in our pipeline of novel therapies and delivering innovative therapies for
patients.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

45

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

Financial

Commercial

•

•

•

•

2021 total revenues of $3,094.2 million increased 31% over 2020

2021 GAAP1 net loss of $329.7 million, or $5.52 per diluted share, compared to 2020 net
income of $238.6 million, or $4.22 per diluted share

2021 non-GAAP adjusted net income of $992.8 million2, or $16.23 per diluted share,
compared to $704.0 million, or $12.46 per diluted share, for 2020

2021 delivered significant revenue diversification with 59% of net product sales in the fourth
quarter of 2021 from products launched or acquired since 20193, compared to 75% of net
product sales derived solely from Xyrem® in 2018

Neuroscience

•

•

•

•

2021 net product sales for the combined oxybate (Xywav and Xyrem) business of
$1,801.1 million increased 3% over 2020

Xywav net product sales were $535.3 million in 2021, reflecting exceptional adoption in
narcolepsy

Launched Xywav for IH in November 2021
Epidiolex/Epidyolex® net product sales were $463.6 million from the closing of the GW
Acquisition on May 5, 2021 to December 31, 2021, with year-over-year revenue growth4 of 29%

Oncology

•

•

•

Zepzelca® net product sales were $246.8 million in 2021, the first full calendar year on the
market following launch in July 2020

Launched Rylaze in July 2021 for treatment of ALL or LBL in adult and pediatric patients;
net product sales of $85.6 million in 2021, including $65.0 million in net product sales in the
fourth quarter alone, reflect strong demand and inventory build

Enhanced pipeline with addition of GW cannabinoid platform; expanded pipeline to 18 novel
candidates in development and 35 active clinical trials in 2021

Research &
Development

Neuroscience

•

•

In June 2021, the U.S. Food and Drug Administration, or FDA, recognized seven years of
Orphan Drug Exclusivity for Xywav in narcolepsy through July 21, 2027. In August 2021,
FDA approved our supplemental New Drug Application for Xywav for the treatment of IH in
adults and in November 2021, we commenced the U.S. commercial launch.

Late-stage clinical trials: Three ongoing Phase 3 clinical trials for nabiximols in multiple
sclerosis (MS)-related spasticity and a Phase 3 trial of Epidiolex in Epilepsy with Myoclonic-
Atonic Seizures, also known as Doose syndrome.

• Meaningful progress across mid-stage pipeline:

O

O

O

In December 2021, JZP150 received Fast Track Designation for development in post-
traumatic stress disorder.

In December 2021 we initiated Phase 2 clinical trials for suvecaltamide (JZP385) for
essential tremor.

These are both patient populations that suffer significant impacts to their quality of life
and for whom there are limited current treatment options.

1

2

3

4

U.S. generally accepted accounting principles (GAAP).
Non-GAAP adjusted net income is a non-GAAP financial measure that both excludes certain items from our GAAP reported net income
and includes certain tax related adjustments. Commencing in 2020, following consultation with the staff of the Division of Corporation
Finance of the U.S. Securities and Exchange Commission, we no longer exclude upfront and milestone payments from non-GAAP
adjusted net income and its line items (and the related per share measure). See “Non-GAAP Financial Measures” and “Reconciliations”
below for a description of non-GAAP adjusted net income and a reconciliation of non-GAAP adjusted net income to its most comparable
GAAP financial measure.
Including the launches in 2020 and 2021 of Xywav (in narcolepsy and IH), Zepzelca, Sunosi®, and Rylaze and the acquisition of Epidiolex
and Sativex®.
On a proforma basis.

46

2022 Proxy Statement | JAZZ PHARMACEUTICALS

2022 NOTICE OF MEETING AND PROXY STATEMENT

Executive Compensation (continued)

Oncology

•

In June 2021, Rylaze was approved by FDA under the Real-Time Oncology Review,
program for use as a component of a multi-agent chemotherapeutic regimen for the
treatment of patients with ALL or LBL in pediatric and adult patients one month and older
who have developed hypersensitivity to E. coli-derived asparaginase. In July 2021, we
launched Rylaze in the U.S.

•

Initiated multiple clinical trials as part of our Zepzelca clinical development program:

Corporate
Development

•

O

Initiated a Phase 2 basket trial evaluating Zepzelca as a monotherapy in select
relapsed/refractory solid tumors

O We and collaborator Hoffmann-La Roche Ltd initiated a Phase 3 trial to evaluate first-
line use of Zepzelca in combination with Tecentriq® (atezolizumab), compared to
Tecentriq alone, as maintenance therapy, in patients with extensive-stage small cell
lung cancer after induction chemotherapy.

In May 2021, we acquired GW with the objective of broadening our neuroscience portfolio,
further diversifying our revenue and driving sustainable, long-term value creation
opportunities. GW was a global leader in discovering, developing, manufacturing and
commercializing novel, regulatory approved therapeutics from its proprietary cannabinoid
research platform to address a broad range of diseases. The total consideration paid by us
for the entire issued share capital of GW was $7.2 billion. The GW Acquisition, closed on
May 5, 2021. As a result, GW became an indirect wholly owned subsidiary of the company.

y
x
o
r
P

Key Executive Compensation Program Changes for 2021

As described in more detail in this CD&A, the compensation committee made the following key changes to our
executive compensation programs and policies in response to feedback from our shareholders:

•

•

Implemented a new performance-based equity program tied to the achievement of critical multi-year financial
and other strategic objectives as well as relative total shareholder return goals. Performance-based restricted
stock unit awards, or PSUs, will now make up 50% of each NEO’s target annual equity grant, with time-vested
restricted stock unit awards, or RSUs making up the other 50%.

Adopted a formal incentive compensation clawback policy that provides the committee discretion to recover
incentive compensation in the event we are required to restate our financial results due to material
noncompliance with any financial requirement and the misconduct of an executive officer covered by the
policy contributed to such noncompliance.

•

Implemented a cap on annual performance bonus awards at 300%.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

47

2022 NOTICE OF MEETING AND PROXY STATEMENT

Executive Compensation (continued)

Key Features of Our Executive Compensation Program

What We Do

What We Don’t Do

✓ Design executive compensation to align pay with

✘ No excessive change in control or severance

performance

payments

✘ No “single-trigger” cash or equity change in

control benefits

✘ No repricing of underwater stock options without

prior shareholder approval
✘ No excessive perquisites
✘ No tax gross ups on severance or change in

control benefits

✘ No post-termination retirement or pension

benefits that are not available to employees
generally

✘ No guaranteed bonuses or base salary increases

✓ Balance short-term and long-term incentive
compensation, with a majority of executive
compensation being “at-risk”

✓ Align annual performance bonus plan for CEO with
that of other executives and non-sales employees,
with 100% of CEO’s bonus based on such corporate
performance goals as approved by the board of
directors

✓ Establish threshold and maximum levels of
achievement for payouts under our annual
performance bonus plan, including an overall cap on
individual payout amounts

✓ Maintain executive share ownership guidelines
✓ Provide “double-trigger” change in control benefits
✓ Prohibit hedging and pledging by executive officers

and directors

✓ Have 100% independent directors on the

compensation committee

✓ Hire independent compensation consultant who
reports directly to the compensation committee

✓ Meet regularly in executive session without

management present

✓ Starting in 2021, grant performance-based equity
awards representing 50% of each NEO’s target
equity compensation
✓ Maintain clawback policy

2021 Pay-for-Performance Overview

As illustrated in the charts below, a substantial majority of target total direct compensation (that is base salary,
target annual bonus and target annual equity grant) for our CEO and other NEOs is structured in the form of
“at-risk” compensation and is dependent upon the achievement of financial and strategic objectives as well as the
performance of our stock price. This aligns our executives’ interests with those of our shareholders for near- and
long-term performance. Despite adverse macroeconomic uncertainties and other conditions created by the
ongoing COVID-19 pandemic that adversely affected our business in 2021, the compensation committee elected
not to adjust the challenging performance goals set for our 2021 annual performance cash bonus plan.

48

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

The pie charts below show the various recurring components of target total direct compensation for 2021 for our
CEO and other NEOs. These components include the following: (i) annual base salary rate for 2021; (ii) annual
target bonus opportunity for 2021; and (iii) the target value of equity awards granted in 2021.

CEO

Other NEO Average

8%
Base
Salary

8%

Target
Performance
Bonus

15%
Base
Salary

y
x
o
r
P

42%
Time-Based
Restricted
Stock Units

42%
Performance-Based
Restricted Stock
Units

92% At  R i s

k

38%
Time-Based
Restricted
Stock Units

9%

Target
Performance
Bonus

38%
Performance-Based
Restricted Stock
Units

85% At  R i s

k

Compensation Philosophy and Objectives

Our executive compensation program is designed with the following objectives and philosophy:

(1) Attract, incentivize, reward and retain diverse, talented individuals with relevant experience in the life
sciences industry through a competitive pay structure. We reward individuals fairly over time and seek to
retain those individuals who continue to meet our high expectations.

(2) Deliver balanced total compensation packages to accomplish our business objectives and mission.

Our executive compensation program focuses on target total direct compensation, combining short-term and
long-term components, cash and equity, and fixed and variable payments, in the proportions that we believe
are the most appropriate to incentivize and reward our executive officers for achieving our corporate goals
while minimizing incentives for excessive risk-taking or unethical conduct.

(3) Align pay with our performance. Our annual performance bonus awards are not earned unless

pre-determined levels of performance are achieved against annual corporate objectives approved by our
board of directors at the beginning of the year. Likewise, our stock option awards will not provide realizable
value and our restricted stock unit awards will not provide increased value unless there is an increase in the
value of our shares, which benefits all shareholders. In addition, our performance-based PSU awards are not
earned unless pre-determined levels of performance are achieved. 50% of each NEO’s target equity
compensation is granted in the form of PSUs and 50% is in the form of time-based RSU awards. We also
have executive share ownership guidelines to further support our ownership culture and align the interests of
executive officers and shareholders.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

49

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

How We Determine Executive Compensation

Role of Our Compensation & Management Development Committee and Executive Officers

We refer to the Compensation & Management Development Committee in this proxy statement as the
compensation committee. The compensation committee is (and was at all times during 2021) composed entirely
of independent directors, as defined by Rule 5605(a)(2) of the Nasdaq listing standards. Our compensation
committee meets as often as it determines necessary to carry out its duties and responsibilities through regularly
scheduled meetings and, if necessary, special meetings. Our compensation committee also has the authority to
take certain actions by written consent of all members. The agenda for each compensation committee meeting is
usually developed by members of our human resources department and our CEO, with input from members of
our legal department, and is reviewed and finalized with the chairperson of the compensation committee.

The compensation committee reviews and oversees our compensation policies, plans and programs and reviews
and generally determines the compensation to be paid to the executive officers, including the NEOs. Either the
compensation committee or the independent members of our board of directors, upon recommendation from the
compensation committee, who receives input and advice from its independent compensation consultant, approve
the compensation of our CEO. References in this Compensation Discussion and Analysis to our board of
directors approving our CEO’s compensation are to the independent members of our board of directors.

In making other executive compensation determinations, the compensation committee considers
recommendations from our CEO. In making his recommendations, our CEO receives input from our human
resources department and from the individuals who manage or report directly to the other executive officers, and
he reviews various sources of market compensation data provided by the independent compensation consultant
to the compensation committee, as described below. While our CEO discusses his recommendations for the other
executive officers with the compensation committee, he does not participate in the deliberations and
recommendations to our board of directors concerning, or our board of directors’ determination of, his own
compensation. Members of our human resources and legal departments also attend compensation committee
meetings.

Below are the highlights of the annual cycle our compensation committee follows in reviewing and making
decisions with respect to our executive compensation program.

1Q
Review prior year’s
performance and
determine bonus payout;
establish goals for short-
and long-term Incentive
plans; set current-year
levels of
compensation

2Q
Consider any 
compensation-related 
proxy proposals and 
disclosures; review 
non-employee director 
compensation

3Q
Review 
compensation-related 
corporate governance trends 
and any feedback received 
from shareholders; 
determine peer group for 
next year

4Q
Discuss compensation 
philosophy and policy 
direction for next year, 
including components of 
compensation

Role of the Independent Compensation Consultant

The compensation committee engages an independent compensation consultant each year to provide a
competitive compensation assessment with respect to the executive officers to assist the compensation
committee in making annual compensation decisions. Since 2010, Aon’s Human Capital Solutions practice, a
division of Aon plc, or Aon, has been engaged by the compensation committee. Aon supports the compensation
committee in addressing the design of the peer group, provides industry compensation data, when requested,
provides the compensation committee with advice regarding executive officers’ compensation, including base
salaries, performance-based bonuses and long-term equity compensation, and similar advice regarding
non-employee directors’ compensation. The compensation committee has also consulted with Aon to update the
peer company and industry compensation data on an annual basis, address specific questions that arise as the
committee fulfills their responsibilities as outlined in the compensation committee charter. The advisor provides

50

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

support in addressing changes in trends and best practices for executive compensation, incentive and equity and/
or other best practices that are requested by the compensation committee, in order to help inform the
compensation committee’s decisions. Aon reports directly to the compensation committee, which maintains the
authority to direct Aon’s work and engagement. As requested, and under the purview of the compensation
committee, Aon may advise the human resources department on projects from time to time. Aon interacts with
management to gain access to company information that is required to perform services and to understand the
culture and policies of the organization. Aon attends compensation committee meetings, and the compensation
committee and Aon meet in executive session with no members of management present, as needed, to address
various compensation matters, including deliberations regarding our CEO’s compensation.

y
x
o
r
P

In assessing Aon’s independence from management in providing executive compensation services to the
compensation committee, the compensation committee considered that Aon is only engaged by, takes direction
from, and reports to, the compensation committee for such services and, accordingly, only the compensation
committee has the right to terminate or replace Aon as its compensation consultant at any time. The
compensation committee also analyzed whether the work of Aon as a compensation consultant with respect to
executive and director compensation raised any conflict of interest, taking into consideration the following factors:
✔ the provision of other services to our company by

Aon and its affiliates;

✔ the amount of fees we paid to Aon and its

affiliates as a percentage of Aon’s total revenue;
✔ any business or personal relationship of Aon or
the individual compensation advisors employed
by it with any executive officer of our company;

✔ any business or personal relationship of the
individual compensation advisors with any
compensation committee member;

✔ Aon’s policies and procedures that are designed

to prevent conflicts of interest; and

✔ any ordinary shares of our company owned by
Aon or the individual compensation advisors
employed by it.

The compensation committee has determined, based on its analysis of the above factors, that the work of Aon
and the individual compensation advisors employed by Aon as compensation consultants to our company has not
created any conflict of interest.

Competitive Assessment of Compensation – Peer Companies and Market Data

Because we aim to attract and retain the most highly qualified executive officers in an extremely competitive
market, the compensation committee believes that it is important when making its compensation decisions to be
informed as to the current practices of comparable public companies with which we compete for top talent. To this
end, the compensation committee reviews market data for each executive officer’s position, compiled by Aon as
described below, including information relating to the mix and levels of compensation for executive officers in the
life sciences industry, with a focus on target total direct compensation in line with the compensation committee’s
holistic approach to executive compensation.

2021 Peer Group. The compensation committee uses a peer group and other market data to provide context for
its executive compensation decision-making. Each year, Aon reviews the external market data and evaluates the
composition of our peer group to ensure it appropriately reflects our growth, the increase in our revenues and
market capitalization and the consolidation in our industry. In July 2020, with the assistance of Aon, the
compensation committee considered companies:

•

•

•

•

in the life sciences industry (specifically biotechnology and select bio/pharma companies) with commercial
products on the market;

with revenues of approximately one-fourth (0.25x) to three times (3x) our then-projected revenue (resulting in
a range of $550 million to $6.6 billion in revenues);

with market value of approximately one-fourth (0.25x) to four times (4x) our market capitalization at the time
(resulting in a range of between $1.5 billion to $24.3 billion in market capitalization); and

primarily located in the U.S. with a secondary focus on companies that are headquartered in Europe.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

51

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

The peer group used for our 2021 compensation decisions consisted of the 16 companies listed in the table
below. At the time the compensation committee approved the peer group, we were at the 66th percentile for
trailing 12 months revenue and the 30th percentile for market capitalization among the new peer group. The
compensation committee considered this a reasonable balance and a good representation of companies that
were of similar scope and complexity.

Alexion Pharmaceuticals, Inc.1

Exelixis, Inc.

Mallinckrodt plc2

Sarepta Therapeutics, Inc.

Alkermes plc

Horizon Therapeutics plc

Nektar Therapeutics

Seagen Inc. (formerly
Seattle Genetics)

BioMarin Pharmaceutical Inc.

Incyte Corporation

Endo International plc

Ionis Pharmaceuticals, Inc.

Neurocrine Biosciences,
Inc.

United Therapeutics
Corporation

Regeneron
Pharmaceuticals, Inc.

Vertex Pharmaceuticals
Incorporated

1

2

Acquired by AstraZeneca plc in July 2021.

Declared bankruptcy in October 2020.

2021 Market Data. In early 2021, Aon completed an assessment of executive compensation based on our 2021
peer group to inform the compensation committee’s determinations of executive compensation for 2021. The
compensation committee reviews target total direct compensation, consisting of target total cash compensation
and equity compensation, against the market data provided by Aon primarily to ensure that our executive
compensation program, as a whole, is positioned competitively to attract and retain the highest caliber of
executive officers and to ensure that the total direct compensation opportunity for the executive officer group is
aligned with our corporate objectives and strategic needs. The compensation committee does not target a specific
percentile for setting the level of compensation for the NEOs and does not otherwise use a formulaic approach to
setting pay against the market data. The compensation committee believes that over-reliance on benchmarking
can result in compensation that is unrelated to the value delivered by our executive officers because
compensation benchmarking does not consider company-to-company variations among actual roles with similar
titles or the specific performance of the executive officers.

52

2022 Proxy Statement | JAZZ PHARMACEUTICALS

2022 NOTICE OF MEETING AND PROXY STATEMENT

Executive Compensation (continued)

Factors Used in Determining Executive Compensation

Our compensation committee sets the compensation of our executive officers at levels that the compensation
committee determines to be competitive and appropriate for each NEO, using the compensation committee’s
professional experience and judgment. The compensation committee’s pay decisions are not driven by a
particular target level of compensation based on market data, and the compensation committee does not
otherwise use a formulaic approach to setting executive pay. Instead, the compensation committee believes that
executive pay decisions require consideration of multiple relevant factors, which may vary from year to year. The
figure below reflects the factors the compensation committee considers in determining and approving the amount,
form and mix of pay for our NEOs.

y
x
o
r
P

Company performance

Each NEO’s criticality to the business

CEO’s recommendations (other than for himself), based
on direct knowledge of NEO performance and his
extensive industry experience

Internal pay equity

FACTORS USED IN
DETERMINING
NEO COMPENSATION

Each NEO’s target total direct compensation
and equity ownership

Range of market data reference points
(generally the 25th, 50th, 60th, and 75th
percentiles of the market data)

Radford’s recommendation on compensation
policy, design and structure

Shareholder feedback

The need to attract and retain talent

Each NEO’s past performance

Aggregate compensation cost and impact on
shareholder dilution

Independent judgment of members of
compensation commitee

2021 Advisory Vote on Executive Compensation and Shareholder Engagement

We hold a say-on-pay advisory vote on executive compensation annually. Accordingly, at our 2021 annual
meeting, we provided shareholders with the opportunity to cast a non-binding vote on a proposal regarding the
compensation of our named executive officers for the year ended December 31, 2020. Of the votes cast,
approximately 90% were voted in favor of the proposal. We believe these results reflect our continuous efforts to
engage with shareholders and solicit their feedback on our executive compensation program.

The compensation committee reviewed the final vote results for the proposal and, given the significant level of
shareholder support and positive feedback received on recent program and governance changes, concluded that
our executive compensation program continues to provide a competitive pay-for-performance package that
effectively incentivizes the NEOs and encourages long-term retention. The compensation committee and, with
respect to our CEO’s compensation, our board of directors, determined not to make any significant changes to
our 2021 executive compensation policies or decisions as a result of the vote. Our compensation committee and,
with respect to our CEO’s compensation, our board of directors will continue to consider the outcome of our
say-on-pay proposals and our shareholders’ views when making future compensation decisions for the NEOs,
such as the new performance-equity program that was adopted in 2021 in response to feedback from our
shareholders that there was strong preference that our long-term incentive program include performance-based
equity awards. In addition, in response to shareholders’ preference for explicit caps on annual performance bonus
payouts, beginning in 2021, the payouts under our annual performance bonus awards will be capped at 300% of
the individual’s target award, although in practice recent payouts for the NEOs have not exceeded ~150% of
target. Our CEO’s annual performance bonus award is generally limited to the actual bonus pool funding
percentage (with a maximum funding of 200%), which is determined based on the achievement of pre-established
financial and other strategic objectives as described in more detail on page 56 under the heading “2021
Performance Bonus Program.”

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

53

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

We also engage with our shareholders when they have topics of particular interest, which may include executive
compensation related matters. Shareholder feedback is reported to our compensation committee (and our
nominating and corporate governance committee, as applicable) throughout the year.

The following graphic describes our typical shareholder outreach and engagement cycle.

Annual General Meeting

Ongoing
Shareholder
Outreach and
Engagement

Prior to Annual
General Meeting
Discuss business strategy and 
performance

Seek feedback on any matters for
shareholder consideration

Publish Annual Report on Form 10-K and 
proxy statement, highlighting recent 
board and company activities

After Annual
General Meeting

Discuss vote outcomes from annual
general meeting in light of existing
governance and compensation practices,
as well as any feedback received 
from shareholders during proxy season

Review corporate governance trends, 
recent regulatory developments, and our
own policies and procedures

Off-Season Engagement and
Evaluation of Practices

Solicit and consider shareholder feedback 
regarding our board governance and executive
compensation practices to better understand 
investor viewpoints and inform discussions in
the boardroom
Evaluate potential changes to board, governance
or executive compensation practices in light of
shareholder feedback and review of practices

Key Components and Design of the Executive Compensation Program
Total Direct Compensation

Our compensation program focuses on target total direct compensation, which consists of base salary, target
performance bonus opportunity (which, together with base salary, we refer to as target total cash compensation),
and target long-term incentive opportunity.

Base
Salary

Performance
Bonus
Opportunity

Long-Term
Incentive
Awards

TOTAL DIRECT
COMPENSATION

We also offer our executive officers severance benefits upon certain types of involuntary terminations in
connection with a change in control. The table below captioned “Components of Total Direct Compensation”
describes key features of each primary component of our executive compensation program and explains why we
provide a particular compensation component.

The compensation committee takes a holistic approach to compensation and seeks to ensure that the aggregate
level of pay, across all of the pay elements is meeting the company’s desired objectives for each executive officer.
The compensation committee does not have any formal policies for allocating compensation among base salary,
target performance bonus opportunity and long-term incentive awards.

54

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

Instead, the compensation committee uses its experience and business judgment to establish a total
compensation program for each NEO that is a mix of current, short-term and long-term incentive compensation,
and cash and non-cash compensation, which it believes is appropriate to achieve the goals of our executive
compensation program and our corporate goals.

Because we believe it is important to our success to pursue both short- and long-term objectives that drive
sustainable shareholder value creation, to avoid excessive risk-taking, and to preserve our cash resources, the
majority of the NEOs’ total direct compensation is comprised of “at-risk” compensation, consisting of performance-
based bonus opportunities and long-term incentives, in the form of RSUs and PSUs, which align the executive
officers’ incentives with the interests of our shareholders. This allocation between “at-risk” and fixed compensation
is consistent with our pay-for-performance philosophy.

y
x
o
r
P

Components of Total Direct Compensation

Component

Key Features

Purpose

Base Salary

/Fixed level of cash compensation
/No amount is contractually guaranteed
/Amounts reviewed and determined annually, and are

generally effective by March 1 each year

/Provides fixed level of compensation that is

competitive within our industry and reflective of the
skills and experience required to be successful in
fulfilling the role

/Cash compensation under the performance bonus

plan, which is “at-risk” because it is dependent upon
achievement of pre-established financial and strategic
objectives

/Target bonus opportunities reviewed and determined

/Provides financial incentives to achieve key corporate
objectives that are aligned with our business strategy

/Rewards NEOs (other than our CEO) for

extraordinary individual contributions to our corporate
achievements

Performance
Bonus Award

Long-Term
Incentive
Compensation

annually

/Actual bonuses paid shortly after the end of each

year, based on the extent corporate goals are attained
as determined by the compensation committee, and
for executive officers other than our CEO, their
individual contributions toward such achievements
/Actual bonuses capped at 300% of executive officer’s

target award

/PSUs vest, if at all, at the end of a multi-year

performance period and represent 50% of the NEO
annual equity grant.

/RSUs generally vest over a 4-year period subject to

executive officer’s continued service

/Awards reviewed and generally granted annually,

early in the year, at time of hire or promotion

/Fosters ownership culture
/Links compensation to long-term success
/PSUs align compensation earned to the achievement

of multi-year strategic objectives and stock price
performance versus peer companies.

/RSUs assist with managing dilution for our

shareholders, while reinforcing the importance of
shareholder value creation over time

/Executive share ownership guidelines to further

support our ownership culture and align the interests
of executive officers and shareholders

Other Benefits. Executive officers based in the United States are eligible to participate in all of our benefit plans,
such as the 401(k) Plan (see the section below titled “Description of Compensation Arrangements–401(k) Plan”),
our medical, dental, vision, short-term disability, long-term disability and group life insurance plans, in each case
generally on the same basis as other employees. Executive officers based in the United States and Ireland are
eligible to participate in our Employee Stock Purchase Plan, or ESPP, generally on the same basis as other
employees. We also have a section 125 flexible benefits healthcare plan and a flexible benefits childcare plan
under which employees can set aside pre-tax funds to pay for qualified healthcare expenses and qualified
childcare expenses not reimbursed by insurance. We do not currently offer pension or other retirement benefits in
the United States; outside the U.S. we offer pension or other retirement benefits that are consistent with local
regulations.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

55

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

Severance Benefits upon Change in Control. Executive officers based in the United States are also eligible to
participate in our Amended and Restated Executive Change in Control and Severance Benefit Plan, or the
change in control plan, which is described below under the headings “Additional Compensation Information—
Change in Control Plan” and “Potential Payments upon Termination or Change in Control—Amended and
Restated Executive Change in Control and Severance Benefit Plan.” The change in control plan provides certain
severance benefits to participants, in connection with specified involuntary termination events, including
termination without cause and constructive termination, following a change in control. Certain executive officers
who are not employed by our U.S. affiliates receive comparable change in control benefits pursuant to their
employment or service agreements, and with respect to Mr. Tovey, pursuant to the UK Change in Control and
Severance Benefit Plan and related participation agreement, which is described below under the heading
“Potential Payments upon Termination or Change in Control—GW UK Change in Control and Severance Benefit
Plan”. The compensation committee believes these severance benefits are important from a retention perspective
to provide some level of protection to our executives who might be terminated following a change in control and
that the amounts are reasonable and maintain the competitiveness of our executive compensation and retention
program. The compensation committee believes this structure serves to mitigate the distraction and loss of key
executive officers that may occur in connection with rumored or actual fundamental corporate changes. Such
payments protect the interests of our shareholders by enhancing executive focus during rumored or actual
change in control activity, retaining executives despite the uncertainty that generally exists while a transaction is
under consideration and encouraging the executives responsible for negotiating potential transactions to do so
with independence and objectivity. We do not provide any tax gross up payments on severance benefits.

2021 Performance Bonus Program

The corporate objectives and relative weightings established by the board of directors for the 2021 performance
bonus program that were communicated to the NEOs in early 2021 are described in the chart below. The revenue
objective described below included strategically important, revenue-related stretch goals with the opportunity to
earn up to an additional 15% bonus pool funding. For each of the five objectives, achievement could have been
between 0% and 200% based on company performance, including the identified stretch objectives for revenue
and adjusted net income. The payouts under the 2021 performance bonus program were capped at 300% of the
NEO’s target award.

Bonus
Opportunity

80%
Quantitative Corporate Objectives

20%
Qualitative Corporate Objectives

Revenue
40%

Adjusted Net Income
10%

Product Development
30%

Corporate Development
10%

Organizational
10%

Following the end of the 2021 fiscal year, after summing the resulting bonus pool funding percentages for the
quantitative and qualitative objectives based on their relative weightings of 80% and 20%, respectively, and
considering achievement of stretch goals, the compensation committee approved an overall bonus pool funding
percentage of 108% of the target bonus pool for the 2021 plan year, as further described below.

The compensation committee did not set specific objectives for individual executive officers. Each executive
officer is responsible for contributing to the corporate objectives, individually and as part of the leadership team,

56

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

with each objective deemed to be important in determining the level of the company’s performance during the
year. In approving individual bonus awards, the compensation committee considers the individual contribution
towards the company’s achievement of the corporate objectives by each executive officer (other than our CEO).
The actual bonus payments approved for each of the NEOs for 2021 are described below under “2021
Compensation Decisions for Our Named Executive Officers.”

No COVID-related adjustments to the goals or to the assessment of their achievement were made in calculating
the 2021 bonus pool.

Individual bonus awards are determined in accordance with the following methodology:

y
x
o
r
P

Annual

Base Salary

X

Target

Bonus %

X

Company

Performance %

X

Individual
Performance %
(if applicable)

Final
Bonus Award

Quantitative Objectives

Each of the three main quantitative objectives for 2021, or objectively measurable goals, had a total relative
overall weighting of 80%, and is described in the table and accompanying footnotes below, including each
objective’s weighting, actual results and performance multipliers, as well as the total bonus pool funding
percentage resulting from the level of achievement of the quantitative objectives.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

57

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

The compensation committee approved, at the start of the performance year, an algorithm with respect to each
main quantitative objective (as well as the strategically important revenue-related stretch goals) for calculating the
bonus pool funding attributable to the extent of achievement for each such objective. The revenue objective, with
a weighting of 40%, was split into an oxybate net product sales objective weighted at 15%, a total revenue
objective, excluding oxybate and Epidiolex/Epidyolex net product sales, weighted at 15%, and an Epidiolex/
Epidyolex net product sales objective weighted at 10%, as well as five related additional, or strategically
important, stretch goals, each weighted at 3%. The compensation committee set specific threshold and maximum
levels of achievement for the revenue objective and the related stretch goals, which are described in the footnotes
to the table below. The compensation committee also approved a goal with its own individual weighting for the
adjusted net income objective. For the quantitative product development objectives, the compensation committee
established various objectively measurable target goals within these objectives but did not set a threshold
performance level; rather, an overall achievement of between 0% and 200%, measured against the multiple
targets as described in more detail below, was determined by the compensation committee and used to calculate
the applicable bonus pool funding percentage attributable to the product development objectives.

Quantitative Objectives

1. Revenue Objective:

Weighting

Actual Results

Multiplier

Bonus Pool
Funding(2)

• Achieve total oxybate net product sales in 2021 of

15%

$1,767 million(1)

• Achieve total revenue, excluding oxybate and

15%

Epidiolex/Epidyolex net product sales, in 2021 of
$898 million(1)

• Achieve Epidiolex/Epidyolex net product sales in

10%

2021 of $507 million(1)

• Stretch goal: Exceed specified percentage of number

3%

of oxybate patients on Xywav by December 31,
2021(3)

• Stretch goal: Launch Xywav in IH before

November 30, 2021(4)

• Stretch goal: Exceed budgeted Sunosi net product

sales(5)

• Stretch goal: Exceed budgeted Zepzelca net product

sales by >10%(6)

• Stretch goal: Launch Rylaze in the United States

mid-year (100% for a launch before 1 July and 50%
for a launch in July)(7)

2. Product Development Objectives: Execute on

defined development projects(8)

3. Adjusted Net Income Objective: Achieve non-GAAP
adjusted net income* in 2021 of $859 million(1)(9)

3%

3%

3%

3%

30%

10%

Total

Note: Amounts may not total due to rounding.

Above target: net
product sales of
$1,801 million

Between threshold and
target: total revenue,
excluding oxybate and
Epidiolex net product
sales, of $829 million

Between threshold and
target: net product sales
of $464 million

Between threshold and
maximum

Achieved

Below threshold

Below threshold

Between threshold and
maximum

Achieved at 101%
level(8)

Above target: non-GAAP
adjusted net income* of
$993 million

110%

16%

61%

9%

58%

16%

100%

0%

0%

50%

6%

1%

3%

0%

0%

2%

101%

30%

177%(9)

18%

84%

(1)

If the specified threshold annual performance level was met (90% of target for the three components of the revenue objective and the
adjusted net income objective), then a pre-established scaled performance multiplier (ranging from 50% to 150% for the oxybate net
product sales and total revenue components of the revenue objective and 50% to 200% for the Epidiolex/Epidyolex net product sales and
adjusted net income objectives) would be used to calculate the applicable bonus pool funding percentage attributable to such quantitative
objective. The performance multiplier would be zero if performance was below the threshold level, 50% if performance was at the
threshold level, and then scaled for performance above 50% up to the applicable maximum level. The performance multiplier was capped

58

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

for performance above the specified maximum performance level (110% of target for the oxybate net product sales and total revenue
components of the revenue objective and 120% of target for the Epidiolex net product sales and adjusted net income objective).

(2) The percentages in this column represent, for each quantitative corporate objective, the weight of the quantitative objective multiplied by

the performance multiplier that corresponds to the actual achievement of such quantitative objective.

(3) With respect to this stretch goal, the performance threshold was set at 40% of total oxybate patients on Xywav by December 31, 2021, at
or below which no addition to the total bonus pool funding would be made. Between 40% and 45% of total oxybate patients on Xywav by
December 31, 2021, the amount added to the total bonus pool funding percentage would increase from 0% to 3%. This stretch goal was
difficult to achieve from the outset given that Xywav launched in the U.S. in November 2020 and achieving 40% adoption in 14 months
would, in the compensation committee’s view, be considered industry leading performance. Actual achievement of 41% of total oxybate
patients on Xywav by December 31, 2021 was between the threshold and maximum achievement levels.

(4) Xywav was launched in the U.S. for the treatment of IH in adults on November 1, 2021.

(5) With respect to this stretch goal, the threshold performance level was set at achievement of the budgeted Sunosi net product sales for

2021. Exceeding the net product sales budget by between 0% and 10% would have resulted in 0% to 3% (scaled linearly) being added to
the total bonus pool funding percentage. This stretch goal was difficult to achieve as the Sunosi launch had been significantly impacted by
the COVID-19 pandemic in 2020 and the budget assumed significant revenue growth requiring adoption rates increasing from actual
trends seen in 2020. Actual Sunosi net product sales for 2021 were below the threshold level of achievement.

(6) With respect to this stretch goal, the threshold performance level was set at achievement of 10% above budgeted Zepzelca net product
sales for 2021. Exceeding budgeted Zepzelca net product sales by between 10% and 50% would have resulted in 0% to 3% (scaled
linearly) being added to the total bonus pool funding percentage. This stretch goal was inherently difficult to achieve from the outset given
the impact of the COVID-19 pandemic on our ability to interact with and educate health providers about Zepzelca.

(7) Rylaze was launched in the U.S. in July 2021.

(8) With respect to the product development objectives, the compensation committee determined that the actual achievement by the company
was 101%, resulting in a performance multiplier of 101%, and therefore, a 30% bonus pool funding percentage, based on achievement
with respect to the target goals as described below:

y
x
o
r
P

Performance Category

Target Goals and Results

Top Priority

High Priority

All Other Development

This performance category consisted of the following goals: (i) complete New Drug Application submission for
Xywav in IH by the first quarter of 2021; (ii) FDA approval of Xywav in IH by fourth quarter of 2021; (iii) FDA
approval of Rylaze by third quarter of 2021; (iv) complete U.S. and European regulatory submissions for
Rylaze by fourth quarter of 2021; (v) enroll first patient in a Phase 3 study evaluating Zepzelca in combination
with Tecentriq® (atezolizumab) in first-line extensive stage SCLC by third quarter of 2021; and (vi) deliver on
clinical program for nabiximols in multiple sclerosis including being New Drug Application submission ready by
fourth quarter of 2021. The compensation committee determined that we had met or exceeded each of the
performance goals for this category except that we had only partially met the goal of completing U.S. and
European regulatory submissions for Rylaze by fourth quarter of 2021, as the European regulatory submission
was delayed for strategic reasons, and completing a clinical program designed to successfully submit a New
Drug Application submission for nabiximols in multiple sclerosis by fourth quarter of 2021. The compensation
committee noted that the approved label for Xywav in IH and orphan designation exceeded expectations, that
the U.S. approval of Rylaze in June was a monumental achievement for patients requiring close collaboration
with FDA and the Children’s Oncology Group , and that the delay in European submission for Rylaze was
strategically made to increase the probability of a highly competitive product in that region. In aggregate, the
compensation committee assessed the performance on Top Priority programs to be 115% of target.

This performance category consisted of the following goals: (i) enroll first patient in a Phase 2 study of
suvecaltamide (JZP385) in essential tremor by the second quarter of 2021; and (ii) enroll first patient in a
Phase 2 study of JZP150 in post-traumatic stress disorder by the fourth quarter of 2021. The compensation
committee determined that we had met the JZP150 goal in this category. The compensation committee noted
that the delayed first patient enrolment in the JZP385 essential tremor study was due to factors not entirely
within the control of the development team. In aggregate, the compensation committee assessed the
performance on High Priority programs to be 75% of target.

This performance category consisted of the following goals: (i) enroll first patient in a Phase 1 study of JZP341
by the third quarter of 2021; (ii) complete go/no-go decision on JZP324 by the first quarter of 2021; (iii) submit
one high potential IND application in each of neuroscience, oncology and cannabinoid science by the fourth
quarter of 2021; and (iv) complete Sunosi and Vyxeos high priority regulatory filings by the fourth quarter of
2021. The compensation committee determined that we had partially met the performance goals for this
category. The compensation committee noted that partial achievement was a result of program specific
strategic decisions and focusing of resources on top priority programs. The compensation committee
assessed the performance on all other development programs to be at 50% of target.

With respect to the product development objectives, all of the “top priority” goals collectively carried a 70% weight.
The “high priority” goals collectively carried a 20% weight. All other goals collectively carried a 10% weight.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

59

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

In determining that the actual achievement by the company was 101% for the product development objective, the
compensation committee employed a holistic analysis that took into account the compensation committee’s
weighting of the product development objectives described above and the degree to which they were met as a
whole against the backdrop of competing development priorities.

* Non-GAAP adjusted net income is a non-GAAP financial measure that both excludes certain items from our GAAP reported net income
and includes certain tax-related adjustments as reconciled under “Reconciliations of Non-GAAP Financial Measures” below, except that
solely for purposes of calculating the threshold performance achievement level and performance multiplier for 2021, non-GAAP adjusted
net income included the additional adjustment as set forth in footnote (9) to this table.

(9) With respect to the adjusted net income objective, the target achievement level for 2021 was set below the target achievement level and
actual performance for 2020 due to the expected dilutive impact of the GW Acquisition. In this regard, the GW Acquisition was dilutive to
both GAAP and non-GAAP adjusted net income for the year ended December 31, 2021. However, we expect that the GW Acquisition will
be adjusted net income accretive in the first full year calendar year of combined operations and substantially accretive thereafter.

Qualitative Objectives

The qualitative corporate objectives approved by the board of directors fell into two categories: (1) progress on
corporate development activities related to closing the GW Acquisition and the successful integration of GW, with
a relative weighting of 10%, and (2) a demonstrated commitment to and progress on certain organizational goals
related to our transformation into an innovative and agile global company, with a relative weighting of 10%.
Achievement of the qualitative objectives is inherently less objectively measurable than the quantitative
objectives.

Corporate Development Objective. The objective relating to progress on corporate development activities
consisted of successfully completing the acquisition of GW in the second quarter of 2021, obtaining financing at
terms consistent with or better than commitment papers, successfully combining the organizations at transaction
closing, including people retention and processes, and completing post-closing integration. The multiplier applied
to the corporate development objective ranged from 0% to 200%, based on the compensation committee’s
determination of the extent to which the corporate development objective was achieved during the year. In
considering the company’s corporate development accomplishments in 2021, the compensation committee noted
that we successfully closed the GW acquisition in May 2021, achieved favorable terms and increased allocation to
pre-payable debt, progressed organizational designs, appropriately maintained retention and tracked well on all
critical applicable deal success factors. The compensation committee weighed heavily our success in executing
the GW transaction and its potential to meaningfully diversify our revenues starting in 2021 and add future
revenue-generating products to our portfolio, our overall deal readiness, and our active and thoughtful corporate
development process. The compensation committee determined that, as a whole, our achievement resulted in a
multiplier of 125% and, therefore, a 13% bonus pool funding percentage for the 2021 corporate development
objective.

Organizational Objective. With respect to the organizational objective, the compensation committee established
five sub-goals. Because the sub-goals are not easily quantifiable, they were not assigned individual weightings.
The multiplier applied to the organizational corporate objective ranged from 0% to 200%, based on the
compensation committee’s determination of the extent to which the aggregate organizational corporate objective,
including sub-goals, were achieved, as a whole, during the year. The organizational corporate objective sub-goals
were:

•

•

•

•

attract, develop and retain talent;

create a more diverse, equitable, and inclusive organization;

strengthen organizational capabilities and evolve our operating culture for agility, global mindset, scalability
and sustainability;

expand and enhance social impact and corporate governance practices;

• maintain culture of compliance and adhere to our Code of Conduct.

In evaluating the organizational objective, the compensation committee determined that our talent and culture
indicators demonstrate achievement in our organizational health and organizational development progress. Key

60

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

human capital metrics demonstrate favorability and/or alignment with external benchmarking trends, particularly in
light of trends surrounding the pandemic, as well as those expected during an acquisition period. Our 2021
successes include defining our environmental, social and governance framework, enhancing our reporting and
engaging in shared value and social impact work. We achieved key progression on organizational initiatives to
strengthen our innovation, development and commercial excellence. We maintained female and improved people
of color representation at the leadership level consistent with DEIB commitments and achieved our hiring goals.
After taking into consideration both our accomplishments and challenges with respect to these sub-goals in light
of the challenges of integrating a significant acquisition and an ongoing pandemic, the compensation committee
determined that as a whole, our overall achievement resulted in a multiplier of 115% and therefore, a 12% bonus
pool funding percentage for the 2021 organizational objective.

y
x
o
r
P

2021 Compensation Decisions for Our Named Executive Officers

General Approach

In making compensation decisions for 2021, the compensation committee considered the factors discussed in
“Factors Used in Determining Executive Compensation” above and the compensation committee’s specific
compensation objectives for 2021. Our compensation committee did not use a formula or assign a particular
weight to any one factor in determining each NEO’s target total direct compensation. Rather, our compensation
committee’s determination of the target total direct compensation, mix of cash and equity and fixed and “at-risk”
pay opportunities was a subjective, individualized decision for each NEO. The compensation committee reviewed
and considered each element of pay in the context of the overall target total direct compensation for each NEO.
When the compensation committee made changes to one element of pay, those changes were made in the
context of the levels of the other elements of pay, and the resulting target total direct compensation for each NEO.
As a result, the 2021 pay decisions for each NEO are presented holistically in this section.

The compensation committee also had access to market data with respect to target total cash compensation and
target equity award grants. However, as described above, the compensation committee believes that over-
reliance on benchmarking can result in compensation that is unrelated to the value delivered by our executive
officers because compensation benchmarking does not take into account company-by-company variations among
actual roles with similar titles or the specific performance of our executive officers.

Summary of 2021 Compensation Decisions

Target Total Cash Compensation. The compensation committee increased each NEO’s base salary for 2021,
and the new base salary rates were effective in March 2021.

Target Equity Compensation and Impact on Target Total Direct Compensation. In determining the
appropriate size of 2021 equity award grants, at the time the compensation committee (and the board of directors,
with respect to Mr. Cozadd) made its decisions, after careful consideration, the compensation committee aimed to
deliver equity awards to each executive officer to balance the need to maintain equity opportunities competitive
with the market, serve the retention and incentive purposes of the awards and manage overall dilution to our
shareholders.

Redesign of Long-Term Incentive Program. In connection with our transformation into an innovative
biopharmaceutical company, line of sight to a set of longer-term value drivers and multi-year goals around our
strategic pathway to success came into clearer focus. It was with this focus, along with feedback from
shareholders, that we determined that 2021 was the appropriate time to adopt a new long-term incentive award
design that we believe sets the foundation for sustained high performance and shareholder returns and strongly
aligns executive pay to achievement of our longer-term strategic objectives.

Starting in 2021, 50% of each NEO’s aggregate annual long-term incentive compensation will be in the form of
PSUs that vest based on achievement of performance goals and 50% in the form of time-based RSUs. The
compensation committee believes this mix strikes the right balance between the variable nature of PSUs and the
retentive nature of RSUs. The share amounts underlying the PSUs and RSUs granted to each executive officer in

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

61

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

2021 were determined by applying the company’s 30-day average share price (immediately preceding the grant
date) to the fair value of the award, which the compensation committee and, in the case of Mr. Cozadd, the board
of directors, intended to deliver (dividing such value by the average share price). A 30-day average share price
was used, rather than a single day share price, to provide a more stabilized share value less susceptible to
possible swings in the market.

2021 – 2023 PSU Program. The 2021-2023 PSU Program grants, or the 2021 PSUs, were made to executives
including each of the NEOs at the closing of the GW Acquisition in May 2021. The compensation committee
determined that it was in the best interests of the company and its shareholders to delay the grant of the 2021
PSUs until the close of the transaction with GW announced in February 2021. Doing so allowed the compensation
committee to select performance goals that reflect the combined company’s financial and strategic priorities
across the new integrated leadership team, which will provide the leadership team with a unifying compensation
strategy for the post-close organization. As a result, the performance will be measured for the period from May 6,
2021 – December 31, 2023.

As described in more detail below, the compensation committee selected performance goals that focus
specifically on (i) growing and diversifying our commercial portfolio; and (ii) enhancing the value of our pipeline.
The compensation committee believes that these metrics create a meaningful incentive and reward for
successfully driving transformation and delivering long-term sustainable value to shareholders and life-changing
medicines to patients.

Below is a summary of the performance metrics and associated weightings and targets applicable to the 2021
PSUs, as well as the TSR modifier.

Performance Goals

Percentage of Revenue in 2022 from “New Product” Launches*

Commercial

Percentage of U.S. oxybate Patients on Xywav by December 31, 2023**

Epidiolex 2023 Revenue

Pipeline

Pipeline Success Scorecard****

*

New product launches include Xywav (all indications), Zepzelca, Rylaze and Sunosi.

** Relative to total patients on Xywav, Xyrem and authorized generic versions of Xyrem.

Weighting

Target

30%

25%

20%

25%

45-50%

60%

***

18 points

*** Target 2023 revenue information is not being disclosed at this time, as it represents confidential commercial and financial information, the

disclosure of which would result in competitive harm to the company. The compensation committee believes that it has set performance
goals at rigorous and challenging levels that will require significant effort and achievement by our executives to be attained, and that such
goals have been established in light of our internal forecast as well as the macroeconomic and industry environments. After the end of the
performance period, the targets and achievement relative to such targets will be disclosed.

**** Points are awarded for successful investigational new drug applications, proof of concept studies, pivotal studies and product approvals

occurring during the performance period.

The four operational performance goals described above can individually, and in the aggregate, be achieved at
50% of target at threshold performance levels up to 160% of target for stretch performance.

Once the aggregate achievement percentage of the four performance goals is determined, that result is modified,
from 75% to 125%, based on the performance of our stock price relative to peers, or what we refer to as a relative
TSR modifier. The compensation committee believes that having a TSR modifier helps balance the importance of
providing executives clearer line of sight to payout opportunities using financial/operational measures with the
need to ensure that those payouts are aligned with shareholders’ experience during the performance period. The
achievement percentage, as adjusted to reflect the TSR modifier, will determine the number of shares underlying
the PSUs that will be earned, vest and be issued to each NEO.

62

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

The 2021 PSUs are subject to potential vesting acceleration upon the NEO’s termination in connection with a
change in control, as well as upon death, disability or retirement, as described below under the heading, “Potential
Payments upon Termination or Change in Control—Treatment of 2021 PSUs.”

Percentile Rank vs.
Comparator Group
≥ 75th percentile

For every increase in percentile rank between 50th and 75th percentiles

50th percentile

For every decrease in percentile rank between 50th and 25th percentiles

≤ 25th percentile

Payout
Modifier

125%

Increase by 1%

100%

Decrease by 1%

75%

y
x
o
r
P

The compensation committee selected the constituents of the Russell 1000 pharmaceutical and biotechnology
component companies as the comparator group for purposes of the relative TSR modifier for the following
reasons:

•

•

•

the number of companies is large enough to withstand any potential industry consolidation;

the group includes 14 of 16 companies in our executive compensation peer group (see page 52); and

the revenue, market cap and volatility of these companies is more aligned with the company’s profile.

Companies that are not in the Russell 1000 Index as of the end of the performance period will be removed from
final calculation.

AbbVie Inc.

Bristol-Myers Squibb
Company

ACADIA Pharmaceuticals Inc.

Catalent, Inc.

Incyte Corporation

Pfizer Inc.

Ionis Phamraceuticals,
Inc.

Reata Pharmaceuticals,
Inc.

Agios Pharmaceuticals, Inc.

Elanco Animal Health
Incorporated.

Iovance Biotherapeutics,
Inc.

Regeneron
Pharmaceuticals, Inc.

Alkermes plc

Eli Lilly and Company

Johnson & Johnson

Sage Therapeutics, Inc.

Alnylam Pharmaceuticals, Inc.

Exact Sciences Corporation Merck & Co., Inc.

Sarepta Therapeutics, Inc.

Amgen Inc.

Biogen Inc.

Exelixis, Inc

Moderna, Inc.

Seagen Inc.

Gilead Sciences, Inc

Nektar Therapeutics

United Therapeutics
Corporation

BioMarin Pharmaceutical Inc

Global Blood Therapeutics,
Inc.

Neurocrine Biosciences,
Inc.

Vertex Pharmaceuticals
Incorporated

bluebird bio, Inc.

Horizon Therapeutics plc

Perrigo Company plc

Zoetis Inc.

Individual NEO Compensation Decisions

Below are summaries, for each NEO individually, of the compensation committee’s decisions about 2021 target
total direct compensation and the changes from each NEO’s 2020 target total direct compensation. As described
above, when making the 2021 compensation decisions, the compensation committee focused primarily on the
target total direct compensation for each NEO while considering the factors set forth in the section titled “Factors
Used in Determining Executive Compensation” and the compensation committee’s specific compensation
objectives for 2021. The footnotes to the tables also include the actual performance bonus paid to each of the
NEOs for 2021 and how that actual bonus compared to each NEO’s target bonus.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

63

Executive Compensation (continued)

Bruce C. Cozadd, Chairperson and CEO

Target Total Cash Compensation

Base Salary(1)

Target Performance Bonus(2)

Target Equity Compensation(3)

Target Total Direct Compensation(4)

2022 NOTICE OF MEETING AND PROXY STATEMENT

2020 Pay ($)

2021 Pay ($)

Change (%)

2,135,723

2,159,354

1.1%

1,050,600

1,082,100

1,085,123

1,077,254

12,400,000

12,000,000

14,535,723

14,159,354

-3.2%

-2.6%

(1) Represents annual base salary rate for the applicable year. 2021 base salary became effective in March 2021.

(2) The 2021 amount reflects a target performance bonus of 100% of base salary earned, unchanged from the target performance bonus

percentage for 2020. An additional pay period in 2020 caused the target performance bonus to be higher than in 2021. The actual 2021
performance bonus paid was $1,163,400, reflecting 108% of the target performance bonus, based entirely on the overall 2021 bonus pool
funding percentage of 108%. The compensation committee (with approval from the board of directors) determined that the overall 2021
bonus pool funding percentage of 108% was applicable to Mr. Cozadd, because, as CEO, Mr. Cozadd is responsible for the company
meeting all of its objectives.

(3) The target equity compensation presented in the chart above reflects the target dollar value recommended by the compensation

committee (and approved by the board of directors). Note that the values shown in the Summary Compensation Table and Grants of Plan-
Based Awards Table for 2020 and 2021, as applicable, represent the fair value of the awards as of the grant date, are reported in
accordance with SEC rules and FASB Accounting Standards Codification Topic 718, Compensation—Stock Compensation, or FASB ASC
718, and differ from the target value recommended by the compensation committee (and approved by the board of directors). This
difference between the intended target value and the actual grant date fair value of the awards is due to our determination of the share
number underlying awards by dividing the target value by the 30-day average share price immediately prior to the grant date. However, the
grant date fair value, as reported in the Summary Compensation Table and Grants of Plan-Based Awards Table, is based on the closing
price of our ordinary shares as of the grant date (with respect to time-based RSUs) and based on a Monte Carlo simulation model (with
respect to performance-based PSUs). As such, the values shown in the Summary Compensation Table and Grants of Plan-Based Awards
Table differ from the intended target values and do not fully reflect the considerations of, and decisions made by, the compensation
committee and the board of directors in its determination of the equity grants in this respect. For a description of the determination of the
share amounts subject to equity grants, see “2021 Compensation Decisions for Our Named Executive Officers—Summary of 2021
Compensation Decisions—Redesign of Long-Term Incentive Program.”

(4) The compensation committee and board of directors designed Mr. Cozadd’s target total direct compensation to be competitive compared

to the market data, appropriate from an internal equity perspective and more heavily weighted towards equity compensation, in line with
our pay-for-performance philosophy. The compensation committee believed it was appropriate to provide a modest increase to his base
salary in 2021 in recognition of his individual performance, the performance of the company under his leadership and to remain in line with
general market increases. As described above, Mr. Cozadd’s target bonus percentage remained the same as in 2020.

64

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Executive Compensation (continued)

Daniel N. Swisher, Jr., President

Target Total Cash Compensation

Base Salary(1)

Target Performance Bonus(2)

Target Equity Compensation(3)

Target Total Direct Compensation(4)

2022 NOTICE OF MEETING AND PROXY STATEMENT

2020 Pay ($)

2021 Pay ($)

Change (%)

1,189,558

1,248,365

4.9%

690,000

499,558

715,000

533,365

3,900,000

3,700,000

5,089,558

4,948,365

-5.1%

-2.8%

y
x
o
r
P

(1) Represents annual base salary rate for the applicable year. 2021 base salary became effective March 2021.

(2) The 2021 amount reflects a target performance bonus of 75% of base salary earned, an increase from 70% in 2020. The compensation
committee determined it was appropriate to increase Mr. Swisher’s target performance bonus opportunity for 2021 to reflect his scope of
responsibility and oversight of significant functions within the organization, as well as to maintain competitive positioning relative to the
market data and the other NEOs. The actual 2021 performance bonus paid was $540,000, reflecting 101.2% of target performance bonus,
based on the overall 2021 bonus pool funding percentage of 108% and Mr. Swisher’s significant individual contributions to such
achievement. Specifically, the compensation committee considered Mr. Swisher’s overall responsibility for the key operating segments of
the company.

(3) The target equity compensation presented in the chart above reflects the target dollar value approved by the compensation committee.
Note that the values shown in the Summary Compensation Table and Grants of Plan-Based Awards Table for 2020 and 2021, as
applicable, represent the fair value of the awards as of the grant date, are reported in accordance with SEC rules and FASB ASC 718, and
differ from the target value approved by the compensation committee. This difference between the intended target value and the actual
grant date fair value of the awards is due to our determination of the share number underlying awards by dividing the target value by the
30-day average share price immediately prior to the grant date. However, the grant date fair value, as reported in the Summary
Compensation Table and Grants of Plan-Based Awards Table, is based on the closing price of our ordinary shares as of the grant date
(with respect to time-based RSUs) and based on a Monte Carlo simulation model (with respect to performance-based PSUs). As such, the
values shown in the Summary Compensation Table and Grants of Plan-Based Awards Table differ from the intended target values and do
not fully reflect the considerations of, and decisions made by, the compensation committee in its determination of the equity grants in this
respect. For a description of the determination of the share amounts subject to equity grants, see “2021 Compensation Decisions for Our
Named Executive Officers—Summary of 2021 Compensation Decisions—Redesign of Long-Term Incentive Program.”

(4) The compensation committee designed Mr. Swisher’s target total direct compensation to be competitive compared to the market data,

appropriate from an internal equity perspective and more heavily weighted towards equity compensation, in line with our
pay-for-performance philosophy. The compensation committee determined it was appropriate to increase Mr. Swisher’s base salary in an
amount necessary to reflect his scope of responsibility and oversight of significant functions within the organization, as well as to maintain
competitive positioning relative to the market data and the other NEOs.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

65

Executive Compensation (continued)

Renée Galá, Executive Vice President and CFO

Target Total Cash Compensation

Base Salary(1)

Target Performance Bonus(2)

Signing Bonus(3)

Target Equity Compensation(4)

Target Total Direct Compensation(5)

2022 NOTICE OF MEETING AND PROXY STATEMENT

2020 Pay ($)

2021 Pay ($)

Change (%)

891,539

600,000

266,539

25,000

959,308

620,000

339,308

—

7.6%

4,000,000

3,200,000

4,891,539

4,159,308

-20.0%

-15.0%

(1) Represents annual base salary rate for the applicable year. 2021 base salary became effective March 2021. Ms. Galá’s actual salary

earned in 2020 was lower due to her joining the company as Executive Vice President and CFO in March 2020.

(2) The 2021 amount reflects a target performance bonus of 55% of base salary earned, unchanged from the target performance bonus

percentage for 2020. The actual 2021 performance bonus paid was $400,000, reflecting 117.9% of target performance bonus, based on
the overall 2021 bonus pool funding percentage of 108% and Ms. Galá’s significant individual contributions to such achievement.
Specifically, the compensation committee considered Ms. Galá’s oversight of complex strategic matters and corporate priorities, such as
planning and execution of our debt offering, development of our long-term strategy, her performance with respect to supporting the
execution of corporate development priorities and her overall criticality to our business. Ms. Galá’s 2020 performance bonus was prorated
to reflect her hire date on March 6, 2020.

(3) Represents the cash signing bonus Ms. Galá received in 2020 in connection with her appointment as Executive Vice President and CFO.

(4) The target equity compensation presented in the chart above reflects the target dollar value approved by the compensation committee.
Note that the values shown in the Summary Compensation Table and Grants of Plan-Based Awards Table for 2020 and 2021, as
applicable, represent the fair value of the awards as of the grant date, are reported in accordance with SEC rules and FASB ASC 718, and
differ from the target value approved by the compensation committee. This difference between the intended target value and the actual
grant date fair value of the awards is due to our determination of the share number underlying awards by dividing the target value by the
30-day average share price immediately prior to the grant date. However, the grant date fair value, as reported in the Summary
Compensation Table and Grants of Plan-Based Awards Table, is based on the closing price of our ordinary shares as of the grant date
(with respect to time-based RSUs) and based on a Monte Carlo simulation model (with respect to performance-based PSUs). As such, the
values shown in the Summary Compensation Table and Grants of Plan-Based Awards Table differ from the intended target values and do
not fully reflect the considerations of, and decisions made by, the compensation committee in its determination of the equity grants in this
respect. For a description of the determination of the share amounts subject to equity grants, see “2021 Compensation Decisions for Our
Named Executive Officers—Summary of 2021 Compensation Decisions—Redesign of Long-Term Incentive Program.”

(5) The compensation committee designed Ms. Galá’s target total direct compensation to be competitive compared to the market data,

appropriate from an internal equity perspective and more heavily weighted towards equity compensation, in line with our
pay-for-performance philosophy. The compensation committee determined it was appropriate to increase Ms. Galá’s base salary in an
amount necessary to reflect her scope of responsibility and oversight of significant functions within the organization, as well as to maintain
competitive positioning relative to the market data and the other NEOs.

66

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Executive Compensation (continued)

Robert Iannone, Executive Vice President, Global Head of Research and Development

2022 NOTICE OF MEETING AND PROXY STATEMENT

Target Total Cash Compensation

Base Salary(1)

Target Performance Bonus(2)

Target Equity Compensation(3)

Target Total Direct Compensation(4)

2020 Pay ($)

2021 Pay ($)

Change (%)

900,769

575,000

325,769

920,558

595,000

325,558

2,600,000

2,700,000

3,500,769

3,620,558

2.2%

3.8%

3.4%

y
x
o
r
P

(1) Represents annual base salary rate for the applicable year. 2021 base salary became effective March 2021.

(2) The 2021 amount reflects a target performance bonus of 55% of base salary earned, unchanged from the target performance bonus

percentage for 2020. The actual 2021 performance bonus paid was $380,000, reflecting 116.7% of target performance bonus, based on
the overall 2021 bonus pool funding percentage of 108% and Dr. Iannone’s individual contributions to achieving both our quantitative and
qualitative objectives for 2021. Specifically, the compensation committee considered Dr. Iannone’s significant individual contributions to
such achievement and outperformance of the research and development organization with respect to the corporate objectives.

(3) The target equity compensation presented in the chart above reflects the target dollar value approved by the compensation committee.
Note that the values shown in the Summary Compensation Table and Grants of Plan-Based Awards Table for 2020 and 2021, as
applicable, represent the fair value of the awards as of the grant date, are reported in accordance with SEC rules and FASB ASC 718, and
differ from the target value approved by the compensation committee. This difference between the intended target value and the actual
grant date fair value of the awards is due to our determination of the share number underlying awards by dividing the target value by the
30-day average share price immediately prior to the grant date. However, the grant date fair value, as reported in the Summary
Compensation Table and Grants of Plan-Based Awards Table, is based on the closing price of our ordinary shares as of the grant date
(with respect to time-based RSUs) and based upon a Monte Carlo simulation model (with respect to performance-based PSUs). As such,
the values shown in the Summary Compensation Table and Grants of Plan-Based Awards Table differ from the intended target values and
do not fully reflect the considerations of, and decisions made by, the compensation committee in its determination of the equity grants in
this respect. For a description of the determination of the share amounts subject to equity grants, see “2021 Compensation Decisions for
Our Named Executive Officers—Summary of 2021 Compensation Decisions—Redesign of Long-Term Incentive Program.”

(4) The compensation committee designed Dr. Iannone’s target total direct compensation to be competitive compared to the market data,

appropriate from an internal equity perspective and more heavily weighted towards equity compensation, in line with our
pay-for-performance philosophy. The compensation committee determined it was appropriate to increase Dr. Iannone’s base salary in an
amount necessary to reflect his scope of responsibility and oversight of significant functions within the organization, as well as to maintain
competitive positioning relative to the market data and the other NEOs.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

67

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

Chris Tovey, Executive Vice President and Chief Operating Officer and Managing Director, Europe &
International

Target Total Cash Compensation(2)

Base Salary(3)

Target Performance Bonus(4)

Transaction Bonus(5)

Target Equity Compensation(6)

Target Total Direct Compensation(7)

2020 Pay($)

2021 Pay($)(1)

Change (%)

—

—

—

—

—

—

969,049

551,116

197,037

220,896

3,000,000

3,969,049

N/A

N/A

N/A

(1)

In connection with the completion of the GW Acquisition, we entered into a service agreement with Mr. Tovey pursuant to which he agreed
to serve as our Executive Vice President and Chief Operating Officer and Managing Director, Europe & International.

(2) Mr. Tovey’s 2021 base salary, performance bonus and transaction bonus were paid in pound sterling. The amounts have been converted

to U.S. dollars based on the conversion rates below.

(3) Represents annual base salary rate for 2021. Mr. Tovey’s base salary was £400,000 which has been converted to USD using a

conversion rate of 1.37779 which is the average foreign exchange rate for January to December 2021. Mr. Tovey’s actual salary earned
was lower due to his joining the company in May 2021.

(4) Reflects the target percentage of 55% of base salary earned for 2021, pro-rated to account for the fact that Mr. Tovey was not employed

the entire year. The actual 2021 performance bonus paid to Mr. Tovey was £158,000 ($211,782), reflecting 107.5% of target performance
bonus, based on the overall 2021 bonus pool funding percentage of 108% and Mr. Tovey’s individual contributions to such achievement
and his overall responsibility for key operating segments of the company. Mr. Tovey’s 2021 performance bonus was pro-rated to reflect his
hire date of May 5, 2021. Mr. Tovey’s performance bonus has been converted to USD using a conversion rate of 1.34039, which is the
average foreign exchange rate for the month of March 2022.

(5) Represents the transaction bonus of £164,800 that Mr. Tovey received in connection with the closing of the GW Acquisition equal to six
months of Mr. Tovey’s base salary in effect immediately prior to the closing. The transaction bonus was contingent upon Mr. Tovey
remaining employed with the company through December 31, 2021 to assist with successful integration. Mr. Tovey’s transaction bonus
has been converted to USD using a conversion rate of 1.34039, which is the average foreign exchange rate for the month of March 2022.
The table does not include a pre-acquisition bonus of £57,200 that was paid to Mr. Tovey in March 2022 for his services at GW, as further
described in the Summary Compensation Table below.

(6) The target equity compensation presented in the chart above reflects the target dollar value approved by the compensation committee.

Note that the values shown in the Summary Compensation Table and Grants of Plan-Based Awards Table for 2021 represent the fair
value of the awards as of the grant date, are reported in accordance with SEC rules and FASB ASC 718 and differ from the target value
approved by the compensation committee. This difference between the intended target value and the actual grant date fair value of the
awards is due to our determination of the share number underlying awards by dividing the target value by the 30-day average share price
immediately prior to the grant date. However, the grant date fair value, as reported in the Summary Compensation Table and Grants of
Plan-Based Awards Table, is based on the closing price of our ordinary shares as of the grant date (with respect to time-based RSUs) and
based upon a Monte Carlo simulation model (with respect to performance-based PSUs). As such, the values shown in the Summary
Compensation Table and Grants of Plan-Based Awards Table differ from the intended target values and do not fully reflect the
considerations of, and decisions made by, the compensation committee in its determination of the equity grants in this respect. For a
description of the determination of the share amounts subject to equity grants, see “2021 Compensation Decisions for Our Named
Executive Officers—Summary of 2021 Compensation Decisions—Redesign of Long-Term Incentive Program.”

(7) The compensation committee designed Mr. Tovey’s target total direct compensation to be competitive compared to the market data,

appropriate from an internal equity perspective and more heavily weighted towards equity compensation, in line with our
pay-for-performance philosophy. In determining his compensation package, the compensation committee received advice from Aon to
design a competitive, market-based compensation package appropriate for a senior executive with Mr. Tovey’s skills and experience and
his overall expected contribution to our business.

68

2022 Proxy Statement | JAZZ PHARMACEUTICALS

2022 NOTICE OF MEETING AND PROXY STATEMENT

Executive Compensation (continued)

Additional Compensation Information

Ownership Guidelines for Executive Officers

We maintain share ownership guidelines for our CEO and certain other employees who serve on our executive
committee, including our NEOs. Under the guidelines, these individuals are expected to own a number of the
company’s ordinary shares with a value equal to six times base salary for the company’s Chief Executive Officer,
two times base salary for each other member of the company’s executive committee who is an officer for
purposes of Section 16 of the Exchange Act, and one times base salary for each other member of the company’s
executive committee. The guidelines provide that the officers are expected to establish the minimum ownership
levels within five years of first becoming subject to the guidelines. Mr. Cozadd was in compliance with the
guidelines as of March 31, 2022. Each of our other continuing NEOs has five years from the date of his or her
appointment to comply with the guidelines.

y
x
o
r
P

Shares that count toward satisfaction of these guidelines include: shares owned outright by the individual
(including RSUs and/or PSUs that have vested or were earned but not yet settled, net of taxes); shares retained
after an option exercise or issuance under another type of equity award granted under the company’s equity
incentive plans; shares retained after purchase under the ESPP; and shares held in trust for the benefit of the
individual. The compensation committee has discretion to develop an alternative individual guideline or an
alternative method of complying with the applicable individual guideline for an individual covered by the guidelines
if compliance would place a significant hardship on such individual.

Clawback Policy

In April 2021, our compensation committee adopted a policy for recoupment of incentive compensation, or a
clawback policy. In the event we are required to restate our financial results due to material noncompliance with
any financial requirement and the misconduct of an executive officer covered by the policy contributed to such
noncompliance, we may recover the amount of any incentive compensation, including any cash or equity
compensation granted, earned or vested based in whole or in part on the attainment of a financial performance
goal or metric that was paid to him or her during the three-year period preceding the date of the restatement and
attributable to the erroneously reported results. The executive officers covered by the policy include our current or
former executive officers who are, or were at the time of the relevant misconduct, designated by the board of
directors as an officer for purposes of Section 16 of the Exchange Act. The misconduct covered by the policy
includes any knowing violation of SEC rules and regulations or company policy, breach of fiduciary duty or willful
commission of an act of fraud, dishonesty, gross recklessness or gross negligence in the performance of the
executive officer’s duties, as determined by the compensation committee.

In addition, as a public company, if we are required to restate our financial results due to our material
noncompliance with any financial reporting requirements under the federal securities laws as a result of
misconduct, our CEO and CFO may be legally required to reimburse our company for any bonus or other
incentive-based or equity-based compensation they receive in accordance with the provisions of section 304 of
the Sarbanes-Oxley Act of 2002.

Change in Control Plan

Our compensation committee periodically reviews the terms of our change in control plan, including its “double-
trigger” structure and benefits, against market data to ensure that the benefits we offer remain appropriate.

Only our executive officers who are employees of our U.S. affiliates are eligible to participate in the change in
control plan, which includes all of our NEOs other than Mr. Tovey. Certain executive officers who are not
employed by our U.S. affiliates receive comparable change in control benefits pursuant to their employment or
service agreements, or with respect to Mr. Tovey, pursuant to the UK Change in Control and Severance Benefit
Plan and related participation agreement. The compensation committee believes that the change in control
benefits we provide are representative of market practice, both in terms of design and cost, and are sufficient to
retain our current executive team and to recruit talented executive officers in the future. The terms of the change

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

69

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

in control plan and Mr. Tovey’s benefits are described below under the heading “Potential Payments upon
Termination or Change in Control—Amended and Restated Executive Change in Control and Severance Benefit
Plan” and “Potential Payments upon Termination or Change in Control—GW UK Change in Control and
Severance Benefit Plan.”

Equity Grant Timing and Equity Plan Information

Our equity incentive grant policy generally provides that grants to executive officers occur on the second trading
day following the filing date of our next quarterly or annual report filed under the Exchange Act that occurs after
the date on which such grants are approved by our board of directors or compensation committee, as applicable.
Accordingly, our equity incentive grant policy generally requires that grants to our executive officers are made
shortly after we have released information about our financial performance to the public for the applicable annual
period. As a result, the timing of equity awards is not coordinated in a manner that intentionally benefits our
executive officers.

We currently grant equity awards to the NEOs, including PSUs and RSUs, under the 2011 Equity Incentive Plan,
or the 2011 Plan. The 2011 Plan was adopted by Jazz Pharmaceuticals, Inc.’s board of directors and approved by
Jazz Pharmaceuticals, Inc.’s stockholders in connection with their approval of the Azur Merger in December 2011
and was assumed by us upon the completion of the Azur Merger. Before the 2011 Plan was adopted, we granted
stock options under our 2007 Equity Incentive Plan, or the 2007 Plan, which was adopted by Jazz
Pharmaceuticals, Inc.’s board of directors and approved by Jazz Pharmaceuticals, Inc.’s stockholders in
connection with Jazz Pharmaceuticals, Inc.’s initial public offering. The 2011 Plan affords the compensation
committee the flexibility to utilize a broad array of equity incentives and performance cash incentives in order to
secure and retain the services of employees of our company and its subsidiaries and to provide long-term
incentives that align the interests of employees with the interests of our shareholders.

Additional long-term equity incentives are provided through the ESPP. Pursuant to the ESPP, all eligible
employees, including the NEOs (if eligible), may allocate up to 15% of their base salary to purchase our stock at a
15% discount to the market price, subject to specified limits.

Accounting and Tax Considerations

Under FASB ASC 718, the company is required to estimate and record an expense for each award of equity
compensation (including stock options, PSUs and RSUs) over the vesting period of the award. We record share-
based compensation expense on an ongoing basis according to FASB ASC 718.

Under Section 162(m) of the Internal Revenue Code, or Section 162(m), compensation paid to each of the
company’s “covered employees” that exceeds $1 million per taxable year is generally non-deductible for tax
purposes unless the compensation qualifies for certain grandfathered exceptions (including the “performance-
based compensation” exception) for certain compensation paid pursuant to a written binding contract in effect on
November 2, 2017, and not materially modified on or after such date.

Although the compensation committee will continue to consider tax implications as one factor in determining
executive compensation, the compensation committee also looks at other factors in making its decisions and
retains the flexibility to provide compensation for the company’s named executive officers in a manner consistent
with the goals of the company’s executive compensation program and the best interests of the company and its
stockholders, which may include providing for compensation that is not deductible by the company due to the
deduction limit under Section 162(m). The compensation committee also retains the flexibility to modify
compensation that was initially intended to be exempt from the deduction limit under Section 162(m) if it
determines that such modifications are consistent with the company’s business needs.

Risk Assessment Concerning Compensation Practices and Policies

The compensation committee periodically reviews the company’s compensation policies and practices to assess
whether they encourage employees to take inappropriate risks. The compensation committee last performed this

70

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

review in 2020 and has determined that any risks arising from our compensation policies and practices for our
employees are not reasonably likely to have a material adverse effect on our company. The compensation
committee continues to believe that that the mix and design of the elements of executive compensation do not
encourage management to assume excessive risks, and significant compensation decisions, as well as decisions
concerning the compensation of the company’s executive officers, include subjective considerations by the
compensation committee or the board of directors, which restrain the influence of formulae or objective factors on
excessive risk-taking. Finally, the mix of short-term compensation (in the form of salary and annual bonus, if any),
and long-term compensation (in the form of PSUs and RSUs) also minimizes undue focus on short-term results
and helps align the interests of the company’s executive officers with the interests of our shareholders.

y
x
o
r
P

Reconciliations of Non-GAAP Financial Measures

To supplement our financial results presented in accordance with U.S. generally accepted accounting principles
(GAAP), we use certain non-GAAP (also referred to as non-GAAP adjusted) financial measures in this
Compensation Discussion and Analysis. In particular, we present non-GAAP adjusted net income (and the related
per share measure), which exclude from reported GAAP net income (loss) (and the related per share measure)
certain items, as detailed in the reconciliation table that follows, adjust for the income tax effect of the non-GAAP
adjustments and impact of the change in the statutory tax rate in the U.K.

We believe that each of these non-GAAP financial measures provides useful supplementary information to, and
facilitates additional analysis by, investors and analysts. In particular, we believe that each of these non-GAAP
financial measures, when considered together with our financial information prepared in accordance with GAAP,
can enhance investors’ and analysts’ ability to meaningfully compare our results from period to period, and to
identify operating trends in our business. In addition, these non-GAAP financial measures are regularly used by
investors and analysts to model and track our financial performance. Our management also regularly uses these
non-GAAP financial measures internally to understand, manage and evaluate our business and to make operating
decisions, and compensation of our executive officers is based in part on certain of these non-GAAP financial
measures, as discussed elsewhere in this Compensation Discussion and Analysis. Because these non-GAAP
financial measures are important internal measurements for our management, we also believe that these
non-GAAP financial measures are useful to investors and analysts since these measures allow for greater
transparency with respect to key financial metrics we use in assessing our own operating performance and
making operating decisions.

These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for
comparable GAAP measures; should be read in conjunction with our consolidated financial statements prepared
in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any
comprehensive set of accounting rules or principles. In addition, from time to time in the future there may be other
items that we may exclude for purposes of our non-GAAP financial measures; and we have ceased, and may in
the future cease, to exclude items that we have historically excluded for purposes of our non-GAAP financial
measures. For example, commencing in 2020, we no longer exclude upfront and milestone payments from
non-GAAP adjusted net income (and the related per share measure). Likewise, we may determine to modify the
nature of our adjustments to arrive at our non-GAAP financial measures. Because of the non-standardized
definitions of non-GAAP financial measures, the non-GAAP financial measures as used by us in this
Compensation Discussion and Analysis have limits in their usefulness to investors and may be calculated
differently from, and therefore may not be directly comparable to, similarly titled measures used by other
companies.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

71

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

Reconciliations of GAAP reported net income (loss) to non-GAAP adjusted net income (and the related per share
measures) for the 2020 and 2021 annual periods are as follows (in millions, except per share amounts):

GAAP reported net income (loss)

Intangible asset amortization

Share-based compensation expense

Transaction and integration related expenses(1)

Non-cash interest expense(2)

Acquisition accounting inventory fair value step-up

Impairment charge(3)

Income tax effect of above adjustments

Impact of U.K. tax rate change(4)

Non-GAAP adjusted net income

GAAP reported net income (loss) per diluted share

Non-GAAP adjusted net income per diluted share

Weighted-average ordinary shares used in diluted per share calculations -GAAP

Weighted-average ordinary shares used in diluted per share calculations non-GAAP

Note: Amounts may not total due to rounding.

Explanation of Adjustments and Certain Line Items:

(1) Transaction and integration expenses related to the GW Acquisition.

(2) Non-cash interest expense associated with debt discount and debt issuance costs.

2020

2021

$ 238.6

$(329.7)

259.6

121.0

—

61.1

—

525.8

169.9

243.7

92.7

223.1

136.1

—

(112.5)

(192.5)

—

259.9

$ 704.0

$ 992.8

$ 4.22

$ (5.52)

$ 12.46

$ 16.23

56.5

56.5

59.7

61.2

(3)

Impairment charge related to our decision to stop enrollment in our Phase 3 clinical trial of defibrotide for the prevention of veno-occlusive
disease.

(4) Expense arising on the remeasurement of our U.K. net deferred tax liability, which arose primarily in relation to the GW Acquisition, due to

a change in the statutory tax rate in the U.K. following enactment of the UK Finance Act 2021.

72

2022 Proxy Statement | JAZZ PHARMACEUTICALS

2022 NOTICE OF MEETING AND PROXY STATEMENT

Executive Compensation (continued)

Summary of Compensation

The following table sets forth certain summary information for the years indicated with respect to the
compensation earned by the NEOs during fiscal years 2021, 2020 and 2019, as applicable.

SUMMARY COMPENSATION TABLE

Name and Principal Position

Year

Salary
($)(1)

Bonus
($)(2)

Stock
Awards
($)(3)

Option
Awards
($)(4)

Non-Equity
Incentive
Plan
Compensation
($)(5)

All Other
Compensation
($)(6)

Bruce C. Cozadd

2021

1,077,254

Chairperson and CEO

2020

1,085,123

2019

1,014,415

13,414,116

—

1,163,400

5,881,195

4,210,661

1,381,400

7,001,495

5,379,925

1,304,500

Daniel N. Swisher, Jr.

President

Renée Galá(7)

Executive Vice President
and CFO

Robert Iannone, M.D.,
M.S.C.E

Executive Vice President,
Global Head of Research
and Development

2021

2020

2019

2021

2020

2021

2020

2019

711,154

713,654

667,308

616,923

4,136,737

—

1,809,598

1,295,588

1,960,419

1,506,379

3,577,891

—

484,616

25,000

1,816,868

1,382,012

591,923

592,308

—

—

3,018,091

—

1,221,479

874,522

313,077

205,000

1,672,863

1,249,216

540,000

636,000

560,000

400,000

405,000

380,000

450,000

245,000

—

—

—

—

—

—

—

y
x
o
r
P

Total ($)

15,679,311

12,573,300

14,713,637

5,403,892

4,471,087

4,707,407

4,605,224

4,123,400

4,001,336

3,149,481

3,693,560

24,541

14,921

13,302

16,001

16,247

13,302

10,410

9,904

11,322

11,172

8,405

Chris Tovey(8)

2021

366,576(9) 297,567(10) 3,287,387

—

211,782(11)

4,689

4,168,001

Executive Vice President and
Chief Operating Officer and
Managing Director, Europe
and International

Note: Amounts may not total due to rounding.

(1) The dollar amounts in this column represent base salary earned during the indicated fiscal year. 2021 base salary rates were effective

March 2021. For more information on salaries in 2021, see “Compensation Discussion and Analysis—2021 Compensation Decisions for
Our Named Executive Officers—Individual NEO Compensation Decisions” above.

(2) The dollar amounts in this column represent cash signing bonuses paid to Dr. Iannone in 2019 and Ms. Galá in 2020, and cash bonuses

paid to Mr. Tovey in connection with the closing of the GW Acquisition.

(3) The dollar amounts in this column reflect the aggregate grant date fair value of all time-based RSU and performance-based PSU awards

granted during the indicated fiscal year computed in accordance with FASB ASC 718, excluding the effect of estimated forfeitures. The
grant date fair value for time-based RSUs is measured in accordance with FASB ASC 718 and based on the closing price of our ordinary
shares on the date of grant. The grant date fair value for performance-based PSUs was calculated in accordance with FASB ASC 718
using a Monte-Carlo simulation model. These amounts do not necessarily correspond to the actual value recognized or that may be
recognized by the NEOs. Assuming that maximum performance is achieved, the value of the performance-based PSU awards made to
Messrs. Cozadd, Swisher, Tovey and Dr. Iannone in 2021 at the date of grant under FASB ASC 718 would have been $13,877,611,
$4,279,868, $3,468,926 and $3,121,652, and for Ms. Gala, $3,701,714, respectively. For additional information on the time-based RSUs
and performance-based PSUs granted to our NEOs in 2021, see “Executive Summary—2021 Compensation Decisions of Our Named
Executive Officers—Summary of 2021 Compensation Decisions” and “Compensation Discussion and Analysis—2021 Compensation
Decisions for Our Named Executive Officers” above and footnote 20 to the notes to our audited consolidated financial statements in the
2021 Annual Report on Form 10-K, and also see footnote 2 to the table entitled “Grants of Plan-Based Awards—2021.”

(4) The dollar amounts in this column reflect the aggregate grant date fair value of all stock option awards granted during the indicated fiscal
year. These amounts have been calculated in accordance with FASB ASC 718, using the Black-Scholes option-pricing model and
excluding the effect of estimated forfeitures. Assumptions used in the calculation of these amounts are included in the notes to our audited
consolidated financial statements included in the 2021 Annual Report on Form 10-K. These amounts do not necessarily correspond to the
actual value recognized or that may be recognized by the NEOs.

(5) The dollar amounts in this column represent the cash bonus awarded under the performance bonus plan for the indicated fiscal year. For
more information on the cash bonus awards for 2021, see “Compensation Discussion and Analysis—2021 Performance Bonus Program”
and “Compensation Discussion and Analysis—2021 Compensation Decisions for Our Named Executive Officers” above.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

73

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

(6) The dollar amounts in this column for 2021 include group term life insurance premiums paid, matching contributions under the 401(k) Plan

and expenses for Mr. Cozadd of $10,923 associated with an annual conference.

(7) Ms. Galá was appointed our Executive Vice President and CFO as of March 16, 2020.

(8) Mr. Tovey was appointed our Executive Vice President and Chief Operating Officer and Managing Director, Europe and International, as

of May 5, 2021.

(9) The actual salary paid to Mr. Tovey was £265,945 which was converted to USD using the average foreign exchange rate from May to

December 2021 of 1.37839.

(10) The actual transaction bonus paid to Mr. Tovey in connection with the closing of the GW Acquisition was £164,800. A pre-acquisition

bonus of £57,200 was paid to Mr. Tovey for his services at GW. Both bonuses were paid to Mr. Tovey in March 2022 and converted to
USD using the average foreign exchange rate for March 2022 of 1.34039.

(11) The actual cash bonus awarded under the performance bonus plan to Mr. Tovey was £158,000, which was converted to USD using the
average foreign exchange rate for March 2022 of 1.34039. Please see “Compensation Discussion and Analysis—Individual NEO
Compensation Decisions” for additional details regarding the cash bonus paid to Mr. Tovey.

74

2022 Proxy Statement | JAZZ PHARMACEUTICALS

2022 NOTICE OF MEETING AND PROXY STATEMENT

Executive Compensation (continued)

Grants of Plan-Based Awards

The following table shows, for the fiscal year ended December 31, 2021, certain information regarding grants of
plan-based awards to the NEOs.

GRANTS OF PLAN-BASED AWARDS IN FISCAL 2021

Award Type Grant Date

Approval
Date

Estimated Possible Payouts
Under Non-Equity Incentive
Plan Awards(1)
Target
($)

Threshold
($)

Maximum
($)

Estimated Future Payouts
Under Equity Incentive
Plan Awards(2)
Target
(#)

Threshold
(#)

Maximum
(#)

All Other
Stock
Awards:
Number of
Shares of
Stock or Units
(#)(3)

Grant
Date Fair
Value of
Stock
Awards
($)(4)

y
x
o
r
P

Annual Cash

—

—

—

1,077,254 2,154,508

PSU 5/5/2021 4/27/2021

RSU 2/25/2021

2/9/2021

13,637

36,365 72,730

6,938,806

37,925

6,475,310

Annual Cash

—

—

—

533,365 1,600,095

PSU 5/5/2021 4/27/2021

RSU 2/25/2021

2/9/2021

4,206

11,215 22,430

2,139,934

11,695

1,996,803

Name

Bruce C.
Cozadd

Daniel N.
Swisher, Jr.

Renée Galá

Annual Cash

—

—

—

339,308 1,017,924

PSU 5/5/2021 4/27/2021

RSU 2/25/2021

2/9/2021

3,638

9,700 19,400

1,850,857

10,115

1,727,034

Annual Cash

—

—

—

325,558

976,674

PSU 5/5/2021 4/27/2021

RSU 2/25/2021

2/9/2021

3,068

8,180 16,360

1,560,826

8,535

1,457,265

Robert
Iannone, M.D.,
M.S.C.E

Chris Tovey

Annual Cash

—

—

—

201,594

604,782

PSU 5/5/2021 4/27/2021

RSU 5/5/2021 4/27/2021

3,409

9,090 18,180

1,734,463

9,091

1,552,924

(1) This column sets forth the target and maximum bonus amount for each NEO for the year ended December 31, 2021 under our Global
Cash Bonus Plan. There are no thresholds amounts for each individual officer established under our Global Cash Bonus Plan. The
amounts shown under “Target” reflects the applicable target payment under the Global Cash Bonus Plan if (i) we achieved 100% of the
pre-determined 2021 corporate goals established by our compensation committee, and (ii) as applicable, each NEO’s individual
performance percentage was assessed at 100% by our compensation committee with respect to his or her contributions toward the
achievement of our corporate goals. The amounts shown under “Maximum” reflects the applicable maximum payment under our Global
Cash Bonus Plan if (i) we achieved maximum pre-determined 2021 corporate goals established by our compensation committee, and
(ii) as applicable, each NEO achieved maximum individual performance as assessed by the compensation committee with respect to his
or her contributions toward the achievement of our corporate goals; provided, however, that the bonus payable under our Global Cash
Bonus Plan may not exceed 200% of the officer’s target bonus in the case of the CEO and 300% for each other NEO. Target bonuses
were set as a percentage of each NEO’s base salary earned for the fiscal year ended December 31, 2021 and were 100% for Mr. Cozadd,
75% for Mr. Swisher, and 55% for each of Ms. Galá, Dr. Iannone and Mr. Tovey. The dollar value of the actual bonus award earned for the
year ended December 31, 2021 for each NEO is set forth in the Summary Compensation Table above. As such, the amounts set forth in
this column do not represent either additional or actual compensation earned by the NEOs for the year ended December 31, 2021. For a
description of the performance bonus plan, see “Compensation Discussion and Analysis—2021 Performance Bonus Program” above.

(2) Performance-based PSU awards were granted to our NEO’s on May 5, 2021 pursuant to the 2011 Plan. Each of the PSU awards vests

depending on the achievement of certain performance criteria to be assessed over a performance period of May 5, 2021 to December 31,
2023. Following the determination of the company’s achievement with respect to the performance criteria, the amount of shares awarded
will be subject to adjustment based on the application of a relative total share return, or “TSR” modifier, which depends on the company’s
relative TSR performance against the constituents of the Russell 1000 pharmaceutical and biotechnology component companies over the
same 2.66-year performance period. The number of shares that may be earned ranges between 37.5% of target for threshold performance
and 200% of target for maximum performance based on the degree of achievement of the applicable performance metric and the
application of the relative TSR modifier. For additional information on performance-based PSUs granted to our NEOs in 2021, see
“Executive Summary—2021 Compensation Decisions of our Named Executive Officers —Summary of 2021 Compensation Decisions” and
“Compensation Discussion and Analysis—2021 Compensation Decisions for Our Named Executive Officers” above. The PSU awards are
subject to potential vesting acceleration as described below under the heading “Potential Payments upon Termination or Change in
Control—Treatment of 2021 PSUs.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

75

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

(3) Each of the annual time-based RSU awards vest in four equal annual installments on the anniversary of the vesting commencement date
of March 5, 2021. As a general matter, time-based RSUs will cease vesting upon each NEO’s last day of service. Time-based RSU
awards are subject to potential vesting acceleration as described below under the headings “Description of Compensation
Arrangements—Equity Compensation Arrangements—2011 Equity Incentive Plan” and “Potential Payments upon Termination or Change
in Control—Amended and Restated Executive Change in Control Plan and Severance Benefit Plan” below. See also “Description of
Compensation Arrangements—Equity Compensation Arrangements—2011 Equity Incentive Plan” below for a general description of the
material terms of the 2011 Plan.

(4) The dollar amounts in this column represent the grant date fair value of each PSU and RSU award, as applicable, granted to the NEOs in
2021. These amounts have been calculated in accordance with FASB ASC 718. The grant date fair value for time-based RSUs is based
on the closing price of our ordinary shares on the date of grant. The grant date fair value for performance-based PSUs is calculated using
a Monte-Carlo simulation model. These amounts do not necessarily correspond to the actual value recognized or that may be recognized
by the NEOs. The fair value for each award may differ based on the applicable data, assumptions, and estimates used in the model.

Description of Compensation Arrangements

Executive Employment and Severance Agreements

We do not have employment agreements currently in effect with any of our NEOs based in the United States. Like
other employees, such executive officers are eligible for annual salary increases, participation in the performance
bonus plan and discretionary equity grants.

From time to time, we have provided an offer letter in connection with the commencement of employment of an
executive officer based in the United States, which describes such executive officer’s initial terms of employment.
We do not have agreements currently in effect with any of our NEOs in the United States entitling such individuals
to severance benefits (other than in connection with a change in control pursuant to our change in control plan
described below).

We have employment or service agreements in effect with certain employees based outside of the United States,
including Chris Tovey. In May 2021, Mr. Tovey entered into a service agreement with our subsidiary, Jazz
Pharmaceuticals UK Limited, or the Service Agreement, which includes his initial base salary, a discretionary
target cash bonus and certain severance benefits and notice requirements, as further described below under the
heading “Potential Payments upon Termination or Change in Control—GW UK Change in Control and Severance
Benefit Plan.” In addition, Mr. Tovey is eligible for certain severance and change in control benefits under the GW
UK Change in Control and Severance Benefit Plan and related participation agreement, or the GW Severance
Plan. The GW Severance Plan also provides for the payment of a cash retention bonus equal to £750,000, which
will be earned and paid if Mr. Tovey remains in continuous employment with us through January 1, 2023.

Amended and Restated Executive Change in Control and Severance Benefit Plan

Each of the current NEOs with the exception of Mr. Tovey is a participant in the change in control plan, a
description of which is included below under the heading “Potential Payments upon Termination or Change in
Control—Amended and Restated Executive Change in Control and Severance Benefit Plan.” Mr. Tovey is eligible
for certain change in control and severance benefits under the Service Agreement and the GW Severance Plan,
descriptions of which are included below under the heading “Potential Payments upon Termination or Change in
Control—GW UK Change in Control and Severance Benefit Plan.”

Equity Compensation Arrangements

Since the Azur Merger, we have granted equity awards to employees, including the NEOs, under the 2011 Plan.
From the initial public offering of Jazz Pharmaceuticals, Inc. until the Azur Merger, we granted equity awards to
our employees, including some of the NEOs, under the 2007 Plan. As a result of the GW Acquisition, we
assumed the GW 2020 Long-Term Incentive Plan. For more information on our current equity compensation
program and decisions regarding the grants of equity awards in 2021 for our NEOs, see “Compensation
Discussion and Analysis—2021 Compensation Decisions for Our Named Executive Officers” above. The following
is a brief summary of the material terms of each of our equity compensation plans.

76

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

2011 Equity Incentive Plan
The following is a brief summary of the material terms of the 2011 Plan, as amended and restated.

Types of Awards. The 2011 Plan provides for the grant of incentive stock options, nonstatutory stock options,
stock appreciation rights, restricted stock awards, RSU awards, other stock awards, and performance awards
(including PSU awards) that may be settled in cash, shares, or other property, which may be granted to
employees, including officers.

Corporate Transactions. In the event of certain significant corporate transactions (as defined in the 2011 Plan and
described below), our board of directors will have the discretion to take one or more of the following actions with
respect to outstanding stock awards (contingent upon the closing or completion of such corporate transaction),
unless otherwise provided in the stock award agreement or other written agreement with the participant or unless
otherwise provided by our board of directors at the time of grant:

y
x
o
r
P

•

•

•

•

•

arrange for assumption, continuation, or substitution of a stock award by a surviving or acquiring corporation
(or its parent company);

arrange for the assignment of any reacquisition or repurchase rights applicable to any shares issued pursuant
to a stock award to the surviving or acquiring corporation (or its parent company);

accelerate the vesting, in whole or in part, and exercisability of a stock award and provide for its termination if
it is not exercised at or prior to the corporate transaction;

arrange for the lapse of any reacquisition or repurchase rights applicable to any shares issued pursuant to a
stock award;

cancel or arrange for the cancellation of a stock award, to the extent not vested or exercised prior to the
effective time of the corporate transaction, in exchange for such cash consideration, if any, as the board of
directors may consider appropriate; or

• make a payment equal to the excess, if any, of (a) the value of the property that the participant would have
received upon the exercise of the stock award over (b) any exercise price payable in connection with such
exercise.

Our board of directors need not take the same action for each stock award or with regard to all participants.

For purposes of the 2011 Plan, a “corporate transaction” generally means (i) a sale or disposition of all or
substantially all our assets or a sale or disposition of at least 90% of our outstanding securities; (ii) a merger,
consolidation or similar transaction after which we are not the surviving corporation; or (iii) a merger, consolidation
or similar transaction after which we are the surviving corporation but our ordinary shares are converted or
exchanged into other property.

Change in Control. The board of directors has the discretion to provide additional acceleration of vesting and
exercisability upon or after a change in control (as defined in the 2011 Plan and described below) as may be
provided in a stock award agreement or any other written agreement between us or any of our affiliates and a
participant. The forms of stock option agreement and RSU award agreement adopted by the board of directors
under the 2011 Plan provide that in the event a participant’s service relationship with us or a successor entity is
terminated due to an involuntary termination without cause (as defined in the stock award agreement and as
described below) within 12 months following, or one month prior to, the effective date of a change in control, the
vesting (and in the case of stock options, exercisability) of the stock award will accelerate in full. The treatment of
the 2021 PSUs in the event of a change in control is described below under the heading, “Potential Payments
upon Termination or Change in Control—Treatment of 2021 PSUs.”

For purposes of the 2011 Plan and the forms of award agreements issued thereunder, a “change in control”
generally means (i) a person or group acquires ownership of more than 30% of the combined voting power of our
outstanding securities (other than directly from our company); (ii) certain compromises or arrangements
sanctioned by the Irish courts, certain schemes, contracts or offers that have become binding on all of our
shareholders, certain takeover bids, certain offers or reverse takeover transactions or a reorganization, merger,
statutory share exchange, consolidation or similar transaction involving us, and (A) after which our shareholders

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

77

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

do not own more than 50% of the combined voting power of the surviving entity or its parent in substantially the
same proportion as their ownership of our outstanding voting securities immediately before the transaction, (B) a
person or group acquires ownership of more than 30% of the combined voting power of the surviving entity or its
parent, or (C) at least a majority of the members of the board of directors of the parent (or the surviving entity, if
there is no parent) following such transaction are not incumbent board members (as defined in (v) below) at the
time our board of directors approves the transaction; (iii) our shareholders or our board of directors approves a
complete dissolution or liquidation of our company, or a complete dissolution or liquidation of our company
otherwise occurs (except for a liquidation into a parent company); (iv) a sale, lease, exclusive license or other
disposition of all or substantially all of our assets, other than to certain entities; or (v) individuals who were
members of our board of directors on the date of adoption of the 2011 Plan (or members of our board of directors
approved or recommended by a majority vote of such members still in office), referred to as “incumbent board
members,” cease to constitute at least a majority of our board of directors.

An “involuntary termination without cause” generally means that a participant’s service relationship with us is
terminated for any reason other than for the following reasons (and not upon a participant’s death or disability): (i)
participant’s commission of any felony or crime involving fraud, dishonesty or moral turpitude under the laws of
the United States or any state thereof (with respect to Irish participants, the participant’s conviction for any
criminal offense (other than an offense under any road traffic legislation in Ireland, the United Kingdom or
elsewhere for which a fine or non-custodial penalty is imposed) or any offense under any regulation or legislation
relating to insider dealing, fraud or dishonesty); (ii) participant’s attempted commission of or participation in a
fraud or act of dishonesty against us; (iii) participant’s intentional, material violation of any contract or agreement
with us or of any statutory duty owed to us; (iv) participant’s unauthorized use or disclosure of our confidential
information or trade secrets; or (v) participant’s gross misconduct.

GW 2020 Long-Term Incentive Plan
For information on the GW 2020 Long-Term Incentive Plan, see note 20 to our audited consolidated financial
statements included in the company’s 2021 Annual Report on Form 10-K, which is incorporated herein by
reference.

2007 Employee Stock Purchase Plan
Additional long-term equity incentives are provided through the ESPP. The ESPP is intended to qualify as an
“employee stock purchase plan” within the meaning of section 423 of the Internal Revenue Code, or the Code.
Under the ESPP, all of our regular employees and employees of any of our parent or subsidiary companies
designated by the board of directors as eligible to participate may participate and may contribute, normally
through payroll deductions, up to 15% of their earnings up to a total of $15,000 per purchase period for the
purchase of our ordinary shares under the ESPP. The ESPP is currently offered to our regular employees in
Ireland, Canada and the United States, including the NEOs. The ESPP is implemented through a series of
offerings of purchase rights to eligible employees. Under the ESPP, we may specify offerings with a duration of
not more than 27 months, and may specify shorter purchase periods within each offering. Each offering will have
one or more purchase dates on which our ordinary shares will be purchased for employees participating in the
offering. Unless otherwise determined by the board of directors, ordinary shares are purchased for accounts of
employees participating in the ESPP at a price per share equal to the lower of (a) 85% of the fair market value of
an ordinary share on the first date of an offering or (b) 85% of the fair market value of an ordinary share on the
date of purchase.

Performance Bonus Plan

We maintain a performance bonus plan to reward executive officers and other employees for successful
achievement of company-wide performance objectives and individual contributions toward those objectives on an
annual basis. More information regarding the performance bonus plan is provided above under the headings
“Compensation Discussion and Analysis—2021 Performance Bonus Program” and “Compensation Discussion
and Analysis—2021 Compensation Decisions for Our Named Executive Officers.”

78

2022 Proxy Statement | JAZZ PHARMACEUTICALS

2022 NOTICE OF MEETING AND PROXY STATEMENT

Executive Compensation (continued)

401(k) Plan

Our employees based in the United States are eligible to participate in the 401(k) Plan. The 401(k) Plan is
intended to qualify as a tax-qualified plan under section 401 of the Code. Employee contributions are held and
invested by the 401(k) Plan’s trustee. The 401(k) Plan provides that each participant may contribute a portion of
his or her pre-tax compensation, up to a statutory annual limit, which was $19,500 for employees under age 50,
and $26,000 for employees age 50 and over in 2021. The 401(k) Plan also permits us to make discretionary
contributions and matching contributions, subject to established limits and a vesting schedule. In 2013, we began
making discretionary matching contributions, which for 2021, consisted of a match of 50% of up to the first 6% of
eligible compensation contributed by each employee toward his or her 401(k) plan.

y
x
o
r
P

Additional Benefits

The NEOs are eligible to participate in our benefit plans generally available to all employees, as described in
“Compensation Discussion and Analysis—Key Components and Design of the Executive Compensation
Program.”

Pension Benefits

Other than with respect to tax-qualified defined contribution plans such as the 401(k) Plan, the NEOs do not
participate in any plan that provides for retirement payments and benefits, or payments and benefits that will be
provided primarily following retirement.

Nonqualified Deferred Compensation

During the year ended December 31, 2021, the NEOs did not contribute to, or earn any amounts with respect to,
any defined contribution or other plan sponsored by us that provides for the deferral of compensation on a basis
that is not tax-qualified.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

79

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

Outstanding Equity Awards at Fiscal Year-End

The following table sets forth, for the fiscal year ended December 31, 2021, certain information regarding
outstanding equity awards at fiscal year-end for the NEOs.

OUTSTANDING EQUITY AWARDS AT 2021 FISCAL YEAR-END TABLE

Options

Number of
Securities
Underlying
Unexercised
Options
(#)
Exercisable

Number of
Securities
Underlying
Unexercised
Options
(#)(1)
Unexercisable

Option
Exercise
Price
($)

Option
Expiration
Date(2)

Number of
Shares or
Units of
Stock That
Have Not
Vested
(#)(3)

Market
Value of
Shares or
Units of
Stock That
Have Not
Vested
($)(4)

Stock Awards
Equity
Incentive Plan
Awards:
Number of
Unearned
Shares, Units
or Other
Rights That
Have Not
Vested
(#)(5)

Equity Incentive Plan
Awards:
Market Value or
Payout Value of
Unearned Shares,
Units or Other
Rights That Have
Not Vested
($)(6)

59,583

88,541

86,718

86,500

77,500

72,500

48,784(7)

73,961(7)

77,532(7)

18,333

24,791

44,062

—

70,417(8)

113.10 2/26/2030

37,925(11) 4,831,645

36,365

4,632,901

36,459(9)

140.03 2/27/2029

39,000(12) 4,968,600

5,782(10)

140.67 2/29/2028

25,000(13) 3,185,000

—

—

—

—

—

—

136.18

3/1/2027

9,250(14) 1,178,450

123.36 2/24/2026

175.19 2/25/2025

166.62 2/26/2024

59.13

3/4/2023

46.83

8/8/2022

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

21,667(8)

113.10 2/26/2030

11,695(11) 1,489,943

11,215

1,428,791

10,209(9)

140.03 2/27/2029

12,000(12) 1,528,800

938

140.67 2/29/2028

7,000(13)

891,800

—

—

—

4,500(15)

573,300

—

—

—

—

—

—

Name

Bruce C. Cozadd

Daniel N. Swisher, Jr.

Renée Galá

18,156

23,344(16)

109.45

5/6/2030

10,115(11) 1,288,651

9,700

1,235,780

Robert Iannone,
M.D.,M.S.C.E.

Chris Tovey

—

12,375

19,697

—

—

—

—

—

12,450(17) 1,586,130

—

—

14,625(8)

113.10 2/26/2030

8,535(11) 1,087,359

8,180

1,042,132

10,803(18)

137.12

8/7/2029

8,100(12) 1,031,940

—

—

—

6,100(19)

777,140

—

—

—

—

8,063(20)

0.02 2/22/2031

9,091(21) 1,158,193

9,090

1,158,066

(1)

In addition to the specific vesting schedule for each stock award, each unvested stock award is subject to the general terms of the 2011
Plan, as applicable, including the potential for future vesting acceleration described above under the heading “Description of
Compensation Arrangements— Equity Compensation Arrangements” as well as the potential vesting acceleration (i) under the terms of
the change in control plan described below under the heading “Potential Payments upon Termination or Change in Control—Amended
and Restated Executive Change in Control and Severance Benefit Plan,” (ii) under the terms of the GW Severance Plan described below
under “Potential Payments upon Termination or Change in Control—GW UK Change in Control and Severance Benefit Plan,” and
(iii) pursuant to the 2021 PSU award agreement described under, “Potential Payments upon Termination or Change in Control—Treatment
of 2021 PSUs.”

(2) As a general matter, stock options granted to NEOs expire on the day before the tenth anniversary of their grant date, or earlier in the

event of an NEO’s termination of service. In the event of an NEO’s termination of service, stock options generally expire three months after
such termination of service, subject to extension under limited circumstances such as if the sale of shares during such time was prohibited
by our insider trading policy or if exercise would result in violation of securities registration requirements. For more information, see
description under the heading “Potential Payments upon Termination or Change in Control—Equity Compensation Plans.”

(3) Subject to the terms of the award agreement, each time-based RSU award listed in this column represents an RSU award that vests in

four equal annual installments on the anniversary of the applicable vesting commencement date.

80

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

(4) The market values of the time-based RSU awards that have not vested are calculated by multiplying the number of shares underlying the

RSU awards shown in the table by $127.40, the closing price of our ordinary shares on December 31, 2021.

(5) The target number of PSUs is shown in each case assuming target performance of 100% and a TSR modifier of 1. The actual number of

PSUs that could be earned is between 0% and 200% of the target number of PSUs, which vest depending on the company’s achievement
with respect to certain performance criteria and our relative TSR compared to the constituents of the Russell 1000 pharmaceutical and
biotechnology component companies over the same 2.66-year performance period. For additional information on these PSUs, see
“Executive Summary—2021 Compensation Decisions of our Named Executive Officers—Summary of 2021 Compensation Decisions” and
“Compensation Discussion and Analysis—2021 Compensation Decisions for Our Named Executive Officers” above.

(6) The market values of the PSU awards that have not vested are calculated by multiplying the number of shares underlying the PSU awards

shown in the table by $127.40, the closing price of our ordinary shares on December 31, 2021.

(7) The number of shares reported reflects the transfer of beneficial ownership of a portion of the indicated stock option awards in 2015 to

y
x
o
r
P

Mr. Cozadd’s former spouse pursuant to a domestic relations order.

(8) The unexercisable shares subject to this stock option award as of December 31, 2021 vest monthly from January 27, 2022 to February 27,

2024.

(9) The unexercisable shares subject to this stock option award as of December 31, 2021 vest monthly from January 28, 2022 to February 28,

2023.

(10) The unexercisable shares subject to this stock option award as of December 31, 2021 vest monthly from January 1, 2022 to March 1,

2022.

(11) Time-based RSUs awarded on February 25, 2021, vesting in equal annual installments over four years measured from the vesting

commencement date of March 5, 2021.

(12) Time-based RSUs awarded on February 27, 2020, vesting in equal annual installments over four years measured from the vesting

commencement date of March 5, 2020.

(13) Time-based RSUs awarded on February 28, 2019, vesting in equal annual installments over four years measured from the vesting

commencement date of March 5, 2019.

(14) Time-based RSUs awarded on March 1, 2018, vesting in equal annual installments over four years measured from the vesting

commencement date of March 5, 2018.

(15) Time- based RSUs awarded on March 1, 2018, vesting in equal annual installments over four years measured from the vesting

commencement date of January 3, 2018.

(16) The unexercisable shares subject to this stock option award as of December 31, 2021 vest monthly from January 16, 2022 to March 16,

2024.

(17) Time-based RSUs awarded on May 7, 2020, vesting in equal annual installments over four years measured from the vesting

commencement date of April 5, 2020.

(18) The unexercisable shares subject to this stock option award as of December 31, 2021 vest monthly from January 29, 2022 to May 29,

2023.

(19) Time-based RSUs awarded on August 8, 2019, vesting in equal annual installments over four years measured from the vesting

commencement date of June 5, 2019.

(20) Option to acquire Jazz Pharmaceutical ordinary shares received upon conversion of options to acquire shares of GW as a result of the GW

Acquisition. Fifty percent of the award will vest and be available for exercise on February 22, 2022 and fifty percent will vest and be
available for exercise on February 22, 2023 in accordance with the terms of the GW Acquisition. In addition to the specific vesting
schedule for the option, unvested shares are subject to the general terms of the GW 2020 Long-Term Incentive Plan, including the
potential for future vesting acceleration described above under the heading “Description of Compensation Arrangements—Equity
Compensation Arrangements” as well as the potential vesting acceleration under the terms of the GW Severance Plan described below
under “Potential Payments upon Termination or Change in Control —GW UK Change in Control and Severance Benefit Plan.”

(21) Time-based RSUs awarded on May 5, 2021, vesting in equal annual installments over four years measured from the vesting

commencement date of May 5, 2021.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

81

2022 NOTICE OF MEETING AND PROXY STATEMENT

Executive Compensation (continued)

Option Exercises and Stock Vested

The following table provides information on RSUs vested and stock options exercised, including the number of
shares acquired upon exercise and the value realized, determined as described below, for the NEOs in the year
ended December 31, 2021.

Name

Bruce C. Cozadd

Daniel N. Swisher, Jr.

Renée Galá

Robert Iannone, M.D., M.S.C.E

Chris Tovey

Option Awards

Stock Awards

Number of
Shares
Acquired on
Exercise (#)

Value Realized
on Exercise
($)(1)

31,752

2,633,783

—

—

—

—

—

—

—

—

Number of
Shares Acquired
on Vesting
(#)

43,400

12,000

4,150

5,750

—

Value Realized on

Vesting
($)(2)

7,150,146

1,957,424

683,546

983,058

—

(1) The value realized on exercise is based on the difference between the closing price of our ordinary shares on the date of exercise and the
applicable exercise price of those options and does not represent actual amounts received by the NEOs as a result of the option exercises.

(2) The value realized on vesting is based on the number of shares underlying the RSUs that vested and the closing price of our ordinary

shares on the vesting date.

Potential Payments upon Termination or Change in Control

Amended and Restated Executive Change in Control and Severance Benefit Plan

All of our executives other than Chris Tovey are eligible for certain severance and change in control benefits
under our change in control plan. The change in control plan applies to eligible executive employees of U.S.
affiliates of Jazz and provides that, in the event that an executive’s employment terminates due to an involuntary
termination without cause or a constructive termination, in each case upon or within 12 months following a change
in control (as such terms are defined in the change in control plan and described generally below), and assuming
all of the other conditions of the change in control plan are met, each executive who is a participant in the change
in control plan (including each of our NEOs) would be entitled to the following benefits under the change in control
plan:

•

A single, lump sum cash severance payment equal to the sum of: (i) the applicable base salary described
below, multiplied by the applicable percentage set forth below; plus (ii) the product of (A) the applicable base
salary, (B) the applicable bonus percentage described below and (C) the applicable percentage set forth
below; plus (iii) the product of (A) the applicable base salary, (B) the applicable bonus percentage and the
quotient obtained by dividing the number of full months that an executive is employed in the year of the
termination by 12.

O

O

O

The “applicable base salary” is the higher of the executive’s base salary in effect (i) on the date of
termination (without giving effect to any reduction in base salary that would constitute grounds for a
constructive termination) or (ii) immediately prior to the change in control, without giving effect to any
voluntary pay reduction taken by the executive during the 12 months preceding the date of termination or
the change in control.

The “applicable percentage” is 200% for our CEO, executive chairperson or president, 150% for senior
vice presidents and above and 100% for vice presidents.

The “applicable bonus percentage” is the greater of (i) the highest amount of any annual bonus paid to
the executive for either of the last two calendar years prior to (A) the date of termination or (B) the change
in control, in each case expressed as a percentage of the executive’s base salary for the applicable year,
and (ii) the higher of the executive’s target bonus for the calendar year in which (A) the termination occurs
or (B) the change in control occurs, in each case expressed as a percentage of the executive’s base
salary for such year.

82

2022 Proxy Statement | JAZZ PHARMACEUTICALS

y
x
o
r
P

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

•

•

Full payment of all of the applicable COBRA premiums for any health, dental or vision plan sponsored by us
for a period of up to (i) 24 months for our CEO, executive chairperson or president, (ii) 18 months for
executive vice presidents and senior vice presidents, and (iii) 12 months for vice presidents, provided that the
executive timely elects continued coverage.

Acceleration in full of the vesting and exercisability, as applicable, of outstanding stock options and other
equity awards held by the executive.

The following key terms are defined in the change in control plan:

•

•

•

A “change in control” generally means: (i) a person or group acquires ownership of more than 30% of the
combined voting power of our outstanding securities (other than directly from our company); (ii) certain
compromises or arrangements sanctioned by the Irish courts, certain schemes, contracts or offers that have
become binding on all of our shareholders, certain takeover bids, certain offers or reverse takeover
transactions, or a reorganization, merger, statutory share exchange, consolidation or similar transaction
involving us, after which our shareholders do not own more than 50% of the combined voting power of the
surviving entity or its parent in substantially the same proportion as their ownership of our outstanding voting
securities immediately before the transaction, or a person or group acquires ownership of more than 30% of
the combined voting power of the surviving entity or its parent, or at least a majority of the members of the
board of directors of the parent (or the surviving entity, if there is no parent) following such transaction are not
incumbent board members (as defined in (v) below) at the time our board of directors approves the
transaction; (iii) our shareholders or our board of directors approves a complete dissolution or liquidation of
our company, or a complete dissolution or liquidation of our company otherwise occurs (except for a
liquidation into a parent company); (iv) a sale, lease, exclusive license or other disposition of all or
substantially all of our assets, other than to certain entities; or (v) individuals who were members of our board
of directors as of February 10, 2016 (or members of our board of directors approved or recommended by a
majority vote of such members still in office), referred to as “incumbent board members,” cease to constitute
at least a majority of the board of directors.

An “involuntary termination without cause” generally means an executive’s employment is terminated for any
reason other than for the following reasons: (i) the executive’s unauthorized use or disclosure of confidential
information or trade secrets which causes material harm to us; (ii) the executive’s material breach of any
agreement with us (or the executive’s material violation of any statutory duty owed to us) after an opportunity
to cure; (iii) the executive’s material failure to comply with our written policies or rules after an opportunity to
cure; (iv) the executive’s conviction or plea of guilty or no contest to any crime involving fraud, dishonesty or
moral turpitude; (v) the executive’s gross misconduct; (vi) the executive’s continued failure to perform his or
her assigned duties after notification; or (vii) the executive’s failure to reasonably cooperate in good faith with
any governmental or internal investigation of us or our directors, officers or employees. An “involuntary
termination without cause” also includes an executive’s termination of employment due to death or disability.

A “constructive termination” generally means an executive resigns employment after any of the following
actions are taken or events occur without the executive’s written consent: (i) one or more reductions in the
executive’s base salary that results in a total reduction in the executive’s base salary, as in effect immediately
prior to the change in control or any higher base salary in effect following the change in control, by more than
10%; (ii) a relocation of the executive’s principal place of employment that increases the executive’s one-way
commute by more than 35 miles; (iii) a substantial reduction in the executive’s authority, duties or
responsibilities that are in effect immediately prior to the change in control, provided that if the executive holds
the same position but the size of the executive’s employing entity or business unit has decreased significantly
or our company or the executive’s employing entity ceases to be a publicly-traded corporation, the executive’s
authority, duties and responsibilities will be considered to be substantially reduced; (iv) a reduction in the
executive’s title; or (v) a substantial increase in executive’s required business travel as compared with the
executive’s required business travel prior to the change in control.

We benefit by requiring the executive to execute an effective general waiver and release of claims in order to be
eligible to receive benefits under the change in control plan. All other benefits (such as life insurance, disability
coverage and 401(k) Plan eligibility) will terminate as of the executive’s termination date.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

83

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

The change in control plan does not provide for the gross up of any excise taxes imposed by section 4999 of the
Code. If any of the severance benefits payable under the change in control plan would constitute a “parachute
payment” within the meaning of section 280G of the Code, subject to the excise tax imposed by section 4999 of
the Code, the change in control plan provides for a best after-tax analysis with respect to such payments, under
which the executive will receive whichever of the following two alternative forms of payment would result in
executive’s receipt, on an after-tax basis, of the greater amount of the transaction payment notwithstanding that
all or some portion of the transaction payment may be subject to the excise tax: (i) payment in full of the entire
amount of the transaction payment, or (ii) payment of only a part of the transaction payment so that the executive
receives the largest payment possible without the imposition of the excise tax.

The executive would not receive benefits under the change in control plan in certain circumstances, including if
(i) the executive voluntarily terminates employment with us to accept employment with another entity that is
controlled, directly or indirectly, by us or is otherwise affiliated with us; (ii) the executive does not confirm in writing
that he or she is subject to agreements with us relating to proprietary and confidential information and our code of
conduct; or (iii) the executive does not return all company property. In addition, benefits would be terminated
under the change in control plan if the executive willfully breaches his or her agreements with us relating to
proprietary and confidential information or our code of conduct.

The structure and amount of benefits provided under the change in control plan are intended to balance our goals
of attracting and retaining highly qualified individuals, providing the appropriate incentive for such individuals to
perform in the best interests of our shareholders and maintaining responsible pay practices. Our compensation
committee periodically reviews market data to gain a general understanding of the change in control benefits
offered by our competitors and reviews the benefits offered under the change in control plan against such market
data to ensure that the benefits under the change in control plan remain appropriate.

GW UK Change in Control and Severance Benefit Plan
Mr. Tovey is eligible for certain severance and change in control benefits under his Service Agreement and the
GW Severance Plan.

The GW Severance Plan provides that, if Mr. Tovey’s employment is terminated due to an involuntary termination
during the change in control period (as such terms are defined in the GW Severance Plan and described
generally below), and assuming all of the other conditions of the GW Severance Plan are met, Mr. Tovey would
be entitled to the following benefits under the GW Severance Plan:

•

•

•

A single lump sum cash severance payment equal to the sum of (i) the applicable base salary described
below plus (ii) the applicable bonus percentage set forth below multiplied by one and a half (1.5).

O

O

The “applicable base salary” is the aggregate of Mr. Tovey’s base salary as of immediately prior to the
closing of the GW Acquisition for 18 months following the date of the termination.

The “applicable bonus percentage” is the higher of (i) Mr. Tovey’s annual target bonus determined as of
immediately prior to the closing of the GW Acquisition and (ii) the average of Mr. Tovey’s actual
annualized bonus payment percentages for the three years 2018, 2019 and 2020.

In monthly installments, cash payment of all health insurance coverage premiums for up to 18 months.

Acceleration in full of the vesting and exercisability, as applicable, of outstanding stock options and other
equity awards granted under the GW 2020 Long-Term Incentive Plan (other than any awards granted in 2021
or after) held by Mr. Tovey.

The GW Severance Plan also provides that, if Mr. Tovey’s employment is terminated without cause by us, he
would be entitled to vesting of a prorated portion of his Sign-On Grant (as such term is defined in the GW
Severance Plan and described generally below), equal to the sum of (i) with respect to the PSUs, the target
number of PSUs subject to the Sign-On Grant multiplied by a fraction equal to the number of days during the
vesting period that has elapsed from the closing of the GW Acquisition through the date of his termination of
employment, relative to the total number of days of the vesting period and (ii) with respect to the RSUs, a
percentage of each tranche based on the number of complete months that has elapsed from the grant date of the

84

2022 Proxy Statement | JAZZ PHARMACEUTICALS

y
x
o
r
P

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

Sign-On Grant through the date of his termination of employment, relative to the number of months in the
applicable vesting period as determined on a tranche by tranche basis.

The following key terms are defined in the GW Severance Plan:

•

•

•

•

•

An “involuntary termination” generally means the termination of Mr. Tovey’s continuous service due to (i) a
termination by us without cause (and other than as a result of death or disability) or (ii) Mr. Tovey’s
resignation for good reason.

conviction, indictment or pleading guilty or no contest to any criminal offence (except for

“Cause” generally means summary termination under the terms of the Service Agreement or any of the
following events: (i)
an offence under the road traffic legislation in the United Kingdom or abroad for which the Mr. Tovey is not
sentenced to any term of imprisonment, whether immediate or suspended); (ii) intentional misconduct;
(iii) sustained poor job performance and/or failure to meet material performance or production standards, as
determined by the plan administrator in good faith; (iv) unauthorized use or disclosure of confidential
information or trade secrets; (v) attempted commission of, or participation in, a fraud or act of dishonesty
against us; (vi) material violation of any contract or agreement between Mr. Tovey and us, any written policy
applicable to Mr. Tovey, or of any statutory duty owed to us; (vii) intentional act that has or is reasonably likely
to lead to a material detrimental effect on our reputation or business; or (viii) failure to cooperate with us in
any investigation or formal proceeding.

A “resignation for good reason” generally means Mr. Tovey resigns employment after any of the following
actions or events occur without his written consent: (i) a material reduction in Mr. Tovey’s authority, duties or
responsibilities (which shall include, but not be limited to, a material reduction in his policy or decision making
authority or a material reduction in the budget or personnel over which he retains authority); (2) a material
reduction of Mr. Tovey’s annual base salary, which is a reduction of more than 10% of such base salary; (3) a
relocation of Mr. Tovey’s principal place of employment to a place that increases his one-way commute by
more than 35 miles as compared to his then-current principal place of employment immediately prior to such
relocation (excluding regular travel in the ordinary course of business); or (4) a material breach of the GW
Severance Plan by us.

The “change in control period” means the period commencing immediately prior to the closing of the GW
Acquisition and ending 24 months following the closing of the GW Acquisition (on May 5, 2023).

The “Sign-On Grant” is Mr. Tovey’s initial long-term stock incentive awards of 9,090 PSUs, which will become
eligible to vest at the end of a three-year performance period, and 9,091 RSUs, which vest ratably over four
years, subject in each case to the term and conditions set forth in the 2011 Plan.

The Service Agreement provides that if Mr. Tovey’s employment is terminated by us prior to January 1, 2023, he
is entitled to the amount of prior written notice required by applicable law or payment in lieu thereof. If Mr. Tovey’s
employment is terminated by us after January 1, 2023, he is entitled to six months’ notice or payment in lieu
thereof. If Mr. Tovey’s employment is terminated due to an involuntary termination by us after May 5, 2023, he is
additionally entitled to cash payment of all health insurance coverage premiums for up to 12 months, paid in
monthly installments. The Service Agreement is further described under the heading “Description of
Compensation Arrangements—Executive Employment and Severance Agreements.

We benefit by requiring Mr. Tovey to execute an effective general waiver and release of claims in order to be
eligible to receive benefits under the GW Severance Plan and the Service Agreement. All other benefits will
terminate as of his termination date.

Mr. Tovey would not receive benefits under the GW Severance Plan or the Service Agreement in certain
circumstances, including if (i) he voluntarily terminates employment with us to accept employment with another
entity that is controlled, directly or indirectly, by us or is otherwise affiliated with us; (ii) Mr. Tovey is offered an
identical or substantially equivalent or comparable position with us which would not give rise to his right to a
resignation for good reason; (iii) Mr. Tovey transfers to a successor and such transfer would not give rise to his
right to a resignation for good reason; (iv) Mr. Tovey is rehired by us and recommences employment prior to the
date the severance benefits are scheduled to commence; (v) Mr. Tovey violates the provisions of the Service
Agreement; and (vi) Mr. Tovey violates the terms of a release, as applicable.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

85

2022 NOTICE OF MEETING AND PROXY STATEMENT

Executive Compensation (continued)

Equity Compensation Plans

The 2011 Plan and award agreements thereunder provide for potential vesting acceleration upon an executive’s
termination in connection with a change in control and, at the discretion of the board of directors, upon certain
change in control events, as further described above under the heading “Description of Compensation
Arrangements—Equity Compensation Arrangements.” In addition, under the terms of the 2011 Plan and the
option award agreements thereunder, the vested portion of stock options granted to the NEOs will generally
expire three months after the applicable NEO’s termination of service, subject to extension under limited
circumstances such as if the sale of shares during such time was prohibited by our insider trading policy or if
exercise would result in violation of securities registration requirements. We refer to the period following the
NEO’s termination during which he or she can continue to exercise his or her vested stock options as the post-
termination exercise period. However, in termination situations involving the death or disability of an NEO, the
post-termination exercise period is generally extended up to 12 months in connection with a termination due to
disability and up to 18 months in connection with a termination due to death. As the value of such extended post-
termination exercise periods is not quantifiable, such value is not included in the table below.

Treatment of 2021 RSUs
The 2021 RSU award agreement provide for potential vesting acceleration upon an executive’s death, disability or
retirement. If an NEO’s continuous service terminates due to death, the vesting of the RSUs subject to the 2021
award agreement shall be accelerated in full, effective as of the date of such termination. If an NEO’s continuous
service terminates due to disability, the NEO’s unvested RSUs will continue to vest pursuant to the original
vesting schedule as provided in the RSU award grant notice. If, on or after the first anniversary of the date of
grant of the 2021 RSU, the NEO’s continuous service terminates due to the NEO’s Regular Retirement or NEO’s
Long-Service Retirement (each as defined below), then provided that (i) the NEO has given the company at least
four months advance written notice of the NEO’s intention to terminate her/his continuous service and (ii) the NEO
executes and delivers a non-solicitation agreement satisfactory to the company that will apply for a period of 12
months after the termination date, then the RSUs will be treated as follows:

(1) In the case of an NEO’s Regular Retirement, a pro-rata portion of each unvested tranche of RSUs will
continue to vest pursuant to the original vesting schedule as provided in the grant notice. For each such unvested
tranche of the RSUs, such pro-rata portion shall be determined by reference to the number of RSUs in such
unvested tranche of the award multiplied by the ratio of (x) the number of calendar days that have elapsed from
the vesting commencement date through the date of an NEO’s termination of continuous service divided by
(y) the total number of calendar days in such vesting tranche (which, for clarity, shall be equal to the number of
calendar days that have elapsed from the vesting commencement date through the vesting date for such
tranche), and rounded down to the nearest whole RSU. For purposes of the foregoing, “Regular Retirement”
means an NEO’s voluntary termination of continuous service, unless circumstances exist at the time of such
termination that would constitute cause, following: (a) the NEO’s completion of five years of continuous service
and (b) the NEO’s attainment of age 55. (2) In the case of the NEO’s Long-Service Retirement, all of the NEO’s
unvested RSUs will continue to vest pursuant to the original vesting schedule as provided in the grant notice. For
purposes of the Award, “Long-Service Retirement” means an NEO’s voluntary termination of continuous service,
unless circumstances exist at the time of such termination that would constitute cause, following: (a) the NEO’s
completion of 10 years of continuous service and (b) the NEO’s attainment of age 55.

Treatment of 2021 PSUs
The 2021 PSU award agreement provide for potential vesting acceleration upon an executive’s termination in
connection with a change in control, as well as upon death, disability or retirement. If a change in control occurs
prior to the last day of the performance period and if the award is assumed or continued or substituted with a
similar stock award in connection with such change in control, then the vesting schedule of the award will be
revised in a manner as though the greater of (i) the number of target PSUs and (ii) the number of certified PSUs
(as determined in accordance with the award agreement), or the CIC PSUs, had been subject solely to a vesting
schedule pursuant to which the CIC PSUs would have vested on the last day of the performance period, subject
to the NEO’s continuous service through such date. In the event an NEO’s service relationship with us or a

86

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

successor entity is terminated due to an involuntary termination without cause (and other than due to death or
disability) within 12 months following, or one month prior to, the effective date of a change in control, the number
of CIC PSUs shall become vested. If the NEO experiences an involuntary termination without cause or a
constructive termination pursuant to the change in control plan, the number of CIC PSUs shall accelerate.

In addition, if the NEO’s continuous service terminates prior to the last day of the performance period due to
death, then a number of PSUs shall become vested in an amount equal to (i) the number of target PSUs,
multiplied by (ii) a ratio, the numerator of which is the number of calendar days during the performance period that
the NEO was in continuous service and the denominator of which is the total number of calendar days in the
performance period, with the resulting number rounded up to the nearest whole PSU. If the NEO’s continuous
service terminates prior to the last day of the performance period due to the NEO’s disability or retirement (as
defined in the PSU award agreement), then effective as of the vesting date, a number of PSUs shall become
vested in an amount equal to (i) the number of certified PSUs determined in accordance with the award
agreement, multiplied by (ii) a ratio, the numerator of which is the number of calendar days during the
performance period that the NEO was in continuous service and the denominator of which is the total number of
calendar days in the performance period, with the resulting number rounded up to the nearest whole PSU.

y
x
o
r
P

Potential Payments upon Termination or Change in Control Table

The following table estimates the potential severance payments and benefits under the change in control plan,
GW Severance Plan and Service Agreement to which the NEOs would have been entitled in connection with
specified termination events, calculated as if each NEO’s employment had terminated as of December 31, 2021.
In addition, the table sets forth the amounts to which the NEOs would have been entitled under the 2011 Plan and
GW Long-Term Incentive Plan, if, upon a corporate transaction or change in control transaction, the board of
directors had exercised its discretion to accelerate the vesting and exercisability of stock options and the vesting
of PSU awards and RSU awards, and such event had occurred on December 31, 2021. The table also reflects
amounts relating to potential vesting acceleration of the PSU awards and RSU awards, as described above.

There are no other agreements, arrangements or plans that entitle any NEOs to severance, perquisites or other
benefits upon termination of employment or a change in control. For purposes of the table below, we have
assumed that none of the potential severance benefits payable under the change in control plan would be subject
to the excise tax imposed by section 4999 of the Code and therefore would not be reduced in accordance with the
terms of the change in control plan.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

87

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE IN CONTROL
AS OF DECEMBER 31, 2021

Name

Bruce C. Cozadd

Daniel N. Swisher, Jr.

Renée Galá

Robert Iannone,
M.D., M.S.C.E

Chris Tovey(6)

Involuntary
Termination
Without
Cause or
Constructive
Termination
in
Connection
with a
Change of
Control($)(1)(8)

Benefit

Certain
Corporate
Transactions($)(2)

Death($)(3)

Disability or
Retirement(4)

Lump Sum Cash Severance
Payment

6,432,655

COBRA Payments

85,732

—

—

—

—

Vesting Acceleration(5)

19,803,544

19,803,544

5,663,903

Benefit Total

26,321,931

19,803,544

5,663,903

Lump Sum Cash Severance
Payment

3,407,130

COBRA Payments

85,732

—

—

—

—

Vesting Acceleration(5)

6,222,467

6,222,467

1,746,612

Benefit Total

9,715,329

6,222,467

1,746,612

Lump Sum Cash Severance
Payment

1,976,250

COBRA Payments

64,299

—

—

—

—

Vesting Acceleration(5)

4,529,583

4,529,583

1,510,647

Benefit Total

6,570,132

4,529,583

1,510,647

Lump Sum Cash Severance
Payment

2,056,630

COBRA Payments

61,170

—

—

—

—

Vesting Acceleration(5)

4,147,705

4,147,705

1,274,568

Benefit Total

6,265,505

4,147,705

1,274,568

Lump Sum Cash Severance
Payment

Health Insurance Coverage
Premium Payments

1,127,489

4,248

—

—

—

—

Vesting Acceleration(5)(7)(9)

2,464,145

2,464,145

1,366,229

Benefit Total

3,595,882(9)

2,464,145

1,366,229

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

—

(1) Except as otherwise provided for Mr. Tovey, these benefits would be payable under the change in control plan if the involuntary

termination without cause or constructive termination occurred upon or within 12 months following a change in control and assuming such
termination took place on December 31, 2021. The forms of equity grant agreements under the 2011 Plan provide for the same vesting
acceleration benefit as shown here under the change in control plan (except as otherwise described above under the heading, “Potential
Payments upon Termination or Change in Control—Treatment of 2021 PSUs”), therefore no separate vesting acceleration benefit is listed.
Pursuant to the change in control plan, an involuntary termination without cause also includes an individual’s death or disability.

(2) These benefits would be payable under the 2011 Plan and GW 2020 Long-Term Incentive Plan, if, upon a corporate transaction event, the
board of directors exercised its discretion to accelerate the vesting and exercisability of outstanding equity grant agreements, assuming the
vesting acceleration took place on December 31, 2021. For a description of the potential vesting acceleration provisions in the 2011 Plan
and GW 2020 Long-Term Incentive Plan, see “Description of Compensation Arrangements—Equity Compensation Arrangements” above.

88

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

(3) The value of RSU and pro-rated portion of PSU vesting upon death from grant date to December 31, 2021. Options are not included as

explained above in “Potential Payments upon Termination or Change in Control— Equity Compensation Plans.”

(4) The value of RSU vesting upon retirement from grant date to December 31, 2021 is not included because vesting acceleration of RSUs

granted in 2021 do not arise until one year from the date of grant. Options are not included as explained above in “Potential Payments
upon Termination or Change in Control— Equity Compensation Plans.” The value of RSU vesting upon disability from grant date to
December 31, 2021 is not included for the same reason as for options. The value of PSU vesting upon retirement or disability from grant
date to December 31, 2021 is not included because no PSUs were earned as of December 31, 2021.

(5) The value of equity grants vesting acceleration is based on the closing price of $127.40 per ordinary share on December 31, 2021, minus,

in the case of stock options, the exercise price of the unvested stock option shares subject to acceleration.

(6)

If Mr. Tovey’s employment is terminated by us prior to January 1, 2023, he is entitled to the amount of prior written notice required by applicable
law or payment in lieu thereof. For example, if Mr. Tovey’s employment was terminated by us on December 31, 2021 with no notice, he would be
entitled to a payment of £69,231 ($93,316), which is equivalent to his compensation for 9 weeks. This amount is not included in the chart above.
£69,231 was converted to $93,316 using the closing foreign exchange rate for December 2021 of 1.34789 for GBP to USD.

y
x
o
r
P

(7)

Includes the vesting of a prorated portion of Mr. Tovey’s Sign-On Grant in the amount of $1,437,080 which Mr. Tovey will receive under
the GW Severance Plan, if he is terminated without cause (with or without a change in control).

(8) The benefits to Mr. Tovey would be payable under the GW Severance Plan if the involuntary termination without cause or resignation for
good reason (as described above under the heading “Potential Payments upon Termination or Change of Control—GW UK Change in
Control and Severance Benefit Plan”) occurred prior to May 5, 2023, and assuming such termination took place on December 31, 2021.
Pursuant to the GW Severance Plan, an involuntary termination without cause excludes an individual’s death or disability. The forms of
PSU and RSU agreements under the 2011 Plan provide for the same vesting acceleration benefit as shown here under the GW
Severance Plan, therefore no separate vesting acceleration benefit is listed.

(9)

Includes $1.0 million relating to accelerated vesting of 8,063 shares exercisable under options, assumed under the GW 2020 Long-Term
Incentive Plan, which options became exercisable for Jazz shares pursuant to the GW Acquisition agreement.

Pay Ratio Disclosure

Under SEC rules, we are required to calculate and disclose the annual total compensation of our median
employee, as well as the ratio of the annual total compensation of our median employee as compared to the
annual total compensation of our CEO, or our CEO pay ratio. For 2021, to identify our median employee, we used
the following methodology:

•

•

•

•

To determine our total population of employees, we included all full-time, part-time, regular and temporary
employees as of October 1, 2021.

To identify our median employee from our employee population, we calculated the annual target amount of
each employee’s 2021 base salary (using a reasonable estimate of the hours worked and no overtime for
hourly employees) and bonus or commission, as applicable, and added the estimated value of all equity
awards granted during 2021. For purposes of base salaries, bonuses and commissions, we used an estimate
based on the rates in effect on October 1, 2021. The value of equity awards was not included in the
calculation of the median of the annual total compensation of our employees for 2021.

In making this determination, we annualized the base salaries, bonuses and commissions of employees who
were employed by us for less than the entire calendar year.

Compensation paid in foreign currencies was converted to U.S. dollars based on the average daily exchange
rates for the year-to-date period ending on October 1, 2021.

Using this approach, we determined our median employee and then calculated the annual total compensation of
this employee for 2021 in accordance with the requirements of the Summary Compensation Table.

For 2021, the median of the annual total compensation of our employees (other than our CEO) was $212,134 and
the annual total compensation of our CEO, as reported in our Summary Compensation Table, was $15,679,311.
Based on this information, the ratio of the annual total compensation of our CEO to the median of the annual total
compensation of all employees was 74 to 1.

The CEO pay ratio above represents our reasonable estimate calculated in a manner consistent with SEC rules and
applicable guidance. SEC rules and guidance provide significant flexibility in how companies identify the median
employee, and each company may use a different methodology and make different assumptions particular to that
company. As a result, and as explained by the SEC when it adopted these rules, in considering the pay ratio

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

89

Executive Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

disclosure, shareholders should keep in mind that the rule was not designed to facilitate comparisons of pay ratios
among different companies, even companies within the same industry, but rather to allow shareholders to better
understand and assess each company’s compensation practices and pay ratio disclosures.

Neither the compensation committee nor our management used our CEO pay ratio measure in making
compensation decisions.

90

2022 Proxy Statement | JAZZ PHARMACEUTICALS

2022 NOTICE OF MEETING AND PROXY STATEMENT

DIRECTOR COMPENSATION

Non-Employee Director Compensation Policy

Overview of Director Compensation. Our non-employee directors receive cash compensation and equity
compensation for their service on the board of directors. The compensation committee reviews the compensation
of our non-employee directors periodically and recommends changes to the board of directors when it deems
appropriate. To assist with the compensation committee’s and the board of directors’ review, the compensation
committee’s external compensation consultant prepares a comprehensive annual assessment of our
non-employee director compensation program. The assessment includes benchmarking director compensation
against the same peer group used for executive compensation decision-making, an update in recent trends in
director compensation and a review of related corporate governance best practices. We target compensation for
service on our board of directors and committees generally at the 50th percentile for board service at companies
in our peer group of companies.

y
x
o
r
P

Non-Employee Director Compensation Policy. Our non-employee director compensation policy, or director
compensation policy, was originally approved by our board of directors in 2013 and has subsequently been
amended, most recently in 2021. The equity grants made pursuant to the director compensation policy are
granted under the Amended and Restated 2007 Non-Employee Directors Stock Award Plan, or 2007 Directors
Plan.

Limit on Director Compensation. In any case, the aggregate value of all compensation granted or paid, as
applicable, to any non-employee director with respect to any period commencing on the date of the annual
general meeting of our shareholders for a particular year and ending on the day immediately prior to the date of
the annual general meeting of our shareholders for the subsequent year, including equity awards granted and
cash fees paid by us to the non-employee director, will not exceed (i) $750,000 in total value or (3) in the event
such non-employee director is first appointed or elected to the board of directors during that same period,
$1,350,000 in total value.

Cash Compensation. Pursuant to our director compensation policy, each non-employee director was entitled to
receive the following cash compensation for board services, as applicable, for 2021 (in each case paid in four
equal quarterly installments, earned upon the completion of service in each quarter):

•

•

•

•

a $60,000 annual retainer for service as a member of our board of directors;

a supplemental $50,000 annual retainer for service as the Lead Independent Director;

a supplemental annual retainer for the chairs of the following board committees in the following amounts:
$25,000 for the chairperson of the audit committee, $22,500 for the chairperson of the compensation
committee, $20,000 for the chairperson of the nominating and corporate governance committee and $22,500
for the chairperson of the transaction committee; and

a supplemental annual retainer for each member of the following board committees other than the chairs, in
the following amounts: $15,000 for service as a member of the audit committee, $12,500 for service as a
member of the compensation committee, $10,000 for service as a member of the nominating and corporate
governance committee and $12,500 for service as a member of the transaction committee.

Equity Compensation—Size of Annual Grants. Beginning with the annual general meeting in 2021, each individual
who is a non-employee director on the date of an annual general meeting of shareholders and continuing as a
non-employee director following such meeting will receive an automatic annual grant in the form of an RSU
having a value of $400,000. Each person who is elected or appointed to be a non-employee director for the first
time other than at an annual general meeting and after the annual general meeting held in 2021, is entitled to
receive an automatic annual grant in the form of an RSU having a value of $400,000, prorated based on the
number of days from the date of election or appointment until the next annual general meeting of shareholders.
The actual share amounts underlying each annual grant are determined by dividing the intended grant date value
by the company’s 30-day average share price.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

91

Director Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

Equity Compensation—Terms of Annual Grants. Starting in 2021, the grant date of automatic annual grants is the
date of our annual general meeting with respect to the automatic annual grants for continuing non-employee
directors and with respect to prorated automatic annual grants, the grant date is the second trading day following
the filing date of our next quarterly or annual report filed under the Exchange Act that occurs after the date the
director first joined our board of directors. Each automatic annual grant vests in full on the first anniversary of the
annual general meeting of our shareholders in the year an award is granted, subject in each case to the
non-employee director’s continuous service through such date. However, if a non-employee director does not
stand for reelection at an annual general meeting of our shareholders in the year in which his or her term expires
or otherwise resigns effective at an annual general meeting of our shareholders and, in either case, the
non-employee director’s continuous service terminates at such meeting, then effective as of the date of such
meeting, any unvested portion of the annual grant will become vested in full. The other terms and conditions
applicable to equity awards made to our non-employee directors are included below under the heading “Equity
Compensation Plans.”

Equity Compensation—Size and Terms of Initial Grants. Prior to April 2021, each individual who first became a
non-employee director was automatically granted the following, with an aggregate grant date value of
approximately $600,000: (a) an initial option to purchase ordinary shares that vests with respect to one-third of the
shares on the first anniversary of the date of such individual’s election or appointment to the board of directors,
and, with respect to the balance, in a series of 24 successive equal monthly installments thereafter and (b) an
initial RSU award that vests in equal annual installments over three years from the date of such individual’s
election or appointment to the board of directors, subject in each case to the non-employee director’s continuous
service through such dates. To allocate such value and determine the share amounts underlying each grant, we
first determined a number of “stock option equivalents” by multiplying our average closing share price for the 90
calendar days preceding and including the grant date by the percentage obtained by dividing the value of a stock
option using the Black-Scholes option pricing model by the 90-day average share price. The stock option
equivalents were then divided by two to determine the number of shares subject to each stock option. The
number of shares subject to each stock option was further divided by 2.5 to determine the number of shares
subject to each RSU. This methodology was intended to mitigate dilution by reflecting the greater value of
receiving shares at full value without the payment of an exercise price. A 90-day average share price was used,
rather than a single day share price, in order to provide a more stabilized share value less susceptible to possible
swings in the market. If a non-employee director does not stand for reelection at an annual general meeting of our
shareholders in the year in which his or her term expires or otherwise resigns effective at an annual general
meeting of our shareholders and, in either case, the non-employee director’s continuous service terminates at
such meeting, then effective as of the date of such meeting, any unvested portion of the initial option award will
become vested and exercisable, and any unvested portion of the initial RSU award will become vested, in each
case with respect to the portion of the award that would have vested through the anniversary of the award’s
vesting commencement date in the year of that meeting.

Travel and Other Reasonable Expenses. In addition, our non-employee directors are reimbursed for travel and
other reasonable expenses incurred in attending board or committee meetings, as are our employees who serve
as directors. If any reimbursement payment is subject to tax imposed by the Irish Revenue Commissioners, each
non-employee director is also entitled to a tax equalization payment in order to allow them to retain the full
reimbursement payment. There were no such tax equalization payments made to any of our non-employer
director with respect to any reimbursement payments in 2021.

Directors Continuing Education

In furtherance of our ongoing commitment to the continuing education of our directors, our nominating and
corporate governance committee adopted a policy for the reimbursement of director continuing education in
February 2013, as amended in February 2014. Under this policy, we will pay or reimburse each director for
enrollment fees and reasonable expenses incurred in connection with attending and participating each year in one
director continuing education program and in one healthcare industry continuing education program, each
sponsored by an outside provider.

92

2022 Proxy Statement | JAZZ PHARMACEUTICALS

2022 NOTICE OF MEETING AND PROXY STATEMENT

Director Compensation (continued)

Ownership Guidelines for Directors

y
x
o
r
P

We maintain share ownership guidelines for our non-employee directors which require each non-employee
director to own a number of the company’s ordinary shares with a value equal to five times his or her annual cash
retainer within five years of first becoming subject to the guidelines. As of March 31, 2022, each non-employee
director was in compliance with his or her share ownership requirement under the applicable guidelines, except
for Ms. Cook and Dr. Smith who joined our board of directors in December 2020 and, accordingly, have five years
from their appointment, or until 2025, to comply with the guidelines.

Equity Compensation Plans

The 2007 Directors Plan, which was initially adopted by the Jazz Pharmaceuticals, Inc. board of directors and
approved by the Jazz Pharmaceuticals, Inc. stockholders in connection with its initial public offering, was
continued and assumed by us upon the consummation of the Azur Merger. Equity awards under our director
compensation policy described above are granted under the 2007 Directors Plan.

With respect to options granted under the 2007 Directors Plan, if a non-employee director’s service relationship
with us or any of our affiliates, whether as a non-employee director or subsequently as our employee, director or
consultant or that of any of our affiliates, ceases for any reason other than disability or death, or after any
12-month period following a change in control, the optionee may exercise any vested options for a period of three
months following the cessation of service. If such optionee’s service relationship with us, or any of our affiliates,
ceases due to disability or death (or an optionee dies within a certain period following cessation of service), the
optionee or a beneficiary may exercise the option for a period of 12 months in the event of disability, and 18
months in the event of death. With respect to options granted under the 2007 Directors Plan, if such optionee’s
service terminates within 12 months following a specified change in control transaction, the optionee may exercise
any vested portion of the option for a period of 12 months following the effective date of such a transaction. The
option term may be extended in the event that exercise of the option following termination of service is prohibited
by applicable securities laws. In no event, however, may an option be exercised beyond the expiration of its term.

With respect to RSU awards granted under the 2007 Directors Plan, if a non-employee director’s service
relationship with us or any of our affiliates, whether as a non-employee director or subsequently as our employee,
director or consultant or that of any of our affiliates, ceases for any reason, any RSU awards that were unvested
as of the date of such termination will be forfeited. RSU awards granted pursuant to the director compensation
policy are also subject to potential acceleration, as described above under the headings, “Equity Compensation—
Terms of Annual Grants” and “Equity Compensation—Size and Terms of Initial Grants.”

In the event of certain significant corporate transactions (which generally have a meaning similar to “corporate
transaction” under the 2011 Plan), all outstanding awards under the 2007 Directors Plan may be assumed,
continued or substituted for by any surviving or acquiring entity (or its parent company). If the surviving or
acquiring entity (or its parent company) elects not to assume, continue or substitute for such awards, then (a) with
respect to any such awards that are held by participants then performing services for us or our affiliates, the
vesting and exercisability of such awards will be accelerated in full and such awards will be terminated if not
exercised (if applicable) prior to the effective date of the corporate transaction and (b) all other outstanding
awards will terminate if not exercised prior to the effective date of the corporate transaction. The board of
directors may also provide that the holder of an outstanding award not assumed in the corporate transaction will
surrender such award in exchange for a payment equal to the excess of (i) the value of the property that the
holder would have received upon exercise of the award, over (ii) the exercise price otherwise payable in
connection with the exercise. In addition, the vesting and exercisability of awards under the 2007 Directors Plan
held by non-employee directors who are either required to resign their position as a condition of a specified
change in control transaction (which generally has a similar meaning as a “change in control” under the 2011
Plan) or are removed from their position in connection with such a change in control will be accelerated in full.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

93

2022 NOTICE OF MEETING AND PROXY STATEMENT

Director Compensation (continued)

2021 Equity Grants

In accordance with our non-employee director compensation policy described above, we made grants to each of
our non-employee directors as a result of their continuing on the board of directors through our annual general
meeting in July 2021, which continuing grants were comprised of an RSU award covering 2,246 ordinary shares.
In addition, in February 2021, Ms. Cook and Dr. Smith were granted initial grants comprised of an option to
purchase 6,475 ordinary shares and an RSU award covering 2,590 ordinary shares. All RSUs and options
granted to non-employee directors during 2021 were granted under the 2007 Directors Plan.

Director Compensation Table

The following table sets forth certain information with respect to the compensation of all of our non-employee
directors for the fiscal year ended December 31, 2021.

Mr. Cozadd, our Chairperson and CEO, is not listed in the following table because he is our employee.
Mr. Cozadd’s compensation is described under “Executive Compensation.” Mr. Cozadd received no additional
compensation for serving on our board of directors in 2021.

DIRECTOR COMPENSATION FOR FISCAL 2021

Name

Paul L. Berns(5)

Jennifer E. Cook

Patrick G. Enright

Peter Gray

Heather Ann McSharry

Seamus Mulligan

Kenneth W. O’Keefe

Anne O’Riordan

Norbert G. Riedel, Ph.D.

Elmar Schnee(5)

Mark D. Smith, M.D.

Catherine A. Sohn, Pharm.D.

Rick E Winningham

Note: Amounts may not total due to rounding.

Fees Earned
Or Paid in
Cash
($)(1)

42,106

68,478

87,500

97,500

107,500

82,500

75,000

75,000

95,000

47,913

66,782

82,500

120,000

—

825,361

383,145

383,145

383,145

383,145

383,145

383,145

383,145

—

825,361

383,145

383,145

Stock Awards
($)(2)(3)

Option Awards
($)(3)(4)

Total
($)

42,106

—

352,283

1,246,122

—

—

—

—

—

—

—

—

470,645

480,645

490,645

465,645

458,145

458,145

478,145

47,913

352,283

1,244,426

—

—

465,645

503,145

(1) The dollar amounts in this column represent each non-employee director’s actual annual cash retainer earned for board services in 2021,
which is equal to the aggregate of his or her annual retainer of $60,000 plus his or her annual retainers for service on one or more board
committees, and for Mr. Winningham, for service as Lead Independent Director. Each non-employee director’s total fees were earned and
payable in four quarterly installments subject to the non-employee director’s continuous service at the end of each quarter. Fees paid to
each of Ms. McSharry, Ms. O’Riordan and Messrs. Gray, Mulligan and Schnee were paid in Euro. The conversion to U.S. dollars was
calculated based on the average exchange rate for each quarter as reported by the OANDA Corporation.

(2) The dollar amounts in this column reflect the aggregate grant date fair value of RSU awards computed in accordance with FASB ASC
718. The grant date fair value of each RSU award is measured based on the closing price of our ordinary shares on the date of grant.
These amounts do not necessarily correspond to the actual value recognized or that may be recognized by the non-employee directors.

(3) The aggregate number of shares subject to outstanding stock options and RSU awards held by the non-employee directors listed in the

table above as of December 31, 2021 was as follows: 37,850 shares subject to outstanding stock options and 2,246 shares subject to
outstanding RSUs for Mr. Mulligan; 15,305 shares subject to outstanding stock options and 2,246 shares subject to outstanding RSUs for
Mr. Enright; 28,850 shares subject to outstanding stock options and 2,246 shares subject to outstanding RSUs for each of Dr. Sohn and

94

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Director Compensation (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

Mr. Winningham; 33,350 shares subject to outstanding stock options and 2,246 shares subject to outstanding RSUs for Mr. O’Keefe;
36,850 shares subject to outstanding stock options and 2,246 shares subject to outstanding RSUs for each of Ms. McSharry, Mr. Gray
and Dr. Riedel; 6,475 shares subject to outstanding stock options and 3,972 shares subject to outstanding RSUs for each of Ms. Cook
and Dr. Smith; and 18,670 shares subject to outstanding stock options and 3,192 shares subject to outstanding RSUs for Ms. O’Riordan.

(4) The dollar amount in this column represents the aggregate grant date fair value of the stock option awards granted to Ms. Cook and

Dr. Smith in 2021. This amount has been calculated in accordance with FASB ASC 718, using the Black-Scholes option-pricing model
and excluding the effect of estimated forfeitures. Assumptions used in the calculation of this amount are included in the notes to our
audited consolidated financial statements included in the 2021 Annual Report on Form 10-K. These amounts do not necessarily
correspond to the actual value recognized or that may be recognized.

(5) Mr. Schnee did not stand for re-election to our board of directors, when his term expired, at our 2021 annual general meeting of

shareholders. Mr. Berns resigned as a director of Jazz Pharmaceuticals effective as of or our 2021 annual general meeting of
shareholders.

y
x
o
r
P

CERTAIN RELATIONSHIPS AND RELATED PARTY
TRANSACTIONS

Policy and Procedures for Review of Related Party Transactions

We have adopted a Related Party Transaction Policy that sets forth our procedures for the identification, review,
consideration and approval or ratification of “related-person transactions.” For purposes of our policy, a “related-
person transaction” is a transaction, arrangement or relationship (or any series of similar transactions,
arrangements or relationships) in which we are, were or will be a participant, and the amount involved exceeds
$120,000, and any “related person” had, has or will have a direct or indirect material interest. Transactions
involving compensation for services provided to us as an employee or director are not covered by this policy. A
related person who has a position or relationship with a firm, corporation or other entity that engages in a
transaction with us will not be deemed to have an indirect material interest in such transaction under this policy
where the interest arises solely where: (i) if such entity is not a partnership, such related person’s position as a
director of such entity and/or the direct or indirect ownership by such related person and all other related persons,
in the aggregate, of less than a 10% equity interest in such entity; or (ii) if such entity is a partnership, from such
related person’s position as a limited partner in such entity and such related person’s and all other related
persons have an interest in such entity of less than 10% in the aggregate, and the related person is not a general
partner of and does not hold another position in such entity. A “related person” is any executive officer, director or
beneficial owner of more than 5% of any class of our voting securities, including any of their immediate family
members and any entity owned or controlled by such persons.

Under the policy, if a transaction has been identified as a related-person transaction (including any transaction
that was not a related-person transaction when originally consummated or any transaction that was not initially
identified as a related-person transaction prior to consummation), our management must present information
regarding the related-person transaction to our audit committee (or, if audit committee approval would be
inappropriate, to another independent body of our board of directors) for review, consideration and approval or
ratification. The presentation must include a description of, among other things, the material facts, the interests,
direct and indirect, of the related person(s), the benefits to us of the transaction and whether the transaction is on
terms that are comparable to the terms available to or from, as the case may be, an unrelated third party or to or
from employees generally. Under the policy, we will, on an annual basis, collect information that our Chief Legal
Officer, or CLO, deems reasonably necessary from each director, executive officer and (to the extent feasible)
significant shareholder to enable us to identify any existing or potential related-person transactions and to
effectuate the terms of the policy. In addition, under our code of conduct, our employees and directors have an
affirmative responsibility to disclose any transaction or relationship that reasonably could be expected to give rise
to a conflict of interest to our CLO, or, if the employee is an executive officer, to our board of directors. In
considering related-person transactions, our audit committee (or other independent body of our board of directors)
will take into account the relevant available facts and circumstances including, but not limited to, the risks, costs
and benefits to us, the terms of the transaction, the availability of other sources for comparable services or
products and, if applicable, the impact on a director’s independence in the event that the related person is a
director, immediate family member of a director or an entity with which a director is affiliated.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

95

Certain Relationships and Related Party Transactions (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

The policy requires that, in determining whether to approve, ratify or reject a related-person transaction, our audit
committee (or other independent body of our board of directors) must consider, in light of known circumstances,
whether the transaction is in, or is not inconsistent with, our best interests and those of our shareholders, as our
audit committee (or other independent body of our board of directors) determines in the good faith exercise of its
discretion.

Transactions with Related Persons; Indemnification

Transactions with Related Persons. Since January 1, 2021, we have not engaged in any transactions, nor are any
such transactions currently proposed, in which we were a participant and the amount involved exceeded
$120,000, and in which any related person had or will have a direct or indirect material interest.

Indemnification. We have entered into indemnification agreements with our directors, executive officers and
certain other of our officers and employees. These indemnification agreements require us, under the
circumstances and to the extent provided for therein, to indemnify such persons to the fullest extent permitted by
applicable law against certain expenses and other amounts incurred by any such person as a result of such
person being made a party to certain actions, suits, proceedings and other actions by reason of the fact that such
person is or was a director, officer, employee, consultant, agent or fiduciary of our company or any of our
subsidiaries or other affiliated enterprises. The rights of each person who is a party to an indemnification
agreement are in addition to any other rights such person may have under our Amended and Restated
Memorandum and Articles of Association, the Irish Companies Act 2014, any other agreement, a vote of the
shareholders of our company, a resolution of directors of our company or otherwise. We believe that these
agreements are necessary to attract and retain qualified persons as our officers and directors. We also maintain
directors’ and officers’ liability insurance.

96

2022 Proxy Statement | JAZZ PHARMACEUTICALS

2022 NOTICE OF MEETING AND PROXY STATEMENT

PROPOSAL 2
RATIFY, ON A NON-BINDING ADVISORY BASIS, THE
APPOINTMENT OF INDEPENDENT AUDITORS AND
AUTHORIZE, IN A BINDING VOTE, THE BOARD OF
DIRECTORS, ACTING THROUGH THE AUDIT
COMMITTEE, TO DETERMINE THE INDEPENDENT
AUDITORS’ REMUNERATION

y
x
o
r
P

Pursuant to authority delegated by the board of directors, the audit committee of the board of directors is
responsible for the appointment, remuneration and retention of our independent auditors. The audit committee
has selected and appointed KPMG, Dublin, a registered public accounting firm, or KPMG, as our independent
auditors to audit our consolidated financial statements for the year ending December 31, 2022. Under Irish law,
KPMG will be deemed to be reappointed as our independent auditors at the annual meeting without the necessity
of a shareholder vote. However, our shareholders are being asked in this proposal to ratify such appointment on a
non-binding advisory basis because we value our shareholders’ views on the company’s independent auditors.
The board of directors and the audit committee intend to consider the results of this vote in making determinations
in the future regarding the appointment of the company’s independent auditors. In addition, our shareholders are
being asked to authorize the board of directors, acting through the audit committee, to determine KPMG’s
remuneration. This authorization is required by Irish law.

KPMG has been engaged to audit our financial statements, beginning with our consolidated financial statements
for the fiscal year ended December 31, 2012, since the consummation of the Azur Merger. Representatives of
KPMG are expected to attend the annual meeting, will have an opportunity to make a statement if they so desire,
and will be available to respond to appropriate questions.

Proposal 2 is an ordinary resolution and must receive the affirmative vote of a majority of the votes cast in person
or by proxy at the annual meeting (including any adjournment thereof) in order to be approved.

Independent Registered Public Accounting Firm Fees and Services
In connection with the audit of our 2021 financial statements, we entered into an engagement agreement with
KPMG which sets forth the terms under which KPMG performed audit and tax services for the company.

The following table represents aggregate fees billed to us for the years ended December 31, 2021 and 2020 by
KPMG, our independent registered public accounting firm (in thousands):

Audit Fees

Audit-Related Fees

Tax Fees

Tax compliance services

Tax advisory services

All Other Fees

Total Fees

Year Ended December 31,

2021

2020

$4,039

$2,075

176

115

1,029

1,137

881

148

3

916

221

3

$5,247

$3,330

Audit Fees: Consists of fees and expenses for professional services in respect of the audit of the company’s
consolidated financial statements and of our internal control over financial reporting, the review of quarterly
consolidated financial statements and statutory audits.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

97

Proposal 2 (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

Audit-Related Fees: Consists of fees for assurance and services related to audit and other attestation services
performed by KPMG as required by statute, regulation or contract and which are not reported under “Audit Fees.”

Tax Fees: Consists of fees and expenses for professional services for tax compliance, tax advice and tax
planning. Tax compliance services consist of professional services related to domestic and international tax
compliance, and assistance with domestic and international tax return preparation. Tax advisory service fees
relate to tax advice and planning services provided to us in connection with certain transactions undertaken by the
company in 2021 and 2020. During the year ended December 31, 2021, fees and expenses of approximately
$881,000 were billed in connection with tax compliance services, and fees and expenses of approximately
$148,000 were billed in connection with tax advice and planning services. During the year ended December 31,
2020, fees and expenses of approximately $916,000 were billed in connection with tax compliance services, and
fees and expenses of approximately $221,000 were billed in connection with tax advice and planning services.

All Other Fees: Consists of fees for products and services other than the services described above. For the years
ended December 31, 2021 and December 31, 2020, these fees were paid in connection with access to the online
accounting and tax research tool of KPMG.

All of the services and fees described above were approved by our audit committee.

As shown in the table above, less than 3% of the total fees that KPMG billed us for in 2021 were for services
other than audit, audit-related and tax compliance services.

Pre-Approval Policies and Procedures

Our audit committee has a policy and procedures for the pre-approval of audit and non-audit services rendered by
our independent registered public accounting firm. Our policy generally requires the pre-approval of specified
services in the defined categories of audit services, audit-related services, and tax services up to specified
amounts. Pre-approval may also be given as part of the audit committee’s approval of the scope of the
engagement of the independent auditor or on an individual explicit case-by-case basis before the independent
auditor is engaged to provide each service. The pre-approval of services may be delegated to one or more of the
audit committee’s members, but the decision must be reported to the full audit committee at its next scheduled
meeting.

Independence

Our audit committee determined that the rendering of the services other than audit services by our independent
registered public accounting firm is compatible with maintaining the principal accountant’s independence.

The board of directors recommends a vote “FOR” Proposal 2.

98

2022 Proxy Statement | JAZZ PHARMACEUTICALS

2022 NOTICE OF MEETING AND PROXY STATEMENT

PROPOSAL 3
NON-BINDING ADVISORY VOTE ON EXECUTIVE
COMPENSATION

Overview

Under the Dodd-Frank Act and Section 14A of the Exchange Act, our shareholders are entitled to vote to approve,
on a non-binding advisory basis, the compensation of our named executive officers, or NEOs, as disclosed in this
proxy statement in accordance with the compensation disclosure rules of the SEC. This non-binding advisory vote
is commonly referred to as a “say-on-pay” vote.

y
x
o
r
P

At our 2021 annual meeting of shareholders, our shareholders indicated their preference that we hold a
non-binding say-on-pay vote every year and our board of directors has adopted a policy that is consistent with
that preference. At our 2021 annual meeting of shareholders, the shareholders also overwhelmingly approved our
say-on-pay proposal, with approximately 90% of the total votes cast voting in favor of the proposal.

This year, we are again asking our shareholders to vote “FOR” the advisory approval of the compensation of our
NEOs as disclosed in the “Compensation Discussion and Analysis,” the compensation tables and the related
narrative disclosure contained in this proxy statement beginning on page 44. As discussed in those disclosures,
our compensation committee designs our executive compensation program with the following objectives and
philosophy:

•

•

•

Attract, incentivize, reward and retain diverse, talented individuals with relevant experience in the life
sciences industry through a competitive pay structure. We reward individuals fairly over time and seek to
retain those individuals who continue to meet our high expectations.

Deliver balanced total compensation packages to accomplish our business objectives and mission.
Our executive compensation program focuses on target total direct compensation, combining short-term and
long-term components, cash and equity, and fixed and variable payments, in the proportions that we believe
are the most appropriate to incentivize and reward our executive officers for achieving our corporate goals
while minimizing incentives for excessive risk-taking or unethical conduct.

Align pay with our performance. Our annual performance bonus awards are not earned unless
pre-determined levels of performance are achieved against annual corporate objectives approved by our
board of directors at the beginning of the year. Likewise, our stock option awards will not provide realizable
value and our restricted stock unit awards will not provide increased value unless there is an increase in the
value of our shares, which benefits all shareholders. We also have executive share ownership guidelines to
further support our ownership culture and align the interests of executive officers and shareholders. Further,
in 2021 we implemented a new performance-based equity program tied to the achievement of critical multi-
year financial and other strategic objectives as well as relative total shareholder return goals, with
performance-based restricted stock unit awards making up approximately 50% of each NEO’s target annual
equity grant, and time-vested restricted stock unit awards making up the other approximately 50%.

The compensation committee will continue to monitor the impact of COVID-19 on the global economy, our
business and the design of our executive compensation program.

Say-on-Pay Vote

This vote is not intended to address any specific item of compensation, but rather the overall compensation of our
NEOs and the philosophy, policies and practices described in this proxy statement. The board of directors is
asking our shareholders to indicate their support for the compensation of our NEOs as described in this proxy
statement by casting a non-binding advisory vote “FOR” the following resolution:

“RESOLVED, that the compensation paid to Jazz Pharmaceuticals’ NEOs, as disclosed pursuant to Item 402 of
Regulation S-K of the Exchange Act, including the Compensation Discussion and Analysis, compensation tables
and narrative discussion, is hereby APPROVED.”

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

99

Proposal 3 (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

Because the vote is advisory, it is not binding on the board of directors or the company. Nevertheless, the views
expressed by our shareholders, whether through this vote or otherwise, are important to management and the
board of directors and, accordingly, the board of directors and the compensation committee intend to consider the
results of this vote in making determinations in the future regarding executive compensation arrangements.

Proposal 3 is an ordinary resolution and must receive the affirmative vote of a majority of the votes cast in person
or by proxy at the annual meeting (including any adjournment thereof) in order to be approved.

Unless our board of directors changes the frequency of future advisory votes on the compensation of our NEOs,
the next advisory vote on the compensation of our NEOs will be held at the 2023 annual meeting of shareholders.

The board of directors recommends a vote “FOR” Proposal 3.

100

2022 Proxy Statement | JAZZ PHARMACEUTICALS

2022 NOTICE OF MEETING AND PROXY STATEMENT

PROPOSAL 4
BOARD AUTHORITY TO ISSUE SHARES FOR CASH
WITHOUT FIRST OFFERING SHARES TO EXISTING
SHAREHOLDERS

Overview

As a matter of Irish law, when an Irish public limited company issues shares for cash (including rights to subscribe
for, convert into or otherwise acquire any shares), unless otherwise authorized by shareholders, it is required first
to offer those shares on the same or more favorable terms to existing shareholders of the company on a pro-rata
basis (commonly referred to as the pre-emption right). Under Irish law, the authority to opt-out of the pre-emption
right, which we call the pre-emption opt-out authority, can be granted by shareholders covering up to the
maximum of a company’s authorized but unissued ordinary share capital for a maximum period of five years, at
which point it lapses unless renewed by shareholders.

At an extraordinary general meeting we held in September 2021, or the 2021 EGM, our shareholders approved
our current pre-emption opt-out authority for an 18 month period from the date of the 2021 EGM. Accordingly, our
current pre-emption opt-out authority will expire on March 23, 2023, unless otherwise varied, renewed or revoked.
Pursuant to this Proposal 4, we are seeking new authority to opt out of the pre-emption rights provision in the
event of an issuance of ordinary shares for cash, if the issuances are limited to up to 20% of our issued ordinary
share capital in the aggregate, for a period expiring on the date being 18 months from the passing of the below
resolution, unless otherwise varied, renewed or revoked.

y
x
o
r
P

Why We are Submitting Proposal 4 for Shareholder Approval

We are listed in the U.S. and incorporated in Ireland.

As a public limited company incorporated in Ireland, we follow the corporate legal requirements of Ireland. Our
board of directors is subject to, and has and will continue to exercise its authority in compliance with, its fiduciary
duties to the company and our shareholders under Irish law. Our ordinary shares are listed exclusively on the
Nasdaq Global Select Market. Because our ordinary shares are listed exclusively in the U.S. and the U.S. capital
markets are the sole capital markets for our ordinary shares, we follow the rules and regulations of the SEC and
the Nasdaq rules and listing standards. We are and will continue to be subject to the same governance and share
issuance requirements and restrictions as all U.S.-incorporated companies listed on Nasdaq.

Last year, we sought and received approval for a limited pre-emption opt-out authority.

Our prior pre-emption opt-out authority had been in place since the Azur Merger in January 2012 and was
renewed by our shareholders in 2016 with over 80% support, in each case covering up to the maximum of our
authorized but unissued ordinary share capital for a full five-year period. In this regard, we refer to our prior pre-
emption opt-out authority as an “unlimited” authority since that prior pre-emption opt-out authority was approved
by shareholders in an amount and duration consistent with the maximums allowable by Irish law. We asked our
shareholders to renew our prior unlimited pre-emption opt-out authority for an additional five-year term at our
2021 annual general meeting of shareholders and although we received over 64% support of the votes cast on
that proposal, we did not receive the affirmative vote of at least 75% of the votes cast as required by the Irish law
super majority voting regime for special resolutions. Accordingly, our then unlimited pre-emption opt-out authority
expired on August 4, 2021. In this regard, feedback we received from certain shareholders in connection with the
2021 annual general meeting indicated that certain of our shareholders preferred limits on the pre-emption opt-out
authority. As a result, we sought and received approval for a much more limited pre-emption opt-out authority at
the 2021 EGM.

When we formulated the pre-emption opt-out authority that was presented at, and approved by, our shareholders
at the 2021 EGM, we followed the market practice for companies whose share capital is listed on Euronext

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

101

Proposal 4 (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

Dublin, which market practice is informed by institutional shareholder guidance created solely with Irish and UK
domestic listed company regimes in mind and is generally to limit the dis-application of statutory pre-emption
rights to up to 5% of a company’s issued ordinary share capital (plus up to an additional 5% of the issued ordinary
share capital if the additional 5% is used to finance an acquisition or a specified capital investment) for a period of
12 to 18 months. As noted above, our then unlimited pre-emption opt-out authority expired on August 4, 2021,
meaning that upon expiration, we had no ability to issue shares for cash (other than pursuant to employee equity
plans) without shareholder approval, and it was therefore critical for us to submit a pre-emption opt-out authority
proposal at the 2021 EGM that we were certain shareholders would support given the Irish law super majority
voting regime for special resolutions. While our current pre-emption opt-out authority was overwhelmingly
approved at the 2021 EGM with over 99% support of the votes cast, it is important to note that the limitations in
amount and duration included in our current pre-emption opt-out authority are not required or mandated by Irish or
U.S. laws or regulations; rather, those limitations are derived from the standards developed solely for, and market
practices of, companies whose share capital is listed on Euronext Dublin, where our ordinary shares are not and
never have been listed.

Upon further analysis and following engagement with our shareholders, we believe at this time that it is in
the best interests of the company and our shareholders to seek approval for a new pre-emption opt-out
authority on the terms set forth in this Proposal 4.

As described in more detail under “Proxy Overview—Shareholder and Other Stakeholder Engagement,” a priority
for our board of directors is soliciting and listening to the views of our shareholders on a variety of topics, including
our business and growth strategy, corporate governance practices, executive compensation matters, and various
other ESG matters. Leading up to and following our 2021 annual general meeting, we reached out to
shareholders who collectively held approximately 29% of our then-outstanding shares to request meetings, and
held meetings with each shareholder who accepted our request for engagement. In discussions we have had with
shareholders about our pre-emption opt-out authority, certain shareholders continued to express a preference for
some limits on the pre-emption opt-out authority while also recognizing the importance of our ability to deploy
capital to execute on our strategy for growth. Although we believe at this time that fully adhering to the standards
and market practices for companies whose share capital is listed on Euronext Dublin, where our ordinary shares
are not and never have been listed, is not appropriate for our company, upon further analysis and the foregoing
engagement, we believe at this time that it is in the best interests of the company and our shareholders to
approve the pre-emption opt-out authority on the terms set forth in this Proposal 4. The terms of Proposal 4 differ
from the terms of the pre-emption opt-out authority proposal presented at our 2021 annual general meeting and
the pre-emption opt-out authority we had from the time of the Azur Merger in January 2012 through August 4,
2021, in that our pre-emption opt-out authority would be limited in both amount and duration, as explained in more
detail below.

What this Proposal 4 is Asking Shareholders to Approve

As noted above, under Irish law, the pre-emption opt-out authority can be granted by shareholders for full five
year-term and can apply to a company’s entire authorized but unissued share capital. Our shareholders
previously granted us this unlimited pre-emption opt-out authority, most recently in August 2016.

In this Proposal 4, however, we are asking shareholders to approve the directors’ authority to opt out of the pre-
emption rights provision in the event of an issuance of shares for cash, if the issuances are limited to up to 20% of
our issued ordinary share capital in the aggregate, for a period expiring on the date being 18 months from the
passing of the below resolution, unless otherwise varied, renewed or revoked. Accordingly, Proposal 4 is much
more limited than Irish law maximally allows for in terms of both amount and duration as it relates to pre-emption
opt-out authorities.

Why Our Shareholders Should Approve this Proposal 4

We believe the proposed pre-emption opt-authority, on the terms set forth in this Proposal 4, is
appropriately balanced between providing us with sufficient flexibility to execute on our strategy for

102

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Proposal 4 (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

growth and providing meaningful protection to shareholders from excessive dilution resulting from
issuances of shares for cash.

Granting our board of directors the pre-emption opt-out authority on the terms set forth in this Proposal 4 is vital to
the way we intend to advance our business. In this regard, our strategy for growth is rooted in executing
commercial launches and ongoing commercialization initiatives; advancing robust research and development
programs and delivering impactful clinical results; effectively deploying capital to strengthen the prospects of
achieving our short- and long-term goals through strategic corporate development; and delivering strong financial
performance. At the 40th Annual J.P. Morgan Healthcare Conference in January 2022, we announced our Vision
2025, which aims to deliver sustainable growth and enhanced value, driving our continued transformation to an
innovative, high-growth global pharmaceutical leader. The three core components of our Vision 2025 focus on
commercial execution, pipeline productivity and operational excellence. In this regard, strategic capital allocation
will continue to be an important driver of our growth, including with respect to achieving our stated deleveraging
targets and facilitating our ability to continue corporate development.

y
x
o
r
P

As indicated above, we received feedback from shareholders during engagement efforts both before and after the
2021 annual general meeting that indicated certain shareholders, including those that did not support our
unlimited pre-emption opt-out authority proposal at the 2021 annual general meeting, preferred limits on our pre-
emption opt-out authority. In light of our strategy for growth and related initiatives and after extensive
consideration, we determined at this time that seeking approval for a pre-emption out-out authority to issue up to
20% of our issued ordinary share capital for cash over the next 18 months would likely provide us with sufficient
flexibility to execute on our strategy while also taking into account shareholder feedback that expressed a
preference for some limits on our pre-emption opt-out authority. Of course, larger scale corporate development
could require or necessitate that we issue shares for cash or for non-cash consideration in an amount in excess of
20% of our issued ordinary share capital, but again, at this time, we believe that the terms of this Proposal 4
would likely provide us with sufficient flexibility to execute on our strategy over the next 18 months.

We also believe that the 20% limit in this Proposal 4 strikes the right balance between protecting shareholders
from excessive dilution resulting from issuances of shares for cash and providing us with sufficient flexibility. In
this regard, Nasdaq rules generally require shareholder approval prior to our issuing shares in connection with
acquisitions, other than in public offerings for cash, when the number of shares to be issued is or will be equal to
or in excess of 20% of the number of our ordinary shares outstanding before the issuance; similarly, Nasdaq rules
also generally require shareholder approval prior to issuing shares for cash at a price less than the Nasdaq-
defined minimum price in a private placement in an amount equal to or in excess of 20% of the number of our
ordinary shares outstanding before the issuance. Importantly, however, these Nasdaq 20% shareholder approval
requirements for issuances of shares for cash generally apply on a transaction by transaction basis and there are
also exceptions to these Nasdaq 20% shareholder approval requirements, including the ability to issue in excess
of 20% of issued share capital in public offerings for cash without shareholder approval, whereas Proposal 4 limits
our ability to issue up to 20% of our issued ordinary share capital for cash in the aggregate without shareholder
pre-emption rights, whether in one or multiple transactions or whether in public offerings or otherwise, for the
entirety of the 18 month authorization period (unless the authority is otherwise varied, renewed or revoked).
Accordingly, because we would be required to obtain shareholder approval to issue shares in excess of 20% of
our issued ordinary share capital for cash without shareholder pre-emptive rights if this Proposal 4 is approved,
and that regardless of whether the shares are issued in one or more transactions or whether in public offerings or
otherwise, we view the terms of the Nasdaq 20% shareholder approval requirements for issuances of shares for
cash to be less restrictive to our U.S.-incorporated peers than the terms of the pre-emption opt-out authority as
set forth in this Proposal 4. To be clear, shareholder approval of Proposal 4 would not impact our existing
obligations under SEC rules and regulations and the Nasdaq rules and listing standards. We are considered to be
a U.S. domestic reporting company under SEC rules and are subject to the same governance and share issuance
requirements as all U.S.-incorporated companies listed on Nasdaq. This means that we will, like all U.S.-
incorporated companies listed on Nasdaq, continue to be subject to the Nasdaq shareholder approval
requirements, including the Nasdaq 20% shareholder approval requirements; however, unlike our U.S.-
incorporated peer companies listed on Nasdaq, we will also be limited by the terms of this Proposal 4, which

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

103

Proposal 4 (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

imposes an overall 20% limit on our ability to issue shares for cash without shareholder pre-emption rights for the
entirety of the 18 month authorization period. As such, we believe that the terms of this Proposal 4 provide even
greater dilutive protection to shareholders with respect to share issuances for cash than our U.S.-incorporated
peer companies listed on Nasdaq.

During our more than ten years as an Irish-incorporated company, our shareholders have entrusted us to
be disciplined stewards of our pre-emption opt-out authorities. In turn, our actions during that time
demonstrate our deliberately disciplined use of equity in furtherance of our strategy for growth.

We believe that we have been successful in executing on our long-term business plan and strategy for growth,
while also creating value for our shareholders. We have been engaged in targeted corporate development,
applying a disciplined approach to allocating our resources between investments in our current commercial and
development portfolio and acquisitions or in-licensing of new assets. Since the Azur Merger, we have completed
company and asset acquisitions or in-licensing transactions valued at over $12 billion in the aggregate. Since that
time, these corporate development transactions have ultimately resulted in the additions of neuroscience therapy
Epidiolex and oncology therapies Zepzelca, Vyxeos, and Defitelio to our commercial portfolio. Since 2015, we
have executed on a total of eleven product approvals and commercial launches, including two product launches in
2021 alone. In addition, in May 2021, we completed the GW Acquisition for approximately $7.2 billion, further
diversifying our commercial portfolio and innovative pipeline with therapies that are complementary to our existing
business, including by adding Epidiolex which exceeded $463 million in net product sales, or $658.3 million on a
proforma basis, in 2021.

Notably, each of these corporate development transactions, other than the GW Acquisition, were funded with
cash on hand and/or through debt financings, and we have otherwise been disciplined in our use of equity to
provide funding for, or to complete, acquisitions or in-licensing of new assets. In this regard, the GW Acquisition
was funded with $6.6 billion in cash ($5.4 billion of which was financed with debt) and only approximately $0.6
billion of our ordinary shares were delivered. Furthermore, following the Azur Merger, we have only issued equity
or equity-linked securities for capital raising purposes in our three offerings of exchangeable senior notes that
provided us with unsecured debt of approximately $2 billion with an interest rate range of 1.50% to 2.00%. Our
prior unlimited pre-emption opt-out authority was key to enabling us to timely and efficiently execute on these
exchangeable senior note offerings, which required a sufficient pre-emption opt-out authority to deliver all of the
shares that could potentially be delivered on an exchange even though we may never exchange such securities
and instead repay in cash in full. In any event, our completed transactions speak to both the vibrancy of our
targeted corporate development efforts and our disciplined use of equity, as well as our commitment to deploy
capital wisely to meet strategic goals that are in the best interests of our shareholders.

We also believe that we have appropriately balanced investment in our growth with managing dilution through our
share repurchase programs, under which we have repurchased approximately 12.5 million of our ordinary shares
from 2013 through March 31, 2022.

Competitive disadvantage and related risks if Proposal 4 is not approved.

Our strategy for growth depends in part on our ability to quickly take advantage of strategic opportunities,
including potential acquisitions and other capital-intensive transactions that we believe would increase
shareholder value. Many of these opportunities are highly competitive, with multiple parties often offering
comparable or even the same economics. If Proposal 4 is not approved, in each case where we propose to issue
shares for cash consideration after March 23, 2023 and/or beyond the more restrictive limits of our current pre-
emption opt-out authority, we would first have to offer those shares on the same or more favorable terms to our
existing shareholders pro-rata to their existing shareholdings following a specific Irish statutory procedure and
timeline in the absence of a new shareholder approval to dis-apply the pre-emption rights provision to the
issuance of those shares. This could put us at a distinct disadvantage vis-a` -vis many of our peers in competing
for acquisitions and similar transactions (particularly since many of the companies with which we compete

104

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Proposal 4 (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

strategically are listed and incorporated in the U.S. and are not subject to similar pre-emption right restrictions),
and might make it difficult for us to complete such transactions in a timely manner or at all, thus potentially limiting
our ability to further our strategy for growth by deploying capital to meet strategic goals that are in the best
interests of our shareholders.

In addition, while we would always have the ability to seek shareholder approval in connection with a specific
issuance of shares for cash consideration that exceeds the limits of our then existing pre-emption opt-authority (if
any), we do not believe that our ability to convene an extraordinary general meeting of shareholders to approve
each specific share issuance that we would seek to undertake in furtherance of our strategy for growth is a
practical alternative to having sufficient pre-emption opt-authority. The uncertainty of whether we could obtain
shareholder approval for a specific issuance in the context of any transaction, as well as the delays we would
experience in seeking and obtaining such approval, could make any transaction bid that we submit less attractive,
even if our bid was on economically better terms than competitive bids submitted by U.S.-listed companies not
subject to similar share issuance restrictions. In addition, this case-by-case shareholder approval approach
ignores market window and other deal timing, confidentiality and competitive realities.

y
x
o
r
P

Limitations on pre-emption opt-out authorities derived from Irish market practice are not required or
mandated by Irish or U.S. laws or regulations, and we believe at this time that fully adhering to limitations
derived from Irish market practice is not appropriate for us.

We understand that certain proxy advisory firms have in prior proxy seasons applied their United Kingdom, or
U.K., and Ireland voting guidelines, which derive from institutional shareholder guidance created solely for
companies with an Irish or U.K. stock exchange listing and which do not take into account NYSE or Nasdaq
shareholder approval requirements for share issuances, in formulating their voting recommendations on pre-
emption opt-authority proposals for U.S.-listed Irish incorporated companies, as was the case with respect to our
pre-emption opt-authority proposal at our 2021 annual general meeting, meaning that they have applied or
otherwise taken into account the market practice for companies whose share capital is listed on Euronext Dublin
(and the equivalent UK exchange) in formulating their voting recommendations on pre-emption opt-authority
proposals for Irish incorporated companies, even if their shares are not listed on Euronext Dublin (or any U.K.
exchange). As explained above, upon further analysis and following engagement with our shareholders, we
believe at this time that fully adhering to the standards and market practices for companies whose share capital is
listed on Euronext Dublin, where our ordinary shares are not and never have been listed, is not appropriate for
our company or in the interests of our shareholders. However, in addition to the 20% limit in amount, we have
determined to limit the duration of the pre-emption opt-out authority for a period expiring 18 months from the
passing of the below resolution, unless otherwise varied, renewed or revoked. We believe this limited period
appropriately balances the directors’ need for flexibility with the preference of certain shareholders to limit our pre-
emption opt-out authority in both amount and duration.

Effect on Authorized Share Capital

We are not asking you to approve an increase in our authorized share capital. Instead, approval of this Proposal 4
will only grant the directors the authority to issue shares for cash in the manner already permitted under our
articles upon the terms set forth in the below resolution. Shareholders should note that the requirement to offer
shares to existing shareholders pursuant to the pre-emption rights provision does not apply where such shares
are issued for non-cash consideration or pursuant to employee equity plans.

Supermajority Voting Standard; Special Resolution

As required under Irish law, Proposal 4 is a special resolution that requires the affirmative vote of at least 75% of
the votes cast in person or by proxy at the AGM (including any adjournment thereof) in order to be approved. If
Proposal 4 is approved, our current pre-emption opt-out authority approved at the 2021 EGM will be revoked
effective upon the passing of the resolution set out below. If Proposal 4 is not approved, our current pre-emption
opt-out authority approved at the 2021 EGM will continue to apply until March 23, 2023 unless otherwise varied,
renewed or revoked following the AGM.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

105

Proposal 4 (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

The board of directors is asking our shareholders to vote “FOR” the following special resolution:

“RESOLVED that the directors be and are hereby empowered pursuant to section 1023 of the Companies Act
2014 of Ireland (the 2014 Act) to allot equity securities (as defined in section 1023 of the 2014 Act) for cash,
pursuant to the authority conferred by shareholders at Jazz Pharmaceuticals’ annual general meeting on July 29,
2021 in accordance with section 1021 of the 2014 Act, as if sub-section (1) of section 1022 of the 2014 Act did not
apply to any such allotment, provided that this power shall be limited to the allotment of equity securities up to an
aggregate nominal value of US$1248.47 (12,484,733 shares) (being equivalent to approximately 20% of the
aggregate nominal value of Jazz Pharmaceuticals’ issued ordinary share capital as at the last practicable date
prior to the issue of the notice of this meeting), and the authority conferred by this resolution shall expire 18
months from the passing of this resolution, unless previously renewed, varied or revoked; provided that Jazz
Pharmaceuticals may make an offer or agreement before the expiry of this authority, which would or might require
any such securities to be allotted after this authority has expired, and in that case, the directors may allot equity
securities in pursuance of any such offer or agreement as if the authority conferred hereby had not expired.”

The board of directors recommends a vote “FOR” Proposal 4.

106

2022 Proxy Statement | JAZZ PHARMACEUTICALS

2022 NOTICE OF MEETING AND PROXY STATEMENT

PROPOSAL 5
ADJOURNMENT PROPOSAL

You are being asked to consider and vote upon an adjournment proposal.

This resolution proposes to approve any motion to adjourn the annual meeting, or any adjournments thereof, to
another time and place to solicit additional proxies if there are insufficient votes at the time of the annual meeting
to approve Proposal 4.

Proposal 4 is subject to the Irish law super majority voting regime of voting by special resolution, which requires
no less than 75% of the votes of shareholders cast (in person or by proxy) at a general meeting to be voted “FOR”
the proposal in order to be passed. Given the high vote threshold associated with Proposal 4, we are seeking
your authority to adjourn the meeting to solicit additional proxies if there are insufficient votes at the time of the
annual meeting to approve Proposal 4.

y
x
o
r
P

The board of directors is asking our shareholders to vote “FOR” the following ordinary resolution:

“RESOLVED, that any motion to adjourn the annual meeting, or any adjournments thereof, to another time and
place to solicit additional proxies if there are insufficient votes at the time of the annual meeting to approve
Proposal 4 set forth in this proxy statement, be approved.”

Proposal 5 is an ordinary resolution and must receive the affirmative vote of a majority of the votes cast in person
or by proxy at the annual meeting (including any adjournment thereof) in order to be approved.

The board of directors recommends a vote “FOR” Proposal 5.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

107

2022 NOTICE OF MEETING AND PROXY STATEMENT

QUESTIONS AND ANSWERS ABOUT
THESE PROXY MATERIALS AND VOTING

Q: Why am I receiving these materials?

A: Our board of directors is soliciting your proxy to vote at the annual meeting, including at any adjournments or
postponements of the annual meeting. This proxy statement contains important information regarding the
annual meeting, the proposals on which you are being asked to vote, information you may find useful in
determining how to vote and voting procedures.

Q: Why did I receive a notice in the mail regarding the internet availability of proxy materials instead of a

full set of proxy materials?

A: We are pleased to take advantage of SEC rules that allow companies to furnish their proxy materials over the
internet. Most of our shareholders will not receive paper copies of our proxy materials (unless requested), and
will instead be sent a Notice of Internet Availability of Proxy Materials, or Notice. All shareholders receiving a
Notice will have the ability to access the proxy materials on the website referred to in the Notice and to
request a printed set of the proxy materials. Instructions on how to access the proxy materials via the internet
or to request a printed set of the proxy materials may be found in the Notice.

Q: Why did I receive a full set of proxy materials in the mail instead of a notice regarding the internet

availability of proxy materials?

A: We are providing shareholders who have previously requested a printed set of our proxy materials with paper

copies of our proxy materials instead of a Notice.

Q: What is the annual report included in the proxy materials?

A: Under applicable U.S. securities laws, we are required to send an annual report to security holders along with
this proxy statement. We intend to satisfy this annual report requirement by sending the 2021 Annual Report
on Form 10-K together with this proxy statement.

Q: How do I attend the annual meeting?

A: The annual meeting will be held on Thursday, July 28, 2022, at 9:45 a.m. local time at our corporate

headquarters located at Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland. For directions to
attend the annual meeting in person, please contact our Investor Relations department at +353.1.634.7892
(Ireland) or +1.650.496.2800 (United States) or by email at investorinfo@jazzpharma.com. Information on
how to vote in person at the annual meeting is discussed below. However, you do not need to attend the
annual meeting to vote your shares and, as noted in the next question, in light of the COVID-19 pandemic, we
strongly recommend that you vote your shares in advance of the meeting as instructed below.

Q: What are the potential impacts of the COVID-19 pandemic on the annual meeting?

A: The company would like to emphasize that we consider the health of our shareholders, employees and other
attendees a top priority. We are monitoring guidance issued by appropriate governmental health agencies,
including the Irish Health Service Executive, or the HSE, the Irish government, the U.S. Centers for Disease
Control and Prevention and the World Health Organization, collectively, the Health Authorities, and we have
implemented, and will continue to implement the measures advised by the relevant Health Authorities to
minimize the spread of COVID-19. Information on such measures and on COVID-19 generally is available on
the HSE’s website at https://www.hse.ie/eng/services/news/newsfeatures/covid19-updates/.

The annual meeting will be held in accordance with HSE and relevant Health Authority guidance. Should we
determine that alternative arrangements are necessitated due to public health recommendations regarding

108

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Questions and Answers About These Proxy Materials and Voting (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

containment of COVID-19, which may include a change in date or time of the meeting, a change in venue or
format of the meeting we will announce our decision by press release and/or filing with the Securities and
Exchange Commission as additional soliciting materials and also post information on the investor relations
page of the company’s website found at https://investor.jazzpharma.com/news. We encourage shareholders
to keep up-to-date with, and follow the guidance from the Government of Ireland and the Department of
Health (of Ireland) (as appropriate), as circumstances may change at short notice. Due to this uncertainty,
shareholders are encouraged to vote their shares by proxy in advance at the annual meeting.

Q: Who can vote at the annual meeting?

A: Only shareholders of record at the close of business on June 1, 2022, the record date for the annual meeting,

will be entitled to vote at the annual meeting.

y
x
o
r
P

Shareholders of Record: Shares registered in your name

If, at the close of business on June 1, 2022, your shares were registered directly in your name with our
transfer agent, Computershare Trust Company, N.A., then you are a shareholder of record. As a shareholder
of record, you may vote in person at the annual meeting or vote by proxy. Whether or not you plan to attend
the annual meeting, we urge you to vote by proxy over the telephone or via the internet as instructed below,
or, for those shareholders who receive a paper proxy card in the mail, by mailing a completed proxy card.

Beneficial Owners: Shares registered in the name of a broker, bank or other agent

If, at the close of business on June 1, 2022, your shares were held not in your name, but rather in an account
at a brokerage firm, bank or other agent, then you are the beneficial owner of shares held in “street name”
and a Notice is being sent to you by that broker, bank or other agent. The broker, bank or other agent holding
your account is considered to be the shareholder of record for purposes of voting at the annual meeting. As a
beneficial owner, you have the right to direct your broker, bank or other agent regarding how to vote the
shares in your account as set forth in the voting instructions in the Notice from your broker, bank or other
agent. You are also invited to attend the annual meeting. However, since you are not the shareholder of
record, you may not vote your shares in person at the annual meeting unless you request and obtain a valid
proxy from your broker, bank or other agent.

Q: What am I voting on?

A: There are five matters scheduled for a vote at the annual meeting:

• Election by separate resolutions of the four named nominees for director to hold office until the 2025

annual meeting of shareholders (Proposal 1).

• Ratification, on a non-binding advisory basis, of the appointment of KPMG as the independent auditors

of the company for the fiscal year ending December 31, 2022 and the authorization, in a binding vote, of
the board of directors, acting through the audit committee, to determine the independent auditors’
remuneration (Proposal 2).

• Approval, on a non-binding advisory basis, of the compensation of our NEOs as disclosed in this proxy

statement (Proposal 3).

• Granting to the board of directors authority under Irish law to allot and issue ordinary shares for cash

without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption
right that would otherwise apply (Proposal 4).

• Approval of any motion to adjourn the annual meeting, or any adjournments thereof, to another time and

place to solicit additional proxies if there are insufficient votes at the time of the annual meeting to
approve Proposal 4 (Proposal 5).

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

109

2022 NOTICE OF MEETING AND PROXY STATEMENT

Questions and Answers About These Proxy Materials and Voting (continued)

Q: What are the board’s voting recommendations?

A: The board of directors recommends that you vote your shares “FOR” each of the director nominees named in
this proxy statement to hold office until the 2025 annual meeting of shareholders, and “FOR” each of the other
five proposals.

Q: What if another matter is properly brought before the annual meeting?

A: The board of directors knows of no other matters that will be presented for consideration at the annual

meeting. If any other matters are properly brought before the annual meeting, it is the intention of the persons
named in the accompanying proxy, referred to in this proxy statement as the “proxy holders,” to vote on those
matters in accordance with their best judgment.

Q: How do I vote?

A: For the election of directors (Proposal 1), you may vote “FOR” or “AGAINST” each nominee, or you may

abstain from voting for all or any of the nominees. For each of the other five proposals, you may vote “FOR”
or “AGAINST” or abstain from voting.

Shareholders of Record: Shares registered in your name

If you are a shareholder of record, you may vote in person at the annual meeting, you may vote by electronic
proxy over the telephone or via the internet as instructed below, or, for those shareholders who receive a
paper proxy card in the mail, by mailing a completed proxy card. Whether or not you plan to attend the annual
meeting, we urge you to vote by proxy to ensure your vote is counted. You may still attend the annual
meeting and vote in person even if you have already voted by proxy. However, as noted above, in light of
the COVID-19 pandemic, we recommend that you vote your shares by proxy in advance of the
meeting.

• To vote in person, come to the annual meeting and we will give you a ballot when you arrive. Please
bring your admission ticket or proof of ownership, as further discussed under “Do I need a ticket to
attend the annual meeting?” below.

• To vote using a proxy card, simply complete, sign and date the proxy card that was mailed to you and

return it promptly in the envelope provided. Proxy cards must be received by July 27, 2022. If you return
your signed proxy card before this time, we will forward it to the company’s registered office
electronically in accordance with Irish law and we will vote your shares as you direct.

• To vote by telephone, dial toll-free +1.800.690.6903 within the United States, U.S. territories and Canada
using a touch-tone phone and follow the recorded instructions to submit an electronic proxy card. You
will be asked to provide the company number and control number from the enclosed proxy card. Your
vote must be received by 11:59 p.m., U.S. Eastern Time, on July 27, 2022 to be counted.

• To vote via the internet, go to www.proxyvote.com to complete an electronic proxy card. You will be

asked to provide the company number and control number from the enclosed proxy card. Your vote must
be received by 11:59 p.m., U.S. Eastern Time, on July 27, 2022 to be counted.

Beneficial Owners: Shares registered in the name of a broker, bank or other agent

If you are a beneficial owner of shares registered in the name of your broker, bank or other agent, you should
have received a Notice or the full set of proxy materials containing voting instructions from that broker, bank
or other agent rather than from us. Simply follow the voting instructions in the Notice or the full set of proxy
materials to ensure that your vote is counted. Alternatively, you may vote by telephone or via the internet as
instructed by your broker, bank or other agent. To vote in person at the annual meeting, you must request
and obtain a valid proxy from your broker, bank, or other agent. Follow the voting instructions from your
broker, bank or other agent, or contact your broker, bank or other agent to request a proxy form. However, as
noted above, in light of the COVID-19 pandemic, we recommend that you vote your shares by proxy in
advance of the meeting.

110

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Questions and Answers About These Proxy Materials and Voting (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

We provide internet proxy voting to allow you to vote your shares online, with procedures designed to
ensure the authenticity and correctness of your proxy vote instructions. However, please be aware
that you must bear any costs associated with your internet access, such as usage charges from
internet access providers and telephone companies.

Q: How many votes do I have?

A: On each matter to be voted upon, you have one vote for each ordinary share you owned as of the close of

business on June 1, 2022.

y
x
o
r
P

Q:

A:

Q:

A:

If I am a shareholder of record and I do not vote, or if I return a proxy card or otherwise vote without
giving specific voting instructions, what happens?

If you are a shareholder of record and you do not vote by completing your proxy card, vote by proxy via the
internet or by telephone, or vote in person at the annual meeting, your shares will not be voted.

If you are a shareholder of record and you do not specify your vote on each proposal individually when voting
by proxy via the internet or by telephone, or if you sign and return a proxy card without giving specific voting
instructions, then the proxy holders will vote your shares in the manner recommended by the board of
directors on all matters presented in this proxy statement and as the proxy holders may determine in their
discretion with respect to any other matters properly presented for a vote at the annual meeting. The voting
recommendations of the board of directors are set forth under “What are the board’s voting
recommendations?” above.

If I am a beneficial owner of shares held in street name and I do not provide my broker or bank with
voting instructions, what happens?

If you are a beneficial owner of shares held in street name and you do not instruct your broker, bank or other
agent how to vote your shares, your broker, bank or other agent may still be able to vote your shares in its
discretion. In this regard, under the rules of the New York Stock Exchange (NYSE), brokers, banks and other
securities intermediaries that are subject to NYSE rules may use their discretion to vote your “uninstructed”
shares with respect to matters considered to be “routine” under NYSE rules, but not with respect to
“non-routine” matters. In this regard, we have been advised by the NYSE that Proposals 1 and 3 are
considered to be “non-routine” under NYSE rules meaning that your broker may not vote your shares on
those proposals in the absence of your voting instructions. We have also been advised by the NYSE that
Proposals 2, 4 and 5 are considered to be a “routine” matter under NYSE rules meaning that if you do not
return voting instructions to your broker by its deadline, your shares may be voted by your broker in its
discretion on Proposals 2, 4 and 5.

If you are a beneficial owner of shares held in street name, in order to ensure your shares are voted in
the way you would prefer, you must provide voting instructions to your broker, bank or other agent by
the deadline provided in the materials you receive from your broker, bank or other agent.

Q: What does it mean if I receive more than one set of proxy materials, more than one Notice, or a

combination thereof?

A:

If you receive more than one set of proxy materials, more than one Notice, or a combination thereof, your
shares may be registered in more than one name or are registered in different accounts. Please follow the
voting instructions on each set of proxy materials or Notices to ensure that all of your shares are voted.

Q: Can I change my vote after submitting my proxy?

A: Yes. You can revoke your proxy at any time before the commencement of the annual meeting. If you are the

record holder of your shares, you may revoke your proxy in any one of the following ways:

• You may submit another properly completed proxy card with a later date.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

111

Questions and Answers About These Proxy Materials and Voting (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

• You may grant a subsequent proxy by telephone or via the internet.

• You may send a timely written notice that you are revoking your proxy to our Company Secretary at Fifth

Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland.

• You may attend the annual meeting and vote in person. Simply attending the annual meeting will not, by

itself, revoke your proxy.

• Your most recent proxy card or telephone or internet proxy is the one that is counted.

•

If your shares are held by your broker, bank or other agent as a nominee or agent, you should follow the
instructions provided by your broker, bank or other agent.

Q: Do I need a ticket to attend the annual meeting?

A: Yes, you will need an admission ticket or proof of ownership of ordinary shares to enter the annual meeting. If
you are a shareholder of record and you received a full set of proxy materials in the mail, your admission
ticket is attached to the proxy card sent to you. If you plan to attend the annual meeting, please so indicate
when you vote and bring the ticket and valid photo identification with you to the annual meeting. If you are a
shareholder of record and you received a Notice in the mail, your admission ticket is your Notice. Please bring
your Notice and valid photo identification with you to the annual meeting. If your shares are held in the name
of a bank, broker or other holder of record, your admission ticket is on your voting instruction form. If you do
not bring your admission ticket, you will need proof of ownership to be admitted to the annual meeting. A
recent brokerage statement or letter from a bank or broker is an example of proof of ownership. If you arrive
at the annual meeting without an admission ticket, we will admit you only if we are able to verify that you are a
shareholder of our company. For directions to attend the annual meeting in person, please contact our
Investor Relations department at +353.1.634.7892 (Ireland) or +1.650.496.2800 (United States) or by email at
investorinfo@jazzpharma.com.

Q: How are votes counted?

A: Votes will be counted by the inspector of elections appointed for the meeting. The inspector of elections will
separately count, with respect to the proposal to elect directors (Proposal 1), votes “FOR,” “AGAINST,”
abstentions and broker non-votes; and, with respect to the other proposals, votes “FOR,” “AGAINST,”
abstentions, and, as applicable, broker non-votes.

Q: What are “broker non-votes”?

A: As discussed above, when a beneficial owner of shares held in street name does not give voting instructions
to his or her broker, bank or other securities intermediary holding his or her shares as to how to vote on
matters deemed to be “non-routine” under NYSE rules, the broker, bank or other such agent cannot vote the
shares. These un-voted shares are counted as “broker non-votes.” We have been advised by the NYSE that
Proposals 1 and 3 are considered to be “non-routine” under NYSE rules and we therefore expect broker
non-votes in connection with those proposals.

As a reminder, if you are a beneficial owner of shares held in street name, in order to ensure your
shares are voted in the way you would prefer, you must provide voting instructions to your broker,
bank or other agent by the deadline provided in the materials you receive from your broker, bank or
other agent.

112

2022 Proxy Statement | JAZZ PHARMACEUTICALS

Questions and Answers About These Proxy Materials and Voting (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

Q: How many votes are needed to approve each proposal?

A: Assuming that a quorum is present at the annual meeting, the following votes will be required for approval:

Proposal

Vote Required for Approval

Proposal 1

Each director nominee must receive the affirmative vote of a majority of the votes cast on his
or her election to hold office until the 2025 annual meeting of shareholders.

Proposal 2

Affirmative vote of a majority of the votes cast

Proposal 3

Affirmative vote of a majority of the votes cast

Proposal 4

Affirmative vote of 75% of the votes cast

Proposal 5

Affirmative vote of a majority of the votes cast

y
x
o
r
P

Q: What are the treatment and effect of abstentions and broker non-votes?

A: Abstentions and broker non-votes will be treated as shares present for purposes of determining the presence
of a quorum for the transaction of business at the annual meeting. Abstentions and broker non-votes will not,
however, be considered votes cast at the annual meeting. Because the approval of all of the proposals is
based on the votes cast at the annual meeting, abstentions and, as applicable, broker non-votes will not have
any effect on the outcome of voting on the proposals.

Q: What is the quorum requirement?

A: A quorum of shareholders is necessary to hold a valid meeting. A quorum will be present if shareholders
holding a majority of the issued and outstanding ordinary shares entitled to vote as of the record date are
present at the annual meeting or represented by

proxy. On the record date, there were 62,442,548 ordinary shares outstanding and entitled to vote. Your
shares will be counted towards the quorum only if you submit a valid proxy (or if one is submitted on your
behalf by your broker, bank or other agent) or, provided that you are a shareholder of record, if you vote in
person at the annual meeting. Abstentions and broker non-votes will be counted towards the quorum
requirement. If there is no quorum within one hour of the time scheduled for the annual meeting, the annual
meeting will stand adjourned to August 4, 2022 at 9:45 a.m. local time at the same location, or such other
time or place as the board of directors may determine.

Q: How can I find out the results of the voting at the annual meeting?

A: Preliminary voting results will be announced at the annual meeting. In addition, final voting results will be

published in a quarterly report on Form 10-Q or a current report on Form 8-K that we expect to file with the
SEC within four business days after the annual meeting. If final voting results are not available to us in time to
file a Form 10-Q or a Form 8-K within four business days after the annual meeting, we intend to file a Form
8-K to publish preliminary results and, within four business days after the final results are known to us, file an
additional Form 8-K to publish the final results.

Q: What are the Irish statutory financial statements and where can I access them?

A: We are presenting for consideration our Irish statutory financial statements, and the respective reports of the
directors and the auditors thereon, at the annual meeting. Since we are an Irish company, we are required to
prepare Irish statutory financial statements under applicable Irish company law and to deliver those financial
statements together with the respective reports of the directors and the auditors thereon to shareholders of
record in connection with our annual meetings of shareholders. The Irish statutory financial statements cover
the results of operations and financial position of Jazz Pharmaceuticals plc for the year ended December 31,
2021. The Irish statutory financial statements were prepared in accordance with the International Financial
Reporting Standards as adopted by the European Union and as applied in accordance with the 2014 Act.
There is no requirement under Irish law that the Irish statutory financial statements be approved by the
shareholders, and no such approval will be sought at the annual meeting.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

113

Questions and Answers About These Proxy Materials and Voting (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

Our Irish statutory financial statements, and the respective reports of the directors and the auditors thereon,
will be delivered to shareholders of record in accordance with our obligations under Irish law. We will mail
without charge, upon written request, a copy of the Irish statutory financial statements, together with the
respective reports of the directors and the auditors thereon, to beneficial “street name” owners of our shares.
Requests should be sent to: Jazz Pharmaceuticals plc, Attention: Company Secretary, Fifth Floor, Waterloo
Exchange, Waterloo Road, Dublin 4, Ireland.

Q: What proxy materials are available on the internet?

A: This proxy statement, our letter to shareholders and the 2021 Annual Report on Form 10-K are available at

https://materials.proxyvote.com/G50871.

Q: Who should I call if I have any questions?

A:

If you require any assistance in voting your shares or have any other questions, please contact Alliance
Advisors, our proxy solicitor, at +1.855.600.8108.

114

2022 Proxy Statement | JAZZ PHARMACEUTICALS

2022 NOTICE OF MEETING AND PROXY STATEMENT

OTHER MATTERS

Presentation of Irish Statutory Financial Statements

Our Irish statutory financial statements for the fiscal year ended December 31, 2021, together with the reports of
the directors and auditors thereon, will be presented and considered at the annual meeting in accordance with the
requirements of the 2014 Act. Our Irish statutory financial statements have been approved by the board of
directors. There is no requirement under Irish law that such statements be approved by shareholders, and no
such approval will be sought at the annual meeting.

y
x
o
r
P

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Exchange Act requires the company’s directors and certain officers, as well as persons who
beneficially own more than 10% of the outstanding shares of Common Stock, to file reports regarding their initial
stock ownership and subsequent changes to their ownership with the SEC. Based solely on a review of the
reports filed for fiscal year 2021 and related written representations, we believe that all Section 16(a) reports were
filed on a timely basis, except for a late filing of a Form 4 due to an inadvertent administrative error to report the
sale of shares by Ms. Carr in September 2021, which was subsequently reported on Form 5.

Registered and Principal Executive Offices

The registered and principal executive offices of Jazz Pharmaceuticals plc are located at Fifth Floor, Waterloo
Exchange, Waterloo Road, Dublin 4, Ireland. Our telephone number there is +353.1.634.7800.

Shareholder Proposals and Director Nominations for the 2023 Annual Meeting

Our shareholders may submit proposals on matters appropriate for shareholder action at shareholder meetings in
accordance with Rule 14a-8 promulgated under the Exchange Act. For such proposals to be included in our proxy
materials relating to our 2023 annual meeting of shareholders, all applicable requirements of Rule 14a-8 must be
satisfied and, pursuant to Rule 14a-8, such proposals must be received by us no later than February 15, 2023.
However, if our 2023 annual meeting of shareholders is not held between June 28, 2023 and August 27, 2023,
then the deadline will be a reasonable time prior to the time that we begin to print and mail our proxy materials.
Such proposals should be delivered to Jazz Pharmaceuticals plc, Attention: Company Secretary, Fifth Floor,
Waterloo Exchange, Waterloo Road, Dublin 4, Ireland.

Our articles provide that shareholder nominations of persons to be elected to the board of directors at an annual
meeting must be made following written notice to our Company Secretary which is executed by a shareholder and
accompanied by certain background and other information specified in our articles. Such written notice and
information must be received by our Company Secretary not later than the close of business on March 17, 2023
nor earlier than January 16, 2023; provided, however, that in the event our 2023 annual meeting of shareholders
is not held between June 28, 2023 and August 27, 2023, notice must be delivered no earlier than 150 days prior
to nor later than the later of 90 days prior to the date of the 2023 annual meeting or the 10th day following the day
on which public announcement of the date of such meeting is first made. Our articles provide that other proposals
may only be proposed at an annual meeting if either (i) it is proposed by or at the direction of our board of
directors; (ii) it is proposed at the direction of the Irish High Court; or (iii) the chairperson of the meeting decides,
in his or her absolute discretion, that the proposal may properly be regarded as within the scope of the relevant
meeting. In addition, the proxy solicited by our board of directors for the 2023 annual meeting of shareholders will
confer discretionary voting authority with respect to (i) any proposal presented by a shareholder at that meeting
for which we have not been provided with notice by May 1, 2023 and (ii), if we have received notice of such
proposal by May 1, 2023, any matter, provided that (i) the 2023 proxy statement briefly describes such matter and
how management’s proxy holders intend to vote on it and (ii) the shareholder does not comply with the
requirements of Rule 14a-4(c)(2) promulgated under the Exchange Act. On any other business which may
properly come before the 2023 annual meeting of shareholders, or any adjournment thereof, and whether

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

115

Other Matters (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

procedural or substantive in nature (including without limitation any motion to amend a resolution or adjourn the
meeting) not specified in this proxy statement, the proxy holder will act at his or her discretion.

In addition to satisfying the foregoing requirements under our articles, to comply with the universal proxy rules
(once effective), stockholders who intend to solicit proxies in support of director nominees other than our
nominees must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act no
later than May 29, 2023.

Householding of Proxy Materials

The SEC has adopted rules that permit companies and intermediaries (such as brokers) to satisfy the delivery
requirements for Notices and proxy materials with respect to two or more shareholders sharing the same address
by delivering a single Notice or a single set of proxy materials, as applicable, addressed to those shareholders.
This process, which is commonly referred to as “householding” potentially means extra convenience for
shareholders and cost savings for companies.

A number of brokers with account holders who are Jazz Pharmaceuticals shareholders will be “householding”
Notices and our proxy materials. A single Notice or a single set of proxy materials, as applicable, may be
delivered to multiple shareholders sharing an address unless contrary instructions have been received from the
affected shareholders. Once you have received notice from your broker that it will be “householding”
communications to your address, “householding” will continue until you are notified otherwise or until you revoke
your consent. If, at any time, you no longer wish to participate in “householding” and would prefer to receive a
separate Notice or set of proxy materials, as applicable, in the future you may: (1) notify your broker, (2) direct
your written request to Jazz Pharmaceuticals plc, Attention: Investor Relations, Fifth Floor, Waterloo Exchange,
Waterloo Road, Dublin 4, Ireland or (3) contact our Investor Relations department at +353.1.634.7892 (Ireland) or
+1.650.496.2800 (United States) or by email at investorinfo@jazzpharma.com. Shareholders who currently
receive multiple copies of Notices or proxy materials at their address and would like to request “householding” of
their communications should contact their broker. In addition, we will promptly deliver, upon written or oral request
to the address or telephone number above, a separate copy of a Notice or set of proxy materials to a shareholder
at a shared address to which a single Notice or set of proxy materials, as applicable, was delivered.

Annual Report on Form 10-K

We will mail without charge, upon written request, a copy of our 2021 Annual Report on Form 10-K,
including the consolidated financial statements, schedules and list of exhibits, and any particular exhibit
specifically requested. Requests should be sent to: Jazz Pharmaceuticals plc, Attention: Aislinn Doody,
Company Secretary, Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland.

Special Note Regarding Forward-Looking Statements

This proxy statement contains forward-looking statements, including, but not limited to, statements related to our
growth prospects and future financial and operating performance, including Vision 2025 and expectations related
thereto; our strategy to create sustainable and enhanced growth and value, including statements related to the
potential ways in which we intend to advance our business, grow and diversify our portfolio and revenues, and
increase shareholder value; the anticipated benefits to us of the GW Acquisition; the goals of our ESG strategies,
efforts and initiatives, including with respect to our efforts to operate our manufacturing facilities in an
environmentally responsible way, the goals of our internal environmental policies and management systems, and
our commitment to advancing our ESG strategies and reporting of our ESG metrics, including our anticipated
2022 ESG report and the standards and metrics by which we measure or expect to measure our ESG progress;
our anticipated needs with respect to our ability to issue our share capital and our flexibility to execute on our
growth strategy; any potential future strategic opportunities, including potential acquisitions or other business
development transactions; the anticipated benefits to us of our corporate development transactions and research
and development efforts; anticipated clinical development timelines and initiatives; the goals of our executive

116

2022 Proxy Statement | JAZZ PHARMACEUTICALS

y
x
o
r
P

Other Matters (continued)

2022 NOTICE OF MEETING AND PROXY STATEMENT

compensation programs; and other statements that are not historical facts. These forward-looking statements are
based on our current plans, objectives, estimates, expectations and intentions and inherently involve significant
risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in
such forward-looking statements as a result of these risks and uncertainties, which include, without limitation,
risks and uncertainties associated with: maintaining or increasing sales of and revenue from our oxybate
products, Zepzelca and other key marketed products; effectively launching and commercializing our other
products and product candidates; obtaining and maintaining adequate coverage and reimbursement for our
products; the time-consuming and uncertain regulatory approval process, including the risk that our current and/or
planned regulatory submissions may not be submitted, accepted or approved by applicable regulatory authorities
in a timely manner or at all; the costly and time-consuming pharmaceutical product development and the
uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing
clinical trials and assessing patients such as those being experienced, and expected to continue to be
experienced, by us as a result of the effects of the COVID-19 pandemic; our failure to realize the expected
benefits of our acquisition of GW Pharmaceuticals, including the failure to realize the blockbuster potential of
Epidiolex and the risk that the legacy GW Pharmaceuticals business will not be integrated successfully or that
such integration may be more difficult, time-consuming or costly than expected; the ultimate duration and severity
of the COVID-19 pandemic and resulting global economic, financial, and healthcare system disruptions and the
current and potential future negative impacts to our business operations and financial results; regulatory initiatives
and changes in tax laws; market volatility; protecting and enhancing our intellectual property rights and our
commercial success being dependent upon obtaining, maintaining and defending intellectual property protection
for our products and product candidates; delays or problems in the supply or manufacture of our products and
product candidates; complying with applicable U.S. and non-U.S. regulatory requirements, including those
governing the research, development, manufacturing and distribution of controlled substances; government
investigations, legal proceedings and other actions; identifying and acquiring, in-licensing or developing additional
products or product candidates, financing these transactions and successfully integrating acquired product
candidates, products and businesses; our ability to realize the anticipated benefits of our collaborations and
license agreements with third parties; the sufficiency of our cash flows and capital resources to fund our debt
service obligations, de-lever and meet our stated leverage targets; challenges inherent in efficiently managing
employees in diverse geographies and creating and maintaining a positive workplace culture; the aspirational
nature of our ESG strategies, efforts and initiatives, which are not guarantees or promises that such goals,
initiatives and objectives will be met; our ability to achieve expected future financial performance and results and
the uncertainty of future tax, accounting and other provisions and estimates; the possibility that, if we do not
achieve the perceived benefits of the acquisition of GW Pharmaceuticals as rapidly or to the extent anticipated by
financial analysts or investors, the market price of our ordinary shares could decline; our ability to achieve
expected future financial performance and results; our ability to meet our projected long-term goals and
objectives, including as part of Vision 2025, in the time periods that we anticipate, or at all, and the inherent
uncertainty and significant judgments and assumptions underlying our long-term goals and objectives; our ability
to identify, compete with others for, and successfully complete any potential future business development
transaction; and other risks and uncertainties affecting us, including those described from time to time under the
caption “Risk Factors” and elsewhere in Jazz Pharmaceuticals’ Securities and Exchange Commission filings and
reports, including Jazz Pharmaceuticals’ Annual Report on Form 10-K for the year ended December 31, 2021,
and future filings and reports by Jazz Pharmaceuticals. Other risks and uncertainties of which we are not currently
aware may also affect our forward-looking statements and may cause actual results and timing of events to differ
materially from those anticipated. The forward-looking statements herein are made only as of the date of this
proxy statement or as of the dates indicated in the forward-looking statements, even if they are subsequently
made available by us on our website or otherwise. We undertake no obligation to update or supplement any
forward-looking statements to reflect actual results, new information, future events, changes in our expectations
or other circumstances that exist after the date as of which the forward-looking statements were made.

JAZZ PHARMACEUTICALS | 2022 Proxy Statement

117

2022 NOTICE OF MEETING AND PROXY STATEMENT

Other Matters (continued)

General

Your proxy is solicited on behalf of our board of directors. Unless otherwise directed, at the annual meeting (or
any adjournment thereof), proxies will be voted “FOR” all of the nominees listed in Proposal 1 and “FOR”
Proposals 2 through 5. If any matter other than those described in this proxy statement properly comes before the
annual meeting (or any adjournment thereof), it is the intention of the persons named in the accompanying proxy
to vote on such matters in accordance with their best judgment.

By order of the board of directors,

/s/ Aislinn Doody
Aislinn Doody, Company Secretary
Dublin, Ireland

June 10, 2022

118

2022 Proxy Statement | JAZZ PHARMACEUTICALS

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K

K
-
0
1
m
r
o
F

(Mark One)
È ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2021

or

‘ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from

to

Commission File Number: 001-33500
JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
(Exact name of registrant as specified in its charter)

Ireland
(State or other jurisdiction of incorporation or organization)

98-1032470
(I.R.S. Employer Identification No.)

Fifth Floor, Waterloo Exchange
Waterloo Road, Dublin 4, Ireland D04 E5W7
011-353-1-634-7800
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Ordinary shares, nominal value $0.0001 per share

JAZZ

The Nasdaq Stock Market LLC

Securities registered pursuant to Section 12(g) of the Act:

None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes È No ‘

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ‘ No È

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the

preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past
90 days. Yes È No ‘

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T

during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes È No ‘

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth
company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer È

Accelerated filer ‘

Non-accelerated filer ‘

Smaller reporting company ‘

Emerging growth company ‘

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised

financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ‘

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over
financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. È

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ‘ No È

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, as of June 30, 2021, the last business day of the
registrant’s most recently completed second fiscal quarter, was approximately $10,591,497,500 based upon the last sale price reported for the registrant’s ordinary shares on
such date on The Nasdaq Global Select Market. The calculation of the aggregate market value of voting and non-voting common equity excludes 1,490,584 ordinary shares of
the registrant held by executive officers, directors and shareholders that the registrant concluded were affiliates of the registrant on that date. Exclusion of such shares should
not be construed to indicate that any such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant or that
such person is controlled by or under common control with the registrant.

As of February 22, 2022, a total of 61,738,841 ordinary shares, nominal value $0.0001 per share, of the registrant were outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Certain information required by Part III, Items 10-14 of this Form 10-K is incorporated by reference to the registrant’s definitive Proxy Statement for the 2022 Annual

General Meeting of Shareholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A. If such Proxy Statement is not filed within 120 days
after the end of the fiscal year covered by this Form 10-K, such information will be included in an amendment to this Form 10-K to be filed within such 120-day period.

[THIS PAGE INTENTIONALLY LEFT BLANK]

JAZZ PHARMACEUTICALS PLC
2021 ANNUAL REPORT ON FORM 10-K

TABLE OF CONTENTS

PART I

Item 1.

Business . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Item 1A. Risk Factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Item 1B. Unresolved Staff Comments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Item 2.

Properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Item 3.

Legal Proceedings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Item 4.

Mine Safety Disclosures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

PART II

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities . . . . . .

Item 6.

Reserved . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations . . . . . . . . . . . . . . . . . . . . . . . .

Item 7A. Quantitative and Qualitative Disclosures About Market Risk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Item 8.

Financial Statements and Supplementary Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure . . . . . . . . . . . . . . . . . . . . . . .

Item 9A. Controls and Procedures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Item 9B. Other Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

PART III

Item 10. Directors, Executive Officers and Corporate Governance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Item 11.

Executive Compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters . . . . . . . . . . . . . . .

Item 13. Certain Relationships and Related Transactions, and Director Independence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Item 14.

Principal Accountant Fees and Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

K
-
0
1
m
r
o
F

Page

3

33

67

68

68

68

69

72

72

93

94

95

95

97

97

97

97

97

97

98

PART IV

Item 15.

Exhibits and Financial Statement Schedules . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

98

Item 16.

Form 10-K Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

108

Signatures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

109

We own or have rights to various copyrights, trademarks, and trade names used in our business in the U.S. and/or other countries,

including the following: Jazz Pharmaceuticals®, Xyrem® (sodium oxybate) oral solution, Xywav® (calcium, magnesium, potassium, and
sodium oxybates) oral solution, Epidiolex® (cannabidiol) oral solution, Epidyolex® (the trade name in Europe and other countries outside
the U.S. for Epidiolex), Sunosi® (solriamfetol), Defitelio® (defibrotide sodium), Defitelio® (defibrotide), CombiPlex®, Vyxeos® (daunorubicin
and cytarabine) liposome for injection, Vyxeos® liposomal 44 mg/100 mg powder for concentrate for solution for infusion, Zepzelca®
(lurbinectedin), Rylaze™ (recombinant Erwinia asparaginase) and Sativex® (nabiximols) oral solution. This report also includes trademarks,
service marks and trade names of other companies. Trademarks, service marks and trade names appearing in this Annual Report on
Form 10-K are the property of their respective owners.

[THIS PAGE INTENTIONALLY LEFT BLANK]

K
-
0
1
m
r
o
F

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of

1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created
by those sections. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently
available to our management. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,”
“would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “predict,” “propose,” “intend,” “continue,” “potential,” “possible,” “strive,”
“seek,” “designed,” “goal”, “foreseeable,” “likely,” “unforeseen” and similar expressions intended to identify forward-looking statements.
These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance, time
frames or achievements to be materially different from any future results, performance, time frames or achievements expressed or implied
by the forward-looking statements. We discuss many of these risks, uncertainties and other factors in greater detail under Risk Factors in
Part I, Item 1A of this Annual Report on Form 10-K. Given these risks, uncertainties and other factors, you should not place undue reliance
on these forward-looking statements. In addition, our goals and objectives are aspirational and are not guarantees or promises that such
goals and objectives will be met. Also, these forward-looking statements represent our estimates and assumptions only as of the date of
this filing. You should read this Annual Report on Form 10-K completely and with the understanding that our actual future results may be
materially different from what we expect. We hereby qualify our forward-looking statements by our cautionary statements. Except as
required by law, we assume no obligation to update our forward-looking statements publicly, or to update the reasons that actual results
could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

SUMMARY RISK FACTORS

Below is a summary of material factors that make an investment in our ordinary shares speculative or risky. Importantly, this summary

does not address all of the risks and uncertainties that we face. Additional discussion of the risks and uncertainties summarized in this
risk factor summary, as well as other risks and uncertainties that we face, can be found under “Risk Factors” in Part I, Item 1A of this
Annual Report on Form 10-K. The below risk factor summary is qualified in its entirety by that more complete discussion of such risks and
uncertainties. You should consider carefully the risks and uncertainties described under “Risk Factors” in Part I, Item 1A of this
Annual Report on Form 10-K as part of your evaluation of an investment in our ordinary shares.

• Our inability to maintain or increase sales from our oxybate franchise would have a material adverse effect on our business,

financial condition, results of operations and growth prospects.

•

•

The introduction of new products in the U.S. market that compete with, or otherwise disrupt the market for, our oxybate products
and product candidates would adversely affect sales of our oxybate products and product candidates.

The distribution and sale of our oxybate products are subject to significant regulatory restrictions, including the requirements of
a risk evaluation and mitigation strategy, or REMS, and safety reporting requirements, and these regulatory and safety
requirements subject us to risks and uncertainties, any of which could negatively impact sales of Xywav® and Xyrem®.

• Our inability to maintain or increase sales of Epidiolex® /Epidyolex® would have a material adverse effect on our business,

financial condition, results of operations and growth prospects.

• While we expect our oxybate products and Epidiolex/Epidyolex to remain the largest parts of our business, our success also
depends on our ability to effectively commercialize other products in our neuroscience and oncology therapeutic areas.

• We face substantial competition from other companies, including companies with larger sales organizations and more

experience working with large and diverse product portfolios, and face competition from generic drugs and potentially from
non-FDA approved cannabidiol preparations.

•

•

•

Adequate coverage and reimbursement from third party payors may not be available for our products and we may be unable to
successfully contract for coverage from pharmacy benefit managers and other organizations; conversely, to secure coverage
from these organizations, we may be required to pay rebates or other discounts or other restrictions to reimbursement, either of
which could diminish our sales or adversely affect our ability to sell our products profitably.

The pricing of pharmaceutical products has come under increasing scrutiny as part of a global trend toward healthcare cost
containment and resulting changes in healthcare law and policy may impact our business in ways that we cannot currently
predict, which could have a material adverse effect on our business and financial condition.

In addition to access, coverage and reimbursement, the commercial success of our products depends upon their market
acceptance by physicians, patients, third party payors and the medical community.

JAZZ PHARMACEUTICALS | 2021 Annual Report

1

•

Delays or problems in the supply of our products for sale or for use in clinical trials, loss of our single source suppliers or failure
to comply with manufacturing regulations could materially and adversely affect our business, financial condition, results of
operations and growth prospects.

• Our future success depends on our ability to successfully develop and obtain and maintain regulatory approvals for our
late-stage product candidates and, if approved, to successfully launch and commercialize those product candidates.

• We may not be able to successfully identify and acquire or in-license additional products or product candidates to grow our
business, and, even if we are able to do so, we may otherwise fail to realize the anticipated benefits of these transactions.

•

Conducting clinical trials is costly and time-consuming, and the outcomes are uncertain. A failure to prove that our product
candidates are safe and effective in clinical trials, or to generate data in clinical trials to support expansion of the therapeutic
uses for our existing products, could materially and adversely affect our business, financial condition, results of operations and
growth prospects.

• We may not realize the anticipated benefits and synergies from the acquisition of GW Pharmaceuticals plc.

•

It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection.

• We have incurred and may in the future incur substantial costs as a result of litigation or other proceedings relating to patents,
other intellectual property rights and related matters, and we may be unable to protect our rights to, or commercialize, our
products.

• Our business is currently adversely affected and could be materially and adversely affected in the future by the evolving effects
of the COVID-19 pandemic and related global economic slowdown, including with respect to our commercialization efforts,
clinical trial activity, research and development activities, supply chain and corporate development activities and other business
operations.

•

Significant disruptions of information technology systems or data security breaches could adversely affect our business.

• We are subject to significant ongoing regulatory obligations and oversight, which may result in significant additional expense

and limit our ability to commercialize our products.

•

If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental
pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could
have a material adverse effect on our business, financial condition, results of operations and growth prospects.

• We have incurred substantial debt, which could impair our flexibility and access to capital and adversely affect our financial

position, and our business would be adversely affected if we are unable to service our debt obligations.

•

To continue to grow our business, we will need to commit substantial resources, which could result in future losses or otherwise
limit our opportunities or affect our ability to operate and grow our business.

NOTE REGARDING COMPANY REFERENCE

In this report, unless otherwise indicated or the context otherwise requires, all references to “Jazz Pharmaceuticals,” “Jazz,” “the

registrant,” “we,” “us,” and “our” refer to Jazz Pharmaceuticals plc and its consolidated subsidiaries.

2

2021 Annual Report

| JAZZ PHARMACEUTICALS

Item 1.

Business

Overview

PART I

Jazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and

their families. We are dedicated to developing life-changing medicines for people with serious diseases – often with limited or no
therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage
development, in neuroscience and oncology. Within these therapeutic areas, we strive to identify new options for patients by actively
exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science.

Our strategy for growth is rooted in executing commercial launches and ongoing commercialization initiatives; advancing robust
research and development, or R&D, programs and delivering impactful clinical results; effectively deploying capital to strengthen the
prospects of achieving our short- and long-term goals through strategic corporate development; and delivering strong financial
performance. We focus on patient populations with high unmet needs. We identify and develop differentiated therapies for these patients
that we expect will be long-lived assets and that we can support with an efficient commercialization model. In addition, we leverage our
efficient, scalable operating model and integrated capabilities across our global infrastructure to effectively reach patients around the world.

At the 40th Annual J.P. Morgan Healthcare Conference in January 2022, we announced our Vision 2025, which aims to deliver
sustainable growth and enhanced value, driving our continued transformation to an innovative, high-growth global pharmaceutical leader.
The three core components of our Vision 2025 focus on commercial execution, pipeline productivity and operational excellence.

K
-
0
1
m
r
o
F

Our lead marketed products are:

Neuroscience

•

•

•

•

•

Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution, a product approved by the U.S. Food and
Drug Administration, or FDA, in July 2020 and launched in the U.S. in November 2020 for the treatment of cataplexy or
excessive daytime sleepiness, or EDS, in patients with narcolepsy aged seven years of age and older, and also approved by
FDA in August 2021 for the treatment of idiopathic hypersomnia, or IH, in adults and launched in the U.S. in November 2021.
Xywav contains 92% less sodium than Xyrem®;

Xyrem (sodium oxybate) oral solution, a product approved by FDA and distributed in the U.S. for the treatment of both
cataplexy and EDS in patients seven years of age and older with narcolepsy; Jazz also markets Xyrem in Canada for the
treatment of cataplexy in patients with narcolepsy. Xyrem is also approved and distributed in Europe, Great Britain and other
markets through a licensing agreement;

Epidiolex® (cannabidiol) oral solution, a product approved by FDA and launched in the U.S. in 2018 by GW Pharmaceuticals
plc, or GW, and currently indicated for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome,
or tuberous sclerosis complex, or TSC, in patients one year of age or older; in Europe (where it is marketed as Epidyolex®) and
other markets, it is approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome or Dravet
syndrome, in conjunction with clobazam (EU and Great Britain only), in patients 2 years of age and older and for adjunctive
treatment of seizures associated with TSC in patients 2 years of age and older;

Sunosi® (solriamfetol), a product approved by FDA and marketed in the U.S., Canada, Europe and Great Britain to improve
wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea, or OSA; and

Sativex® (nabiximols) oral solution, a product approved and marketed in the U.K., Canada and other markets as treatment
for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis, or MS, who have not
responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in
spasticity-related symptoms during an initial trial of therapy.

Oncology

•

Zepzelca® (lurbinectedin), a product approved by FDA in June 2020 and launched in the U.S. in July 2020 for the treatment of
adult patients with metastatic small cell lung cancer, or SCLC, with disease progression on or after platinum-based
chemotherapy; in Canada, Zepzelca was approved in September 2021 for the treatment of adults with Stage III or metastatic
SCLC, who have progressed on or after platinum-containing therapy;

JAZZ PHARMACEUTICALS | 2021 Annual Report

3

•

•

•

Rylaze™ (recombinant Erwinia asparaginase), a product approved by FDA in June 2021 and launched in the U.S. in July 2021 for use
as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia, or ALL, or lymphoblastic
lymphoma, or LBL, in adults and pediatric patients who have developed hypersensitivity to E. coli-derived asparaginase;

Vyxeos® (daunorubicin and cytarabine) liposome for injection, a product approved in the U.S., Canada, Europe and Great
Britain (marketed as Vyxeos® liposomal in Europe and Great Britain) for the treatment of adults with newly-diagnosed
therapy-related acute myeloid leukemia, or t-AML, or AML with myelodysplasia-related changes (AML-MRC). An expanded
indication was granted in the U.S. for the treatment of newly diagnosed t-AML or AML-MRC in pediatric patients aged 1 year
and older; and

Defitelio® (defibrotide sodium), is a product approved in the U.S. and Brazil for the treatment of hepatic veno-occlusive
disease, or VOD, with renal or pulmonary dysfunction following hematopoietic stem cell transplantation, or HSCT, and in Japan
for the treatment of hepatic sinusoidal obstruction syndrome (hepatic-veno occlusive disease). It is currently approved in the EU,
Great Britain, Canada, Israel, South Korea, Australia and Switzerland for the treatment of severe hepatic VOD, also known as
sinusoidal obstructive syndrome, or SOS, in HSCT therapy. It is indicated in adults and pediatric patients over 1 month of age.

In 2021, consistent with our strategy, we continued to focus on research and development activities within our neuroscience and

oncology therapeutic areas. For a summary of our ongoing research and development activities, see “Business—Research and
Development” in this Part I, Item 1.

Acquisition of GW Pharmaceuticals

In May 2021, we acquired GW Pharmaceuticals plc, or GW. The total consideration paid by us for the entire issued share capital of

GW was $7.2 billion. The acquisition, which we refer to as the GW Acquisition, closed on May 5, 2021. We acquired GW with the objective
of broadening our neuroscience portfolio, further diversifying our revenue and driving sustainable, long-term value creation opportunities.
GW was a global leader in discovering, developing, manufacturing and commercializing novel, regulatory approved therapeutics from its
proprietary cannabinoid research platform to address a broad range of diseases. For further information regarding the GW Acquisition,
please see Note 3 Business Combinations, Asset Acquisitions and Collaborations of the Notes to Consolidated Financial Statements,
included in Part IV of this Annual Report on Form 10-K.

Our Commercialized Products

Neuroscience

Xywav. Xywav is a product approved by FDA for the treatment of cataplexy or EDS in both adult and pediatric patients aged seven

years of age and older with narcolepsy and for the treatment of adults with IH. Xywav is an oxybate product that contains 92% less sodium
than Xyrem.

In July 2020, FDA approved Xywav for the treatment of both cataplexy and EDS in patients with narcolepsy. We commenced the U.S.

launch in November 2020. We met our goal to obtain broad payor coverage of Xywav within six months of launch. To date, we have
entered into agreements with various entities and have achieved benefit coverage for Xywav for approximately 90% of commercial lives.

Narcolepsy is a chronic, debilitating neurological disorder characterized by EDS and the inability to regulate sleep-wake cycles
normally. It affects an estimated one in 2,000 people in the U.S., with symptoms typically appearing in childhood. There are five primary
symptoms of narcolepsy, including EDS, cataplexy, disrupted nighttime sleep, sleep-related hallucinations, and sleep paralysis. While
patients with narcolepsy may not experience all five symptoms, EDS, an essential symptom of narcolepsy, is present in all narcolepsy
patients and is characterized by chronic, pervasive sleepiness as well as sudden irresistible and overwhelming urges to sleep (inadvertent
naps and sleep attacks). Narcolepsy may affect many areas of life, including limiting a patient’s education and employment opportunities,
and may lead to difficulties at work, school, or in daily life activities like driving, operating machinery or caring for children. Patients with
narcolepsy may also suffer from significant medical comorbidities, including cardiac disorders, depression, suicide risk, anxiety, diseases of
the digestive system and respiratory diseases.

Cataplexy, the sudden loss of muscle tone with retained consciousness, can be one of the most debilitating symptoms of narcolepsy.
Cataplexy is present in approximately 70% of patients with narcolepsy. Cataplexy can range from slight weakness or a drooping of facial muscles
to the complete loss of muscle tone resulting in postural collapse. It may also impair a patient’s vision or speech. Cataplexy is often triggered by
strong emotions such as laughter, anger or surprise. Cataplexy can severely impair a patient’s quality of life and ability to function.

Narcolepsy patients, by virtue of their diagnosis, are at increased risk of cardiovascular events and disease, and the impact of sodium

on cardiovascular health is well established. There is also extensive scientific evidence that reducing sodium consumption, which is a

4

2021 Annual Report

| JAZZ PHARMACEUTICALS

modifiable risk factor, is associated with clinically meaningful reductions in blood pressure and cardiovascular disease risk. Therefore, we
believe that reducing sodium intake compared to the standard of care by 92% each and every day is a significant advancement for these
patients. The 92% reduction of sodium translates into a reduction of approximately 1,000 to 1,500 milligrams per day for a patient
prescribed Xyrem, depending on the dose. When patients transition from Xyrem to Xywav, Xywav treatment is initiated at the same dose
and regimen (gram for gram) and titrated as needed based on efficacy and tolerability. The label for Xywav, unlike Xyrem, does not include
a warning to prescribers to monitor patients sensitive to sodium intake, including patients with heart failure, hypertension or renal
impairment.

Our internal market research finds that health care providers and patients who understand the increased risk of cardiovascular
disease faced by narcolepsy patients and who have been educated on the meaningful reduction in sodium from Xyrem to Xywav cite that
meaningful reduction as a key reason for prescribing or starting on Xywav. In June 2021, FDA recognized seven years of Orphan Drug
Exclusivity, or ODE, for Xywav in narcolepsy through July 21, 2027, stating that Xywav is clinically superior to Xyrem by means of greater
safety due to reduced chronic sodium burden.

In approving Xywav, FDA approved a REMS to cover both Xywav and Xyrem. The Xywav and Xyrem REMS has the same
requirements for both products and both products are also distributed by the central pharmacy through exclusive agreements described
more fully below.

On August 12, 2021, FDA approved Xywav for the treatment of IH in adults. Xywav is the first and only FDA-approved therapy to treat

IH. We initiated the U.S. commercial launch of Xywav for the treatment of IH in adults on November 1, 2021. IH is a debilitating neurologic
sleep disorder characterized by chronic EDS (the inability to stay awake and alert during the day resulting in the irrepressible need to sleep
or unplanned lapses into sleep or drowsiness), severe sleep inertia, and prolonged and non-restorative nighttime sleep. Although there are
overlapping clinical features with other conditions, including narcolepsy, IH has its own specific diagnostic criteria. IH can significantly affect
social, educational and occupational functioning. An estimated 37,000 people in the U.S. have been diagnosed with IH and are actively
seeking healthcare. In January 2022, FDA recognized seven years of ODE for Xywav in IH through August 12, 2028.

K
-
0
1
m
r
o
F

In 2021, net product sales of Xywav were $535.3 million, which represented 17% of our total net product sales. There were

approximately 6,900 active patients on Xywav exiting the fourth quarter of 2021, including approximately 6,650 active patients with
narcolepsy and approximately 250 active patients with IH. With respect to Xywav and Xyrem in the aggregate, the average number of
active oxybate patients on therapy was approximately 16,200 in the fourth quarter of 2021.

Xyrem. Xyrem is a product approved by FDA and distributed in the U.S. for the treatment of both cataplexy and EDS in both adult

and pediatric patients with narcolepsy. Sodium oxybate, the active pharmaceutical ingredient, or API, in Xyrem, is a formulation of the
sodium salt of gamma-hydroxybutyrate, an endogenous neurotransmitter and metabolite of gamma-aminobutyric acid.

Xyrem was approved in the U.S. for the treatment of cataplexy in adult patients with narcolepsy in 2002 and was approved for EDS in

adult patients with narcolepsy in 2005. In October 2018, Xyrem was also approved in the U.S. for the treatment of cataplexy or EDS in
pediatric narcolepsy patients ages seven and older. In its updated 2021 treatment guidelines, the American Academy of Sleep Medicine
gives sodium oxybate a strong recommendation for the treatment of narcolepsy in adults. To support the development and
commercialization of Xyrem internationally, we have license and distribution agreement with UCB Pharma Limited, or UCB, across other
countries. This agreement provides UCB and its affiliates with the sole right to commercialize Xyrem in exclusive territories for all
indications.

In 2021, net product sales of Xyrem were $1.3 billion, which represented 41% of our total net product sales.

Xywav and Xyrem REMS. Our marketing, sales and distribution of Xywav and Xyrem in the U.S. are subject to a REMS, which is
required by FDA to mitigate the risks of serious adverse outcomes resulting from inappropriate prescribing, abuse, misuse and diversion of
Xywav and Xyrem. Under this REMS, all of the Xywav and Xyrem sold in the U.S. must be dispensed and shipped directly to patients or
caregivers through a central pharmacy. Xywav and Xyrem may not be stocked in retail pharmacies. Physicians and patients must complete
an enrollment process prior to fulfillment of Xywav and Xyrem prescriptions, and each physician and patient must receive materials
concerning the serious risks associated with Xywav and Xyrem before the physician can prescribe, or a patient can receive, the product.
The central certified pharmacy must monitor and report instances of patient or prescriber behavior giving rise to a reasonable suspicion of
abuse, misuse or diversion of Xywav and Xyrem, and maintains enrollment and prescription monitoring information in a central database.
The central pharmacy ships the product directly to the patient (or caregiver) by a courier service.

We have had exclusive agreements with Express Scripts Specialty Distribution Services, Inc., or ESSDS, the central pharmacy for Xywav

and Xyrem, to distribute Xywav and Xyrem in the U.S. and provide patient support services related to Xyrem since 2002. In July 2020, upon

JAZZ PHARMACEUTICALS | 2021 Annual Report

5

expiration of the existing exclusive agreements with ESSDS, we entered into new agreements with ESSDS with a two-year term. Our current
agreements with ESSDS, which expire on July 1, 2022, may be terminated by either party at any time without cause on 180 days’ prior written
notice to the other party.

Epidiolex. We acquired Epidiolex (Epidyolex outside the U.S.) in May 2021 as part of the GW Acquisition, which expands our
growing neuroscience business with a global, high-growth childhood-onset epilepsy franchise. Epidiolex is a pharmaceutical formulation
comprising highly purified plant-derived cannabidiol, or CBD, for which we retain global commercial rights. Epidiolex was approved in the
U.S. in June 2018 for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome, or LGS,
and Dravet syndrome, or DS, in patients two years of age and older, and subsequently approved in July 2020 for the treatment of seizures
associated with tuberous sclerosis complex, or TSC, in patients one year of age and older. FDA also approved the expansion of the prior
approved indications, LGS and DS, to patients one year of age and older. The rolling European launch of Epidyolex is also underway
following European Commission, or EC, approval in September 2019 for use as adjunctive therapy of seizures associated with LGS or DS,
in conjunction with clobazam, for patients two years of age and older. The clobazam restriction is limited to EU and Great Britain. Outside
the U.S. and Europe, Epidiolex/Epidyolex is approved in Israel and Australia. See “Research and Development” below for a discussion of
clinical development activities for Epidiolex.

LGS and DS are severe childhood-onset, drug-resistant epilepsy syndromes. LGS and DS affect approximately 35,000-50,000 and

approximately 10,000 individuals in the U.S., respectively. TSC is a rare genetic disorder that causes non-malignant tumors to form in
many different organs and is a leading cause of genetic epilepsy. TSC affects approximately 50,000 individuals in the U.S. Epidiolex has
received ODE to treat seizures associated with LGS and DS through 2025 and TSC through 2027.

Net product sales of Epidiolex/Epidyolex in 2021, beginning from the closing of the GW Acquisition on May 5, 2021 were

$463.6 million, which represented 15% of our total net product sales. On a pro forma basis, assuming the GW Acquisition had closed on
January 1, 2021, Epidiolex/Epidyolex net product sales in 2021 were $658.3 million. For a detailed discussion of the GW Acquisition, see
“Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II, Item 7 of this Annual Report on
Form 10-K.

Sunosi. Sunosi received FDA approval in March 2019 and was launched in the U.S. in July 2019 to improve wakefulness in adult

patients with EDS associated with narcolepsy or OSA. Sunosi was also approved in January 2020 by the EC to improve wakefulness and
reduce EDS in adults with narcolepsy (with or without cataplexy) or OSA. We launched Sunosi in Germany for the treatment of narcolepsy
in May 2020 followed by OSA in July 2021 and for the treatment of both indications in Denmark in October 2020, in France in March 2021,
and in Italy in April 2021. We expect to continue the rolling launch in Europe as we secure pricing and reimbursement approvals in more
European countries. Sunosi was approved in Canada in May 2021 for the treatment of EDS associated with narcolepsy or OSA in adult
patients.

OSA, commonly referred to as sleep apnea, is a highly prevalent disease, and EDS, a major symptom of OSA, is characterized by the

inability to stay awake and alert during the day resulting in unplanned lapses into sleep or drowsiness. Although positive airway pressure
therapy, with its most common form being continuous positive airway pressure, or CPAP, has been shown to be an effective therapy for
sleep apnea that frequently results in improvement in EDS in many patients, not all patients tolerate CPAP therapy and among those who
tolerate CPAP, usage is highly variable. EDS may persist in people with OSA despite using CPAP.

In 2021, net product sales of Sunosi were $57.9 million, which represented 2% of our total net product sales.

Sativex. We acquired Sativex (nabiximols) in May 2021 as part of the GW Acquisition. Sativex is approved in the U.K. and certain
other countries outside the U.S. as treatment for symptom improvement in adult patients with moderate to severe spasticity due to MS, who
have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in
spasticity-related symptoms during an initial trial of therapy.

Nabiximols is a complex botanical mixture formulated from extracts of the cannabis sativa plant that contains the principal
cannabinoids delta-9-tetrahydrocannabinol, or THC, and CBD as well as specific minor cannabinoids and other non-cannabinoid
components. We developed nabiximols to be administered as an oromucosal spray, whereby the active ingredients are absorbed in part in
the lining of the mouth, either under the tongue or inside the cheek. Nabiximols is already approved in more than 25 countries outside the
U.S. for the treatment of spasticity due to multiple sclerosis under the brand name Sativex. We market Sativex directly in the U.K. To
support the development and commercialization of Sativex internationally, we have license and development agreements with commercial
partners across other countries. These agreements provide our collaborators with the sole right to commercialize Sativex in exclusive
territories for all indications. See “Research and Development” below for a discussion of clinical development activities for nabiximols.

6

2021 Annual Report

| JAZZ PHARMACEUTICALS

Net product sales of Sativex in 2021, beginning from the closing of the GW Acquisition on May 5, 2021 were $12.7 million, which

represented less than 1% of our total net product sales. On a pro forma basis, assuming the GW Acquisition had closed on
January 1, 2021, Sativex net product sales in 2021 were $18.5 million.

Oncology

Zepzelca. In December 2019, we entered into an exclusive license agreement with Pharma Mar, S.A., or PharmaMar, pursuant to
which we obtained exclusive U.S. development and commercialization rights to Zepzelca. In October 2020, we entered into an amendment
to the license agreement with PharmaMar to expand our exclusive license to include rights to develop and commercialize Zepzelca in
Canada. The term of the amended license agreement extends on a licensed product-by-licensed product and country-by-country basis until
the latest of: (i) expiration of the last PharmaMar patent covering Zepzelca in that country (subject to certain exclusions), (ii) expiration of
regulatory exclusivity for Zepzelca in that country and (iii) 12 years after the first commercial sale of Zepzelca in that country. We have the
right to terminate the amended license agreement at will upon a specified notice period, and either party can terminate the amended
license agreement for the other party’s uncured material breach or bankruptcy. For a description of additional terms of the amended license
agreement, including financial terms, see Note 3, Business Combinations, Asset Acquisitions and Collaborations—License Agreement of
the Notes to Consolidated Financial Statements included in Part IV of this Annual Report on Form 10-K.

Zepzelca for injection (4 mg) is approved by FDA to treat adults with metastatic SCLC, with disease progression on or after
platinum-based chemotherapy. Zepzelca is an alkylating drug that binds guanine residues within DNA. This triggers a cascade of events
that can affect the activity of DNA binding proteins, including some transcription factors, and DNA repair pathways, resulting in disruption of
the cell cycle and eventual cell death. Zepzelca was granted Orphan Drug Designation for SCLC by FDA in August 2018. In December
2019, PharmaMar submitted a New Drug Application, or NDA, to FDA for accelerated approval of Zepzelca for relapsed SCLC based on
data from a Phase 2 trial, and in February 2020, FDA accepted the NDA for filing with priority review. In June 2020, FDA granted
accelerated approval of Zepzelca for the treatment of adult patients with metastatic SCLC with disease progression on or after platinum-
based chemotherapy. Zepzelca is approved based on response rate and duration of response. After discussion with FDA, PharmaMar
initiated a confirmatory trial in second-line SCLC in December 2021. This is a three-arm trial comparing Zepzelca as either monotherapy or
in combination with irinotecan to investigator’s choice of irinotecan or topotecan. Data from this trial, if positive, will serve as the
confirmatory trial for Zepzelca to secure full approval in the U.S. See “Research and Development” below for a discussion of clinical
development activities for Zepzelca.

K
-
0
1
m
r
o
F

In 2021, net product sales of Zepzelca were $246.8 million, which represented 8% of our total net product sales.

Rylaze. Rylaze was approved by FDA in June 2021 under the Real-Time Oncology Review (RTOR) program, and was launched in
the U.S. in July 2021, for use as a component of a multi-agent chemotherapeutic regimen for the treatment of ALL or LBL in pediatric and
adult patients one month and older who have developed hypersensitivity to E. coli-derived asparaginase. Rylaze is the only recombinant
erwinia asparaginase manufactured product that maintains a clinically meaningful level of serum asparaginase activity throughout the
entire intended duration of treatment. We developed Rylaze with the goal of addressing the needs of patients and health care providers for
an innovative, high-quality erwinia asparaginase with reliable supply. Rylaze has been granted Orphan Drug Designation for the treatment
of patients with ALL or LBL. See “Research and Development” below for a discussion of clinical development activities for Rylaze.

In 2021, net product sales of Rylaze were $85.6 million, which represented 3% of our total net product sales.

Vyxeos. Vyxeos is a liposomal formulation of a fixed ratio combination of daunorubicin and cytarabine for intravenous infusion that is

indicated for the treatment of adults with newly-diagnosed t-AML or AML-MRC and has been shown to have synergistic effects at killing
leukemia cells in vitro and in animal models. Vyxeos is the first drug delivery combination product based on our CombiPlex® technology
platform to be approved by FDA and the EC.

AML is a rapidly progressing and life-threatening blood cancer that begins in the bone marrow, which produces most of the body’s
new blood cells. AML cells crowd out healthy cells and move aggressively into the bloodstream to spread cancer to other parts of the body.
AML is a relatively rare disease representing about 1% of all new cancer cases and has the lowest survival rate of any form of leukemia.
Patients with newly diagnosed t-AML or AML-MRC may have a particularly poor prognosis.

In 2017, we launched Vyxeos in the U.S. after FDA approved our NDA for the treatment of adults with newly-diagnosed t-AML or
AML-MRC. In August 2018, the EC granted marketing authorization for Vyxeos and, as part of our rolling launch of Vyxeos in Europe, we
are continuing to make pricing and reimbursement submissions in European countries.

JAZZ PHARMACEUTICALS | 2021 Annual Report

7

In March 2021, FDA approved a revised label to include a new indication to treat newly-diagnosed t-AML or AML with

myelodysplasia-related changes in pediatric patients aged one year and older. We have a number of ongoing development activities and
continue to expand into new markets internationally. See “Research and Development” below for a discussion of clinical development
activities for Vyxeos.

In 2021, Vyxeos product sales were $134.1 million, which represented 4% of our total net product sales.

Defitelio. Defibrotide, the API in Defitelio, is approved for the treatment of VOD, a potentially life-threatening complication of HSCT,

and is in development for other complications following anti-cancer treatment. Defibrotide is the sodium salt of a complex mixture of
single-stranded oligodeoxyribonucleotides derived from porcine DNA. Defibrotide mediates its effects via interaction with endothelial cells.
Non-clinical data suggest that defibrotide stabilizes endothelial cells by reducing endothelial cell activation and by protecting them from
further damage.

Stem cell transplantation is a frequently used treatment modality for hematologic cancers and other conditions in both adults and
children. Certain conditioning regimens used as part of HSCT can damage the cells that line the hepatic vessels, which is thought to lead to
the development of VOD, also referred to as SOS, a blockage of the small vessels in the liver, that can lead to liver failure and potentially
result in significant dysfunction in other organs such as the kidneys and lungs. Severe VOD is the most extreme form of VOD and is
associated with multi-organ failure and high rates of morbidity and mortality. An analysis of retrospective data, prospective cohort studies
and clinical trials published between 1979 and 2007 found that the 100-day mortality rate in severe VOD cases is greater than 80%.

The EC granted marketing authorization under exceptional circumstances for Defitelio for the treatment of severe VOD in adults and

children undergoing HSCT in 2013. We commenced a rolling launch of Defitelio in European countries in 2014.

In 2016, FDA approved our NDA for Defitelio for the treatment of adult and pediatric patients with VOD with renal or pulmonary
dysfunction following HSCT. We launched Defitelio in the U.S. shortly after FDA approval. We also launched defibrotide in Canada in 2017.
In June 2019, Nippon Shinyaku Co., Ltd., the partner to whom we have granted exclusive rights to develop and commercialize defibrotide
in Japan, received marketing authorization from Japan’s Ministry of Health, Labour and Welfare and launched defibrotide in Japan in
September 2019. Further geographic expansion occurred in July 2020 and September 2020, as Defitelio was approved by the Australian
Therapeutic Goods Administration and Swissmedic in Switzerland, respectively, for the treatment of VOD.

In 2021, Defitelio/defibrotide product sales were $197.9 million, which represented 6% of our total net product sales.

Revenue Diversification

As part of our objective to reduce business risk by diversifying our revenue sources, we have been actively seeking to expand our

commercial portfolio thorough a combination of launching internally developed therapies and corporate development. In 2018, 75% of net
product sales were generated by one product, Xyrem. In the fourth quarter of 2021, 59% of net product sales were generated from
products that we launched or acquired since 2019, including Xywav, Zepzelca, Epidiolex, Sunosi, Sativex and Rylaze.

Product

NEUROSCIENCE

Xywav® (calcium, magnesium,
potassium, and sodium oxybates)

Xyrem® (sodium oxybate)

Indication(s)

Initial Approval Date

Market(s)

Treatment of cataplexy or EDS in
patients seven years of age and
older with narcolepsy.

Treatment of IH in adults.

Treatment of cataplexy or EDS in
patients seven years of age and
older with narcolepsy.

For the treatment of cataplexy in
patients with narcolepsy.

Treatment of narcolepsy with
cataplexy in adult patients,
adolescents and children from age
of 7 years.

July 2020

August 2021

July 2002

U.S.

U.S.

U.S.

August 2005

Canada

October 2005

EU, Great Britain, other
markets (through licensing
agreement)

8

2021 Annual Report

| JAZZ PHARMACEUTICALS

Epidiolex® (cannabidiol)

Epidyolex® (cannabidiol)

Sunosi® (solriamfetol)

Sativex® (nabiximols)

ONCOLOGY

Zepzelca® (lurbinectedin)

Rylaze™ (asparaginase erwinia
chrysanthemi (recombinant)- rywn)

Vyxeos® (daunorubicin and cytarabine)
liposome for injection

Treatment of seizures associated
with LGS, DS or TSC, in patients
1 year of age and older.

For adjunctive therapy of seizures
associated with LGS or DS, in
conjunction with clobazam, for
patients 2 years of age and older.*

For adjunctive therapy of seizures
associated with TSC for patients
2 years of age and older.**

Improve wakefulness in adult
patients with EDS associated with
narcolepsy or OSA.

Improve wakefulness and reduce
EDS in adult patients with
narcolepsy (with or without
cataplexy) or adult patients with
OSA whose EDS has not been
satisfactorily treated by primary
OSA therapy, such as CPAP.

Treatment of EDS in adult patients
with narcolepsy or OSA.

Treatment for adult patients with
moderate to severe spasticity due
to MS, who have not responded
adequately to other anti-spasticity
medication and who demonstrate
clinically significant improvement in
spasticity related symptoms during
an initial trial of therapy.

Treatment of adult patients with
metastatic SCLC, with disease
progression on or after platinum-
based chemotherapy.

Treatment of adults with Stage III or
metastatic SCLC who have
progressed on or after
platinum-containing therapy.

A component of a multi-agent
chemotherapeutic regimen for the
treatment of ALL, and LBL, in adult
and pediatric patients 1 month or
older who have developed
hypersensitivity to E. coli-derived
asparaginase.

Treatment of newly-diagnosed
therapy- related t-AML or
AML-MRC in adults and pediatric
patients one year and older.

June 2018

U.S.

September 2019

EU, Great Britain, other
markets

April 2021

EU, Great Britain, other
markets

March 2019

U.S.

January 2020

EU, Great Britain

K
-
0
1
m
r
o
F

May 2021

Canada

June 2010

U.K. and Canada (other
markets through licensing
agreements with partners)

June 2020

U.S. (licensed from
PharmaMar)

September 2021

Canada (licensed from
PharmaMar)

June 2021

U.S.

August 2017

U.S.

JAZZ PHARMACEUTICALS | 2021 Annual Report

9

Vyxeos® liposomal 44 mg/100 mg
powder for concentrate for solution for
infusion

Treatment of adults with
newly-diagnosed t-AML or
AML-MRC.

August 2018

EU, Great Britain

Vyxeos® Daunorubicin and cytarabine
liposome for injection Powder, 44 mg
daunorubicin and 100 mg cytarabine
per vial, intravenous infusion

Defitelio® (defibrotide sodium)

Defitelio® (defibrotide)

Treatment of adults with newly
diagnosed therapy-related t-AML or
AML with AML-MRC.

Treatment of adult and pediatric
patients with hepatic VOD, also
known as SOS, with renal or
pulmonary dysfunction following
HSCT.

Treatment of severe hepatic VOD,
also known as SOS, following
HSCT therapy.

*
**

The Clobazam restriction limited to EU and Great Britain
TSC approval pending in certain markets

Research and Development

April 2021

Canada

March 2016

U.S.

October 2013

EU, Great Britain, other
markets

A key aspect of our strategy is our continued investment in expanding our research and development organization and initiatives. We

actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery
technologies. We are focused on research and development activities within our neuroscience and oncology therapeutic areas, such as our
expansion into movement disorders and solid tumors, and exploring and potentially investing in adjacent therapeutic areas.

Our development activities encompass all stages of development and currently include clinical testing of new product candidates and
activities related to clinical improvements of, or additional indications or new clinical data for, our existing marketed products. We also have
active preclinical programs for novel therapies, including precision medicines in hematology and oncology and the GW cannabinoid
platform. We are increasingly leveraging our growing internal research and development function, and we have also entered into
collaborations with third parties for the research and development of innovative early-stage product candidates and have supported
additional investigator-sponsored trials, or ISTs, that are anticipated to generate additional data related to our products. We also seek out
investment opportunities in support of development of early- and mid-stage technologies in our therapeutic areas and adjacencies. We
have a number of licensing and collaboration agreements with third parties, including biotechnology companies, academic institutions and
research-based companies and institutions, related to preclinical and clinical research and development activities in hematology and in
precision oncology, as well as in neuroscience.

Our current and planned development activities in our neuroscience therapeutic area are focused on an additional indication for

Epidiolex, and advancing novel therapies, including nabiximols, suvecaltamide (JZP385) and JZP150.

Epidiolex. We anticipate the initiation of a pivotal Phase 3 clinical trial of Epidiolex for the treatment of Epilepsy with Myoclonic-Atonic

Seizures, or EMAS, also known as Doose syndrome, in the first half of 2022. This trial is designed to evaluate Epidiolex in a fourth
childhood-onset epileptic encephalopathy with high unmet need. EMAS is characterized by generalized myoclonic-atonic seizures, and this
trial is designed to provide the first randomized, controlled clinical data with Epidiolex in this syndrome type. Seizure types including atonic,
tonic, clonic, tonic-clonic, and partial onset seizures are seen in LGS, DS and TSC.

Nabiximols. We have three ongoing Phase 3 clinical trials in multiple sclerosis (MS)-related spasticity. Collectively these trials will
expand the body of evidence on the safety and efficacy of nabiximols in addressing spasticity in MS patients, and either individually or
jointly may support an NDA submission to FDA. Spasticity occurs in up to 84% of MS patients, and approximately one-third of those who
experience spasticity live with uncontrolled symptoms. The first trial is a smaller, shorter trial relative to the other two. The first trial is
assessing changes in muscle tone using elements of the Modified Ashworth scale. If results from this first trial are positive, there is the
potential for an NDA submission to FDA by the end of 2022. The two additional trials have larger sample sizes.

Suvecaltamide. Suvecaltamide (JZP385) is a highly selective modulator of T-type calcium channels currently in development for the

treatment of essential tremor, or ET. ET is the most common pathological movement disorder, and there have been no new approved
therapies in more than 50 years. We acquired suvecaltamide in our acquisition of Cavion, Inc., or Cavion, a clinical-stage biotechnology

10

2021 Annual Report

| JAZZ PHARMACEUTICALS

company, in August 2019. We initiated a Phase 2b clinical trial of suvecaltamide in December 2021. In this multicenter, double-blind,
randomized, placebo-controlled trial, we are evaluating the safety and efficacy of suvecaltamide in the treatment of adults with moderate to
severe ET. The primary efficacy outcome measure is the change from baseline to Week 12 on the Tremor Research Group Essential
Tremor Rating Assessment Scale (TETRAS) composite outcome score, which represents items from the TETRAS-Activities of Daily Living
and TETRAS-Performance Subscale, and measures the functional impact due to tremor.

JZP150. JZP150 is a fatty acid amide hydrolase, or FAAH, inhibitor program for the potential treatment of post-traumatic stress
disorder, or PTSD, and associated symptoms. PTSD affects up to 8% of adults during their lifetime, and there are limited treatment options
available. In October 2020, we entered into an asset purchase and exclusive license agreement with SpringWorks, under which we
acquired SpringWorks’ FAAH inhibitor program, including an assignment of SpringWorks’ proprietary FAAH inhibitor PF-04457845, or
PF-’845, now named JZP150. We initiated a Phase 2 clinical trial of JZP150 for PTSD in December 2021. In this trial, we are evaluating the
safety and efficacy of JZP150 in the treatment of adults with PTSD as measured by improvement in the Clinician Administered Post
Traumatic Stress Disorder (PTSD) Scale (CAPS-5) Total Symptom Severity Score, a validated clinical instrument for assessing the severity
of PTSD symptoms.

Our current and planned research and development activities in our oncology therapeutic area are focused on Rylaze and Zepzelca,

including in combination with other therapeutic agents, exploring additional indications for Vyxeos, and the research and development of
new product candidates through our external collaborations.

Zepzelca. In collaboration with F. Hoffmann-La Roche Ltd, or Roche, we have initiated a Phase 3 pivotal clinical trial in first-line

extensive stage SCLC of Zepzelca in combination with Tecentriq® (atezolizumab). After discussion with FDA, our licensor PharmaMar
initiated a confirmatory trial in second-line SCLC in December 2021. This is a three-arm trial comparing Zepzelca as either monotherapy or
in combination with irinotecan to investigator’s choice of irinotecan or topotecan. Data from this trial, if positive, would serve as the
confirmatory trial for Zepzelca to secure full approval in the U.S.

We initiated a Phase 2 basket trial in the first quarter of 2022 to explore Zepzelca monotherapy in patients with select advanced or

metastatic solid tumors. Cohorts will include advanced urothelial cancer, large cell neuroendocrine tumor of the lung, and homologous
recombinant deficient positive (HRD+) cancers. In addition, we have initiated a Phase 4 observational study to collect real world safety and
outcome data in adult Zepzelca monotherapy patients with SCLC who progress on or after prior platinum-containing chemotherapy.

K
-
0
1
m
r
o
F

Rylaze. The current approved recommended dosage of Rylaze is for an intramuscular, or IM, administration of 25 mg/m2 every
48 hours. In February 2022, we announced the submission of a supplemental Biologics License Application, or sBLA, to FDA with data to
support a Monday/Wednesday/Friday (M/W/F) IM dosing schedule, which has also been granted review under the RTOR program. An
additional part of the ongoing Rylaze study has evaluated intravenous, or IV, administration and, if the data are supportive, we expect to
submit an additional sBLA to FDA in 2022 in support of IV administration. We also are planning a regulatory submission in Europe for IM
and IV administration in mid-2022.

Vyxeos. Our Vyxeos clinical development strategy is designed to target potential new patient segments across the AML landscape
and to generate clinical data on Vyxeos when used in combination with other therapeutic agents. As reflected in the table below, we are
pursuing this strategy by sponsoring clinical trials, working with cooperative groups who are conducting clinical trials, and partnering with
The University of Texas MD Anderson Cancer Center, or MD Anderson. In August 2018, we announced a five-year collaboration with MD
Anderson to evaluate potential treatment options for hematologic malignancies, with a near-term focus on Vyxeos, and shortly thereafter,
commenced development activities under this collaboration. In addition, there are multiple ongoing ISTs studying Vyxeos.

CombiPlex Platform. We are also evaluating the use of our CombiPlex delivery technology platform in a number of therapeutic
formulations and combinations in oncology as part of our internal oncology research and development activities. CombiPlex enables the
design and rapid evaluation of various combinations of therapies to deliver enhanced anti-cancer activity by identifying an optimal
synergistic ratio of drugs in vitro and fixing this ratio in a nanoscale delivery complex that maintains and then coordinates the release of the
synergistic combination after administration. CombiPlex utilizes two proprietary nanoscale delivery platforms: liposomes to control the
release and distribution of water-soluble drugs and drugs that are both water- and fat-soluble (amphipathic), and nanoparticles to control
the release and distribution of non-water-soluble (hydrophobic) drugs.

Through third parties, we are also pursuing preclinical and clinical research and development activities in hematology and in precision

oncology under a number of licensing and collaboration agreements, including with:

•

Codiak BioSciences, Inc., or Codiak, for an exclusive, worldwide, royalty-bearing license to develop, manufacture and
commercialize potential therapeutic candidates directed at up to four targets to be developed using Codiak’s engEx™ precision
engineering platform for exosome therapeutics;

JAZZ PHARMACEUTICALS | 2021 Annual Report

11

•

•

•

Pfenex, Inc., which was acquired by Ligand Pharmaceuticals Incorporated, or Ligand, for rights to JZP341, an early-stage
long-acting Erwinia asparaginase;

XL-protein GmbH, or XLp, for rights to use XLp’s PASylation® technology to extend the plasma half-life of selected
asparaginase product candidates; and

Redx Pharma, or Redx, for preclinical collaboration activities related to the pan-Raf inhibitor program that we purchased from
Redx for the potential treatment of Raf and Ras mutant tumors and to discover and develop drug candidates for two cancer
targets in the Ras/Raf/MAP kinase pathway.

Below is a summary of our key ongoing and planned development projects related to our products and pipeline and their

corresponding current stages of development:

Product Candidates

NEUROSCIENCE
Phase 3

Epidiolex
Nabiximols

Phase 2b

Suvecaltamide (JZP385)

Phase 2

JZP150
Additional cannabinoids

Phase 1

JZP324
Additional cannabinoids

Preclinical

Undisclosed targets

ONCOLOGY

Regulatory Review

Rylaze

Phase 3

Zepzelca

Vyxeos

Phase 2

Zepzelca

Vyxeos

Vyxeos + venetoclax

Phase 1

Vyxeos
Vyxeos + other approved therapies

Description

EMAS, also known as Doose syndrome (planned study)
MS Spasticity (multiple studies ongoing)
Spinal cord injury spasticity (planned study)

ET (ongoing study)

PTSD (ongoing study)
Schizophrenia (ongoing study)
Autism spectrum disorders (ongoing study)

Oxybate extended-release formulation (planned study)
Neonatal hypoxic-ischemic encephalopathy (ongoing study)
Neuropsychiatry targets (ongoing study)

Neuroscience
Cannabinoids

ALL/LBL
FDA approval in June 2021; announced completion of sBLA submission to FDA in January seeking
approval for Monday/Wednesday/Friday intramuscular dosing schedule; regulatory submission
planned for Europe in mid-2022

First-line extensive stage SCLC in combination with Tecentriq (collaboration with Roche) (ongoing
study)
Confirmatory Study (Pharma Mar study) (ongoing study)
AML or high-risk Myelodysplastic Syndrome, or MDS (AML18) (cooperative group studies) (ongoing
study) Newly diagnosed adults with standard- and high-risk AML (AML Study Group cooperative
group study) (ongoing study) Newly diagnosed pediatric patients with AML (Children’s Oncology
Group cooperative group study) (ongoing study)

Basket trial including urothelial cancer, large cell neuroendocrine tumor of the lung, and HRD+
(homologous recombinant deficient) cancers (ongoing study)
High-risk MDS (European Myelodysplastic Syndromes Cooperative Group cooperative group study)
(ongoing study)
Newly diagnosed older adults with high-risk AML (cooperative group study) (planned study)
De novo or relapsed/refractory, or R/R, AML (MD Anderson collaboration study) (ongoing study)

Low intensity dosing for higher risk MDS (MD Anderson collaboration study) (ongoing study)
R/R AML or hypomethylating agent failure MDS (MD Anderson collaboration study) (ongoing study)
First-line, fit AML (Phase 1b study) (ongoing study)
Low intensity therapy for first-line, unfit AML (Phase 1b study) (ongoing study)

12

2021 Annual Report

| JAZZ PHARMACEUTICALS

Preclinical

CombiPlex®
JZP341 (long-acting Erwinia asparaginase)
Pan-Raf inhibitor program
Undisclosed targets

Exosome targets (up to 4)
Undisclosed targets

Hematology/oncology exploratory activities
ALL and other hematological malignancies (collaboration with Ligand)
Raf and Ras mutant tumors (acquired from Redx, which is continuing development)
Ras/Raf/MAP kinase pathway (collaboration with Redx)
Oncology
Hematological malignancies/solid tumors (collaboration with Codiak BioSciences, Inc., or Codiak)
Oncology

As a result of the effects of the COVID-19 pandemic, we have taken measures to implement remote and virtual approaches, including

remote data monitoring where possible, to maintain patient safety and trial continuity and to preserve study integrity. For a more detailed
discussion of the impact of the COVID-19 pandemic on our clinical trial activities, see “Management’s Discussion and Analysis of Financial
Condition and Results of Operations—Overview—COVID-19 Business Update” in Part II, Item 7 of this Annual Report on Form 10-K and
“Risk Factors” in Part I, Item 1A of this Annual Report on Form 10-K.

Commercialization Activities

We have commercial operations primarily in the U.S., Europe and Canada. In the U.S., our products are commercialized through a

number of teams, including a team of experienced, trained sales professionals who provide education and promote Xywav, Xyrem,
Epidiolex, Sunosi, Zepzelca, Rylaze, Vyxeos and Defitelio to healthcare providers in the appropriate specialties for each product, a team
that interacts with payors and institutions to ensure access and coverage for the products, and a team that distributes the products
throughout the U.S. healthcare system (wholesalers, pharmacies, hospitals, and community and academic institutions) and provides
patient services.

K
-
0
1
m
r
o
F

In Canada and in approved markets in Europe where we commercialize Defitelio and Vyxeos, we have a field force of hematology
sales specialists. In markets where these products either are not approved or are unable to be promoted under local regulation, we have
medical affairs personnel responsible for responding to medical information requests and for providing information consistent with local
treatment protocols with respect to such products. In certain European markets, we have a sales team and a team of medical science
liaisons supporting our rolling launches of Epidyolex and Sunosi. Outside the U.S., we directly market Xyrem, Sunosi and Zepzelca in
Canada. We also utilize distributors in certain markets outside the U.S. where we do not market our products directly.

Other commercial activities include marketing related services, industry analytics and insights, distribution services and commercial

support services. We employ third party vendors, such as advertising agencies, market research firms and suppliers of marketing and other
sales support-related services, to assist with our commercial activities. We also provide reimbursement support for our U.S. markets.

We intend to scale the size of our sales force as appropriate to effectively reach our target audience in the specialty markets in which
we currently operate. We promote Zepzelca, Rylaze, Vyxeos and Defitelio to many hematology and oncology specialists who operate in the
same hospitals and outpatient clinical sites, and we believe that we benefit from operational synergies from this overlap. We expect that a
potential launch of Rylaze in Europe would require minimal additional support. Continued growth of our current marketed products and the
launch of any future products may require a reevaluation of our field force and support organization in and outside the U.S. In addition,
beginning in March 2020, we transitioned our field-based sales, market access, reimbursement and medical employees out of the field and
suspended work-related travel and in-person customer interactions as a result of the COVID-19 pandemic. We utilized technology to
continue to engage healthcare professionals and other customers virtually to support patient care. In late June 2020, as clinics and
institutions began to allow in-person interactions pursuant to local health authority and government guidelines, our field teams resumed
in-person interactions with healthcare professionals and clinics combined with virtual engagement. The level of renewed engagement
varies by account, region and country. There continues to be some negative impact on demand, new patient starts and treatments for our
products arising from the pandemic, primarily due to the inherent limitations of telemedicine and a reprioritization of healthcare resources
toward COVID-19. As healthcare systems have adapted to cope with the ongoing situation, we have seen improvements. The lack of
access to health care providers has caused, and may continue to cause, delays in appropriate diagnosis, treatment and ongoing care for
some patients, which could subsequently impact prescribing and use of our products. For a more detailed discussion of the impact of the
COVID-19 pandemic on our commercialization activities, see “Management’s Discussion and Analysis of Financial Condition and Results
of Operations—Overview—COVID-19 Business Update” in Part II, Item 7 of this Annual Report on Form 10-K.

Human Capital Management and Environment, Health and Safety

Jazz is committed to creating a company where the culture embodies our corporate purpose to innovate to transform the lives of
patients and reflects our key goals: (1) be a great place to work; and (2) live our core values of Integrity, Collaboration, Passion, Innovation,
and Pursuit of Excellence.

JAZZ PHARMACEUTICALS | 2021 Annual Report

13

Employee Demographics. As of February 22, 2022, Jazz employed approximately 3,200 people worldwide, of which approximately 50%
were employed in the U.S. and approximately 50% were outside the U.S. primarily in the U.K., Ireland and across the European Union, or EU.
As an innovative biopharmaceutical company, we have over 700 full-time employees — greater than 22% of our global workforce —
supporting our research and development activities. We consider our employee relations to be very good.

Diversity, Equity, Inclusion and Belonging. We make diversity, equity, inclusion and belonging, or DEIB, a priority because it is a key

to unlocking the potential of our people and living our core values.

We strive to create a workplace culture that fosters the ability of our employees to be their authentic selves and contribute boldly. We

aspire to have multi-dimensional diversity through our entire Jazz workforce. We seek to surround underrepresented groups with allies to
enable all employees to thrive equitably. Our Board and management team are committed to fostering DEIB in all parts of our business.

Our DEIB strategy includes: (1) building a more diverse workforce in terms of gender identity, race, ethnicity and sexual orientation
and that represent unique backgrounds, experiences, thoughts and talents; (2) investing in developing our diverse talent and driving equity;
and (3) and creating a culture of inclusion and belonging.

We designed our Employee DEIB program to empower employees to guide and support our strategy and programs related to hiring
diverse talent and using education and communication to continue fostering an inclusive environment. We also have a DEIB Delegation, a
committee of employees focused on helping to embed DEIB into all we do.

Jazz ConcERTos, our employee resource teams, are self-led teams of employee volunteers with diverse backgrounds who come
together to promote innovation through inclusion and to increase awareness of all dimensions of diversity. We believe that these groups will
contribute positively to Jazz’s culture and business success by working cross-functionally to drive innovation, helping to decrease
unconscious bias, and encouraging employees to be their whole selves so they can perform at their best.

We have established goals related to increasing all dimensions of diversity, including representation of females and people of color,

particularly at the leadership level (i.e., employees at executive director and above). In this regard, we have made some meaningful
progress, as demonstrated by the following, as of February 9, 2022:

•

•

•

50% of each of our board of directors and Executive Committee is diverse in terms of gender, ethnicity and sexual orientation.

Females represent 55% of our global workforce and 43% at the leadership level (employees at executive director and above).

In the U.S., people of color represent 33% of our U.S. workforce and 20% at the leadership level.

While we are proud of what we have accomplished to date, we recognize there is still much to do. We remain committed to furthering

our goals of providing a diverse, equitable and inclusive workplace that is supportive of all backgrounds, including among our broader
leadership.

Employee Engagement. Jazz has a strong employee value proposition anchored in our shared commitment to our purpose to
innovate to transform the lives of patients. We are committed to ensuring that we create a rich culture that provides a great place to work
for our employees through company-wide efforts to connect employees to our shared purpose and to create an environment where our
people feel valued, respected, and able to contribute to their full potential. We believe employee engagement and the power of our
employee voices is foundational to strong performance. We have transparent and regular communication channels with our employees
consisting of many forms – including all employee meetings, regular communication messages from executive leadership, top leadership
forums, pulse check feedback mechanisms and engagement surveys.

Our employee feedback surveys are designed to help us measure overall employee engagement and we consistently achieve
participation rates between 80 to 90% in our annual engagement survey. We consistently have high levels of engagement measured by
feelings of connection to our mission, Jazz as a great place to work where their well-being is supported and they feel valued and included.
It also provides important insight into the areas where we need to focus in the year ahead for several key components of our company
objectives, such as decision-making, opportunities for development, and diversity, equity and inclusion. Our survey informs programs and
activities aligned with achieving our corporate objectives and achieving our goal of evolving our operating culture for agility and scalability.

Our Community Beat teams are employee volunteers and representatives that promote company culture and create a sense of

belonging and camaraderie among our employees. They foster programs and engagement activities on a local level to draw better
connections to employees with the company strategy and business milestones, give back through community service, and promote
different health and well-being initiatives.

14

2021 Annual Report

| JAZZ PHARMACEUTICALS

Growth, Development and Total Rewards. Our talent strategy focuses on attracting the best talent, recognizing and rewarding the

performance of our employees as defined by both what they accomplished and how they accomplished it, and continually developing our
talent through new experiences and learning opportunities. We believe there is ample opportunity for growth and development at Jazz and
there is not a one size fits all approach to growing our talent. We strive to create the best career experience for all of our employees. We
work with each employee to chart their own course that matches their career ambitions and strengths with customized development.

Our performance management process supports our culture of continual feedback and coaching, and ongoing growth and
development through new experiences and learning. We encourage all employees to have an individual development plan to outline
learning and growth interests and focus areas.

We leverage several digital learning platforms to provide on demand bite sized learning to all employees that can be accessed 24/7

on a range of topics from leadership, personal effectiveness and well-being. We deliver our “Harmonize” program to all managers to ensure
they are grounded in our core Leadership Behaviors we expect all leaders to demonstrate (Instills Trust, Values Differences, Executes
through Teams, Develops Talent, Drives Accountability and Provides and Receives Feedback).

In 2021, we targeted a development effort towards our Global Leadership Team (top 70 leaders) and created a 9-month learning

journey to build leadership excellence, strengthen relationships, and encourage cross functional collaboration in pursuit of our enterprise
strategic goals. Additionally, we focused on diverse early career talent by piloting an executive coaching program to support their
development. We offer tuition reimbursement in our major markets aimed at growth and career development.

Our management and leadership teams place significant focus and attention to diversity, capability development, and succession

planning for critical roles. We regularly review talent development and succession plans for each of our functions to successfully maintain
business operations and develop a pipeline of talent. We have goals concerning employee retention, diversity, and talent development.

K
-
0
1
m
r
o
F

We provide our employees with what we believe to be market competitive and locally relevant compensation and benefits that support

our overarching strategy to attract, retain and reward highly talented employees in an extremely competitive and dynamic industry.

We strive to create a culture of health and well-being throughout the organization by offering a diverse and customizable set of
programs focusing on employee experience, self-care, work-life balance, flexibility and early intervention. In addition to traditional employee
benefits, Jazz supports employees and their families through access to a suite of innovative programs that are designed to enhance their
physical, financial, emotional and social well-being. For 2022, we are introducing an enhanced suite of differentiated global leave and
time-off polices to address the needs of our diverse employee population through varying stages of life, including minimum standards for
new parent leave (irrespective of gender or how a family is created), family caregiver leave, and bereavement leave. Additionally, in 2022,
we are launching a new global volunteer day, which will provide employees time off with full pay to give back to their communities.

Workplace Safety & Employee Care During COVID-19. Workplace safety is always a top priority for Jazz. To create and sustain a
safe and healthy workplace, we have implemented initiatives designed to address risk evaluation, education and training of employees, use
of appropriate personal protective equipment, and compliance with relevant national and international health and safety standards.

In response to COVID-19, we launched an employee support framework focused on Care, Connection, Continuity and

Consciousness (our “4Cs”) to enable our employees to live into our values and support one another while doing everything we can to
deliver on our patient mission. Important to this framework were new leader expectations and tools given the rise and complexity of
emerging employee demands and needs – including more flexibility to address personal needs, a greater connection to understand the
whole person and their lives, and more active support surrounding social injustice. For example, we provided productivity and collaboration
tools and resources for employees working remotely, including training and toolkits to help leaders effectively lead and manage remote
teams; increased flexibility within work schedules and leave programs to support employees caring for children and others; expanded
employees assistance and mindfulness programs to help employees and their families manage anxiety, stress, and overall wellbeing; and
increased investment in resources focused on inclusion and belonging.

Environment, Health and Safety. Our operations are subject to complex and increasingly stringent environmental, health and safety

laws and regulations in the countries where we operate and, in particular, in Ireland, the U.K. and Italy where we have manufacturing
facilities. Our manufacturing activities involve the controlled storage, use and disposal of chemicals and solvents. Environmental and health
and safety authorities in Ireland, the U.K. and Italy administer laws governing, among other matters, the emission of pollutants into the air
(including the workplace), the discharge of pollutants into bodies of water, the storage, use, handling and disposal of hazardous
substances, the exposure of persons to hazardous substances, and the general health, safety and welfare of employees and members of
the public. In certain cases, such laws, directives and regulations may impose strict liability for pollution of the environment and
contamination resulting from spills, disposals or other releases of hazardous substances or waste. Costs, damages and/or fines may result

JAZZ PHARMACEUTICALS | 2021 Annual Report

15

from the presence, investigation and remediation of such contamination at properties currently or formerly owned, leased or operated by us or at
off-site locations, including where we have arranged for the disposal of hazardous substances or waste. In addition, we may be subject to third
party claims, including for natural resource damages, personal injury and property damage, in connection with such contamination.

We seek to operate our manufacturing facilities in an environmentally responsible way to protect our people, our business, our
environment and the local communities in which we operate. In light of the potential impact of our business on the environment, we have
adopted a number of internal environmental policies and management systems designed to manage our operations in compliance with
applicable laws, directives and regulations on environmental protection and in support of environmental sustainability and local biodiversity.
Our environmental policies and management systems include procedures for assessing compliance with applicable environmental laws
and regulations and reporting incidents of non-compliance to applicable governmental authorities. For example, we have environmental
policies governing our manufacturing facilities in Ireland, the U.K. and Italy, which demonstrate our commitment to environmental
sustainability and require us to minimize resource use (e.g., energy and water) and waste generation, optimize the use of raw materials,
and undertake continuous improvement in environmental performance, with an emphasis on pollution prevention.

Competition

The biopharmaceutical industry is highly competitive. Our products compete, and our product candidates may in the future compete,

with currently existing therapies, product candidates currently under development by us and others and/or future product candidates,
including new chemical entities that may be safer, more effective or more convenient than our products. Any products that we develop may
be commercialized in competitive markets, and our competitors, which include large global pharmaceutical companies and small research-
based companies and institutions, may succeed in developing products that render our products obsolete or noncompetitive.

With respect to competition we face from generic drugs, certain U.S. state laws allow for, and in some instances in the absence of

specific instructions from the prescribing physician mandate, the dispensing of generic products rather than branded products when a
generic version is available. Generic competition often results in decreases in the prices at which branded products can be sold.

We are aware of: exploratory research into the effects of THC and CBD drug formulations; discovery research within the

pharmaceutical industry into synthetic agonists and antagonists of CB1 and CB2 receptors; companies that supply synthetic cannabinoids
and cannabis extracts to researchers for pre-clinical and clinical investigation; and various companies that cultivate cannabis plants with a
view to supplying herbal cannabis or nonpharmaceutical cannabis-based formulations to patients. These activities have not been approved
by the FDA but may in the future compete with our products.

In particular, our products and most advanced product candidates face or may face competition as described below:

•

Xywav and Xyrem. While Xywav and Xyrem are currently the only products approved by FDA and marketed in the U.S. for the
treatment of both cataplexy and EDS in both adult and pediatric patients with narcolepsy, we and others have launched
products to treat EDS in narcolepsy and may in the future launch products to treat cataplexy in narcolepsy that are competitive
with or disrupt the market. We expect to face competition from authorized generic and generic versions of sodium oxybate. For
a description of generic versions of sodium oxybate and/or new products for the treatment of cataplexy and/or EDS that could
compete with, or otherwise disrupt the market for, Xywav and Xyrem, as well as a description of our settlement agreements with
abbreviated new drug application, or ANDA, filers, see the risk factor under the heading “The introduction of new products in the
U.S. market that compete with, or otherwise disrupt the market for, our oxybate products and product candidates would
adversely affect sales of our oxybate products and product candidates” in Part I, Item 1A of this Annual Report on Form 10-K.

In addition to generic competition, Xywav and Xyrem may face competition in the future from other new sodium oxybate
formulations for treatment of narcolepsy. In February 2021, FDA accepted for filing an NDA submitted by Avadel Pharmaceuticals
plc, or Avadel, for an extended-release formulation of sodium oxybate which uses its proprietary technology for the treatment of
EDS and cataplexy in patients with narcolepsy with a Prescription Drug User Fee Act, or PDUFA, target action date of October 15,
2021. On October 15, 2021, Avadel announced that FDA review is ongoing and FDA will likely not take action in October 2021 and
will provide a new target action date. To obtain approval with ODE, Avadel will have to show clinical superiority to Xywav and
Xyrem. We cannot predict the timing or approvability of Avadel’s sodium oxybate product candidate or how FDA will evaluate any
clinical superiority arguments that either we or Avadel may make, but in any event, we expect to face competition from Avadel, if its
product candidate is approved.

Xywav and Xyrem may also face increased competition from new branded entrants to treat EDS or cataplexy in narcolepsy such
as pitolisant, which has been approved by FDA for the treatment of both cataplexy and EDS in adult patients with narcolepsy.
Other companies have announced that they have product candidates in various phases of development to treat the symptoms
of narcolepsy, such as Axsome Therapeutics, Inc.’s reboxetine, and various companies are performing research on orexin
agonists for the treatment of sleep disorders.

16

2021 Annual Report

| JAZZ PHARMACEUTICALS

K
-
0
1
m
r
o
F

In addition, we are also aware that prescribers often prescribe branded or generic medications for cataplexy before prescribing
or instead of prescribing oxybate therapy in Xywav or Xyrem, and that payors often require patients to try such medications
before they will cover Xywav or Xyrem, even if they are not approved for this use. For example, prescribers often treat mild
cataplexy with drugs that have not been approved by FDA for this indication, including tricyclic antidepressants and selective
serotonin reuptake inhibitors or selective norepinephrine reuptake inhibitors. We are also aware that branded or generic
stimulants may be prescribed off-label for treatment of EDS in narcolepsy. Wake-promoting agents modafinil and armodafinil,
including both branded and generic equivalents, are approved for the treatment of EDS in narcolepsy and other conditions, and
may be used in conjunction with or instead of Xywav or Xyrem.

Epidiolex. Patients in the U.S. suffering from seizures associated with Dravet or LGS are treated with a variety of FDA-approved
products, including clobazam, clonazepam, valproate, lamotrigine, levetiracetam, rufinamide, topiramate, ethosuximide, and
zonisamide. FDA approved Zogenix, Inc.’s low-dose fenfluramine, or Fintepla, in DS in June 2020, and Zogenix submitted its
supplemental NDA for LGS in 2021. In January 2022, Zogenix announced that it entered into a definitive agreement with UCB
S.A. for the acquisition of Zogenix by UCB. Ovid Therapeutics Inc./Takeda Pharmaceutical Company Limited and Marinus
Pharmaceuticals, Inc. are developing therapies for treating Developmental and Epileptic Encephalopathies (includes Dravet and
LGS). Stiripentol has been approved in Europe for several years to treat DS and was approved in 2018 by the FDA. Zynerba
Pharmaceuticals, Inc. is developing a topical formulation of CBD, for which it is working with FDA on a path forward on
CONNECT-FX data for Zygel in Fragile X syndrome. There are a number of public and private companies in the early stages of
developing genetic therapies for DS, including Stoke Therapeutics, Inc., which has an antisense oligonucleotide, STK-001, in
early clinical trials.

Sunosi. Sunosi faces competition from existing branded and generic products that treat EDS or improve wakefulness in adult
patients with narcolepsy or OSA in a competitive retail pharmacy market. To successfully commercialize Sunosi, we need to
differentiate Sunosi from other branded and generic products that treat EDS in patients with narcolepsy, including stimulants,
wake-promoting agents, such as modafinil and armodafinil, and generic versions of stimulants and wake-promoting agents. We
are also aware that stimulants are prescribed off-label for patients to treat excessive sleepiness in OSA. Sunosi faces
competition from new branded entrants such as pitolisant, a drug that was approved by FDA in August 2019 for the treatment of
EDS in adult patients with narcolepsy and in October 2020 for the treatment of cataplexy in adult patients with narcolepsy.
Pitolisant became commercially available in the U.S. in the fourth quarter of 2019, and has also been approved and marketed in
Europe to treat adult patients with narcolepsy, with or without cataplexy, and OSA. Sunosi may also face competition from other
products in development as potential treatments for EDS in patients with narcolepsy or OSA.

Nabiximols. Nabiximols aims to treat adult patients with MS-related spasticity. Patients in the U.S. suffering from MS-related
spasticity are currently treated with a variety of FDA-approved therapies such as baclofen, tizanidine, gabapentin, dantrolene
and various botulinum toxin products. Bionorica SE is in late stage development of an oral solution containing dronabinol for
spasticity due to MS. Ipsen and Echo pharmaceuticals are in the early stages of development with various oral products aimed
to treat MS-related spasticity.

Zepzelca. Zepzelca faces competition from topotecan, which is also an approved treatment in second line SCLC in the U.S., as
well as other regimens for relapsed SCLC currently recommended in compendia guidelines. There are also a number of
products and immunotherapies for the treatment of second line SCLC in various phases of development.

Rylaze. Rylaze may face competition from Erwinase, which was previously approved and commercialized by Jazz as a
treatment for ALL patients with hypersensitivity to E. coli-derived asparaginase. In April 2020, Porton Biopharma Limited, or
PBL, granted Clinigen Group plc, or Clinigen, a global license for Erwinase. However, in December 2021, Clinigen announced
that FDA has issued a Complete Response Letter to PBL’s BLA for Erwinaze, indicating that the BLA cannot be approved in its
current form. Rylaze may also face competition from other companies who have developed or are developing new treatments
for ALL, including an L-asparaginase product candidate that is in development for the treatment of ALL patients. In addition,
some new asparaginase treatments could reduce the rate of hypersensitivity in patients with ALL, and new treatment protocols
are being developed and approved for ALL that may not include asparaginase-containing regimens, including some for the
treatment of relapsed or refractory ALL patients. As a biologic product, Rylaze also faces potential competition from biosimilar
products.

Vyxeos. With respect to Vyxeos, there are a number of alternative established therapies in AML. A key consideration in the
treatment of AML patients is the patient’s suitability for chemotherapy. The AML patient population studied in the Vyxeos
Phase 3 clinical trial supporting our NDA included 60-75 year old fit patients, or those deemed able to tolerate intensive
induction chemotherapy. Prior to Vyxeos, the most widely recognized option for the treatment of newly-diagnosed t-AML and
AML-MRC in fit patients was cytarabine in combination with daunorubicin, known as 7+3, which is still used today in this
population, along with other intensive chemotherapy regimens, particularly in patients under the age of 60. Also, since Vyxeos

•

•

•

•

•

•

JAZZ PHARMACEUTICALS | 2021 Annual Report

17

was approved, several other products have been approved by FDA or are in development as treatment options for newly
diagnosed AML patients eligible for intensive chemotherapy, such as targeted agents (e.g. midostaurin, enasidenib and
ivosidenib), immunotherapies (e.g., gemtuzumab ozogamicin and chimeric antigen receptor T-cell therapy), and agents
disrupting leukemia cell survival (e.g., glasdegib). We are also aware of the increasing use of venetoclax combined with either a
hypomethylating agent or low-dose cytarabine, a treatment approved by FDA in newly diagnosed AML patients who are age 75
years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

•

Defitelio. While there is currently no direct competition to Defitelio to treat severe VOD, changes in the types of conditioning
regimens used as part of HSCT may affect the incidence of VOD diagnosis and demand for Defitelio.

An important part of our corporate strategy is to build a diversified product pipeline, including by acquiring or in-licensing and
developing, or partnering to license and develop, additional products and product candidates that we believe are highly differentiated and
have significant commercial potential. Our ability to continue to grow our product portfolio requires that we compete successfully with other
pharmaceutical companies, many of which may have substantially greater financial sales and marketing resources, to acquire or in-license
products and product candidates.

Customers

In the U.S., Xywav and Xyrem are sold to one certified specialty pharmacy, ESSDS, that ships Xywav and Xyrem directly to patients.

Also in the U.S., Epidiolex is sold to specialty pharmacies, wholesalers and specialty distributors. Sunosi is distributed through a retail
channel consisting of numerous distributors who sell Sunosi to retail pharmacies. Defitelio is sold to hospital customers through subsidiary
specialty distributors of McKesson Corporation, or McKesson. Zepzelca, Rylaze and Vyxeos are sold to customers through subsidiary
specialty distributors of McKesson, AmerisourceBergen Corporation, or ABC, and Cardinal Health, Inc., or Cardinal. We have distribution
services agreements made in the ordinary course of business with McKesson, ABC and Cardinal and a pharmacy services agreement with
ESSDS that provides for the distribution of Xywav and Xyrem to patients. For more information regarding our relationship with ESSDS, see
“Business—Our Commercialized Products—Xyrem” in this Part I, Item 1. Purchases are made on a purchase order basis.

In certain countries in Europe, Sunosi, Defitelio and Vyxeos are sold pursuant to marketing authorizations. We distribute these
products through Durbin PLC, a U.K.-based wholesaler and distributor, and O&M Movianto Nederland BV, our centralized European
logistics services provider, to hospitals and local wholesalers in Europe where we market these products directly and, in other markets in
Europe and elsewhere where we do not market these products directly, to local distributors and wholesalers. In certain countries in Europe,
Epidyolex is sold pursuant to marketing authorizations. We distribute Epidyolex through a variety of wholesalers and distributors. Sativex is
sold outside of the United States for the treatment of spasticity due to MS, pursuant to license agreements with commercial partners and
directly to customers in the U.K. In countries where there is no marketing authorization, Defitelio, Vyxeos, Epidyolex and Sativex are sold
pursuant to named patient programs, temporary use authorizations or similar authorizations.

We directly market Xyrem in Canada for the treatment of cataplexy in patients with narcolepsy. Xyrem is also sold in 21 countries by

UCB (which has rights to market Xyrem in 54 countries).

Manufacturing

We have a manufacturing and development facility in Athlone, Ireland where we manufacture Xywav and Xyrem, a manufacturing
and development facility in the U.K. in Kent Science Park, where we produce Epidiolex/Epidyolex and Sativex, and a manufacturing plant in
Villa Guardia, Italy where we produce the defibrotide drug substance. We currently do not have our own commercial manufacturing or
packaging capability for our other products, product candidates or their APIs. As a result, our ability to develop and supply products in a
timely and competitive manner depends primarily on third party suppliers being able to meet our ongoing commercial and clinical trial
needs for API, other raw materials, packaging materials and finished products. Our manufacturing facilities currently continue to be
operational with essential staff onsite and office-based staff working onsite and remotely as business needs require.

Lead Marketed Products

Xywav. Xywav is manufactured at our Athlone facility. Xywav, like Xyrem, is a Schedule III controlled substance in the U.S. The API
of Xywav are the calcium, magnesium, potassium and sodium salts of gamma-hydroxybutyric acid (as gamma-hydroxybutyric acid is the
API for Xyrem), which are Schedule I controlled substances in the U.S. As a result, Xywav and Xyrem are subject to regulation by the
U.S. Drug Enforcement Administration, or DEA, under the Federal Controlled Substances Act, or CSA, and its manufacturing and
distribution are highly restricted. Quotas from the DEA are required in order to manufacture and package calcium, magnesium, potassium
and sodium oxybate, Xywav and Xyrem in the U.S. For information related to DEA quota requirements, see “Business—Government
Regulation—Other Post-Approval Pharmaceutical Product Regulation—Controlled Substance Regulations” in this Part I, Item 1.

18

2021 Annual Report

| JAZZ PHARMACEUTICALS

K
-
0
1
m
r
o
F

Xyrem. Xyrem is manufactured by us in our Athlone facility and by Patheon Pharmaceuticals Inc., which we refer to together with its
affiliates as Patheon, under a Master Manufacturing Services Agreement, or the Patheon Agreement, entered into with Patheon in 2015.
We manufacture Xyrem in our Athlone facility for most of our U.S. commercial supply and rely on Patheon to supply Xyrem for other
markets, though we are not required to purchase Xyrem exclusively from Patheon. The current term of the Patheon Agreement will expire
in December 2024, subject to further automatic two-yearly extensions if Patheon is then providing manufacturing services for any product,
unless either party provides prior notice of termination. In addition, we may terminate the Patheon Agreement for any reason upon
12 months’ prior written notice.

Siegfried USA, LLC and its European affiliates, or Siegfried, supply sodium oxybate, the API of Xyrem, to Patheon and our Athlone

facility. Although Siegfried has been our only supplier of sodium oxybate since 2012, we have the right to purchase a portion of our
worldwide requirements of sodium oxybate from other suppliers. The agreement with Siegfried expires in April 2024, subject to automatic
three-year extensions until either party provides advance notice of its intent to terminate the agreement. During the term of the agreement
and, under certain circumstances for 18 months after the agreement terminates, Siegfried is not permitted to manufacture sodium oxybate
for any other company.

Epidiolex. Epidiolex/Epidyolex is manufactured by us in our Kent Science Park facility in the U.K. Epidiolex is a pharmaceutical
formulation comprising highly purified plant-derived CBD. We cultivate our cannabinoid plants in the U.K. under highly controlled and
standardized conditions.

Sunosi. Siegfried AG is our sole supplier of both the API and finished product for Sunosi for both commercial sale as well as
development activities. Although Siegfried AG is currently our only manufacturer and supplier of Sunosi, we have the right to purchase a
portion of our worldwide requirements of API and drug product from other suppliers. Under our agreement, we provide periodic rolling
forecasts to Siegfried AG, and a portion of each rolling forecast is binding. The initial term of the agreement with Siegfried AG will expire in
December 2024 and will then be subject to automatic one-year extensions until either party provides advance notice of its intent to
terminate the agreement. Solriamfetol, the API of Sunosi, and Sunosi were designated Schedule IV controlled substances by the DEA
under the CSA.

Sativex. Sativex is manufactured by us in our Kent Science Park facility in the U.K. Sativex (nabiximols) is a complex botanical
mixture formulated from extracts of the cannabis sativa plant that contains the principal cannabinoids THC and CBD as well as specific
minor cannabinoids and other non-cannabinoid components. We cultivate our cannabinoid plants in the U.K. under highly controlled and
standardized conditions.

Zepzelca. Zepzelca is manufactured by Baxter. The initial term of the agreement with Baxter will expire in December 2023 and will

then be subject to automatic two-year extensions, unless either party provides advance notice of its intent to terminate the agreement.
PharmaMar retains manufacturing rights for the API for U.S. and Canadian commercial supply of Zepzelca. We also entered into a
manufacturing agreement for ongoing commercial supply of the drug product Zepzelca with GP Pharm S.A.

Rylaze. Rylaze is currently manufactured by Patheon, and the API of Rylaze is manufactured by AGC Biologics A/S. The initial term
of the agreement with Patheon will expire in December 2025 and will then be subject to automatic two-year extensions, unless either party
provides advance notice of its intent to terminate the agreement. The initial term of the agreement with AGC Biologics A/S will expire in
October 2026 and will then be subject to automatic three-year extensions, unless either party provides advance notice of its intent to
terminate the agreement.

Vyxeos. Vyxeos is manufactured by Baxter Oncology GmbH, or Baxter, which is a sole source supplier from a single site location,

using our CombiPlex technology platform. CombiPlex products represent formulations with increased manufacturing complexities
associated with producing drug delivery vehicles encapsulating two or more drugs that are maintained at a fixed ratio and, in the case of
Vyxeos, two drugs that are co-encapsulated in a freeze-dried liposomal format. Our manufacturing agreement with Baxter expires in
August 2025, subject to automatic three-year renewal terms, unless either party provides advance notice of its intent to terminate the
agreement. While other contract manufacturers may be able to produce Vyxeos, the proprietary technology that supports the manufacture
of Vyxeos is not easily transferable. The marketing authorization in the EU for Vyxeos also requires us to comply with certain
manufacturing-related post-approval commitments.

Defitelio. We are our own sole supplier of, and we believe that we are currently the sole worldwide producer of, the defibrotide API.
We manufacture the defibrotide API from porcine DNA in a single facility located in Villa Guardia, Italy. Patheon currently processes the
defibrotide API into its finished vial form under a specific product agreement entered into under a separate agreement with Patheon.
Patheon is the sole provider of our commercial and clinical supply of Defitelio; however, we are not required to purchase Defitelio
exclusively from Patheon. If Patheon does not or is not able to supply us with Defitelio for any reason, it may take time and resources to

JAZZ PHARMACEUTICALS | 2021 Annual Report

19

implement and execute the necessary technology transfer to another processor, and such delay could negatively impact our anticipated
revenues from Defitelio and could potentially cause us to breach contractual obligations with customers or to violate local laws requiring us
to deliver the product to those in need.

Product Candidates

For discussion of the challenges we face with respect to supply of our products and product candidates, see the risk factor under the
heading “Delays or problems in the supply of our products for sale or for use in clinical trials, loss of our single source suppliers or failure to
comply with manufacturing regulations could materially and adversely affect our business, financial condition, results of operations and
growth prospects” in Part I, Item 1A of this Annual Report on Form 10-K.

Patents and Proprietary Rights

We actively seek to patent, or to acquire or obtain licenses to third party patents, to protect our products and product candidates and

related inventions and improvements that we consider important to our business. We own a portfolio of U.S. and non-U.S. patents and
patent applications and have licensed rights to a number of issued patents and patent applications. Our owned and licensed patents and
patent applications cover or relate to our products and product candidates, including certain formulations, used to treat particular
conditions, distribution methods and methods of administration, drug delivery technologies and delivery profiles and methods of making
and use. Patents extend for varying periods according to the date of the patent filing or grant and the legal term of patents in the various
countries where patent protection is obtained. The patent laws of non-U.S. countries differ from those in U.S., and the degree of protection
afforded by non-U.S. patents may be different from the protection offered by U.S. patents. In addition to patents, our products and product
candidates are in some instances protected by various regulatory exclusivities. For a description of those exclusivities and their regulatory
background, see “Business—Government Regulation—Marketing Exclusivity—The Hatch-Waxman Act” in this Part I, Item 1.

The patents, patent applications and regulatory exclusivities that relate to our marketed products include:

•

•

•

Xywav. We have 12 U.S. patents that relate to Xywav. These patents expire from 2023 to 2033. In addition, we have patent
applications that relate to Xywav for use in additional indications that would, if issued, expire between 2040 and 2041. Xywav
has been granted ODE by FDA to treat narcolepsy through 2027 and to treat IH through 2028.

Xyrem. We currently have six issued, unexpired patents in the U.S. relating to Xyrem. These patents are listed in FDA’s
publication “Approved Drug Products with Therapeutic Equivalence Evaluations,” or the Orange Book. Our patents relate to
Xyrem’s restricted distribution system and a drug-drug interaction, or DDI, between Xyrem and divalproex sodium. In
October 2018, as a result of FDA’s grant of pediatric exclusivity, an additional six months was added to the original expiration
dates of all of our Orange Book-listed patents that existed at that time. As a result, our Orange Book-listed patents have periods
of exclusivity between December 2022 and September 2033. Some of our Xyrem patents have been subject to patent litigation
with the companies who filed ANDAs seeking to market a generic version of Xyrem, including challenge through the inter partes
review, or IPR, procedures of the Patent Trial and Appeal Board, or PTAB, of the U.S. Patent and Trademark Office, or USPTO.
Some IPR petitions were dismissed by the PTAB. However, in July 2018, the United States Court of Appeals for the Federal
Circuit upheld on appeal PTAB decisions finding that six patents associated with the Xywav and Xyrem REMS and three claims
of a seventh REMS patent were unpatentable. As a result, we will not be able to enforce patents or claims that the PTAB found
unpatentable. Although we have settled all patent litigation against the nine companies that filed ANDAs, it is possible that
additional companies may challenge our U.S. patents for Xyrem in the future. For a description of our Xyrem settlements, see
the risk factor under the heading “The introduction of new products in the U.S. market that compete with, or otherwise disrupt
the market for, our oxybate products and product candidates would adversely affect sales of our oxybate products and product
candidates” in Part I, Item 1A of this Annual Report on Form 10-K.

A Xyrem formulation patent that had issued in multiple non-U.S. countries expired in 2019. The European Patent Office has
issued a method of administration patent relating to the DDI between Xyrem and divalproex sodium that will expire in 2034. That
patent is licensed to UCB as the marketing authorization holder outside of the U.S. and Canada, and UCB has the right to
enforce it. In addition to our issued patents, we have patent applications relating to Xyrem pending in the U.S. and other
countries.

Epidiolex. Our patent portfolio relating to the use of CBD in the treatment of epileptic encephalopathies includes 90 distinct
patent families that are either granted or filed. Most of the patent families in this portfolio claim the use of CBD in the treatment
of particular childhood epilepsy syndromes, seizure sub-types and interactions with other concomitantly dosed anti-seizure
drugs. To date, we have obtained 21 issued U.S. patents, including patents with claims for the use of CBD for the treatment of
convulsive, drop and atonic seizures associated with both LGS and DS, an oral composition of CBD, as well as the use of CBD

20

2021 Annual Report

| JAZZ PHARMACEUTICALS

K
-
0
1
m
r
o
F

with clobazam, and the teaching that dose adjustment may be needed when concomitantly prescribed. These issued patents
are directly aligned with the Epidiolex label, and we have listed them in the Orange Book. These patents have expiry between
2022 and 2041. We have filed corresponding patent applications in many jurisdictions worldwide, including Europe, UK,
Canada, Japan, Mexico, Australia and New Zealand. The USPTO has granted a patent based on data that demonstrates that
Epidiolex provides a benefit over synthetic CBD in an animal model of epilepsy, which has an expiry date of 2039 and we have
listed it in the Orange Book. Epidiolex has received ODE to treat seizures associated with LGS and DS through 2025 and TSC
through 2027.

Sunosi. We acquired worldwide development, manufacturing and commercial rights to solriamfetol from Aerial BioPharma LLC,
or Aerial, in 2014, including Aerial’s patent rights relating to solriamfetol, other than in certain jurisdictions in Asia where SK
Biopharmaceuticals Co., Ltd. retains rights. We have a portfolio of U.S. and non-U.S. patents and patent applications for
solriamfetol relating to various compositions, formulations and methods of use. Four of our U.S. patents are method of use
patents covering treatment of sleep-related conditions expiring between 2026 and 2027 and another U.S. patent is directed to
dose escalation regimens expiring in 2038. Two other U.S. patents cover, respectively, the formulation of solriamfetol and the
method of treating select conditions with formulations of solriamfetol (both expiring in 2037). A request for a patent term
extension for one of the above method of use patents has been filed. Requests for Supplementary Protection Certificate in
certain European validation countries for a related European patent have been granted in Austria, Denmark, France, Ireland,
Italy, Netherlands, Spain and Sweden (expiring in 2031) and remain pending in the others. Sunosi has also been granted ODE
for narcolepsy and new chemical entity exclusivity in the U.S.

Sativex. In the U.S., our patents (and our pending applications if they issue) relating to nabiximols would expire on various dates
between 2022 and 2029, excluding possible patent term extensions. We have at least seven different patent families containing
one or more pending and/or issued patents directed to the nabiximols formulation, the medical use of nabiximols, the extracts
from which nabiximols is composed, the extraction technique used to produce the extracts and the therapeutic use of
nabiximols. Due to the product’s significant complexity, we believe that nabiximols will benefit from strong long-term market
regulatory protection.

Zepzelca. In December 2019, we entered into an exclusive license agreement with PharmaMar pursuant to which we obtained
exclusive U.S. development and commercialization rights to Zepzelca. In October 2020, we entered into the amended license
agreement which expanded our exclusive license to include rights to develop and commercialize Zepzelca in Canada. We have
a portfolio of in-licensed U.S. and Canadian patents for lurbinectedin relating to compositions, methods of use, and processes.
For example, one U.S. patent (expiring in 2024) covers a genus of compounds, including lurbinectedin, and use in treating
various cancers. A request for a patent term extension for this U.S. patent has been filed and, if granted, would extend to 2029.
A request for extension (CSP) has also been filed in Canada. Zepzelca has also been granted orphan drug exclusivity for the
treatment of adults with metastatic SCLC with disease progression on or after platinum-based chemotherapy until 2027 and new
chemical entity exclusivity until 2025 in the U.S.

Rylaze. In 2016, we obtained worldwide rights from Pfenex, Inc., including Pfenex’s patent rights relating to Rylaze, to develop
and commercialize multiple early-stage hematology product candidates, including a license to two U.S. process patents relating
to Rylaze, with respective expirations in 2026 and 2038. Pfenex has been acquired by Ligand Pharmaceuticals Incorporated.
Rylaze has been granted ODE for the treatment of patients with ALL or LBL until 2028. We have two patent application families
relating to dosing regimens. One covers the current dosing regimen (25mg/m2 intramuscularly every 48 hours), while the other
covers various dosing regimens of interest. If issued, these would expire in 2040 and 2042, respectively. Another application
relating to formulations of asparaginase would expire in 2042 if issued.

Vyxeos. We have a portfolio of U.S. and non-U.S. patents and patent applications for Vyxeos and the CombiPlex technology
platform relating to various compositions and methods of making and use. These include seven U.S. patents covering Vyxeos
compositions and methods of use expiring between 2025 and 2034 and two U.S. patents covering CombiPlex (which also cover
Vyxeos) expiring in January 2027. These patents are listed in the Orange Book. Vyxeos has been granted ODE by FDA until
August 2024, seven years from its FDA approval, for the treatment of adults with newly-diagnosed t-AML or AML-MRC. In
March 2021, FDA approved an expanded label for Vyxeos for the treatment of t-AML or AML-MRC in pediatric patients 1 year
and older. In addition, Vyxeos has been granted orphan drug designation by the EC until August 2028, ten years from its EC
approval for the treatment of adults with newly-diagnosed t-AML or AML-MRC and was approved by Health Canada for
treatment of adults with newly diagnosed t-AML or AML-MRC in April 2021.

Defitelio. The unique process of deriving defibrotide from porcine DNA is extensive and uses both chemical and biological
processes that rely on complex characterization methods. We have U.S. and non-U.S. patents and patent applications relating
to various compositions, methods of use and methods of characterization, with the issued patents expiring at various times
between 2021 and 2035. One U.S. patent is listed in the Orange Book and an additional allowed patent is expected to be

•

•

•

•

•

•

JAZZ PHARMACEUTICALS | 2021 Annual Report

21

Orange Book listed in 2022. Defibrotide has been granted ODE by FDA to treat and prevent VOD until March 2023. Defibrotide
has also been granted orphan drug designation by the EC and the Korean Ministry of Food and Drug Safety to treat and prevent
VOD, by the Commonwealth of Australia-Department of Health for the treatment of VOD and by the EC for the prevention of
acute Graft-versus-Host Disease, or aGvHD, and have also received approvals in Canada, Brazil and Switzerland. We acquired
the rights to defibrotide for the treatment and prevention of VOD in North America, Central America and South America from
Sigma-Tau Pharmaceuticals, Inc. in 2014.

The patents and/or patent applications that relate to our product candidates include:

•

•

Suvecaltamide (JZP385). Through the acquisition of Cavion in 2019, we obtained a portfolio of U.S. and non-U.S. patents and
patent applications, including rights relating to compositions and methods of using suvecaltamide. The portfolio includes a U.S.
composition of matter patent relating to suvecaltamide, which expires in 2027, but which can be extended to 2032 depending on
regulatory approval. Two further U.S. patents to the treatment of specific conditions (Angelman Syndrome and memory and
cognitive disorders) provide supplemental protection to 2038.

JZP150. Through the asset purchase and exclusive license agreement with SpringWorks in 2020, we obtained a license to a
portfolio of U.S. and non-U.S. patents and patent applications, including rights relating to compositions and methods of using
JZP150. The portfolio includes a U.S. composition of matter patent relating to JZP150, which expires in 2029.

In addition, we have rights to a number of trademarks and service marks, and pending trademark and service mark applications, in

the U.S. and elsewhere in the world to further protect the proprietary position of our products. For a discussion of the challenges we face in
obtaining or maintaining patent and/or trade secret protection, see the risk factors under the heading “Risks Related to Our Intellectual
Property” in Part I, Item 1A of this Annual Report on Form 10-K.

Government Regulation

As a global pharmaceutical company, our activities are subject to extensive regulation in the U.S., Europe and other countries where

we do business. Regulatory requirements encompass the entire life cycle of pharmaceutical products, from research and development
activities to marketing approval, manufacturing, labeling, packaging, adverse event and safety reporting, storage, advertising, promotion,
sale, pricing and reimbursement, recordkeeping, distribution, importing and exporting. Regulations differ from country to country and are
constantly evolving.

Testing and Approval of Pharmaceutical Products

We are not permitted to market a product in a country until we receive approval from the relevant regulatory authority, such as FDA in
the U.S. and the EC or the competent authorities of the EU member states. An application for marketing approval must contain information
generated by the applicant, also called a sponsor, demonstrating the quality, safety and efficacy of the product candidate, including data
from preclinical and clinical trials, proposed product packaging and labeling and information pertaining to product formulation and the
manufacture and analytical testing of the API and the finished product.

In the U.S., FDA reviews and, if warranted, approves applications for marketing approval. The process for obtaining marketing

approval in the U.S. for a drug or biologic product candidate generally includes:

•

•

•

•

conducting preclinical laboratory and animal testing and submitting the results to FDA in an investigational new drug, or IND,
application requesting approval to test the product candidate in human clinical trials;

conducting adequate and well-controlled human clinical trials to establish the safety and efficacy of the product candidate in the
desired indication;

submitting an NDA, sNDA, or BLA, as appropriate, to FDA seeking approval for a specific indication; and

completing inspections by FDA of the facilities where the product candidate is manufactured, analyzed and stored to
demonstrate compliance with current Good Manufacturing Practices, or cGMP, and any requested FDA audits of the clinical trial
sites that generated the data supporting the application.

Human clinical trials conducted before approval of a product generally proceed in three sequential phases, although the phases may

overlap. In Phase 1, the initial introduction of the product candidate in humans, the product candidate is typically tested to assess
metabolism, pharmacokinetics, pharmacological actions and tolerability, including side effects associated with increasing doses. Phase 2
usually involves clinical trials in a limited patient population to determine the effectiveness of the product candidate for a particular
indication or indications, dosage tolerance and optimum dosage and to identify common adverse effects and safety risks. If a product

22

2021 Annual Report

| JAZZ PHARMACEUTICALS

candidate demonstrates evidence of effectiveness and an acceptable safety profile in Phase 2, Phase 3 clinical trials are undertaken to
obtain additional information about clinical efficacy and safety in a larger number of patients. Clinical trials must be conducted in
accordance with specific protocols, as well as FDA requirements related to conducting the trials and recording and reporting the results,
commonly referred to as good clinical practices, to ensure that the resulting data are credible and accurate and that the trial participants
are adequately protected. FDA enforces good clinical practices through periodic inspections of trial sponsors, clinical investigators and trial
sites.

Once an NDA, sNDA or BLA has been compiled and submitted, FDA performs an initial review before it accepts the application for

filing. FDA may refuse to file an application and/or request additional information before acceptance. Once accepted for filing, FDA begins
an in-depth review of the application. Under the current goals and policies agreed to by FDA under the PDUFA for a new molecular entity,
FDA has ten months from the filing decision in which to complete its initial review of a standard application and respond to the applicant,
and six months from the filing decision for a priority application. FDA does not always meet its PDUFA goal dates, and in certain
circumstances, the PDUFA goal date may be extended.

FDA also has various programs, including Fast Track, Priority Review, Breakthrough Therapy and Accelerated Approval (Subpart H

and E), RTOR pilot program, that are intended to expedite the process for reviewing certain applications and/or provide for approval on the
basis of surrogate endpoints or restricted distribution. Generally, products may be eligible for one or more of these programs if they are
intended for serious or life-threatening diseases or conditions, have potential to address unmet medical needs, or may provide meaningful
benefit over existing treatments. For example, FDA granted Vyxeos Breakthrough Therapy and Fast Track designations and granted
Priority Review with respect to our NDA for Vyxeos for the treatment of t-AML and AML-MRC that was approved in August 2017. In
addition, a priority review voucher, or PRV, may be used to obtain priority review by FDA for one of our future regulatory submissions. We
used the PRV we acquired in May 2018 to obtain priority review for our Xywav for the treatment of IH sNDA, which was approved by FDA
in August 2021. In June 2020, FDA granted Accelerated Approval to Zepzelca for relapsed SCLC. In December 2020, we initiated the
submission of a BLA for Rylaze for ALL under the RTOR pilot program, which was approved by FDA in June 2021.

K
-
0
1
m
r
o
F

During its review of an application, FDA evaluates whether the product demonstrates the required level of safety and efficacy for the
indication for which approval is sought and conducts the inspections and audits described above. FDA may also refer an application to an
advisory committee, typically a panel of clinicians, for review, evaluation and a non-binding recommendation as to whether the application
should be approved. When FDA completes its evaluation, it issues either an approval letter or a complete response letter. A complete
response letter generally outlines what FDA considers to be the deficiencies in the application and may indicate that substantial additional
testing or information is required prior to FDA approval of the product. If and when identified deficiencies have been addressed to FDA’s
satisfaction after a review of the resubmission of the application FDA will issue an approval letter.

Even if a product is approved, the approval may be subject to limitations based on FDA’s interpretation of the data submitted in the
application. For example, as a condition of approval, FDA may require the sponsor to agree to certain post-marketing requirements, such
as conducting Phase 4, or post-approval, clinical trials to gain additional safety data or to document a clinical benefit in the case of products
approved under Accelerated Approval regulations. FDA’s approval of the NDA for Defitelio included a number of post-marketing
commitments and requirements, including the requirement that we conduct a clinical trial to analyze the safety of defibrotide versus best
supportive care in the prevention of VOD in adult and pediatric patients. For its approval of Vyxeos, FDA required that we conduct a safety
study to characterize infusion-related reactions in patients treated with Vyxeos and a clinical trial to determine dosing to minimize toxicity in
patients with moderate and severe renal impairment. Further, FDA granted Accelerated Approval to Zepzelca for relapsed SCLC based on
data from a Phase 2 trial, which approval is contingent upon verification and description of clinical benefit in a post-marketing clinical trial.

In addition, if FDA determines that a REMS is necessary to ensure that the benefits of the product outweigh the risks, a sponsor may
be required to include a proposed REMS (either as part of the application or after approval), which may include a patient package insert or
a medication guide to provide information to consumers about the product’s risks and benefits; a plan for communication to healthcare
providers; or conditions on the product’s prescribing or distribution referred to as elements to assure safe use. Xywav and Xyrem are
required to have a REMS. For more discussion regarding the Xywav and Xyrem REMS, see the risk factors under the headings “The
distribution and sale of our oxybate products are subject to significant regulatory restrictions, including the requirements of a REMS, and
these regulatory requirements subject us to risks and uncertainties, any of which could negatively impact sales of Xywav and Xyrem” and
“Risks Related to Our Intellectual Property” in Part I, Item 1A of this Annual Report on Form 10-K.

The EU and many individual countries have regulatory structures similar to the U.S. for conducting preclinical and clinical testing and
applying for marketing approval or authorization, although specifics may vary widely from country to country. Clinical trials in the EU must
be conducted in accordance with the requirements of the EU Clinical Trials Regulation and applicable good clinical practice standards. In
the EU, there are several procedures for requesting marketing authorization which can be more efficient than applying for authorization on

JAZZ PHARMACEUTICALS | 2021 Annual Report

23

a country-by-country basis. There is a “centralized” procedure allowing submission of a single marketing authorization application to the
European Medicines Agency, or EMA. If the EMA issues a positive opinion, the EC will grant a centralized marketing authorization that is
valid in all EU member states and three of the four European Free Trade Association countries (Iceland, Liechtenstein and Norway). The
centralized procedure is mandatory for certain medicinal products, including orphan medicinal products and biotechnology-derived
medicinal products, and optional for others. There is also a “decentralized” procedure allowing companies to file identical applications to
several EU member states simultaneously for product candidates that have not yet been authorized in any EU member state and a “mutual
recognition” procedure allowing companies that have a product already authorized in one EU member state to apply for that authorization
to be recognized by the competent authorities in other EU member states. The U.K.’s withdrawal from the EU on January 31, 2020,
commonly referred to as Brexit, has created uncertainty concerning the future relationship between the U.K. and the EU. Among the
changes that have had a direct impact are that Great Britain (England, Scotland and Wales) is now treated as a third country. To mitigate
the immediate impact of this in December 2020, the EU and U.K. reached an agreement in principle on the framework for their future
relationship, the EU-U.K. Trade and Cooperation Agreement, or TCA. With regard to EU regulations, Northern Ireland continues to follow
the EU regulatory rules. As part of the TCA, the EU and the U.K. recognize Good Manufacturing Practice, or GMP, inspections carried out
by the other party and the acceptance of official GMP documents issued by the other party. The TCA also encourages, although it does not
oblige, the parties to consult one another on proposals to introduce significant changes to technical regulations or inspection procedures.
Among the areas of absence of mutual recognition are batch testing and batch release. The U.K. has unilaterally agreed to accept EU
batch testing and batch release for a period of at least 2 years until January 1, 2023. However, the EU continues to apply EU laws that
require batch testing and batch release to take place in the EU territory. This means that medicinal products that are tested and released in
the U.K. must be retested and re-released when entering the EU market for commercial use. As regards marketing authorizations, Great
Britain has introduced a separate regulatory submission process, approval process and a separate national marketing authorization.
Northern Ireland, however, continues to be covered by the marketing authorizations granted by the EC.

The maximum timeframe for the evaluation of an application in the EU under the centralized procedure is 210 days, subject to certain
exceptions and clock stops. An initial marketing authorization granted in the EU is valid for five years, with renewal subject to re-evaluation
of the risk-benefit profile of the product. Once renewed, the authorization is usually valid for an unlimited period unless the national
competent authority or the EC decides on justified grounds to proceed with one additional five-year renewal.

In the EU, if an applicant can demonstrate that comprehensive data on the efficacy and safety of the product under normal conditions of

use cannot be provided due to certain specified objective and verifiable reasons, products may be granted marketing authorization “under
exceptional circumstances.” A marketing authorization granted under exceptional circumstances is valid for five years, subject to an annual
reassessment of conditions imposed by the EC. The marketing authorization in the EU for Defitelio was granted under exceptional
circumstances because it was not possible to obtain complete information about the product due to the rarity of the disease and because
ethical considerations prevented conducting a study directly comparing Defitelio with best supportive care or a placebo. As a result, the
marketing authorization requires us to comply with a number of post-marketing obligations, including obligations relating to the manufacture of
the drug substance and finished product, the submission of data concerning patients treated with the product collected through a third-party
patient registry and the establishment of a multi-center, multinational and prospective observational patient registry to investigate the long-term
safety, health outcomes and patterns of utilization of Defitelio during normal use. We are in the process of conducting the post-authorization
study in the EU to provide further data on long-term safety, health outcomes and patterns of utilization of Defitelio in normal use.

Similar to the use of REMS in the U.S. to ensure that the benefits of a product outweigh its risks, in the EU and other countries we are
required and may, in the future in relation to new products, be required to agree to post-marketing obligations or conditions in the marketing
authorization for our products, to include a patient package insert or a medication guide to provide information to consumers about the
product’s risks and benefits, to implement a plan for communication to healthcare providers, and to impose restrictions on the product’s
distribution. For example, the marketing authorization in the EU for Vyxeos requires us to comply with certain manufacturing-related
post-approval commitments.

After approval, certain changes to the approved product, such as adding new indications, making certain manufacturing changes,

modifying a REMS, or making certain additional labeling claims, are subject to further regulatory review and approval. Obtaining approval
for a new indication generally requires that additional clinical studies be conducted to demonstrate that the product is safe and effective for
the new intended use. Such regulatory reviews can result in denial or modification of the planned changes, or requirements to conduct
additional tests or evaluations that can substantially delay or increase the cost of the planned changes.

Manufacture of Pharmaceutical Products

The manufacturing process for pharmaceutical products is highly regulated, and regulators may shut down manufacturing facilities
that they believe do not comply with regulations. We and the third party suppliers of our products are subject to cGMP, which are extensive

24

2021 Annual Report

| JAZZ PHARMACEUTICALS

regulations governing manufacturing processes, stability testing, recordkeeping and quality standards as defined by FDA, the EC, the
EMA, competent authorities of EU member states and other regulatory authorities. FDA also periodically inspects manufacturing facilities
and the sponsor’s and manufacturer’s records related to manufacturing, and assesses compliance with cGMP. Following such inspections,
FDA may issue notices on Form FDA 483 and warning letters. In addition to Form FDA 483 notices and warning letters, failure to comply
with the statutory and regulatory requirements may result in suspension of manufacturing, product seizure, withdrawal of the product from
the market, administrative, civil and criminal penalties, among other enforcement remedies both in the U.S. and in non-U.S. countries.

In the EU, a manufacturing authorization is required to manufacture medicinal products, and the manufacturing authorization holder
must comply with various requirements set out in applicable EU laws, regulations and guidance. These requirements include compliance
with EU cGMP standards when manufacturing products and their APIs, including APIs manufactured outside of the EU with the intention of
importing them into the EU. In addition to inspection reports, manufacturers and marketing authorization holders may be subject to civil,
criminal or administrative sanctions, including suspension of manufacturing authorization, in cases of non-compliance with the EU or EU
member states’ requirements applicable to manufacturing.

Sales and Marketing of Pharmaceutical Products

Advertising and Promotional Activities

FDA regulates advertising and promotional activities for products in the U.S., requiring advertising, promotional materials and labeling
to be truthful and not misleading, and products to be marketed only for their approved indications and in accordance with the provisions of
the approved label. FDA actively investigates allegations of off-label promotion in order to enforce regulations prohibiting these types of
activities. FDA routinely issues informal and more formal communications such as untitled letters or warning letters interpreting its authority
over these matters. While such communications may not be considered final agency decisions, many companies may decide not to contest
the agency’s interpretations so as to avoid disputes with FDA, even if they believe the claims they were making to be truthful, not
misleading and otherwise lawful.

K
-
0
1
m
r
o
F

In the EU, the advertising and promotion of our products are subject to laws governing promotion of medicinal products, interactions

with physicians, misleading and comparative advertising and unfair commercial practices. For example, applicable laws require that
promotional materials and advertising in relation to medicinal products comply with the product’s Summary of Product Characteristics, or
SmPC, as approved by the competent authorities in connection with a marketing authorization approval. The SmPC is the document that
provides information to physicians concerning the safe and effective use of the product. Promotional activity that does not comply with the
SmPC is considered off-label and is prohibited in the EU. Other applicable laws at the EU level and in the individual EU member states also
apply to the advertising and promotion of medicinal products, including laws that prohibit the direct-to-consumer advertising of prescription-
only medicinal products and further limit or restrict the advertising and promotion of our products to the general public and to health care
professionals. Violations of the rules governing the promotion of medicinal products in the EU could be penalized by administrative
measures, fines and imprisonment.

Fraud and Abuse

We are also subject to numerous fraud and abuse laws and regulations globally. In the U.S., there are a variety of federal and state

laws restricting certain marketing practices in the pharmaceutical industry pertaining to healthcare fraud and abuse, including anti-kickback
laws and false claims laws. Our sales, marketing, patient support and medical activities may be subject to scrutiny under these laws. The
U.S. federal healthcare program Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or
receiving anything of value to induce (or in return for) the referral of business, including the purchase, recommendation or prescription of a
particular drug reimbursable under Medicare, Medicaid or other federally financed healthcare programs. The statute has been interpreted
to apply to arrangements between pharmaceutical companies on one hand and patients, prescribers, purchasers and formulary managers
on the other. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common manufacturer
business arrangements and activities from prosecution and administrative sanction, the exemptions and safe harbors are drawn narrowly
and are subject to regulatory revision or changes in interpretation by the U.S Department of Justice, or DOJ, and the Office of Inspector
General of the U.S. Department of Health and Human Services, or OIG. Practices or arrangements that involve remuneration may be
subject to scrutiny if they do not qualify for an exemption or safe harbor. For example, in November 2020, the OIG issued a Special Fraud
Alert to highlight certain inherent risks of remuneration related to speaker programs sponsored by drug and device companies, which do
not fall under either safe harbor or statutory exception protection. The Special Fraud Alert sent a clear signal that speaker programs will be
subject to potentially heightened enforcement scrutiny, in particular for those programs with certain characteristics identified as risk factors
by OIG, including meals exceeding modest value or where alcohol is made available; lack of substantive or new content presented;
programs held at venues not conducive to the exchange of educational information; repeat attendees or attendees without a legitimate

JAZZ PHARMACEUTICALS | 2021 Annual Report

25

business interest; sales or marketing influence on speaker selection; and excessive speaker compensation. Violations of the federal
Anti-Kickback Statute may be established without providing specific intent to violate the statute, and may be punishable by civil, criminal,
and administrative fines and penalties, damages, imprisonment, and/or exclusion from participation in federal healthcare programs.

The federal civil False Claims Act prohibits, among other things, any person from knowingly presenting, or causing to be presented, a

false or fraudulent claim for payment of federal funds, or knowingly making, or causing to be made, a false statement to get a false claim
paid. A claim resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim. The False Claims Act
also permits a private individual acting as a “whistleblower” to bring actions on behalf of themselves and the federal government alleging
violations of the statute and to share in any monetary recovery. Violations of the False Claims Act may result in significant financial
penalties (including mandatory penalties on a per claim or statement basis), treble damages and exclusion from participation in federal
health care programs.

Pharmaceutical companies are subject to other federal false claim and statements laws, some of which extend to non-government

health benefit programs. For example, the healthcare fraud provisions under the Health Insurance Portability and Accountability Act of
1996 and its implementing regulations, or HIPAA, impose criminal liability for, among other things, knowingly and willfully executing, or
attempting to execute, a scheme to defraud any health care benefit program, including private third party payors, or falsifying or covering
up a material fact or making any materially false or fraudulent statement in connection with the delivery of or payment for health care
benefits, items or services. Violations of HIPAA fraud provisions may result in criminal, civil and administrative penalties, fines and
damages, including exclusion from participation in federal healthcare programs.

The majority of individual states also have statutes or regulations similar to the federal anti-kickback law and the False Claims Act,

which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the
payor. Other states restrict whether and when pharmaceutical companies may provide meals to health care professionals or engage in
other marketing-related activities, and certain states and cities require identification or licensing of sales representatives.

Other Post-Approval Pharmaceutical Product Regulation

Safety Reporting/Pharmacovigilance

FDA, the EMA and other governmental authorities track information on side effects and adverse events reported during clinical
studies and after marketing approval. We are required to file periodic safety update reports with the authorities concerning adverse events.
If, upon review, an authority determines that any events and/or reports indicate a trend or signal, they can require a change in a product
label, restrict sales and marketing, require post-approval safety studies, require a labor intensive collection of data regarding the risks and
benefits of marketed products and ongoing assessments of those risks and benefits and/or require or conduct other actions, potentially
including withdrawal or suspension of the product from the market. For example, if the EMA has concerns that the risk-benefit profile of a
product has changed, it can, following an investigation procedure, adopt an opinion advising that the existing marketing authorization for
the product be varied or suspended and requiring the marketing authorization holder to conduct post-authorization safety studies. The
opinion is then submitted for approval by the EC. Also, from time to time, FDA issues drug safety communications on its adverse event
reporting system based on its review of reported adverse events.

FDA and the competent authorities of the EU member states on behalf of the EMA also periodically inspect our records related to

safety reporting. Following such inspections, FDA may issue notices on FDA Form 483 and warning letters that could cause us to modify
certain activities. An FDA Form 483 notice, if issued, can list conditions FDA investigators believe may have violated relevant FDA
regulations or guidance. Failure to adequately and promptly correct the observation(s) can result in a warning letter or other regulatory
enforcement action. Similarly, the EMA’s Pharmacovigilance Risk Assessment Committee may propose to the Committee for Medicinal
Products for Human Use that the marketing authorization holder be required to take specific steps. Non-compliance can lead to the
variation, suspension or withdrawal of marketing authorization or imposition of financial penalties or other enforcement measures.

Sunshine Act and Transparency Laws

The Physician Payment Sunshine Act requires tracking of payments and transfers of value to physicians and teaching hospitals and

ownership interests held by physicians and their families, and reporting to the federal government and public disclosure of these data.
Beginning in 2022, reporting will also be required of information regarding payments and transfers of value provided to physician
assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse-midwives. A number of states now
require pharmaceutical companies to report expenses relating to the marketing and promotion of pharmaceutical products and to report
gifts and payments to healthcare providers in the states. Government agencies and private entities may inquire about our marketing
practices or pursue other enforcement activities based on the disclosures in those public reports.

26

2021 Annual Report

| JAZZ PHARMACEUTICALS

Outside the U.S., interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations,

industry self-regulation codes of conduct and physicians’ codes of professional conduct. The provision of benefits or advantages to
physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products,
which is prohibited in the EU, is governed by the national anti-bribery laws of the EU member states, as described below in “Business—
Government Regulation—Anti-Corruption Legislation” in this Part I, Item 1. Violation of these laws could result in substantial fines and
imprisonment. Certain EU member states, or industry codes of conduct, require that payments made to physicians be publicly disclosed.
Moreover, agreements with physicians must often be the subject of prior notification and approval by the physician’s employer, his/her
competent professional organization, and/or the competent authorities of the individual EU member states. Failure to comply with these
requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.

Controlled Substance Regulations

A drug product approved by FDA may be subject to scheduling as a controlled substance under the CSA depending on the drug’s
potential for abuse. Controlled substances that are pharmaceutical products are subject to a high degree of regulation under the CSA,
which establishes, among other things, certain registration, manufacturing quotas, security, recordkeeping, reporting, import, export and
other requirements administered by the DEA. The DEA classifies controlled substances into five schedules. Schedule I substances by
definition have a high potential for abuse, have no currently “accepted medical use” in the U.S., lack accepted safety for use under medical
supervision, and may not be prescribed, marketed or sold in the U.S. Pharmaceutical products approved for use in the U.S. may be listed
as Schedule II, III, IV or V, with Schedule II substances considered to present the highest potential for abuse or dependence and
Schedule V substances the lowest relative risk of abuse. The API of Xywav and Xyrem, oxybate salts, are regulated by the DEA as
Schedule I controlled substances, and Xywav and Xyrem are regulated as Schedule III controlled substances. The API of Sunosi,
solriamfetol, and Sunosi are regulated as Schedule IV controlled substances. Individual countries also impose similar requirements for
controlled substances. Nabiximols and certain other product candidates we are developing contain controlled substances as defined in the
CSA. Drug products approved by FDA that contain cannabis or cannabis extracts may be controlled substances and will be rescheduled to
Schedules II-V after approval, or, like Epidiolex, removed completely from the schedules by operation of other laws.

K
-
0
1
m
r
o
F

The DEA limits the quantity of certain Schedule I controlled substances that may be manufactured and procured in the U.S. in any

given calendar year through a quota system and, as a result, quotas from the DEA are required in order to manufacture and package
sodium oxybate and Xyrem in the U.S. Accordingly, we require DEA quotas for Siegfried, our U.S. based sodium oxybate supplier, to
procure sodium oxybate and for Patheon, our U.S.-based Xyrem supplier, to obtain the sodium oxybate from Siegfried in order to
manufacture and supply us with Xyrem. Xywav and Xyrem manufactured at our plant in Ireland enters the U.S. as a Schedule III drug and
thus does not require a manufacturing quota.

As Schedule III drugs, Xywav and Xyrem are also subject to DEA import volume limits and state regulations relating to manufacturing,

storage, distribution and physician prescription procedures, including limitations on prescription refills. In addition, the third parties who
perform our clinical and commercial manufacturing, distribution, dispensing and clinical studies for Xywav and Xyrem are required to
maintain necessary DEA registrations and state licenses. The DEA periodically inspects facilities for compliance with its rules and
regulations.

Other Regulations

There are many other requirements and restrictions in the U.S. and elsewhere imposed on pharmaceutical companies and their
activities, including those related to the posting of information relating to clinical studies and their outcomes, the export and importation of
products, required authorizations for distributors, the identification or licensing of sales representatives, restrictions on the ability of
manufacturers to offer co-pay support to patients for certain prescription drugs, implementation of required compliance programs or
marketing codes of conduct, protection of the environment, taxation and work safety. Non-compliance with such requirements may result in
civil, criminal or administrative sanctions.

Anti-Corruption Legislation

Our business activities outside of the U.S. are subject to the U.S. Foreign Corrupt Practices Act, or FCPA, and similar anti-bribery or
anti-corruption laws, regulations, industry self-regulation codes of conduct and physicians’ codes of professional conduct or rules of other
countries in which we operate, including the U.K. Bribery Act of 2010, or the U.K. Bribery Act. The FCPA and similar anti-corruption laws in
other countries generally prohibit the offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly,
to U.S. or non-U.S. government officials in order to improperly influence any act or decision, secure an improper advantage, or obtain or
retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the

JAZZ PHARMACEUTICALS | 2021 Annual Report

27

transactions of the company and to devise and maintain an adequate system of internal accounting controls. The U.K. Bribery Act prohibits
giving, offering, or promising bribes to any person, including U.K. and non-U.K. government officials and private persons, as well as
requesting, agreeing to receive, or accepting bribes from any person. In addition, under the U.K. Bribery Act, companies that carry on a
business or part of a business in the U.K. may be held liable for bribes given, offered or promised to any person, including U.K. and
non-U.K. government officials and private persons in any country, by employees and persons associated with the company in order to
obtain or retain business or a business advantage for the company. Liability is strict, with no element of a corrupt state of mind, but a
defense of having in place adequate procedures designed to prevent bribery is available. As described above, our business is heavily
regulated and therefore involves significant interaction with government officials in many countries. Additionally, in certain countries, the
health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are
government entities; therefore, our dealings with these prescribers and purchasers may be subject to the FCPA, the U.K. Bribery Act and
similar laws. Recently the Securities and Exchange Commission, or SEC, and the DOJ have increased their FCPA enforcement activities
with respect to pharmaceutical companies. In addition, under the Dodd-Frank Wall Street Reform and Consumer Protection Act, private
individuals who report to the SEC original information that leads to successful enforcement actions may be eligible for a monetary award.
We engage in ongoing efforts designed to ensure our compliance with these laws, including due diligence, training, policies, procedures,
and internal controls. However, there is no certainty that all employees and third party business partners (including our distributors,
wholesalers, agents, contractors, and other partners) will comply with anti-bribery laws. In particular, we do not control the actions of our
suppliers and other third party agents, although we may be liable for their actions. Violation of these laws may result in civil or criminal
sanctions, which could include monetary fines, criminal penalties, and disgorgement of past profits.

Data Protection and Privacy

We are subject to data protection and privacy laws and regulations globally, which restrict the processing of personal data. The
legislative and regulatory landscape for privacy and data security continues to evolve with an increased attention in countries globally that
could potentially affect our business. In particular, we are subject to the EU General Data Protection Regulation, which imposes penalties
up to 4% of annual global revenue, and the California Consumer Privacy Act of 2018. These laws and regulations applicable to our
business, increase potential enforcement and litigation activity. In order to manage these evolving risks, we have adopted a global privacy
program that governs the processing of personal data across our business.

Marketing Exclusivity

The Hatch-Waxman Act

The marketing approval process described above for the U.S. is premised on the applicant being the owner of, or having obtained a

right of reference to, all of the data required to prove the safety and effectiveness of a drug product. This type of marketing application,
sometimes referred to as a “full” or “stand-alone” NDA, is governed by Section 505(b)(1) of the United States Federal Food, Drug, and
Cosmetic Act, or FDCA. A Section 505(b)(1) NDA contains full reports of investigations of safety and effectiveness, which includes the
results of preclinical and clinical trials, together with detailed information on the manufacture and composition of the product, in addition to
other information. As an alternative, the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act,
provides two abbreviated approval pathways for certain drug products.

The first path, under Section 505(b)(2) of the FDCA, usually is used for the approval of a product that is similar, but not identical, to a

previously-approved brand-name product, referred to as the reference listed drug, or RLD. Under this path, the applicant is permitted to
rely to some degree on FDA’s finding that the RLD is safe and effective and must submit its own product-specific data on safety and
effectiveness only to the extent necessary to bridge the differences between the products. The second abbreviated path established under
the Hatch-Waxman Act is for the approval of generic drugs. Section 505(j) of the FDCA permits the submission of an ANDA for a generic
version of an approved, brand-name drug. Generally, an ANDA must contain data and information showing that the proposed generic
product and the RLD (i) have the same active ingredient, in the same strength and dosage form, to be delivered via the same route of
administration, (ii) are intended for the same uses, and (iii) are bioequivalent. This data and information are provided instead of data and
information independently demonstrating the proposed generic product’s safety and effectiveness.

The Hatch-Waxman Act requires an ANDA or a Section 505(b)(2) NDA applicant to certify that there are no patents listed for that
product in the Orange Book, or that for each Orange Book-listed patent either the listed patent has expired, the listed patent will expire on a
particular date and approval is sought after patent expiration, or the listed patent is invalid or will not be infringed by the manufacture, use
or sale of the new product. A certification that approval is sought after patent expiration is called a “Paragraph III Certification.” A
certification that the new product will not infringe the RLD’s Orange Book-listed patents, or that such patents are invalid, is called a
“Paragraph IV Certification.” If a relevant patent covers an approved method of use, an ANDA or Section 505(b)(2) NDA applicant can also
file a statement, called, in the case of an ANDA, a “section viii statement,” that the application does not seek approval of the method of use

28

2021 Annual Report

| JAZZ PHARMACEUTICALS

covered by the listed patent. With such a statement, the applicant must “carve out” the protected method of use (typically an indication and
related material) from the proposed product’s labeling. If the applicant makes a Paragraph III Certification, the ANDA or the
Section 505(b)(2) NDA will not be approved until the listed patents claiming the RLD have expired.

If the applicant has provided a Paragraph IV Certification to FDA, the applicant must also send a notice of that certification to the NDA

holder and the relevant patent holders once FDA accepts the ANDA or the Section 505(b)(2) NDA for filing. The NDA and patent holders
then have 45 days to initiate a patent infringement lawsuit. Filing the lawsuit triggers an automatic stay on FDA’s approval of the ANDA or
the Section 505(b)(2) NDA until the earliest of 30 months after the NDA holder’s receipt of the notice of Paragraph IV Certification,
expiration of the patent, certain settlements of the lawsuit, or a decision in the infringement case that is favorable to the applicant. FDA may
issue tentative approval of an application if the application meets all conditions for approval but cannot receive effective approval because
the 30-month stay or another period of regulatory exclusivity has not expired. If an ANDA or Section 505(b)(2) NDA is approved before
conclusion of any relevant patent litigation, the applicant can choose to launch the product, but does so “at risk” of being liable for
damages, and potentially treble damages, if the RLD sponsor or patent holder ultimately prevails in patent litigation.

Under the Hatch-Waxman Act, newly approved drugs and indications may benefit from statutory periods of non-patent marketing
exclusivity that can potentially delay review or approval of an ANDA or Section 505(b)(2) application. For example, the Hatch-Waxman Act
provides five-year marketing exclusivity to the first applicant to gain approval of an NDA for a new chemical entity, meaning a drug
containing an active moiety that FDA has not previously approved. During this period, FDA cannot accept for review an ANDA or a
Section 505(b)(2) NDA for a product containing the same moiety, except that an application containing a Paragraph IV Certification may be
submitted after four years, which may trigger the litigation and stay described above. The Hatch-Waxman Act also provides three years of
marketing exclusivity with the approval of an NDA, including a Section 505(b)(2) NDA, for a product containing a previously-approved
moiety but that incorporates a change (such as a new indication, dosage form or strength) from an approved product with the same moiety,
if the change required clinical data from new investigations that were conducted or sponsored by the applicant. This three-year exclusivity
does not preclude submission of the ANDA or Section 505(b)(2) NDA for such a product, but prevents FDA from giving final approval to
such product.

K
-
0
1
m
r
o
F

The Hatch-Waxman Act also permits a patent term extension of up to five years (but not beyond 14 years from the date of approval)

for an NDA, including a Section 505(b)(2) NDA, that is approved for a product that contains an active ingredient that has not previously
been approved. The extension, which compensates for patent term lost during product development and FDA regulatory review process, is
generally equal to the sum of one-half the time between the effective date of an IND application and the submission date of an NDA, and all
of the time between the submission date of an NDA and the approval of that application. It is available for only one patent for a given
product, and it must be a patent that claims the product or a method of using or manufacturing the product. The USPTO, in consultation
with FDA, reviews and approves applications for patent term extension.

In the EU, innovative medicinal products that are subject to marketing authorization on the basis of a full dossier qualify for eight years’

data exclusivity upon marketing authorization and an additional two years’ market exclusivity. Data exclusivity prevents regulatory authorities in
the EU from referencing the innovator’s data to assess a generic application or biosimilar application for eight years from the date of
authorization of the innovative product, after which a generic or biosimilar marketing authorization application can be submitted, and the
innovator’s data may be referenced. However, the generic product or biosimilar products cannot be marketed in the EU for a further two years
thereafter. The overall ten-year period may be extended for a further year to a maximum of 11 years if, during the first eight years of those ten
years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific
evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.

Orphan Drug and Other Exclusivities

Some jurisdictions, including the U.S., may designate drugs or biologics for relatively small patient populations as orphan drugs. FDA

grants orphan drug designation to drugs or biologics intended to treat a rare disease or condition, which is one that affects fewer than
200,000 individuals in the U.S., or more than 200,000 individuals, but for which there is no reasonable expectation that the cost of
developing the product and making it available in the U.S. for the disease or condition will be recovered from U.S. sales of the product.
Orphan drug designation does not shorten the duration of the regulatory review process or lower the approval standards, but can provide
important benefits, including consultation with FDA. If a product is approved for its orphan designated use, it may be entitled to ODE, which
blocks FDA from approving for seven years any other application for a product that is the same drug for the same indication. If there is a
previously-approved product that is the same drug for the same indication, orphan drug designation requires the sponsor to provide a
plausible hypothesis of clinical superiority over the approved product, whereas ODE requires the sponsor to actually demonstrate clinical
superiority. Clinical superiority can be established by way of greater efficacy, greater safety, or making a major contribution to patient care.
Additionally, a later product can be approved if the sponsor holding ODE consents, or cannot adequately supply the market. ODE does not

JAZZ PHARMACEUTICALS | 2021 Annual Report

29

prevent approval of another sponsor’s application for different indications or uses of the same drug, or for different drugs for the same
indication. Defibrotide has been granted ODE by FDA to treat and prevent VOD until March 2023. Vyxeos has been granted ODE by FDA
for the treatment of AML until August 2024. Epidiolex has received ODE to treat seizures associated with LGS and DS through 2025 and
TSC through 2027. In June 2021, FDA, recognized seven years of ODE for Xywav stating that Xywav is clinically superior to Xyrem by
means of greater safety due to reduced chronic sodium burden. Xywav has been granted ODE by FDA to treat narcolepsy through 2027
and to treat IH through 2028. Rylaze has been granted ODE for the treatment of patients with ALL or LBL until 2028.

Biologic products approved under a BLA are subject to the Biologics Price Competition and Innovation Act, or BPCIA, which

authorizes an abbreviated approval pathway for a biological product that is “biosimilar” to an already approved biologic, or reference
product. The BPCIA provides periods of exclusivity that protect a reference product from competition by biosimilars. FDA may not accept a
biosimilar application for review until four years after the date of first licensure of the reference product, and the biosimilar cannot be
licensed until 12 years after the reference product was first licensed.

Under certain circumstances, the exclusivity periods applicable to drugs and biologics and the patent-related protections applicable to

drugs may be eligible for a six-month extension if the sponsor submits pediatric data that fairly respond to a written request from FDA for
such data. This exclusivity may be granted even if the data does not support a pediatric indication. We consider seeking pediatric
exclusivity for our products whenever appropriate. For example, in response to a written request from FDA, we conducted a Phase 3
clinical trial to assess the safety and efficacy of Xyrem in children and adolescents aged seven to 17 who have narcolepsy with cataplexy,
and submitted study results in a supplement to the Xyrem NDA, seeking approval for this indication. In October 2018, FDA approved the
sNDA and notified us that we had been granted pediatric exclusivity, extending by six months the preclusive effect of our Orange
Book-listed patents for Xyrem, as well as the three-year regulatory exclusivity period granted to the Xyrem pediatric indication because of
the clinical studies that were necessary for approval of the sNDA.

In the EU, orphan drug designation may be granted to products that can be used to treat life-threatening diseases or chronically debilitating

conditions with an incidence of no more than five in 10,000 people or that, for economic reasons, would be unlikely to be developed without
incentives. Orphan designated medicinal products are entitled to a range of benefits during the development and regulatory review process and ten
years of market exclusivity in all EU member states upon approval. As in the U.S., a similar medicinal product with the same orphan indication may
be approved, notwithstanding orphan product exclusivity, if the exclusivity holder gives consent or if the manufacturer of the original orphan
medicinal product is unable to supply sufficient quantities. Marketing authorization may also be granted to a similar medicinal product with the same
orphan indication if the similar product is deemed safer, more effective or otherwise clinically superior to the original orphan medicinal product. The
period of market exclusivity granted in relation to the original orphan medicinal product may, in addition, be reduced to six years if it can be
demonstrated, on the basis of available evidence, that the original orphan medicinal product is sufficiently profitable not to justify maintenance of
market exclusivity. Defibrotide has been granted orphan drug designation by the EC for the treatment of VOD and prevention of GvHD until
October 2023, by the Korean Ministry of Food and Drug Safety to treat and prevent VOD, and by the Commonwealth of Australia-Department of
Health for the treatment of VOD. Vyxeos has been granted orphan drug designation by the EC until August 2028. We also received Orphan
Designation from EMA’s Committee for Orphan Medicinal Products, or COMP, for Epidyolex for DS, LGS and TSC, and the COMP reconfirmed
the designation for DS, LGS and TSC upon EC’s approval.

Pharmaceutical Pricing, Reimbursement by Government and Private Payors and Patient Access

Pricing and Reimbursement

Successful commercialization of our products depends in significant part on adequate financial coverage and reimbursement from
third party payors, including governmental payors (such as the Medicaid and Medicare programs in the U.S.), managed care organizations
and private health insurers. Third party payors decide which drugs will be reimbursed and establish reimbursement and co-pay levels and
conditions for reimbursement. Third party payors are increasingly challenging the prices charged for medical products and services by
examining their cost effectiveness, as demonstrated in pharmacoeconomic and/or clinical studies, in addition to their safety and efficacy. In
some cases, for example, third party payors try to encourage the use of less expensive products, when available, through their prescription
benefits coverage and reimbursement, co-pay and prior authorization policies. The process for determining whether a payor will provide
coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product
once coverage is approved. Third party payors may require prior approval before covering a specific product, or may require patients and
health care providers to try other covered products first. Third party payors may also limit coverage to specific products on an approved list,
or formulary, which might not include all of the approved products for a particular indication. For certain categories of products, third party
payors, principally through contracted pharmacy benefit managers, or PBMs, negotiate rebates with drug manufacturers for inclusion of
products on their formularies in specific positions or coverage criteria. Beginning in the third quarter of 2019, we have been entering into
agreements with certain PBMs to provide rebates for our products where coverage was provided and products were listed in certain
formulary positions, among other conditions.

30

2021 Annual Report

| JAZZ PHARMACEUTICALS

Medicaid is a joint federal and state program that is administered by the states for low-income and disabled beneficiaries. Medicare is

a federal program that is administered by the federal government covering individuals age 65 and over as well as those with certain
disabilities. Medicare Part B pays physicians who administer our products. Under the Medicaid Drug Rebate Program, as a condition of
having federal funds made available to the states for our drugs under Medicare Part B, we are required to pay a rebate to each state
Medicaid program for our covered outpatient drugs that are dispensed to Medicaid beneficiaries and paid for by a state Medicaid program.
Medicaid rebates are based on pricing data we report on a monthly and quarterly basis to the U.S. Centers for Medicare & Medicaid
Services, or CMS, the federal agency that administers the Medicaid Drug Rebate Program and Medicare. These data include the average
manufacturer price and, in the case of innovator products, the best price for each drug which, in general, represents the lowest price
available from the manufacturer to any entity in the U.S. in any pricing structure, calculated to include all applicable sales and associated
rebates, discounts and other price concessions. If we become aware that our reporting for a prior quarter was incorrect, or has changed as
a result of recalculation of the pricing data, we are obligated to resubmit the corrected data for up to three years after those data originally
were due. We are required to provide average sales price, or ASP, information for certain of our products to CMS on a quarterly basis. The
ASP is calculated based on a statutorily defined formula as well as regulations and interpretations of the statute by CMS. This information
is used to compute Medicare payment rates, with rates for Medicare Part B drugs outside the hospital outpatient setting and in the hospital
outpatient setting consisting of ASP plus a specified percentage.

Federal law requires that any company that participates in the Medicaid Drug Rebate Program also participate in the Public Health
Service’s 340B program, or the 340B program, in order for federal funds to be available for the manufacturer’s drugs under Medicaid and
Medicare Part B. The 340B program, which is administered by the Health Resources and Services Administration, or HRSA, requires
participating manufacturers to agree to charge statutorily defined covered entities no more than the 340B “ceiling price” for the
manufacturer’s covered drugs used in an outpatient setting. These 340B covered entities include certain qualifying community health
clinics, a variety of entities that receive health services grants from the Public Health Service, and multiple categories of hospitals, including
children’s hospitals, critical access hospitals, free standing cancer hospitals and hospitals that serve a disproportionate share of
low-income patients. The 340B ceiling price is calculated using a statutory formula, which is based on the average manufacturer price and
rebate amount for the covered outpatient drug as calculated under the Medicaid Drug Rebate Program, and in general, products subject to
Medicaid price reporting and rebate liability are also subject to the 340B ceiling price calculation and discount requirement. A regulation
regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and
intentionally overcharge covered entities became effective on January 1, 2019. We also are required to report our 340B ceiling prices to
HRSA on a quarterly basis and HRSA then publishes them to 340B covered entities. In addition, legislation may be introduced that, if
passed, would further expand the 340B program to additional covered entities or would require participating manufacturers to agree to
provide 340B discounted pricing on drugs used in an inpatient setting.

K
-
0
1
m
r
o
F

A provision in The American Rescue Plan Act of 2021 eliminates, effective January 2024, the statutory cap on rebates drug

manufacturers are required to pay under the Medicaid Drug Rebate Program. Since 2010, the total Medicaid rebate amount a drug
manufacturer is required to pay under the Medicaid Drug Rebate Program has been capped at 100 percent of the Average Manufacturer
Price. The elimination of the cap on rebates means that manufacturer discounts to Medicaid may rise beginning in 2024 and, in certain
circumstances, rebates could exceed the amount that state Medicaid programs pay for the drug. This policy change will have the greatest
impact on drugs whose prices have reached the 100 percent Average Manufacturer Price rebate cap.

Effective January 2023, a provision of the Infrastructure Investment and Jobs Act requires a manufacturer of single source drugs or
biologicals in single-use packages or single dose containers to pay a refund on discarded amounts of drug under Medicare Part B where
the discarded amount exceeds an applicable threshold.

In order to be eligible to have our products paid for with federal funds under the Medicaid and Medicare Part B programs and
purchased by certain federal agencies and grantees, we also participate in the U.S. Department of Veterans Affairs, or VA, Federal Supply
Schedule, or FSS, pricing program. Under this program, we are obligated to make our products available for procurement on an FSS
contract under which we must comply with standard government terms and conditions and charge a price to certain federal agencies that is
no higher than the statutory Federal Ceiling Price, or FCP. The FCP is based on the non-federal average manufacturer price, or
Non-FAMP, which we calculate and report to the VA on a quarterly and annual basis. We also participate in the Tricare Retail Pharmacy
program, under which we pay quarterly rebates on utilization of innovator products that are dispensed through the Tricare Retail Pharmacy
network to Tricare beneficiaries. The rebates are calculated as the difference between the annual Non-FAMP and FCP. Pricing and rebate
calculations vary across products and programs, are complex, and are often subject to interpretation by us, governmental or regulatory
agencies and the courts, which can change and evolve over time.

In addition, in the U.S., drug pricing by pharmaceutical companies is currently, and is expected to continue to be, under close

scrutiny, including with respect to companies that have increased the price of products after acquiring those products from other
companies. There are numerous ongoing efforts at the federal and state level seeking to indirectly or directly regulate drug prices to reduce

JAZZ PHARMACEUTICALS | 2021 Annual Report

31

overall healthcare costs using tools such as price ceilings, value-based pricing and increased transparency and disclosure obligations.
Several states have passed or are considering legislation that requires or purports to require companies to report pricing information,
including proprietary pricing information. For example, in 2017, California adopted a prescription drug price transparency state bill requiring
advance notice of and an explanation for price increases of certain drugs that exceed a specified threshold. Similar bills have been
previously introduced at the federal level and additional legislation could be introduced this year.

Similar to what is occurring in the U.S., political, economic and regulatory developments outside of the U.S. are also subjecting the

healthcare industry to fundamental changes and challenges. Pressure by governments and other stakeholders on prices and
reimbursement levels continue to exist. In various EU member states we expect to be subject to continuous cost-cutting measures, such as
lower maximum prices, lower or lack of reimbursement coverage and incentives to use cheaper, usually generic, products as an
alternative. Health technology assessment, or HTA, of medicinal products is becoming an increasingly common part of the pricing and
reimbursement procedures in some EU member states, including countries representing major markets. The HTA process, which is
governed by the national laws of these countries, is the procedure according to which the assessment of the public health impact,
therapeutic impact and the economic and societal impact of use of a given medicinal product in the national healthcare systems of the
individual country is conducted. HTA generally compares attributes of individual medicinal products, as compared with other treatment
options available on the market. The outcome of HTA regarding specific medicinal products will often influence the pricing and
reimbursement status granted to these medicinal products by the competent authorities of individual EU member states. In December
2021, the EC adopted a HTA regulation intended to boost cooperation among EU member states in assessing health technologies,
including new medicinal products. The regulation will apply to all EU member states from January 2025 provides that EU member states
will be able to use common HTA tools, methodologies, and procedures across the EU. Individual EU member states will continue to be
responsible for drawing conclusions on the overall value of a new health technology for their healthcare system, and pricing and
reimbursement decisions.

In the EU, our products are marketed through various channels and within different legal frameworks. The making available or placing
on the EU market of unauthorized medicinal products is generally prohibited. However, the competent authorities of the EU member states
may exceptionally and temporarily allow and reimburse the supply of such unauthorized products, either on a named patient basis or
through a compassionate use process, to individual patients or a group of patients with a chronically or seriously debilitating disease or
whose disease is considered to be life-threatening, and who cannot be treated satisfactorily by an authorized medicinal product. Such
reimbursement may no longer be available if authorization for named patient or compassionate use programs expire or is terminated or if
marketing authorization is granted for the product. In some EU member states, authorization and reimbursement policies may also delay
commercialization of our products, or may adversely affect our ability to sell our products on a profitable basis. After initial price and
reimbursement approvals, reductions in prices and changes in reimbursement levels can be triggered by multiple factors, including
reference pricing systems and publication of discounts by third party payors or authorities in other countries. In the EU, prices can be
reduced further by parallel distribution and parallel trade, or arbitrage between low-priced and high-priced EU member states.

For more information, including with respect to recent legal developments regarding the Medicaid Drug Rebate Program, Medicare
Part B, and the 340B program, see the risk factors under the headings “Adequate coverage and reimbursement from third party payors
may not be available for our products and we may be unable to successfully contract for coverage from pharmacy benefit managers and
group purchasing organizations, which could diminish our sales or affect our ability to sell our products profitably; conversely, to secure
coverage from these organizations, we may be required to pay rebates or other discounts or other restrictions to reimbursement that could
diminish our sales,” “The pricing of pharmaceutical products has come under increasing scrutiny as part of a global trend toward healthcare
cost containment and resulting changes in healthcare law and policy may impact our business in ways that we cannot currently predict,
which could have a material adverse effect on our business and financial condition” and “If we fail to comply with our reporting and payment
obligations under the Medicaid Drug Rebate Program or other governmental pricing programs, we could be subject to additional
reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial
condition, results of operations and growth prospects” in Part I, Item 1A of this Annual Report on Form 10-K.

Patient Copay Assistance and Free Product Programs

We have various patient programs to help patients access and pay for our products, including co-pay coupons for certain products,

services that help patients determine their insurance coverage for our products, and a free product program. We also make grants to
independent charitable foundations that help financially needy patients with their premium, and co-pay and co-insurance obligations. There
has been enhanced scrutiny of company-sponsored patient assistance programs, including co-pay assistance programs and donations to
third-party charities that provide such assistance, as well as reimbursement support offerings.

The OIG has established guidelines for pharmaceutical manufacturers who make donations to charitable organizations providing

co-pay assistance to Medicare patients. Such donations are unlikely to run afoul of the anti-kickback laws provided that the organizations

32

2021 Annual Report

| JAZZ PHARMACEUTICALS

K
-
0
1
m
r
o
F

receiving donations, among other things, are bona fide charities, are entirely independent of and not controlled by the manufacturer,
provide aid to applicants on a first-come basis according to consistent financial criteria, and do not link aid to use of a donor’s product. In
2016 and 2017, we received subpoenas from the U.S. Attorney’s Office for the District of Massachusetts requesting documents related to
our support of charitable organizations that provide financial assistance to Medicare patients. In April 2019, we finalized our civil settlement
agreement with the DOJ and OIG, and entered into a corporate integrity agreement requiring us to maintain our ongoing corporate
compliance program and obligating us to implement or continue, as applicable, a set of defined corporate integrity activities to ensure
compliance with OIG’s policies around charitable contributions for a period of five years from the effective date of the corporate integrity
agreement.

About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc was formed under the laws of Ireland (registered number 399192) as a private limited liability company in
March 2005 under the name Azur Pharma Limited and was subsequently re-registered as a public limited company under the name Azur
Pharma Public Limited Company, or Azur Pharma, in October 2011. On January 18, 2012, the businesses of Jazz Pharmaceuticals, Inc.
and Azur Pharma were combined in a merger transaction, in connection with which Azur Pharma was re-named Jazz Pharmaceuticals plc
and we became the parent company of and successor to Jazz Pharmaceuticals, Inc.

Our predecessor, Jazz Pharmaceuticals, Inc., was incorporated in California in March 2003 and was reincorporated in Delaware in

January 2004.

Available Information

The mailing address of our headquarters is Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland, and our telephone

number at that location is 353-1-634-7800. Our website is www.jazzpharmaceuticals.com.

We file or furnish pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as applicable, our Annual
Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, amendments to those reports, proxy statements
and other information electronically with the SEC. Through a link on our website, we make copies of our periodic and current reports,
amendments to those reports, proxy statements and other information available, free of charge, as soon as reasonably practicable after we
electronically file such material with, or furnish it to, the SEC. Information found on, or accessible through, our website is not a part of, and
is not incorporated into, this Annual Report on Form 10-K.

Item 1A.

Risk Factors

We have identified the following risks and uncertainties that may have a material adverse effect on our business, financial condition or

results of operations. The risks described below are not the only ones we face. Additional risks not presently known to us or that we
currently believe are immaterial may also significantly impair our business operations. Our business could be harmed by any of these risks.
The trading price of our ordinary shares could decline due to any of these risks, and you may lose all or part of your investment. In
assessing these risks, you should also refer to the other information contained in this Annual Report on Form 10-K, including our
consolidated financial statements and accompanying notes.

Risks Related to Our Lead Products and Product Candidates

Our inability to maintain or increase sales from our oxybate franchise would have a material adverse effect on our business,
financial condition, results of operations and growth prospects.

Our business has been substantially dependent on Xyrem® (sodium oxybate) oral solution, and our financial results have been
significantly influenced by sales of Xyrem. Our future plans assume that Xywav®, our oxybate product launched in November 2020 with
92%, or approximately 1,000 to 1,500 milligrams per day, less sodium than Xyrem, depending on the dose, absence of a sodium warning
and dosing titration option, will become the treatment of choice for patients who can benefit from oxybate treatment, current Xyrem
patients, and patients who previously were not prescribed Xyrem, including those patients for whom sodium content is a concern. In
June 2021, U.S. Food and Drug Administration, or FDA, recognized seven years of Orphan Drug Exclusivity through July 21, 2027 for
Xywav in narcolepsy stating that Xywav is clinically superior to Xyrem by means of greater safety due to reduced chronic sodium burden.
Our ability to successfully commercialize Xywav will depend on, among other things, our ability to maintain adequate coverage and
reimbursement for Xywav and acceptance of Xywav by payors, physicians and patients.

Our ability to maintain or increase oxybate product sales and realize the anticipated benefits from our investment in Xywav is subject
to a number of additional risks and uncertainties as discussed in greater detail below, including those related to the near-term introduction

JAZZ PHARMACEUTICALS | 2021 Annual Report

33

of authorized generic and generic versions of sodium oxybate and new products for treatment of cataplexy and/or excessive daytime
sleepiness, or EDS, in narcolepsy in the U.S. market; the current and potential impacts of the COVID-19 pandemic, including the current
and expected future negative impact on demand for our products and the uncertainty with respect to our ability to meet commercial
demand in the future; increased pricing pressure from, changes in policies by, or restrictions on reimbursement imposed by, third party
payors, including our ability to maintain adequate coverage and reimbursement for Xywav; and challenges to our intellectual property
around Xyrem and/or Xywav. While we expect that our business will continue to be substantially dependent on oxybate product sales, there
is no guarantee that we can maintain oxybate sales at or near historical levels, or that oxybate sales will continue to grow. A significant
decline in oxybate sales could cause us to reduce our operating expenses or seek to raise additional funds, which would have a material
adverse effect on our business, financial condition, results of operations and growth prospects, including on our ability to acquire, in-license
or develop new products to grow our business.

The introduction of new products in the U.S. market that compete with, or otherwise disrupt the market for, our oxybate products
and product candidates would adversely affect sales of our oxybate products and product candidates.

While Xywav and Xyrem are currently the only products approved by FDA and marketed in the U.S. for the treatment of both
cataplexy and EDS in both adult and pediatric patients with narcolepsy, new treatment options for cataplexy and EDS in narcolepsy have
launched, and in the future, other products may be launched that are competitive with or disrupt the market for our oxybate products.

For example, in the future, we expect Xywav and Xyrem to face competition from authorized generic and generic versions of sodium

oxybate. Nine companies have sent us notices that they had filed abbreviated new drug applications, or ANDAs, seeking approval to
market a generic version of Xyrem, and we have filed and settled patent lawsuits with all nine companies. To date, FDA has approved or
tentatively approved four of these ANDAs, and we believe that it is likely that FDA will approve or tentatively approve some or all of the
others. In our patent litigation settlement with the first filer, West-Ward Pharmaceuticals Corp. (a wholly owned subsidiary of Hikma
Pharmaceuticals PLC and now known as Hikma in the U.S.), or Hikma, we granted Hikma the right to sell an authorized generic product, or
AG Product, with royalties back to us, in the U.S. beginning on January 1, 2023, or earlier under certain circumstances. Hikma has a right
to elect to continue to sell the Hikma AG Product for a total of up to five years. We also granted Hikma a license to launch its own generic
sodium oxybate product as early as six months after it has the right to sell the Hikma AG Product, but if it elects to launch its own generic
product, Hikma will no longer have the right to sell the Hikma AG Product. In our settlements with Amneal Pharmaceuticals LLC, or
Amneal, Lupin Inc., or Lupin, and Par Pharmaceutical, Inc., or Par, we granted each party the right to sell a limited volume of an AG
Product in the U.S. beginning on July 1, 2023, or earlier under certain circumstances, and ending on December 31, 2025, with royalties
back to us. AG Products will be distributed through the same risk evaluation and mitigation strategy, or REMS, as Xywav and Xyrem. We
also granted each of Amneal, Lupin and Par a license to launch its own generic sodium oxybate product under its ANDA on or after
December 31, 2025, or earlier under certain circumstances, including the circumstance where Hikma elects to launch its own generic
product. If Amneal, Lupin or Par elects to launch its own generic product under such circumstance, it will no longer have the right to sell an
AG Product. In our settlements with each of the other five ANDA filers, we granted each a license to launch its own generic sodium oxybate
product under its ANDA on or after December 31, 2025, or earlier under certain circumstances, including circumstances where Hikma
launches its own generic sodium oxybate product. The actual timing of the launch of an AG Product or generic sodium oxybate product is
uncertain because the launch dates of the AG Products and generic sodium oxybate products under our settlement agreements are
subject to acceleration under certain circumstances. It is possible that additional companies may file ANDAs seeking to market a generic
version of Xyrem which could lead to additional patent litigation or challenges with respect to Xyrem.

Any ANDA holder launching an AG Product or another generic sodium oxybate product will independently establish the price of the
AG Product and/or its own generic sodium oxybate product. Generic competition often results in decreases in the prices at which branded
products can be sold. After any introduction of a generic product, whether or not it is an AG Product, a significant percentage of the
prescriptions written for Xyrem will likely be filled with the generic product. Certain U.S. state laws allow for, and in some instances in the
absence of specific instructions from the prescribing physician mandate, the dispensing of generic products rather than branded products
when a generic version is available. This would result in reduction in sales of, and revenue from, Xyrem, although we would continue to
receive royalties and other revenue based on sales of an AG Product in accordance with the terms of our settlement agreements.

A circumstance that could trigger acceleration of Hikma’s launch date for an AG Product, which would also accelerate Amneal, Lupin

and Par’s launch dates for their AG Products and ultimately could lead to acceleration of the other settling ANDA filers’ launch dates for
their generic sodium oxybate products, is a substantial reduction in Xyrem net sales. Such a reduction could occur under various
circumstances, including from our sales of Xywav or if a third party introduces a product to treat EDS or cataplexy in narcolepsy that leads
to a substantial decline in Xyrem net sales. Accordingly, our strategy to drive revenue growth in our key franchises through, among other
things, rapid adoption and broad access of Xywav in the U.S. could lead to the acceleration of such launch dates. Other companies may
develop a sodium oxybate product for treatment of narcolepsy, using an alternative formulation or a different delivery technology, and seek

34

2021 Annual Report

| JAZZ PHARMACEUTICALS

approval in the U.S. using a new drug application, or NDA, approval pathway under Section 505(b)(2) and referencing the safety and
efficacy data for Xyrem. In February 2021, FDA accepted for filing an NDA submitted by Avadel Pharmaceuticals plc, or Avadel, for an
extended-release formulation of sodium oxybate which uses its proprietary technology for the treatment of EDS and cataplexy in patients
with narcolepsy with a Prescription Drug User Fee Act, or PDUFA, target action date of October 15, 2021. On October 15, 2021, Avadel
announced that FDA review is ongoing and FDA will likely not take action in October 2021 and will provide a new target action date. Xyrem
may also face increased competition from new branded entrants to treat EDS in narcolepsy such as pitolisant. Other companies have
announced that they have product candidates in various phases of development to treat the symptoms of narcolepsy, such as Axsome
Therapeutics, Inc.’s reboxetine, and various companies are performing research and development on orexin agonists for the treatment of
sleep disorders.

We expect that Xywav for the treatment of both cataplexy and EDS in patients with narcolepsy will face competition similar to that

described above for Xyrem, including from generic or authorized generic sodium oxybate products or new branded entrants in narcolepsy
notwithstanding FDA recognizing Orphan Drug Exclusivity for Xywav. For example, we received notice in June 2021 that Lupin filed an
ANDA for a generic version of Xywav. Additional companies may file ANDAs seeking to market a generic version of Xywav which could
lead to additional patent litigation or challenges with respect to Xywav. Moreover, Avadel has announced that it has obtained an orphan
drug designation from FDA for its extended-release sodium oxybate formulation. To obtain approval with Orphan Drug Exclusivity, Avadel
will have to show clinical superiority to Xywav and Xyrem. We cannot predict the timing or approvability of Avadel’s sodium oxybate product
candidate or how FDA will evaluate any clinical superiority arguments that either we or Avadel may make, but in any event, we expect to
face competition from Avadel, if its product candidate is approved.

Moreover, non-oxybate products intended for the treatment of EDS or cataplexy in narcolepsy, including new market entrants, even if

not directly competitive with Xywav or Xyrem, could have the effect of changing treatment regimens and payor or formulary coverage of
Xywav or Xyrem in favor of other products, and indirectly materially and adversely affect sales of Xywav and Xyrem. To date, we have not
seen a material impact to our business from the introduction of these new market entrants. Examples of such new market entrants include
our product, Sunosi, and pitolisant, a drug that was approved by FDA in 2019 for the treatment of EDS in adult patients with narcolepsy and
approved by FDA in October 2020 pursuant to a complete response resubmission for an adult cataplexy indication in the U.S. Pitolisant
has also been approved and marketed in Europe to treat adult patients with narcolepsy, with or without cataplexy, and to treat EDS in
obstructive sleep apnea, or OSA. In addition, we are also aware that prescribers often prescribe branded or generic medications for
cataplexy, before or instead of prescribing oxybate therapy in Xywav and Xyrem, and that payors often require patients to try such
medications before they will cover Xywav or Xyrem, even if they are not approved for this use. Examples of such products are described in
“Business—Competition” in Part I, Item 1 of this Annual Report on Form 10-K.

K
-
0
1
m
r
o
F

We expect that the approval and launch of an AG Product or other generic version of Xyrem could have a material adverse effect on

our sales of Xywav and Xyrem and on our business, financial condition, results of operations and growth prospects. We also expect that
sales of Xywav will, and the approval and launch of any other sodium oxybate (including Avadel’s extended-release sodium oxybate
formulation) or alternative product that treats narcolepsy could, have a material adverse effect on our sales of Xyrem, which could have the
additional impact of potentially triggering acceleration of market entry of AG Products or other generic sodium oxybate products under our
patent litigation settlement agreements.

The distribution and sale of our oxybate products are subject to significant regulatory restrictions, including the requirements of
a REMS and safety reporting requirements, and these regulatory and safety requirements subject us to risks and uncertainties,
any of which could negatively impact sales of Xywav and Xyrem.

The active pharmaceutical ingredient, or API, of Xywav and Xyrem, is a form of gamma-hydroxybutyric acid, or GHB, a central
nervous system depressant known to be associated with facilitated sexual assault as well as with respiratory depression and other serious
side effects. As a result, FDA requires that we maintain a REMS with elements to assure safe use, or ETASU, for Xywav and Xyrem to help
ensure that the benefits of the drug in the treatment of cataplexy and EDS in narcolepsy outweigh the serious risks of the drug. The REMS
imposes extensive controls and restrictions on the sales and marketing of Xywav and Xyrem that we are responsible for implementing. Any
failure to demonstrate our substantial compliance with our REMS obligations, including as a result of business or other interruptions
resulting from the evolving effects of the COVID-19 pandemic, or a determination by FDA that the REMS is not meeting its goals, could
result in enforcement action by FDA, lead to changes in our REMS obligations, negatively affect sales of Xywav or Xyrem, result in
additional costs and expenses for us and/or require us to invest a significant amount of resources, any of which could materially and
adversely affect our business, financial condition, results of operations and growth prospects.

FDA has stated that it will evaluate the Xywav and Xyrem REMS on an ongoing basis and will require modifications as may be
appropriate. We cannot predict whether FDA will request, seek to require or ultimately require modifications to, or impose additional

JAZZ PHARMACEUTICALS | 2021 Annual Report

35

requirements on, the Xywav and Xyrem REMS, including in connection with the submission of new oxybate products or indications, the
introduction of authorized generics, or to accommodate generics, or whether FDA will approve modifications to the Xywav and Xyrem
REMS that we consider warranted. Any modifications approved, required or rejected by FDA could change the safety profile of Xywav or
Xyrem, and have a significant negative impact in terms of product liability, public acceptance of Xywav or Xyrem as a treatment for
cataplexy and EDS in narcolepsy, and prescribers’ willingness to prescribe, and patients’ willingness to take, Xywav or Xyrem, any of which
could have a material adverse effect on our oxybate business. Modifications approved, required or rejected by FDA could also make it
more difficult or expensive for us to distribute Xywav or Xyrem, make distribution easier for oxybate competitors, disrupt continuity of care
for Xywav or Xyrem patients and/or negatively affect sales of Xywav or Xyrem.

We depend on outside vendors, including Express Scripts Specialty Distribution Services, Inc., the central certified pharmacy, to
distribute Xywav and Xyrem in the U.S., provide patient support services and implement the requirements of the Xywav and Xyrem REMS.
If the central pharmacy fails to meet the requirements of the Xywav and Xyrem REMS applicable to the central pharmacy or otherwise
does not fulfill its contractual obligations to us, moves to terminate our agreement, refuses or fails to adequately serve patients, or fails to
promptly and adequately address operational challenges or challenges in implementing REMS modifications, whether due to business or
other interruptions resulting from the evolving effects of the COVID-19 pandemic or otherwise, the fulfillment of Xywav or Xyrem
prescriptions and our sales would be adversely affected. If we change to a new central pharmacy, new contracts might be required with
government payors and other insurers who pay for Xywav or Xyrem, and the terms of any new contracts could be less favorable to us than
current agreements. In addition, any new central pharmacy would need to be registered with the U.S. Drug Enforcement Administration, or
DEA, and certified under the REMS and would also need to implement the particular processes, procedures and activities necessary to
distribute under the Xywav and Xyrem REMS. Transitioning to a new pharmacy could result in product shortages, which would negatively
affect sales of Xywav and Xyrem, result in additional costs and expenses for us and/or take a significant amount of time, any of which could
materially and adversely affect our business, financial condition, results of operations and growth prospects.

In its approval of Hikma’s ANDA, FDA waived the requirement of a single shared REMS between the brand drug and generic versions,
approving Hikma’s ANDA with a generic sodium oxybate REMS separate from the Xywav and Xyrem REMS, except for the requirement that the
generic sodium oxybate REMS program pharmacies contact the Xywav and Xyrem REMS by phone to verify and report certain information. The
generic sodium oxybate REMS was approved with the condition that it be open to all future sponsors of ANDAs or NDAs for sodium oxybate
products. A sodium oxybate distribution system that is less restrictive than the Xywav and Xyrem REMS, such as the generic sodium oxybate
REMS, which provides that generic sodium oxybate products and potentially new sodium oxybate products approved under a Section 505(b)(2)
NDA approval pathway could be distributed through multiple pharmacies, could increase the risks associated with oxybate distribution. Because
patients, consumers and others may not differentiate generic sodium oxybate from Xyrem or differentiate between the different REMS programs,
any negative outcomes, including risks to the public, caused by or otherwise related to a separate sodium oxybate REMS, could have a significant
negative impact in terms of product liability, our reputation and good will, public acceptance of Xywav or Xyrem as a treatment for cataplexy and
EDS in narcolepsy, and prescribers’ willingness to prescribe, and patients’ willingness to take, Xywav or Xyrem, any of which could have a material
adverse effect on our oxybate business.

We may face pressure to further modify the Xywav and Xyrem REMS or to license or share intellectual property pertinent to that
REMS, including proprietary data required for the safe distribution of sodium oxybate, in connection with FDA’s approval of the generic
sodium oxybate REMS or another oxybate REMS that may be submitted or approved in the future. Our settlement agreements with ANDA
filers do not directly impact FDA’s waiver of the single shared system REMS requirement, any other ANDA or NDA filer’s ability to develop
and implement the generic sodium oxybate REMS for its sodium oxybate product, or our ability to take any action with respect to the safety
of the generic sodium oxybate REMS. We cannot predict the outcome or impact on our business of any future action that we may take with
respect to FDA’s waiver of the single shared system REMS requirement, its approval and tentative approval of generic versions of sodium
oxybate or the consequences of distribution of sodium oxybate through the generic sodium oxybate REMS approved by FDA or another
separate REMS.

REMS programs have increasingly drawn public scrutiny from the U.S. Congress, the Federal Trade Commission, or FTC, and FDA,
with allegations that such programs are used as a means of improperly blocking or delaying competition. In December 2019, as part of the
Further Consolidated Appropriations Act of 2020, the U.S. Congress passed legislation known as the Creating and Restoring Equal Access
To Equivalent Samples Act, or CREATES. CREATES is intended to prevent companies from using REMS and other restricted distribution
programs as a means to deny potential competitors access to product samples that are reasonably necessary to conduct testing in support
of an application that references a listed drug or biologic, and provides such potential competitors a potential private right of action if the
innovator fails to timely provide samples upon request. CREATES also grants FDA additional authority regarding approval of generic
products with REMS.

It is possible that the FTC, FDA or other governmental authorities could claim that, or launch an investigation into whether, we are

using our REMS programs in an anticompetitive manner or have engaged in other anticompetitive practices. The Federal Food, Drug and

36

2021 Annual Report

| JAZZ PHARMACEUTICALS

Cosmetic Act further states that a REMS ETASU shall not be used by an NDA holder to block or delay generic drugs or drugs covered by
an application under Section 505(b)(2) from entering the market. In its 2015 letter approving the Xyrem REMS, FDA expressed concern
that we were aware that the Xyrem REMS is blocking competition. From June 2020 to October 2021, we were served with a number of
lawsuits that included allegations that we had used the Xyrem REMS to delay approval of generic sodium oxybate. In December 2020,
these cases were centralized and transferred to the United States District Court for the Northern District of California, where the multidistrict
litigation will proceed for the purpose of discovery and pre-trial proceedings. For additional information on these lawsuits, see Note 14,
Commitments and Contingencies-Legal Proceedings of the Notes to Consolidated Financial Statements, included in Part IV of this Annual
Report on Form 10-K. It is possible that additional lawsuits will be filed against us making similar or related allegations. We cannot predict
the outcome of these or potential additional lawsuits; however, if the plaintiffs were to be successful in their claims, they may be entitled to
injunctive relief or we may be required to pay significant monetary damages, which could have a material adverse effect on our business,
financial condition, results of operations and growth prospects.

Pharmaceutical companies, including their agents and employees, are required to monitor adverse events occurring during the use of
their products and report them to FDA. The patient counseling and monitoring requirements of the Xywav and Xyrem REMS provide more
extensive information about adverse events experienced by patients taking Xywav and Xyrem, including deaths, than is generally available
for other products that are not subject to similar REMS requirements. As required by FDA and other regulatory agencies, the adverse event
information that we collect for Xywav and Xyrem is regularly reported to FDA and could result in FDA requiring changes to Xywav and/or
Xyrem labeling, including additional warnings or additional boxed warnings, or requiring us to take other actions that could have an adverse
effect on patient and prescriber acceptance of Xywav and Xyrem. As required by FDA, Xywav’s and Xyrem’s current labeling includes a
boxed warning regarding the risk of central nervous system depression and misuse and abuse.

Any failure to demonstrate our substantial compliance with the REMS or any other applicable regulatory requirements to the

satisfaction of FDA or another regulatory authority could result in such regulatory authorities taking actions in the future which could have a
material adverse effect on oxybate product sales and therefore on our business, financial condition, results of operations and growth
prospects.

K
-
0
1
m
r
o
F

Our inability to maintain or increase sales of Epidiolex/Epidyolex would have a material adverse effect on our business, financial
condition, results of operations and growth prospects.

Our ability to maintain or increase sales of Epidiolex/Epidyolex (cannabidiol) is subject to many risks. While we have established our
Epidiolex commercial team and have hired our U.S. and European sales forces, we will need to continue to maintain and further develop
the teams in order to successfully coordinate the commercialization of Epidiolex. Even if we are successful in maintaining and continuing to
develop our Epidiolex commercial team, there are many factors that could cause the commercialization of Epidiolex to be unsuccessful,
including a number of factors that are outside our control. The commercial success of Epidiolex depends on the extent to which patients
and physicians accept and adopt Epidiolex as a treatment for Lennox-Gastaut syndrome, or LGS, Dravet syndrome and Tuberous
Sclerosis Complex, and we do not know whether our or others’ estimates in this regard will be accurate. Physicians may not prescribe
Epidiolex and patients may be unwilling to use Epidiolex if coverage is not provided or reimbursement is inadequate to cover a significant
portion of the cost. Additionally, any negative development for Epidiolex in the market, in clinical development for additional indications, or
in regulatory processes in other jurisdictions, may adversely impact the commercial results and potential of Epidiolex.

While we expect our oxybate products and Epidiolex/Epidyolex to remain the largest parts of our business, our success also
depends on our ability to effectively commercialize other products in our neuroscience and oncology therapeutic areas.

In addition to Xywav, Xyrem, Epidiolex/Epidyolex and our other neuroscience products and product candidates, we are

commercializing a portfolio of products, including our other lead marketed products, Sunosi, Zepzelca, Rylaze, Vyxeos and Defitelio. An
inability to effectively commercialize our other lead marketed products and to maximize their potential where possible through successful
research and development activities, whether due to the evolving effects of the COVID-19 pandemic or otherwise, could have a material
adverse effect on our business, financial condition, results of operations and growth prospects.

Sunosi

We obtained approval of Sunosi® (solriamfetol) in the U.S. in 2019, in the European Union, or EU, in January 2020, in Canada in May 2021

and subsequently in other countries for the treatment of EDS associated with narcolepsy or OSA. Our ability to realize the anticipated benefits from
our investment in Sunosi is subject to a number of risks and uncertainties, including the potential impacts of the continuing COVID-19 pandemic on
the successful commercialization in the U.S. and the rolling launch in Europe; market acceptance of Sunosi; our ability, in a competitive retail
pharmacy market, to differentiate Sunosi from other products that are prescribed to treat excessive sleepiness in patients with OSA or EDS in

JAZZ PHARMACEUTICALS | 2021 Annual Report

37

patients with narcolepsy; adequate coverage and reimbursement by government programs and other third party payors, including the impact of
future coverage decisions by payors; restrictions on permitted promotional activities based on any additional limitations on the labeling for the
product that may be required by FDA, or the European Commission, or the EC, or other regulatory authorities; and our ability to satisfy FDA’s post-
marketing requirements.

Zepzelca

Our ability to realize the anticipated benefits from our investment in Zepzelca® (lurbinectedin) is subject to a number of risks and
uncertainties, including our ability to successfully commercialize Zepzelca in the U.S.; adequate supply of Zepzelca to meet demand;
availability of favorable pricing and adequate coverage and reimbursement; the limited experience of, and need to educate, physicians in
the use of Zepzelca for the treatment of metastatic small cell lung cancer, or SCLC; the potential for negative trial data read-outs in ongoing
or future Zepzelca clinical trials; our and Pharma Mar, S.A., or PharmaMar’s, ability to maintain accelerated approval or successfully
complete a confirmatory study of Zepzelca; and the impact of the evolving effects of the COVID-19 pandemic on our ability to educate
health care providers about Zepzelca in the treatment of relapsed, metastatic SCLC in the U.S. and on patients’ access to lung cancer
screening, diagnosis and treatment. If we are unable to successfully commercialize Zepzelca in the U.S. and Canada, or if sales of
Zepzelca do not reach the levels we expect, our anticipated revenue from Zepzelca will be negatively affected, which would have an
adverse effect on our business, financial condition, results of operations and growth prospects.

Rylaze

Our ability to realize the anticipated benefits from our investments in RylazeTM (recombinant Erwinia asparaginase) is subject to a
number of uncertainties, including our ability to successfully commercialize Rylaze in the U.S. including creating awareness among health
care professionals and ensuring physicians are confident in its supply and that patients with acute lymphoblastic leukemia, or ALL, or
lymphoblastic lymphoma, or LBL, will be given the appropriate course of therapy based on current FDA approval. In addition, there
continues to be the potential of a competitive erwinia product being reintroduced into the marketplace that could create uncertainty in
demand and utilization of Rylaze moving forward.

Vyxeos

Our ability to realize the anticipated benefits from our investment in Vyxeos® (daunorubicin and cytarabine) liposome for injection by

successfully and sustainably growing sales is subject to a number of risks and uncertainties, including our ability to differentiate Vyxeos
from other liposomal chemotherapies and generically available chemotherapy combinations with which physicians and treatment centers
are more familiar; acceptance by hospital pharmacy and therapeutics committees in the U.S., the EU and other countries; the increasing
complexity of the acute myeloid leukemia, or AML, landscape requiring changes in patient identification and treatment selection, including
diagnostic tests and monitoring that clinicians may find challenging to incorporate; the use of new and novel compounds in AML that are
either used off-label or are only approved for use in combination with other agents and that have not been tested in combination with
Vyxeos; the increasing use of venetoclax, which received full FDA approval in October 2020 for AML treatment; the limited size of the
population of high-risk AML patients who may potentially be indicated for treatment with Vyxeos, particularly as a result of the shift of
healthcare resources toward less intensive outpatient AML treatments in the U.S. in light of the COVID-19 pandemic which is directly
negatively impacting, or delaying, the use of Vyxeos, as well as the suspension of in-person interactions with healthcare professionals due
to the COVID-19 pandemic; the availability of adequate coverage, pricing and reimbursement approvals; and competition from new and
existing products and potential competition from products in development. Although we saw some recovery in demand for Vyxeos
beginning in the end of the second quarter of 2020, due to the ongoing impacts of the COVID-19 pandemic, we continue to expect a
negative impact on demand growth trends for and utilization of Vyxeos compared to historical periods. If sales of Vyxeos do not reach the
levels we expect, our anticipated revenue from the product would be negatively affected, which would have an adverse effect on our
business, financial condition, results of operations and growth prospects.

Defitelio

Our ability to maintain and grow sales and to realize the anticipated benefits from our investment in Defitelio® (defibrotide sodium) is
subject to a number of risks and uncertainties, including continued acceptance by hospital pharmacy and therapeutics committees in the
U.S., the EU and other countries; the continued availability of favorable pricing and adequate coverage and reimbursement; the limited
experience of, and need to educate, physicians in recognizing, diagnosing and treating hepatic veno-occlusive disease, or VOD,
particularly in adults; the possibility that physicians recognizing VOD symptoms may not initiate or may delay initiation of treatment while
waiting for those symptoms to improve, or may terminate treatment before the end of the recommended dosing schedule; and the limited
size of the population of VOD patients who are indicated for treatment with Defitelio (particularly if changes in hematopoietic stem cell
transplantation treatment protocols reduce the incidence of VOD diagnosis and demand for Defitelio).

38

2021 Annual Report

| JAZZ PHARMACEUTICALS

Although we saw a resurgence in demand for Defitelio in the U.S. and outside the U.S. beginning in the end of the second quarter of

2020, due to the evolving effects of the COVID-19 pandemic, the reprioritization of healthcare resources and related delays,
postponements or suspensions of certain medical procedures such as stem cell transplants, we continue to expect a negative impact on
demand growth trends and utilization of Defitelio compared to historical periods. If sales of Defitelio do not reach the levels we expect, our
anticipated revenue from the product would be negatively affected and our business, financial condition, results of operations and growth
prospects would be adversely affected. In addition, because VOD is an ultra-rare disease, we have experienced inter-quarter variability in
our Defitelio sales, which makes Defitelio sales difficult to predict from period to period. As a result, Defitelio sales results or trends in any
period may not necessarily be indicative of future performance.

We face substantial competition from other companies, including companies with larger sales organizations and more
experience working with large and diverse product portfolios, and face competition from generic drugs and potentially from
non-FDA approved cannabidiol preparations.

Our products compete, and our product candidates may in the future compete, with currently existing therapies, including generic
drugs, product candidates currently under development by us and others and/or future product candidates, including new chemical entities
that may be safer or more effective or more convenient than our products. Any products that we develop may be commercialized in
competitive markets, and our competitors, which include large global pharmaceutical companies and small research-based companies and
institutions, may succeed in developing products that render our products obsolete or noncompetitive. Many of our competitors, particularly
large pharmaceutical and life sciences companies, have substantially greater financial, operational and human resources than we do.
Smaller or earlier stage companies may also prove to be significant competitors, particularly through focused development programs and
collaborative arrangements with large, established companies. In addition, many of our competitors deploy more personnel to market and
sell their products than we do, and we compete with other companies to recruit, hire, train and retain pharmaceutical sales and marketing
personnel. If our sales force and sales support organization are not appropriately resourced and sized to adequately promote our products,
the commercial potential of our current and any future products may be diminished. In any event, the commercial potential of our current
products and any future products may be reduced or eliminated if our competitors develop or acquire and commercialize generic or
branded products that are safer or more effective, are more convenient or are less expensive than our products. If we are unable to
compete successfully, our commercial opportunities will be reduced and our business, results of operations and financial conditions may be
materially harmed.

K
-
0
1
m
r
o
F

There is a substantial amount of change occurring in the U.S. regarding the use of medical and recreational marijuana products.
While federal law prohibits the sale and distribution of most marijuana products not approved or authorized by FDA, 46 states and the
District of Columbia have legalized either cannabidiol, or CBD, or marijuana for either recreational or medical use, or both. Under the
U.S. Farm Bill, enacted in late 2018, certain extracts and other material derived from cannabis are no longer controlled under the Federal
Controlled Substances Act, or CSA. Although the marketing of such products as a food, dietary supplement, or for medical purposes
remains subject to FDA requirements, FDA continues to evaluate regulatory pathways to permit CBD in conventional foods and dietary
supplements. In addition, Congressional efforts related to legalization of marijuana continue. Although our business is distinct from that of
entities marketing FDA-unapproved marijuana and CBD-containing dietary supplement, future legislation or federal government action
authorizing the sale, distribution, use, and insurance reimbursement of non-FDA approved marijuana or cannabinoid products could
increase competition for and adversely affect our ability to generate sales of Epidiolex and our cannabinoid product candidates.

In addition, Epidiolex and nabiximols compete with product offerings from a variety of companies. FDA approved Zogenix, Inc.’s

low-dose fenfluramine, or Fintepla, in Dravet syndrome in June 2020, and Zogenix submitted its supplemental NDA for LGS in 2021. In
January 2022, Zogenix announced that it entered into a definitive agreement with UCB for the acquisition of Zogenix by UCB. Ovid
Therapeutics Inc./Takeda Pharmaceutical Company Limited, Eisai Company Limited, and Marinus Pharmaceuticals, Inc. are developing
therapies for treating Developmental and Epileptic Encephalopathies (includes Dravet and LGS). Stiripentol has been approved in Europe
for several years to treat Dravet syndrome and was approved in 2018 by FDA. Zynerba Pharmaceuticals, Inc. is developing a topical
formulation of CBD, for which it is working with FDA on a path forward on CONNECT-FX data for Zygel in Fragile X syndrome. There are a
number of public and private companies in the early stages of developing genetic therapies for the underlying causes of Dravet syndrome,
including Stoke Therapeutics, Inc., which has an antisense oligonucleotide, STK-001, in early clinical trials. Other companies, including
those with greater resources than us may announce similar plans in the future. In addition, there are non-FDA approved CBD preparations
being made available from companies in the medical marijuana industry, which might attempt to compete with Epidiolex and, if approved by
FDA, nabiximols. If we are unable to compete successfully, our commercial opportunities will be reduced and our business, results of
operations and financial conditions may be materially harmed.

For a description of the competition that our lead marketed products and most advanced product candidates face or may face, see

the discussion in “Business—Competition” in Part I, Item 1 of this Annual Report on Form 10-K and the risk factor under the heading

JAZZ PHARMACEUTICALS | 2021 Annual Report

39

“The introduction of new products in the U.S. market that compete with, or otherwise disrupt the market for, our oxybate products and
product candidates would adversely affect sales of our oxybate products and product candidates” in this Part I, Item 1A.

Adequate coverage and reimbursement from third party payors may not be available for our products and we may be unable to
successfully contract for coverage from pharmacy benefit managers and other organizations; conversely, to secure coverage
from these organizations, we may be required to pay rebates or other discounts or other restrictions to reimbursement, either of
which could diminish our sales or adversely affect our ability to sell our products profitably.

In both U.S. and non-U.S. markets, our ability to successfully commercialize and achieve market acceptance of our products depends

in significant part on adequate financial coverage and reimbursement from third party payors, including governmental payors (such as the
Medicare and Medicaid programs in the U.S.), managed care organizations and private health insurers. Without third party payor
reimbursement, patients may not be able to obtain or afford prescribed medications. In addition, reimbursement guidelines and incentives
provided to prescribing physicians by third party payors may have a significant impact on the prescribing physicians’ willingness and ability
to prescribe our products. The demand for, and the profitability of, our products could be materially harmed if state Medicaid programs, the
Medicare program, other healthcare programs in the U.S. or elsewhere, or third party commercial payors in the U.S. or elsewhere deny
reimbursement for our products, limit the indications for which our products will be reimbursed, or provide reimbursement only on
unfavorable terms. In particular, we cannot predict to what extent the evolving effects of the COVID-19 pandemic may disrupt global
healthcare systems and access to our products or result in a widespread loss of individual health insurance coverage due to
unemployment, a shift from commercial payor coverage to government payor coverage, or an increase in demand for patient assistance
and/or free drug programs, any of which could adversely affect net revenue.

As part of the overall trend toward cost containment, third party payors often require prior authorization for, and require

reauthorization for continuation of, prescription products or impose step edits, which require prior use of another medication, usually a
generic or preferred brand, prior to approving coverage for a new or more expensive product. Such restrictive conditions for reimbursement
and an increase in reimbursement-related activities can extend the time required to fill prescriptions and may discourage patients from
seeking treatment. We cannot predict actions that third party payors may take, or whether they will limit the access and level of
reimbursement for our products or refuse to provide any approvals or coverage. From time to time, third party payors have refused to
provide reimbursement for our products, and others may do so in the future.

Third party payors increasingly examine the cost-effectiveness of pharmaceutical products, in addition to their safety and efficacy,
when making coverage and reimbursement decisions. We may need to conduct expensive pharmacoeconomic and/or clinical studies in
order to demonstrate the cost-effectiveness of our products. If our competitors offer their products at prices that provide purportedly lower
treatment costs than our products, or otherwise suggest that their products are safer, more effective or more cost-effective than our
products, this may result in a greater level of access for their products relative to our products, which would reduce our sales and harm our
results of operations. In some cases, for example, third party payors try to encourage the use of less expensive generic products through
their prescription benefit coverage and reimbursement and co-pay policies. Because some of our products compete in a market with both
branded and generic products, obtaining and maintaining access and reimbursement coverage for our products may be more challenging
than for products that are new chemical entities for which no therapeutic alternatives exist.

Third party pharmacy benefit managers, or PBMs, other similar organizations and payors can limit coverage to specific products on
an approved list, or formulary, which might not include all of the approved products for a particular indication, and to exclude drugs from
their formularies in favor of competitor drugs or alternative treatments, or place drugs on formulary tiers with higher patient co-pay
obligations, and/or to mandate stricter utilization criteria. Formulary exclusion effectively encourages patients and providers to seek
alternative treatments, make a complex and time-intensive request for medical exemptions, or pay 100% of the cost of a drug. In addition,
in many instances, certain PBMs, other similar organizations and third party payors may exert negotiating leverage by requiring
incremental rebates, discounts or other concessions from manufacturers in order to maintain formulary positions, which could continue to
result in higher gross to net deductions for affected products. In this regard, we have entered into agreements with PBMs and payor
accounts to provide rebates to those entities related to formulary coverage for our products, but we cannot guarantee that we will be able to
agree to coverage terms with other PBMs and other third party payors. Payors could decide to exclude our products from formulary
coverage lists, impose step edits that require patients to try alternative, including generic, treatments before authorizing payment for our
products, limit the types of diagnoses for which coverage will be provided or impose a moratorium on coverage for products while the payor
makes a coverage decision. An inability to maintain adequate formulary positions could increase patient cost-sharing for our products and
cause some patients to determine not to use our products. Any delays or unforeseen difficulties in reimbursement approvals could limit
patient access, depress therapy adherence rates, and adversely impact our ability to successfully commercialize our products. If we are
unsuccessful in maintaining broad coverage for our products, our anticipated revenue from and growth prospects for our products could be
negatively affected.

40

2021 Annual Report

| JAZZ PHARMACEUTICALS

In many countries outside the U.S., procedures to obtain price approvals, coverage and reimbursement can take considerable time

after the receipt of marketing authorization. Many European countries periodically review their reimbursement of medicinal products, which
could have an adverse impact on reimbursement status. In addition, we expect that legislators, policymakers and healthcare insurance
funds in the EU member states will continue to propose and implement cost-containing measures, such as lower maximum prices, lower or
lack of reimbursement coverage and incentives to use cheaper, usually generic, products as an alternative to branded products, and/or
branded products available through parallel import to keep healthcare costs down. Moreover, in order to obtain reimbursement for our
products in some European countries, including some EU member states, we may be required to compile additional data comparing the
cost-effectiveness of our products to other available therapies. Health Technology Assessment, or HTA, of medicinal products is becoming
an increasingly common part of the pricing and reimbursement procedures in some EU member states, including those representing the
larger markets. The HTA process, which is currently governed by national laws in each EU member state, is the procedure to assess
therapeutic, economic and societal impact of a given medicinal product in the national healthcare systems of the individual country. The
outcome of an HTA will often influence the pricing and reimbursement status granted to these medicinal products by the competent
authorities of individual EU member states. The extent to which pricing and reimbursement decisions are influenced by the HTA of the
specific medicinal product currently varies between EU member states, although beginning in January 2025, the EU HTA regulation will
apply; this regulation aims to harmonize the clinical benefit assessment of HTA across the EU. If we are unable to maintain favorable
pricing and reimbursement status in EU member states that represent significant markets, our anticipated revenue from and growth
prospects for our products in the EU could be negatively affected. For example, the EC granted marketing authorization for Vyxeos in
August 2018, for Epidyolex in September 2019 and for Sunosi in January 2020, and, as part of our rolling launches of Vyxeos, Epidyolex
and Sunosi in Europe, we are making pricing and reimbursement submissions in European countries. Due to the evolving effects of the
COVID-19 pandemic, we currently anticipate delays by certain European regulatory authorities in their pricing and reimbursement reviews.
If we experience setbacks or unforeseen difficulties in obtaining favorable pricing and reimbursement decisions, including as a result of
regulatory review delays due to the COVID-19 pandemic, planned launches in the affected EU member states would be delayed, which
could negatively impact anticipated revenue from and growth prospects for Vyxeos, Epidyolex and/or Sunosi.

K
-
0
1
m
r
o
F

The pricing of pharmaceutical products has come under increasing scrutiny as part of a global trend toward healthcare cost
containment and resulting changes in healthcare law and policy may impact our business in ways that we cannot currently
predict, which could have a material adverse effect on our business and financial condition.

Political, economic and regulatory influences are subjecting the healthcare industry in the U.S. to fundamental changes, particularly

given the current atmosphere of mounting criticism of prescription drug costs in the U.S. We expect there will continue to be legislative and
regulatory proposals to change the healthcare system in ways that could impact our ability to sell our products profitably, as governmental
oversight and scrutiny of biopharmaceutical companies is increasing. For example, we anticipate that the U.S. Congress, state legislatures,
and federal and state regulators may adopt or accelerate adoption of new healthcare policies and reforms intended to curb healthcare
costs, such as federal and state controls on reimbursement for drugs (including under Medicare, Medicaid and commercial health plans),
new or increased requirements to pay prescription drug rebates and penalties to government health care programs, and additional
pharmaceutical cost transparency policies that aim to require drug companies to justify their prices through required disclosures.

Legislative and regulatory proposals that have recently been considered include, among other things, proposals to limit the terms of

patent litigation settlements with generic sponsors, to define certain conduct around patenting and new product development as unfair
competition, to facilitate the importation of drugs into the U.S. from other countries, and to increase manufacturer liability in the Medicare
Part D pharmaceutical benefit. Legislative and regulatory proposals to reform the regulation of the pharmaceutical industry and
reimbursement for pharmaceutical drugs are continually changing, and all such considerations may adversely affect our business and
industry in ways that we cannot accurately predict.

There is also ongoing activity related to health care coverage. The Affordable Care Act substantially changed the way healthcare is
financed by both governmental and private insurers. These changes impacted previously existing government healthcare programs and
have resulted in the development of new programs, including Medicare payment-for-performance initiatives. Further, the Biden
administration and U.S. Congress have taken and are expected to continue to take notable steps towards expanding health care coverage
beyond the Affordable Care Act, which could have ramifications for the pharmaceutical industry. Additional legislative changes, regulatory
changes, or guidance could be adopted, which may impact the marketing approvals and reimbursement for our product candidates. For
example, there has been increasing legislative, regulatory, and enforcement interest in the U.S. with respect to drug pricing practices.
There have been several Congressional inquiries and proposed and enacted federal and state legislation and regulatory initiatives
designed to, among other things, bring more transparency to product pricing, evaluate the relationship between pricing and manufacturer
patient programs, and reform government healthcare program reimbursement methodologies for drug products.

If healthcare policies or reforms intended to curb healthcare costs are adopted or if we experience negative publicity with respect to

pricing of our products or the pricing of pharmaceutical drugs generally, the prices that we charge for our products may be affected, our

JAZZ PHARMACEUTICALS | 2021 Annual Report

41

commercial opportunity may be limited and/or our revenues from sales of our products may be negatively impacted. We have periodically
increased the price of Xyrem, most recently in January 2022, and there is no guarantee that we will make similar price adjustments to
Xywav and Xyrem in the future or that price adjustments we have taken or may take in the future will not negatively affect Xywav or Xyrem
sales volumes and revenues. We also have made and may in the future make price adjustments on our other products. There is no
guarantee that such price adjustments will not negatively affect our reputation and our ability to secure and maintain reimbursement
coverage for our products, which could limit the prices that we charge for our products, including Xywav and Xyrem, limit the commercial
opportunities for our products and/or negatively impact revenues from sales of our products.

If we become the subject of any future government investigation or U.S. Congressional oversight with respect to drug pricing or other

business practices, we could incur significant expense and could be distracted from operation of our business and execution of our
strategy. Any such investigation or hearing could also result in reduced market acceptance and demand for our products, could harm our
reputation and our ability to market our products in the future, and could have a material adverse effect on our business, financial condition,
results of operations and growth prospects.

We expect that legislators, policymakers and healthcare insurance funds in Europe will continue to propose and implement
cost-containing measures to keep healthcare costs down; particularly due to the financial strain that the COVID-19 pandemic has placed
on their healthcare systems. These measures could include limitations on the prices we will be able to charge for our products or the level
of reimbursement available for these products from governmental authorities or third party payors. Further, an increasing number of
European and other foreign countries use prices for medicinal products established in other countries as “reference prices” to help
determine the price of the product in their own territory. Consequently, a downward trend in prices of medicinal products in some countries
could contribute to similar downward trends elsewhere.

In addition to access, coverage and reimbursement, the commercial success of our products depends upon their market
acceptance by physicians, patients, third party payors and the medical community.

If physicians do not prescribe our products, we cannot generate the revenues we anticipate from product sales. Market acceptance of

each of our products by physicians, patients, third party payors and the medical community depends on:

•

•

•

•

•

•

•

•

•

•

•

•

•

•

the clinical indications for which a product is approved and any restrictions placed upon the product in connection with its
approval, such as a REMS or equivalent obligation imposed in a European or other foreign country, patient registry
requirements or labeling restrictions;

the prevalence of the disease or condition for which the product is approved and its diagnosis;

the efficacy of the product in regular use;

the severity of side effects and other risks in relation to the benefits of our products;

unanticipated serious adverse events;

acceptance by physicians and patients of each product as a safe and effective treatment;

availability of sufficient product inventory to meet demand;

physicians’ decisions relating to treatment practices based on availability of product;

perceived clinical superiority and/or advantages over alternative treatments;

overcoming negative publicity surrounding illicit use of

O GHB or

O cannabinoid and marijuana products

and the view of patients, law enforcement agencies, physicians and regulators of our products as being the same or similar to
illicit products;

relative convenience and ease of administration;

with respect to Xywav and Xyrem, physician and patient assessment of the burdens associated with obtaining or maintaining the
certifications required under the Xywav and Xyrem REMS;

the cost of treatment in relation to alternative treatments, including generic products; and

the availability of financial or other assistance for patients who are uninsured or underinsured.

42

2021 Annual Report

| JAZZ PHARMACEUTICALS

Because of our dependence upon market acceptance of our products, any adverse publicity associated with harm to patients or other
adverse events resulting from the use or misuse of any of our products or any similar products distributed by other companies, including generic
versions of our products, could materially and adversely affect our business, financial condition, results of operations and growth prospects.

Delays or problems in the supply of our products for sale or for use in clinical trials, loss of our single source suppliers or failure
to comply with manufacturing regulations could materially and adversely affect our business, financial condition, results of
operations and growth prospects.

The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of

process controls required to consistently produce the API and the finished product in sufficient quantities while meeting detailed product
specifications on a repeated basis. We and our suppliers may encounter difficulties in production, including difficulties with the supply of
manufacturing materials, production costs and yields, process controls, quality control and quality assurance, including testing of stability,
impurities and impurity levels and other product specifications by validated test methods, and compliance with strictly enforced U.S., state
and non-U.S. regulations. In addition, we and our suppliers are subject to FDA’s current Good Manufacturing Practices, or cGMP,
requirements, DEA regulations and equivalent rules and regulations prescribed by non-U.S. regulatory authorities. If we or any of our
suppliers encounter manufacturing, quality or compliance difficulties with respect to any of our products, whether due to the evolving effects
of the COVID-19 pandemic (including as a result of disruptions of global shipping and the transport of products) or otherwise, we may be
unable to obtain or maintain regulatory approval or meet commercial demand for such products, which could adversely affect our business,
financial condition, results of operations and growth prospects. In addition, we could be subject to enforcement action by regulatory
authorities for our failure to comply with cGMP with respect to the products we manufacture in our facilities as well as for our failure to
adequately oversee compliance with cGMP by any of our third party suppliers operating under contract. Moreover, failure to comply with
applicable legal and regulatory requirements subjects us and our suppliers to possible regulatory action, including restrictions on supply or
shutdown, which may adversely affect our or a supplier’s ability to supply the ingredients or finished products we need.

K
-
0
1
m
r
o
F

We have a manufacturing and development facility in Athlone, Ireland where we manufacture Xywav and Xyrem, a manufacturing

plant in Villa Guardia, Italy where we produce the defibrotide drug substance and a manufacturing and development facility in the U.K. at
Kent Science Park, where we produce Epidiolex/Epidyolex and Sativex. We currently do not have our own commercial manufacturing or
packaging capability for our other products, product candidates or their APIs. As a result, our ability to develop and supply products in a
timely and competitive manner depends primarily on third party suppliers being able to meet our ongoing commercial and clinical trial
needs for API, other raw materials, packaging materials and finished products.

In part due to the limited market size for our products and product candidates, we have a single source of supply for most of our

marketed products, product candidates and their APIs. Single sourcing puts us at risk of interruption in supply in the event of
manufacturing, quality or compliance difficulties. If one of our suppliers fails or refuses to supply us for any reason, it would take a
significant amount of time and expense to implement and execute the necessary technology transfer to, and to qualify, a new supplier. FDA
and similar international or national regulatory bodies must approve manufacturers of the active and inactive pharmaceutical ingredients
and certain packaging materials used in our products. If there are delays in qualifying new suppliers or facilities or a new supplier is unable
to meet FDA’s or similar international regulatory body’s requirements for approval, there could be a shortage of the affected products for
the marketplace or for use in clinical studies, or both, which could negatively impact our anticipated revenues and could potentially cause
us to breach contractual obligations with customers or to violate local laws requiring us to deliver the product to those in need.

We are responsible for the manufacture and supply of Sativex (nabiximols) to our collaboration partners and for the manufacture and supply
of Epidiolex/Epidyolex, nabiximols and other cannabinoid product candidates for commercial use and for use in clinical trials. The manufacturing of
Epidiolex/Epidyolex, nabiximols and our product candidates necessitates compliance with GMP and other regulatory requirements in jurisdictions
internationally. Our ability to successfully manufacture Epidiolex/Epidyolex, nabiximols and other cannabinoid product candidates involves
cultivation of botanical raw material from specific cannabinoid plants, extraction and purification processes, manufacture of finished products and
labeling and packaging, which includes product information, tamper evidence and anti-counterfeit features, under tightly controlled processes and
procedures. In addition, we must ensure chemical consistency among our batches, including clinical batches and, if approved, marketing batches.
Demonstrating such consistency may require typical manufacturing controls as well as clinical data. We must also ensure that our batches conform
to complex release specifications. For certain steps in the manufacturing process for nabiximols, we are currently reliant on single manufacturing
facilities and no back-up facilities are yet in place. We have a second site at which we can grow the specific cannabinoid plants that produce the
CBD used in Epidiolex/Epidyolex, a second site at which we can extract CBD from botanical raw material and a second site at which we can
crystallize the purified CBD from the liquid plant extract. Because nabiximols is a complex mixture manufactured from plant materials, and because
the release specifications may not be identical in all countries, certain batches may fail release testing and not be able to be commercialized. A
number of our product candidates (excluding Epidiolex/Epidyolex) also consist of a complex mixture manufactured from plant materials, and are
therefore subject to a similar risk. If we are unable to manufacture Epidiolex/Epidyolex, nabiximols or other product candidates in accordance with
regulatory specifications, including Good Manufacturing Practice, or GMP, or if there are disruptions in our manufacturing process due to damage,

JAZZ PHARMACEUTICALS | 2021 Annual Report

43

loss or otherwise, or failure to pass regulatory inspections of our manufacturing facilities, we may not be able to meet current demand or supply
sufficient product for use in clinical trials, and this may also harm our ability to commercialize Epidiolex/Epidyolex, nabiximols and our product
candidates on a timely or cost-competitive basis, if at all. Our manufacturing program requires significant time and resources and may not be
successful, may lead to delays, interruptions to supply or may prove to be more costly than anticipated.

Vyxeos is manufactured by Baxter Oncology GmbH, or Baxter, which is a sole source supplier from a single site location. There have

been batch failures due to mechanical, component, raw materials and other issues in the production of Vyxeos, and batches have been
produced that have otherwise not been in compliance with applicable specifications. We are continuing to work with Baxter and others to
address manufacturing complexities related to Vyxeos. Moreover, the proprietary technology that supports the manufacture of Vyxeos is
not easily transferable. Consequently, engaging an alternate manufacturer may be difficult, costly and time-consuming. If we fail to obtain a
sufficient supply of Vyxeos in accordance with applicable specifications on a timely basis, our sales of Vyxeos, our future maintenance and
potential growth of the market for this product, our ability to conduct ongoing and future clinical trials of Vyxeos, and our business, financial
condition, results of operations and growth prospects could be materially adversely affected. In addition, while the APIs in Vyxeos,
daunorubicin and cytarabine, are available from a number of suppliers, certain suppliers have received warning letters from FDA. As a
result, we have qualified other suppliers for each API, and we provided the qualification data to FDA. If FDA restricts importation of API
from either supplier, and we are unable to qualify API from additional suppliers in a timely manner, or at all, our ability to successfully
commercialize Vyxeos and generate sales of this product at the level we expect and to conduct ongoing and future clinical trials of Vyxeos
could be materially and adversely affected.

Rylaze drug substance is manufactured by AGC Biologics at its facility in Copenhagen, Denmark and the drug product is
manufactured and packaged by Patheon at its facility in Greenville, North Carolina. Both sites have ample capacity to support forecast
demand and we have secured supply for more than one year’s forecast demand. To successfully manufacture Rylaze, the manufacturer
must have an adequate master and working cell bank. If we fail to obtain a sufficient supply of Rylaze in accordance with applicable
specifications on a timely basis, our sales of Rylaze, our future maintenance and potential growth of the market for this product, our
competitive advantage over competing products that have supply constraints, and our business, financial condition, results of operations
and growth prospects could be materially adversely affected.

In addition, in order to conduct our ongoing and any future clinical trials of, complete marketing authorization submissions for, and

potentially launch our other product candidates, we also need to have sufficient quantities of product manufactured.

Moreover, to obtain approval from FDA or a similar international or national regulatory body of any product candidate, we or our
suppliers for that product must obtain approval by the applicable regulatory body to manufacture and supply product, in some cases based
on qualification data provided to the applicable body as part of our regulatory submission. Any delay in generating, or failure to generate,
data required in connection with submission of the chemistry, manufacturing and controls portions of any regulatory submission could
negatively impact our ability to meet our anticipated submission dates, and therefore our anticipated timing for obtaining FDA or similar
international or national regulatory body approval, or our ability to obtain regulatory approval at all. In addition, any failure of us or a supplier
to obtain approval by the applicable regulatory body to manufacture and supply product or any delay in receiving, or failure to receive,
adequate supplies of a product on a timely basis or in accordance with applicable specifications could negatively impact our ability to
successfully launch and commercialize products and generate sales of products at the levels we expect.

If the effects of the COVID-19 pandemic become more severe and begin to impact supply of manufacturing materials or essential
distribution systems such as general delivery services, or require us or our suppliers to again cease or restrict operations at our respective
manufacturing facilities, we could experience disruptions to our supply chain and operations, and associated delays in the manufacturing and
supply of our products, which would adversely impact our ability to generate sales of our approved products and our business, financial
condition, results of operations and growth prospects would be materially adversely affected. For example, supply chain interruptions and
shortage of construction materials could lead to delays and rising costs associated with our planned construction project at our commercial
manufacturing facility in the U.K. at Kent Science Park. In addition, energy prices have spiked recently due to global macro-economic issues,
which can have a direct impact on CO2 prices and availability. CO2 is a critical raw material for manufacturing our cannabinoid products.

Risks Related to Growth of Our Product Portfolio and Research and Development

Our future success depends on our ability to successfully develop and obtain and maintain regulatory approvals for our late-
stage product candidates and, if approved, to successfully launch and commercialize those product candidates.

The testing, manufacturing and marketing of our products require regulatory approvals, including approval from FDA and similar bodies in

Europe and other countries. If FDA, the European Medicines Agency, or EMA, or the competent authorities of the EU member states or other
European countries determine that our quality, safety or efficacy data do not warrant marketing approval for a product candidate, we could be
required to conduct additional clinical trials as a condition to receiving approval, which could be costly and time-consuming and could delay or

44

2021 Annual Report

| JAZZ PHARMACEUTICALS

preclude the approval of our application. Our inability to obtain and maintain regulatory approval for our product candidates in the U.S. and
internationally and to successfully commercialize new products that are approved would prevent us from receiving a return on our investments
and could have a material adverse effect on our business, financial condition, results of operations and growth prospects.

Due to the evolving effects of the COVID-19 pandemic, it is possible that we could experience delays in the timing of marketing

application review by regulatory authorities and/or our interactions with regulatory authorities due to limited staffing or working hours of
governmental employees, governmental “stay-at-home” orders and travel restrictions with respect to physical inspections if required for
regulatory approval, or the diversion of regulatory authority efforts and attention to approval of other therapeutics or other activities related
to COVID-19, which could delay anticipated approval decisions and otherwise delay or limit our ability to make planned regulatory
submissions or obtain new product approvals. For example, due to travel restrictions in 2021 that prevented an on-site inspection, we
experienced a delay in FDA’s approval of GP Pharm as a second manufacturer of Zepzelca. It is possible that we could experience delays
in regulatory interactions and review of submissions due to COVID-19 impacts described above, such as with respect to our development
pathway for nabiximols.

Even if we receive approval of a product, regulatory authorities may impose significant labeling restrictions or requirements, including

limitations on the dosing of the product, requirements around the naming or strength of a product, restrictions on indicated uses for which
we may market the product, the imposition of a boxed warning or other warnings and precautions, and/or the requirement for a REMS or
equivalent obligation imposed in a European or other foreign country to ensure that the benefits of the drug outweigh the risks. FDA
requires a REMS and a boxed warning for Xywav and Xyrem, and similar restrictions could be imposed on other products in the future. Our
receipt of approval for narrower indications than sought, restrictions on marketing through a REMS or equivalent obligation imposed in a
European or other foreign country, or significant labeling restrictions or requirements in an approved label such as a boxed warning, could
have a negative impact on our ability to recoup our research and development costs and to successfully commercialize that product, any of
which could materially and adversely affect our business, financial condition, results of operations and growth prospects.

K
-
0
1
m
r
o
F

Regulatory authorities may also impose post-marketing obligations as part of their approval, which may lead to additional costs and
burdens associated with commercialization of the drug, and may pose a risk to maintaining approval of the drug. We are subject to certain
post-marketing requirements and commitments in connection with the approval of certain of our products, including Epidiolex, Defitelio,
Vyxeos, Sunosi, Rylaze and Zepzelca. These post-marketing requirements and commitments include satisfactorily conducting multiple
post-marketing clinical trials and safety studies. For example, FDA granted accelerated approval to Zepzelca for relapsed SCLC based on
data from a Phase 2 trial, which approval is contingent upon verification and description of clinical benefit in a post-marketing clinical trial.
We and our licensor PharmaMar are committed to the further study of lurbinectedin, both as a single agent and in combination, and have
reached agreement with FDA regarding a confirmatory clinical development program. Our failure to confirm its clinical benefit could result
in the withdrawal of approval of Zepzelca, which could have a material adverse effect on our business, financial condition, results of
operations and growth prospects. With respect to FDA’s and EC’s approvals of Epidiolex/Epidyolex, we are subject to certain post-
marketing requirements. Failure to comply with these post-marketing requirements could result in withdrawal of our marketing approvals for
Epidiolex/Epidyolex and/or other civil or criminal penalties. In any event, if we are unable to comply with our post-marketing obligations
imposed as part of the marketing approvals in the U.S., the EU, or other countries, our approval may be varied, suspended or revoked,
product supply may be delayed and our sales of our products could be materially adversely affected.

We are pursuing activities related to the development of additional asparaginase products for patients with ALL or other hematological
malignancies. Several of our external research and development collaborations are focused on these efforts, including our agreement with
Ligand Pharmaceuticals Incorporated, or Ligand. We developed Rylaze, a recombinant Erwinia asparaginase product for the treatment of
patients with ALL and LBL who have hypersensitivity to E. coli-derived asparaginase, under our Ligand agreement. We also have clinical
development efforts in a variety of other areas, including those focused on expanding the potential of Defitelio, Epidiolex/Epidyolex,
Vyxeos, Sunosi, Rylaze and Xywav, as well as clinical development efforts focused on suvecaltamide (JZP385) for the treatment of
essential tremor, JZP150 for post-traumatic stress disorder and nabiximols for multiple sclerosis-related spasticity. Because combination
regimens and the continual generation of new data have become particularly important in AML, if we are unable to initiate multiple
combination studies, safely combine Vyxeos with novel agents, or if efficacy results do not meet clinicians’ expectations, our growth
prospects could be materially adversely affected. Epidiolex has been administered only to a limited number of patients and in limited
populations in clinical trials. While FDA and EC granted approval of Epidiolex/Epidyolex based on the data included in GW’s NDA, sNDA
and marketing authorization application, we do not know whether the results will be consistent with those resulting from administration of
the drug to a large number of patients. New data relating to Epidiolex/Epidyolex, including from adverse event reports and post-marketing
studies in the U.S. and Europe, and from other ongoing clinical trials, may result in changes to the product label and/or imposition of a
REMS and may adversely affect sales, or result in withdrawal of Epidiolex/Epidyolex from the market. FDA, EMA and regulatory authorities
in other jurisdictions may also consider the new data in reviewing Epidiolex/Epidyolex marketing applications for indications other than our
approved uses in other jurisdictions, or impose additional post-approval requirements. If any of these actions were to occur, it could result
in significant expense and delay or limit our ability to generate sales of Epidiolex/Epidyolex. If we are not successful in the clinical

JAZZ PHARMACEUTICALS | 2021 Annual Report

45

development of our product candidates, if we are unable to obtain regulatory approval for our product candidates in a timely manner, or at all,
or if sales of an approved product do not reach the levels we expect, our anticipated revenue from our product candidates would be negatively
affected, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.

We may not be able to successfully identify and acquire or in-license additional products or product candidates to grow our
business, and, even if we are able to do so, we may otherwise fail to realize the anticipated benefits of these transactions.

In addition to continued investment in our research and development pipeline, we intend to grow our business by acquiring or
in-licensing, and developing, including with collaboration partners, additional products and product candidates that we believe are highly
differentiated and have significant commercial potential. However, we may be unable to identify or consummate suitable acquisition or
in-licensing opportunities, and this inability could impair our ability to grow our business. Other companies, many of which may have
substantially greater financial, sales and marketing resources, compete with us for these opportunities. Even if appropriate opportunities
are available, we may not be able to successfully identify them, or we may not have the financial resources necessary to pursue them.

Even if we are able to successfully identify and acquire, in-license or develop additional products or product candidates, we may not

be able to successfully manage the risks associated with integrating any products or product candidates into our portfolio or the risks
arising from anticipated and unanticipated problems in connection with an acquisition or in-licensing. Further, while we seek to mitigate
risks and liabilities of potential acquisitions and in-licensing transactions through, among other things, due diligence, there may be risks and
liabilities that such due diligence efforts fail to discover, that are not disclosed to us, or that we inadequately assess. Any failure in
identifying and managing these risks, liabilities and uncertainties effectively, could have a material adverse effect on our business, results
of operations and financial condition. In addition, product and product candidate acquisitions, particularly when the acquisition takes the
form of a merger or other business consolidation such as our acquisition of GW, have required, and any similar future transactions also will
require, significant efforts and expenditures, including with respect to transition and integration activities. We may encounter unexpected
difficulties, or incur substantial costs, in connection with potential acquisitions and similar transactions, which include:

•

•

•

•

•

•

•

•

•

the need to incur substantial debt and/or engage in dilutive issuances of equity securities to pay for acquisitions;

the potential disruption of our historical core business;

the strain on, and need to continue to expand, our existing operational, technical, financial and administrative infrastructure;

the difficulties in integrating acquired products and product candidates into our portfolio;

the difficulties in assimilating employees and corporate cultures;

the failure to retain key managers and other personnel;

the need to write down assets or recognize impairment charges;

the diversion of our management’s attention to integration of operations and corporate and administrative infrastructures; and

any unanticipated liabilities for activities of or related to the acquired business or its operations, products or product candidates.

As a result of these or other factors, products or product candidates we acquire, or obtain licenses to, may not produce the revenues,
earnings or business synergies that we anticipated, acquired or in-licensed product candidates may not result in regulatory approvals, and
acquired or licensed products may not perform as expected. Failure to manage effectively our growth through acquisitions or in-licensing
transactions could adversely affect our growth prospects, business, results of operations and financial condition.

Conducting clinical trials is costly and time-consuming, and the outcomes are uncertain. A failure to prove that our product
candidates are safe and effective in clinical trials, or to generate data in clinical trials to support expansion of the therapeutic
uses for our existing products, could materially and adversely affect our business, financial condition, results of operations and
growth prospects.

As a condition to regulatory approval, each product candidate must undergo extensive and expensive preclinical studies and clinical trials to

demonstrate that the product candidate is safe and effective. The results at any stage of the development process may lack the desired safety,
efficacy or pharmacokinetic characteristics. If FDA determines that the safety or efficacy data included in any marketing application we submit do
not warrant marketing approval for the affected product or product candidate, we may be required to conduct additional preclinical studies or clinical
trials, which could be costly and time-consuming. Even if we believe we have successfully completed testing, FDA or any equivalent non-U.S.
regulatory agency may determine our data is not sufficiently compelling to warrant marketing approval for the indications sought, if at all, and may
require us to engage in additional clinical trials or provide further analysis which may be costly and time-consuming. Any adverse events or other
data generated during the course of clinical trials of our product candidates and/or clinical trials related to additional indications for our
commercialized products could result in action by FDA or an equivalent non-U.S. regulatory agency, which may restrict our ability to sell, or

46

2021 Annual Report

| JAZZ PHARMACEUTICALS

adversely affect sales of, currently marketed products, or such events or other data could otherwise have a material adverse effect on a related
commercial product, including with respect to its safety profile. Any failure or delay in completing such clinical trials could materially and adversely
affect the maintenance and growth of the markets for the related marketed products, which could adversely affect our business, financial condition,
results of operations and overall growth prospects.

In addition to issues relating to the results generated in clinical trials, clinical trials can be delayed or halted for a variety of reasons, including:

•

•

•

•

•

•

•

•

•

•

•

•

direct and indirect impacts of the evolving effects of the COVID-19 pandemic on various aspects and stages of the clinical
development process, including the inherent limitations of remote and virtual approaches, and interruption of key clinical trial
activities, such as clinical trial site monitoring, due to limitations on travel, quarantines or social distancing protocols imposed or
recommended by federal or state governments, employers and others;

difficulty identifying, recruiting or enrolling eligible patients, often based on the number of clinical trials, particularly with
enrollment criteria targeting the same patient population, and in rare diseases with small patient populations;

difficulty identifying a clinical development pathway, including viable indications and appropriate clinical trial protocol design,
particularly where there is no applicable regulatory precedent;

delays or failures in obtaining regulatory authorization to commence a trial because of safety concerns of regulators relating to
our product candidates or similar product candidates of our competitors or failure to follow regulatory guidelines;

delays or failures in obtaining clinical materials and manufacturing sufficient quantities of the product candidate for use in trials;

delays or failures in reaching agreement on acceptable terms with prospective study sites;

delays or failures in obtaining approval of our clinical trial protocol from an institutional review board, known as an ethics
committee in Europe, to conduct a clinical trial at a prospective study site;

failure of our clinical trials and clinical investigators, including contract research organizations or other third parties assisting us
with clinical trials, to satisfactorily perform their contractual duties, meet expected deadlines and comply with FDA and other
regulatory agencies’ requirements, including good clinical practices;

K
-
0
1
m
r
o
F

unforeseen safety issues;

inability to monitor patients adequately during or after treatment;

difficulty monitoring multiple study sites; or

insufficient funds to complete the trials.

In some jurisdictions such as the EU, initiating phase 3 clinical trials and clinical trials in the pediatric population is subject to a
requirement to obtain approval or a waiver from the competent authorities of the EU Member States and/or the EMA. If we do not obtain
such approval our ability to conduct clinical trials and obtain marketing authorizations or approvals may be severely impaired and our
business may be adversely impacted.

Our ability to recruit and retain patients and principal investigators and site staff who, as health care providers, may have heightened

exposure to COVID-19, may adversely impact our clinical trial operations. In light of the evolving effects of the COVID-19 pandemic, we
have taken measures to implement remote and virtual approaches, including remote data monitoring where possible, to maintain patient
safety and trial continuity and to preserve study integrity. We have seen limited COVID-19-related impact to our mid- and late-stage clinical
trial activity, despite delays in initiating trial sites. However, GW had begun to recruit patients for an early-stage clinical trial of Epidiolex in
the treatment of Rett syndrome and GW terminated this trial in November 2020 due to severe feasibility challenges arising from COVID-19.
We could also see an impact on the ability to supply study drug, report trial results, or interact with regulators, ethics committees or other
important agencies due to limitations in regulatory authority employee resources or otherwise. In addition, we rely on contract research
organizations or other third parties to assist us with clinical trials, and we cannot guarantee that they will continue to perform their
contractual duties in a timely and satisfactory manner as a result of the evolving effects of the COVID-19 pandemic. If these effects
become more severe, we could experience significant disruptions to our clinical development timelines, which would adversely affect our
business, financial condition, results of operations and growth prospects. In addition, some patients may not be able to comply with clinical
trial protocols if quarantines impede patient movement or interrupt healthcare services.

Risks Related to the GW Acquisition

We may not realize the anticipated benefits from the acquisition of GW.

On May 5, 2021, we completed the acquisition of GW. The success of the acquisition will depend, in part, on our ability to realize the

anticipated benefits from successfully combining our and GW’s historical businesses and the integration of our business practices and

JAZZ PHARMACEUTICALS | 2021 Annual Report

47

operations with GW’s so that we can fully realize the anticipated benefits of the acquisition. Epidiolex and the other products and
technologies acquired may not be successful or continue to grow at the same rate as if our companies operated independently or they may
require significantly greater resources and investments than originally anticipated. Conversely, the liabilities assumed in the transaction
could be greater than originally anticipated. In addition, difficulties may arise during the process of combining the operations of our
companies that could result in the failure to achieve the synergies or free cash flow that we anticipate, the failure to integrate operations
and internal systems, programs and controls, the loss of key employees that may be difficult to replace in the very competitive
pharmaceutical field, the failure to harmonize both companies’ corporate cultures, and the disruption of each company’s ongoing
businesses or inconsistencies in standards, controls, procedures and policies that adversely affect our ability to maintain relationships with
customers, suppliers, distributors, collaboration partners, clinical trial investigators or managers of our clinical trials. As a result, the
anticipated benefits of the acquisition may not be realized fully within the expected timeframe or at all or may take longer to realize or cost
more than expected, which could materially and adversely affect our business, financial condition, results of operations and growth
prospects.

Risks Related to Our Intellectual Property

It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection.

Our commercial success depends in part on obtaining, maintaining and defending intellectual property protection for our products and
product candidates, including protection of their use and methods of manufacturing and distribution. Our ability to protect our products and
product candidates from unauthorized making, using, selling, offering to sell or importation by third parties depends on the extent to which
we have rights under valid and enforceable patents or have adequately protected trade secrets that cover these activities.

The degree of protection to be afforded by our proprietary rights is uncertain because legal means afford only limited protection and

may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:

•

•

•

•

•

•

•

our patent applications, or those of our licensors or partners, may not result in issued patents;

others may independently develop similar or therapeutically equivalent products without infringing our patents, or those of our
licensors, such as products that are not covered by the claims of our patents, or for which we do not have adequate exclusive
rights under our license agreements;

our issued patents, or those of our licensors or partners, may be held invalid or unenforceable as a result of legal challenges by
third parties or may be vulnerable to legal challenges as a result of changes in applicable law;

our patents covering certain aspects of our products could be delisted from FDA’s publication “Approved Drug Products with
Therapeutic Equivalence Evaluations,” or Orange Book, as a result of challenges by third parties before FDA or the courts;

we or our licensors or partners might not have been the first to invent or file, as appropriate, subject matters covered by our
issued patents or pending patent applications or those of our licensors or partners;

competitors may manufacture products in countries where we have not applied for patent protection or that have a different
scope of patent protection or that do not respect our patents; or

others may be issued patents that prevent the sale of our products or require licensing and the payment of significant fees or
royalties.

Patent enforcement generally must be sought on a country-by-country basis, and issues of patent validity and infringement may be

judged differently in different countries. Many companies have encountered significant problems in protecting, defending and enforcing
intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not
favor the enforcement of patents and other intellectual property rights, particularly those relating to pharmaceuticals, which could make it
difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally.
Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from
other aspects of our business.

Changes in either the patent laws or in interpretations of patent laws in the U.S. and other countries may diminish the value of our

intellectual property portfolio. Even if we are able to obtain patents covering our products and product candidates, any patent may be
challenged, and potentially invalidated or held unenforceable, including through patent litigation or through patent office procedures that
permit challenges to patent validity. Patents can also be circumvented, potentially including by FDA approval of an ANDA or
Section 505(b)(2) application that avoids infringement of our intellectual property.

In June 2021, we received notice from Lupin that it has filed with FDA an ANDA for a generic version of Xywav. The notice from Lupin
included a “paragraph IV certification” with respect to ten of our patents listed in FDA’s Orange Book for Xywav on the date of our receipt of

48

2021 Annual Report

| JAZZ PHARMACEUTICALS

the notice. A paragraph IV certification is a certification by a generic applicant that patents covering the branded product are invalid,
unenforceable, and/or will not be infringed by the manufacture, use or sale of the generic product.

On July 28, 2021, we filed a patent infringement suit against Lupin in the United States District Court for the District of New Jersey.

The complaint alleges that by filing its ANDA, Lupin has infringed ten of our Orange Book listed patents. We are seeking a permanent
injunction to prevent Lupin from introducing a generic version of Xywav that would infringe our patents. As a result of this lawsuit, we
expect that a stay of approval of up to 30 months will be imposed by FDA on Lupin’s ANDA. In June 2021, FDA recognized seven years of
Orphan Drug Exclusivity for Xywav through July 21, 2027. On October 4, 2021, Lupin filed an answer to the complaint and counterclaims
asserting that the patents are invalid or not enforceable, and that its product, if approved, will not infringe our patents.

We have settled patent litigation with nine companies seeking to introduce generic versions of Xyrem in the U.S. by granting those

companies licenses to launch their generic products (and in certain cases, an authorized generic version of Xyrem) in advance of the
expiration of the last of our patents. Notwithstanding our Xyrem patents and settlement agreements, additional third parties may also
attempt to introduce generic versions of Xyrem, Xywav or other sodium oxybate products for treatment of cataplexy and/or EDS in
narcolepsy that design around our patents or assert that our patents are invalid or otherwise unenforceable. Such third parties could launch
a generic or 505(b)(2) product referencing Xyrem before the dates provided in our patents or settlement agreements. For example, we
have several method of use patents listed in the Orange Book, that expire in 2033 that cover treatment methods included in the Xyrem
label related to a drug-drug interaction, or DDI, with divalproex sodium. Although FDA has stated, in granting a Citizen Petition we
submitted in 2016, that it would not approve any sodium oxybate ANDA referencing Xyrem that does not include the portions of the
currently approved Xyrem label related to the DDI patents, we cannot predict whether a future ANDA filer, or a company that files a
Section 505(b)(2) application for a drug referencing Xyrem, may pursue regulatory strategies to avoid infringing our DDI patents
notwithstanding FDA’s response to the Citizen Petition, or whether any such strategy would be successful. Likewise, we cannot predict
whether we will be able to maintain the validity of these patents or will otherwise obtain a judicial determination that a generic or other
sodium oxybate product, its package insert or the generic sodium oxybate REMS or another separate REMS will infringe any of our patents
or, if we prevail in proving infringement, whether a court will grant an injunction that prevents a future ANDA filer or other company
introducing a different sodium oxybate product from marketing its product, or instead require that party to pay damages in the form of lost
profits or a reasonable royalty.

K
-
0
1
m
r
o
F

Since Xyrem’s regulatory exclusivity has expired in the EU, we are aware that generic or hybrid generic applications have been approved by

various EU regulatory authorities, and additional generic or hybrid generic applications may be submitted and approved. We cannot predict
whether our licensee in the EU will be able to enforce our existing European patents against generic or hybrid generic filers in the EU.

We also currently rely on trade secret protection for several of our products, including Defitelio, and product candidates, including

nabiximols. Trade secret protection does not protect information or inventions if another party develops that information or invention
independently, and establishing that a competitor developed a product through trade secret misappropriation rather than through legitimate
means may be difficult to prove. We seek to protect our trade secrets and other unpatented proprietary information in part through
confidentiality and invention agreements with our employees, consultants, advisors and partners. Nevertheless, our employees,
consultants, advisors and partners may unintentionally or willfully disclose our proprietary information to competitors, and we may not have
adequate remedies for such disclosures. Moreover, if a dispute arises with our employees, consultants, advisors or partners over the
ownership of rights to inventions, including jointly developed intellectual property, we could lose patent protection or the confidentiality of
our proprietary information, and possibly also lose the ability to pursue the development of certain new products or product candidates.

We have incurred and may in the future incur substantial costs as a result of litigation or other proceedings relating to patents, other
intellectual property rights and related matters, and we may be unable to protect our rights to, or commercialize, our products.

Our ability, and that of our partners, to commercialize any approved products will depend, in part, on our ability to obtain patents,

enforce those patents and operate without infringing the proprietary rights of third parties. If we choose to go to court to stop a third party
from infringing our patents, our licensed patents or our partners’ patents, that third party has the right to ask the court or an administrative
agency to rule that these patents are invalid and/or should not be enforced. These lawsuits and administrative proceedings are expensive
and consume time and other resources, and we may not be successful in these proceedings or in stopping infringement. In addition, the
inter partes review process, or IPR, under the Leahy-Smith America Invents Act permits any person, whether they are accused of infringing
the patent at issue or not, to challenge the validity of certain patents through a proceeding before the Patent Trial and Appeal Board, or
PTAB, of the U.S. Patent and Trademark Office.

There is a risk that a court could decide that our patents or certain claims in our patents are not valid or infringed, and that we do not

have the right to stop a third party from using the inventions covered by those claims. In addition, the PTAB may invalidate a patent, as
happened with six of our patents covering the Xywav and Xyrem REMS, which were invalidated through the IPR process and delisted from

JAZZ PHARMACEUTICALS | 2021 Annual Report

49

the Orange Book. In addition, even if we prevail in establishing that another product infringes a valid claim of one of our patents, a court
may determine that we can be compensated for the infringement in damages, and refuse to issue an injunction. As a result, we may not be
entitled to stop another party from infringing our patents for their full term.

Litigation involving patent matters is frequently settled between the parties, rather than continuing to a court ruling, and we have
settled patent litigation with all nine Xyrem ANDA filers. The FTC has publicly stated that, in its view, certain types of agreements between
branded and generic pharmaceutical companies related to the settlement of patent litigation or the manufacture, marketing and sale of
generic versions of branded drugs violate the antitrust laws and has commenced investigations and brought actions against some
companies that have entered into such agreements. In particular, the FTC has expressed its intention to take aggressive action to
challenge settlements that include an alleged transfer of value from the brand company to the generic company (so-called “pay for delay”
patent litigation settlements). The U.S. Congress and state legislatures have also identified pharmaceutical patent litigation settlements as
potential impediments to generic competition and have introduced, and in states like California passed, legislation to regulate them. Third
party payors have also challenged such settlements on the grounds that they increase drug prices. Because there is currently no precise
legal standard with respect to the lawfulness of such settlements, many pharmaceutical companies, including us, have faced extensive
litigation over whether patent litigation settlements they have entered into are reasonable and lawful. From June 2020 to October 2021, a
number of lawsuits were filed on behalf of purported direct and indirect Xyrem purchasers, alleging that the patent litigation settlement
agreements we entered with Hikma and other ANDA filers violate state and federal antitrust and consumer protection laws. For additional
information on these lawsuits, see Note 14, Commitments and Contingencies-Legal Proceedings of the Notes to Consolidated Financial
Statements, included in Part IV of this Annual Report on Form 10-K. It is possible that additional lawsuits will be filed against us making
similar or related allegations. We cannot predict the outcome of these or potential additional lawsuits or government actions; however, if the
plaintiffs in the class action complaints were to be successful in their claims, they may be entitled to injunctive relief or we may be required
to pay significant monetary damages, which could have a material adverse effect on our business, financial condition, results of operations
and growth prospects.

Parties to such settlement agreements in the U.S. are required by law to file the agreements with the FTC and the U.S. Department of
Justice, or DOJ, for review. Accordingly, we have submitted our patent litigation settlement agreements to the FTC and the DOJ for review.
We may receive formal or informal requests from the FTC regarding our ANDA litigation settlements, and there is a risk that the FTC may
commence a formal investigation or action against us, which could divert the attention of management and cause us to incur significant
costs, regardless of the outcome. Any claim or finding that we or our business partners have failed to comply with applicable laws and
regulations could be costly to us and could have a material adverse effect on our business, financial condition, results of operations and
growth prospects.

A third party may claim that we or our manufacturing or commercialization partners are using inventions covered by the third party’s
patent rights, or that we or such partners are infringing, misappropriating or otherwise violating other intellectual property rights, and may
go to court to stop us from engaging in our normal operations and activities, including making or selling our products. Such lawsuits are
costly and could affect our results of operations and divert the attention of management and development personnel. There is a risk that a
court could decide that we or our partners are infringing, misappropriating or otherwise violating third party patent or other intellectual
property rights, which could be very costly to us and have a material adverse effect on our business. If we are sued for patent infringement,
we would need to demonstrate that our products or methods do not infringe the patent claims of the relevant patent and/or that the patent
claims are invalid or unenforceable, which we may not be able to do.

In December 2020, Canopy Growth Corporation, or Canopy, filed a complaint against GW alleging infringement of its patent, U.S.
Patent No. 10,870,632. Canopy claims that our extraction process used to produce material used to produce Epidiolex infringes its patent.
Canopy seeks a judgment that we have infringed their patent and an award of monetary damages. On July 28, 2021, we filed an answer to
the amended complaint, and counterclaims seeking judgment that the ‘632 patent is invalid and that we have not infringed the patent. In
October 2021, the court held a claim construction hearing regarding the disputed terms of the ‘632 patent. If we were found to infringe upon
a patent or other intellectual property right, or if we failed to obtain or renew a license under a patent or other intellectual property right from
a third party, or if a third party that we were licensing technologies from was found to infringe upon a patent or other intellectual property
rights of another third party, we may be required to pay damages, including damages of up to three times the damages found or assessed,
if the infringement is found to be willful, suspend the manufacture of certain products or reengineer or rebrand our products, if feasible, or
we may be unable to enter certain new product markets. Litigation, whether filed by us or against us, can be expensive and time
consuming to defend and divert management’s attention and resources. Our competitive position could suffer as a result. In addition, if we
have declined or failed to enter into a valid non-disclosure or assignment agreement for any reason, we may not own the invention or our
intellectual property, and our products may not be adequately protected.

50

2021 Annual Report

| JAZZ PHARMACEUTICALS

K
-
0
1
m
r
o
F

With respect to our products and product candidates targeting rare indications, relevant regulatory exclusivities such as orphan
drug exclusivity or pediatric exclusivity may not be granted or, if granted, may be limited.

The first NDA applicant with an Orphan Drug Designation for a particular active moiety to treat a specific disease or condition that
receives FDA approval is usually entitled to a seven-year exclusive marketing period in the U.S. for that drug, for that indication. We rely in
part on this Orphan Drug Exclusivity and other regulatory exclusivities to protect Xywav, Epidiolex, Zepzelca, Sunosi, Defitelio (defibrotide),
Vyxeos and, potentially, our other products and product candidates from competitors, and we expect to continue relying in part on these
regulatory exclusivities in the future. The duration of our regulatory exclusivity period could be impacted by a number of factors, including
FDA’s later determination that our request for orphan designation was materially defective, that the manufacturer is unable to supply
sufficient quantities of the drug, that the extension of the exclusivity period established by the Improving Regulatory Transparency for New
Medical Therapies Act does not apply, or the possibility that we are unable to successfully obtain pediatric exclusivity. There is no
assurance that we will successfully obtain Orphan Drug Designation for other products or product candidates or other rare diseases or that
a product candidate for which we receive Orphan Drug Designation will be approved, or that we will be awarded orphan drug exclusivity
upon approval as, for example, FDA may reconsider whether the eligibility criteria for such exclusivity have been met and/or maintained.
Moreover, a drug product with an active moiety that is different from that in our drug candidate or, under limited circumstances, the same
drug product, may be approved by FDA for the same indication during the period of marketing exclusivity. The limited circumstances
include a showing that the second drug is clinically superior to the drug with marketing exclusivity through a demonstration of superior
safety or efficacy or that it makes a major contribution to patient care. In addition, if a competitor obtains approval and marketing exclusivity
for a drug product with an active moiety that is the same as that in a product candidate we are pursuing for the same indication before us,
approval of our product candidate would be blocked during the period of marketing exclusivity unless we could demonstrate that our
product candidate is clinically superior to the approved product. In addition, if a competitor obtains approval and marketing exclusivity for a
drug product with an active moiety that is the same as that in a product candidate we are pursuing for a different orphan indication, this
may negatively impact the market opportunity for our product candidate. There have been legal challenges to aspects of FDA’s regulations
and policies concerning the exclusivity provisions of the Orphan Drug Act, including whether two drugs are the same drug product, and
future challenges could lead to changes that affect the protections potentially afforded our products in ways that are difficult to predict. In a
successful legal challenge, a court invalidated FDA’s denial of orphan exclusivity to a drug on the grounds that the drug was not proven to
be clinically superior to a previously approved product containing the same ingredient for the same orphan use. In response to the decision,
FDA released a policy statement stating that the court’s decision is limited just to the facts of that particular case and that FDA will continue
to require the sponsor of a designated drug that is the “same” as a previously approved drug to demonstrate that its drug is clinically
superior to that drug upon approval in order to be eligible for orphan drug exclusivity, or in some cases, to even be eligible for marketing
approval. In the future, there is the potential for additional legal challenges to FDA’s orphan drug regulations and policies, and it is
uncertain how such challenges might affect our business.

In the European Union, if a marketing authorization is granted for a medicinal product that is designated an orphan drug, that product

is entitled to ten years of marketing exclusivity. We rely in part on this orphan drug exclusivity and other regulatory exclusivities to protect
Epidyolex, Vyxeos, Defitelio, and Sunosi. During the period of marketing exclusivity, subject to limited exceptions, no similar medicinal
product may be granted a marketing authorization for the orphan indication. There is no assurance that we will successfully obtain Orphan
Drug Designation for future rare indications or orphan exclusivity upon approval of any of our product candidates that have already
obtained designation. Even if we obtain orphan exclusivity for any product candidate, the exclusivity period can be reduced to six years if at
the end of the fifth year it is established that the orphan designation criteria are no longer met or if it is demonstrated that the orphan drug is
sufficiently profitable that market exclusivity is no longer justified. Further, a similar medicinal product may be granted a marketing
authorization for the same indication notwithstanding our marketing exclusivity if we are unable to supply sufficient quantities of our
product, or if the second product is safer, more effective or otherwise clinically superior to our orphan drug. In addition, if a competitor
obtains marketing authorization and orphan exclusivity for a product that is similar to a product candidate we are pursuing for the same
indication, approval of our product candidate would be blocked during the period of orphan marketing exclusivity unless we could
demonstrate that our product candidate is safer, more effective or otherwise clinically superior to the approved product.

Other Risks Related to Our Business and Industry

Changes in the market for directors and officers liability insurance could make it more difficult and more expensive for us to
obtain directors and officers liability insurance.

In recent years, the market for directors and officers liability insurance for biopharmaceuticals and life sciences companies has

changed in ways adverse to us. The premiums charged for such policies have generally increased and the terms of such policies have
generally become less favorable. As a result, it is currently expensive and may become significantly more expensive for us to maintain
directors and officers liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher
costs to obtain the same or similar coverage. In any event, there can be no assurance that directors and officers liability insurance will be

JAZZ PHARMACEUTICALS | 2021 Annual Report

51

adequate to cover our potential liabilities or will be generally available to us in the future or, if available, that the cost of such insurance will
be commercially justifiable. The increased cost and decreased availability of directors and officers liability insurance could make it more
difficult for us to attract and retain qualified persons to serve on our board of directors or as executive officers, and could also make it more
difficult and more expensive for us to negotiate and consummate future corporate development transactions, all of which could have a
material adverse effect on our business, financial condition, results of operations and growth prospects.

Our business is currently adversely affected and could be materially and adversely affected in the future by the evolving effects
of the COVID-19 pandemic and related global economic slowdown, including with respect to our commercialization efforts,
clinical trial activity, research and development activities, supply chain and corporate development activities and other business
operations.

The COVID-19 pandemic continues to have a significant impact on the global healthcare delivery system. Many healthcare systems

have had to restructure operations to prioritize caring for COVID-19 patients and limit or cease other activities. The severe burden on
healthcare systems caused by this pandemic has impaired the ability to diagnose and treat patients with non-COVID-19 related conditions
and impaired the ability of many clinical research sites to start new studies, enroll new patients and monitor patients in clinical trials. Health
care provider offices and institutions have experienced workforce disruption, including the inability to hire staff and challenges maintaining
appropriate staffing. The lack of access to health care providers has caused, and may continue to cause, delays in appropriate diagnosis,
treatment and ongoing care for some patients, which could subsequently impact prescribing and use of our products. The evolving effects
of the COVID-19 pandemic and government measures taken in response have had a significant impact, both direct and indirect, on
businesses and commerce, as significant reductions in business related activities have occurred, supply chains have been disrupted, and
manufacturing and clinical development activities have been curtailed or suspended.

Continued remote work policies, quarantines, shelter-in-place and similar government orders, shutdowns or other restrictions on the

conduct of business operations related to the effects of the COVID-19 pandemic may materially and adversely affect our business, our
ability to generate sales of our approved products, our supply chain, regulatory, clinical development and corporate development activities.
With respect to our commercialization activities, the evolving effects of the COVID-19 pandemic continue to have a negative impact on
demand, new patient starts and treatments for our products, primarily due to the inherent limitations of telemedicine and a reprioritization of
healthcare resources toward COVID-19. Due to the nature of the pandemic, we are not able to accurately predict the duration or extent of
these impacts on demand for our products. Beginning in March 2020, we transitioned our field-based sales, market access, reimbursement
and medical employees out of the field and suspended work-related travel and in-person customer interactions. We utilized technology to
continue to engage healthcare professionals and other customers virtually to support patient care. In late June 2020, as clinics and
institutions began to allow in-person interactions pursuant to local health authority and government guidelines, our field teams resumed
in-person interactions with healthcare professionals and clinics combined with virtual engagement. The level of renewed in-person
engagement varies by account, region and country and may be adversely impacted in the future as a result of the continuing impact of the
COVID-19 pandemic. The absence of in-person interactions has had a negative impact our ability to effectively communicate product
benefits to physicians, limiting their awareness and understanding and use of our products.

For Xywav and Xyrem, COVID-19 protocols and staffing shortages at sleep labs across the U.S. have resulted in reduced access to
sleep testing. Since the end of the first quarter of 2020, we have seen a decline in prescribers’ ability to diagnose new narcolepsy patients
and a related overall decline in new patients starting on therapy. Although patient persistence and compliance with oxybate therapy
remained steady during 2021, we continue to expect that delays in obtaining a narcolepsy diagnosis will have a negative impact on new
Xywav and Xyrem patient enrollments in future quarters. We believe these dynamics have negatively impacted new patient starts in the
U.S. For Sunosi, the impact on demand has been primarily related to the reduced ability of our field-based teams to interact with
prescribers and patients’ inability to meet with health care providers during this time. As a result, we have seen slower than expected
growth of Sunosi prescribers and new patient starts in the U.S. We also anticipate that pricing and reimbursement reviews by certain
European regulatory authorities may take longer in certain countries due to the pandemic, which could delay our rolling Sunosi launch and
growth prospects for Vyxeos and Epidyolex in those EU member states. In addition, due to the ongoing impacts of the COVID-19
pandemic, we continue to expect a negative impact on demand for and utilization of Defitelio and Vyxeos.

We have also seen an upward trend in demand for patient assistance programs since the end of the first quarter of 2020. In this

regard, total revenue bottle volume on a combined basis for Xywav and Xyrem decreased by 1% in the year ended December 31, 2021,
compared to the same period in 2020 reflecting our continued investment in patient access programs during the launch of Xywav.
Depending on the ultimate duration and severity of the COVID-19 pandemic and the extent of a global economic slowdown, widespread
unemployment and resulting loss of employer-sponsored insurance coverage or other market dynamics, we may experience an increasing
shift from commercial payor coverage to government payor coverage or increasing demand for patient assistance and/or free drug
programs, which could continue to adversely affect net product sales.

52

2021 Annual Report

| JAZZ PHARMACEUTICALS

K
-
0
1
m
r
o
F

In addition, the COVID-19 pandemic continues to rapidly evolve and has resulted in significant volatility in the global financial markets.

If this volatility persists and deepens, we could experience an inability to access additional capital or our liquidity could otherwise be
impacted, which could in the future negatively affect our capacity for certain corporate development transactions or our ability to make
other important, opportunistic investments. In addition, the current recession or additional market corrections resulting from the impact of
the evolving effects of the COVID-19 pandemic could materially affect our business and the value of our ordinary shares. While we expect
these effects to adversely affect our business operations and financial results, the extent of the impact on our ability to generate sales of
our approved products, execute on new product launches, our clinical development and regulatory efforts, our corporate development
objectives and the value of and market for our ordinary shares, will depend on future developments that are highly uncertain and cannot be
predicted with confidence at this time. Such developments include continued spread of the Delta and Omicron variants in the U.S. and
other countries and the potential emergence of other SARS-CoV-2 variants that may prove especially contagious or virulent, the ultimate
duration and severity of the pandemic, governmental “stay-at-home” orders and travel restrictions, quarantines, social distancing and
business closure requirements in the U.S., Ireland and other countries, and the effectiveness of vaccination programs and other actions
taken globally to contain and treat the disease. For example, the inability of our workforce to return to office and field-based work and the
ongoing stress and reprioritization within the healthcare systems in our key markets may require us to reassess the timing and scope of
key business activities for 2022, including with respect to our ability to continue the launch momentum for Epidiolex, Sunosi, Xywav,
Zepzelca and Rylaze. These effects could materially and adversely affect our business, financial condition, results of operations and
growth prospects, as further described in the risks and uncertainties described elsewhere in this ‘‘Risk Factors’’ section.

We have substantially expanded our international footprint and operations, and we may expand further in the future, which
subjects us to a variety of risks and complexities which, if not effectively managed, could negatively affect our business.

We are headquartered in Dublin, Ireland and have offices in multiple locations, including the U.S., the U.K., Italy and Canada. We

may further expand our international operations into other countries in the future, either organically or by acquisition. Conducting our
business in multiple countries subjects us to a variety of risks and complexities that may materially and adversely affect our business,
results of operations, financial condition and growth prospects, including:

•

•

•

•

•

the diverse regulatory, financial and legal requirements in the countries where we are located or do business, and any changes
to those requirements;

the impact of Brexit on trade relations between the EU and the U.K.;

challenges inherent in efficiently managing employees in diverse geographies, including the need to adapt systems, policies,
benefits and compliance programs to differing labor and employment law and other regulations, as well as maintaining positive
interactions with our unionized employees;

costs of, and liabilities for, our international operations, products or product candidates; and

public health risks, such as the COVID-19 pandemic and potential related effects on supply chain, travel and employee health
and availability.

In addition, there can be no guarantee that we will effectively manage the increasing, global complexity of our business without

experiencing operating inefficiencies or control deficiencies. Our failure to do so could have a material adverse effect on our business,
financial condition, results of operations and growth prospects.

The U.K.’s withdrawal from the EU, commonly referred to as Brexit, could increase our cost of doing business, reduce our gross
margins or otherwise negatively impact our business and our financial results.

Brexit continues to create uncertainty concerning the future relationship between the U.K. and the EU, following the U.K. withdrawal

from the EU in January 2020. We have a commercial manufacturing facility in the U.K. at Kent Science Park, and multiple offices in
England. Since a significant portion of the regulatory framework in the U.K. is derived from EU laws, Brexit materially impacts the regulatory
regime with respect to the development, manufacture, importation, approval and commercialization of our product candidates in the U.K. or
the EU. In this regard, in December 2020, the EU and U.K. reached an agreement in principle on the framework for their future relationship,
the EU-U.K. Trade and Cooperation Agreement, or TCA. Among the changes that have had a direct impact are that Great Britain (England,
Scotland and Wales) will be treated as a “third country,” a country that is not a member of the EU and whose citizens do not enjoy the EU
right to free movement. Northern Ireland continues to follow many aspects of the EU regulatory rules, particularly in relation to trade in
goods. As part of the TCA, the EU and the U.K. will recognize GMP inspections carried out by the other party and the acceptance of official
GMP documents issued by the other party. The TCA also encourages, although it does not oblige, the parties to consult one another on
proposals to introduce significant changes to technical regulations or inspection procedures. Among the areas of absence of mutual
recognition are batch testing and batch release. The U.K. has unilaterally agreed to accept EU batch testing and batch release for a period

JAZZ PHARMACEUTICALS | 2021 Annual Report

53

of at least 2 years until January 1, 2023. However, the EU continues to apply EU laws that require batch testing and batch release to take
place in the EU territory. This means that medicinal products that are tested and released in the U.K. must be retested and re-released
when entering the EU market for commercial use. As it relates to marketing authorizations, Great Britain has introduced a separate
regulatory submission process, approval process and a separate national marketing authorization. Northern Ireland, however, continues to
be covered by the marketing authorizations granted by the EC. Therefore, our medicine candidates require a separate marketing
authorization for Great Britain, which involves additional administrative burden. Any delay in obtaining, or an inability to obtain, any
marketing approvals, as a result of Brexit or otherwise, could prevent us from or delay us commercializing our medicine candidates in the
U.K. and/or the European Economic Area, or EEA, and restrict our ability to generate revenue and achieve and sustain profitability. If any
of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the U.K. and/or EEA for our medicine
candidates, which could significantly and materially harm our business. In addition, the EU’s regulatory environment for clinical trials has
been harmonized as part of the Clinical Trials Regulation from January 31, 2022, but it is currently unclear as to what extent the U.K. will
seek to align its regulations with the EU. Failure of the U.K. to closely align its regulations with the EU may have an effect on the cost of
conducting clinical trials in the U.K. as opposed to other countries and/or make it harder to seek a marketing authorization for our medicine
candidates in the EEA on the basis of clinical trials conducted in the U.K. In the short term there is a risk of disrupted import and export
processes due to a lack of administrative processing capacity by the respective U.K. and EU customs agencies that may delay time-
sensitive shipments and may negatively impact our product supply chain. All of these changes could increase our costs and otherwise
adversely affect our business.

Significant disruptions of information technology systems or data security breaches could adversely affect our business.

In the ordinary course of our business, we collect, store, process and transmit large amounts of confidential information, including
intellectual property, proprietary business information and personal data. We have also outsourced some of our operations (including parts
of our information technology infrastructure) to a number of third party vendors who may have, or could gain, access to our confidential
information. In addition, many of those third parties, in turn, subcontract or outsource some of their responsibilities to third parties.

Our information technology systems, and those of our vendors, are large and complex and store large amounts of confidential information.

The size and complexity of these systems make them potentially vulnerable to service interruptions or to security breaches from inadvertent or
intentional actions by our employees, third party vendors and/or business partners, or from cyber-attacks by malicious third parties. Attacks of this
nature are increasing in frequency, persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and
individuals with a wide range of motives (including, but not limited to, industrial espionage) and expertise, including organized criminal groups,
“hacktivists,” nation states and others. In addition to the extraction of important information, such attacks could include the deployment of harmful
malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality,
integrity and availability of our information. Although the aggregate impact on our operations and financial condition has not been material to date,
we and our vendors have been the target of events of this nature and expect them to continue.

Significant disruptions of our, our third party vendors’ and/or business partners’ information technology systems or security breaches,

including in our remote work environment as a result of the COVID-19 pandemic, could adversely affect our business operations and/or
result in the loss, misappropriation, and/or unauthorized access, use or disclosure of, or the prevention of access to, confidential
information (including trade secrets or other intellectual property, proprietary business information and personal data), and could result in
financial, legal, business and reputational harm to us. Any such event that leads to unauthorized access, use or disclosure of personal
data, including personal data regarding our patients or employees, could harm our reputation, compel us to comply with federal and/or
state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, require us to verify the correctness of
database contents and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal data.
This could disrupt our business, result in increased costs or loss of revenue, and/or result in significant legal and financial exposure. In
addition, security breaches and other inappropriate access can be difficult to detect, and any delay in identifying them may further harm us.
Moreover, the prevalent use of mobile devices to access confidential information increases the risk of security breaches. While we have
implemented security measures to protect our information technology systems and infrastructure, there can be no assurance that such
measures will prevent service interruptions or security breaches that could adversely affect our business. In addition, failure to maintain
effective internal accounting controls related to security breaches and cybersecurity in general could impact our ability to produce timely
and accurate financial statements and subject us to regulatory scrutiny.

We are subject to significant ongoing regulatory obligations and oversight, which may result in significant additional expense
and limit our ability to commercialize our products.

FDA and Equivalent Non-U.S. Regulatory Authorities

Our activities are subject to extensive regulation encompassing the entire life cycle of our products, from research and development

activities to marketing approval (including specific post-marketing obligations), manufacturing, labeling, packaging, adverse event and

54

2021 Annual Report

| JAZZ PHARMACEUTICALS

safety reporting, storage, advertising, promotion, sale, pricing and reimbursement, recordkeeping, distribution, importing and exporting. The
failure by us or any of our third party partners, including our corporate development and collaboration partners, clinical trial sites, suppliers,
distributors and our central pharmacy for Xywav and Xyrem, to comply with applicable requirements could subject us to administrative or
judicial sanctions or other negative consequences, such as delays in approval or refusal to approve a product candidate, restrictions on our
products, our suppliers, our other partners or us, the withdrawal, suspension or variation of product approval or manufacturing
authorizations, untitled letters, warning letters, fines and other monetary penalties, unanticipated expenditures, product recall, withdrawal or
seizure, total or partial suspension of production or distribution, interruption of manufacturing or clinical trials, operating restrictions,
injunctions, suspension of licenses, civil penalties and/or criminal prosecution, any of which could result in a significant drop in our
revenues from the affected products and harm to our reputation and could have a significant impact on our sales, business and financial
condition.

We monitor adverse events resulting from the use of our products, as do the regulatory authorities, and we file periodic reports with
the authorities concerning adverse events. The authorities review these events and reports, and if they determine that any events and/or
reports indicate a trend or signal, they can require a change in a product label, restrict sales and marketing and/or require conduct or other
actions, potentially including variation, withdrawal or suspension of the marketing authorization, any of which could result in reduced market
acceptance and demand for our products, could harm our reputation and our ability to market our products in the future, and could have a
material adverse effect on our business, financial condition, results of operations and growth prospects. FDA, the competent authorities of
the EU member states on behalf of the EMA, and the competent authorities of other European countries, also periodically inspect our
records related to safety reporting. The EMA’s Pharmacovigilance Risk Assessment Committee may propose to the Committee for
Medicinal Products for Human Use that the marketing authorization holder be required to take specific steps or advise that the existing
marketing authorization be varied, suspended or revoked. Failure to adequately and promptly correct the observation(s) can result in
further regulatory enforcement action, which could include the variation, suspension or withdrawal of marketing authorization or imposition
of financial penalties or other enforcement measures.

K
-
0
1
m
r
o
F

Defibrotide, Vyxeos, Epidyolex and Sativex are available on a named patient basis or through a compassionate use process in many

countries where they are not commercially available. If any such country’s regulatory authorities determine that we are promoting such
products without proper authorization, we could be found to be in violation of pharmaceutical advertising laws or the regulations permitting
sales under named patient programs. In that case, we may be subject to financial or other penalties. Any failure to maintain revenues from
sales of products on a named patient basis and/or to generate revenues from commercial sales of these products exceeding historical
sales on a named patient basis could have an adverse effect on our business, financial condition, results of operations and growth
prospects.

FDA, the competent authorities of the EU member states and other European countries, and other governmental authorities require

advertising and promotional materials to be truthful and not misleading, and products to be marketed only for their approved indications
and in accordance with the provisions of the approved label. Regulatory authorities actively investigate allegations of off-label promotion in
order to enforce regulations prohibiting these types of activities. A determination that we have promoted an approved product for off-label
uses could subject us to significant liability, including civil and administrative financial penalties and other remedies as well as criminal
financial penalties, other sanctions and imprisonment. Even if we are not determined to have engaged in off-label promotion, an allegation
that we have engaged in such activities could have a significant impact on our sales, business and financial condition. The U.S.
government has also required companies to enter into complex corporate integrity agreements and/or non-prosecution agreements that
impose significant reporting and other burdens on the affected companies. Failure to maintain a comprehensive and effective compliance
program, and to integrate the operations of acquired businesses into a combined comprehensive and effective compliance program on a
timely basis, could subject us to a range of regulatory actions and/or civil or criminal penalties that could affect our ability to commercialize
our products and could harm or prevent sales of the affected products, or could substantially increase the costs and expenses of
commercializing and marketing our products.

Other Regulatory Authorities

We are also subject to regulation by other regional, national, state and local agencies, including the DEA, the DOJ, the FTC, the
United States Department of Commerce, the Office of Inspector General of the U.S. Department of Health and Human Services, or OIG,
and other regulatory bodies, as well as similar governmental authorities in those non-U.S. countries in which we commercialize our
products.

We are subject to numerous fraud and abuse laws and regulations globally and our sales, marketing, patient support and medical
activities may be subject to scrutiny under these laws and regulations. These laws are described in “Business—Government Regulation” in
Part I, Item 1 of this Annual Report on Form 10-K. While we maintain a comprehensive compliance program to try to ensure that our

JAZZ PHARMACEUTICALS | 2021 Annual Report

55

practices and the activities of our third-party contractors and employees fall within the scope of available statutory exceptions and
regulatory safe harbors whenever possible, and otherwise comply with applicable laws, regulations or guidance, regulators and
enforcement agencies may disagree with our assessment or find fault with the conduct of our employees or contractors. In addition,
existing regulations are subject to regulatory revision or changes in interpretation by the DOJ or OIG. For example, in November 2020, the
U.S. Department of Health and Human Services finalized a previously abandoned proposal to amend the discount safe harbor regulation of
the federal anti-kickback statute in a purported effort to create incentives to manufacturers to lower their list prices, and to lower federal
program beneficiary out-of-pocket costs. The rule, which is currently slated to take full effect January 1, 2023, revises the discount safe
harbor to exclude manufacturer rebates to Medicare Part D plans, either directly or through PBMs, creates a new safe harbor for
point-of-sale price reductions that are set in advance and are available to the beneficiary at the point-of-sale, and creates a new safe
harbor for service fees paid by manufacturers to PBMs for services rendered to the manufacturer. The effective date of the rule was
already delayed by the Biden Administration and legal challenges. It is unclear whether the rule will be further delayed, rewritten, or allowed
to go into effect, and if so, what the effect of the rule will be on negotiations of coverage for our products with Medicare Part D plans, or
whether the rule will affect our coverage arrangements with commercial insurers. It is also unclear whether the rule will have the intended
effect of reducing net prices and beneficiary out-of-pocket costs without also increasing Medicare Part D premiums, which may impact the
willingness of Part D plans to cover our products and the price concessions or other terms the plans or their PBMs may seek from us. In
addition, in November 2020, the OIG issued a Special Fraud Alert to highlight certain inherent fraud and abuse risks associated with
speaker fees, honorariums and expenses paid by pharmaceutical and medical device companies to healthcare professionals participating
in company-sponsored events. The Special Fraud Alert sent a clear signal that speaker programs will be subject to potentially heightened
enforcement scrutiny.

Many companies have faced government investigations or lawsuits by whistleblowers who bring a qui tam action under the False
Claims Act on behalf of themselves and the government for a variety of alleged improper marketing activities, including providing free
product to customers expecting that the customers would bill federal programs for the product, providing consulting fees, grants, free travel
and other benefits to physicians to induce them to prescribe the company’s products, and inflating prices reported to private price
publication services, which are used to set drug reimbursement rates under government healthcare programs. In addition, the government
and private whistleblowers have pursued False Claims Act cases against pharmaceutical companies for causing false claims to be
submitted as a result of the marketing of their products for unapproved uses or violations of the federal anti-kickback statute. If we become
the subject of a government False Claims Act or other investigation or whistleblower suit, we could incur substantial legal costs (including
settlement costs) and business disruption responding to such investigation or suit, regardless of the outcome.

Public reporting under the Physician Payment Sunshine Act, or Sunshine provisions, and other similar state laws, the requirements of
which are discussed in “Business—Government Regulation” in Part I, Item 1 of this Annual Report on Form 10-K, has resulted in increased
scrutiny of the financial relationships between industry, teaching hospitals, physicians and other health care providers. Such scrutiny may
negatively impact our ability to engage with physicians and other health care providers on matters of importance to us. In addition,
government agencies and private entities may inquire about our marketing practices or pursue other enforcement activities based on the
disclosures in those public reports. If the data reflected in our reports are found to be in violation of any of the Sunshine provisions or any
other U.S. federal, state or local laws or regulations that may apply, or if we otherwise fail to comply with the Sunshine provisions or similar
requirements of state or local regulators, we may be subject to significant civil, and administrative penalties, damages or fines.

We have various programs to help patients access our products, including patient assistance programs, which include co-pay
coupons for certain of our products, assistance to help patients determine their insurance coverage for our products, and a free product
program. Co-pay coupon programs for commercially insured patients, including our program for Xyrem, have received negative publicity
related to allegations regarding their use to promote branded pharmaceutical products over other less costly alternatives, and some states
have imposed restrictions on manufacturer co-pay programs when therapeutic equivalents are available. In September 2014, the OIG
issued a Special Advisory Bulletin warning manufacturers that they may be subject to sanctions under the federal Anti-Kickback Statute
and other laws if they do not take appropriate steps to exclude Medicare Part D beneficiaries from using co-pay coupons. It is possible that
changes in insurer policies regarding co-pay coupons and/or the introduction and enactment of new legislation or regulatory action could
restrict or otherwise negatively affect these patient support programs, which could result in fewer patients using affected products, including
Xyrem, and therefore could have a material adverse effect on our sales, business and financial condition.

We have established programs to consider grant applications submitted by independent charitable organizations, including

organizations that provide co-pay support to patients who suffer from the diseases treated by our drugs. The OIG has issued guidance for
how pharmaceutical manufacturers can lawfully make donations to charitable organizations who provide co-pay assistance to Medicare
patients, provided that such organizations, among other things, are bona fide charities, are entirely independent of and not controlled by
the manufacturer, provide aid to applicants on a first-come basis according to consistent financial criteria, and do not link aid to use of a
donor’s product. In April 2019, we finalized our civil settlement agreement with the DOJ and OIG and entered into a corporate integrity

56

2021 Annual Report

| JAZZ PHARMACEUTICALS

agreement requiring us to maintain our ongoing corporate compliance program and obligating us to implement or continue, as applicable, a
set of defined corporate integrity activities for a period of five years from the effective date of the corporate integrity agreement. These
obligations are being extended to the GW legacy organization as part of ongoing integration efforts, and we are working with OIG in that
regard. Although we have structured our programs to follow available guidance and the requirements of our corporate integrity agreement,
including with regard to our ongoing integration of GW, if we or our vendors or donation recipients are deemed to fail to comply with
relevant laws, regulations or evolving government guidance in the operation of these programs, such facts could be used as the basis for
an enforcement action against us by the federal government or other enforcement agencies or private litigants, or we could become liable
for payment of certain stipulated penalties or could be excluded from participation in federal health care programs, which would have a
material adverse effect on our sales, business and financial condition.

We may also become subject to similar investigations by other state or federal governmental agencies or offices of our patient
assistance programs or other business practices, which could result in damages, fines, penalties, exclusion from participation in federal
health care programs or other criminal, civil or administrative sanctions or enforcement actions, as well as negative publicity, reduction in
demand for, or patient access to, our products and/or reduced coverage of our products, including by federal and state health care
programs. If any or all of these events occur, our business, financial condition, results of operations and stock price could be materially and
adversely affected.

Our business activities outside of the U.S. are subject to the U.S. Foreign Corrupt Practices Act, or FCPA, and similar anti-bribery or
anti-corruption laws, regulations or rules of other countries in which we operate, including the U.K. Bribery Act of 2010, or the U.K. Bribery
Act. In certain countries, the health care providers who prescribe pharmaceuticals are employed by their government and the purchasers of
pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers may be subject to regulation under
the FCPA, the U.K. Bribery Act and equivalent national laws in other countries. As an example, recently the U.S. Securities and Exchange
Commission and the DOJ have increased their FCPA enforcement activities with respect to pharmaceutical companies. Violation of these
laws by us or our suppliers and other third party agents for which we may be liable may result in civil or criminal sanctions, which could
include monetary fines, criminal penalties, and disgorgement of past profits, which could have a material adverse impact on our business
and financial condition.

K
-
0
1
m
r
o
F

Outside the U.S., interactions between pharmaceutical companies and physicians are also governed by strict laws, such as national

anti-bribery laws of European countries, national sunshine rules, regulations, industry self-regulation codes of conduct and physicians’
codes of professional conduct. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative
penalties, fines or imprisonment.

We are also subject to federal, state, national and international laws and regulations governing the privacy and security of health

related and other personal data we collect and maintain (e.g., Section 5 of the Federal Trade Commission Act, the California Consumer
Privacy Act, or CCPA, and the EU’s General Data Protection Regulation, or GDPR). These laws and regulations are evolving and subject
to interpretation, and may impose limitations on our activities or otherwise adversely affect our business. Because of the remote work
policies we implemented due to the COVID-19 pandemic, information that is normally protected, including company confidential
information, may be less secure. Cybersecurity and data security threats continue to evolve and raise the risk of an incident that could
affect our operations or compromise our business information or sensitive personal data, including health data. We may also need to
collect more extensive health-related information from our employees to manage our workforce. If we or our third party partners fail to
comply or are alleged to have failed to comply with applicable data protection and privacy laws and regulations, and related employment
rules, or if we were to experience a data breach involving personal data, we could be subject to government enforcement actions or private
lawsuits. In addition, our business could be adversely impacted if our ability to transfer personal data outside of the European Economic
Area or Switzerland is restricted, which could adversely impact our operating results. For example, in July 2020, the Court of Justice of the
European Union, or the Court of Justice, declared the EC’s privacy shield framework between the EU and U.S. was invalid, which could
adversely impact our ability to transfer personal data from the EU to the U.S. The Court of Justice further ruled that in order to transfer data
outside of the EU, under the existing mechanism known as the Standard Contractual Clauses, or SCCs, the importing country’s level of
protection must be adequate. If the level of protection in the U.S. or any other importing country is called into question under the SCCs, this
could further impact our ability to transfer data outside of the EU or Switzerland. Furthermore, following the U.K.’s exit from the EU, the
U.K. became a third country to the EU in terms of personal data transfers. The EC has adopted an Adequacy Decision concerning the level
of personal data protection in the U.K. under which personal data may now flow freely from the EU to the U.K. However, personal data
transfers from the EU to the U.K. may nevertheless be at a greater risk than before because the Adequacy Decision may be suspended.

In addition, numerous other federal, state, national and international laws and regulations govern the privacy and security of the
personal data we collect and maintain, including data breach notification laws, state health information and/or genetic privacy laws, federal
and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act, and the CCPA), and laws outside of the

JAZZ PHARMACEUTICALS | 2021 Annual Report

57

United States that may apply to us, such as the GDPR and other country laws. Many of these laws and regimes, across countries but even
within the United States, differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.
Compliance with these laws is difficult, constantly evolving, and time consuming. International regulators, federal regulators, state attorneys
general, and plaintiffs’ attorneys, including class action attorneys, have been and will likely continue to be active in this space.

In California, the CCPA establishes certain requirements for data use and sharing transparency and creates new data privacy rights

for California residents. The CCPA and its implementing regulations have already been amended multiple times since their enactment.
These laws and regulations are evolving and subject to interpretation, and may impose limitations on our activities or otherwise adversely
affect our business. Similarly, there are a number of legislative proposals in the European Union, the United States (at both the federal and
state level) as well as in other jurisdictions that could impose new obligations or limitations in areas affecting our business. In addition,
some countries are considering or have passed legislation implementing data protection or privacy requirements or requiring local storage
and processing of data or similar requirements that could increase the cost and complexity of delivering our services and research
activities.

If we or our third party partners fail to comply or are alleged to have failed to comply with these or other applicable data protection and

privacy laws and regulations, or if we were to experience a data breach involving personal data, we could be subject to government
enforcement actions or private lawsuits. Any associated claims, inquiries, or investigations or other government actions could lead to
unfavorable outcomes that have a material impact on our business including through significant penalties or fines, monetary judgments or
settlements including criminal and civil liability for us and our officers and directors, increased compliance costs, delays or impediments in
the development of new products, negative publicity, increased operating costs, diversion of management time and attention, or other
remedies that harm our business, including orders that we modify or cease existing business practices.

If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental
pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could
have a material adverse effect on our business, financial condition, results of operations and growth prospects.

We participate in the Medicaid Drug Rebate Program, the 340B program, the U.S. Department of Veterans Affairs, Federal Supply
Schedule, or FSS, pricing program, and the Tricare Retail Pharmacy program, and have obligations to report the average sales price for
certain of our drugs to the Medicare program. All of these programs are described in more detail under the heading “Business—
Pharmaceutical Pricing, Reimbursement by Government and Private Payors and Patient Access” in Part I, Item 1 of this Annual Report on
Form 10-K. For calendar quarters beginning January 1, 2022, manufacturers will need to start reporting the average sales price for drugs
under the Medicare program regardless of whether they are enrolled in the Medicaid Drug Rebate Program. Currently, only manufacturers
participating in the Medicaid Drug Rebate Program are obligated to do so.

Pricing and rebate calculations vary across products and programs, are complex, and are often subject to interpretation by us,
governmental or regulatory agencies and the courts, which can change and evolve over time. In the case of our Medicaid pricing data, if we
become aware that our reporting for a prior quarter was incorrect, or has changed as a result of recalculation of the pricing data, we are
generally obligated to resubmit the corrected data for up to three years after those data originally were due. Such restatements and
recalculations increase our costs for complying with the laws and regulations governing the Medicaid Drug Rebate Program and could
result in an overage or underage in our rebate liability for past quarters. Price recalculations also may affect the ceiling price at which we
are required to offer our products under the 340B program and give rise to an obligation to refund entities participating in the 340B program
for overcharges during past quarters impacted by a price recalculation.

Civil monetary penalties can be applied if we are found to have knowingly submitted any false price or product information to the
government, if we are found to have made a misrepresentation in the reporting of our average sales price, if we fail to submit the required
price data on a timely basis, or if we are found to have charged 340B covered entities more than the statutorily mandated ceiling price. The
Centers for Medicare & Medicaid Services, or CMS, could also decide to terminate our Medicaid drug rebate agreement, in which case
federal payments may not be available under Medicaid or Medicare Part B for our covered outpatient drugs. We cannot assure you that our
submissions will not be found by CMS to be incomplete or incorrect.

Our failure to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program and other governmental
programs could negatively impact our financial results. CMS issued a final regulation, which became effective in April 2016, to implement
the changes to the Medicaid Drug Rebate Program under the Affordable Care Act. In December 2020, CMS issued a final regulation that
modified prior Medicaid Drug Rebate Program regulations to permit reporting multiple best price figures with regard to value-based
purchasing arrangements (beginning in 2022); provide definitions for “line extension,” “new formulation,” and related terms, with the
practical effect of expanding the scope of drugs considered to be line extensions that are subject to an alternative rebate formula

58

2021 Annual Report

| JAZZ PHARMACEUTICALS

(beginning in 2022); and revise best price and average manufacturer price exclusions of manufacturer-sponsored patient benefit programs,
specifically regarding applicability of such exclusions in the context of pharmacy benefit manager “accumulator” programs (beginning in
2023). The pharmaceutical industry has challenged the provisions of the rule applicable to patient benefit programs in court. It is currently
unclear whether CMS will delay or suspend implementation of any of the provisions of this rule or whether any other provisions will become
subject to judicial challenge. Regulatory and legislative changes, and judicial rulings relating to the Medicaid Drug Rebate Program and
related policies (including coverage expansion), have increased and will continue to increase our costs and the complexity of compliance,
have been and will continue to be time-consuming to implement, and could have a material adverse effect on our results of operations,
particularly if CMS or another agency challenges the approach we take in our implementation.

The Health Resources and Services Administration, or HRSA, issued a final regulation regarding the calculation of the 340B ceiling
price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities, which
became effective in January 2019. Implementation of this regulation could affect our obligations and potential liability under the 340B
program in ways we cannot anticipate. We are also required to report the 340B ceiling prices for our covered outpatient drugs to HRSA,
which then publishes them to 340B covered entities. Any charge by HRSA that we have violated this regulation or other requirements of the
program could negatively impact our financial results. Moreover, HRSA newly established an administrative dispute resolution, or ADR,
process under a final regulation effective January 2021, for claims by covered entities that a manufacturer engaged in overcharging,
including claims that a manufacturer limited the ability of a covered entity to purchase the manufacturer’s drugs at the 340B ceiling price,
and by manufacturers that a covered entity violated the prohibitions against diversion or duplicate discounts. Such claims are to be
resolved through an ADR panel of government officials rendering a decision that could be appealed only in federal court. This ADR
regulation has been challenged in separate litigation instituted by PhRMA and by pharmaceutical manufacturers in multiple federal courts.
Also, a public notice published in December 2021 by the Office of Management and Budget revealed that HRSA intends to propose a new
ADR rule to replace the ADR rule which became effective in January 2021 and that this new rule will propose new requirements and
procedures for the 340B program’s ADR process. Under the ADR final rule which became effective in January 2021, an ADR proceeding
could potentially subject us to discovery by covered entities and other onerous procedural requirements and could result in additional
liability. HRSA could also decide to terminate a manufacturer’s agreement to participate in the 340B program for a violation of that
agreement or other good cause shown, in which case the manufacturer’s covered outpatient drugs may no longer be eligible for federal
payment under the Medicaid or Medicare Part B program.

K
-
0
1
m
r
o
F

Further, legislation may be introduced that, if passed, would, among other things, further expand the 340B program to additional
covered entities or would require participating manufacturers to agree to provide 340B discounted pricing on drugs used in an inpatient
setting, and any additional future changes to the definition of average manufacturer price or the Medicaid rebate amount could affect our
340B ceiling price calculations and negatively impact our results of operations.

We have obligations to report the average sales price for certain of our drugs to the Medicare program. Statutory or regulatory
changes or CMS guidance could affect the average sales price calculations for our products and the resulting Medicare payment rate, and
could negatively impact our results of operations.

Pursuant to applicable law, knowing provision of false information in connection with price reporting under the U.S. Department of

Veterans Affairs, FSS or Tricare Retail Pharmacy, or Tricare, programs can subject a manufacturer to civil monetary penalties. These
program obligations also contain extensive disclosure and certification requirements. If we overcharge the government in connection with
our arrangements with FSS or Tricare, we are required to refund the difference to the government. Failure to make necessary disclosures
and/or to identify contract overcharges can result in allegations against us under the False Claims Act and other laws and regulations.
Unexpected refunds to the government, and responding to a government investigation or enforcement action, would be expensive and
time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and growth prospects.

Product liability and product recalls could harm our business.

The development, manufacture, testing, marketing and sale of pharmaceutical products are associated with significant risks of
product liability claims or recalls. Side effects or adverse events known or reported to be associated with, or manufacturing defects in, the
products sold by us could exacerbate a patient’s condition, or could result in serious injury or impairment or even death. This could result in
product liability claims against us and/or recalls of one or more of our products. In many countries, including in EU member states, national
laws provide for strict (no-fault) liability which applies even where damages are caused both by a defect in a product and by the act or
omission of a third party.

Product recalls may be issued at our discretion or at the discretion of our suppliers, government agencies and other entities that have

regulatory authority for pharmaceutical sales. Any recall of our products could materially adversely affect our business by rendering us

JAZZ PHARMACEUTICALS | 2021 Annual Report

59

unable to sell that product for some time and by adversely affecting our reputation. A recall could also result in product liability claims by
individuals and third party payors. In addition, product liability claims could result in an investigation of the safety or efficacy of our products,
our manufacturing processes and facilities, or our marketing programs conducted by FDA, the EC or the competent authorities of the EU
member states. Such investigations could also potentially lead to a recall of our products or more serious enforcement actions, limitations
on the therapeutic indications for which they may be used, or suspension, variation, or withdrawal of approval. Any such regulatory action
by FDA, the EC or the competent authorities of the EU member states could lead to product liability lawsuits as well.

Product liability insurance coverage is expensive, can be difficult to obtain and may not be available in the future on acceptable terms,

or at all. Our product liability insurance may not cover all of the future liabilities we might incur in connection with the development,
manufacture or sale of our products. A successful claim or claims brought against us in excess of available insurance coverage could
subject us to significant liabilities and could have a material adverse effect on our business, financial condition, results of operations and
growth prospects. Such claims could also harm our reputation and the reputation of our products, adversely affecting our ability to market
our products successfully.

We use hazardous materials in our manufacturing facilities, and any claims relating to the improper handling, storage, release or
disposal of these materials could be time-consuming and expensive.

Our operations are subject to complex and increasingly stringent environmental, health and safety laws and regulations in the
countries where we operate and, in particular, in Ireland, the U.K. and Italy where we have manufacturing facilities. If an accident or
contamination involving pollutants or hazardous substances occurs, an injured party could seek to hold us liable for any damages that
result and any liability could exceed the limits or fall outside the coverage of our insurance. We may not be able to maintain insurance with
sufficient coverage on acceptable terms, or at all. Costs, damages and/or fines may result from the presence, investigation and remediation
of such contamination at properties currently or formerly owned, leased or operated by us or at off-site locations, including where we have
arranged for the disposal of hazardous substances or waste. In addition, we may be subject to third party claims, including for natural
resource damages, personal injury and property damage, in connection with such contamination.

Risks Related to Controlled Substances

Xyrem, Xywav, Sunosi and nabiximols are controlled substances and certain other cannabis-derived product candidates we are
developing may be subject to U.S. federal and state controlled substance laws and regulations, and our failure to comply with
these laws and regulations, or the cost of compliance with these laws and regulations, could materially and adversely affect our
business, results of operations, financial condition and growth prospects.

Xyrem, Xywav, Sunosi, nabiximols and certain other product candidates we are developing contain controlled substances as defined
in the CSA. Controlled substances are subject to a number of requirements and restrictions under the CSA and implementing regulations,
including certain registration, security, recordkeeping, reporting, import, export and other requirements administered by the DEA. The DEA
classifies controlled substances into five schedules: Schedule I, II, III, IV or V substances. Schedule I substances by definition have a high
potential for abuse, no currently “accepted medical use” in the U.S., lack accepted safety for use under medical supervision, and may not
be prescribed, marketed or sold in the U.S. Pharmaceutical products approved for use in the U.S. which contain a controlled substance are
listed as Schedule II, III, IV or V, with Schedule II substances considered to present the highest potential for abuse or dependence and
Schedule V substances the lowest relative risk of abuse among such substances. Schedule I and II drugs are subject to the strictest
controls under the CSA, including manufacturing and procurement quotas, heightened security requirements and additional criteria for
importation. In addition, dispensing of Schedule II drugs is further restricted. For example, they may not be refilled without a new
prescription.

Drug products approved by FDA that contain cannabis or cannabis extracts may be controlled substances and will be rescheduled to

Schedules II-V after approval, or, like Epidiolex, removed completely from the schedules by operation of other laws.

Individual states have also established controlled substance laws and regulations. Though state-controlled substances laws often
mirror federal law, they may separately schedule our products or our product candidates as well. We or our partners may also be required
to obtain separate state registrations, permits or licenses in order to be able to manufacture, distribute, administer or prescribe controlled
substances for clinical trials or commercial sale, and failure to meet applicable regulatory requirements could lead to enforcement and
sanctions by the states in addition to those from the DEA or otherwise arising under federal law.

U.S facilities conducting research, manufacturing, distributing, importing or exporting, or dispensing controlled substances must be
registered (licensed) to perform these activities and must comply with the security, control, recordkeeping and reporting obligations under
the CSA, DEA regulations and corresponding state requirements. DEA and state regulatory bodies conduct periodic inspections of certain

60

2021 Annual Report

| JAZZ PHARMACEUTICALS

registered establishments that handle controlled substances. Obtaining and maintaining the necessary registrations and complying with the
regulatory obligations may result in delay of the importation, manufacturing, distribution or clinical research of our commercial products and
products candidates. Furthermore, failure to maintain compliance with the CSA and DEA and state regulations by us or any of our
contractors, distributors or pharmacies can result in regulatory action that could have a material adverse effect on our business, financial
condition and results of operations. DEA and state regulatory bodies may seek civil penalties, refuse to renew necessary registrations, or
initiate proceedings to restrict, suspend or revoke those registrations. In certain circumstances, violations could lead to criminal penalties.

Schedule I and II substances are subject to DEA’s annual manufacturing and procurement quota requirements. The annual quota
allocated to us or our contract manufacturers for the active ingredients in our products may not be sufficient to complete clinical trials or
meet commercial demand. Consequently, any delay or refusal by the DEA in establishing our, or our contract manufacturers’, procurement
and/or production quota for controlled substances could delay or stop our clinical trials or product launches, which could have a material
adverse effect on our business, results of operations, financial condition and growth prospects.

Nabiximols and other cannabinoid product candidates are currently controlled substances, the use of which may generate
public controversy.

Since nabiximols and some of our other product candidates derived from botanical marijuana contain controlled substances, their

regulatory approval may generate public controversy. Political and social pressures and adverse publicity could lead to challenges in the
approval of, and increased expenses for, nabiximols and our product candidates. These pressures could also limit or restrict the
introduction and marketing of nabiximols and our product candidates. Adverse publicity from cannabis misuse or adverse side effects from
cannabis or other cannabinoid products may adversely affect the commercial success or market penetration achievable by nabiximols and
our other cannabinoid product candidates. The nature of our business attracts a high level of public and media interest, and in the event of
any resultant adverse publicity, our reputation may be harmed.

K
-
0
1
m
r
o
F

Our ability to research, develop and commercialize Epidiolex, nabiximols and certain of our product candidates is dependent on
our ability to maintain licenses relating to the cultivation, possession and supply of botanical cannabis, a controlled substance.

Our cannabinoid research and manufacturing facilities are located exclusively in the U.K. In the U.K., licenses to cultivate, possess

and supply cannabis for medical research are granted by the Home Office on an annual basis. Although the Home Office has renewed our
licenses each year since 1998, it may not do so in the future, in which case we may not be in a position to carry on our research and
development program in the U.K. In addition, we are required to maintain our existing commercial licenses to cultivate, produce and supply
cannabis. However, if the Home Office were not prepared to renew such licenses, we would be unable to manufacture and distribute our
products on a commercial basis in the U.K. or beyond. In order to carry out research in countries other than the U.K., similar licenses to
those outlined above are required to be issued by the relevant authority in each country. In addition, we will be required to obtain licenses
to export from the U.K. and to import into the recipient country. To date, we have obtained necessary import and export licenses to over 30
countries. Although we have an established track record of successfully obtaining such licenses as required, this may change in the future,
which could materially and adversely affect our business, results of operations, financial condition and growth prospects.

Controlled substance legislation differs between countries and legislation in certain countries may restrict or limit our ability to
sell Epidyolex, nabiximols and certain of our product candidates.

Most countries are parties to the Single Convention on Narcotic Drugs 1961, which governs international trade and domestic control
of narcotic substances, including cannabis extracts. Countries may interpret and implement their treaty obligations in a way that creates a
legal obstacle to our obtaining regulatory approval for Epidyolex, nabiximols and certain of our other products in those countries. These
countries may not be willing or able to amend or otherwise modify their laws and regulations to permit Epidyolex, nabiximols or certain of
our other products to be marketed, or achieving such amendments to the laws and regulations may take a prolonged period of time. In the
case of countries with similar obstacles, we would be unable to market Epidyolex, nabiximols and certain of our product candidates in
countries in the near future or perhaps at all if the laws and regulations in those countries do not change.

Risks Related to Our Financial Condition and Results

We have incurred substantial debt, which could impair our flexibility and access to capital and adversely affect our financial
position, and our business would be adversely affected if we are unable to service our debt obligations.

As of December 31, 2021, we had total indebtedness of approximately $6.4 billion. Our substantial indebtedness may:

•

limit our ability to use our cash flow or borrow additional funds for working capital, capital expenditures, acquisitions,
investments or other general business purposes;

JAZZ PHARMACEUTICALS | 2021 Annual Report

61

•

•

•

•

•

•

require us to use a substantial portion of our cash flow from operations to make debt service payments;

limit our flexibility to plan for, or react to, changes in our business and industry, or our ability to take specified actions to take
advantage of certain business opportunities that may be presented to us;

expose us to the risk of increased interest rates as certain of our borrowings, including borrowings under the credit agreement,
are at variable rates of interest;

result in dilution to our existing shareholders in the event exchanges of our exchangeable senior notes are settled in our
ordinary shares;

place us at a competitive disadvantage compared to our less leveraged competitors; and

increase our vulnerability to the impact of adverse economic and industry conditions.

If our cash flows and capital resources are insufficient to fund our debt service obligations, we may be forced to reduce or delay
investments and capital expenditures, seek additional capital or restructure or refinance our debt. These alternative measures may not be
successful and may not permit us to meet our debt service obligations. In the absence of such cash flows and resources, we could face
substantial liquidity problems and might be required to dispose of material assets or operations to meet our debt service and other
obligations. In addition, if we are unable to repay amounts under our secured credit agreement or senior secured notes, the credit
agreement lenders and note holders could proceed against the collateral granted to them to secure that debt, which would seriously harm
our business.

Covenants in our credit agreement and indenture governing our senior secured notes restrict our business and operations in
many ways and if we do not effectively manage our covenants, our financial conditions and results of operations could be
adversely affected.

The credit agreement and the indenture governing our senior secured notes contain various covenants that, among other things, limit

our ability and/or our restricted subsidiaries’ ability to:

•

•

•

incur or assume liens or additional debt or provide guarantees in respect of obligations of other persons;

pay dividends or distributions or redeem or repurchase capital stock;

prepay, redeem or repurchase certain debt;

• make loans, investments, acquisitions (including certain acquisitions of exclusive licenses) and capital expenditures;

•

•

•

•

•

enter into agreements that restrict distributions from our subsidiaries;

enter into transactions with affiliates;

enter into sale and lease-back transactions;

sell, transfer or exclusively license certain assets, including material intellectual property, and capital stock of our subsidiaries;
and

consolidate or merge with or into, or sell substantially all of our assets to, another person.

If we undergo a change of control triggering event, we would be required to make an offer to purchase all of the senior secured notes

at a purchase price in cash equal to 101% of their principal amount, plus accrued and unpaid interest, subject to certain exceptions. If we
engage in certain asset sales, we will be required under certain circumstances to make an offer to purchase the senior secured notes at
100% of the principal amount, plus accrued and unpaid interest.

The credit agreement also includes certain financial covenants that require us to maintain a maximum secured leverage ratio and a

minimum interest coverage ratio as long as we have drawn funds under the revolving credit facility (or letters of credit in excess of
$50 million have been issued and remain undrawn).

As a result of these restrictions, we may be:

•

•

•

limited in how we conduct our business;

unable to raise additional debt or equity financing to operate during general economic or business downturns; or

unable to compete effectively, take advantage of new business opportunities or grow in accordance with our plans.

62

2021 Annual Report

| JAZZ PHARMACEUTICALS

K
-
0
1
m
r
o
F

Our failure to comply with any of the covenants could result in a default under the credit agreement and the indenture governing our
senior secured notes, which, if not cured or waived, could result in us having to repay our borrowings before their due dates. Such default
may allow the lenders or the note holders to accelerate the related debt and may result in the acceleration of any other debt to which a
cross-acceleration or cross-default provision applies. If we are forced to refinance these borrowings on less favorable terms or if we were to
experience difficulty in refinancing the debt prior to maturity, our results of operations or financial condition could be materially affected. In
addition, an event of default under the credit agreement may permit the lenders to refuse to permit additional borrowings under the
revolving credit facility or to terminate all commitments to extend further credit under the revolving credit facility. Furthermore, if we are
unable to repay the amounts due and payable under the credit agreement or senior secured notes, the lenders and note holders may be
able to proceed against the collateral granted to them to secure that indebtedness. In the event our lenders or note holders accelerate the
repayment of such borrowings, we cannot assure you that we will have sufficient assets to repay such indebtedness.

Moreover, our failure to repurchase our senior secured notes or our exchangeable senior notes at a time when the repurchase is

required by the indentures governing our senior secured notes and our exchangeable senior notes or to pay any cash payable on future
exchanges of our exchangeable senior notes as required by the indenture governing our exchangeable senior notes, would constitute a
default under those indentures.

A default under the indentures governing our exchangeable senior notes could also lead to a default under other debt agreements or

obligations, including the credit agreement and indenture governing the senior secured notes. Likewise, a default under the credit
agreement or senior secured notes could lead to a default under other debt agreements or obligations, including the indentures governing
our exchangeable senior notes.

To continue to grow our business, we will need to commit substantial resources, which could result in future losses or otherwise
limit our opportunities or affect our ability to operate and grow our business.

The scope of our business and operations has grown substantially since 2012, including through a series of business combinations
and acquisitions. To continue to grow our business over the longer term, we plan to commit substantial resources to product acquisition
and in-licensing, product development, clinical trials of product candidates and expansion of our commercial, development, manufacturing
and other operations. Acquisition opportunities that we pursue could materially affect our liquidity and capital resources and may require us
to incur additional indebtedness, seek equity capital or both. Our ability to raise additional capital may be adversely impacted by potential
worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the U.S. and
worldwide resulting from the effects of the COVID-19 pandemic. In addition, under Irish law, we must have authority from our shareholders
to issue any ordinary shares, including ordinary shares that are part of our authorized but unissued share capital. Moreover, as a matter of
Irish law, when an Irish public limited company issues ordinary shares to new shareholders for cash, the company must first offer those
shares on the same or more favorable terms to existing shareholders on a pro-rata basis, unless this statutory pre-emption obligation is
dis-applied, or opted-out of, by approval of its shareholders. At our extraordinary general meeting of shareholders in September 2021, our
shareholders voted to approve our proposal to dis-apply the statutory pre-emption obligation on terms that are substantially more limited
than our general pre-emption opt-out authority that had been in effect prior to August 4, 2021, which could adversely affect our ability to
effectively use our unissued share capital to fund in-licensing or acquisition opportunities, or to otherwise raise additional capital for our
business. In any event, an inability to borrow or raise additional capital in a timely manner and on attractive terms could prevent us from
expanding our business or taking advantage of acquisition opportunities, and could otherwise have a material adverse effect on our
business and growth prospects. In addition, if we use a substantial amount of our funds to acquire or in-license products or product
candidates, we may not have sufficient additional funds to conduct all of our operations in the manner we would otherwise choose.

We have significant intangible assets and goodwill. Consequently, the future impairment of our intangible assets and goodwill
may significantly impact our profitability.

Our intangible assets and goodwill are significant and are subject to an impairment analysis whenever events or changes in
circumstances indicate the carrying amount of the asset may not be recoverable. Additionally, goodwill and indefinite-lived assets are
subject to an impairment test at least annually. Events giving rise to impairment are an inherent risk in the pharmaceutical industry and
cannot be predicted. For example, in the first quarter of 2020, we recorded a $136.1 million asset impairment charge following the decision
to stop enrollment in our Phase 3 clinical study of defibrotide for the prevention of VOD due to a determination that the study is highly
unlikely to reach one of its primary endpoints. Our results of operations and financial position in future periods could be negatively impacted
should future impairments of intangible assets or goodwill occur.

Our financial results have been and may continue to be adversely affected by foreign currency exchange rate fluctuations.

Because our financial results are reported in U.S. dollars, we are exposed to foreign currency exchange risk as the functional
currency financial statements of non-U.S. subsidiaries are translated to U.S. dollars for reporting purposes. To the extent that revenue and

JAZZ PHARMACEUTICALS | 2021 Annual Report

63

expense transactions are not denominated in the functional currency, we are also subject to the risk of transaction losses. For example,
because our product sales outside of the U.S. are primarily denominated in the euro, our sales of those products have been and may
continue to be adversely affected by fluctuations in foreign currency exchange rates. Given the volatility of exchange rates, as well as our
expanding operations, there is no guarantee that we will be able to effectively manage currency transaction and/or translation risks, which
could adversely affect our operating results. Although we utilize foreign exchange forward contracts to manage currency risk primarily
related to certain intercompany balances denominated in non-functional currencies, our efforts to manage currency risk may not be
successful.

Changes in our effective tax rates could adversely affect our business and financial condition, results of operations and growth
prospects.

We are incorporated in Ireland and maintain subsidiaries in North America, the U.K. and a number of other foreign jurisdictions. As a

result, our effective tax rate is derived from a combination of applicable tax rates in the various jurisdictions where we operate. Our
effective tax rate may fluctuate depending on a number of factors, including, but not limited to, the distribution of our profits or losses
between the jurisdictions where we operate and changes to or differences in interpretation of tax laws. For example, our income tax
expense for the year ended December 31, 2021 included an expense of $259.9 million arising on the remeasurement of our U.K. net
deferred tax liability, which arose primarily in relation to the GW Acquisition, due to a change in the statutory tax rate in the U.K. following
enactment of the U.K. Finance Act 2021.

We are subject to reviews and audits by the U.S. Internal Revenue Services, or IRS, and other taxing authorities from time to time,

and the IRS or other taxing authority may challenge our structure, transfer pricing arrangements and tax positions through an audit or
lawsuit. Responding to or defending against challenges from taxing authorities could be expensive and consume time and other resources.
If we are unsuccessful, we may be required to pay taxes for prior periods, interest, fines or penalties, and may be obligated to pay
increased taxes in the future, any of which could require us to reduce our operating expenses, decrease efforts in support of our products
or seek to raise additional funds. Any of these actions could have a material adverse effect on our business, financial condition, results of
operations and growth prospects.

The IRS may not agree with the conclusion that we should be treated as a foreign corporation for U.S. federal tax purposes.

Although we are incorporated in Ireland, the IRS may assert that we should be treated as a U.S. corporation (and, therefore, a
U.S. tax resident) for U.S. federal tax purposes pursuant to Section 7874 of the U.S. Internal Revenue Code, or the Code. For U.S. federal
tax purposes, a corporation generally is considered a tax resident in the jurisdiction of its organization or incorporation. Because we are an
Irish incorporated entity, we would be classified as a foreign corporation (and, therefore, a non-U.S. tax resident) under these rules.
Section 7874 of the Code provides an exception under which a foreign incorporated entity may, in certain circumstances, be treated as a
U.S. corporation for U.S. federal tax purposes. Because we indirectly acquired all of Jazz Pharmaceuticals, Inc.’s assets through the
acquisition of the shares of Jazz Pharmaceuticals, Inc. common stock when the businesses of Jazz Pharmaceuticals, Inc. and Azur
Pharma Public Limited Company were combined in a merger transaction in January 2012, or the Azur Merger, the IRS could assert that we
should be treated as a U.S. corporation for U.S. federal tax purposes under Section 7874. The IRS continues to scrutinize transactions that
are potentially subject to Section 7874, and has issued several sets of final and temporary regulations under Section 7874 since 2012. We
do not expect these regulations to affect the U.S. tax consequences of the Azur Merger. Nevertheless, new statutory and/or regulatory
provisions under Section 7874 of the Code or otherwise could be enacted that could adversely affect our status as a foreign corporation for
U.S. federal tax purposes, and any such provisions could have prospective or retroactive application to us, our shareholders, Jazz
Pharmaceuticals, Inc. and/or the Azur Merger.

Our affiliates’ ability to use their net operating losses and carryforward tax losses to offset potential taxable income is limited
under applicable law and could be subject to further limitations if we do not generate taxable income in a timely manner or if
certain “ownership change” provisions of applicable law result in further limitations.

Following certain acquisitions of a U.S. corporation by a foreign corporation, Section 7874 of the Code can limit the ability of the
acquired U.S. corporation and its U.S. affiliates to use U.S. tax attributes such as net operating losses, or NOLs, to offset U.S. taxable
income resulting from certain transactions. Our U.S. affiliates have a significant amount of NOLs. As a result of Section 7874 of the Code,
after the Azur Merger, our U.S. affiliates have not been able and will continue to be unable, for a period of time, to utilize their U.S. tax
attributes to offset their U.S. taxable income, if any, resulting from certain taxable transactions. While we expect to be able to fully utilize
our U.S. affiliates’ U.S. NOLs before they expire, as a result of this limitation, it may take our U.S. affiliates longer to use their NOLs.

Our ability to use these NOLs to offset potential future taxable income and related income taxes that would otherwise be due also
depends on our ability to generate future income that is taxable in the U.S. before the NOLs expire. We cannot predict with certainty when,

64

2021 Annual Report

| JAZZ PHARMACEUTICALS

or whether, our U.S. affiliates will generate sufficient taxable income to use all of the NOLs. In addition, the use of NOLs to offset potential
future taxable income and related income taxes that would otherwise be due is subject to limitations under the “ownership change”
provisions of Sections 382 and 383 of the Code and similar state provisions. Additionally, U.K. carryforward tax losses may become subject
to limitations in the event of certain changes in the ownership interest of significant shareholders where there is also a major change in the
nature of conduct of a trade or business within a specified period of time. These limitations may cause us to lose or forfeit additional NOLs
or carryforward tax losses before we can use these attributes. Subsequent ownership changes and changes to the U.S. federal or state or
U.K. tax rules with respect to the use of NOLs and carryforward tax losses may further affect our ability to use these losses in future years.

Changes to tax laws relating to multinational corporations could adversely affect us.

The U.S. Congress, the EU, the Organization for Economic Co-operation and Development, or OECD, and other government

agencies in jurisdictions where we and our affiliates do business have had an extended focus on issues related to the taxation of
multinational corporations. One example is the OECD’s initiative in the area of “base erosion and profit shifting,” or BEPS. Many countries
have implemented or begun to implement legislation and other guidance to align their international tax rules with the OECD’s BEPS
recommendations. In addition, the OECD has been working on an extension of the BEPS project, referred to as BEPS 2.0, focusing on
(1) global profit allocation and (2) a global minimum tax rate. In particular, the OECD has released a framework proposal reflecting the
agreement of over 130 jurisdictions, including Ireland, to implement a global minimum tax rate of 15% for large multinational corporations
on a jurisdiction-by-jurisdiction basis by 2023. As a result of the focus on the taxation of multinational corporations, the tax laws in Ireland,
the U.S. and other countries in which we and our affiliates do business could change on a prospective or retroactive basis, and any such
changes could adversely affect us.

Further, the Biden administration and U.S. Congress continue to consider changes in U.S. tax laws. In April 2021, the Biden
administration released the Made in America Tax Plan, which includes significant modifications to key provisions of the existing U.S.
corporate income tax regime, including an increase in the U.S. corporate income tax rate and an increase in the tax rate on certain
earnings of controlled foreign corporations. In November 2021, the U.S. House of Representatives passed the “Build Back Better Act”
budget reconciliation bill, which proposes significant changes to the U.S. tax treatment of multinational corporations. Congress continues to
consider these and other legislative proposals. These changes, if enacted, could adversely impact our tax provision, cash tax liability and
effective tax rate. At this stage, it is not possible to predict which, if any, proposals the U.S. Congress will ultimately accept, reject or modify
and whether any proposals will be enacted into law.

K
-
0
1
m
r
o
F

A substantial portion of our indebtedness bears interest at variable interest rates based on USD LIBOR and certain of our
financial contracts are also indexed to USD LIBOR. Changes in the method of determining LIBOR, or the replacement of LIBOR
with an alternative reference rate, may adversely affect interest rates on our current or future indebtedness and may otherwise
adversely affect our financial condition and results of operations.

In July 2017, the Financial Conduct Authority, or FCA, the authority that regulates the London Inter-bank Offered Rate, or LIBOR,
announced that it intended to stop compelling banks to submit rates for the calculation of LIBOR after 2021. FCA also announced that
certain of the commonly used USD LIBOR tenors will continue to be published until June 30, 2023; however, the Federal Reserve, Federal
Deposit Insurance Corporation and the Office of the Comptroller of Currency in the U.S. as well as the FCA announced that all market
participants should stop using LIBOR in new contracts after December 31, 2021, subject to limited exemptions for loans and derivative
products. Accordingly, new contracts entered into after December 31, 2021, must utilize an alternative reference rate. We have certain
financial contracts, including the credit agreement and our derivative instruments, that are indexed to USD LIBOR. Changes in the method
of determining LIBOR, or the replacement of LIBOR with an alternative reference rate, may adversely affect interest rates on our current or
future indebtedness. Any transition process may involve, among other things, increased volatility or illiquidity in markets for instruments that
rely on LIBOR, reductions in the value of certain instruments or the effectiveness of related transactions such as hedges, increased
borrowing costs, uncertainty under applicable documentation, or difficult and costly consent processes. In addition, we have certain
financial contracts, including the credit agreement and our derivative instruments, that are indexed to Euro Inter-bank Offered Rate, or
EURIBOR (which is based on the average interest rates at which a large panel of European banks borrow funds from one another). There
is no indication at this time that EURIBOR will cease to be published in the near future. However, the transition away from LIBOR, and also
potentially EURIBOR, may result in increased expenses, may impair our ability to refinance our indebtedness or hedge our exposure to
floating rate instruments, or may result in difficulties, complications or delays in connection with future financing efforts, any of which could
adversely affect our financial condition and results of operations.

JAZZ PHARMACEUTICALS | 2021 Annual Report

65

Risks Related to Our Ordinary Shares

The market price of our ordinary shares has been volatile and is likely to continue to be volatile in the future, and the value of
your investment could decline significantly.

The stock market in general, including the market for life sciences companies, has experienced extreme price and trading volume
fluctuations that have often been unrelated or disproportionate to the operating performance of those companies, which has resulted in
decreased market prices, notwithstanding the lack of a fundamental change in the underlying business models of those companies.
Worsening economic conditions and other adverse effects or developments may negatively affect the market price of our ordinary shares,
regardless of our actual operating performance. The market price for our ordinary shares is likely to continue to be volatile and subject to
significant price and volume fluctuations in response to market, industry and other factors, including the risk factors described in this
“Risk Factors” section.

Our share price may be dependent upon the valuations and recommendations of the analysts who cover our business. If our results
do not meet these analysts’ forecasts, the expectations of our investors or the financial guidance we provide to investors in any period, the
market price of our ordinary shares could decline. Our ability to meet analysts’ forecasts, investors’ expectations and our financial guidance
is substantially dependent on our ability to maintain or increase sales of our marketed products.

In addition, the market price of our ordinary shares may decline if the effects of our acquisition of GW and other strategic transactions

on our financial or operating results are not consistent with the expectations of financial analysts or investors. The market price of our
ordinary shares could also be affected by possible sales of our ordinary shares by holders of our exchangeable senior notes who may view
our exchangeable senior notes as a more attractive means of equity participation in our company and by hedging or arbitrage trading
activity involving our ordinary shares by the holders of our exchangeable senior notes.

We are subject to Irish law, which differs from the laws in effect in the U.S. and may afford less protection to holders of our
securities.

It may not be possible to enforce court judgments obtained in the U.S. against us in Ireland based on the civil liability provisions of the

U.S. federal or state securities laws. In addition, there is some uncertainty as to whether the courts of Ireland would recognize or enforce
judgments of U.S. courts obtained against us or our directors or officers based on the civil liability provisions of the U.S. federal or state
securities laws or hear actions against us or those persons based on those laws. We have been advised that the U.S. currently does not
have a treaty with Ireland providing for the reciprocal recognition and enforcement of judgments in civil and commercial matters. Therefore,
a final judgment for the payment of money rendered by any U.S. federal or state court based on civil liability, whether or not based solely
on U.S. federal or state securities laws, would not automatically be enforceable in Ireland.

As an Irish company, we are governed by the Irish Companies Act 2014, which differs in some material respects from laws generally

applicable to U.S. corporations and shareholders, including, among others, differences relating to interested director and officer
transactions, mergers, amalgamations and acquisitions, takeovers and shareholder lawsuits. The duties of directors and officers of an Irish
company are generally owed to the company only. Shareholders of Irish companies generally do not have a personal right of action against
directors or officers of the company and may exercise such rights of action on behalf of the company only in limited circumstances.
Accordingly, holders of our securities may have more difficulty protecting their interests than would holders of securities of a corporation
incorporated in a U.S. jurisdiction.

Our articles of association, Irish law, our credit agreement and the indentures governing our senior secured notes and
exchangeable senior notes contain provisions that could delay or prevent a takeover of us by a third party.

Our articles of association could delay, defer or prevent a third party from acquiring us, despite the possible benefit to our

shareholders, or otherwise adversely affect the price of our ordinary shares. In addition to our articles of association, several mandatory
provisions of Irish law could prevent or delay an acquisition of us. We are also subject to various provisions of Irish law relating to
mandatory bids, voluntary bids, requirements to make a cash offer and minimum price requirements, as well as substantial acquisition
rules and rules requiring the disclosure of interests in our shares in certain circumstances. Furthermore, our credit agreement limits our
ability to enter into certain fundamental changes, and the indentures governing our senior secured notes and exchangeable senior notes
require us to offer to repurchase such notes for cash if we undergo certain fundamental changes. Additionally, in certain circumstances, the
indentures governing our exchangeable senior notes require us to increase the exchange rate for a holder of our exchangeable senior
notes in connection with a fundamental change. A takeover of us may trigger a default under the credit agreement or the requirement that
we offer to purchase our senior secured notes or exchangeable senior notes and/or increase the exchange rate applicable to our
exchangeable senior notes, which could make it more costly for a potential acquirer to engage in a business combination transaction with
us.

66

2021 Annual Report

| JAZZ PHARMACEUTICALS

These provisions, whether alone or together, may discourage potential takeover attempts, discourage bids for our ordinary shares at

a premium over the market price or adversely affect the market price of, and the voting and other rights of the holders of, our ordinary
shares. These provisions, whether alone or together, could also discourage proxy contests and make it more difficult for our shareholders
to elect directors other than the candidates nominated by our board.

Future sales and issuances of our ordinary shares, securities convertible into our ordinary shares or rights to purchase ordinary
shares or convertible securities could result in additional dilution of the percentage ownership of our shareholders and could
cause our share price to decline.

We expect to continue to opportunistically seek access to additional capital to license or acquire additional products, product
candidates or companies to expand our operations or for general corporate purposes. To the extent we raise additional capital by issuing
equity securities or securities convertible into or exchangeable for ordinary shares, our shareholders may experience substantial dilution.
We may sell ordinary shares, and we may sell convertible or exchangeable securities or other equity securities in one or more transactions
at prices and in a manner we determine from time to time. If we sell such ordinary shares, convertible or exchangeable securities or other
equity securities in subsequent transactions, existing shareholders may be materially diluted.

We have never declared or paid dividends on our capital stock and we do not anticipate paying dividends in the foreseeable
future.

We do not currently plan to pay cash dividends in the foreseeable future. Any future determination as to the payment of dividends will,

subject to Irish legal requirements, be at the sole discretion of our board of directors and will depend on our financial condition, results of
operations, capital requirements, compliance with the terms of the credit agreement and the indenture governing our senior secured notes,
and other factors our board of directors deems relevant. Accordingly, holders of our ordinary shares must rely on increases in the trading
price of their shares for returns on their investment in the foreseeable future. In addition, in the event that we pay a dividend on our ordinary
shares, in certain circumstances, as an Irish tax resident company, some shareholders may be subject to withholding tax, which could
adversely affect the price of our ordinary shares.

K
-
0
1
m
r
o
F

General Risk Factors

If we fail to attract, retain and motivate key personnel or to retain the members of our executive management team, our
operations and our future growth may be adversely affected.

Our success and our ability to grow depend in part on our continued ability to attract, retain and motivate highly qualified personnel,
including our executive management team. In addition, changes we make to our current and future work environments may not meet the
needs or expectations of our employees or may be perceived as less favorable compared to other companies’ policies, which could
negatively impact our ability to hire and retain qualified personnel, whether in a remote or in-office environment. The loss of services and
institutional knowledge of one or more additional members of our executive management team or other key personnel could delay or
prevent the successful completion of some of our vital activities and may negatively impact our operations and future growth. We do not
carry “key person” insurance. In addition, changes in our organization as a result of executive management transition may have a
disruptive impact on our ability to implement our strategy. Until we integrate new personnel, and unless they are able to succeed in their
positions, we may be unable to successfully manage and grow our business. In any event, if we are unable to attract, retain and motivate
quality individuals, or if there are delays, or if we do not successfully manage personnel and executive management transitions, our
business, financial condition, results of operations and growth prospects could be adversely affected.

Our business and operations could be negatively affected if we become subject to shareholder activism or hostile bids, which
could cause us to incur significant expense, hinder execution of our business strategy and impact our stock price.

Shareholder activism, which takes many forms and arises in a variety of situations, has been increasingly prevalent. Stock price declines due
to the evolving effects of the COVID-19 may also increase our vulnerability to unsolicited approaches. If we become the subject of certain forms of
shareholder activism, such as proxy contests or hostile bids, the attention of our management and our board of directors may be diverted from
execution of our strategy. Such shareholder activism could give rise to perceived uncertainties as to our future strategy, adversely affect our
relationships with business partners and make it more difficult to attract and retain qualified personnel. Also, we may incur substantial costs,
including significant legal fees and other expenses, related to activist shareholder matters. Our stock price could be subject to significant fluctuation
or otherwise be adversely affected by the events, risks and uncertainties of any shareholder activism.

Item 1B.

Unresolved Staff Comments

There are no material unresolved written comments that were received from the SEC staff 180 days or more before the end of our

2021 fiscal year relating to our periodic or current reports under the Securities Exchange Act of 1934, as amended.

JAZZ PHARMACEUTICALS | 2021 Annual Report

67

Item 2.

Properties

Our corporate headquarters are located in Dublin, Ireland, and our U.S. operations are located in Palo Alto, California, Carlsbad,

California and Philadelphia, Pennsylvania. In addition to our owned manufacturing and development facilities and our leased
administrative, manufacturing and development facilities, we also have dedicated growing facilities operated by contract partners. The
following table contains information about our significant properties as of December 31, 2021:

Type

Location

Administrative office . . . . . . . . . . . . . . . . . . . . . Dublin, Ireland
Administrative office . . . . . . . . . . . . . . . . . . . . . Palo Alto, United States
Administrative office . . . . . . . . . . . . . . . . . . . . . Carlsbad, United States
Administrative office . . . . . . . . . . . . . . . . . . . . . Philadelphia, United States
Administrative office . . . . . . . . . . . . . . . . . . . . . Oxford, United Kingdom
Administrative office . . . . . . . . . . . . . . . . . . . . . Cambridge, United Kingdom
Administrative office . . . . . . . . . . . . . . . . . . . . .
Administrative office and laboratory . . . . . . . . . . Villa Guardia (Como), Italy
. . . . . . . . . . . . Athlone, Ireland
Manufacturing and development
. . . . . . . . . . . . Villa Guardia (Como), Italy
Manufacturing and development
. . . . . . . . . . . . Southern United Kingdom
Manufacturing and development
Growing facility . . . . . . . . . . . . . . . . . . . . . . . . . Eastern United Kingdom
Growing facility . . . . . . . . . . . . . . . . . . . . . . . . . Northern United Kingdom
Growing facility . . . . . . . . . . . . . . . . . . . . . . . . . Southern United Kingdom
Growing facility under construction . . . . . . . . . . Southern United Kingdom

London, United Kingdom

Approximate Square Feet

Lease / Contract
Expiration Date

45,000
99,000
52,000
60,000
26,000
22,000
7,000
34,000
58,000
45,000
150,000
1,960,000
915,000
165,000
370,000

2036
2029
2023-2027
2029
2028
2030-2031
2028
2023
Owned
Owned
2022-2033
2023
2022
2028
2035

In addition, we have offices in Canada, Japan, Australia, France and elsewhere in Europe.

We believe that our existing properties are in good condition and suitable for the conduct of our business. As we continue to expand

our operations, we may need to lease additional or alternative facilities.

Item 3.

Legal Proceedings

The information required to be set forth under this Item 3 is incorporated by reference to Note 14, Commitments and Contingencies—

Legal Proceedings of the Notes to Consolidated Financial Statements, included in Part IV of this Annual Report on Form 10-K.

Item 4.

Mine Safety Disclosures.

Not applicable.

68

2021 Annual Report

| JAZZ PHARMACEUTICALS

PART II

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Market Information

Our ordinary shares trade on The Nasdaq Global Select Market under the trading symbol “JAZZ.”

Holders of Ordinary Shares

As of February 22, 2022, there were 907 holders of record of our ordinary shares. Because almost all of our ordinary shares are held

by brokers, nominees and other institutions on behalf of shareholders, we are unable to estimate the total number of shareholders
represented by these record holders.

Dividends

In 2021 and 2020, we did not declare or pay cash dividends on our common equity. Under Irish law, dividends may only be paid, and share
repurchases and redemptions must generally be funded only out of, “distributable reserves.” In addition, the terms of our credit agreement restrict
our ability to make certain restricted payments, including dividends and other distributions by us in respect of our ordinary shares, subject to,
among other exceptions, (1) a general exception for dividends and restricted payments up to $30 million in the aggregate and (2) an exception that
allows for restricted payments, subject to a cap equal to the sum of (i) $100 million plus (ii) so long as our secured leverage ratio (as defined in our
credit agreement) does not exceed 3:1 after giving pro forma effect to the restricted payment, a formula-based amount tied to our consolidated net
income; provided that such cap applies only if our total leverage ratio (as defined in our credit agreement) exceeds 2:1 after giving pro forma effect
to the restricted payment. Any future determination as to the payment of dividends will, subject to Irish legal requirements, be at the sole discretion
of our board of directors and will depend on our consolidated financial condition, results of operations, capital requirements, compliance with the
terms our credit agreement or other future borrowing arrangements, and other factors our board of directors deems relevant.

K
-
0
1
m
r
o
F

Unregistered Sales of Equity Securities

Except as previously reported in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the Securities and

Exchange Commission, or SEC, during the year ended December 31, 2021, there were no unregistered sales of equity securities by us
during the year ended December 31, 2021.

Irish Law Matters

As we are an Irish incorporated company, the following matters of Irish law are relevant to the holders of our ordinary shares.

Irish Restrictions on Import and Export of Capital

Except as indicated below, there are no restrictions on non-residents of Ireland dealing in Irish domestic securities, which includes
ordinary shares of Irish companies. Dividends and redemption proceeds also continue to be freely transferable to non-resident holders of such
securities. The Financial Transfers Act, 1992 gives power to the Minister for Finance of Ireland to restrict financial transfers between Ireland
and other countries and persons. Financial transfers are broadly defined and include all transfers that would be movements of capital or
payments within the meaning of the treaties governing the member states of the European Union. The acquisition or disposal of interests in
shares issued by an Irish incorporated company and associated payments falls within this definition. In addition, dividends or payments on
redemption or purchase of shares and payments on a liquidation of an Irish incorporated company would fall within this definition. At present
the Financial Transfers Act, 1992 prohibits financial transfers involving the late Slobodan Milosevic and associated persons, Belarus, certain
persons indicted by the International Criminal Tribunal for the former Yugoslavia, the late Osama bin Laden, Al-Qaida, the Taliban of
Afghanistan, Democratic Republic of Congo, Democratic People’s Republic of Korea (North Korea), Iran, Iraq, Côte d’Ivoire, Lebanon, Liberia,
Zimbabwe, Sudan, Somalia, Republic of Guinea, Republic of Guinea-Bissau, Afghanistan, Libya, Syria, Tunisia, certain known terrorists and
terrorist groups, countries that harbor certain terrorist groups and Ukraine without the prior permission of the Central Bank of Ireland.

Any transfer of, or payment in respect of, a share or interest in a share involving the government of any country that is currently the

subject of United Nations sanctions, any person or body controlled by any of the foregoing, or by any person acting on behalf of the
foregoing, may be subject to restrictions pursuant to such sanctions as implemented into Irish law.

Irish Taxes Applicable to U.S. Holders

Irish Tax on Dividends. While we have no current plans to pay dividends, dividends on our ordinary shares would generally be subject

to Irish Dividend Withholding Tax at the standard rate (currently 25%), unless an exemption applies.

JAZZ PHARMACEUTICALS | 2021 Annual Report

69

Irish Tax on Capital Gains. A shareholder who is neither resident nor ordinarily resident in Ireland and does not hold our ordinary
shares in connection with a trade or business carried on by such shareholder in Ireland through a branch or agency should not be subject
to Irish tax on capital gains on a disposal of our ordinary shares.

Capital Acquisitions Tax. Irish capital acquisitions tax, or CAT, is comprised principally of gift tax and inheritance tax. CAT could apply

to a gift or inheritance of our ordinary shares irrespective of the place of residence, ordinary residence or domicile of the parties. This is
because our ordinary shares are regarded as property situated in Ireland as our share register must be held in Ireland. The person who
receives the gift or inheritance has primary liability for CAT.

CAT is levied at a rate of 33% above certain tax-free thresholds. The appropriate tax-free threshold is dependent upon (i) the
relationship between the donor and the donee and (ii) the aggregation of the values of previous gifts and inheritances received by the
donee from persons within the same category of relationship for CAT purposes. Gifts and inheritances passing between spouses are
exempt from CAT. Our shareholders should consult their own tax advisers as to any tax consequences of holding our ordinary shares,
including whether CAT is creditable or deductible in computing any domestic tax liabilities.

Stamp Duty. Irish stamp duty (if any) may become payable in respect of ordinary share transfers. However, a transfer of our ordinary
shares from a seller who holds shares through Depository Trust Company, or DTC, to a buyer who holds the acquired shares through DTC
will not be subject to Irish stamp duty. A transfer of our ordinary shares (i) by a seller who holds ordinary shares outside of DTC to any
buyer or (ii) by a seller who holds the ordinary shares through DTC to a buyer who holds the acquired ordinary shares outside of DTC, may
be subject to Irish stamp duty (currently at the rate of 1% of the price paid or the market value of the ordinary shares acquired, if greater).
The person accountable for payment of stamp duty is the buyer or, in the case of a transfer by way of a gift or for less than market value,
all parties to the transfer.

A shareholder who holds ordinary shares outside of DTC may transfer those ordinary shares into DTC without giving rise to Irish stamp

duty provided that the shareholder would be the beneficial owner of the related book-entry interest in those ordinary shares recorded in the
systems of DTC (and in exactly the same proportions) as a result of the transfer and at the time of the transfer into DTC there is no sale of
those book-entry interests to a third party being contemplated by the shareholder. Similarly, a shareholder who holds ordinary shares through
DTC may transfer those ordinary shares out of DTC without giving rise to Irish stamp duty provided that the shareholder would be the beneficial
owner of the ordinary shares (and in exactly the same proportions) as a result of the transfer, and at the time of the transfer out of DTC there is
no sale of those ordinary shares to a third party being contemplated by the shareholder. In order for the share registrar to be satisfied as to the
application of this Irish stamp duty treatment where relevant, the shareholder must confirm to us that the shareholder would be the beneficial
owner of the related book-entry interest in those ordinary shares recorded in the systems of DTC (and in exactly the same proportions) (or
vice-versa) as a result of the transfer and there is no agreement being contemplated for the sale of the related book-entry interest or the
ordinary shares or an interest in the ordinary shares, as the case may be, by the shareholder to a third party.

70

2021 Annual Report

| JAZZ PHARMACEUTICALS

Performance Measurement Comparison (1)

The following graphs show the total shareholder return on the last day of each year of an investment of $100 in cash as if made on

December 31, 2016 and December 31, 2011, respectively, in (i) our ordinary shares; (ii) the Nasdaq Composite Index; and (iii) the Nasdaq
Biotechnology Index through December 31, 2021. The shareholder return shown in the graphs below are not necessarily indicative of
future performance, and we do not make or endorse any predictions as to future shareholder returns.

COMPARISON OF FIVE YEAR CUMULATIVE TOTAL RETURN (2)

$350

$300

$250

$200

$150

$100

$50

$0

12/16

K
-
0
1
m
r
o
F

12/17

12/18

12/19

12/20

12/21

Jazz Pharmaceuticals

NASDAQ Composite

NASDAQ Biotechnology

COMPARISON OF TEN YEAR CUMULATIVE TOTAL RETURN (2)

$800

$700

$600

$500

$400

$300

$200

$100

$0

12/11

12/12

12/13

12/14

12/15

12/16

12/17

12/18

12/19

12/20

12/21

Jazz Pharmaceuticals

NASDAQ Composite

NASDAQ Biotechnology

JAZZ PHARMACEUTICALS | 2021 Annual Report

71

(1) This section is not “soliciting material,” is not deemed “filed” with the SEC and is not to be incorporated by reference into any of our

filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, or Exchange Act, whether
made before or after the date hereof and irrespective of any general incorporation language in any such filing.
Information used in the graph was obtained from Research Data Group, Inc.

(2)

Issuer Purchases of Equity Securities

In November 2016, our board of directors authorized a share repurchase program and as of December 31, 2021 had authorized the

repurchase of ordinary shares having an aggregate purchase price of up to $1.5 billion, exclusive of any brokerage commissions. Under
this program, which has no expiration date, we may repurchase ordinary shares from time to time on the open market. In 2021, we did not
repurchase any of our ordinary shares under the share repurchase program. As of December 31, 2021, the remaining amount authorized
under the share repurchase program was $431.2 million.

Under the share repurchase program, we are authorized to repurchase shares from time to time through open market repurchases.

Such repurchases may be pursuant to Rule 10b-18 or Rule 10b5-1 agreements as determined by our management and in accordance with
the requirements of the Securities and Exchange Commission.

Item 6.

Reserved

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

The purpose of the Management Discussion and Analysis is to present information that management believes is relevant to promote
a understanding of our results of operations and cash flows for the fiscal year ended December 31, 2021 and our financial condition as of
December 31, 2021 and should be read in conjunction with the consolidated financial statements and notes to consolidated financial
statements included elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risks
and uncertainties. When reviewing the discussion below, you should keep in mind the substantial risks and uncertainties that impact our
business. In particular, we encourage you to review the risks and uncertainties described in “Risk Factors” in Part I, Item 1A in this Annual
Report on Form 10-K. These risks and uncertainties could cause actual results to differ materially from those projected in forward-looking
statements contained in this report or implied by past results and trends.

Overview

Jazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and

their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no
therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage
development, in neuroscience and oncology. Within these therapeutic areas, we strive to identify new options for patients by actively
exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science.

Our strategy for growth is rooted in executing commercial launches and ongoing commercialization initiatives; advancing robust
research and development, or R&D, programs and delivering impactful clinical results; effectively deploying capital to strengthen the
prospects of achieving our short- and long-term goals through strategic corporate development; and delivering strong financial
performance. We focus on patient populations with high unmet needs. We identify and develop differentiated therapies for these patients
that we expect will be long-lived assets and that we can support with an efficient commercialization model. In addition, we leverage our
efficient, scalable operating model and integrated capabilities across our global infrastructure to effectively reach patients around the world.

At the 40th Annual J.P. Morgan Healthcare Conference in January 2022, we announced our Vision 2025, which aims to deliver
sustainable growth and enhanced value, driving our continued transformation to an innovative, high-growth global pharmaceutical leader.
The three core components of our Vision 2025 focus on commercial execution, pipeline productivity and operational excellence.

Our lead marketed products are:

Neuroscience

•

Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution, a product approved by the U.S. Food and
Drug Administration, or FDA, in July 2020 and launched in the U.S. in November 2020 for the treatment of cataplexy or
excessive daytime sleepiness, or EDS, in patients with narcolepsy aged seven years of age and older, and also approved by
FDA in August 2021 for the treatment of idiopathic hypersomnia, or IH, in adults and launched in the U.S. in November 2021.
Xywav contains 92% less sodium than Xyrem®;

72

2021 Annual Report

| JAZZ PHARMACEUTICALS

K
-
0
1
m
r
o
F

•

•

•

•

Xyrem (sodium oxybate) oral solution, a product approved by FDA and distributed in the U.S. for the treatment of both
cataplexy and EDS in patients seven years of age and older with narcolepsy; Jazz also markets Xyrem in Canada for the
treatment of cataplexy in patients with narcolepsy. Xyrem is also approved and distributed in Europe, Great Britain and other
markets through a licensing agreement;

Epidiolex® (cannabidiol) oral solution, a product approved by FDA and launched in the U.S. in 2018 by GW Pharmaceuticals
plc, or GW, and currently indicated for the treatments of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome,
or tuberous sclerosis complex (TSC) in patients one year of age or older; in Europe (where it is marketed as Epidyolex®) and
other markets, it is approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome or Dravet
syndrome, in conjunction with clobazam (EU and Great Britain only), in patients 2 years of age and older and for adjunctive
treatment of seizures associated with TSC in patients 2 years of age and older;

Sunosi® (solriamfetol), a product approved by FDA and marketed in the U.S., Canada, Europe and Great Britain to improve
wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea, or OSA; and

Sativex® (nabiximols) oral solution, a product approved and marketed in the U.K., Canada and other markets as treatment
for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis, or MS, who have not
responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in
spasticity-related symptoms during an initial trial of therapy.

Oncology

•

•

•

•

Zepzelca® (lurbinectedin), a product approved by FDA in June 2020 and launched in the U.S. in July 2020 for the treatment of
adult patients with metastatic small cell lung cancer, or SCLC, with disease progression on or after platinum-based
chemotherapy; in Canada, Zepzelca was approved in September 2021 for the treatment of adults with Stage III or metastatic
SCLC, who have progressed on or after platinum-containing therapy;

Rylaze™ (recombinant Erwinia asparaginase), a product approved by FDA in June 2021 and launched in the U.S. in July 2021
for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia, or ALL,
or lymphoblastic lymphoma, or LBL, in adults and pediatric patients who have developed hypersensitivity to E. coli-derived
asparaginase;

Vyxeos® (daunorubicin and cytarabine) liposome for injection, a product approved in the U.S., Canada, Europe and
Great Britain (marketed as Vyxeos® liposomal in Europe and Great Britain) for the treatment of adults with newly-diagnosed
therapy-related acute myeloid leukemia, or t-AML, or AML with myelodysplasia-related changes (AML-MRC). An expanded
indication was granted in the U.S. for the treatment of newly diagnosed t-AML or AML-MRC in pediatric patients aged 1 year
and older; and

Defitelio® (defibrotide sodium) is a product approved in the U.S. and Brazil for the treatment of hepatic veno-occlusive
disease, or VOD, with renal or pulmonary dysfunction following hematopoietic stem cell transplantation, or HSCT, and in Japan
for the treatment of hepatic sinusoidal obstruction syndrome (hepatic-veno occlusive disease). It is currently approved in the EU,
Great Britain, Canada, Israel, South Korea, Australia and Switzerland for the treatment of severe hepatic VOD, also known as
sinusoidal obstructive syndrome, or SOS, in HSCT therapy. It is indicated in adults and pediatric patients over 1 month of age.

Our strategy to deliver sustainable growth and enhanced value is focused on:

•

•

•

•

•

•

Strong commercial execution to drive diversified revenue growth and address unmet medical needs of our patients across our
product portfolio, which focuses on neuroscience and oncology medicines;

Expanding and advancing our pipeline to achieve a valuable product portfolio of durable, highly differentiated programs;

Continuing to build a flexible, efficient and productive development engine for targeted therapeutic areas to identify and progress
early-, mid- and late-stage assets;

Identifying and acquiring novel product candidates and approved therapies to complement our existing pipeline and commercial
portfolio;

Investing in an efficient, scalable operating model and differentiated capabilities to enable growth; and

Unlocking further value through indication expansion and entry into global markets.

In 2021, consistent with our strategy, we continued to focus on research and development activities within our neuroscience and

oncology therapeutic areas. For a summary of our ongoing research and development activities, see “Business—Research and
Development” in Part I, Item 1 of this Annual Report on Form 10-K.

JAZZ PHARMACEUTICALS | 2021 Annual Report

73

Research and Development Progress

Our development activities encompass all stages of development and currently include clinical testing of new product candidates and
activities related to clinical improvements of, or additional indications or new clinical data for, our existing marketed products. We also have
active preclinical programs for novel therapies, including precision medicines in hematology and oncology and the GW cannabinoid
platform. We are increasingly leveraging our growing internal research and development function, and we have also entered into
collaborations with third parties for the research and development of innovative early-stage product candidates and have supported
additional investigator-sponsored trials, or ISTs, that are anticipated to generate additional data related to our products. We also seek out
investment opportunities in support of development of early- and mid-stage technologies in our therapeutic areas and adjacencies. We
have a number of licensing and collaboration agreements with third parties, including biotechnology companies, academic institutions and
research-based companies and institutions, related to preclinical and clinical research and development activities in hematology and in
precision oncology, as well as in neuroscience.

With the approvals and launches of Rylaze for the treatment ALL or LBL in pediatric and adult patients one month and older who have

developed hypersensitivity to E. coli-derived asparaginase and Xywav for IH in 2021, we accomplished our goal to deliver five product
launches through 2020 and 2021. We have taken both Rylaze and Xywav from concept to commercialization.

Our neuroscience R&D efforts include the planned initiation of a pivotal Phase 3 clinical trial of Epidiolex for the treatment of Epilepsy

with Myoclonic-Atonic Seizures, or EMAS, also known as Doose syndrome, in the first half of 2022. This trial is expected to evaluate
Epidiolex in a fourth childhood-onset epileptic encephalopathy with high unmet need. EMAS is characterized by generalized
myoclonic-atonic seizures, and this trial is designed to provide the first randomized, controlled clinical data with Epidiolex in this syndrome
type. Seizure types including atonic, tonic, clonic, tonic-clonic, and partial onset seizures are seen in Lennox-Gastaut syndrome, or LGS,
Dravet syndrome, or DS, and tuberous sclerosis complex, or TSC.

For nabiximols, we have three ongoing Phase 3 clinical trials in multiple sclerosis (MS)-related spasticity. Spasticity occurs in up to
84% of MS patients, and approximately one-third of those who experience spasticity live with uncontrolled symptoms. The first trial is a
smaller, shorter trial relative to the other two. If results from this first trial are positive, there is the potential for a New Drug Application, or
NDA, submission in the U.S. by the end of 2022.

Additionally, in December 2021 we initiated Phase 2 clinical trials for suvecaltamide (JZP385) for essential tremor, or ET, and for
JZP150 for post-traumatic stress disorder, or PTSD. These are both patient populations that suffer significant impacts to their quality of life
and for whom there are limited current treatment options. We are also pursuing early-stage activities related to the development of JZP324,
an extended-release low sodium, oxybate formulation that we believe could provide a clinically meaningful option for narcolepsy patients.

Within our oncology R&D program, there is a robust development plan being executed for Zepzelca. We are collaborating with Roche on

a pivotal Phase 3 clinical trial evaluating Zepzelca in combination with Tecentriq in first-line extensive stage SCLC. In December 2021, our
licensor PharmaMar initiated a confirmatory trial in second-line SCLC. This is expected to be a three-arm trial comparing Zepzelca as either
monotherapy or in combination with irinotecan to investigator’s choice of irinotecan or topotecan. Data from this trial, if positive, could confirm
the benefit of Zepzelca in the treatment of SCLC when patients progress following first-line treatment with a platinum-based regimen.

In 2022 we initiated a Phase 2 basket trial to explore Zepzelca monotherapy in patients with select advanced or metastatic solid

tumors. Cohorts will include advanced urothelial cancer, large cell neuroendocrine tumor of the lung, and homologous recombinant
deficient positive (HRD+) cancers. In addition, we have initiated a Phase 4 observational study to collect real world safety and outcome
data in adult Zepzelca monotherapy patients with SCLC who progress on or after prior platinum-containing chemotherapy.

For Rylaze, in January 2022 we submitted a sBLA with data in support of a Monday/Wednesday/Friday (M/W/F) IM dosing schedule,

which has been granted review under the Real-Time Oncology Review, or RTOR, program. Part two of the ongoing Rylaze study is
evaluating intravenous administration. We are planning regulatory submissions in Europe in mid-2022.

A summary of our key ongoing and planned development projects is provided under “Business—Research and Development” in

Part I, Item 1 of this Annual Report on Form 10-K.

2021 Highlights and Recent Developments

Regulatory Submissions, Approvals and Commercial Launches

Oxybate Franchise

•

In June 2021, FDA recognized seven years of Orphan Drug Exclusivity (ODE) for Xywav in narcolepsy through July 21, 2027.

74

2021 Annual Report

| JAZZ PHARMACEUTICALS

•

•

In August 2021, FDA approved our sNDA for Xywav for the treatment of IH in adults and in November 2021, we commenced the
U.S. commercial launch.

In January 2022, FDA recognized seven years of ODE for Xywav in IH through August 12, 2028.

Epidiolex/Epidyolex

•

In 2021, the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA), as well as the EU, approved a new indication
for Epidyolex as an adjunctive treatment of seizures associated with TSC, for patients two years of age and older.

Sunosi

•

In May 2021, Sunosi was approved in Canada for the treatment of EDS associated with narcolepsy or OSA in adult patients.

Zepzelca

•

In September 2021, Zepzelca received conditional approval in Canada for the treatment of adult patients with Stage III or
metastatic SCLC who have progressed on or after platinum-containing therapy. In November 2021, Zepzelca was made
commercially available in Canada.

Rylaze

•

•

In June 2021, Rylaze was approved by FDA under the Real-Time Oncology Review, or RTOR, program for use as a component of
a multi-agent chemotherapeutic regimen for the treatment of patients with ALL or LBL in pediatric and adult patients one month and
older who have developed hypersensitivity to E. coli-derived asparaginase. In July 2021, we launched Rylaze in the U.S.

In January 2022, we submitted a sBLA for Rylaze with additional data in support of a Monday/Wednesday/Friday (M/W/F) IM
dosing schedule, which has been granted review under the RTOR program.

K
-
0
1
m
r
o
F

Vyxeos

•

In March 2021, FDA approved a revised label for Vyxeos to include a new indication to treat newly-diagnosed t-AML or AML
with myelodysplasia-related changes in pediatric patients aged one year and older.

Research & Development

•

•

•

In December 2021, we initiated a Phase 2 clinical trial for suvecaltamide (JZP385) for ET.

In December 2021, we initiated a Phase 2 trial for JZP150 for PTSD.

In December 2021, in collaboration with Roche, we have initiated a Phase 3 pivotal clinical trial in first-line extensive stage
SCLC of Zepzelca in combination with Tecentriq® (atezolizumab).

Other Significant Developments

•

•

In May 2021, we acquired GW. The total consideration paid by us for the entire issued share capital of GW was $7.2 billion. The
GW Acquisition, closed on May 5, 2021. As a result, GW became an indirect wholly owned subsidiary of the Company.

In connection with the financing of the transaction, in April 2021, we closed an offering of $1.5 billion in aggregate principal amount
of 4.375% senior secured notes, due 2029, or the Secured Notes. In May 2021, we entered into a credit agreement, or the Credit
Agreement, that provides for (i) a seven-year $3.1 billion term loan B facility, or the Dollar Term Loan, (ii) a seven-year
€625.0 million term loan B facility, or the Euro Term Loan and, together with the Dollar Term Loan, collectively known as the Term
Loan and (iii) a five-year $500.0 million revolving credit facility, or the Revolving Credit Facility. We financed the cash portion of the
GW Acquisition consideration through a combination of cash on hand and borrowings under the Term Loan and the Secured Notes.
The Revolving Credit Facility is currently undrawn.

Acquisition of GW Pharmaceuticals Plc

In May 2021, we acquired GW with the objectives of broadening our neuroscience portfolio, further diversifying our revenue and driving

sustainable, long-term value creation opportunities. The total consideration paid by us for the entire issued share capital of GW was $7.2 billion.

JAZZ PHARMACEUTICALS | 2021 Annual Report

75

GW’s lead product, Epidiolex (cannabidiol) oral solution, is approved in patients one-year and older for the treatment of seizures

associated with LGS, DS and TSC, all of which are rare diseases characterized by severe early-onset epilepsy. Epidiolex was the
first plant-derived cannabinoid medicine ever approved by FDA, and has also been approved in Europe under the trade name Epidyolex. In
addition to the approved indications for Epidiolex, we believe there are considerable opportunities to pursue other indications within the
epilepsy field, including other treatment-resistant epilepsies where significant unmet needs of patients exist. We plan to initiate a pivotal
Phase 3 clinical trial of Epidiolex for the treatment of seizures associated with EMAS, known as Doose syndrome, in the first half of 2022.
EMAS represents the fourth target indication for Epidiolex.

We plan to continue to leverage the GW cannabinoid platform and significant expertise in discovering, developing, manufacturing and
commercializing therapeutics to address a broad range of diseases. This platform includes nabiximols, which is in Phase 3 clinical trials for
the treatment of spasticity associated with multiple sclerosis with an additional planned Phase 3 clinical trial in spasticity associated with
spinal cord injury, as well as earlier-stage cannabinoid product candidates.

We view the GW Acquisition as consistent with our overall business and capital allocation strategy to expand our neuroscience

portfolio and drive substantial value for our shareholders.

Operational Excellence

We remain focused on continuing to build excellence in areas that we believe will give us a competitive advantage, including building
an increasingly agile and adaptable commercialization engine and strengthening our customer-focused market expertise across patients,
providers and payors. We are refining our approach to engaging our customers by strengthening alignment and integration across
functions and across regions. This includes a more integrated approach to brand planning, a heightened focus on launch and operational
excellence and multichannel customer engagement. We have fully adapted to virtual scientific congresses designed to ensure we can
continue to provide promotional and non-promotional interactions and have supported our field-based teams with virtual customer
interaction tools, training and content. These initiatives mark a significant operational evolution that is directly linked to our corporate
strategy and are designed to better enable our teams to work collaboratively on an aligned and shared agenda through both virtual and
in-person interactions. We anticipate that our teams will increase the frequency of in-person interactions as medical congresses and
healthcare practices begin to resume in-person activities, taking into account applicable public health authority and local government
guidelines which are designed to ensure community and employee safety.

COVID-19 Business Update

We have implemented a comprehensive response strategy designed to manage the impact of the COVID-19 pandemic on our
employees, patients and our business. The prolonged nature of the pandemic is negatively impacting our business in a varied manner due
to the emergence of the Delta and Omicron variants and other variants with increased transmissibility, even in some cases in vaccinated
people, including limited access to health care provider offices and institutions and the willingness of patients or parents of patients to seek
treatment or change existing treatments. We expect that our business, financial condition, results of operations and growth prospects may
continue to be negatively impacted by the pandemic on a limited basis that may vary depending on the context. However we have begun to
observe, and expect to continue to observe, a gradual normalization in patient and healthcare provider practices, as providers and patients
have adapted their behaviors and procedures to the evolving circumstances and as COVID-19 vaccines continue to be administered.

Workplace and Employees

We support broad public health strategies designed to prevent the spread of COVID-19 and are focused on the health and welfare of
our employees. Our global organization has mobilized to enable our employees to accomplish our most critical goals through a combination
of remote work and in-person initiatives. In addition to rolling out new technologies and collaboration tools, we have implemented
processes and resources to support our employees in the event an employee receives a positive COVID-19 diagnosis. We have developed
plans regarding the opening of our sites to enable our employees to return to work in our global offices, the field and our manufacturing
facilities, which take into account applicable public health authority and local government guidelines and which are designed to ensure
community and employee safety. We are moving to a more flexible mix of virtual and in-person working to advance our culture, drive
innovation and agility and enable greater balance and well-being for our workforce. This will also enable us to reconfigure our physical
workspaces to optimize the footprint of our company-owned or leased office spaces.

Commercialization

There continues to be some negative impact on demand, new patient starts and treatments for our products arising from the
pandemic, primarily due to the inherent limitations of telemedicine and a reprioritization of healthcare resources toward COVID-19. As

76

2021 Annual Report

| JAZZ PHARMACEUTICALS

healthcare systems have adapted to cope with the ongoing situation, we have seen improvements. We are utilizing technology to continue
to engage healthcare professionals and other customers virtually to support patient care. As more clinics and institutions begin to allow
in-person interactions pursuant to local health authority and government guidelines, our field teams continue to resume in-person
interactions with healthcare professionals and clinics combined with virtual engagement. The level of renewed in-person engagement
varies by account, region and country and may be adversely impacted in the future as a result of the continuing impact of the COVID-19
pandemic. The lack of access to health care providers has caused, and may continue to cause, delays in appropriate diagnosis, treatment
and ongoing care for some patients, which has negatively impacted, and could continue to impact, prescribing and use of our products.

Supply Chain

Our manufacturing facilities in Athlone, Ireland, which produces Xywav and Xyrem, Villa Guardia, Italy, which produces defibrotide,

and Kent Science Park, U.K., which produces Epidiolex/Epidyolex and Sativex, are operational with essential staff onsite and office-based
staff working onsite and remotely as business needs require. We currently expect to have adequate global supply of all products for 2022.

Research and Development

With respect to our clinical trial activities, we have taken measures to implement remote and virtual approaches, including remote data
monitoring where possible, to maintain patient safety and trial continuity and to preserve study integrity. We have seen limited COVID-19-related
impact to our mid- and late-stage clinical trial activity, despite delays in initiating trial sites. We rely on contract research organizations or other
third parties to assist us with clinical trials, and we cannot guarantee that they will continue to perform their contractual duties in a timely and
satisfactory manner as a result of the evolving effects of the COVID-19 pandemic. Similarly, our ability to recruit and retain patients and principal
investigators and site staff who, as health care providers, may have heightened exposure to COVID-19, may adversely impact our clinical trial
operations. Supply chain disruptions related to the pandemic may also impact our ability to initiate clinical trials in a timely manner.

K
-
0
1
m
r
o
F

Corporate Response

The COVID-19 pandemic has caused a significant burden on health systems globally and has highlighted the need for companies to

evaluate existing therapies to assess if they can be utilized beyond their current indications to treat COVID-19 as well as consider
developing new therapies. To this end, we have granted requests for several ISTs to evaluate the use of defibrotide in COVID-19 patients
experiencing respiratory distress.

In addition, we are supporting our local communities and patient-focused organizations in COVID-19 relief efforts including through
corporate donations to charitable organizations providing food and medical relief to communities in which we operate, and other localities
where the needs related to the impact of COVID-19 are greatest. We are engaging with patient advocacy organizations to better understand
the impact of COVID-19 and working to enable patients living with sleep disorders, epilepsies and oncology conditions with access to
treatments and that their other needs are addressed given the impact of COVID-19 on the healthcare system. We are committed to enabling
our employees to give back, including allowing licensed healthcare practitioners employed by us to support local response efforts.

Other Challenges, Risks and Trends Related to Our Business

Our business has been substantially dependent on Xyrem. Our future plans assume that our newly launched oxybate product Xywav,
with 92% lower sodium compared to Xyrem, depending on the dose, absence of a sodium warning and dosing titration option, will become the
treatment of choice for patients who can benefit from oxybate treatment, current Xyrem patients, and patients who previously were not
prescribed Xyrem, including those patients for whom sodium content is a concern. In June 2021, FDA recognized seven years of ODE for
Xywav in narcolepsy through July 21, 2027 stating that Xywav is clinically superior to Xyrem by means of greater safety due to reduced chronic
sodium burden. While we expect that our business will continue to be substantially dependent on oxybate product sales from both Xywav and
Xyrem, there is no guarantee that we can maintain oxybate sales at or near historical levels, or that oxybate sales will continue to grow.

Our ability to successfully commercialize Xywav will depend on, among other things, our ability to maintain adequate coverage and
reimbursement for Xywav and acceptance of Xywav by payors, physicians and patients, including of Xywav for the treatment of idiopathic
hypersomnia in adults. In an effort to support strong adoption of Xywav, we are focused on providing robust patient copay and savings
programs and facilitating payor coverage for Xywav. Moreover, we have increasingly experienced pressure from third party payors to agree
to discounts, rebates or restrictive pricing terms, and we cannot guarantee we will be able to agree to commercially reasonable terms with
pharmacy benefit managers, or PBMs, and other third party payors, or that we will be able to ensure patient access and acceptance on
institutional formularies. Entering into agreements with PBMs and payors to ensure patient access has and will likely continue to result in
higher gross to net deductions. In addition to the COVID-19 related impacts described above, in the future, we expect our oxybate products
to face competition from generic and authorized generic versions of sodium oxybate pursuant to the settlement agreements we have

JAZZ PHARMACEUTICALS | 2021 Annual Report

77

entered into with multiple abbreviated new drug application, or ANDA, filers. Generic competition can decrease the prices at which Xywav
and Xyrem are sold and the number of prescriptions written for Xywav and Xyrem. Xywav and Xyrem may also face increased competition
from new branded products for treatment of cataplexy and/or EDS in narcolepsy in the U.S. market.

Our financial condition, results of operations and growth prospects are also dependent on our ability to maintain or increase sales of

Epidiolex/Epidyolex in the U.S. and Europe, which is subject to many risks and there is no guarantee that we will be able to continue to
successfully commercialize Epidiolex for its approved indications. While we have established our Epidiolex commercial team and have hired
our U.S. and European sales forces, we will need to continue to maintain and further develop the teams to continue to successfully coordinate
the commercialization of Epidiolex. The commercial success of Epidiolex depends on the extent to which patients and physicians accept and
adopt Epidiolex as a treatment for seizures associated with LGS, DS and TSC, and we do not know whether our or others’ estimates in this
regard will be accurate. Physicians may not prescribe Epidiolex and patients may be unwilling to use Epidiolex if coverage is not provided or
reimbursement is inadequate to cover a significant portion of the cost. Additionally, any negative development for Epidiolex in the market after
launch, in clinical development for additional indications, or in regulatory processes in other jurisdictions, may adversely impact the commercial
results and potential of Epidiolex. Thus, significant uncertainty remains regarding the commercial potential of Epidiolex.

In addition to our neuroscience products and product candidates, we are commercializing a portfolio of oncology products, including
Defitelio, Vyxeos, Rylaze and Zepzelca. An inability to effectively commercialize Defitelio, Vyxeos, Rylaze and Zepzelca and to maximize
their potential where possible through successful research and development activities could have a material adverse effect on our
business, financial condition, results of operations and growth prospects.

A key aspect of our growth strategy is our continued investment in our evolving and expanding research and development activities. If

we are not successful in the clinical development of these or other product candidates, if we are unable to obtain regulatory approval for
our product candidates in a timely manner, or at all, or if sales of an approved product do not reach the levels we expect, our anticipated
revenue from our product candidates would be negatively affected, which could have a material adverse effect on our business, financial
condition, results of operations and growth prospects.

In addition to continued investment in our research and development pipeline, we intend to continue to grow our business by
acquiring or in-licensing, and developing, including with collaboration partners, additional products and product candidates that we believe
are highly differentiated and have significant commercial potential. Failure to identify and acquire, in-license or develop additional products
or product candidates, successfully manage the risks associated with integrating any products or product candidates into our portfolio or
the risks arising from anticipated and unanticipated problems in connection with an acquisition or in-licensing, such as the GW Acquisition,
could have a material adverse effect on our business, results of operations and financial condition.

The success of the GW Acquisition will depend, in part, on our ability to realize the anticipated benefits from successfully combining our

and GW’s businesses and we plan to continue to devote substantial management attention and resources to integrating our business practices
and operations with GW’s in an effort to fully realize the anticipated benefits of the GW Acquisition. Nonetheless, Epidiolex and the other
products and technologies acquired may not be successful or continue to grow at the same rate as if our companies operated independently or
they may require significantly greater resources and investments than originally anticipated. Conversely, the liabilities assumed in the GW
Acquisition may be greater than originally anticipated. In addition, difficulties may arise during the process of combining the operations of our
companies that could result in the failure to achieve the synergies or free cash flow that we anticipate, the failure to integrate operations and
internal systems, programs and controls, the loss of key employees that may be difficult to replace in the very competitive pharmaceutical field,
the failure to harmonize both companies’ corporate cultures, and the disruption of each company’s ongoing businesses or inconsistencies in
standards, controls, procedures and policies that adversely affect our ability to maintain relationships with customers, suppliers, distributors,
collaboration partners, clinical trial investigators or managers of our clinical trials. As a result, the anticipated benefits of the GW Acquisition
may not be realized fully within the expected timeframe or at all or may take longer to realize or cost more than expected, which could
materially and adversely affect our business, financial condition, results of operations and growth prospects.

Our industry has been, and is expected to continue to be, subject to healthcare cost containment and drug pricing scrutiny by regulatory
agencies in the U.S. and internationally. If healthcare policies or reforms intended to curb healthcare costs are adopted or if we experience negative
publicity with respect to pricing of our products or the pricing of pharmaceutical drugs generally, the prices that we charge for our products may be
affected, our commercial opportunity may be limited and/or our revenues from sales of our products may be negatively impacted. We are also
subject to increasing pricing pressure and restrictions on reimbursement imposed by payors. If we fail to obtain and maintain adequate formulary
positions and institutional access for our products and future approved products, we will not be able to achieve a return on our investment and our
business, financial condition, results of operations and growth prospects would be materially adversely affected.

While certain preparations of cannabis remain Schedule I controlled substances, if such products are approved by FDA for medical
use in the U.S. they are rescheduled to Schedules II-V, since approval by FDA satisfies the “accepted medical use” requirement; or may be

78

2021 Annual Report

| JAZZ PHARMACEUTICALS

removed from control under the Controlled Substances Act entirely. If any of our product candidates receive FDA approval, the U.S. Drug
Enforcement Administration, or DEA, will make a scheduling determination. If any foreign regulatory authority determines that Epidyolex
may have potential for abuse, or if DEA makes a similar determination for nabiximols, it may require us to generate more clinical or other
data than we currently anticipate to establish whether or to what extent the substance has an abuse potential, which could increase the
cost, delay the approval and/or delay the launch of that product. In addition, there are non-FDA approved cannabidiol preparations being
made available from companies through the state-enabled medical marijuana industry, which might attempt to compete with Epidiolex and,
if approved by FDA, nabiximols. If we are unable to compete successfully, our commercial opportunities will be reduced and our business,
results of operations and financial conditions may be materially harmed.

Finally, business practices by pharmaceutical companies, including product formulation improvements, patent litigation settlements,

and risk evaluation and mitigation strategy, or REMS, programs, have increasingly drawn public scrutiny from legislators and regulatory
agencies, with allegations that such programs are used as a means of improperly blocking or delaying competition. If we become the
subject of any future government investigation with respect to our business practices, including as they relate to the Xywav and Xyrem
REMS, the launch of Xywav, our Xyrem patent litigation settlement agreements or otherwise, we could incur significant expense and could
be distracted from operation of our business and execution of our strategy. From June 2020 to October 2021, a number of lawsuits were
filed on behalf of purported direct and indirect Xyrem purchasers, alleging that the patent litigation settlement agreements we entered with
certain generic companies violate state and federal antitrust and consumer protection laws. For additional information on these lawsuits,
see Note 14, Commitments and Contingencies-Legal Proceedings of the Notes to Consolidated Financial Statements, included in Part IV of
this Annual Report on Form 10-K. It is possible that additional lawsuits will be filed against us making similar or related allegations. We
cannot predict the outcome of these or potential additional lawsuits or government action; however, if the plaintiffs were to be successful in
their claims, they may be entitled to injunctive relief or we may be required to pay significant monetary damages. Any of the foregoing risks
and uncertainties could have a material adverse effect on our business, financial condition, results of operations and growth prospects. In
addition, to the extent the COVID-19 pandemic continues to adversely affect our business and results of operations, it may also have the
effect of heightening many of the other risks and uncertainties described above. All of these risks and uncertainties are discussed in
greater detail, along with other risks and uncertainties, in “Risk Factors” in Part I, Item 1A of this Annual Report on Form 10-K.

K
-
0
1
m
r
o
F

Results of Operations

The following table presents revenues and expenses for the years ended December 31, 2021, 2020 and 2019 (in thousands except

percentages):

Product sales, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Royalties and contract revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cost of product sales (excluding amortization of acquired developed

technologies)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Selling, general and administrative . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Research and development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Intangible asset amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Impairment charge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acquired in-process research and development . . . . . . . . . . . . . . . . . . . . . . .
Interest expense, net
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Foreign exchange loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Income tax expense (benefit)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Equity in loss of investees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2021(1)

Change

2020

Change

2019

$3,079,001
15,237

31% $2,346,660
16,907
(10)%

10% $2,135,601
26,160
(35)%

440,760
1,451,683
505,748
525,769
—
—
278,766
4,350
216,116
714

196%
70%
51%
103%
N/A(2)
N/A(2)
180%
33%
545%
(76)%

148,917
854,233
335,375
259,580
136,139
251,250
99,707
3,271
33,517
2,962

16%
16%
12%
(27)%
N/A(2)
N/A(2)
38%
(44)%
N/A(2)
(28)%

127,930
736,942
299,726
354,814
—
109,975
72,261
5,811
(73,154)
4,089

(1) The results of operations of the GW business have been included from the closing of the GW Acquisition on May 5, 2021.
(2) Comparison to prior period is not meaningful.

JAZZ PHARMACEUTICALS | 2021 Annual Report

79

Revenues

The following table presents product sales, royalties and contract revenues, and total revenues for the years ended

December 31, 2021, 2020 and 2019 (in thousands except percentages):

Xyrem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Xywav . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$1,265,830
535,297

(27)% $1,741,758
15,264
N/A(1)

6% $1,642,525
—

N/A(1)

2021

Change

2020

Change

2019

Total Oxybate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Epidiolex/Epidyolex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sunosi
Sativex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total Neuroscience . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Zepzelca . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Rylaze . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Vyxeos . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Defitelio/defibrotide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Erwinaze/Erwinase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total Oncology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Other

1,801,127
463,645
57,914
12,707

2,335,393
246,808
85,629
134,060
197,931
69,382

733,810
9,798

3% 1,757,022
—
28,333
—

N/A(2)
104%
N/A(2)

7% 1,642,525
—
3,714
—

N/A(2)
N/A(1)
N/A(2)

31% 1,785,355
90,380
173%
—
N/A(1)
11%
1%
(53)%

N/A(1)
N/A(1)
121,105 — %
13%
195,842
(17)%
147,136

8% 1,646,239
—
—
121,407
172,938
177,465

32%
43%

554,463
6,842

18%
(61)%

471,810
17,552

Product sales, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Royalties and contract revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

3,079,001
15,237

31% 2,346,660
16,907
(10)%

10% 2,135,601
26,160
(35)%

Total revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$3,094,238

31% $2,363,567

9% $2,161,761

(1) Comparison to prior period is not meaningful.
(2) The results of operations of the GW business have been included from the closing of the GW Acquisition on May 5, 2021 and

comparison to prior period is not meaningful.

Product Sales, Net

Total oxybate product sales increased in 2021 compared to 2020 primarily due to a higher average selling price, partially offset by

higher gross to net deductions driven by higher Tricare rebates and additional commercial payor contracts, and to a lesser extent a
decrease in commercial sales volumes. Total oxybate revenue bottle volume decreased by 1% in 2021 compared to 2020 reflecting our
continued investment in patient access programs during the launch of Xywav. Average active oxybate patients on therapy were
approximately 16,200 in the fourth quarter of 2021, an increase of approximately 6% compared to the same period in 2020. Xyrem product
sales decreased in 2021 compared to 2020 primarily due to a decrease in sales volume, due to the strong adoption of Xywav by existing
Xyrem patients, partially offset by a higher average net selling price. Price increases were instituted in January 2021 and January 2020.
Xywav product sales were $535.3 million in 2021 compared to $15.3 million in 2020, following its U.S. launch in November 2020. Total
oxybate product sales increased in 2020 compared to 2019 primarily due to a higher average selling price and, to a lesser extent, an
increase in commercial sales volume, partially offset by higher gross to net deductions. Total oxybate revenue bottle volume increased by
4% in 2020 compared to 2019 primarily driven by persistence and compliance among existing Xyrem patients. Xyrem product sales
increased in 2020 compared to 2019 primarily due to a higher average selling price and, to a lesser extent, an increase in sales volume,
partially offset by higher gross to net deductions driven by managed care plans and commercial payor contracts. Price increases were
instituted in January 2020, and in January and July 2019. In 2020 new patient diagnoses and enrollments were negatively impacted by
COVID-19. Epidiolex/Epidyolex product sales in 2021, from the closing of the GW Acquisition on May 5, 2021 to December 31, 2021 were
$463.6 million. On a pro forma basis, Epidiolex/Epidyolex product sales increased by 29% in 2021 compared to 2020, primarily due to an
increase in commercial sales volumes. Sunosi product sales increased in 2021, compared to 2020 primarily due to an increase in sales
volume, partially offset by higher gross to net deductions. Sunosi product sales increased in 2020 compared to 2019 following launch in the
U.S. in July 2019 and the European rolling launch commenced in May 2020.

Zepzelca product sales increased in 2021 compared to 2020 primarily due to higher sales volumes following launch in the U.S in
July 2020. Rylaze product sales were $85.6 million in 2021, following its U.S. launch in July 2021. Vyxeos product sales increased in 2021
compared to 2020 primarily due to lower gross to net deductions driven by a reduction in the returns provision due to lower than estimated
actual returns. Vyxeos product sales in 2020 were in line with 2019. Defitelio/defibrotide product sales increased in 2021 compared to
2020, primarily due to the positive impact of foreign exchange rates, partially offset by lower average net selling price due to regional mix.

80

2021 Annual Report

| JAZZ PHARMACEUTICALS

Defitelio/defibrotide product sales increased in 2020 compared to 2019, primarily due to higher sales volumes, partially offset by lower
average net selling price due to regional mix. We distributed our final Erwinaze inventory in June 2021 following expiration of our license
and supply agreement. Erwinaze/Erwinase product sales decreased in 2020 compared to 2019 primarily due to limited availability of supply
of inventory from the manufacturer. We expect product sales, net will increase in 2022 over 2021, primarily due to an increase in sales of
Xywav partially offset by a decrease in sales of Xyrem as patients continue to transition to Xywav, expected growth in, and the inclusion of
a full year sales of, Epidiolex and Rylaze and expected growth in sales of Zepzelca.

Royalties and Contract Revenues

Royalties and contract revenues decreased in 2021 compared to 2020 primarily due to lower contract revenues from out-licensing

agreements. Royalties and contract revenues decreased in 2020 compared to 2019 primarily due to lower milestone revenues from
out-licensing agreements. We expect royalties and contract revenues to increase in 2022 compared to 2021 primarily due to increased
royalty revenue.

Cost of Product Sales

Cost of product sales increased in 2021 compared to 2020, primarily due to the cost of product sales acquired in the GW Acquisition,
including the acquisition accounting inventory fair value step-up expense, or fair value step-up expense. Cost of product sales increased in
2020 compared to 2019, primarily due to a change in product mix and an increase in net product sales. Gross margin as a percentage of
net product sales was 85.7%, 93.7% and 94.0% in 2021, 2020 and 2019, respectively. The decrease in our gross margin percentage in
2021 compared to 2020 was primarily due to the impact of the fair value step-up expense. We expect our cost of product sales to increase
in 2022 compared to 2021 primarily driven by the inclusion of a full year of fair value step-up expense.

K
-
0
1
m
r
o
F

Selling, General and Administrative Expenses

Selling, general and administrative expenses increased in 2021 compared to 2020 primarily due to transaction and integration-related

expenses of $229.0 million in 2021, an increase in compensation-related expenses driven by higher headcount as a result of the GW
Acquisition and increased investment in sales and marketing spend primarily related to Sunosi, Epidiolex and Xywav. Selling, general and
administrative expenses increased in 2020 compared to 2019 primarily due to increased investment in sales, marketing and launch
activities related to the launches of Zepzelca and Xywav in the U.S., and the continuation of the launch of Sunosi in the U.S., as well as an
increase in other expenses related to the expansion of our business. We expect selling, general and administrative expenses in 2022 to
decrease compared to 2021, primarily due to a reduction in transaction and integration-related expenses, together with synergies expected
to be realized connected to the GW Acquisition, partially offset by the inclusion of full year expense related to the GW Acquisition.

Research and Development Expenses

Research and development expenses consist primarily of costs related to clinical studies and outside services, personnel expenses,

milestone expenses and other research and development costs. Clinical study and outside services costs relate primarily to services
performed by clinical research organizations, materials and supplies, and other third party fees. Personnel expenses relate primarily to
salaries, benefits and share-based compensation. Other research and development expenses primarily include overhead allocations
consisting of various support and facilities-related costs. We do not track fully-burdened research and development expenses on a
project-by-project basis. We manage our research and development expenses by identifying the research and development activities that
we anticipate will be performed during a given period and then prioritizing efforts based on our assessment of which development activities
are important to our business and have a reasonable probability of success, and by dynamically allocating resources accordingly. We also
continually review our development pipeline projects and the status of their development and, as necessary, reallocate resources among
our development pipeline projects that we believe will best support the future growth of our business.

The following table provides a breakout of our research and development expenses by major categories of expense (in thousands):

Clinical studies and outside services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Personnel expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Milestone expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$234,462
193,716
15,000
62,570

$169,904
127,794
1,000
36,677

$133,042
100,090
26,000
40,594

Total

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$505,748

$335,375

$299,726

Year Ended December 31,

2021

2020

2019

JAZZ PHARMACEUTICALS | 2021 Annual Report

81

Research and development expenses increased by $170.4 million in 2021 compared to 2020. Clinical studies and outside services
costs increased in 2021 compared to 2020 primarily due to the addition of costs related to clinical programs for nabiximols, Epidiolex and
cannabinoids and an increase in costs related to suvecaltamide (JZP385) and JZP150. Personnel expenses increased by $65.9 million in
2021 compared to 2020, primarily due to increased headcount primarily driven by the GW Acquisition. Milestone expense of $15.0 million
in 2021 primarily related to milestones expense of $13.0 million made under our asset purchase and collaboration agreements with
Redx Pharma, or Redx. Research and development expenses increased by $35.6 million in 2020 compared to 2019. Clinical studies and
outside services costs increased in 2020 compared to 2019 primarily due to the progress made on our clinical programs, including JZP458
and JZP385. Personnel expenses increased by $27.7 million in 2020 compared to 2019, primarily due to increased headcount in support of
our development programs. Milestone expense of $26.0 million in 2019 related to milestone payments made under our license and option
agreement with Ligand Pharmaceuticals Incorporated, or Ligand.

For 2022, we expect that our research and development expenses will continue to increase from previous levels due to the inclusion

of a full year of expense with respect to the acquired GW business and as we prepare for anticipated data read-outs from clinical trials,
initiate and undertake additional clinical trials and related development work and potentially acquire rights to additional product candidates.

Intangible Asset Amortization

Intangible asset amortization increased by $266.2 million in 2021 compared to 2020 primarily due to the commencement of
amortization on the intangible assets arising from the GW Acquisition in May 2021, primarily related to Epidiolex. Intangible asset
amortization decreased in 2020 compared to 2019 primarily due to the amortization of the cost of the priority review voucher, or PRV, of
$111.1 million in full in 2019 following the notification to FDA of our intention to redeem it in the NDA submission for Xywav, partially offset
by the commencement of amortization of the Zepzelca intangible asset upon FDA approval in June 2020. Intangible asset amortization is
expected to increase in 2022 compared to 2021 primarily as a result of the inclusion of a full years amortization on the intangible assets
acquired in the GW Acquisition.

Impairment Charges

In 2020, we recorded an acquired in-process research and development, or IPR&D, asset impairment charge of $136.1 million
following the decision to stop enrollment in our Phase 3 clinical study of defibrotide for the prevention of VOD due to a determination that
the study was highly unlikely to reach one of its primary endpoints.

Acquired In-Process Research and Development

Acquired IPR&D expense in 2020 primarily related to an upfront payment of $200.0 million to PharmaMar in connection with our license

agreement for Zepzelca. In 2019, acquired IPR&D expense primarily related to an upfront payment of $56.0 million to Codiak in connection
with our strategic collaboration agreement and the value attributed to suvecaltamide (JZP385) in the acquisition of Cavion, Inc., or Cavion.

Interest Expense, Net

Interest expense, net increased by $179.1 million in 2021 compared to 2020, primarily due to increased interest expense incurred on

the Term Loan and the Secured Notes which were used, in part, to finance the cash portion of the GW Acquisition and higher non-cash
interest expense following the issuance of our 2.00% exchangeable senior notes due 2026, or the 2026 Notes, in June 2020. Interest
expense, net increased by $27.4 million in 2020 compared to 2019, primarily due to higher non-cash interest expense following the
issuance of the 2026 Notes, lower interest income and a loss on extinguishment of debt related to the partial repurchases of our 1.875%
exchangeable senior notes due 2021, or the 2021 Notes. We adopted ASU No. 2020-06, “Debt—Debt with Conversion and Other Options
(Subtopic 470-20) and Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible
Instruments and Contracts in an Entity’s Own Equity”, or ASU 2020-06, on January 1, 2022, and as a result we expect interest expense,
net to decrease in 2022 compared to 2021 due to decreased non-cash interest expense on our 1.50% exchangeable senior notes due
2024, or the 2024 Notes and the 2026 Notes, as we will no longer recognize non-cash interest expense on the debt discount, partially
offset by an increase in interest expense primarily related to a full year of interest expense on the Term Loan and Secured Notes. For more
information relating to ASU 2020-06 see Note 2, Summary of Significant Accounting Policies included in the Notes to Consolidated
Financial Statements, included in Part IV of this Annual Report on Form 10-K.

Foreign Exchange Loss

The foreign exchange loss is primarily related to the translation of euro and sterling-denominated net monetary liabilities, primarily

intercompany balances, held by subsidiaries with a U.S. dollar functional currency and related foreign exchange forward contracts not
designated as hedging instruments.

82

2021 Annual Report

| JAZZ PHARMACEUTICALS

K
-
0
1
m
r
o
F

Income Tax Expense (Benefit)

Our income tax expense was $216.1 million and $33.5 million in 2021 and 2020, respectively, and our income tax benefit was
$73.2 million in 2019. Our income tax expense in 2021 included an expense of $259.9 million arising on the remeasurement of our U.K. net
deferred tax liability, which arose primarily in relation to the GW Acquisition, due to a change in the statutory tax rate in the U.K. following
enactment of the U.K. Finance Act 2021. Excluding this impact, the increase in benefit for income taxes in 2021 compared to 2020 resulted
primarily from the mix of pre-tax income and losses incurred across tax jurisdictions, deductions on subsidiary equity and the impacts
recognized in 2020 of the disallowance of certain interest deductions and a provision for a proposed settlement reached with the French taxing
authorities. Our income tax benefit in 2019 included a discrete tax benefit of $112.3 million resulting from an intra-entity intellectual property
asset transfer. Excluding this effect, the increase in the effective tax rate for 2020 compared to 2019 was primarily due to the benefit
recognized in 2019 from the application of the Italian patent box incentive regime 2015 through 2019 and the impacts recognized in 2020 of the
disallowance of certain interest deductions and a provision for a proposed settlement reached with the French taxing authorities.

Equity in Loss of Investees

Equity in loss of investees relates to our share in the net loss of companies in which we have made investments accounted for under

the equity method of accounting.

Liquidity and Capital Resources

As of December 31, 2021, we had cash and cash equivalents of $591.4 million, borrowing availability under our revolving credit
facility of $500.0 million and a long-term debt principal balance of $6.4 billion. Our long-term debt included $3.3 billion aggregate principal
amount Term Loan, $1.5 billion principal amount of the Secured Notes, $575.0 million principal amount of the 2024 Notes, and $1.0 billion
principal amount of the 2026 Notes. During 2021, 2020 and 2019, we generated cash flows from operations of $778.5 million,
$899.6 million and $776.4 million, respectively, and we expect to continue to generate positive cash flow from operations which will enable
us to operate our business and de-lever our balance sheet over time.

In April 2021, we issued $1.5 billion in aggregate principal amount of the Secured Notes and in May 2021 we entered into the Credit

Agreement that provides for $3.8 billion in aggregate principal amount of the Term Loan, and a five-year $500.0 million Revolving Credit
Facility, which is currently undrawn. We used the proceeds from the Term Loan (i) to repay in full $575.9 million that was outstanding under
our credit agreement, dated as of June 18, 2015, or the Existing Credit Agreement, (ii) to fund, in part, the cash consideration payable in
connection with the GW Acquisition and (iii) to pay related fees and expenses. We expect to use future loans under the Revolving Credit
Facility, if any, for general corporate purposes, including potential business development activities.

In September and December 2021, we made voluntary prepayments totaling €416.7 million or $502.0 million on the Euro Term Loan

and in August 2021 we repurchased the remaining $218.8 million aggregate principal amount of our 1.875% exchangeable senior notes
due 2021, or the 2021 Notes.

We have a significant amount of debt outstanding on a consolidated basis. For a more detailed description of our debt arrangements,

including information relating to our scheduled maturities with respect to our long-term debt see Note 12, Debt, of the Notes to
Consolidated Financial Statements, included in Part IV of this Annual Report on Form 10-K. This substantial level of debt could have
important consequences to our business, including, but not limited to the factors set forth in in Part I, Item 1A “Risk Factors” of this Annual
Report on Form 10-K under the heading “We have incurred substantial debt, which could impair our flexibility and access to capital and
adversely affect our financial position, and our business would be adversely affected if we are unable to service our debt obligations.”

We believe that our existing cash and cash equivalents balance, cash we expect to generate from operations and funds available
under our revolving credit facility will be sufficient to fund our operations and to meet our existing obligations for the foreseeable future. The
adequacy of our cash resources depends on many assumptions, including primarily our assumptions with respect to product sales and
expenses, as well as the other factors set forth in “Risk Factors” in Part I, Item 1A of this Annual Report on Form 10-K under the headings
“Risks Related to our Lead Products and Product Candidates” and “To continue to grow our business, we will need to commit substantial
resources, which could result in future losses or otherwise limit our opportunities or affect our ability to operate and grow our business.” Our
assumptions may prove to be wrong or other factors may adversely affect our business, and as a result we could exhaust or significantly
decrease our available cash resources, and we may not be able to generate sufficient cash to service our debt obligations which could,
among other things, force us to raise additional funds and/or force us to reduce our expenses, either of which could have a material
adverse effect on our business.

To continue to grow our business over the longer term, we plan to commit substantial resources to product acquisition and

in-licensing, product development, clinical trials of product candidates and expansion of our commercial, development, manufacturing and

JAZZ PHARMACEUTICALS | 2021 Annual Report

83

other operations. In this regard, we have evaluated and expect to continue to evaluate a wide array of strategic transactions as part of our
strategy to acquire or in-license and develop additional products and product candidates. Acquisition opportunities that we pursue could
materially affect our liquidity and capital resources and may require us to incur additional indebtedness, seek equity capital or both. We
regularly evaluate the performance of our products and product candidates to ensure fit within our portfolio and support efficient allocation
of capital. In addition, we may pursue new operations or continue the expansion of our existing operations. Accordingly, we expect to
continue to opportunistically seek access to additional capital to license or acquire additional products, product candidates or companies to
expand our operations or for general corporate purposes. Raising additional capital could be accomplished through one or more public or
private debt or equity financings, collaborations or partnering arrangements. However, the COVID-19 pandemic continues to rapidly evolve
and has resulted in significant volatility in the global financial markets. If this volatility persists and deepens, we could experience an
inability to access additional capital or our liquidity could otherwise be impacted, which could in the future negatively affect our capacity for
certain corporate development transactions or our ability to make other important, opportunistic investments. In addition, as a matter of
Irish law, when an Irish public limited company issues ordinary shares to new shareholders for cash, the company must first offer those
shares on the same or more favorable terms to existing shareholders on a pro rata basis, unless this statutory pre-emption obligation is
dis-applied, or opted-out of, by approval of its shareholders. At our extraordinary general meeting of shareholders in September 2021, our
shareholders voted to approve our proposal to dis-apply the statutory pre-emption obligation on terms that are substantially more limited
than our general pre-emption opt-out authority that had been in effect prior to August 4, 2021, which could adversely affect our ability to
effectively use our unissued share capital to fund in-licensing or acquisition opportunities, or to otherwise raise additional capital for our
business. In any event, an inability to borrow or raise additional capital in a timely manner and on attractive terms could prevent us from
expanding our business or taking advantage of acquisition opportunities, and could otherwise have a material adverse effect on our
business and growth prospects. In addition, if we use a substantial amount of our funds to acquire or in-license products or product
candidates, we may not have sufficient additional funds to conduct all of our operations in the manner we would otherwise choose.
Furthermore, any equity financing would be dilutive to our shareholders, and could require the consent of the lenders under the Credit
Agreement and the indenture for the Secured Notes for certain financings.

In November 2016, our board of directors authorized a share repurchase program and as of December 31, 2021 had authorized the

repurchase of up to $1.5 billion, exclusive of any brokerage commissions. Under this program, which has no expiration date, we may
repurchase ordinary shares from time to time on the open market. The timing and amount of repurchases will depend on a variety of
factors, including the price of our ordinary shares, alternative investment opportunities, restrictions under the amended credit agreement,
corporate and regulatory requirements and market conditions. The share repurchase program may be modified, suspended or discontinued
at any time without prior notice. In 2021, we did not repurchase any of our ordinary shares under the share repurchase program. In 2020,
we spent a total of $146.5 million to repurchase 1.2 million of our ordinary shares at an average total purchase price, including brokerage
commissions, of $121.98 per share. All ordinary shares repurchased were canceled. As of December 31, 2021, the remaining amount
authorized under the share repurchase program was $431.2 million.

The following table shows a summary of our cash flows for the periods indicated (in thousands):

Net cash provided by operating activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net cash used in investing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net cash provided by (used in) financing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Effect of exchange rates on cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

778,507
(5,212,143)
3,970,522
(3,207)

$

899,648
(1,007,670)
528,073
374

$ 776,401
(155,300)
(293,745)
366

Net increase (decrease) in cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ (466,321) $

420,425

$ 327,722

Year Ended December 31,

2021

2020

2019

Operating activities

Net cash provided by operating activities decreased by $121.1 million in 2021 compared to 2020, primarily due to the payment of

transaction and integration-related costs related to the GW Acquisition.

Net cash provided by operating activities increased by $123.2 million in 2020 compared to 2019, primarily due to a decrease in net
outflow related to changes in operating assets and liabilities including the impact of the $58.6 million payment related to a civil settlement
agreement with the DOJ and the OIG in 2019 together with an increase in accounts receivable of $38.6 million due to higher product sales
together with the timing of receipts from customers and other working capital movements.

84

2021 Annual Report

| JAZZ PHARMACEUTICALS

K
-
0
1
m
r
o
F

Investing activities

Net cash used in investing activities increased by $4,204.5 million in 2021 compared to 2020, primarily due to the following:

•

•

•

•

$6,234.8 million outflow related to the net cash paid for the GW Acquisition; partially offset by

$1,710.9 million increase in net proceeds from maturity of investments, primarily time deposits;

$251.3 million decrease in upfront payments for acquired IPR&D primarily driven by the $200.0 million payment under our
license agreement with PharmaMar and the $35.0 million payment under our asset purchase and exclusive license agreement
with SpringWorks in 2020; and

$95.1 million decrease in acquisition of intangible assets primarily related to our $100.0 million milestone payment to
PharmaMar on FDA approval of Zepzelca in 2020.

Net cash used in investing activities increased by $852.4 million in 2020 compared to 2019, primarily due to the following:

•

•

•

$710.6 million net increase in the acquisition of investments, primarily time deposits; and

$189.6 million increase in upfront payments for acquired IPR&D primarily driven by our $200.0 million payment to PharmaMar
and the $35.0 million to SpringWorks in 2020, compared to 2019 which included a payment of $56.0 million under our strategic
collaboration agreement with Codiak; partially offset by

The impact of consideration, net of cash acquired of $55.1 million related to our acquisition of Cavion in 2019.

Financing activities

Net cash provided by financing activities increased by $3,442.4 million in 2021 compared to 2020, primarily due to:

•

An increase of $3,279.1 million in debt financing due to:

O Net proceeds from issuance of borrowings under the Credit Agreement of $3,719.9 million and the Secured Notes of

$1,471.5 million, partially offset by $1,101.8 million in repayment of long-term debt and payments for repurchase of the
2021 Notes of $218.8 million in the year ended December 31, 2021; compared to

O Net proceeds from issuance of the 2026 Notes of $981.4 million, partially offset by payments for partial repurchase of the
2021 Notes of $356.2 million and repayment of long-term debt of $33.4 million in the year ended December 31, 2020.

•

•

The impact of share repurchases of $146.5 million in the year ended December 31, 2020; and

An increase of $35.6 million in proceeds from employee equity incentive and purchase plans in the year ended
December 31, 2021.

Net cash provided by (used in) financing activities increased by $821.8 million in 2020 compared to 2019, primarily due to:

•

•

•

The receipt of $981.4 million in net proceeds from the issuance of the 2026 Notes, partially offset by $356.2 million of payments
for partial repurchases of the 2021 Notes;

A decrease of $154.9 million in share repurchases; and

An increase of $41.9 million in proceeds from employee equity incentive and purchase plans.

Credit Agreement

On May 5, 2021, the Company, Jazz Financing Lux S.à.r.l., or Jazz Lux, and certain of our other subsidiaries, as borrowers,
(collectively with the Company and Jazz Lux, the “Borrowers”), entered into the Credit Agreement, that provides for (i) the Dollar Term
Loan which was drawn by Jazz Lux on the Closing Date in U.S. dollars (ii) the Euro Term Loan which was drawn by Jazz Lux on the
Closing Date in Euros and (iii) the Revolving Credit Facility, which is available to be drawn by any Borrower in U.S. dollars.

We used the proceeds from the Term Loan (i) to repay in full $575.9 million under the Existing Credit Agreement, (ii) to fund, in part,

the cash consideration payable in connection with the GW Acquisition and (iii) to pay related fees and expenses. Upon the repayment in full
of loans under the Existing Credit Agreement, it was terminated and all guarantees and liens thereunder were released.

Loans under the Term Loan and Revolving Credit Facility bear interest at a rate equal to (A) in the case of the Dollar Term Loan and

the Revolving Credit Facility, at the applicable Borrower’s option, either (a) London Inter-Bank Offered Rate, or LIBOR or (b) the prime
lending rate and (B) in the case of the Euro Term Loan, Euro Inter-Bank Offered Rate, or EURIBOR, in each case, plus an applicable

JAZZ PHARMACEUTICALS | 2021 Annual Report

85

margin. The applicable margin for the Term Loan is 3.50% (in the case of LIBOR or EURIBOR borrowings) and 2.50% (in the case of
borrowings at the prime lending rate). The applicable margin for the Revolving Credit Facility ranges from 3.25% to 2.75% (in the case of
LIBOR borrowings) and 2.25% to 1.75% (in the case of borrowings at the prime lending rate), depending on our first lien secured net
leverage ratio level. The Dollar Term Loan is subject to a LIBOR floor of 0.50%, the Euro Term Loan and loans under the Revolving Credit
Facility are not subject to a EURIBOR or LIBOR (as applicable) floor. The Revolving Credit Facility has a commitment fee payable on the
undrawn amount ranging from 0.50% to 0.40% per annum based upon our first lien secured net leverage ratio.

As of December 31, 2021, the interest rate and effective interest rate on the Dollar Term Loan were 4.00% and 4.55%, respectively.

The interest rate and effective interest rate on the Euro Term Loan were 4.43% and 4.93%, respectively. As of December 31, 2021, we had
an undrawn Revolving Credit Facility totaling $500.0 million.

The Borrowers’ obligations under the Credit Agreement and any hedging or cash management obligations entered into with any

lender thereunder are guaranteed by the Company, the other borrowers, and each of the Company’s other existing or subsequently
acquired or organized direct and indirect subsidiaries (subject to certain exceptions), or the Guarantors. We refer to the Borrowers and the
Guarantors collectively as the “Loan Parties.”

The Loan Parties’ obligations under the Credit Agreement are secured, subject to customary permitted liens and other exceptions, by

a security interest in (a) all tangible and intangible assets of the Loan Parties, except for certain excluded assets, and (b) all of the equity
interests of the subsidiaries of the Loan Parties held by the Loan Parties.

We may make voluntary prepayments at any time without payment of a premium or penalty, subject to certain exceptions, and are

required to make certain mandatory prepayments of outstanding indebtedness under the Credit Agreement in certain circumstances.

Principal repayments of the Dollar Term Loan, which are due quarterly, began in September 2021 and are equal to 1.0% per annum

of the original principal amount of $3.1 billion with any remaining balance payable on the maturity date. The Euro Term Loan does not have
any mandatory principal repayments during its term, however in September and December 2021, we made voluntary prepayments totaling
€416.7 million or $502.0 million.

The Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants
applicable to the Company and its restricted subsidiaries, including, among other things, restrictions on indebtedness, liens, investments,
mergers, dispositions, prepayment of junior indebtedness and dividends and other distributions. The Credit Agreement contains financial
covenants that require the Company and its restricted subsidiaries to (a) not exceed a maximum first lien secured net leverage ratio and
(b) not fall below a minimum interest coverage ratio, provided that such covenants apply only to the Revolving Credit Facility and are
applicable only if amounts are drawn (or non-cash collateralized letters of credit in excess of $50 million are outstanding) under the
Revolving Credit Facility. The Credit Agreement also contains customary events of default relating to, among other things, failure to make
payments, breach of covenants and breach of representations.

2029 Senior Secured Notes

2029 Notes. On April 29, 2021, Jazz Securities Designated Activity Company, or Jazz Securities, a direct wholly owned subsidiary of
the Company, closed the offering of the Secured Notes in a private placement. We used the proceeds from the Secured Notes to fund, in
part, the cash consideration payable in connection with the GW Acquisition.

Interest on the Secured Notes is payable semi-annually in arrears on January 15 and July 15 of each year, beginning on

January 15, 2022, at a rate of 4.375% per year. The Secured Notes mature on January 15, 2029.

The Secured Notes are jointly and severally guaranteed by the Company and each of its restricted subsidiaries, other than Jazz

Securities, that is a borrower, or a guarantor, under the Credit Agreement. The Secured Notes and related guarantees are secured by a
first priority lien (subject to permitted liens and certain other exceptions), equally and ratably with the Credit Agreement, on the collateral
securing the Credit Agreement.

Except as described below, the Secured Notes may not be optionally redeemed before July 15, 2024. Thereafter, some or all of the
Secured Notes, may be redeemed at any time and from time to time at a specified redemption prices, plus accrued and unpaid interest, if
any, to, but excluding, to the redemption date. Jazz Securities may redeem all but not part of the Secured Notes at its option at any time in
connection with certain tax-related events and may redeem some or all of the Secured Notes at any time and from time to time prior to
July 15, 2024 at a price equal to 100% of the principal amount of the Secured Notes to be redeemed plus a “make whole” premium, plus
accrued and unpaid interest, if any, to, but excluding, the redemption date. In addition, Jazz Securities may redeem up to 40% of the

86

2021 Annual Report

| JAZZ PHARMACEUTICALS

K
-
0
1
m
r
o
F

aggregate principal amount of the Secured Notes at any time and from time to time prior to July 15, 2024, with the net proceeds of certain
equity offerings at a price of 104.375% of the principal amount of such Secured Notes, plus accrued and unpaid interest, if any, to, but
excluding, the redemption date. In addition, during each of the three consecutive twelve-month periods commencing on the issue date of
the Secured Notes, Jazz Securities may redeem up to 10% of the original aggregate initial principal amount of the Secured Notes at a
redemption price of 103% of the principal amount of such Secured Notes, plus accrued and unpaid interest, if any, to, but excluding, the
redemption date.

If Jazz undergoes a change of control, Jazz Securities will be required to make an offer to purchase all of the Secured Notes at a
purchase price in cash equal to 101% of the principal amount thereof, plus accrued and unpaid interest, if any, to, but excluding, the date of
repurchase, subject to certain exceptions.

The indenture governing the Secured Notes contains customary affirmative covenants and negative covenants applicable to the

Company and its restricted subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers,
dispositions, prepayment of junior indebtedness and dividends and other distributions. If Jazz Securities or the Company’s restricted
subsidiaries engage in certain asset sales, Jazz Securities will be required under certain circumstances to make an offer to purchase the
Secured Notes at 100% of the principal amount, plus accrued and unpaid interest, if any, to, but excluding, the repurchase date.

As of December 31, 2021, the interest rate and effective interest rate on the Secured Notes were 4.375% and 4.64%, respectively.

Exchangeable Senior Notes

2026 Notes. In the second quarter of 2020, Jazz Investments I Limited, our wholly owned subsidiary, completed a private placement

of $1.0 billion principal amount of the 2026 Notes. We used a portion of the net proceeds from this offering to repurchase for cash
$332.9 million aggregate principal amount of the 2021 Notes through privately-negotiated transactions concurrently with the offering of the
2026 Notes. Interest on the 2026 Notes is payable semi-annually in cash in arrears on June 15 and December 15 of each year, beginning
on December 15, 2020, at a rate of 2.00% per year. In certain circumstances, we may be required to pay additional amounts as a result of
any applicable tax withholding or deductions required in respect of payments on the 2026 Notes. The 2026 Notes mature on June 15,
2026, unless earlier exchanged, repurchased or redeemed.

The holders of the 2026 Notes have the ability to require us to repurchase all or a portion of their 2026 Notes for cash in the event we
undergo certain fundamental changes, such as specified change of control transactions, our liquidation or dissolution or the delisting of our
ordinary shares from any of The New York Stock Exchange, The Nasdaq Global Market, The Nasdaq Global Select Market or The Nasdaq
Capital Market (or any of their respective successors). Additionally, the terms and covenants in the indenture related to the 2026 Notes
include certain events of default after which the 2026 Notes may be due and payable immediately. Prior to June 15, 2026, we may redeem
the 2026 Notes, in whole but not in part, subject to compliance with certain conditions, if we have, or on the next interest payment date
would, become obligated to pay to the holder of any 2026 Notes additional amounts as a result of certain tax-related events. We also may
redeem the 2026 Notes on or after June 20, 2023 and prior to March 15, 2026, in whole or in part, if the last reported sale price per
ordinary share has been at least 130% of the exchange price then in effect for at least 20 trading days (whether or not consecutive) during
any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which we provide the
notice of redemption.

The 2026 Notes are exchangeable at an initial exchange rate of 6.4182 ordinary shares per $1,000 principal amount of 2026 Notes,

which is equivalent to an initial exchange price of approximately $155.81 per ordinary share. Upon exchange, the 2026 Notes may be
settled in cash, ordinary shares or a combination of cash and ordinary shares, at our election. Our intent and policy is to settle the principal
amount of the 2026 Notes in cash upon exchange. The exchange rate will be subject to adjustment in some events but will not be adjusted
for any accrued and unpaid interest. In addition, following certain make-whole fundamental changes occurring prior to the maturity date of
the 2026 Notes or upon our issuance of a notice of redemption, we will in certain circumstances increase the exchange rate for holders of
the 2026 Notes who elect to exchange their 2026 Notes in connection with that make-whole fundamental change or during the related
redemption period. Prior to March 15, 2026, the 2026 Notes will be exchangeable only upon satisfaction of certain conditions and during
certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the
maturity date.

2024 Notes. In the third quarter of 2017, our wholly owned subsidiary Jazz Investments I Limited, completed a private placement of
$575.0 million principal amount of 2024 Notes. We used the net proceeds from this offering to repay $500.0 million in outstanding loans
under the revolving credit facility under the amended credit agreement and to pay related fees and expenses. We used the remainder of
the net proceeds for general corporate purposes. The 2024 Notes are senior unsecured obligations of Jazz Investments I Limited and are
fully and unconditionally guaranteed on a senior unsecured basis by Jazz Pharmaceuticals plc and will rank pari passu in right of payment

JAZZ PHARMACEUTICALS | 2021 Annual Report

87

with the existing 2021 Notes. Interest on the 2024 Notes is payable semi-annually in cash in arrears on February 15 and August 15 of each
year, beginning on February 15, 2018, at a rate of 1.50% per year. In certain circumstances, we may be required to pay additional amounts
as a result of any applicable tax withholding or deductions required in respect of payments on the 2024 Notes. The 2024 Notes mature on
August 15, 2024, unless earlier exchanged, repurchased or redeemed.

The holders of the 2024 Notes have the ability to require us to repurchase all or a portion of their 2024 Notes for cash in the event we
undergo certain fundamental changes, such as specified change of control transactions, our liquidation or dissolution or the delisting of our
ordinary shares from The Nasdaq Global Select Market. Prior to August 15, 2024, we may redeem the 2024 Notes, in whole but not in part,
subject to compliance with certain conditions, if we have, or on the next interest payment date would, become obligated to pay to the holder
of any 2024 Notes additional amounts as a result of certain tax-related events. We also may redeem the 2024 Notes on or after August 20,
2021, in whole or in part, if the last reported sale price per ordinary share has been at least 130% of the exchange price then in effect for at
least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day
immediately preceding the date on which we provide the notice of redemption.

The 2024 Notes are exchangeable at an initial exchange rate of 4.5659 ordinary shares per $1,000 principal amount of 2024 Notes,

which is equivalent to an initial exchange price of approximately $219.02 per ordinary share. Upon exchange, the 2024 Notes may be
settled in cash, ordinary shares or a combination of cash and ordinary shares, at our election. Our intent and policy is to settle the principal
amount of the 2024 Notes in cash upon exchange. The exchange rate will be subject to adjustment in some events but will not be adjusted
for any accrued and unpaid interest. In addition, following certain make-whole fundamental changes occurring prior to the maturity date of
the 2024 Notes or upon our issuance of a notice of redemption, we will in certain circumstances increase the exchange rate for holders of
the 2024 Notes who elect to exchange their 2024 Notes in connection with that make-whole fundamental change or during the related
redemption period. Prior to May 15, 2024, the 2024 Notes will be exchangeable only upon satisfaction of certain conditions and during
certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the
maturity date.

2021 Notes. In 2014, we completed a private placement of the 2021 Notes with a maturity date of August 15, 2021. Interest on the

2021 Notes was payable semi-annually in cash in arrears on February 15 and August 15 of each year, beginning on February 15, 2015, at
a rate of 1.875% per year. The exchange rate was 5.0057 ordinary shares per $1,000 principal amount of 2021 Notes, which was
equivalent to an exchange price of approximately $199.77 per ordinary share.

In 2020 we repurchased $356.2 million aggregate principal amount of the 2021 Notes and we repurchased the remaining

$218.8 million on maturity in August 2021.

Contractual Obligations

Our primary contractual obligations relate to our outstanding indebtedness, as described above. We also have obligations under
lease agreements and third-party manufacturing agreements. For information relating to our scheduled maturities with respect to our long-
term debt and our lease liabilities see Note 12 Debt and Note 13 Leases, respectively, and for information relating to our noncancelable
purchase commitments due within one year see Note 14 Commitments and Contingencies, included in the Notes to Consolidated Financial
Statements, included in Part IV of this Annual Report on Form 10-K.

We also have potential future milestone payments or royalty obligations to third parties under asset purchase, product development,

license and other agreements as the timing and likelihood of such milestone payments are not known, and, in the case of royalty
obligations, as the amount of such obligations are not estimable. Our contingent obligations to third parties, in the form of development,
regulatory and sales-based milestone payments, as of December 31, 2021 included $1,025.0 million across five targets under our strategic
collaboration agreement with Codiak, $706.0 million under our amended license agreement with PharmaMar, $610.0 million under asset
purchase and collaboration agreements with Redx, $375.0 million under the asset purchase and exclusive license agreement with
SpringWorks, $260.0 million in connection with our acquisition of Cavion, $165.0 million to Aerial BioPharma LLC and SK
Biopharmaceuticals Co. Ltd in connection with our acquisition of the rights to Sunosi, $155.5 million under our license agreement with
Ligand and $391.2 million related to other agreements.

Critical Accounting Policies and Significant Estimates

A critical accounting policy is one that is both important to the portrayal of our financial condition and results of operations and
requires management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of
matters that are inherently uncertain. While our significant accounting policies are described in more detail in Note 2, Summary of
Significant Accounting Policies, of the Notes to Consolidated Financial Statements included in Part IV of this Annual Report on Form 10-K,
we believe the following accounting estimates and policies to be critical.

88

2021 Annual Report

| JAZZ PHARMACEUTICALS

Revenue Recognition

Revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects

the consideration we expect to be entitled to in exchange for those goods or services.

Product Sales, Net

Product sales revenue is recognized when control has transferred to the customer, which occurs at a point in time, which is typically
on delivery to the customer or, in the case of products that are subject to consignment agreements, when the customer removes product
from our consigned inventory location for shipment directly to a patient.

A significant portion of our net product revenues is derived from sales of Xywav and Xyrem. We sell Xywav and Xyrem in the U.S. to
a single central pharmacy, Express Scripts Specialty Distribution Services, Inc., or ESSDS. In 2021, sales of Xywav and Xyrem to Express
Scripts accounted for 58% of our net product sales. We recognize revenues from sales of Xywav and Xyrem within the U.S. when control
has transferred to the customer, which occurs when ESSDS removes product from our consigned inventory location at its facility for
shipment directly to a patient. We do not accept returns of Xywav or Xyrem from ESSDS.

Items Deducted from Gross Product Sales. Revenues from sales of products are recorded net of government rebates and rebates
under managed care plans and commercial payor contracts, estimated allowances for sales returns, government chargebacks, prompt
payment discounts, patient coupon programs, and specialty distributor and wholesaler fees. Calculating certain of these items involves
estimates and judgments based on sales or invoice data, contractual terms, historical utilization rates, new information regarding changes
in applicable regulations and guidelines that would impact the amount of the actual rebates, our expectations regarding future utilization
rates and channel inventory data. We review the adequacy of our provisions for sales deductions on a quarterly basis. Amounts accrued
for sales deductions are adjusted when trends or significant events indicate that adjustment is appropriate and to reflect actual experience.
Because we derive a significant portion of our revenues from sales of Xywav and Xyrem in the U.S. to one specialty pharmacy customer,
ESSDS, we have a much higher level of knowledge about each prescription than if we sold the product through the normal pharmaceutical
wholesaler channel as we do with most of our other products. The most significant items deducted from gross product sales where we
exercise judgment are rebates, sales returns and chargebacks.

K
-
0
1
m
r
o
F

The following table presents the activity and ending balances for our sales-related accruals and allowances (in thousands):

Rebates
Payable

Sales Returns
Reserve

Balance at December 31, 2018 . . . . . . . . . . . . . . . . . . . . . . . . . . .
Provision, net
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Payments/credits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 81,114
153,930
(152,191)

$ 2,510
5,519
(4,567)

Balance at December 31, 2019 . . . . . . . . . . . . . . . . . . . . . . . . . . .
Provision, net
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Payments/credits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Balance at December 31, 2020 . . . . . . . . . . . . . . . . . . . . . . . . . . .
GW Acquisition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Provision, net
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Payments/credits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

82,853
288,052
(260,020)

110,885
53,872
440,776
(409,818)

3,462
18,448
(3,542)

18,368
5
(1,765)
(794)

Chargebacks

$

408
41,864
(41,139)

1,133
45,550
(41,390)

5,293
1,322
91,425
(86,651)

Discounts and
Distributor Fees

$

5,457
56,041
(47,378)

14,120
69,332
(66,659)

16,793
3,260
125,859
(124,104)

Total

$ 89,489
257,354
(245,275)

101,568
421,382
(371,611)

151,339
58,459
656,295
(621,367)

Balance at December 31, 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 195,715

$15,814

$ 11,389

$ 21,808

$ 244,726

Total items deducted from gross product sales were $656.3 million, $421.4 million and $257.4 million, or 17.6%, 15.2% and 10.8% as

a percentage of gross product sales, in 2021, 2020 and 2019, respectively. Included in these amounts are immaterial adjustments related
to prior-year sales due to changes in estimates. Such amounts represented less than 1% of net product sales for each of the years ended
December 31, 2021, 2020 and 2019.

Rebates

We are subject to rebates on sales made under governmental and managed-care pricing programs and commercial payor contracts

in the U.S. The largest of these rebates is associated with sales covered by Medicaid. We participate in state government-managed
Medicaid programs as well as certain other qualifying federal and state government programs under the terms of which discounts and
rebates are provided to participating government entities. We offer rebates and discounts to managed health care organizations and
commercial payors in the U.S. In estimating our provisions for rebates, we consider relevant statutes with respect to governmental pricing

JAZZ PHARMACEUTICALS | 2021 Annual Report

89

programs and contractual sales terms with managed-care providers, commercial payors and group purchasing organizations. We estimate
the rebate provision based on historical utilization rates, historical payment experience, new information regarding changes in regulations
and guidelines that would impact the amount of the actual rebates, our expectations regarding future utilization rates and channel inventory
data obtained from our major distributors in accordance with our inventory management agreements. Estimating these rebates is complex,
in part due to the time delay between the date of sale and the actual settlement of the liability. We believe that the methodology we use to
estimate rebates on product sales made under governmental and managed-care pricing programs is reasonable and appropriate given
current facts and circumstances. However, estimates may vary from actual experience.

Rebates were $440.8 million, $288.1 million and $153.9 million, or 11.8%, 10.4% and 6.5% as a percentage of gross product sales, in

2021, 2020 and 2019, respectively. Rebates as a percentage of gross product sales increased in 2021 compared to 2020 primarily due to
the entry into additional contracts with commercial payors and the addition of Epidiolex to our product portfolio. Rebates as a percentage of
gross product sales increased in 2020 compared to 2019 primarily due to the entry into additional contracts with commercial payors.
Rebates as a percentage of gross product sales are expected to increase in 2022 compared to 2021, primarily due to rebate rate increases
and additional commercial rebates.

Sales returns

For certain products, we allow customers to return product within a specified period before and after the applicable expiration date
and issue credits which may be applied against existing or future invoices. We account for sales returns as a reduction in net revenue at
the time a sale is recognized by establishing an accrual in an amount equal to the estimated value of products expected to be returned.
The sales return accrual is estimated principally based on historical experience, the level and estimated shelf life of inventory in the
distribution channel, our return policy and expected market events including generic competition.

Sales returns were $(1.8) million, $18.4 million and $5.5 million, or (0.05)%, 0.7% and 0.2% as a percentage of gross product sales in
2021, 2020 and 2019, respectively. Sales returns as a percentage of gross product sales decreased in 2021 compared to 2020 driven by a
reduction in the returns provision due to lower than estimated actual returns. The increase in sales returns in 2020 compared to 2019 was due
to the commencement of a product return policy for certain products in 2020. Sales returns as a percentage of gross product sales did not
change materially in 2020 compared to 2019. Sales returns as a percentage of gross product sales are not expected to change materially in
2022 compared to 2021.

Chargebacks

We participate in chargeback programs with a number of entities, principally Federal Supply Schedule, Group Purchasing

Organizations, and other public parties, under which pricing on products below wholesalers’ list prices is provided to participating entities.
These entities purchase product through wholesalers at the contract price and the wholesalers charge back to us the difference between
their acquisition cost and the lower negotiated price. We record the difference as allowances against accounts receivable. We determine
our estimate of the chargebacks provision primarily based on historical experience on a product and program basis, current contract prices
under the chargeback programs and channel inventory data.

Chargebacks were $91.4 million, $45.6 million and $41.9 million, or 2.4%, 1.6% and 1.8% as a percentage of gross product sales in

2021, 2020 and 2019, respectively. Chargebacks as a percentage of gross product sales increased in 2021 compared to 2020 primarily
due to the addition of Epidiolex to Jazz’s portfolio. Chargebacks as a percentage of gross product sales did not change materially in 2020
compared to 2019. We expect that chargebacks will continue to significantly impact our reported net product sales. Chargebacks as a
percentage of gross product sales are not expected to change materially in 2022 compared to 2021.

Discounts and distributor fees

Discounts and distributor fees comprise prompt payment discounts, patient coupon programs and specialty distributor and wholesaler

fees. We offer customers a cash discount on gross product sales as an incentive for prompt payment. We estimate provisions for prompt pay
discounts based on contractual sales terms with customers and historical payment experience. To help patients afford our products, we have
various programs to assist them, including patient assistance programs, a free product voucher program and co-pay coupon programs for
certain products. We estimate provisions for these programs primarily based on expected program utilization, adjusted as necessary to reflect
our actual experience on a product and program basis. Specialty distributor and wholesaler fees comprise fees for distribution of our products.
We estimate provisions for distributor and wholesaler fees primarily based on sales volumes and contractual terms with our distributors.

Discounts and distributor fees were $125.9 million, $69.3 million and $56.0 million, or 3.4%, 2.5% and 2.4% as a percentage of gross

product sales in 2021, 2020 and 2019, respectively. Discounts and distributor fees as a percentage of gross product sales increased in

90

2021 Annual Report

| JAZZ PHARMACEUTICALS

2021 compared to 2020 primarily due to the addition of Epidiolex to Jazz’s portfolio. Discounts and distributor fees as a percentage of gross
product sales did not change materially in 2020 compared to 2019. We expect that discounts and distributor fees as a whole will continue
to significantly impact our reported net product sales. Discounts and distributor fees as a percentage of gross product sales are not
expected to change materially in 2022 compared to 2021.

Acquisitions and Valuation of Intangibles

We make certain judgments to determine whether transactions should be accounted for as acquisitions of assets or as business

combinations. If it is determined that substantially all of the fair value of gross assets acquired in a transaction is concentrated in a single
asset (or a group of similar assets), the transaction is treated as an acquisition of assets. We evaluate the inputs, processes, and outputs
associated with the acquired set of activities. If the assets in a transaction include an input and a substantive process that together
significantly contribute to the ability to create outputs, the transaction is treated as an acquisition of a business.

We account for business combinations using the acquisition method of accounting, which requires that assets acquired and liabilities

assumed generally be recorded at their fair values as of the acquisition date. Goodwill represents the excess of the acquisition
consideration over the fair value of assets acquired and liabilities assumed. We test goodwill for impairment annually in October and when
events or changes in circumstances indicate that the carrying value may not be recoverable. We have determined that we operate in a
single segment and have a single reporting unit associated with the development and commercialization of pharmaceutical products. In
performing the annual impairment test, the fair value of the reporting unit is compared to its corresponding carrying value, including
goodwill. If the carrying value exceeds the fair value of the reporting unit an impairment loss will be recognized for the amount by which the
reporting unit’s carrying amount exceeds its fair value, not to exceed the carrying amount of goodwill. We have determined the fair value of
our single reporting unit to be equal to our market capitalization, as determined by our traded share price, plus a control premium. The
control premium used was based on a review of such premiums identified in recent acquisitions of companies of similar size and in similar
industries. We performed our annual goodwill impairment test in October 2021 and concluded that goodwill was not impaired as the fair
value of the reporting unit significantly exceeded its carrying amount, including goodwill. As of December 31, 2021, we had $1.8 billion of
goodwill resulting from acquisitions accounted for as business combinations.

K
-
0
1
m
r
o
F

In transactions accounted for as acquisitions of assets, no goodwill is recorded and contingent consideration such as payments upon

achievement of various developmental, regulatory and commercial milestones generally is not recognized at the acquisition date. In an
asset acquisition, upfront payments allocated to IPR&D projects at the acquisition date are expensed unless there is an alternative future
use. In addition, product development milestones are expensed upon achievement.

Valuation of Intangible Assets

We have acquired, and expect to continue to acquire, intangible assets through asset acquisitions or business combinations. When
significant identifiable intangible assets are acquired, we engage an independent third party valuation firm to assist in determining the fair
values of these assets as of the acquisition date. Discounted cash flow models are typically used in these valuations, which require the use
of significant estimates and assumptions, including but not limited to:

•

•

•

•

estimating the timing of and expected costs to complete the in-process projects;

projecting regulatory approvals;

estimating future cash flows including revenues and operating profits resulting from completed products and in-process projects;
and

developing appropriate discount rates and probability rates by project.

We believe the fair values that we assign to the intangible assets acquired are based upon reasonable estimates and assumptions

given available facts and circumstances as of the acquisition dates. No assurance can be given, however, that the underlying assumptions
used to estimate expected cash flows will transpire as estimated. In addition, we are required to estimate the period of time over which to
amortize the intangible assets, which requires significant judgment.

Impairment of Intangible Assets

Finite-lived intangible assets consist primarily of purchased developed technology and are amortized on a straight-line basis over their

estimated useful lives, which range from two to 20 years. The estimated useful lives associated with intangible assets are consistent with
the estimated lives of the products and may be modified when circumstances warrant. Intangible assets with finite lives are reviewed for
impairment whenever events or circumstances indicate that the carrying value of an asset may not be recoverable. Events giving rise to

JAZZ PHARMACEUTICALS | 2021 Annual Report

91

impairment are an inherent risk in the pharmaceutical industry and cannot be predicted. Factors that we consider in deciding when to
perform an impairment review include significant under-performance of a product in relation to expectations, significant negative industry or
economic trends, and significant changes or planned changes in our use of the assets. An impairment loss would be recognized when
estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are less than its carrying
amount. Estimating future cash flows related to an intangible asset involves estimates and assumptions. If our assumptions are not correct,
there could be an impairment loss or, in the case of a change in the estimated useful life of the asset, a change in amortization expense.

IPR&D is not amortized but is tested for impairment annually or when events or circumstances indicate that the fair value may be
below the carrying value of the asset. If the carrying value of the assets is not expected to be recovered, the assets are written down to
their estimated fair values.

As of December 31, 2021, we had $7.0 billion of finite-lived intangible assets, which included $4.9 billion associated with the Epidiolex

intangible asset which we acquired in the GW Acquisition.

We did not recognize an impairment charge related to our intangible assets in 2021 or 2019. In 2020, we recorded an acquired
in-process research and development, or IPR&D, asset impairment charge of $136.1 million following the decision to stop enrollment in our
Phase 3 clinical study of defibrotide for the prevention of VOD due to a determination that the study is highly unlikely to reach one of its
primary endpoints.

Please refer to Note 10, Goodwill and Intangible Assets, of the Notes to Consolidated Financial Statements included in Part IV of this
Annual Report on Form 10-K, for further information about our intangible assets and the remaining useful lives of our finite-lived intangible
assets as of December 31, 2021.

Income Taxes

We use the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are
determined based on differences between the financial statement carrying amount and the tax basis of assets and liabilities and are
measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. We provide a valuation
allowance when it is more-likely-than-not that deferred tax assets will not be realized.

Our most significant tax jurisdictions are Ireland, the U.K. and the U.S. Significant estimates are required in determining our expense
for income taxes. Some of these estimates are based on management’s interpretations of jurisdiction-specific tax laws or regulations and
the likelihood of settlement related to tax audit issues. Various internal and external factors may have favorable or unfavorable effects on
our future effective income tax rate. These factors include, but are not limited to, changes in tax laws, regulations and/or rates, changing
interpretations of existing tax laws or regulations, changes in estimates of prior years’ items, the impact of accounting for share-based
compensation, changes in our international organization, likelihood of settlement, and changes in overall levels of income before taxes.

Realization of our deferred tax assets is dependent upon the generation of future taxable income, the amount and timing of which are

uncertain. In evaluating our ability to recover our deferred tax assets, we consider all available positive and negative evidence, including
cumulative income in recent fiscal years, our forecast of future taxable income exclusive of certain reversing temporary differences and
significant risks and uncertainties related to our business. In determining future taxable income, we are responsible for assumptions utilized
including the amount of state, federal and international pre-tax operating income, the reversal of certain temporary differences and the
implementation of feasible and prudent tax planning strategies. These assumptions require significant judgment about the forecasts of
future taxable income in applicable tax jurisdictions, which are based on our commercial experience to date and are consistent with the
plans and estimates that we are using to manage our underlying business.

We maintain a valuation allowance against certain other deferred tax assets where realizability is not certain. We periodically evaluate
the likelihood of the realization of deferred tax assets and reduce the carrying amount of these deferred tax assets by a valuation allowance
to the extent we believe a portion will not be realized. This determination depends on a variety of factors, some of which are subjective,
including our recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income, carryforward periods
available to us for tax reporting purposes, various income tax strategies and other relevant factors. If we determine that the deferred tax
assets are not realizable in a future period, we would record material changes to income tax expense in that period.

We have also provided for unrecognized tax benefits that we believe are not more-likely-than-not to be sustained upon examination
by tax authorities. The evaluation of unrecognized tax benefits is based on factors that include, but are not limited to, changes in tax law,
the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new
audit activity and changes in facts or circumstances related to a tax position. We evaluate unrecognized tax benefits on a quarterly basis

92

2021 Annual Report

| JAZZ PHARMACEUTICALS

and adjust the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions. Our liabilities
for unrecognized tax benefits can be relieved only if the contingency becomes legally extinguished through either payment to the taxing
authority or the expiration of the statute of limitations, the recognition of the benefits associated with the position meet the more-likely-
than-not threshold or the liability becomes effectively settled through the examination process. We consider matters to be effectively settled
once the taxing authority has completed all of its required or expected examination procedures, including all appeals and administrative
reviews. We also accrue for potential interest and penalties related to unrecognized tax benefits in income tax expense (benefit).

Recent Accounting Pronouncements

For a discussion of recent accounting pronouncements, please see Note 2, Summary of Significant Accounting Policies, of the Notes

to Consolidated Financial Statements included in Part IV of this Annual Report on Form 10-K.

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk. The primary objectives of our investment policy, in order of priority, are as follows: safety and preservation of

principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and competitive yield. Although our
investments are subject to market risk, our investment policy specifies credit quality standards for our investments and limits the amount of
credit exposure from any single issue, issuer or certain types of investment. Our investment policy allows us to maintain a portfolio of cash
equivalents and short-term investments in a variety of securities, including U.S. federal government and federal agency securities,
corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual
funds, certain repurchase agreements, and tax-exempt obligations of states, agencies and municipalities in the U.S. Our cash equivalents
as of December 31, 2021 consist of money market funds which are not subject to significant interest rate risk.

K
-
0
1
m
r
o
F

We are exposed to risks associated with changes in interest rates in connection with our term loan borrowings. In May 2021 we entered

into a credit agreement, or the Credit Agreement, that provides for (i) a seven-year $3.1 billion term loan B facility, or the Dollar Term Loan,
(ii) a seven-year €625.0 million term loan B facility, or the Euro Term Loan and, together with the Dollar Term Loan, collectively known as the
Term Loan and (iii) a five-year $500.0 million revolving credit facility, or the Revolving Credit Facility. We used the proceeds from the Term
Loan (i) to repay in full $575.9 million under that certain credit agreement, dated as of June 18, 2015 (as amended) among the Company, and
certain of our other subsidiaries as borrowers, the lenders party thereto and Bank of America, N.A., as administrative agent and collateral
agent, or the Existing Credit Agreement, (ii) to fund, in part, the cash consideration payable in connection with the GW Acquisition and (iii) to
pay related fees and expenses. There were no borrowings outstanding under the Revolving Credit Facility as of December 31, 2021. In
September and December 2021, we made voluntary prepayments totaling €416.7 million or $502.0 million on the Euro Term Loan. The Dollar
Term Loan is subject to a London Inter-Bank Offering Rate, or LIBOR, floor of 0.50%. Based on the outstanding borrowings of $3.3 billion as of
December 31, 2021, a hypothetical 1% increase or decrease in interest rates, above the LIBOR floor in the case of Dollar Term Loan
borrowings, would increase or decrease net income for 2022 by approximately $33.2 million.

In April 2021, we issued $1.5 billion in aggregate principal amount of 4.375% senior secured notes, due 2029, or the Secured Notes.
In 2017, we completed a private placement of $575.0 million aggregate principal amount of 1.50% exchangeable senior notes due 2024, or
the 2024 Notes, and in June 2020, we completed a private offering of $1.0 billion aggregate principal amount of 2.00% exchangeable
senior notes due 2026, or the 2026 Notes.

The Secured Notes, the 2024 Notes and the 2026 Notes have fixed annual interest rates of 4.375%, 1.50% and 2.00%, respectively, and

we therefore, do not have economic interest rate exposure on the Secured Notes, the 2024 Notes and the 2026 Notes. However, the fair
values of the Secured Notes, the 2024 Notes and the 2026 Notes are exposed to interest rate risk. Generally, the fair values of the Secured
Notes, the 2024 Notes and the 2026 Notes will increase as interest rates fall and decrease as interest rates rise. The fair values of the 2024
Notes and the 2026 Notes are also affected by volatility in our ordinary share price. As of December 31, 2021 the fair values of the Secured
Notes, the 2024 Notes and the 2026 Notes were estimated to be approximately $1.6 billion, $576.0 million and $1.1 billion, respectively.

In July 2017, the Financial Conduct Authority, or FCA, the authority that regulates LIBOR, announced it intended to stop compelling
banks to submit rates for the calculation of LIBOR after 2021. In a further update, on November 30, 2020, ICE Benchmark Administration,
the administrator of LIBOR, with the support of the U.S. Federal Reserve and FCA, announced plans to consult on ceasing publication of
LIBOR on December 31, 2021 for only the one week and two month LIBOR tenors, and on June 30, 2023 for all other LIBOR tenors. While
this announcement extends the transition period to June 2023, the U.S. Federal Reserve concurrently issued a statement advising banks
to stop new LIBOR issuances by the end of 2021. The Alternative Reference Rates Committee, or ARRC, in the U.S. has proposed that
the Secured Overnight Financing Rate, or SOFR, is the rate that represents best practice as the alternative to the U.S. dollar, or USD,
LIBOR for use in derivatives and other financial contracts that are currently indexed to USD LIBOR. ARRC has proposed a paced market
transition plan to SOFR from USD LIBOR and organizations are currently working on industry wide and company specific transition plans

JAZZ PHARMACEUTICALS | 2021 Annual Report

93

as it relates to derivatives and cash markets exposed to USD LIBOR. We currently have a USD LIBOR cross currency swap which matures
in March 2022; as such, the impact of Inter-Bank Offering Rate, or IBOR, reform is not expected to be material.

Foreign Exchange Risk. We have significant operations in Europe as well as in the U.S. The functional currency of each foreign

subsidiary is generally the local currency. We are exposed to foreign currency exchange risk as the functional currency financial
statements of foreign subsidiaries are translated to U.S. dollars. The assets and liabilities of our foreign subsidiaries having a functional
currency other than the U.S. dollar are translated into U.S. dollars at the exchange rate prevailing at the balance sheet date, and at the
average exchange rate for the reporting period for revenue and expense accounts. The cumulative foreign currency translation adjustment
is recorded as a component of accumulated other comprehensive loss in shareholders’ equity. The reported results of our foreign
subsidiaries will be influenced by their translation into U.S. dollars by currency movements against the U.S. dollar. Our primary currency
translation exposure is related to our subsidiaries that have functional currencies denominated in sterling and euro. A hypothetical 10%
strengthening or weakening in the rates used to translate the results of our foreign subsidiaries that have functional currencies
denominated in sterling and euro would have increased or decreased net income for the year ended December 31, 2021 by approximately
$14.6 million and $9.9 million, respectively.

Transactional exposure arises where transactions occur in currencies other than the functional currency. Transactions in foreign
currencies are recorded at the exchange rate prevailing at the date of the transaction. The resulting monetary assets and liabilities are
translated into the appropriate functional currency at exchange rates prevailing at the balance sheet date and the resulting gains and
losses are reported in foreign exchange gain (loss) in the consolidated statements of income (loss). As of December 31, 2021, our
exposure to transaction risk primarily related to the translation of our Euro Term Loan and sterling and euro denominated net monetary
liabilities, including intercompany loans, held by subsidiaries with a U.S. dollar functional currency.

In order to hedge our exposure to foreign currency exchange risk associated with our Euro Term Loan, we entered into a cross-

currency interest rate swap contract in May 2021 with a maturity date of March 31, 2022. The terms of this contract convert the principal
repayments and interest payments on our Euro Term Loan into U.S. dollar. As of December 31, 2021, the cross-currency interest rate
swap had a notional amount of $251.0 million which is designated for accounting purposes as a fair value hedge. The net liability fair value
of the cross currency swap was $15.2 million as of December 31, 2021. The carrying amount of the Euro Term Loan and the fair value of
the cross-currency interest rate swap contract will be remeasured with changes in the euro to U.S. dollar foreign exchange rates
recognized within foreign exchange gain (loss) in the consolidated statements of income (loss). The impact of a hypothetical increase or
decrease in the euro to U.S. dollar exchange rate on the fair value of our cross-currency interest rate swap contract would be offset by a
change in the value of the Euro Term Loan.

We have entered into foreign exchange forward contracts to manage the currency risk associated with the translation of our other
sterling and euro-denominated net monetary liabilities, including intercompany loans. These foreign exchange forward contracts are not
designated as hedges; gains and losses on these derivative instruments are designed to offset gains and losses on the underlying balance
sheet exposures. As of December 31, 2021, we held foreign exchange forward contracts with notional amounts totaling $347.2 million. The
net liability fair value of outstanding foreign exchange forward contracts was $2.6 million as of December 31, 2021. Based on our foreign
currency exchange rate exposures as of December 31, 2021, a hypothetical 10% adverse fluctuation in exchange rates would decrease
the fair value of our foreign exchange forward contracts by approximately $15.4 million as of December 31, 2021. The resulting loss on
these forward contracts would be offset by a positive impact on the underlying monetary assets and liabilities.

Item 8.

Financial Statements and Supplementary Data

Our consolidated financial statements as listed below are included in this Annual Report on Form 10-K as pages F-1 through F-44.

Jazz Pharmaceuticals plc
F-1
. . . . . . . . . . . . . . . . . . .
Report of Independent Registered Public Accounting Firm (KPMG, Dublin, Ireland, Auditor Firm ID: 1116)
F-3
Consolidated Balance Sheets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
F-4
Consolidated Statements of Income (Loss) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
F-5
Consolidated Statements of Comprehensive Income (Loss)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
F-6
Consolidated Statements of Shareholders’ Equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Consolidated Statements of Cash Flows . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
F-8
Notes to Consolidated Financial Statements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . F-10

Page

94

2021 Annual Report

| JAZZ PHARMACEUTICALS

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Not applicable.

Item 9A.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures. We have carried out an evaluation under the supervision and with the participation

of management, including our principal executive officer and principal financial officer, of our disclosure controls and procedures (as
defined in Rule 13a-15(e) of the Exchange Act) as of the end of the period covered by this Annual Report on Form 10-K. Based on their
evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were
effective as of December 31, 2021.

Limitations on the Effectiveness of Controls. A control system, no matter how well conceived and operated, can provide only
reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control
systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected.
Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our
disclosure control system are met and, as set forth above, our principal executive officer and principal financial officer have concluded,
based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to
provide reasonable assurance that the objectives of our disclosure control system were met.

Changes in Internal Control over Financial Reporting. As discussed above, the GW Acquisition closed on May 5, 2021. The GW

Acquisition was accounted for using the acquisition method of accounting. The results of operations of the acquired GW business have
been included in our results of operations since May 5, 2021, and we have evaluated and integrated GW’s historical internal controls with
ours throughout the fiscal year.

During the quarter ended December 31, 2021, there were no changes to our internal control over financial reporting that have

materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Management’s Report on Internal Control over Financial Reporting. The following report is provided by management in respect of our

internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act):

1.

2.

Our management is responsible for establishing and maintaining adequate internal control over financial reporting.

Our management used the Committee of Sponsoring Organizations of the Treadway Commission Internal Control—Integrated
Framework (2013), or the COSO framework, to evaluate the effectiveness of internal control over financial reporting.
Management believes that the COSO framework is a suitable framework for its evaluation of financial reporting because it is
free from bias, permits reasonably consistent qualitative and quantitative measurements of our internal control over financial
reporting, is sufficiently complete so that those relevant factors that would alter a conclusion about the effectiveness of our
internal control over financial reporting are not omitted and is relevant to an evaluation of internal control over financial reporting.

3. Management has assessed the effectiveness of our internal control over financial reporting as of December 31, 2021 and has

concluded that such internal control over financial reporting was effective. There were no material weaknesses in internal control
over financial reporting identified by management.

4.

KPMG, our independent registered public accounting firm, has audited the consolidated financial statements of Jazz
Pharmaceuticals plc as of and for the year ended December 31, 2021, included herein, and has issued an audit report on our
internal control over financial reporting, which is included below.

K
-
0
1
m
r
o
F

JAZZ PHARMACEUTICALS | 2021 Annual Report

95

Report of Independent Registered Public Accounting Firm

To the Shareholders and Board of Directors
Jazz Pharmaceuticals plc:

Opinion on Internal Control Over Financial Reporting

We have audited Jazz Pharmaceuticals plc and subsidiaries’ (the ‘Company’) internal control over financial reporting as of
December 31, 2021, based on criteria established in Internal Control—Integrated Framework (2013) issued by the Committee of
Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal
control over financial reporting as of December 31, 2021, based on criteria established in Internal Control—Integrated Framework
(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the
consolidated balance sheets of the Company as of December 31, 2021 and 2020, the related consolidated statements of income (loss),
comprehensive income (loss), stockholders’ equity, and cash flows for each of the years in the three-year period ended
December 31, 2021, and the related notes and financial statement schedule at Item 15(a)2 (collectively, ‘the consolidated financial
statements’), and our report dated March 1, 2022 expressed an unqualified opinion on those consolidated financial statements.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the
effectiveness of internal control over financial reporting, included in the accompanying Managements Report on Internal Control over
Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our
audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in
accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and
the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our
audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing
the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the
assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe
that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control Over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting
principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance
of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide
reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with
generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with
authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely
detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial
statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of
any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in
conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ KPMG

Dublin, Ireland
March 1, 2022

96

2021 Annual Report

| JAZZ PHARMACEUTICALS

Item 9B.

Other Information

Not applicable.

Item 9C.

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Not applicable.

PART III

Certain information required by Part III is omitted from this Annual Report on Form 10-K and incorporated by reference to our

definitive proxy statement for our 2022 annual general meeting of shareholders, or our 2022 Proxy Statement, to be filed pursuant to
Regulation 14A of the Securities Exchange Act of 1934, as amended, or Exchange Act. If our 2022 Proxy Statement is not filed within
120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, the omitted information will be included in an
amendment to this Annual Report on Form 10-K filed not later than the end of such 120-day period.

Item 10.

Directors, Executive Officers and Corporate Governance

The information required by this item is to be included in our 2022 Proxy Statement as follows and is incorporated by reference:

•

•

•

•

The information relating to our directors and nominees for director is to be included in the section entitled
Election of Directors;”

“Proposal 1—

The information relating to our executive officers is to be included in the section entitled “Executive Officers;”

The information relating to our audit committee, audit committee financial expert and procedures by which shareholders may
recommend nominees to our board of directors is to be included in the section entitled “Corporate Governance and Board
Matters;” and

If required, the information regarding compliance with Section 16(a) of the Exchange Act is to be included in the section entitled
“Delinquent Section 16(a) Reports.”

K
-
0
1
m
r
o
F

Such information is incorporated herein by reference to our 2022 Proxy Statement, provided that if the 2022 Proxy Statement is not

filed within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, the omitted information will be included in
an amendment to this Annual Report on Form 10-K filed not later than the end of such 120-day period.

Our Code of Conduct applies to all of our employees, directors and officers, including our principal executive officer, principal financial

officer, principal accounting officer or controller, or persons performing similar functions, and those of our subsidiaries. The Code of
Conduct is available on our website at www.jazzpharmaceuticals.com under the section entitled “About” under “Corporate Ethics.” We
intend to satisfy the disclosure requirements under Item 5.05 of the SEC Form 8-K regarding an amendment to, or waiver from, a provision
of our Code of Conduct by posting such information on our website at the website address and location specified above.

Item 11.

Executive Compensation

The information required by this item is to be included in our 2022 Proxy Statement under the sections entitled “Executive

Compensation,” “Director Compensation,” “Corporate Governance and Board Matters—Compensation Committee Interlocks and Insider
Participation” and “Corporate Governance and Board Matters—Compensation Committee Report” and is incorporated herein by reference.

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The information required by this item with respect to equity compensation plans is to be included in our 2022 Proxy Statement under
the section entitled “Equity Compensation Plan Information” and the information required by this item with respect to security ownership of
certain beneficial owners and management is to be included in our 2022 Proxy Statement under the section entitled “Security Ownership of
Certain Beneficial Owners and Management” and in each case is incorporated herein by reference.

Item 13.

Certain Relationships and Related Transactions, and Director Independence

The information required by this item is to be included in our 2022 Proxy Statement under the sections entitled “Certain Relationships

and Related Party Transactions” and “Corporate Governance and Board Matters—Independence of the Board of Directors” and is
incorporated herein by reference.

JAZZ PHARMACEUTICALS | 2021 Annual Report

97

Item 14.

Principal Accountant Fees and Services

The information required by this item is to be included in our 2022 Proxy Statement under the section entitled “Proposal 2—On a
Non-Binding Advisory Basis, Ratify Appointment of Independent Registered Accounting Firm and, On a Binding Basis, Authorize the Board
of Directors, Acting Through the Audit Committee, to Determine the Independent Auditors’ Remuneration” and is incorporated herein by
reference.

PART IV

Item 15.

Exhibits and Financial Statement Schedules

(a) The following documents are filed as part of this Annual Report on Form 10-K:

1.

Financial Statements:

See Consolidated Financial Statements in Part II, Item 8 of this Annual Report on Form 10-K.

2.

Financial Statement Schedules:

The following financial statement schedule of Jazz Pharmaceuticals plc is filed as part of this Annual Report on Form 10-K on

page F-51 and should be read in conjunction with the consolidated financial statements of Jazz Pharmaceuticals plc.

Schedule II: Valuation and Qualifying Accounts

All other schedules are omitted because they are not applicable, not required under the instructions, or the requested information is

shown in the consolidated financial statements or related notes thereto.

(b) Exhibits—The following exhibits are included herein or incorporated herein by reference:

Exhibit
Number

2.1

2.2

2.3

2.4

2.5

Description of Document

Agreement and Plan of Merger and Reorganization, dated as of September 19, 2011, by and among Azur Pharma Limited
(now Jazz Pharmaceuticals plc), Jaguar Merger Sub Inc., Jazz Pharmaceuticals, Inc. and Seamus Mulligan, solely in his
capacity as the Indemnitors’ Representative (incorporated herein by reference to Exhibit 2.1 in Jazz Pharmaceuticals, Inc.’s
Current Report on Form 8-K (File No. 001-33500) filed with the SEC on September 19, 2011).

Letter Agreement, dated as of January 17, 2012, by and among Jazz Pharmaceuticals plc, Jaguar Merger Sub Inc.,
Jazz Pharmaceuticals, Inc. and Seamus Mulligan, solely in his capacity as the Indemnitors’ Representative (incorporated
herein by reference to Exhibit 2.2 in Jazz Pharmaceuticals plc’s Current Report on Form 8-K (File No. 001-33500), as filed with
the SEC on January 18, 2012).

Agreement and Plan of Merger, dated as of April 26, 2012, by and among Jazz Pharmaceuticals plc, Jewel Merger Sub Inc.,
EUSA Pharma Inc., and Essex Woodlands Health Ventures, Inc., Mayflower L.P., and Bryan Morton, in their capacity as the
representatives of the equity holders of EUSA Pharma Inc. (incorporated herein by reference to Exhibit 2.1 in Jazz
Pharmaceuticals plc’s Current Report on Form 8-K (File No. 001-33500), as filed with the SEC on April 27, 2012).

Assignment, dated as of June 11, 2012, by and among Jazz Pharmaceuticals plc and Jazz Pharmaceuticals, Inc.
(incorporated herein by reference to Exhibit 2.1B in Jazz Pharmaceuticals plc’s Current Report on Form 8-K (File
No. 001-33500), as filed with the SEC on June 12, 2012).

Tender Offer Agreement, dated December 19, 2013, by and among Jazz Pharmaceuticals Public Limited Company,
Jazz Pharmaceuticals Italy S.r.l. and Gentium S.p.A. (incorporated herein by reference to Exhibit 2.1 in Jazz Pharmaceuticals
plc’s Current Report on Form 8-K/A (File No. 001-33500), as filed with the SEC on December 20, 2013).

2.6†

Asset Purchase Agreement, dated January 13, 2014, by and among Jazz Pharmaceuticals International III Limited, Aerial
BioPharma, LLC and Jazz Pharmaceuticals plc (incorporated herein by reference to Exhibit 2.1 in Jazz Pharmaceuticals plc’s
Current Report on Form 8-K (File No. 001-33500), as filed with the SEC on January 13, 2014).

98

2021 Annual Report

| JAZZ PHARMACEUTICALS

K
-
0
1
m
r
o
F

Exhibit
Number

2.7†

2.8

2.9

Description of Document

Assignment Agreement, dated July 1, 2014, by and among Jazz Pharmaceuticals International II Limited, Sigma-Tau
Pharmaceuticals, Inc., Jazz Pharmaceuticals plc and Gentium S.p.A. (incorporated herein by reference to Exhibit 2.1 in Jazz
Pharmaceuticals plc’s Current Report on Form 8-K (File No. 001-33500), as filed with the SEC on August 5, 2014).

Amended and Restated Agreement for the Acquisition of the Topaz Portfolio Business of Jazz Pharmaceuticals plc, dated
March 20, 2015, between Jazz Pharmaceuticals plc and Essex Bidco Limited (incorporated herein by reference to Exhibit 2.1
in Jazz Pharmaceuticals plc’s Current Report on Form 8-K (File No. 001-33500), as filed with the SEC on March 23, 2015).

Agreement and Plan of Merger, dated as of May 27, 2016, by and among Jazz Pharmaceuticals plc, Plex Merger Sub, Inc.,
and Celator Pharmaceuticals, Inc. (incorporated herein by reference to Exhibit 2.1 in Jazz Pharmaceuticals plc’s Current
Report on Form 8-K (File No. 001-33500), as filed with the SEC on May 31, 2016).

2.10‡

Transaction Agreement, dated as of February 3, 2021, by and among Jazz Pharmaceuticals UK Holdings Limited, Jazz
Pharmaceuticals Public Limited Company and GW Pharmaceuticals PLC (incorporated herein by reference to Exhibit 2.1 in
Jazz Pharmaceuticals plc’s Current Report on Form 8-K (File No. 001-33500), as filed with the SEC on February 4, 2021).

3.1

4.1

4.2A

4.2B

4.3A

4.3B

4.4A

4.4B

4.5A

4.5B

4.5C

4.6

10.1

Amended and Restated Memorandum and Articles of Association of Jazz Pharmaceuticals plc, as amended on August 4,
2016 (incorporated herein by reference to Exhibit 3.1 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File
No. 001-33500) for the period ended June 30, 2016, as filed with the SEC on August 9, 2016).

Reference is made to Exhibit 3.1.

Investor Rights Agreement, dated July 7, 2009 by and between Jazz Pharmaceuticals, Inc. and the other parties named
therein (incorporated herein by reference to Exhibit 10.88 in Jazz Pharmaceuticals, Inc.’s Current Report on Form 8-K (File
No. 001-33500), as filed with the SEC on July 7, 2009).

Assignment, Assumption and Amendment Agreement, dated as of January 18, 2012, by and among Jazz Pharmaceuticals,
Inc., Jazz Pharmaceuticals plc and the other parties named therein (incorporated herein by reference to Exhibit 4.7B in the
Annual Report on Form 10-K (File No. 001-33500) for the period ended December 31, 2011, as filed by Jazz Pharmaceuticals
plc on behalf of and as successor to Jazz Pharmaceuticals, Inc. with the SEC on February 28, 2012).

Indenture, dated as of August 23, 2017, among Jazz Pharmaceuticals Public Limited Company, Jazz Investments I Limited
and U.S. Bank National Association (incorporated herein by reference to Exhibit 4.1 in Jazz Pharmaceuticals plc’s Current
Report on Form 8-K (File No. 001-33500), as filed with the SEC on August 23, 2017).

Form of 1.50% Exchangeable Senior Note due 2024 (incorporated herein by reference to Exhibit 4.1 in Jazz Pharmaceuticals
plc’s Current Report on Form 8-K (File No. 001-33500), as filed with the SEC on August 23, 2017).

Indenture, dated as of June 11, 2020 among Jazz Pharmaceuticals Public Limited Company, Jazz Investments I Limited and
U.S. Bank National Association (incorporated herein by reference to Exhibit 4.1 in Jazz Pharmaceuticals plc’s Current Report
on Form 8-K (File No. 001-033500), as filed with the SEC on June 11, 2020).

Form of 2.000% Exchangeable Senior Note due 2026 (incorporated herein by reference to Exhibit 4.2 in Jazz Pharmaceuticals
plc’s Current Report on Form 8-K (File No. 001-033500), as filed with the SEC on June 11, 2020).

Indenture, dated as of April 29, 2021, among Jazz Securities Designated Activity Company, the guarantors party thereto, U.S.
Bank National Association, as trustee and acknowledged by U.S. Bank National Association, as collateral trustee.
(incorporated herein by reference to Exhibit 4.1 in Jazz Pharmaceuticals plc’s Current Report on Form 8-K (File
No. 001-033500), as filed with the SEC on April 29, 2021).

Form of 4.375% Senior Notes due 2029 (incorporated herein by reference to Exhibit 4.2 in Jazz Pharmaceuticals plc’s Current
Report on Form 8-K (File No. 001-033500), as filed with the SEC on April 29, 2021).

First Supplemental Indenture, dated as of July 21, 2021, among GW Pharmaceuticals Limited, GW Global Services
(International) Limited, GW Pharma Limited, GW Research Limited, GW UK Services Limited and Greenwich Biosciences,
Inc., Jazz Securities Designated Activity Company, and U.S. Bank National Association, as trustee under the Indenture, dated
as of April 29, 2021 (incorporated herein by reference to Exhibit 4.5C in Jazz Pharmaceuticals, plc’s Quarterly Report on
Form 10-Q (File No. 001-33500) for the period ended June 30, 2021, as filed with the SEC on August 3, 2021).

Description of Share Capital.

Settlement Agreement, dated as of April 5, 2017, by and between Jazz Pharmaceuticals, Inc. and Jazz Pharmaceuticals
Ireland Limited, and Roxane Laboratories, Inc., West-Ward Pharmaceuticals Corp., Eurohealth (USA), Inc., and Hikma
Pharmaceuticals PLC (incorporated herein by reference to Exhibit 10.1 in Jazz Pharmaceuticals plc’s Quarterly Report on
Form 10-Q (File No. 001-33500) for the period ended June 30, 2017, as filed with the SEC on August 8, 2017).

JAZZ PHARMACEUTICALS | 2021 Annual Report

99

Exhibit
Number

10.2

10.3

10.4†

10.5†

10.6

10.7

10.8‡

Description of Document

Settlement Agreement, dated as of April 4, 2019, by and among United States of America, acting through the United States
Department of Justice and on behalf of the Office of Inspector General of the Department of Health and Human Services, Jazz
Pharmaceuticals plc, Jazz Pharmaceuticals, Inc., and Jazz Pharmaceuticals Ireland Ltd. (incorporated herein by reference to
Exhibit 10.7 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period ended
March 31, 2019, as filed with the SEC on May 7, 2019).

Corporate Integrity Agreement, dated as of April 3, 2019, by and between Jazz Pharmaceuticals plc and the Office of Inspector
General of the United States Department of Health and Human Services (incorporated herein by reference to Exhibit 10.6 in
Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period ended March 31, 2019, as filed
with the SEC on May 7, 2019).

Supply Agreement, dated as of April 1, 2010, by and between Jazz Pharmaceuticals, Inc. and Siegfried (USA) Inc.
(incorporated herein by reference to Exhibit 10.54 in Jazz Pharmaceuticals, Inc.’s Quarterly Report on Form 10-Q
(File No. 001-33500) for the period ended March 31, 2010, as filed with the SEC on May 6, 2010).

Royalty Bearing Licence Agreement and Supply Agreement Re Erwinia-Derived Asparaginase, dated July 22, 2005, between
Public Health England (formerly Health Protection Agency) and EUSA Pharma SAS (formerly OPi, S.A.), as amended on each
of December 22, 2009, March 23, 2012 and August 8, 2012 (incorporated herein by reference to Exhibit 10.11 in Jazz
Pharmaceuticals plc’s Quarterly Report on Form 10-Q/A (File No. 001-33500) for the period ended June 30, 2012, as filed with
the SEC on August 9, 2012).

Novation Agreement relating to Royalty Bearing Licence Agreement and Supply Agreement re Erwinia-Derived Asparaginase,
dated as of May 13, 2015, by and among EUSA Pharma SAS, the Secretary of State for Health acting through Public Health
England and Porton Biopharma Limited (incorporated herein by reference to Exhibit 10.3 in Jazz Pharmaceuticals plc’s
Quarterly Report on Form 10-Q (File No. 001-33500) for the period ended June 30, 2015, as filed with the SEC on August 5,
2015).

Contract Variation Agreement by and between Porton Biopharma Limited and Jazz Pharmaceuticals France SAS, dated as of
December 20, 2018 (incorporated herein by reference to Exhibit 10.5 in Jazz Pharmaceuticals plc’s Annual Report on Form
10-K (File No. 001-33500) for the period ended December 31, 2018, as filed with the SEC on February 26, 2019).

Master Manufacturing Services Agreement, dated as of October 1, 2015, by and between Jazz Pharmaceuticals Ireland
Limited and Patheon Pharmaceuticals Inc. (incorporated herein by reference to Exhibit 10.8 in Jazz Pharmaceuticals plc’s
Annual Report on Form 10-K (File No. 001-33500) for the period ended December 31, 2020, as filed with the SEC on
February 23, 2021).

10.9A†

10.9B†

Clinical and Commercial Manufacturing and Supply Agreement, dated as of December 22, 2010, between Celator
Pharmaceuticals, Inc. and Baxter Oncology GmbH (incorporated herein by reference to Exhibit 10.8 in Jazz Pharmaceuticals
plc’s Annual Report on Form 10-K (File No. 001-33500) for the year ended December 31, 2017, as filed with the SEC on
February 27, 2018).

Amendment No. 1 Clinical and Commercial Manufacturing and Supply Agreement, dated as of January 18, 2018, by and
between Jazz Pharmaceuticals Ireland Limited and Baxter Oncology GmbH (incorporated herein by reference to Exhibit 10.3
in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period ended March 31, 2018, as
filed with the SEC on May 8, 2018).

10.10‡

Contract Manufacturing Agreement, dated as of January 20, 2020, by and between Jazz Pharmaceuticals Ireland Limited and
Siegfried AG (incorporated herein by reference to Exhibit 10.10 in Jazz Pharmaceuticals plc’s Annual Report on Form 10-K
(File No. 001-33500) for the period ended December 31, 2019, as filed with the SEC on February 25, 2020).

10.11A‡ Pharmacy Master Services Agreement, dated as of July 1, 2020, by and between Jazz Pharmaceuticals, Inc. and Express
Scripts Specialty Distribution Services, Inc. (incorporated herein by reference to Exhibit 10.2 in Jazz Pharmaceuticals plc’s
Quarterly Report on Form 10-Q (File No. 001-33500) for the period ended June 30, 2020, as filed with the SEC on August 4,
2020).

10.11B

Amendment No. 1, dated as of July 4, 2021 to Pharmacy Master Services Agreement, dated as of July 1, 2020, by and
between Jazz Pharmaceuticals, Inc. and Express Scripts Specialty Distribution Services, Inc. (incorporated herein by
reference to Exhibit 10.1A in Jazz Pharmaceuticals, plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period
ended June 30, 2021, as filed with the SEC on August 3, 2021).

100

2021 Annual Report

| JAZZ PHARMACEUTICALS

Exhibit
Number

10.11C

Description of Document

Amendment No. 2, dated as of July 19, 2021 to Pharmacy Master Services Agreement, dated as of July 1, 2020, by and
between Jazz Pharmaceuticals, Inc. and Express Scripts Specialty Distribution Services, Inc. (incorporated herein by
reference to Exhibit 10.1B in Jazz Pharmaceuticals, plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period
ended June 30, 2021, as filed with the SEC on August 3, 2021).

10.11D

Amendment No. 3, dated as of December 7, 2021 to Pharmacy Master Services Agreement, dated as of July 1, 2020, by and
between Jazz Pharmaceuticals, Inc. and Express Scripts Specialty Distribution Services, Inc.

10.12A‡ Amended and Restated License Agreement, dated as of October 14, 2020, between Pharma Mar, S.A. and Jazz

Pharmaceuticals Ireland Limited (incorporated herein by reference to Exhibit 10.12 in Jazz Pharmaceuticals plc’s Annual
Report on Form 10-K (File No. 001-33500) for the period ended December 31, 2020, as filed with the SEC on February 23,
2021).

10.12B‡ Amendment No. 1, dated as of May 6, 2021, to Amended and Restated License Agreement, dated as of October 14, 2020,

between Pharma Mar, S.A. and Jazz Pharmaceuticals Ireland Limited (incorporated herein by reference to Exhibit 10.2 in Jazz
Pharmaceuticals, plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period ended June 30, 2021, as filed with
the SEC on August 3, 2021).

10.13A

10.13B

10.13C

10.13D

10.14

10.15A

10.15B

Credit Agreement, dated as of June 18, 2015, among Jazz Pharmaceuticals plc, Jazz Securities Limited, Jazz
Pharmaceuticals, Inc., Jazz Financing I Limited, Jazz Pharmaceuticals Ireland Limited, the lenders party thereto and Bank of
America, N.A., as Collateral Agent, Administrative Agent, Swing Line Lender and L/C Issuer (incorporated herein by reference
to Exhibit 10.1 in Jazz Pharmaceuticals plc’s Current Report on Form 8-K (File No. 001-33500), as filed with the SEC on
June 18, 2015).

K
-
0
1
m
r
o
F

Amendment No. 1, dated as of July 12, 2016, to Credit Agreement, dated as of June 18, 2015, among Jazz Pharmaceuticals
plc, Jazz Securities Limited, Jazz Pharmaceuticals, Inc., Jazz Financing I Limited, Jazz Pharmaceuticals Ireland Limited, the
lenders party thereto and Bank of America, N.A., as Collateral Agent, Administrative Agent, Swing Line Lender and L/C Issuer
(incorporated herein by reference to Exhibit 10.1 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File
No. 001-33500) for the period ended June 30, 2016, as filed with the SEC on August 9, 2016).

Amendment No. 2, dated as of June 7, 2018, to Credit Agreement, dated as of June 18, 2015 (as previously amended by
Amendment No. 1, dated as of July 12, 2016), among Jazz Pharmaceuticals plc, Jazz Securities Designated Activity
Company, Jazz Pharmaceuticals, Inc., Jazz Financing I Designated Activity Company, Jazz Pharmaceuticals Ireland Limited,
the lenders party thereto and Bank of America, N.A., as Collateral Agent, Administrative Agent, Swing Line Lender and L/C
Issuer (incorporated herein by reference to Exhibit 10.4 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File
No. 001-33500) for the period ended June 30, 2018, as filed with the SEC on August 7, 2018).

Amendment No. 3, dated as of April 20, 2021, to Credit Agreement, dated as of June 18, 2015 (as previously amended by
Amendment No. 1, dated as of July 12, 2016 and Amendment No.2, dated as of June 7, 2018), among Jazz Pharmaceuticals
plc, Jazz Securities Designated Activity Company, Jazz Pharmaceuticals, Inc., Jazz Financing I Designated Activity Company,
Jazz Pharmaceuticals Ireland Limited, the lenders party thereto and Bank of America, N.A., as Collateral Agent, Administrative
Agent, Swing Line Lender and L/C Issuer (incorporated herein by reference to Exhibit 10.1 in Jazz Pharmaceuticals plc’s
Current Report on Form 8-K (File No. 001-33500), as filed with the SEC on April 20, 2021.

Credit Agreement, dated as of May 5, 2021, by and among Jazz Pharmaceuticals Public Limited Company, the other
borrowers from time to time party thereto, the lenders and issuing banks from time to time party thereto, Bank of America,
N.A., as administrative agent, and U.S. Bank National Association, as collateral trustee (incorporated herein by reference to
Exhibit 10.1 in Jazz Pharmaceuticals plc’s Current Report on Form 8-K (File No. 001-033500), as filed with the SEC on May 5,
2021).

Commercial Lease, dated as of June 2, 2004, by and between Jazz Pharmaceuticals, Inc. and The Board of Trustees of the
Leland Stanford Junior University (incorporated herein by reference to Exhibit 10.52 in Jazz Pharmaceuticals, Inc.’s
registration statement on Form S-1, as amended (File No. 333-141164), as filed with the SEC on March 27, 2007).

First Amendment of Lease, dated June 1, 2009, by and between Jazz Pharmaceuticals, Inc. and Wheatley-Fields, LLC,
successor in interest to The Board of Trustees of the Leland Stanford Junior University (incorporated herein by reference to
Exhibit 10.86 in Jazz Pharmaceuticals, Inc.’s Current Report on Form 8-K (File No. 001-33500), as filed with the SEC on
June 4, 2009).

JAZZ PHARMACEUTICALS | 2021 Annual Report

101

Exhibit
Number

10.15C

10.16

10.17A

10.17B

10.17C

10.18+

10.19+

10.20+

Description of Document

Second Amendment of Lease, dated February 28, 2012, by and between Jazz Pharmaceuticals, Inc. and Wheatley-Fields,
LLC, successor in interest to The Board of Trustees of the Leland Stanford Junior University (incorporated herein by reference
to Exhibit 10.31 in the Annual Report on Form 10-K (File No. 001-33500) for the period ended December 31, 2011, as filed by
Jazz Pharmaceuticals plc on behalf of and as successor to Jazz Pharmaceuticals, Inc. with the SEC on February 28, 2012).

Lease, dated May 8, 2012, by and between John Ronan and Castle Cove Property Developments Limited and Jazz
Pharmaceuticals plc (incorporated herein by reference to Exhibit 10.2 in Jazz Pharmaceuticals plc’s Quarterly Report on
Form 10-Q (File No. 001-33500) for the period ended June 30, 2012, as filed with the SEC on August 7, 2012).

Commercial Lease, dated as of January 7, 2015, by and between The Board of Trustees of the Leland Stanford Junior
University and Jazz Pharmaceuticals, Inc. (incorporated herein by reference to Exhibit 10.10 in Jazz Pharmaceuticals plc’s
Annual Report on Form 10-K (File No. 001-33500) for the period ended December 31, 2014, as filed with the SEC on
February 24, 2015).

First Amendment, dated as of January 29, 2018, to Commercial Lease, dated as of January 7, 2015, by and between The
Board of Trustees of the Leland Stanford Junior University and Jazz Pharmaceuticals, Inc. (incorporated herein by reference to
Exhibit 10.5 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period ended June 30,
2018, as filed with the SEC on August 7, 2018).

Second Amendment, dated as of July 26, 2018, to Commercial Lease, dated as of January 7, 2015, by and between The
Board of Trustees of the Leland Stanford Junior University and Jazz Pharmaceuticals, Inc., as previously amended by the First
Amendment to Lease, dated as of January 29, 2018 (incorporated herein by reference to Exhibit 10.1 in Jazz Pharmaceuticals
plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period ended September 30, 2018, as filed with the SEC on
November 6, 2018).

Form of Indemnification Agreement between Jazz Pharmaceuticals plc and its officers and directors (incorporated herein by
reference to Exhibit 10.1 in Jazz Pharmaceuticals plc’s Current Report on Form 8-K (File No. 001-33500), as filed with the
SEC on January 18, 2012).

Offer Letter from Jazz Pharmaceuticals, Inc. to Daniel N. Swisher, Jr. (incorporated herein by reference to Exhibit 10.21 in
Jazz Pharmaceuticals plc’s Annual Report on Form 10-K (File No. 001-33500) for the year ended December 31, 2017, as filed
with the SEC on February 27, 2018).

Offer Letter from Jazz Pharmaceuticals, Inc. to Robert Iannone dated as of April 11, 2019 (incorporated herein by reference to
Exhibit 10.4 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period ended June 30,
2019, as filed with the SEC on August 6, 2019).

10.21A+ Employment Agreement, dated as of May 16, 2012 by and between Patricia Carr and Jazz Pharmaceuticals plc (incorporated
herein by reference to Exhibit 10.1 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the
period ended September 30, 2019, as filed with the SEC on November 5, 2019).

10.21B+ Change in Control Severance Terms, dated as of May 15, 2016, by and between Jazz Pharmaceuticals Ireland Ltd. and

Patricia Carr (incorporated herein by reference to Exhibit 10.2 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q
(File No. 001-33500) for the period ended September 30, 2019, as filed with the SEC on November 5, 2019).

10.21C+ Change in Control Stock Award Acceleration Agreement, dated as of May 15, 2016 by and between Jazz Pharmaceuticals plc
and Patricia Carr (incorporated herein by reference to Exhibit 10.3 in Jazz Pharmaceuticals plc’s Quarterly Report on
Form 10-Q (File No. 001-33500) for the period ended September 30, 2019, as filed with the SEC on November 5, 2019).

10.22+

Offer Letter, dated as of July 5, 2019 by and between Jazz Pharmaceuticals, Inc. and Neena M. Patil (incorporated herein by
reference to Exhibit 10.4 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period
ended September 30, 2019, as filed with the SEC on November 5, 2019).

10.23A+ Employment Contract, dated as of February 22, 2013, by and between Jazz Pharmaceuticals Ireland Limited and Finbar

Larkin (incorporated herein by reference to Exhibit 10.27 in Jazz Pharmaceuticals plc’s Annual Report on Form 10-K
(File No. 001-33500) for the period ended December 31, 2019, as filed with the SEC on February 25, 2020).

10.23B+ Amendment to Employment Contract, dated as of February 26, 2020, by and between Jazz Pharmaceuticals Ireland Limited

and Finbar Larkin ((incorporated herein by reference to Exhibit 10.2 in Jazz Pharmaceuticals plc’s Quarterly Report on
Form 10-Q (File No. 001-33500) for the period ended March 31, 2020, as filed with the SEC on May 5, 2020).

102

2021 Annual Report

| JAZZ PHARMACEUTICALS

Exhibit
Number

Description of Document

10.24A+ Employment Contract, dated as of December 14, 2019, by and between Jazz Pharmaceuticals UK Limited and Samantha

Pearce (incorporated herein by reference to Exhibit 10.28A in Jazz Pharmaceuticals plc’s Annual Report on Form 10-K
(File No. 001-33500) for the period ended December 31, 2019, as filed with the SEC on February 25, 2020).

10.24B+ Amendment to Employment Contract, dated as of April 21, 2020, by and between Jazz Pharmaceuticals UK Limited and

Samantha Pearce (incorporated herein by reference to Exhibit 10.4 in Jazz Pharmaceuticals plc’s Quarterly Report on
Form 10-Q (File No. 001-33500) for the period ended March 31, 2020, as filed with the SEC on May 5, 2020).

10.24C+ Equity Award Letter, dated as of December 9, 2019, by and between Jazz Pharmaceuticals UK Limited and Samantha Pearce

(incorporated herein by reference to Exhibit 10.28B in Jazz Pharmaceuticals plc’s Annual Report on Form 10-K
(File No. 001-33500) for the period ended December 31, 2019, as filed with the SEC on February 25, 2020).

10.25+

10.26+

Offer Letter, dated as of February 23, 2020, by and between Jazz Pharmaceuticals, Inc. and Renée Galá (incorporated herein
by reference to Exhibit 10.1 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period
ended March 31, 2020, as filed with the SEC on May 5, 2020).

Offer Letter, dated as of May 2, 2020, by and between Jazz Pharmaceuticals, Inc. and Kim Sablich (incorporated herein by
reference to Exhibit 10.1 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period
ended June 30, 2020, as filed with the SEC on August 4, 2020).

10.27A+ Service Agreement, dated as of May 5, 2021, by and between Chris Tovey and Jazz Pharmaceuticals UK Limited

(incorporated herein by reference to Exhibit 10.4 in Jazz Pharmaceuticals, plc’s Quarterly Report on Form 10-Q
(File No. 001-33500) for the period ended June 30, 2021, as filed with the SEC on August 3, 2021).

10.27B+ Participation Agreement, dated as of May 5, 2021, by and between Chris Tovey and Jazz Pharmaceuticals UK Limited

(incorporated herein by reference to Exhibit 10.5 in Jazz Pharmaceuticals, plc’s Quarterly Report on Form 10-Q
(File No. 001-33500) for the period ended June 30, 2021, as filed with the SEC on August 3, 2021).

10.28A+

Jazz Pharmaceuticals plc 2007 Equity Incentive Plan (incorporated herein by reference to Exhibit 99.3 in Jazz
Pharmaceuticals plc’s registration statement on Form S-8 (File No. 333-179075), as filed with the SEC on January 18, 2012).

10.28B+

Jazz Pharmaceuticals plc 2007 Equity Incentive Plan Sub-Plan Governing Awards to Participants in the Republic of Ireland
(incorporated herein by reference to Exhibit 10.3B in the Annual Report on Form 10-K (File No. 001-33500) for the period
ended December 31, 2011, as filed by Jazz Pharmaceuticals plc on behalf of and as successor to Jazz Pharmaceuticals Inc.
with the SEC on February 28, 2012).

10.28C+ Form of Notice of Grant of Stock Options and Form of Option Agreement (U.S.) under the Jazz Pharmaceuticals plc 2007
Equity Incentive Plan (incorporated herein by reference to Exhibit 10.27C in Jazz Pharmaceuticals plc’s Annual Report on
Form 10-K (File No. 001-33500) for the period ended December 31, 2012, as filed with the SEC on February 26, 2013).

10.28D+ Form of Notice of Grant of Stock Options and Form of Option Agreement (Irish) under Jazz Pharmaceuticals plc 2007 Equity

Incentive Plan (incorporated herein by reference to Exhibit 10.27D in Jazz Pharmaceuticals plc’s Annual Report on Form 10-K
(File No. 001-33500) for the period ended December 31, 2012, as filed with the SEC on February 26, 2013).

10.28E+ Form of Restricted Stock Unit Grant Notice and Form of Restricted Stock Unit Award Agreement (U.S.) under the Jazz

Pharmaceuticals plc 2007 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.27E in Jazz Pharmaceuticals
plc’s Annual Report on Form 10-K (File No. 001-33500) for the period ended December 31, 2012, as filed with the SEC on
February 26, 2013).

10.28F+

Form of Restricted Stock Unit Grant Notice and Form of Restricted Stock Unit Award Agreement (Irish) under the Jazz
Pharmaceuticals plc 2007 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.27F in Jazz Pharmaceuticals
plc’s Annual Report on Form 10-K (File No. 001-33500) for the period ended December 31, 2012, as filed with the SEC on
February 26, 2013).

10.28G+ Jazz Pharmaceuticals plc 2007 Equity Incentive Plan—Form of Non-U.S. Option Grant Notice and Form of Non-U.S. Option

Agreement (approved July 31, 2013) (incorporated herein by reference to Exhibit 10.1 in Jazz Pharmaceuticals plc’s Quarterly
Report on Form 10-Q (File No. 001-33500) for the period ended September 30, 2013, as filed with the SEC on November 5,
2013).

K
-
0
1
m
r
o
F

JAZZ PHARMACEUTICALS | 2021 Annual Report

103

Exhibit
Number

Description of Document

10.28H+ Jazz Pharmaceuticals plc 2007 Equity Incentive Plan—Form of Non-U.S. Restricted Stock Unit Award Grant Notice and
Form of Non-U.S. Restricted Stock Unit Award Agreement (approved July 31, 2013) (incorporated herein by reference to
Exhibit 10.2 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period ended
September 30, 2013, as filed with the SEC on November 5, 2013).

10.29A+

Jazz Pharmaceuticals plc 2011 Equity Incentive Plan (incorporated herein by reference to Exhibit 99.1 in Jazz
Pharmaceuticals plc’s registration statement on Form S-8 (File No. 333-179075), as filed with the SEC on January 18, 2012).

10.29B+

Jazz Pharmaceuticals plc 2011 Equity Incentive Plan Sub-Plan Governing Awards to Participants in the Republic of Ireland
(incorporated herein by reference to Exhibit 10.39B in the Annual Report on Form 10-K (File No. 001-33500) for the period
ended December 31, 2011, as filed by Jazz Pharmaceuticals plc on behalf of and as successor to Jazz Pharmaceuticals Inc.
with the SEC on February 28, 2012).

10.29C+ Form of Stock Option Grant Notice and Form of Option Agreement (U.S.) under the Jazz Pharmaceuticals plc 2011 Equity

Incentive Plan (incorporated herein by reference to Exhibit 10.7 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q
(File No. 001-33500) for the period ended June 30, 2012, as filed with the SEC on August 7, 2012).

10.29D+ Form of Stock Option Grant Notice and Form of Option Agreement (Irish) under the Jazz Pharmaceuticals plc 2011 Equity

Incentive Plan (incorporated herein by reference to Exhibit 10.8 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q
(File No. 001-33500) for the period ended June 30, 2012, as filed with the SEC on August 7, 2012).

10.29E+ Form of Non-U.S. Option Grant Notice and Form of Non-U.S. Option Agreement under the Jazz Pharmaceuticals plc 2011
Equity Incentive Plan (incorporated herein by reference to Exhibit 10.28E in Jazz Pharmaceuticals plc’s Annual Report on
Form 10-K (File No. 001-33500) for the period ended December 31, 2012, as filed with the SEC on February 26, 2013).

10.29F+

Form of Restricted Stock Unit Grant Notice and Form of Restricted Stock Unit Award Agreement (U.S.) under the Jazz
Pharmaceuticals plc 2011 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.9 in Jazz Pharmaceuticals plc’s
Quarterly Report on Form 10-Q (File No. 001-33500) for the period ended June 30, 2012, as filed with the SEC on August 7,
2012).

10.29G+ Form of Restricted Stock Unit Grant Notice and Form of Restricted Stock Unit Award Agreement (Irish) under the Jazz

Pharmaceuticals plc 2011 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.10 in Jazz Pharmaceuticals
plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period ended June 30, 2012, as filed with the SEC on
August 7, 2012).

10.29H+ Form of Non-U.S. Restricted Stock Unit Grant Notice and Form of Non-U.S. Restricted Stock Unit Agreement under the Jazz
Pharmaceuticals plc 2011 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.28H in Jazz Pharmaceuticals
plc’s Annual Report on Form 10-K (File No. 001-33500) for the period ended December 31, 2012, as filed with the SEC on
February 26, 2013).

10.29I+

10.29J+

10.29K+

10.29L+

Jazz Pharmaceuticals plc 2011 Equity Incentive Plan—Form of U.S. Option Grant Notice and Form of U.S. Option Agreement
(approved July 31, 2013) (incorporated herein by reference to Exhibit 10.3 in Jazz Pharmaceuticals plc’s Quarterly Report on
Form 10-Q (File No. 001-33500) for the period ended September 30, 2013, as filed with the SEC on November 5, 2013).

Jazz Pharmaceuticals plc 2011 Equity Incentive Plan—Form of U.S. Restricted Stock Unit Award Grant Notice and Form of
U.S. Restricted Stock Unit Award Agreement (approved July 31, 2013) (incorporated herein by reference to Exhibit 10.4 in
Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period ended September 30, 2013, as
filed with the SEC on November 5, 2013).

Jazz Pharmaceuticals plc 2011 Equity Incentive Plan—Form of Non-U.S. Option Grant Notice and Form of Non-U.S. Option
Agreement (approved July 31, 2013) (incorporated herein by reference to Exhibit 10.5 in Jazz Pharmaceuticals plc’s Quarterly
Report on Form 10-Q (File No. 001-33500) for the period ended September 30, 2013, as filed with the SEC on November 5,
2013).

Jazz Pharmaceuticals plc 2011 Equity Incentive Plan—Form of Non-U.S. Restricted Stock Unit Award Grant Notice and
Form of Non-U.S. Restricted Stock Unit Award Agreement (approved July 31, 2013) (incorporated herein by reference to
Exhibit 10.6 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period ended
September 30, 2013, as filed with the SEC on November 5, 2013).

10.29M+ Jazz Pharmaceuticals plc 2011 Equity Incentive Plan—Form of Non-U.S. Option Grant Notice and Form of Non-U.S. Option
Agreement (incorporated herein by reference to Exhibit 10.1 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q
(File No. 001-33500) for the period ended March 31, 2016, as filed with the SEC on May 10, 2016).

104

2021 Annual Report

| JAZZ PHARMACEUTICALS

Exhibit
Number

Description of Document

10.29N+ Jazz Pharmaceuticals plc 2011 Equity Incentive Plan—Form of Non-U.S. Restricted Stock Unit Grant Notice and Form of

Non-U.S. Restricted Stock Unit Award Agreement (incorporated herein by reference to Exhibit 10.2 in Jazz Pharmaceuticals
plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period ended March 31, 2016, as filed with the SEC on
May 10, 2016).

10.29O+ Amended and Restated 2011 Equity Incentive Plan (approved August 4, 2016) (incorporated herein by reference to Exhibit

10.8 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period ended June 30, 2016,
as filed with the SEC on August 9, 2016).

10.29P+ Amended and Restated 2011 Equity Incentive Plan (approved November 3, 2016) (incorporated herein by reference to Exhibit

10.2 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period ended September 30,
2016, as filed with the SEC on November 8, 2016).

10.29Q+ Form of U.S. Restricted Stock Unit Award Grant Notice and Form of U.S. Restricted Stock Unit Award Agreement under the

Jazz Pharmaceuticals plc Amended and Restated 2011 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.6
in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period ended September 30, 2016,
as filed with the SEC on November 8, 2016).

10.29R+ Form of U.S. Option Grant Notice and Form of U.S. Option Agreement under the Jazz Pharmaceuticals plc Amended and

Restated 2011 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.7 in Jazz Pharmaceuticals plc’s Quarterly
Report on Form 10-Q (File No. 001-33500) for the period ended September 30, 2016, as filed with the SEC on November 8,
2016).

K
-
0
1
m
r
o
F

10.29S+ Form of Non-U.S. Restricted Stock Unit Award Grant Notice and Form of Non-U.S. Restricted Stock Unit Award Agreement
under the Jazz Pharmaceuticals plc Amended and Restated 2011 Equity Incentive Plan (incorporated herein by reference to
Exhibit 10.8 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period ended
September 30, 2016, as filed with the SEC on November 8, 2016).

10.29T+

Form of Non-U.S. Option Grant Notice and Non-U.S. Option Agreement under the Jazz Pharmaceuticals plc Amended and
Restated 2011 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.2 in Jazz Pharmaceuticals plc’s Quarterly
Report on Form 10-Q (File No. 001-33500) for the period ended June 30, 2018, as filed with the SEC on August 7, 2018).

10.29U+ Form of Non-U.S. Restricted Stock Unit Award Grant Notice and Non-U.S. Restricted Stock Unit Award Agreement under the

Jazz Pharmaceuticals plc Amended and Restated 2011 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.3
in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period ended June 30, 2018, as
filed with the SEC on August 7, 2018).

10.29V+ Form of Non-U.S. Option Grant Notice and Non-U.S. Option Agreement under the Jazz Pharmaceuticals plc 2011 Equity

Incentive Plan (incorporated herein by reference to Exhibit 10.4 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q
(File No. 001-33500) for the period ended March 31, 2019, as filed with the SEC on May 7, 2019).

10.29W+ Form of Non-U.S. Restricted Stock Unit Award Grant Notice and Non-U.S. Restricted Stock Unit Award Agreement under the

Jazz Pharmaceuticals plc 2011 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.5 in Jazz
Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period ended March 31, 2019, as filed with
the SEC on May 7, 2019).

10.29X+ Form of U.S. Restricted Stock Unit Award Grant Notice and Form of U.S. Restricted Stock Unit Award Agreement under the

Jazz Pharmaceuticals plc Amended and Restated 2011 Equity Incentive Plan (incorporated herein by reference to Exhibit 10.8
in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period ended June 30, 2021, as
filed with the SEC on August 3, 2021).

10.29Y+ Form of Non-U.S. Restricted Stock Unit Award Grant Notice and Form of Non-U.S. Restricted Stock Unit Award Agreement
under the Jazz Pharmaceuticals plc Amended and Restated 2011 Equity Incentive Plan (incorporated herein by reference to
Exhibit 10.9 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period ended June 30,
2021, as filed with the SEC on August 3, 2021).

10.29Z+

Form of Non-U.S. Restricted Stock Unit Award Grant Notice and Form of Non-U.S. Restricted Stock Unit Award Agreement
under the Jazz Pharmaceuticals plc Amended and Restated 2011 Equity Incentive Plan (incorporated herein by reference to
Exhibit 10.1 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period ended
September 30, 2021, as filed with the SEC on November 9, 2021).

JAZZ PHARMACEUTICALS | 2021 Annual Report

105

Exhibit
Number

Description of Document

10.29AA+ Form of U.S. Performance Restricted Stock Unit Award Grant Notice and Form of U.S. Performance Restricted Stock

Unit Award Agreement under the Jazz Pharmaceuticals plc Amended and Restated 2011 Equity Incentive Plan (incorporated
herein by reference to Exhibit 10.6 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the
period ended June 30, 2021, as filed with the SEC on August 3, 2021).

10.29BB+ Form of Non-U.S. Performance Restricted Stock Unit Award Grant Notice and Form of Non-U.S. Performance Restricted

Stock Unit Award Agreement under the Jazz Pharmaceuticals plc Amended and Restated 2011 Equity Incentive Plan
(incorporated herein by reference to Exhibit 10.7 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q
(File No. 001-33500) for the period ended June 30, 2021, as filed with the SEC on August 3, 2021).

10.30+

10.31A+

Jazz Pharmaceuticals plc Amended and Restated Directors Deferred Compensation Plan (incorporated herein by reference to
Exhibit 99.6 in Jazz Pharmaceuticals plc’s registration statement on Form S-8 (File No. 333-179075), as filed with the SEC on
January 18, 2012).

Jazz Pharmaceuticals plc Amended and Restated 2007 Non-Employee Directors Stock Option Plan (incorporated herein by
reference to Exhibit 99.4 in Jazz Pharmaceuticals plc’s registration statement on Form S-8 (File No. 333-179075), as filed with
the SEC on January 18, 2012).

10.31B+ Form of Non-U.S. Option Grant Notice and Form of Non-U.S. Option Agreement under the Jazz Pharmaceuticals plc Amended
and Restated 2007 Non-Employee Directors Stock Option Plan (incorporated herein by reference to Exhibit 10.30B in
Jazz Pharmaceuticals plc’s Annual Report on Form 10-K (File No. 001-33500) for the period ended December 31, 2012, as
filed with the SEC on February 26, 2013).

10.31C+ Jazz Pharmaceuticals plc Amended and Restated 2007 Non-Employee Directors Stock Option Plan—Form of Non-U.S.

Option Grant Notice and Form of Non-U.S. Option Agreement (approved August 1, 2013) (incorporated herein by reference to
Exhibit 10.7 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period ended
September 30, 2013, as filed with the SEC on November 5, 2013).

10.31D+ Amended and Restated 2007 Non-Employee Directors Stock Award Plan (approved August 4, 2016) (incorporated herein by

reference to Exhibit 10.9 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period
ended June 30, 2016, as filed with the SEC on August 9, 2016).

10.31E+ Amended and Restated 2007 Non-Employee Directors Stock Award Plan (approved November 3, 2016) (incorporated herein
by reference to Exhibit 10.3 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period
ended September 30, 2016, as filed with the SEC on November 8, 2016).

10.31F+ Amended and Restated 2007 Non-Employee Directors Stock Award Plan (approved July 30, 2020) (incorporated herein by
reference to Exhibit 10.3 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period
ended June 30, 2020, as filed with the SEC on August 4, 2020).

10.31G+ Form of Non-U.S. Restricted Stock Unit Award Grant Notice and Form of Non-U.S. Restricted Stock Unit Award Agreement
under the Jazz Pharmaceuticals plc Amended and Restated 2007 Non-Employee Directors Stock Award Plan (incorporated
herein by reference to Exhibit 10.4 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the
period ended September 30, 2016, as filed with the SEC on November 8, 2016).

10.31H+ Form of Non-U.S. Option Grant Notice and Form of Non-U.S. Option Agreement under the Jazz Pharmaceuticals plc Amended
and Restated Non-Employee Directors 2007 Stock Award Plan (incorporated herein by reference to Exhibit 10.5 in
Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period ended September 30, 2016, as
filed with the SEC on November 8, 2016).

10.31I+

10.31J+

Form of Non-U.S. Option Grant Notice and Non-U.S. Option Agreement under the Jazz Pharmaceuticals plc Amended and
Restated 2007 Non-Employee Directors Stock Award Plan (incorporated herein by reference to Exhibit 10.2 in
Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period ended September 30, 2018, as
filed with the SEC on November 6, 2018).

Form of Non-U.S. Restricted Stock Unit Award Grant Notice and Non-U.S. Restricted Stock Unit Award Agreement under the
Jazz Pharmaceuticals plc Amended and Restated 2007 Non-Employee Directors Stock Award Plan (incorporated herein by
reference to Exhibit 10.3 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period
ended September 30, 2018, as filed with the SEC on November 6, 2018).

106

2021 Annual Report

| JAZZ PHARMACEUTICALS

K
-
0
1
m
r
o
F

Exhibit
Number

Description of Document

10.31K+ Form of Non-U.S. Option Grant Notice and Non-U.S. Option Agreement under the Jazz Pharmaceuticals plc Amended and

Restated 2007 Non-Employee Directors Stock Award Plan (incorporated herein by reference to Exhibit 10.2 in Jazz
Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period ended March 31, 2019, as filed with
the SEC on May 7, 2019).

10.31L+

Form of Non-U.S. Restricted Stock Unit Award Grant Notice and Non-U.S. Restricted Stock Unit Award Agreement under the
Jazz Pharmaceuticals plc Amended and Restated 2007 Non-Employee Directors Stock Award Plan (incorporated herein by
reference to Exhibit 10.3 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period
ended March 31, 2019, as filed with the SEC on May 7, 2019).

10.31M+ Form of Non-U.S. Option Grant Notice and Non-U.S. Option Agreement under the Jazz Pharmaceuticals plc Amended and

Restated 2007 Non-Employee Directors Stock Award Plan (incorporated herein by reference to Exhibit 10.2 in Jazz
Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period ended September 30, 2020, as filed
with the SEC on November 2, 2020).

10.31N+ Form of Non-U.S. Restricted Stock Unit Award Grant Notice and Non-U.S. Restricted Stock Unit Award Agreement under the

Jazz Pharmaceuticals plc Amended and Restated 2007 Non-Employee Directors Stock Award Plan (incorporated herein by
reference to Exhibit 10.3 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period
ended September 30, 2020, as filed with the SEC on November 2, 2020).

10.32A+ GW Pharmaceuticals plc 2020 Long-Term Incentive Plan (incorporated herein by reference to Exhibit 4.1 in GW’s Registration

Statement on Form S-8 (file no. 333-238737), filed with the SEC on May 27, 2020).

10.32B+ Form of Restricted Stock Unit Award Agreement under the GW Pharmaceuticals plc 2020 Long-Term Incentive Plan

(incorporated herein by reference to Exhibit 10.10B in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q
(File No. 001-33500) for the period ended June 30, 2021, as filed with the SEC on August 3, 2021).

10.32C+ Form of Replacement Stock Option Award Agreement under the GW Pharmaceuticals plc 2020 Long-Term Incentive Plan

(incorporated herein by reference to Exhibit 10.10C in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q
(File No. 001-33500) for the period ended June 30, 2021, as filed with the SEC on August 3, 2021).

10.32D+ Form of Replacement Restricted Stock Unit Award Agreement under the GW Pharmaceuticals plc 2020 Long-Term Incentive

Plan (incorporated herein by reference to Exhibit 10.10D in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q
(File No. 001-33500) for the period ended June 30, 2021, as filed with the SEC on August 3, 2021).

10.33A+

10.33B+

10.34A+

10.34B+

Jazz Pharmaceuticals plc 2007 Employee Stock Purchase Plan, as amended and restated (incorporated herein by reference
to Exhibit 10.31A in Jazz Pharmaceuticals plc’s Annual Report on Form 10-K (File No. 001-33500) for the period ended
December 31, 2012, as filed with the SEC on February 26, 2013).

Jazz Pharmaceuticals plc 2007 Employee Stock Purchase Plan Sub-Plan Governing Purchase Rights to Participants in the
Republic of Ireland (incorporated herein by reference to Exhibit 10.14C in Jazz Pharmaceuticals plc’s Quarterly Report on
Form 10-Q (File No. 001-33500) for the period ended March 31, 2012, as filed with the SEC on May 8, 2012 ).

Jazz Pharmaceuticals plc Cash Bonus Plan for U.S. Affiliates (approved October 30, 2019) (incorporated herein by reference
to Exhibit 10.34C in Jazz Pharmaceuticals plc’s Annual Report on Form 10-K (File No. 001-33500) for the period ended
December 31, 2019, as filed with the SEC on February 25, 2020).

Jazz Pharmaceuticals Cash Bonus Plan (Ireland and Other Specified Affiliates) (Calendar Year 2020) (incorporated herein by
reference to Exhibit 10.34D in Jazz Pharmaceuticals plc’s Annual Report on Form 10-K (File No. 001-33500) for the period
ended December 31, 2019, as filed with the SEC on February 25, 2020).

10.34C+ Jazz Pharmaceuticals plc Cash Bonus Plan for U.S. Affiliates (approved October 30, 2020) (incorporated herein by reference

to Exhibit 10.33C in Jazz Pharmaceuticals plc’s Annual Report on Form 10-K (File No. 001-33500) for the period ended
December 31, 2020, as filed with the SEC on February 23, 2021).

10.34D+ Jazz Pharmaceuticals Cash Bonus Plan (Ireland and Other Specified Affiliates) (Calendar Year 2021) (incorporated herein by

reference to Exhibit 10.33D in Jazz Pharmaceuticals plc’s Annual Report on Form 10-K (File No. 001-33500) for the period
ended December 31, 2020, as filed with the SEC on February 23, 2021).

10.34E+

Jazz Pharmaceuticals plc Global Cash Bonus Plan (approved November, 2021).

10.35+

Amended and Restated Executive Change in Control and Severance Benefit Plan, dated as of July 31, 2019 (incorporated
herein by reference to Exhibit 10.5 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the
period ended September 30, 2019, as filed with the SEC on November 5, 2019).

JAZZ PHARMACEUTICALS | 2021 Annual Report

107

Exhibit
Number

Description of Document

10.36A+ Amended and Restated Non-Employee Director Compensation Policy (approved May 3, 2018) (incorporated herein by

reference to Exhibit 10.1 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period
ended June 30, 2018, as filed with the SEC on August 7, 2018).

10.36B+ Amended and Restated Non-Employee Director Compensation Policy (approved July 21, 2020) (incorporated herein by

reference to Exhibit 10.1 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period
ended September 30, 2020, as filed with the SEC on November 2, 2020).

10.36C+ Amended and Restated Non-Employee Director Compensation Policy (approved July 29, 2021) (incorporated herein by

reference to Exhibit 10.11 in Jazz Pharmaceuticals plc’s Quarterly Report on Form 10-Q (File No. 001-33500) for the period
ended June 30, 2021, as filed with the SEC on August 3, 2021).

21.1

23.1

24.1

31.1

31.2

32.1*

Subsidiaries of Jazz Pharmaceuticals plc.

Consent of KPMG, Independent Registered Public Accounting Firm.

Power of Attorney (included on the signature page hereto).

Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities
Exchange Act of 1934, as amended.

Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities
Exchange Act of 1934, as amended.

Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

XBRL Instance Document—The instance document does not appear in the Interactive Data File because its XBRL tags are
embedded within the Inline XBRL document

101.SCH

Inline XBRL Taxonomy Extension Schema Document

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

Inline XBRL Taxonomy Extension Labels Linkbase Document

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

+

†

‡

*

Indicates management contract or compensatory plan.

Confidential treatment has been granted for portions of this exhibit. Omitted portions have been filed separately with the Securities
and Exchange Commission.

Certain portions of this exhibit have been omitted pursuant to Item 601(b)(2) of Regulation S-K.

The certifications attached as Exhibit 32.1 accompany this Annual Report on Form 10-K pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the Registrant for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended.

Item 16.

Form 10-K Summary

None.

108

2021 Annual Report

| JAZZ PHARMACEUTICALS

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report

to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: March 1, 2022

Jazz Pharmaceuticals public limited company
(Registrant)

/S/ BRUCE C. COZADD

Bruce C. Cozadd
Chairman and Chief Executive Officer and Director
(Principal Executive Officer)

/S/ RENÉE GALÁ
Renée Galá
Executive Vice President and Chief Financial Officer
(Principal Financial Officer)

/S/ PATRICIA CARR

Patricia Carr
Senior Vice President, Chief Accounting Officer
(Principal Accounting Officer)

K
-
0
1
m
r
o
F

JAZZ PHARMACEUTICALS | 2021 Annual Report

109

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Bruce C.

Cozadd, Renée Galá, Neena M. Patil and Patricia Carr, and each of them, as his or her true and lawful attorneys-in-fact and agents, with
full power of substitution for him or her, and in his or her name in any and all capacities, to sign any and all amendments to this Annual
Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and
Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each
and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he or she might or could do in
person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and any of them, his or her substitute or substitutes, may
lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, the following persons on behalf of the registrant and in the

capacities and on the dates indicated have signed this report below:

Signature

/S/ BRUCE C. COZADD
Bruce C. Cozadd

/S/ RENÉE GALÁ
Renée Galá

/S/ PATRICIA CARR
Patricia Carr

/S/ JENNIFER E. COOK
Jennifer E. Cook

/S/ PATRICK G. ENRIGHT
Patrick G. Enright

/S/ PETER GRAY
Peter Gray

/S/ HEATHER ANN MCSHARRY
Heather Ann McSharry

/S/ SEAMUS C. MULLIGAN
Seamus C. Mulligan

/S/ KENNETH W. O’KEEFE
Kenneth W. O’Keefe

/S/ ANNE O’RIORDAN
Anne O’Riordan

/S/ NORBERT G. RIEDEL, PH.D.
Norbert G. Riedel, Ph.D.

/S/ MARK D. SMITH, M.D.
Mark D. Smith, M.D.

/S/ CATHERINE A. SOHN, PHARM.D.
Catherine A. Sohn, Pharm.D.

/S/ RICK E WINNINGHAM
Rick E Winningham

Title

Chairman, Chief Executive Officer and Director
(Principal Executive Officer)

Date

March 1, 2022

Executive Vice President and Chief Financial Officer
(Principal Financial Officer)

March 1, 2022

Senior Vice President, Chief Accounting Officer
(Principal Accounting Officer)

Director

Director

Director

Director

Director

Director

Director

Director

Director

Director

Director

March 1, 2022

March 1, 2022

March 1, 2022

March 1, 2022

March 1, 2022

March 1, 2022

March 1, 2022

March 1, 2022

March 1, 2022

March 1, 2022

March 1, 2022

March 1, 2022

110

2021 Annual Report

| JAZZ PHARMACEUTICALS

Report of Independent Registered Public Accounting Firm

To the Shareholders and Board of Directors
Jazz Pharmaceuticals plc:

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of Jazz Pharmaceuticals plc and subsidiaries (the ‘Company’) as of
December 31, 2021 and 2020, the related consolidated statements of income (loss), comprehensive income (loss), stockholders’ equity,
and cash flows for each of the years in the three-year period ended December 31, 2021, and the related notes and financial statement
schedules at Item 15(a)2 (collectively, ‘the consolidated financial statements’). In our opinion, the consolidated financial statements present
fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations
and its cash flows for each of the years in the three-year period ended December 31, 2021, in conformity with U.S. generally accepted
accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the
Company’s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control—Integrated
Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated March 1,
2022 expressed an unqualified opinion on the effectiveness of the Company’s internal control over financial reporting.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion
on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and
regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error
or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements,
whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis,
evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the
accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the
consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

K
-
0
1
m
r
o
F

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements
that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are
material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The
communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole,
and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the
accounts or disclosures to which they relate.

Preliminary measurement of fair value of acquired developed technology assets related to a business combination

As discussed in Note 3 to the consolidated financial statements, on May 5, 2021, the Company acquired GW Pharmaceuticals plc (‘GW’) in
a business combination for a purchase price of $7,190.7 million. In allocating the purchase price, the Company recognized intangible
assets at fair value in the amount of $5,640.0 million, including acquired developed technology of $5,480.0 million.

We identified the assessment of the preliminary measurement of fair value of acquired developed technology assets acquired in the GW
Acquisition as a critical audit matter. A high degree of auditor judgment was required in evaluating the key fair value assumptions,
specifically revenue forecasts. Changes to these assumptions could have a significant effect on the initial measurement of fair value.

The following are the primary procedures we performed to address this critical audit matter:

– We evaluated the design and tested the operating effectiveness of certain internal controls related to the business combinations

process, including the control over the development of the key assumptions;

JAZZ PHARMACEUTICALS | 2021 Annual Report

F-1

– We evaluated the reasonableness of the Company’s revenue forecasts by comparing certain underlying assumptions to (1) company-specific
operational information and management’s communications to the Board of Directors and (2) available industry or other third-party reports or
data.

/s/ KPMG

We have served as the Company’s auditor since 2012.

Dublin, Ireland
March 1, 2022

F-2

2021 Annual Report

| JAZZ PHARMACEUTICALS

JAZZ PHARMACEUTICALS PLC

CONSOLIDATED BALANCE SHEETS
(In thousands, except per share amounts)

Current assets:

ASSETS

Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accounts receivable, net of allowances of $13,813 and $5,487 at December 31, 2021 and 2020,

respectively . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Inventories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Prepaid expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Property, plant and equipment, net
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Operating lease assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Intangible assets, net
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Goodwill . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred tax assets, net
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred financing costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other non-current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

December 31,

2021

2020

$

591,448
—

$1,057,769
1,075,000

563,360
1,072,721
131,413
252,392

2,611,334
256,837
86,586
7,152,328
1,827,609
311,103
12,029
40,813

396,490
95,396
62,422
152,491

2,839,568
127,935
129,169
2,195,051
958,303
254,916
5,238
25,721

K
-
0
1
m
r
o
F

Total assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$12,298,639

$6,535,901

Current liabilities:

LIABILITIES AND SHAREHOLDERS’ EQUITY

Accounts payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Current portion of long-term debt
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Income taxes payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 100,298
666,304
31,000
9,608
2,093

$ 26,945
352,732
246,322
25,200
2,546

Total current liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred revenue, non-current
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Long-term debt, less current portion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Operating lease liabilities, less current portion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred tax liabilities, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other non-current liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Commitments and contingencies (Note 14)
Shareholders’ equity:

Ordinary shares, nominal value $0.0001 per share; 300,000 shares authorized; 61,633 and

56,171 shares issued and outstanding at December 31, 2021 and 2020, respectively . . . . . . . . . . . .

Non-voting euro deferred shares, €0.01 par value per share; 4,000 shares authorized, issued and

outstanding at both December 31, 2021 and 2020 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Capital redemption reserve . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Additional paid-in capital
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accumulated other comprehensive loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Retained earnings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

809,303
463
6,018,943
87,200
1,300,541
116,998

653,745
2,315
1,848,516
140,035
130,397
101,148

6

6

55
472
3,534,792
(400,360)
830,226

55
472
2,633,670
(134,352)
1,159,894

Total shareholders’ equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

3,965,191

3,659,745

Total liabilities and shareholders’ equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$12,298,639

$6,535,901

The accompanying notes are an integral part of these consolidated financial statements.

JAZZ PHARMACEUTICALS | 2021 Annual Report

F-3

JAZZ PHARMACEUTICALS PLC

CONSOLIDATED STATEMENTS OF INCOME (LOSS)
(In thousands, except per share amounts)

Year Ended December 31,

2021

2020

2019

Revenues:

Product sales, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Royalties and contract revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$3,079,001
15,237

$2,346,660
16,907

$2,135,601
26,160

Total revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

3,094,238

2,363,567

2,161,761

Operating expenses:

Cost of product sales (excluding amortization of acquired developed technologies) . . . . . . .
Selling, general and administrative . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Research and development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Intangible asset amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Impairment charge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acquired in-process research and development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

440,760
1,451,683
505,748
525,769
—
—

148,917
854,233
335,375
259,580
136,139
251,250

127,930
736,942
299,726
354,814
—
109,975

Total operating expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2,923,960

1,985,494

1,629,387

Income from operations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Interest expense, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Foreign exchange loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Income (loss) before income tax expense (benefit) and equity in loss of investees . . . . . . . . . . .
Income tax expense (benefit)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Equity in loss of investees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

170,278
(278,766)
(4,350)

(112,838)
216,116
714

378,073
(99,707)
(3,271)

275,095
33,517
2,962

532,374
(72,261)
(5,811)

454,302
(73,154)
4,089

Net income (loss)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ (329,668) $ 238,616

$ 523,367

Net income (loss) per ordinary share:

Basic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Diluted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Weighted-average ordinary shares used in per share calculations—basic . . . . . . . . . . . . . .

Weighted-average ordinary shares used in per share calculations—diluted . . . . . . . . . . . . .

$

$

(5.52) $

(5.52) $

4.28

4.22

$

$

59,694

59,694

55,712

56,517

9.22

9.09

56,749

57,550

The accompanying notes are an integral part of these consolidated financial statements.

F-4

2021 Annual Report

| JAZZ PHARMACEUTICALS

JAZZ PHARMACEUTICALS PLC

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(In thousands)

Net income (loss) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other comprehensive income (loss):

Foreign currency translation adjustments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Unrealized gain (loss) on cash flow hedging activities, net of income tax expense (benefit) of

Year Ended December 31,

2021

2020

2019

$(329,668) $238,616

$523,367

(268,347)

90,183

(20,720)

$353, ($163) and ($697), respectively . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2,468

(1,142)

(4,882)

Unrealized loss on fair value hedging activities, net of income tax benefit of $43, $— and $—,

respectively . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(129)

—

—

Other comprehensive income (loss)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(266,008)

89,041

(25,602)

Total comprehensive income (loss) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$(595,676) $327,657

$497,765

K
-
0
1
m
r
o
F

The accompanying notes are an integral part of these consolidated financial statements.

JAZZ PHARMACEUTICALS | 2021 Annual Report

F-5

JAZZ PHARMACEUTICALS PLC

CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
(In thousands)

Ordinary Shares

Non-voting Euro
Deferred

Shares Amount Shares Amount

Capital
Redemption
Reserve

Additional
Paid-in
Capital

Accumulated
Other
Comprehensive
Loss

Retained
Earnings

Total
Equity

$ 6

4,000

$55

$472

$2,113,630

$(197,791) $ 841,050 $2,757,422

— —

—

—

Balance at December 31, 2018 . . . . . . . 57,504
Cumulative effect adjustment from
adoption of new accounting standards . . .
Issuance of ordinary shares in
conjunction with exercise of share
options . . . . . . . . . . . . . . . . . . . . . . . . . .
Issuance of ordinary shares under
employee stock purchase plan . . . . . . . .
Issuance of ordinary shares in
conjunction with vesting of restricted
stock units . . . . . . . . . . . . . . . . . . . . . . .
Shares withheld for payment of
employee’s withholding tax liability . . . . .
Share-based compensation . . . . . . . . . .
Shares repurchased . . . . . . . . . . . . . . . .
Other comprehensive loss . . . . . . . . . . .
Net income . . . . . . . . . . . . . . . . . . . . . . .

265 —

— —
— —
(2,250) —
— —
— —

515 —

106 —

37 —

— —

— —

780 —

125 —

Balance at December 31, 2019 . . . . . . . 56,140
Stock issued under directors deferred
compensation plan . . . . . . . . . . . . . . . . .
Issuance of Exchangeable Senior Notes,
due 2026 . . . . . . . . . . . . . . . . . . . . . . . .
Partial repurchase of Exchangeable
Senior Notes, due 2021 . . . . . . . . . . . . .
Issuance of ordinary shares in
conjunction with exercise of share
options . . . . . . . . . . . . . . . . . . . . . . . . . .
Issuance of ordinary shares under
employee stock purchase plan . . . . . . . .
Issuance of ordinary shares in
conjunction with vesting of restricted
stock units . . . . . . . . . . . . . . . . . . . . . . .
Shares withheld for payment of
employee’s withholding tax liability . . . . .
Share-based compensation . . . . . . . . . .
Shares repurchased . . . . . . . . . . . . . . . .
Other comprehensive income . . . . . . . . .
Net income . . . . . . . . . . . . . . . . . . . . . . .

290 —

— —
— —
(1,201) —
— —
— —

6

4,000

—

—

—

—
—
—
—
—

—

—

—

—

—

—

—
—
—
—
—

—

—

—

—
—
—
—
—

55

—

—

—

—

—

—

—
—
—
—
—

—

—

—

—

—
—
—
—
—

—

46,477

11,354

—

(16,739)
111,304
—
—
—

—

—

—

—

4,848

4,848

—

—

—

46,477

11,354

—

—
—
—
(25,602)
—

—
—
(301,450)
—
523,367

(16,739)
111,304
(301,450)
(25,602)
523,367

472

2,266,026

(223,393)

1,067,815

3,110,981

—

—

—

—

—

—

—
—
—
—
—

—

176,260

(12,513)

86,984

12,697

—

(16,877)
121,093
—
—
—

—

—

—

—

—

—

—

—

—

—

—

—

—

176,260

(12,513)

86,984

12,697

—

—
—
—
89,041
—

—
—
(146,537)
—
238,616

(16,877)
121,093
(146,537)
89,041
238,616

Balance at December 31, 2020 . . . . . . . 56,171

$ 6

4,000

$55

$472

$2,633,670

$(134,352) $1,159,894 $3,659,745

F-6

2021 Annual Report

| JAZZ PHARMACEUTICALS

JAZZ PHARMACEUTICALS PLC

CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY—(Continued)
(In thousands)

Ordinary Shares

Non-voting Euro
Deferred

Shares Amount Shares Amount

Capital
Redemption
Reserve

Additional
Paid-in
Capital

Accumulated
Other
Comprehensive
Loss

Retained
Earnings

Total
Equity

$ 6

4,000

$55

$472

$2,633,670

$(134,352) $1,159,894 $3,659,745

3,798 —

— —

1,042 —

157 —

Balance at December 31, 2020 . . . . . . . 56,171
Issuance of ordinary shares in connection
with the acquisition of GW
Pharmaceuticals plc . . . . . . . . . . . . . . . .
Share-based payment—precombination
service in connection with the acquisition
of GW Pharmaceuticals plc . . . . . . . . . . .
Issuance of ordinary shares in
conjunction with exercise of share
options . . . . . . . . . . . . . . . . . . . . . . . . . .
Issuance of ordinary shares under
employee stock purchase plan . . . . . . . .
Issuance of ordinary shares in
conjunction with vesting of restricted
stock units . . . . . . . . . . . . . . . . . . . . . . .
Shares withheld for payment of
employee’s withholding tax liability . . . . .
Share-based compensation . . . . . . . . . .
Other comprehensive loss . . . . . . . . . . .
Net loss . . . . . . . . . . . . . . . . . . . . . . . . .

465 —

— —
— —
— —
— —

—

—

—

—

—

—

—

—
—
—
—

—

—

—

—
—
—
—

—

—

—

—

—

—
—
—
—

608,456

3,555

119,058

16,203

—

—

—

—

—

—

—

608,456

—

—

—

—

3,555

119,058

16,203

—

K
-
0
1
m
r
o
F

(35,602)
189,452

—
—
— (266,008)
—
—

(35,602)
—
—
189,452
— (266,008)
(329,668)

(329,668)

Balance at December 31, 2021 . . . . . . . 61,633

$ 6

4,000

$55

$472

$3,534,792

$(400,360) $ 830,226 $3,965,191

The accompanying notes are an integral part of these consolidated financial statements.

JAZZ PHARMACEUTICALS | 2021 Annual Report

F-7

JAZZ PHARMACEUTICALS PLC

CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)

Operating activities
Net income (loss) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Adjustments to reconcile net income (loss) to net cash provided by operating activities:

Intangible asset amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . .
Acquisition accounting inventory fair value step-up adjustment
Share-based compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Non-cash interest expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred tax expense (benefit)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Depreciation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Provision for losses on accounts receivable and inventory . . . . . . . . . . . . . . . . . . . . . . . . .
Impairment charge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acquired in-process research and development
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other non-cash transactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Distributions from equity method investees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Changes in assets and liabilities:

Accounts receivable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Inventories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Prepaid expenses and other current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Operating lease assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other non-current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accounts payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Income taxes payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred revenue . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Operating lease liabilities, less current portion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other non-current liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net cash provided by operating activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Investing activities

Proceeds from maturity of investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Purchases of property, plant and equipment
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acquisition of intangible assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acquisition of investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acquisition of a business, net of cash acquired . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acquired in-process research and development
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Asset acquisition, net of cash acquired . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net proceeds from sale of assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net cash used in investing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Financing activities

Net proceeds from issuance of borrowings under credit agreement
. . . . . . . . . . . . . . . . . .
Net proceeds from issuance of Senior Secured Notes, due 2029 . . . . . . . . . . . . . . . . . . . .
Proceeds from employee equity incentive and purchase plans . . . . . . . . . . . . . . . . . . . . . .
Payment of employee withholding taxes related to share-based awards . . . . . . . . . . . . . . .
Payments for repurchase of Exchangeable Senior Notes, due 2021 . . . . . . . . . . . . . . . . . .
Repayments of long-term debt
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net proceeds from issuance of Exchangeable Senior Notes, due 2026 . . . . . . . . . . . . . . .
Net proceeds from revolving credit facility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Share repurchases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Repayments under revolving credit facility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net cash provided by (used in) financing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Effect of exchange rates on cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net increase (decrease) in cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cash and cash equivalents, at beginning of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cash and cash equivalents, at end of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

F-8

2021 Annual Report

| JAZZ PHARMACEUTICALS

Year Ended December 31,

2021

2020

2019

$ (329,668) $

238,616

$ 523,367

525,769
223,085
189,006
92,655
69,198
26,714
19,668
—
—
10,032
—

(92,735)
(48,861)
(83,320)
15,583
817
57,021
142,355
(15,524)
(2,305)
(16,037)
(4,946)
778,507

259,580
—
120,998
61,748
(136,937)
18,673
15,000
136,139
251,250
14,580
5,438

(38,647)
(30,537)
(98,042)
12,366
21,913
(18,935)
79,477
13,038
(4,720)
(12,383)
(8,967)
899,648

1,095,000
(27,641)
(17,891)
(26,819)
(6,234,792)

—
—
—

(5,212,143)

3,719,930
1,471,533
135,261
(35,602)
(218,812)
(1,101,788)

—
—
—
—
3,970,522
(3,207)
(466,321)
1,057,769
591,448

$

1,755,000
(15,004)
(113,000)
(2,397,675)

—

(251,250)

—
14,259
(1,007,670)

—
—
99,681
(16,877)
(356,188)
(33,387)
981,381
500,000
(146,537)
(500,000)
528,073
374
420,425
637,344
$ 1,057,769

354,814
—
110,563
46,396
(236,610)
15,342
6,668
—
109,975
59
—

(92,326)
(32,790)
(25,650)
14,148
(18,919)
4,770
(5,565)
10,056
(5,414)
(6,044)
3,561
776,401

985,000
(40,135)
(80,500)
(917,100)

—
(61,700)
(55,074)
14,209
(155,300)

—
—
57,831
(16,739)
—
(33,387)
—
—

(301,450)

—

(293,745)
366
327,722
309,622
$ 637,344

JAZZ PHARMACEUTICALS PLC

CONSOLIDATED STATEMENTS OF CASH FLOWS—(Continued)
(In thousands)

Supplemental disclosure of cash flow information:

Cash paid for interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cash paid for income taxes, net of refunds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$138,271
271,217

$ 42,470
226,823

$ 43,002
183,610

Year Ended December 31,

2021

2020

2019

K
-
0
1
m
r
o
F

The accompanying notes are an integral part of these consolidated financial statements.

JAZZ PHARMACEUTICALS | 2021 Annual Report

F-9

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. Organization and Description of Business

Jazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and

their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no
therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage
development, in neuroscience and oncology. Within these therapeutic areas, we strive to identify new options for patients by actively
exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science.

Our lead marketed products are:

Neuroscience

•

•

•

•

•

Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution, a product approved by the U.S. Food and
Drug Administration, or FDA, in July 2020 and launched in the U.S. in November 2020 for the treatment of cataplexy or
excessive daytime sleepiness, or EDS, in patients with narcolepsy aged seven years of age and older, and also approved by
FDA in August 2021 for the treatment of idiopathic hypersomnia, or IH, in adults and launched in the U.S. in November 2021.
Xywav contains 92% less sodium than Xyrem®;

Xyrem (sodium oxybate) oral solution, a product approved by FDA and distributed in the U.S. for the treatment of both
cataplexy and EDS in patients seven years of age and older with narcolepsy; Jazz also markets Xyrem in Canada for the
treatment of cataplexy in patients with narcolepsy. Xyrem is also approved and distributed in Europe, Great Britain and other
markets through a licensing agreement;

Epidiolex® (cannabidiol) oral solution, a product approved by FDA and launched in the U.S. in 2018 by GW Pharmaceuticals
plc, or GW, and currently indicated for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome,
or tuberous sclerosis complex in patients one year of age or older; in Europe (where it is marketed as Epidyolex®) and other
markets, it is approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome, in
conjunction with clobazam (EU and Great Britain only), in patients 2 years of age and older and for adjunctive treatment of
seizures associated with tuberous sclerosis complex in patients 2 years of age and older;

Sunosi® (solriamfetol), a product approved by FDA and marketed in the U.S., Canada, Europe and Great Britain to improve
wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea; and

Sativex® (nabiximols) oral solution, a product approved and marketed in the U.K., Canada and other markets as treatment
for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis, or MS, who have not
responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity-
related symptoms during an initial trial of therapy.

Oncology

•

•

•

•

Zepzelca® (lurbinectedin), a product approved by FDA in June 2020 and launched in the U.S. in July 2020 for the treatment of
adult patients with metastatic small cell lung cancer, or SCLC, with disease progression on or after platinum-based
chemotherapy; in Canada, Zepzelca was approved in September 2021 for the treatment of adults with Stage III or metastatic
SCLC, who have progressed on or after platinum-containing therapy;

Rylaze™ (recombinant Erwinia asparaginase), a product approved by FDA in June 2021 and launched in the U.S. in July 2021
for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia, or ALL,
or lymphoblastic lymphoma, or LBL, in adults and pediatric patients who have developed hypersensitivity to E. coli-derived
asparaginase;

Vyxeos® (daunorubicin and cytarabine) liposome for injection, a product approved in the U.S., Canada, Europe and Great
Britain (marketed as Vyxeos® liposomal in Europe and Great Britain) for the treatment of adults with newly-diagnosed
therapy-related acute myeloid leukemia, or t-AML, or AML with myelodysplasia-related changes (AML-MRC). An expanded
indication was granted in the U.S. for the treatment of newly diagnosed t-AML or AML-MRC in pediatric patients aged 1 year
and older; and

Defitelio® (defibrotide sodium), is a product approved in the U.S. and Brazil for the treatment of hepatic veno-occlusive
disease, or VOD, with renal or pulmonary dysfunction following hematopoietic stem cell transplantation, or HSCT, and in Japan

F-10

2021 Annual Report

| JAZZ PHARMACEUTICALS

K
-
0
1
m
r
o
F

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

for the treatment of hepatic sinusoidal obstruction syndrome (hepatic-veno occlusive disease). It is currently approved in the EU,
Great Britain, Canada, Israel, South Korea, Australia and Switzerland for the treatment of severe hepatic VOD, also known as
sinusoidal obstructive syndrome, or SOS, in HSCT therapy. It is indicated in adults and pediatric patients over 1 month of age.

In May 2021, we acquired GW Pharmaceuticals plc, or GW, with the objectives of broadening our neuroscience portfolio, further

diversifying our revenue and driving sustainable, long-term value creation opportunities. The total consideration paid by us for the entire
issued share capital of GW was $7.2 billion. The acquisition, which we refer to as the GW Acquisition, closed on May 5, 2021. For further
information regarding the GW Acquisition, please see Note 3.

Throughout this report, unless otherwise indicated or the context otherwise requires, all references to “Jazz Pharmaceuticals,” “the
registrant,” “the Company”, “we,” “us,” and “our” refer to Jazz Pharmaceuticals plc and its consolidated subsidiaries. Throughout this report,
all references to “ordinary shares” refer to Jazz Pharmaceuticals plc’s ordinary shares.

2. Summary of Significant Accounting Policies

Basis of Presentation

The consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or U.S.
GAAP, and include the accounts of Jazz Pharmaceuticals plc and our subsidiaries and intercompany transactions and balances have been
eliminated. Our consolidated financial statements include the results of operations of businesses we have acquired from the date of each
acquisition for the applicable reporting periods.

The results of operations of the acquired GW business, along with the estimated fair values of the assets acquired and liabilities

assumed in the GW Acquisition, have been included in our consolidated financial statements since the closing of the GW Acquisition on
May 5, 2021.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that

affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the consolidated financial statements
and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under
the circumstances. Actual results could differ materially from those estimates.

Adoption of New Accounting Standards

In December 2019, the Financial Accounting Standards Board, or FASB, issued ASU No. 2019-12, “Income Taxes (Topic 740):
Simplifying the Accounting for Income Taxes”, which simplifies the accounting for income taxes by removing certain exceptions to the
general principles in the existing guidance for income taxes and making other minor improvements. We adopted this standard on
January 1, 2021 and adoption did not have a material impact on our consolidated financial statements.

Significant Risks and Uncertainties

We have implemented a comprehensive response strategy designed to manage the ongoing impact of the COVID-19 pandemic on
our employees, patients and our business. The prolonged nature of the pandemic is negatively impacting our business in a varied manner
due to the emergence of the Delta and Omicron variants and other variants with increased transmissibility, even in some cases in
vaccinated people, limited access to health care provider offices and institutions and the willingness of patients or parents of patients to
seek treatment. We expect that our business, financial condition, results of operations and growth prospects may continue to be negatively
impacted by the pandemic on a limited basis that may vary depending on the context. However we have begun to observe, and expect to
continue to observe, a gradual normalization in patient and healthcare provider practices, as providers and patients have adapted their
behaviors and procedures to the evolving circumstances and as COVID-19 vaccines continue to be administered. With respect to our
commercialization activities, while there continues to be some negative impact on demand, new patient starts and treatments for our
products arising from the pandemic, primarily due to the inherent limitations of telemedicine and a reprioritization of healthcare resources
toward COVID-19, we have seen improvements as healthcare systems have adapted to cope with the ongoing situation. We believe these

JAZZ PHARMACEUTICALS | 2021 Annual Report

F-11

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

dynamics have negatively impacted new patient starts in the U.S. and Europe. The extent of the impact on our ability to generate sales of
approved products, execute on new product launches, our clinical development and regulatory efforts, our corporate development
objectives and the value of and market for our ordinary shares, will depend on future developments that are highly uncertain and cannot be
predicted with confidence at this time. Such developments include continued spread of the Delta and Omicron variants in the U.S. and
other countries and the potential emergence of other SARS-CoV-2 variants that may prove especially contagious or virulent, the ultimate
duration and severity of the pandemic, governmental “stay-at-home” orders and travel restrictions, quarantines, social distancing and
business closure requirements in the U.S., Ireland and other countries, and the effectiveness of vaccination programs and other actions
taken globally to contain and treat the disease.

Our business has been substantially dependent on Xyrem and while we expect that our business will continue to be substantially
dependent on oxybate product sales from both Xywav and Xyrem, there is no guarantee that we can maintain oxybate revenues at or near
current levels, or that oxybate revenues will continue to grow. Our ability to maintain or increase oxybate revenues and realize the
anticipated benefits from our investment in Xywav are subject to a number of risks and uncertainties including, without limitation, those
related to the launch of Xywav for the treatment of idiopathic hypersomnia in adults and adoption in that indication; competition from the
introduction of authorized generic and generic versions of sodium oxybate and new products for treatment of cataplexy and/or EDS in
narcolepsy in the U.S. market and from other competitors; the current and potential impacts of the COVID-19 pandemic, including the
current and expected future negative impact on demand for our products; increased pricing pressure from, changes in policies by, or
restrictions on reimbursement imposed by, third party payors, including our ability to maintain adequate coverage and reimbursement for
Xywav; increased rebates required to maintain access to our products; challenges to our intellectual property around Xyrem and/or Xywav,
including pending antitrust and intellectual property litigation; and continued acceptance of Xywav and Xyrem by physicians and patients.

In addition to risks related specifically to Xywav and Xyrem, we are subject to other challenges and risks related to successfully
commercializing a portfolio of oncology products and other neuroscience products, including Epidiolex, Sunosi, Defitelio, Vyxeos, Rylaze
and Zepzelca, and other risks specific to our business and our ability to execute on our strategy, as well as risks and uncertainties common
to companies in the pharmaceutical industry with development and commercial operations, including, without limitation, risks and
uncertainties associated with: ongoing clinical research activity and related outcomes, obtaining regulatory approval of our late-stage
product candidates; effectively commercializing our recently approved or acquired products such as Xywav, Epidiolex, Zepzelca and
Rylaze; obtaining and maintaining adequate coverage and reimbursement for our products; contracting and rebates to pharmacy benefit
managers that reduces our net revenue; increasing scrutiny of pharmaceutical product pricing and resulting changes in healthcare laws
and policy; market acceptance; regulatory concerns with controlled substances generally and the potential for abuse; future legislation,
Drug enforcement agency, or DEA, action or FDA action authorizing the sale, distribution, use, and insurance reimbursement of non-FDA
approved cannabinoid products; delays or problems in the supply of our products, loss of single source suppliers or failure to comply with
manufacturing regulations; delays or problems with third parties that are part of our manufacturing and supply chain; identifying, acquiring
or in-licensing additional products or product candidates; pharmaceutical product development and the inherent uncertainty of clinical
success; the challenges of protecting and enhancing our intellectual property rights; complying with applicable regulatory requirements;
and possible restrictions on our ability and flexibility to pursue certain future opportunities as a result of our substantial outstanding debt
obligations. In addition, the success of the GW Acquisition will depend, in part, on our ability to realize the anticipated benefits from
successfully combining our and GW’s historical businesses and the integration of our business practices and operations with GW’s so that
we can fully realize the anticipated benefits of the acquisition. The anticipated benefits to us of the GW Acquisition may not be realized fully
within the expected timeframe or at all or may take longer to realize or cost more than expected, which could materially and adversely
affect our business, financial condition, results of operations and growth prospects. Moreover, to the extent the COVID-19 pandemic
continues to adversely affect our business and results of operations, it may also have the effect of heightening many of the other risks and
uncertainties discussed above.

Concentrations of Risk

Financial instruments that potentially subject us to concentrations of credit risk consist of cash, cash equivalents, investments and
derivative contracts. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds
or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain
repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings,
maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding
our cash, cash equivalents and investments to the extent recorded on the balance sheet.

F-12

2021 Annual Report

| JAZZ PHARMACEUTICALS

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

We manage our foreign currency transaction risk and interest rate risk within specified guidelines through the use of derivatives. All of
our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes. As of
December 31, 2021 and 2020, we had foreign exchange forward contracts with notional amounts totaling $347.2 million and $357.4 million,
respectively. As of December 31, 2021 and 2020, the outstanding foreign exchange forward contracts had a net liability fair value of
$2.6 million and a net asset fair value of $11.1 million, respectively. As of December 31, 2021, we had a cross-currency interest rate swap
with a notional amount of $251.0 million. This outstanding cross-currency interest rate swap contract had a net liability fair value of
$15.2 million as of December 31, 2021. The counterparties to these contracts are large multinational commercial banks, and we believe the
risk of nonperformance is not significant.

We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts

receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to pharmaceutical wholesale
distributors and specialty pharmaceutical distribution companies, primarily in the U.S., and to other international distributors and hospitals.
Customer creditworthiness is monitored and collateral is not required. We monitor economic conditions in certain European countries which
may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts
receivable outstanding. Historically, we have not experienced significant credit losses on our accounts receivable and as of
December 31, 2021, allowances on receivables were not material. As of December 31, 2021, three customers accounted for 74% of gross
accounts receivable, Express Scripts Specialty Distribution Services, Inc. and its affiliates, or ESSDS, which accounted for 52% of gross
accounts receivable, McKesson Corporation and affiliates, or McKesson, which accounted for 12% of gross accounts receivable and
Cardinal Health Inc., or Cardinal, which accounted for 10% of gross accounts receivable. As of December 31, 2020, three customers
accounted for 84% of gross accounts receivable, ESSDS, which accounted for 68% of gross accounts receivable, McKesson, which
accounted for 12% of gross accounts receivable and Cardinal which accounted for 4% of gross accounts receivable.

K
-
0
1
m
r
o
F

We depend on single source suppliers for most of our products, product candidates and their active pharmaceutical ingredients, or

APIs. With respect to our oxybate products, the API is manufactured for us by a single source supplier and the finished product are
manufactured both by us in our facility in Athlone, Ireland and by our U.S.-based supplier.

Business Acquisitions

Our consolidated financial statements include the results of operations of an acquired business from the date of acquisition. We
account for acquired businesses using the acquisition method of accounting. The acquisition method of accounting for acquired businesses
requires, among other things, that assets acquired, liabilities assumed and any noncontrolling interests in the acquired business be
recognized at their estimated fair values as of the acquisition date, with limited exceptions, and that the fair value of acquired in-process
research and development, or IPR&D, be recorded on the balance sheet. Also, transaction costs are expensed as incurred. Any excess of
the acquisition consideration over the assigned values of the net assets acquired is recorded as goodwill. Contingent consideration is
included within the acquisition cost and is recognized at its fair value on the acquisition date. A liability resulting from contingent
consideration is remeasured to fair value at each reporting date until the contingency is resolved and changes in fair value are recognized
in earnings.

Cash Equivalents and Investments

We consider all highly liquid investments, readily convertible to cash, that mature within three months or less from date of purchase to

be cash equivalents.

Investments consist of time deposits with initial maturities of greater than three months. Collectively, cash equivalents and
investments are considered available-for-sale and are recorded at fair value. Unrealized gains and losses, net of tax, are recorded in
accumulated other comprehensive loss in shareholders’ equity. We use the specific-identification method for calculating realized gains and
losses on securities sold. Realized gains and losses and declines in value judged to be other than temporary on investments are included
in interest expense, net in the consolidated statements of income (loss).

Derivative Instruments and Hedging Activities

We record the fair value of derivative instruments as either assets or liabilities on the consolidated balance sheets. Changes in the fair
value of derivative instruments are recorded each period in current earnings or other comprehensive income (loss), depending on whether

JAZZ PHARMACEUTICALS | 2021 Annual Report

F-13

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

a derivative instrument is designated as part of a hedging transaction and, if it is, the type of hedging transaction. For a derivative to qualify
as a hedge at inception and throughout the hedged period, we formally document the nature and relationships between the hedging
instruments and hedged item.

For derivatives formally designated as hedges, we assess both at inception and quarterly thereafter, whether the hedging derivatives

are highly effective in offsetting changes in either the fair value or cash flows of the hedged item.

Gains or losses on cash flow hedges are reclassified from other comprehensive income (loss) to earnings when the hedged

transaction occurs. If we determine that a forecasted transaction is no longer probable of occurring, we discontinue hedge accounting and
any related unrealized gain or loss on the derivative instrument is recognized in current earnings.

We designate cross-currency interest rate swaps as fair value hedges to hedge foreign currency risks related to our borrowings

denominated in currencies other than the U.S. dollar. Fair value hedge amounts included in the assessment of hedge effectiveness are
recognized in foreign exchange gain (loss) within the consolidated statements of income (loss), along with the offsetting gains and losses of
the related hedged item. We have elected to exclude the total forward points or currency basis from the assessment of hedge effectiveness
and account for them as excluded components. The initial fair value of the excluded component is amortized to foreign exchange gain
(loss) and the difference between changes in fair value of the excluded component and the amount recorded in earnings is recorded in
other comprehensive income (loss).

Derivatives that are not designated and do not qualify as hedges are adjusted to fair value through current earnings.

Inventories

Inventories are valued at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method for all
inventories. Our policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net
realizable value and inventory in excess of expected requirements. The estimate of excess quantities is subjective and primarily dependent
on our estimates of future demand for a particular product. If our estimate of future demand changes, we consider the impact on the
reserve for excess inventory and adjust the reserve as required. Increases in the reserve are recorded as charges in cost of product sales.

We capitalize inventory costs associated with our products prior to regulatory approval when, based on management’s judgment,
future commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are
expensed as research and development. The determination to capitalize inventory costs is based on various factors, including status and
expectations of the regulatory approval process, any known safety or efficacy concerns, potential labeling restrictions, and any other
impediments to obtaining regulatory approval. We had no pre-approval inventory on our consolidated balance sheet as of December 31,
2021 or 2020.

Our inventory production process for our cannabinoid products includes the cultivation of botanical raw material. Because of the
duration of the cultivation process, a portion of our inventory will not be sold within one year. Consistent with the practice in other industries
that cultivate botanical raw materials, all inventory is classified as a current asset.

Property, Plant and Equipment

Property, plant and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line

method over the estimated useful lives of the assets. Estimated useful lives are as follows:

Buildings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Manufacturing equipment and machinery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Computer software and equipment
Furniture and fixtures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

40 years
4-20 years
3-7 years
5 years

Leasehold improvements are amortized over the shorter of the noncancelable term of our leases or their economic useful lives.

Maintenance and repairs are expensed as incurred.

F-14

2021 Annual Report

| JAZZ PHARMACEUTICALS

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Leases

We determine if an arrangement is a lease at inception. Leases are classified at lease commencement as either operating leases or

finance leases. Operating leases are included in operating lease assets, other current liabilities, and operating lease liabilities on our
consolidated balance sheets. Finance lease assets are included in property, plant and equipment, net, and finance lease liabilities are
included in other current liabilities and other non-current liabilities in our consolidated balance sheets. Lease assets and lease liabilities are
recognized based on the present value of the future minimum lease payments over the lease term at commencement date. In determining
the net present value of lease payments, we use our incremental borrowing rate based on the information available at the lease
commencement date. The lease asset also includes any lease payments made, reduced by lease incentives and increased by initial direct
costs incurred. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that
option. Operating lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Finance lease
expense is recognized as depreciation expense of fixed assets and interest expense on finance lease liabilities.

We have lease agreements with lease and non-lease components, which are generally accounted for separately. For vehicle leases

we account for the lease and non-lease components as a single lease component.

We have elected the short-term lease exemption and, therefore, do not recognize a lease asset or corresponding liability for lease

arrangements with an original term of 12 months or less. Rent expense under short-term leases is recognized on a straight-line basis over
the lease term.

K
-
0
1
m
r
o
F

Goodwill

Goodwill represents the excess of the acquisition consideration over the fair value of assets acquired and liabilities assumed. We

have determined that we operate in a single segment and have a single reporting unit associated with the development and
commercialization of pharmaceutical products. In performing the annual impairment test, the fair value of the reporting unit is compared to
its corresponding carrying value, including goodwill. If the carrying value exceeds the fair value of the reporting unit an impairment loss will
be recognized for the amount by which the reporting unit’s carrying amount exceeds its fair value, not to exceed the carrying amount of
goodwill. We test goodwill for impairment annually in October and when events or changes in circumstances indicate that the carrying
value may not be recoverable.

Acquired In-Process Research and Development

The initial costs of rights to IPR&D projects acquired in an asset acquisition are expensed as IPR&D unless the project has an
alternative future use. The fair value of IPR&D projects acquired in a business combination are capitalized and accounted for as indefinite-
lived intangible assets until the underlying project receives regulatory approval, at which point the intangible asset will be accounted for as
a finite-lived intangible asset, or discontinued, at which point the intangible asset will be written off. Development costs incurred after an
acquisition are expensed as incurred.

Intangible Assets

Intangible assets with finite useful lives consist primarily of purchased developed technology and are amortized on a straight-line

basis over their estimated useful lives, which range from two to twenty years. The estimated useful lives associated with finite-lived
intangible assets are consistent with the estimated lives of the associated products and may be modified when circumstances warrant.
Such assets are reviewed for impairment when events or circumstances indicate that the carrying value of an asset may not be
recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an
asset and its eventual disposition are less than its carrying amount. The amount of any impairment is measured as the difference between
the carrying amount and the fair value of the impaired asset.

Revenue Recognition

Our revenue comprises product sales, net and royalty and contract revenues. Revenues are recognized when control of the promised

goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for
those goods or services. Prior to recognizing revenue, we make estimates of the transaction price, including variable consideration that is
subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a
significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable
consideration is subsequently resolved.

JAZZ PHARMACEUTICALS | 2021 Annual Report

F-15

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Product Sales, Net

Product sales revenue is recognized when control has transferred to the customer, which occurs at a point in time, which is typically
on delivery to the customer or, in the case of products that are subject to consignment agreements, when the customer removes product
from our consigned inventory location for shipment directly to a patient.

Reserves for Variable Consideration

Revenues from sales of products are recorded at the net sales price, which includes estimates of variable consideration for which
reserves are established and which relate to returns, specialty distributor fees, wholesaler fees, prompt payment discounts, government
rebates, government chargebacks, coupon programs and rebates under managed care plans and commercial payor contracts. Calculating
certain of these reserves involves estimates and judgments and we determine their expected value based on sales or invoice data,
contractual terms, historical utilization rates, new information regarding changes in these programs’ regulations and guidelines that would
impact the amount of the actual rebates, our expectations regarding future utilization rates for these programs and channel inventory data.
These reserves reflect our best estimates of the amount of consideration to which we are entitled based on the terms of the contract. The
amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to
the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future
period. We reassess our reserves for variable consideration at each reporting date. Historically, adjustments to estimates for these
reserves have not been material.

Reserves for returns, specialty distributor fees, wholesaler fees, government rebates, coupon programs and rebates under managed

care plans and commercial payor contracts are included within current liabilities in our consolidated balance sheets. Reserves for
government chargebacks and prompt payment discounts are shown as a reduction in accounts receivable.

Royalties and Contract Revenues

We enter into out-licensing agreements under which we license certain rights to our products or product candidates to third parties. If

a licensing arrangement includes multiple goods or services, we consider whether the license is distinct. If the license to our intellectual
property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenue from
non-refundable, upfront fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and
benefit from the license. If the license to our intellectual property is determined not to be distinct, it is combined with other goods or services
into a combined performance obligation. We consider whether the combined performance obligation is satisfied over time or at a point in
time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, upfront
fees. We evaluate the measure of progress each reporting date and, if necessary, adjust the measure of performance and related revenue
recognition.

At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are
considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount
method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction
price. Milestone payments that are not within our control or that of the licensee, such as regulatory approvals, are not considered probable
of being achieved until those approvals are received. The transaction price is allocated to each performance obligation on a relative stand-
alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the
end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related
constraint, and if necessary, adjust our estimate of the overall transaction price.

For arrangements that include sales-based royalties and milestone payments based on the level of sales, and the license is deemed

to be the predominant item to which the royalties and sales-based milestones relate, we recognize revenue at the later of (i) when the
related sales occur, or (ii) when the performance obligation to which some or all of the royalty or sales-based milestone has been allocated
has been satisfied (or partially satisfied).

Cost of Product Sales

Cost of product sales includes manufacturing and distribution costs, the cost of drug substance, royalties due to third parties on
product sales, product liability and cargo insurance, FDA user fees, freight, shipping, handling and storage costs and salaries and related
costs of employees involved with production. Excluded from cost of product sales shown on the consolidated statements of income (loss) is
amortization of acquired developed technology of $525.8 million, $259.6 million and $243.7 million in 2021, 2020 and 2019, respectively.

F-16

2021 Annual Report

| JAZZ PHARMACEUTICALS

K
-
0
1
m
r
o
F

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Research and Development

Research and development expenses consist primarily of costs related to clinical studies and outside services, personnel expenses
and other research and development costs, including milestone payments incurred prior to regulatory approval of products. Clinical study
and outside services costs relate primarily to services performed by clinical research organizations, clinical studies performed at clinical
sites, materials and supplies, and other third party fees. Personnel expenses relate primarily to salaries, benefits and share-based
compensation. Other research and development expenses primarily include overhead allocations consisting of various support and
facilities-related costs. Research and development costs are expensed as incurred. For product candidates that have not been approved
by FDA, inventory used in clinical trials is expensed at the time of production and recorded as research and development expense. For
products that have been approved by FDA, inventory used in clinical trials is expensed at the time the inventory is packaged for the trial.

Advertising Expenses

We expense the costs of advertising, including promotional expenses, as incurred. Advertising expenses were $161.5 million,

$99.6 million and $65.4 million in 2021, 2020 and 2019, respectively.

Income Taxes

We use the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are
determined based on differences between the financial statement carrying amount and the tax basis of assets and liabilities and are
measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is
provided when it is more-likely-than-not that some portion or all of a deferred tax asset will not be realized. We recognize the benefits of a
tax position if it is “more-likely-than-not” of being sustained. A recognized tax benefit is then measured as the largest amount of tax benefit
that is greater than fifty percent likely of being realized upon settlement. Interest and penalties related to an underpayment of income taxes
are included in the income tax expense and classified with the related liability on the consolidated balance sheets.

Foreign Currency

Our functional and reporting currency is the U.S. dollar. The assets and liabilities of our subsidiaries that have a functional currency

other than the U.S. dollar are translated into U.S. dollars at the exchange rate prevailing at the balance sheet date with the results of
operations of subsidiaries translated at the weighted average exchange rate for the reporting period. The cumulative foreign currency
translation adjustment is recorded as a component of accumulated other comprehensive income (loss) in shareholders’ equity.

Transactions in foreign currencies are translated into the functional currency of the relevant subsidiary at the weighted average
exchange rate for the reporting period. Any monetary assets and liabilities arising from these transactions are translated into the relevant
functional currency at exchange rates prevailing at the balance sheet date or on settlement. Resulting gains and losses are recorded in
foreign exchange gain (loss) in our consolidated statements of income (loss).

Deferred Financing Costs

Deferred financing costs are reported at cost, less accumulated amortization and are presented in the consolidated balance sheets as

a direct deduction from the carrying value of the associated debt, with the exception of deferred financing costs associated with revolving-
debt arrangements which are presented as assets. The related amortization expense is included in interest expense, net in our
consolidated statements of income (loss).

Contingencies

From time to time, we may become involved in claims and other legal matters arising in the ordinary course of business. We record

accruals for loss contingencies to the extent that we conclude that it is probable that a liability has been incurred and the amount of the
related loss can be reasonably estimated. Legal fees and other expenses related to litigation are expensed as incurred and included in
selling, general and administrative expenses.

Share-Based Compensation

We account for compensation cost for all share-based awards at fair value on the date of grant. The fair value is recognized as
expense over the service period, net of estimated forfeitures, using the straight-line method. The estimation of share-based awards that will

JAZZ PHARMACEUTICALS | 2021 Annual Report

F-17

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

ultimately vest requires judgment, and, to the extent actual results or updated estimates differ from current estimates, such amounts will be
recorded as a cumulative adjustment in the period estimates are revised. We primarily consider historical experience when estimating
expected forfeitures.

Performance-Based Restricted Stock Unit Awards

Performance-based restricted stock units, or PRSUs, awarded to employees vest upon the achievement of certain performance
criteria at the end of a specified performance period, subject to a relative total shareholder return, or TSR, modifier. The estimated fair
value of these PRSUs is based on a Monte Carlo simulation model. Compensation expense for PRSUs is recognized from the date the
Company determines the performance criteria probable of being achieved to the date the award, or relevant portion of the award, is
expected to vest. Cumulative adjustments are recorded on a quarterly basis to reflect subsequent changes to the estimated outcome of the
performance criteria until the date results are determined.

Variable Interest Entity

In the year ended December 31, 2021, we invested in a cell of a protected cell company, or the protected cell, as part of our directors’

and officers’ liability risk financing strategy. Based on our control and the structure of the protected cell, we concluded that Jazz is the
primary beneficiary of the protected cell and is required to consolidate the protected cell. The insurance premium payable to the protected
cell for the year ended December 31, 2021 and the protected cell’s assets and liabilities as of December 31, 2021 were immaterial.

Recent Accounting Pronouncements

In August 2020, the FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and

Derivatives and Hedging— Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an
Entity’s Own Equity”, which simplifies the accounting for convertible instruments by eliminating the requirement to separate embedded
conversion features from the host contract when the conversion features are not required to be accounted for as derivatives under
Topic 815, Derivatives and Hedging, or that do not result in substantial premiums accounted for as paid-in capital. By removing the
separation model, a convertible debt instrument will be reported as a single liability instrument with no separate accounting for embedded
conversion features. This new standard also removes certain settlement conditions that are required for contracts to qualify for equity
classification and eliminates the treasury stock method to calculate diluted earnings per share for convertible instruments and requires the
use of the if-converted method. The Company adopted ASU 2020-06 on January 1, 2022, on a modified retrospective basis. As a result of
adoption, the Company increased its convertible debt liabilities, retained earnings and deferred tax assets on January 1, 2022 by
$206.2 million, $127.4 million and $0.1 million, respectively and decreased its additional paid-in capital by $333.5 million.

In October 2021, the FASB issued ASU 2021-08, “Business Combinations (Topic 805): Accounting for Contract Assets and Contract

Liabilities from Contracts with Customers”, which requires entities to recognize and measure contract assets and contract liabilities
acquired in a business combination in accordance with ASC 2014-09, “Revenue from Contracts with Customers (Topic 606)”. The update
will generally result in an entity recognizing contract assets and contract liabilities at amounts consistent with those recorded by the
acquiree immediately before the acquisition date rather than at fair value. The new standard is effective on a prospective basis for fiscal
years beginning after December 15, 2022, with early adoption permitted. The new guidance is not expected to have a material impact on
our results of operations, financial position, or cash flows.

3. Business Combination, Asset Acquisitions and Collaborations

GW Acquisition

On May 5, 2021, or the Closing Date, we acquired the entire issued share capital of GW. As a result, GW became an indirect wholly

owned subsidiary of the Company.

We acquired GW with the objective of broadening our neuroscience portfolio, further diversifying our revenue and driving sustainable,

long-term value creation opportunities. GW was a global leader in discovering, developing, manufacturing and commercializing novel,
regulatory approved therapeutics from its proprietary cannabinoid research platform to address a broad range of diseases.

F-18

2021 Annual Report

| JAZZ PHARMACEUTICALS

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The aggregate consideration for the GW Acquisition was $7.2 billion as follows (all amounts in thousands except American

Depositary Shares, or ADS, and per GW ADS amounts):

GW ADS outstanding May 5, 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cash consideration per GW ADS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

31,556,200
200

$

Total cash consideration to GW ADS holders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cash consideration to GW share option holders (inclusive of payroll taxes) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 6,311,240
267,450

Total cash consideration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Equity consideration to GW ADS holders (1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Consideration related to replacement share option pre-combination service . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total equity consideration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

6,578,690
608,456
3,555

612,011

Total purchase consideration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 7,190,701

(1)

3.8 million ordinary shares were issued to GW ADS holders. The closing price of the ordinary shares on May 4, 2021 ($160.20) was used to
determine the fair value of this equity consideration because the closing of the transaction on May 5, 2021 occurred prior to the opening of regular
trading.

In April 2021, we closed an offering of $1.5 billion in aggregate principal amount of 4.375% senior secured notes, due 2029, or the
Secured Notes. In May 2021, we entered into a credit agreement, or the Credit Agreement, that provides for (i) a seven-year $3.1 billion
term loan B facility, or the Dollar Term Loan, (ii) a seven-year €625.0 million term loan B facility, or the Euro Term Loan and, together with
the Dollar Term Loan, collectively known as the Term Loan and (iii) a five-year $500.0 million revolving credit facility, or the Revolving
Credit Facility. We financed the cash portion of the GW Acquisition consideration through a combination of cash on hand and borrowings
under the Term Loan and the Secured Notes. For further information on the Term Loan and the Secured Notes, please see Note 12.

The GW Acquisition was accounted for as a business combination using the acquisition method under which assets and liabilities of
GW were recorded at their respective estimated fair values as of the Closing Date and added to the assets and liabilities of the Company,
including an amount for goodwill representing the difference between the acquisition consideration and the estimated fair value of the
identifiable net assets. The results of operations of GW and the estimated fair values of the assets acquired and liabilities assumed have
been included in our consolidated financial statements since the Closing Date.

K
-
0
1
m
r
o
F

In 2021, we incurred $81.9 million in acquisition-related costs related to the GW Acquisition, which primarily consisted of banking,
legal, accounting and valuation-related expenses. These expenses were recorded in selling, general and administrative expense in the
accompanying consolidated statements of income (loss). In 2021, our consolidated statements of income (loss) included revenues of
$476.4 million and a net loss of $704.6 million from the acquired GW business, as measured from the Closing Date.

The following table summarizes the preliminary fair values of assets acquired and liabilities assumed at the Closing Date before and

after the measurement period adjustment (in thousands):

Before
Measurement
Period Adjustment

Measurement
Period Adjustment

After Measurement
Period Adjustment

Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accounts receivable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Inventory . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Prepaid expenses and other current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Property, plant and equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Acquired developed technologies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
In-process research and development . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total acquired identifiable intangible assets . . . . . . . . . . . . . . . . . . . . . . . . .
Goodwill
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred tax liabilities, net
Accrued liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other assets/liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

343,898
76,355
1,206,290
72,758
154,407
5,480,000
160,000

5,640,000
947,831
(1,083,673)
(131,971)
(35,194)

$ —
—
—
—
—
—
—

—
(14,597)
14,597
—
—

$

343,898
76,355
1,206,290
72,758
154,407
5,480,000
160,000

5,640,000
933,234
(1,069,076)
(131,971)
(35,194)

Total purchase consideration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 7,190,701

$ —

$ 7,190,701

JAZZ PHARMACEUTICALS | 2021 Annual Report

F-19

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The fair value estimates for the assets acquired and liabilities assumed were based upon preliminary calculations, and our estimates

and assumptions are subject to change as we obtain additional information for our estimates during the measurement period (up to one
year from the Closing Date). During the three months ended December 31, 2021, we recorded a measurement period adjustment which
reduced deferred tax liabilities, net and goodwill by $14.6 million. The measurement period adjustment primarily related to the refinement of
the opening UK net operating loss position of GW.

Inventory

Inventories acquired included raw materials, work in progress and finished goods. Inventories were recorded at their estimated fair

values. The inventory was valued at estimated selling price less the estimated costs to be incurred to complete (in the case of work in
progress) and sell the inventory, the associated margins on these activities and holding costs. A step-up in value of inventory of
$1,062.6 million was recorded in connection with the GW Acquisition. The step-up expense will be recorded in cost of product sales on our
consolidated statements of income (loss) as the inventory is sold to customers from the Closing Date.

Intangible assets

The fair value of acquired intangible assets was $5,640.0 million. The intangible assets include acquired developed technologies,

primarily related to Epidiolex, and IPR&D.

The fair value of the Epidiolex acquired developed technology asset was determined by applying the income approach, which
recognizes that the fair value of an asset is premised upon the expected receipt of future economic benefits such as earnings and cash
inflows based on current sales projections and estimated direct costs, using a discount rate of 9.4% that reflects the return requirements of
the market. This intangible asset is being amortized over an estimated useful life of 12 years.

Acquired IPR&D relates to nabiximols, which is currently in Phase 3 clinical trials for the treatment of spasticity associated with
multiple sclerosis and spinal cord injury. The fair value of acquired IPR&D was determined using the income approach, including the
application of probability factors related to the likelihood of success of nabiximols reaching final development and commercialization. The
fair value of acquired IPR&D was capitalized as of the Closing Date and is subsequently accounted for as an indefinite-lived intangible
asset until completion or abandonment of the associated research and development efforts. Accordingly, during the development period
after the Closing Date, this asset will not be amortized into earnings; instead, it will be subject to periodic impairment testing.

Some of the more significant assumptions inherent in the development of intangible asset fair values include: the amount and timing

of projected future cash flows (including revenue, cost of sales, research and development cost and sales and marketing expenses);
probability of success; the discount rate selected to measure inherent risk of future cash flows; and the assessment of the asset’s life cycle
and the competitive trends impacting the asset, among other factors.

Deferred tax liabilities, net

The net deferred tax liability relates to the difference between the financial statement carrying amount and the tax basis of acquired

intangible assets and inventory, partially offset by acquired net operating loss carryforwards and other temporary differences.

Other tangible assets and liabilities

Other tangible assets and liabilities were valued at their respective carrying amounts as management believes that these amounts

approximated their acquisition-date fair values.

Goodwill

Goodwill represents the excess of the total purchase consideration over the estimated fair value of net assets acquired and was
recorded in the consolidated balance sheet as of the Closing Date. The goodwill was primarily attributable to the establishment of the
deferred tax liability for the acquired intangible assets and inventory. We do not expect any portion of this goodwill to be deductible for
income tax purposes.

F-20

2021 Annual Report

| JAZZ PHARMACEUTICALS

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Pro Forma Financial Information (Unaudited)

The following unaudited supplemental pro forma information presents the combined historical results of income (loss) of the Company

and GW for 2021 and 2020, respectively, as if the GW Acquisition had been completed on January 1, 2020. The primary pro forma
adjustments include:

•

•

•

•

The exclusion of acquisition-related and integration expenses of $357.6 million in 2021 and related income tax expense of
$23.6 million. The inclusion of acquisition-related and integration expenses of $386.7 million in 2020 and related income tax
benefit of $27.9 million.

An increase in amortization expense of $159.1 million in 2021 and related income tax benefit of $30.2 million. An increase in
amortization expense of $464.6 million in 2020 and related income tax benefit of $88.3 million.

An increase in cost of product sales of $81.9 million in 2021 and related income tax benefit of $12.4 million. An increase in cost
of product sales of $296.3 million in 2020 and related income tax benefit of $59.5 million.

An increase in interest expense of $49.1 million in 2021 and related income tax benefit of $9.0 million. An increase in interest
expense of $241.0 million in 2020 and related income tax benefit of $51.9 million. The increase in interest arose on additional
borrowings made to partially fund the GW Acquisition as if the borrowings had occurred on January 1, 2020.

The unaudited pro forma results do not assume any operating efficiencies as a result of the consolidation of operations and are as

follows (in thousands):

K
-
0
1
m
r
o
F

Year Ended
December 31,

2021

2020

Total revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$2,890,772
$3,294,697
$ (422,588) $ (980,481)

Asset Acquisition and Exclusive License Agreement

In October 2020, we entered into an asset purchase and exclusive license agreement with SpringWorks Therapeutics, Inc., or
SpringWorks, under which we acquired SpringWorks’ fatty acid amide hydrolase, or FAAH, inhibitor program. Under the terms of the
agreement, SpringWorks has assigned or exclusively licensed all assets relating to its FAAH inhibitor program to us, including assignment
of SpringWorks’ proprietary FAAH inhibitor PF-04457845, or PF-’845, now named JZP150 and its license agreement with Pfizer, Inc., or
Pfizer, under which Pfizer exclusively licensed PF-’845 to SpringWorks in 2017. In addition to assuming all milestone and royalty
obligations owed by SpringWorks to Pfizer, we made an upfront payment of $35.0 million to SpringWorks, which was recorded as acquired
IPR&D expense in our consolidated statement of income for the year ended December 31, 2020, and may make potential milestone
payments to SpringWorks of up to $375.0 million upon the achievement of certain clinical, regulatory and commercial milestones, and pay
incremental tiered royalties to SpringWorks on future net sales of JZP150 in the mid- to high-single digit percentages.

License Agreement

In December 2019, we entered into an exclusive license agreement, or original license agreement, with Pharma Mar, S.A., or
PharmaMar, for development and U.S. commercialization of Zepzelca. Zepzelca was granted orphan drug designation for relapsed SCLC
by FDA in August 2018. In December 2019, PharmaMar submitted a new drug application, or NDA, to FDA for accelerated approval of
Zepzelca for relapsed SCLC based on data from a Phase 2 trial, and in February 2020, FDA accepted the NDA for filing with priority
review. In June 2020, FDA approved the NDA for Zepzelca for the treatment of adult patients with metastatic SCLC with disease
progression on or after platinum-based chemotherapy.

Under the terms of the original license agreement, which became effective in January 2020 upon expiration of the waiting period
under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, we paid PharmaMar an upfront payment of $200.0 million,
which was recorded as acquired IPR&D expense in our consolidated statement of income for the year ended December 31, 2020. In
June 2020, we made a milestone payment of $100.0 million to PharmaMar following FDA accelerated approval of Zepzelca, which was
capitalized as an intangible asset on our consolidated balance sheet. In October 2021, we reached our first sales milestone triggering a
payment of $25.0 million, which was capitalized as an intangible asset on our consolidated balance sheet.

JAZZ PHARMACEUTICALS | 2021 Annual Report

F-21

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

PharmaMar is eligible to receive potential future regulatory milestone payments of up to $150.0 million upon the achievement of

continued U.S. regulatory approval of Zepzelca following the successful completion of confirmatory trials within certain timelines.
PharmaMar is also eligible to receive up to $525.0 million in potential U.S. commercial milestone payments, as well as incremental tiered
royalties on future net sales of Zepzelca ranging from the high teens up to 30 percent. PharmaMar may receive additional payments on
approval of other indications, with any such payments creditable against commercial milestone payment obligations. PharmaMar retains
production rights for Zepzelca and will supply the product to us.

In October 2020, we entered into an amendment and restatement of the original license agreement with PharmaMar, or the amended
license agreement, which expanded our exclusive license to include rights to develop and commercialize Zepzelca in Canada. To date, we
have paid PharmaMar an upfront payment of $1.0 million, which was recorded as acquired IPR&D expense in our consolidated statement
of income for the year ended December 31, 2020, and a milestone payment of $1.0 million in September 2021 following the first NDA
Approval by Health Canada, which was capitalized as an intangible asset on our consolidated balance sheet. PharmaMar is also eligible to
receive up to $6.0 million in potential Canadian regulatory and commercial milestone payments, as well as incremental tiered royalties on
future Canadian net sales of Zepzelca ranging from the high teens up to 30 percent.

Asset Acquisition

In August 2019, we announced the acquisition of Cavion, Inc., or Cavion, a clinical-stage biotechnology company, for an upfront

payment of $52.5 million with the potential for additional payments of up to $260.0 million upon the achievement of certain clinical,
regulatory and commercial milestones, for a total potential consideration of $312.5 million. As a result of the acquisition, we added JZP385,
a modulator of T-type calcium channels, for the potential treatment of essential tremor, to our clinical pipeline. The acquisition of Cavion
was accounted for as an asset acquisition because it did not meet the definition of a business.

The following table summarizes the total consideration for the acquisition and the value of assets acquired and liabilities assumed (in

thousands):

Consideration
Upfront payment for acquisition of Cavion’s outstanding shares . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cash acquired . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Working capital adjustment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Transaction costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$52,500
397
(255)
2,829

Total consideration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$55,471

Assets Acquired and Liabilities Assumed
Cash . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
In-process research and development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred tax assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other assets and liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

397
48,275
7,995
(1,196)

Total net assets acquired . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$55,471

The value attributed to in-process research and development related to JZP385 and was expensed as it was determined to have no

alternative future use.

Collaboration and License Agreement

In January 2019, we entered into a strategic collaboration agreement with Codiak BioSciences, Inc., or Codiak, focused on the
research, development and commercialization of exosome therapeutics to treat cancer. Codiak granted us an exclusive, worldwide,
royalty-bearing license to develop, manufacture and commercialize therapeutic candidates directed at five targets to be developed using
Codiak’s engEx™ precision engineering platform for exosome therapeutics.

Under the terms of the agreement, Codiak is responsible for the execution of preclinical and early clinical development of therapeutic

candidates directed at all five targets through Phase 1/2 proof of concept studies. Following the conclusion of the applicable Phase 1/2
study, we will be responsible for future development, potential regulatory submissions and commercialization for each product. Codiak has
the option to participate in co-commercialization and cost/profit-sharing in the U.S. and Canada on up to two products.

F-22

2021 Annual Report

| JAZZ PHARMACEUTICALS

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

As part of the agreement, we paid Codiak an upfront payment of $56.0 million in January 2019, which was recorded as acquired

IPR&D expense in our consolidated statement of income for the year ended December 31, 2020. Codiak is eligible to receive up
to $20.0 million in preclinical development milestone payments. Codiak is also eligible to receive milestone payments totaling up
to $200.0 million per target based on investigational new drug application acceptance, clinical and regulatory milestones, including
approvals in the U.S., the European Union and Japan, and certain sales milestones. Codiak is also eligible to receive tiered royalties on net
sales of each approved product.

Collaboration and Option Agreement

In 2017, we entered into a collaboration and option agreement with ImmunoGen, Inc. and we paid them a non-refundable upfront

payment of $75.0 million, which was charged to acquired IPR&D expense upon closing of the transaction.

This agreement was amended in November 2019. Under the amended agreement we had the right to opt into an exclusive,

worldwide license to develop and commercialize IMGN632, a CD123-targeted antibody-drug conjugate for hematological malignancies. In
December 2020, we exercised our opt-out rights with respect to IMGN632, thereby relinquishing the development and commercialization
option.

4. Cash and Available-for-Sale Securities

Cash and cash equivalents and investments consisted of the following (in thousands):

December 31, 2021

Amortized
Cost

Gross
Unrealized
Gains

Gross
Unrealized
Losses

Estimated
Fair Value

Cash and
Cash
Equivalents

Investments

Cash . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Money market funds . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$510,747
80,701

Totals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$591,448

$—
—

$—

$—
—

$—

$510,747
80,701

$510,747
80,701

$591,448

$591,448

$—
—

$—

K
-
0
1
m
r
o
F

December 31, 2020

Amortized
Cost

Gross
Unrealized
Gains

Gross
Unrealized
Losses

Estimated
Fair Value

Cash and
Cash
Equivalents

Cash . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Time deposits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Money market funds . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 517,117
1,360,000
255,652

Totals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$2,132,769

$—
—
—

$—

$—
—
—

$—

$ 517,117
1,360,000
255,652

$ 517,117
285,000
255,652

Investments

$

—
1,075,000
—

$2,132,769

$1,057,769

$1,075,000

Cash equivalents and investments are considered available-for-sale securities. We use the specific-identification method for

calculating realized gains and losses on securities sold and include them in interest expense, net in the consolidated statements of income
(loss). Our investment balances represent time deposits with original maturities of greater than three months and less than one year.
Interest income from available-for-sale securities was $1.8 million, $11.1 million and $20.5 million in 2021, 2020 and 2019, respectively.

JAZZ PHARMACEUTICALS | 2021 Annual Report

F-23

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

5. Fair Value Measurement

The following table summarizes, by major security type, our available-for-sale securities and derivative contracts that were measured

at fair value on a recurring basis and were categorized using the fair value hierarchy (in thousands):

December 31, 2021

December 31, 2020

Quoted
Prices in
Active
Markets for
Identical
Assets
(Level 1)

Significant
Other
Observable
Inputs
(Level 2)

Total
Estimated
Fair Value

Quoted
Prices in
Active
Markets for
Identical
Assets
(Level 1)

Significant
Other
Observable
Inputs
(Level 2)

Total
Estimated
Fair Value

Assets:
Available-for-sale securities:

Time deposits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Money market funds . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Foreign exchange forward contracts . . . . . . . . . . . . . . . . . . .

$ —
80,701
—

$ —
—
580

$ —
80,701
580

$

— $1,360,000
—
11,907

255,652
—

$1,360,000
255,652
11,907

Totals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$80,701

$

580

$81,281

$255,652

$1,371,907

$1,627,559

Liabilities:

Cross-currency interest rate contracts . . . . . . . . . . . . . . . .
Interest rate contracts . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Foreign exchange forward contracts . . . . . . . . . . . . . . . . .

$ —
—
—

$15,232
—
3,187

$15,232
—
3,187

$

— $
—
—

— $

2,835
790

Totals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ —

$18,419

$18,419

$

— $

3,625

$

—
2,835
790

3,625

As of December 31, 2021 our available-for-sale securities were comprised of money market funds and the carrying value was
approximately equal to the fair values. Money market funds were measured using quoted prices in active markets, which represent Level 1
inputs. As of December 31, 2020 our available-for-sale securities comprised money market funds and time deposits. Time deposits were
measured at fair value using Level 2 inputs. Level 2 inputs are obtained from various third party data providers and represent quoted prices
for similar assets in active markets, or these inputs were derived from observable market data, or if not directly observable, were derived
from or corroborated by other observable market data.

Our derivative assets and liabilities include cross-currency interest rate and foreign exchange derivatives that are measured at fair

value using observable market inputs such as forward rates, interest rates, our own credit risk as well as an evaluation of our
counterparties’ credit risks. Based on these inputs, the derivative assets and liabilities are classified within Level 2 of the fair value
hierarchy. The interest rate swap agreements matured in July 2021.

There were no transfers between the different levels of the fair value hierarchy in 2021 or in 2020.

As of December 31, 2021 and 2020, the carrying amount of investments measured using the measurement alternative for equity

investments without a readily determinable fair value was $5.0 million and $4.5 million, respectively. The carrying amount, which is
recorded within other non-current assets, is based on the latest observable transaction price.

As of December 31, 2021, the estimated fair values of our 1.50% exchangeable senior notes due 2024, or the 2024 Notes, and our

2.00% exchangeable senior notes due 2026, or the 2026 Notes, were approximately $576.0 million and $1.1 billion, respectively. The 2024
Notes and the 2026 Notes, together with the 1.875% exchangeable senior notes due 2021, or the 2021 Notes, that were repurchased on
maturity on August 15, 2021, are collectively known as the Exchangeable Senior Notes. As of December 31, 2021, the estimated fair value
of the Secured Notes, the Dollar Term Loan and the Euro Term Loan, were approximately $1.6 billion, $3.1 billion and $236.0 million,
respectively. The fair values of each of these debt facilities was estimated using quoted market prices obtained from brokers (Level 2).

6. Derivative Instruments and Hedging Activities

We are exposed to certain risks arising from operating internationally, including fluctuations in foreign exchange rates primarily related
to the translation of the Euro Term Loan and sterling and euro-denominated net monetary liabilities, including intercompany balances, held

F-24

2021 Annual Report

| JAZZ PHARMACEUTICALS

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

by subsidiaries with a U.S. dollar functional currency. We manage these exposures within specified guidelines through the use of
derivatives. All of our derivative instruments are utilized for risk management purposes, we do not use derivatives for speculative trading
purposes.

In order to hedge our exposure to foreign currency exchange risk associated with our Euro Term Loan, we entered into a cross-

currency interest rate swap contract in May 2021 with a maturity date of March 31, 2022. The terms of this contract convert the principal
repayments and interest payments on our Euro Term Loan into U.S. dollar. As of December 31, 2021, the cross-currency interest rate
swap had a notional amount of $251.0 million which is designated for accounting purposes as a fair value hedge. The carrying amount of
the Euro Term Loan and the fair value of the cross-currency interest rate swap contract will be remeasured with changes in the euro to
U.S. dollar foreign exchange rates recognized within foreign exchange loss in the consolidated statements of income (loss).

The impact on accumulated other comprehensive income (loss) and earnings from the cross-currency interest rate swap contract was

as follows (in thousands):

Year Ended
December 31, 2021

Cross-Currency Interest Rate Contract:
Loss recognized in accumulated other comprehensive income (loss), net of tax . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Loss reclassified from accumulated other comprehensive income (loss) to foreign exchange loss, net of tax . . . . . . . .
Loss recognized in foreign exchange loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ (375)
246
35,885

During the next 12 months, we expect to reclassify $0.1 million of losses, net of tax, on the cross-currency interest rate contract

recognized in accumulated other comprehensive income (loss) to foreign exchange gain (loss).

We enter into foreign exchange forward contracts, with durations of up to 12 months, designed to limit the exposure to fluctuations in
foreign exchange rates related to the translation of certain non-U.S. dollar denominated liabilities, including intercompany balances. Hedge
accounting is not applied to these derivative instruments as gains and losses on these hedge transactions are designed to offset gains and
losses on underlying balance sheet exposures. As of December 31, 2021 and 2020, the notional amount of foreign exchange contracts
where hedge accounting was not applied was $347.2 million and $357.4 million, respectively.

The foreign exchange loss in our consolidated statements of income (loss) included the following gains and losses associated with

foreign exchange contracts not designated as hedging instruments (in thousands):

K
-
0
1
m
r
o
F

Year Ended December 31,

2021

2020

2019

Foreign Exchange Forward Contracts:
Gain (loss) recognized in foreign exchange loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$(19,585) $19,843

$(6,192)

The cash flow effects of our derivative contracts are included within net cash provided by operating activities in the consolidated

statements of cash flows, except for the settlement of notional amounts of the cross-currency swap, which are included in net cash
provided by (used in) financing activities.

To achieve a desired mix of floating and fixed interest rates on our variable rate debt, we entered into interest rate swap agreements
in March 2017. In May 2021, we repaid the term loan to which these interest rate swap agreements related, at which point the interest rate
swap contracts were de-designated as cash flow hedges. The interest rate swap agreements matured in July 2021.

The impact on accumulated other comprehensive income (loss) and earnings from interest rate swap contracts was as follows (in

thousands):

Interest Rate Contracts:
Loss recognized in accumulated other comprehensive income (loss), net of tax . . . . . . . . . . . . . . . . . . . . . $ (14) $(4,543) $(3,903)
$ (979)
Loss (gain) reclassified from accumulated other comprehensive income (loss) to interest expense, net of tax . . . $2,482

$ 3,401

JAZZ PHARMACEUTICALS | 2021 Annual Report

F-25

Year Ended December 31,

2021

2020

2019

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The following tables summarize the fair value of outstanding derivatives (in thousands):

December 31, 2021

Asset Derivatives

Liability Derivatives

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Derivatives designated as hedging instruments:

Cross-currency interest rate contracts . . . . . . . . . . . . . . . . . . . . . . Other current assets

$—

Accrued liabilities

$15,232

Derivatives not designated as hedging instruments:

Foreign exchange forward contracts . . . . . . . . . . . . . . . . . . . . . . . Other current assets

Total fair value of derivative instruments . . . . . . . . . . . . . . . . . . . . . .

580

$580

Accrued liabilities

3,187

$18,419

December 31, 2020

Asset Derivatives

Liability Derivatives

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Derivatives designated as hedging instruments:

Interest rate contracts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Other current assets

$ —

Accrued liabilities

$2,835

Derivatives not designated as hedging instruments:

Foreign exchange forward contracts . . . . . . . . . . . . . . . . . . . . . . . Other current assets

11,907

Accrued liabilities

Total fair value of derivative instruments . . . . . . . . . . . . . . . . . . . . . .

$11,907

790

$3,625

Although we do not offset derivative assets and liabilities within our consolidated balance sheets, our International Swap and
Derivatives Association agreements provide for net settlement of transactions that are due to or from the same counterparty upon early
termination of the agreement due to an event of default or other termination event. The following tables summarize the potential effect on
our consolidated balance sheets of offsetting our interest rate contracts and foreign exchange forward contracts subject to such provisions
(in thousands):

December 31, 2021

Description

Gross
Amounts of
Recognized
Assets/
Liabilities

Gross
Amounts
Offset in the
Consolidated
Balance
Sheet

Net Amounts of
Assets/
Liabilities
Presented in
the Consolidated
Balance Sheet

Gross Amounts Not Offset in the
Consolidated Balance Sheet

Derivative
Financial
Instruments

Cash
Collateral
Received
(Pledged)

Derivative assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Derivative liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$
580
$(18,419)

$—
$—

$
580
$(18,419)

$(567)
$ 567

$—
$—

December 31, 2020

Description

Gross
Amounts of
Recognized
Assets/
Liabilities

Gross
Amounts
Offset in the
Consolidated
Balance
Sheet

Net Amounts of
Assets/
Liabilities
Presented in
the Consolidated
Balance Sheet

Derivative assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Derivative liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$11,907
$ (3,625)

$—
$—

$11,907
$ (3,625)

Gross Amounts Not Offset in the
Consolidated Balance Sheet

Derivative
Financial
Instruments

$(2,207)
$ 2,207

Cash
Collateral
Received
(Pledged)

$—
$—

Net
Amount

$ 9,700
$(1,418)

F-26

2021 Annual Report

| JAZZ PHARMACEUTICALS

Net
Amount

$
13
$(17,852)

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

7. Inventories

Inventories consisted of the following (in thousands):

Raw materials . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Work in process . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Finished goods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

21,550
886,849
164,322

$16,003
45,758
33,635

Total inventories . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$1,072,721

$95,396

As of December 31, 2021, inventories included $811.3 million related to the purchase accounting inventory fair value step-up on

December 31,

2021

2020

inventory acquired in the GW Acquisition.

8. Other Current Assets

Other current assets consisted of the following (in thousands):

K
-
0
1
m
r
o
F

December 31,

2021

2020

Deferred charge for income taxes on intercompany profit
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$203,480
48,912

$114,234
38,257

Total other current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$252,392

$152,491

9. Property, Plant and Equipment

Property, plant and equipment consisted of the following (in thousands):

Construction-in-progress . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Manufacturing equipment and machinery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Leasehold improvements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Land and buildings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Computer software . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Computer equipment
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Furniture and fixtures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

December 31,

2021

$ 86,511
69,079
66,318
64,008
25,646
16,234
14,412

$

2020

7,262
33,465
54,113
47,555
22,781
18,749
11,598

Subtotal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Less accumulated depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

342,208
(85,371)

195,523
(67,588)

Property, plant and equipment, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$256,837

$127,935

Depreciation and amortization expense on property, plant and equipment amounted to $26.7 million, $18.7 million and $15.3 million

for the years ended December 31, 2021, 2020 and 2019, respectively.

10. Goodwill and Intangible Assets

The gross carrying amount of goodwill was as follows (in thousands):

Balance at December 31, 2020 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Goodwill arising from the GW Acquisition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Foreign exchange . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 958,303
933,234
(63,928)

Balance at December 31, 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$1,827,609

JAZZ PHARMACEUTICALS | 2021 Annual Report

F-27

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The gross carrying amounts and net book values of our intangible assets were as follows (in thousands):

December 31, 2021

December 31, 2020

Remaining
Weighted-
Average Useful
Life
(In years)

Gross
Carrying
Amount

Accumulated
Amortization

Net Book
Value

Gross
Carrying
Amount

Accumulated
Amortization

Net Book
Value

11.4
—
—

$8,195,675
12,124
2,893

$(1,198,333) $6,997,342
—
—

(12,124)
(2,893)

$3,379,162
13,135
2,917

$(1,184,111) $2,195,051
—
—

(13,135)
(2,917)

8,210,692
154,986

(1,213,350)

—

6,997,342
154,986

3,395,214
—

(1,200,163)

—

2,195,051
—

Acquired developed technologies . . .
Manufacturing contracts . . . . . . . . .
Trademarks . . . . . . . . . . . . . . . . . . .

Total finite-lived intangible

assets . . . . . . . . . . . . . . . . . . .
Acquired IPR&D assets . . . . . . . . . .

Total intangible assets . . . . . . . . . . .

$8,365,678

$(1,213,350) $7,152,328

$3,395,214

$(1,200,163) $2,195,051

The increase in the gross carrying amount of intangible assets as of December 31, 2021 compared to December 31, 2020 primarily

reflects the intangible assets arising from the GW Acquisition, as described in Note 3, partially offset by the de-recognition of the fully
amortized Erwinaze intangible assets and the negative impact of foreign currency translation adjustments due to the weakening of sterling
and euro against the U.S. dollar.

The assumptions and estimates used to determine future cash flows and remaining useful lives of our intangible and other long-lived

assets are complex and subjective. They can be affected by various factors, including external factors, such as industry and economic
trends, and internal factors such as changes in our business strategy and our forecasts for specific product lines.

Based on finite-lived intangible assets recorded as of December 31, 2021, and assuming the underlying assets will not be impaired

and that we will not change the expected lives of any other assets, future amortization expenses were estimated as follows (in thousands):

Year Ending December 31,

2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2024 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2025 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2026 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Thereafter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Estimated
Amortization
Expense

$ 627,866
627,866
627,866
627,866
627,866
3,858,012

Total

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$6,997,342

F-28

2021 Annual Report

| JAZZ PHARMACEUTICALS

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

11. Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

December 31,

2021

2020

Rebates and other sales deductions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Employee compensation and benefits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Clinical trial accruals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued milestones . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Consulting and professional services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Selling and marketing accruals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued royalties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Derivative instrument liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Inventory-related accruals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sales return reserve . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Current portion of lease liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued construction-in-progress . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$215,397
158,870
48,640
25,612
25,000
22,507
21,566
20,345
18,419
16,166
15,814
15,763
2,894
59,311

$127,534
102,601
5,722
9,108
—
6,660
6,742
15,230
3,625
9,809
18,368
14,457
1,119
31,757

Total accrued liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$666,304

$352,732

K
-
0
1
m
r
o
F

12. Debt

The following table summarizes the carrying amount of our indebtedness (in thousands):

December 31,

2021

2020

2021 Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Unamortized discount and debt issuance costs on 2021 Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

— $ 218,812
(5,883)
—

2021 Notes, net

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

—

2024 Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Unamortized discount and debt issuance costs on 2024 Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

575,000
(71,237)

212,929

575,000
(95,275)

2024 Notes, net

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

503,763

479,725

2026 Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Unamortized discount and debt issuance costs on 2026 Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1,000,000
(150,730)

1,000,000
(179,518)

2026 Notes, net

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

849,270

820,482

Secured Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1,473,810

—

Term Loan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

3,223,100

581,702

Total debt . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Less current portion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

6,049,943
31,000

2,094,838
246,322

Total long-term debt

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$6,018,943

$1,848,516

Credit Agreement

On May 5, 2021, the Company, Jazz Financing Lux S.à.r.l., or Jazz Lux, and certain of our other subsidiaries, as borrowers,
(collectively with the Company and Jazz Lux, the “Borrowers”), entered into the Credit Agreement, that provides for (i) the Dollar Term
Loan which was drawn by Jazz Lux on the Closing Date in U.S. dollars (ii) the Euro Term Loan which was drawn by Jazz Lux on the
Closing Date in Euros and (iii) the Revolving Credit Facility, which is available to be drawn by any Borrower in U.S. dollars.

JAZZ PHARMACEUTICALS | 2021 Annual Report

F-29

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

We used the proceeds from the Term Loan (i) to repay in full $575.9 million under that certain credit agreement, dated as of June 18,

2015 (as amended) among the Company, and certain of our other subsidiaries as borrowers, the lenders party thereto and Bank of
America, N.A., as administrative agent and collateral agent, or the Existing Credit Agreement, (ii) to fund, in part, the cash consideration
payable in connection with the GW Acquisition and (iii) to pay related fees and expenses. Upon the repayment in full of loans under the
Existing Credit Agreement, it was terminated and all guarantees and liens thereunder were released.

Loans under the Term Loan and Revolving Credit Facility bear interest at a rate equal to (A) in the case of the Dollar Term Loan and

the Revolving Credit Facility, at the applicable Borrower’s option, either (a) London Inter-Bank Offered Rate, or LIBOR or (b) the prime
lending rate and (B) in the case of the Euro Term Loan, Euro Inter-Bank Offered Rate, or EURIBOR, in each case, plus an applicable
margin. The applicable margin for the Term Loan is 3.50% (in the case of LIBOR or EURIBOR borrowings) and 2.50% (in the case of
borrowings at the prime lending rate). The applicable margin for the Revolving Credit Facility ranges from 3.25% to 2.75% (in the case of
LIBOR borrowings) and 2.25% to 1.75% (in the case of borrowings at the prime lending rate), depending on our first lien secured net
leverage ratio level. The Dollar Term Loan is subject to a LIBOR floor of 0.50%, the Euro Term Loan and loans under the Revolving Credit
Facility are not subject to a EURIBOR or LIBOR (as applicable) floor. The Revolving Credit Facility has a commitment fee payable on the
undrawn amount ranging from 0.50% to 0.40% per annum based upon our first lien secured net leverage ratio.

As of December 31, 2021, the interest rate and effective interest rate on the Dollar Term Loan were 4.00% and 4.55%, respectively.

The interest rate and effective interest rate on the Euro Term Loan were 4.43% and 4.93%, respectively. As of December 31, 2021, we had
an undrawn Revolving Credit Facility totaling $500.0 million.

The Borrowers’ obligations under the Credit Agreement and any hedging or cash management obligations entered into with any

lender thereunder are guaranteed by the Company, the other borrowers, and each of the Company’s other existing or subsequently
acquired or organized direct and indirect subsidiaries (subject to certain exceptions), or the Guarantors. We refer to the Borrowers and the
Guarantors collectively as the “Loan Parties.”

The Loan Parties’ obligations under the Credit Agreement are secured, subject to customary permitted liens and other exceptions, by

a security interest in (a) all tangible and intangible assets of the Loan Parties, except for certain excluded assets, and (b) all of the equity
interests of the subsidiaries of the Loan Parties held by the Loan Parties.

We may make voluntary prepayments at any time without payment of a premium or penalty, subject to certain exceptions, and are

required to make certain mandatory prepayments of outstanding indebtedness under the Credit Agreement in certain circumstances.

Principal repayments of the Dollar Term Loan, which are due quarterly, began in September 2021 and are equal to 1.0% per annum

of the original principal amount of $3.1 billion with any remaining balance payable on the maturity date. The Euro Term Loan does not have
any mandatory principal repayments during its term, however in September and December 2021, we made voluntary prepayments totaling
€416.7 million or $502.0 million.

The Credit Agreement contains customary representations and warranties and customary affirmative and negative covenants
applicable to the Company and its restricted subsidiaries, including, among other things, restrictions on indebtedness, liens, investments,
mergers, dispositions, prepayment of junior indebtedness and dividends and other distributions. The Credit Agreement contains financial
covenants that require the Company and its restricted subsidiaries to (a) not exceed a maximum first lien secured net leverage ratio and
(b) not fall below a minimum interest coverage ratio, provided that such covenants apply only to the Revolving Credit Facility and are
applicable only if amounts are drawn (or non-cash collateralized letters of credit in excess of $50 million are outstanding) under the
Revolving Credit Facility. The Credit Agreement also contains customary events of default relating to, among other things, failure to make
payments, breach of covenants and breach of representations.

2029 Senior Secured Notes

On April 29, 2021, Jazz Securities Designated Activity Company, or Jazz Securities, a direct wholly owned subsidiary of the

Company, closed the offering of the Secured Notes in a private placement. We used the proceeds from the Secured Notes to fund, in part,
the cash consideration payable in connection with the GW Acquisition.

Interest on the Secured Notes is payable semi-annually in arrears on January 15 and July 15 of each year, beginning on

January 15, 2022, at a rate of 4.375% per year. The Secured Notes mature on January 15, 2029.

F-30

2021 Annual Report

| JAZZ PHARMACEUTICALS

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

The Secured Notes are jointly and severally guaranteed by the Company and each of its restricted subsidiaries, other than Jazz

Securities, that is a borrower, or a guarantor, under the Credit Agreement. The Secured Notes and related guarantees are secured by a
first priority lien (subject to permitted liens and certain other exceptions), equally and ratably with the Credit Agreement, on the collateral
securing the Credit Agreement.

Except as described below, the Secured Notes may not be optionally redeemed before July 15, 2024. Thereafter, some or all of the
Secured Notes, may be redeemed at any time and from time to time at a specified redemption prices, plus accrued and unpaid interest, if
any, to, but excluding, to the redemption date. Jazz Securities may redeem all but not part of the Secured Notes at its option at any time in
connection with certain tax-related events and may redeem some or all of the Secured Notes at any time and from time to time prior to
July 15, 2024 at a price equal to 100% of the principal amount of the Secured Notes to be redeemed plus a “make whole” premium, plus
accrued and unpaid interest, if any, to, but excluding, the redemption date. In addition, Jazz Securities may redeem up to 40% of the
aggregate principal amount of the Secured Notes at any time and from time to time prior to July 15, 2024, with the net proceeds of certain
equity offerings at a price of 104.375% of the principal amount of such Secured Notes, plus accrued and unpaid interest, if any, to, but
excluding, the redemption date. In addition, during each of the three consecutive twelve-month periods commencing on the issue date of
the Secured Notes, Jazz Securities may redeem up to 10% of the original aggregate initial principal amount of the Secured Notes at a
redemption price of 103% of the principal amount of such Secured Notes, plus accrued and unpaid interest, if any, to, but excluding, the
redemption date.

If Jazz undergoes a change of control, Jazz Securities will be required to make an offer to purchase all of the Secured Notes at a
purchase price in cash equal to 101% of the principal amount thereof, plus accrued and unpaid interest, if any, to, but excluding, the date of
repurchase, subject to certain exceptions.

K
-
0
1
m
r
o
F

The indenture governing the Secured Notes contains customary affirmative covenants and negative covenants applicable to the

Company and its restricted subsidiaries, including, among other things, restrictions on indebtedness, liens, investments, mergers,
dispositions, prepayment of junior indebtedness and dividends and other distributions. If Jazz Securities or the Company’s restricted
subsidiaries engage in certain asset sales, Jazz Securities will be required under certain circumstances to make an offer to purchase the
Secured Notes at 100% of the principal amount, plus accrued and unpaid interest, if any, to, but excluding, the repurchase date.

As of December 31, 2021, the interest rate and effective interest rate on the Secured Notes were 4.375% and 4.64%, respectively.

Exchangeable Senior Notes Due 2026

In 2020 we completed a private placement of $1.0 billion principal amount of the 2026 Notes. We used a portion of the net proceeds

from this offering to repurchase for cash $332.9 million aggregate principal amount of the 2021 Notes through privately-negotiated
transactions concurrently with the offering of the 2026 Notes. Interest on the 2026 Notes is payable semi-annually in cash in arrears on
June 15 and December 15 of each year, beginning on December 15, 2020, at a rate of 2.00% per year. In certain circumstances, we may
be required to pay additional amounts as a result of any applicable tax withholding or deductions required in respect of payments on the
2026 Notes. The 2026 Notes mature on June 15, 2026, unless earlier exchanged, repurchased or redeemed.

The holders of the 2026 Notes have the ability to require us to repurchase all or a portion of their 2026 Notes for cash in the event we
undergo certain fundamental changes, such as specified change of control transactions, our liquidation or dissolution or the delisting of our
ordinary shares from any of The New York Stock Exchange, The Nasdaq Global Market, The Nasdaq Global Select Market or The Nasdaq
Capital Market (or any of their respective successors). Additionally, the terms and covenants in the indenture related to the 2026 Notes
include certain events of default after which the 2026 Notes may be due and payable immediately. Prior to June 15, 2026, we may redeem
the 2026 Notes, in whole but not in part, subject to compliance with certain conditions, if we have, or on the next interest payment date
would, become obligated to pay to the holder of any 2026 Notes additional amounts as a result of certain tax-related events. We also may
redeem the 2026 Notes on or after June 20, 2023 and prior to March 15, 2026, in whole or in part, if the last reported sale price per
ordinary share has been at least 130% of the exchange price then in effect for at least 20 trading days (whether or not consecutive) during
any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which we provide the
notice of redemption.

The 2026 Notes are exchangeable at an initial exchange rate of 6.4182 ordinary shares per $1,000 principal amount of 2026 Notes,

which is equivalent to an initial exchange price of approximately $155.81 per ordinary share. Upon exchange, the 2026 Notes may be

JAZZ PHARMACEUTICALS | 2021 Annual Report

F-31

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

settled in cash, ordinary shares or a combination of cash and ordinary shares, at our election. Our intent and policy is to settle the principal
amount of the 2026 Notes in cash upon exchange. The exchange rate will be subject to adjustment in some events but will not be adjusted
for any accrued and unpaid interest. In addition, following certain make-whole fundamental changes occurring prior to the maturity date of
the 2026 Notes or upon our issuance of a notice of redemption, we will in certain circumstances increase the exchange rate for holders of
the 2026 Notes who elect to exchange their 2026 Notes in connection with that make-whole fundamental change or during the related
redemption period. Prior to March 15, 2026, the 2026 Notes will be exchangeable only upon satisfaction of certain conditions and during
certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the
maturity date.

In accounting for the issuance of the 2026 Notes, we separated the 2026 Notes into liability and equity components. The carrying

amount of the liability component was calculated by measuring the estimated fair value of a similar liability that does not have an
associated exchange feature. The carrying amount of the equity component representing the exchange option was determined by
deducting the fair value of the liability component from the face value of the 2026 Notes as a whole. The excess of the principal amount of
the liability component over its carrying amount will be amortized to interest expense over the expected life of the 2026 Notes using the
effective interest method with an effective interest rate of 5.98% per annum. We have determined the expected life of the 2026 Notes to be
equal to the original 6-year term. The equity component is not remeasured as long as it continues to meet the conditions for equity
classification. As of December 31, 2021, the “if converted value” of the 2026 Notes did not exceed the principal amount of the 2026 Notes.
As of December 31, 2020, the “if converted value” of the 2026 Notes exceeded the principal amount by $59.3 million.

We allocated the total issuance costs incurred of $18.6 million to the liability and equity components based on their relative values.
Issuance costs attributable to the liability component will be amortized to expense over the term of the 2026 Notes, and issuance costs
attributable to the equity component were included with the equity component in our shareholders’ equity.

As of December 31, 2021 and 2020, the carrying value of the equity component of the 2026 Notes, net of equity issuance costs, was

$176.3 million.

Exchangeable Senior Notes Due 2024

In 2017, we completed a private placement of $575.0 million principal amount of 2024 Notes. We used the net proceeds from this

offering to repay $500.0 million in outstanding loans under the revolving credit facility and to pay related fees and expenses. We used the
remainder of the net proceeds for general corporate purposes. Interest on the 2024 Notes is payable semi-annually in cash in arrears on
February 15 and August 15 of each year, beginning on February 15, 2018, at a rate of 1.50% per year. In certain circumstances, we may
be required to pay additional amounts as a result of any applicable tax withholding or deductions required in respect of payments on the
2024 Notes. The 2024 Notes mature on August 15, 2024, unless earlier exchanged, repurchased or redeemed.

The holders of the 2024 Notes have the ability to require us to repurchase all or a portion of their 2024 Notes for cash in the event we
undergo certain fundamental changes, such as specified change of control transactions, our liquidation or dissolution or the delisting of our
ordinary shares from The Nasdaq Global Select Market. Prior to August 15, 2024, we may redeem the 2024 Notes, in whole but not in part,
subject to compliance with certain conditions, if we have, or on the next interest payment date would, become obligated to pay to the holder
of any 2024 Notes additional amounts as a result of certain tax-related events. We also may redeem the 2024 Notes on or after August 20,
2021, in whole or in part, if the last reported sale price per ordinary share has been at least 130% of the exchange price then in effect for at
least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the trading day
immediately preceding the date on which we provide the notice of redemption.

The 2024 Notes are exchangeable at an initial exchange rate of 4.5659 ordinary shares per $1,000 principal amount of 2024 Notes,

which is equivalent to an initial exchange price of approximately $219.02 per ordinary share. Upon exchange, the 2024 Notes may be
settled in cash, ordinary shares or a combination of cash and ordinary shares, at our election. Our intent and policy is to settle the principal
amount of the 2024 Notes in cash upon exchange. The exchange rate will be subject to adjustment in some events but will not be adjusted
for any accrued and unpaid interest. In addition, following certain make-whole fundamental changes occurring prior to the maturity date of
the 2024 Notes or upon our issuance of a notice of redemption, we will in certain circumstances increase the exchange rate for holders of
the 2024 Notes who elect to exchange their 2024 Notes in connection with that make-whole fundamental change or during the related
redemption period. Prior to May 15, 2024, the 2024 Notes will be exchangeable only upon satisfaction of certain conditions and during
certain periods, and thereafter, at any time until the close of business on the second scheduled trading day immediately preceding the
maturity date.

F-32

2021 Annual Report

| JAZZ PHARMACEUTICALS

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

In accounting for the issuance of the 2024 Notes, we separated the 2024 Notes into liability and equity components. The carrying

amount of the liability component was calculated by measuring the estimated fair value of a similar liability that does not have an
associated exchange feature. The carrying amount of the equity component representing the exchange option was determined by
deducting the fair value of the liability component from the face value of the 2024 Notes as a whole. The excess of the principal amount of
the liability component over its carrying amount will be amortized to interest expense over the expected life of the 2024 Notes using the
effective interest method with an effective interest rate of 6.8% per annum. We have determined the expected life of the 2024 Notes to be
equal to the original seven-year term. The equity component is not remeasured as long as it continues to meet the conditions for equity
classification. As of December 31, 2021 and 2020, the “if-converted value” did not exceed the principal amount of the 2024 Notes.

We allocated the total issuance costs incurred of $15.6 million to the liability and equity components based on their relative values.
Issuance costs attributable to the liability component will be amortized to expense over the term of the 2024 Notes, and issuance costs
attributable to the equity component were included with the equity component in our shareholders’ equity.

As of December 31, 2021 and 2020, the carrying value of the equity component of the 2024 Notes, net of equity issuance costs, was

$149.8 million.

Exchangeable Senior Notes Due 2021

In 2014, we completed a private placement of the 2021 Notes with a maturity date of August 15, 2021. Interest on the 2021 Notes
was payable semi-annually in cash in arrears on February 15 and August 15 of each year, beginning on February 15, 2015, at a rate of
1.875% per year. The exchange rate was 5.0057 ordinary shares per $1,000 principal amount of 2021 Notes, which was equivalent to an
exchange price of approximately $199.77 per ordinary share.

In accounting for the issuance of the 2021 Notes, we separated the 2021 Notes into liability and equity components. The carrying

amount of the liability component was calculated by measuring the estimated fair value of a similar liability that does not have an
associated exchange feature. The carrying amount of the equity component representing the exchange option was determined by
deducting the fair value of the liability component from the face value of the 2021 Notes as a whole. The excess of the principal amount of
the liability component over its carrying amount was amortized to interest expense over the expected life of the 2021 Notes using the
effective interest method with an effective interest rate of 6.4% per annum.

We allocated the total issuance costs incurred of $16.1 million to the liability and equity components based on their relative values.

Issuance costs attributable to the liability component were amortized to interest expense, net over the term of the 2021 Notes, and
issuance costs attributable to the equity component were included with the equity component in our shareholders’ equity. In 2020 we
repurchased $356.2 million aggregate principal amount of the 2021 Notes and we repurchased the remaining $218.8 million aggregate
principal amount on maturity in August 2021.

The Exchangeable Senior Notes were issued by Jazz Investments I Limited, or the Issuer, a 100%-owned finance subsidiary of Jazz

Pharmaceuticals plc. The Exchangeable Senior Notes are senior unsecured obligations of the Issuer and are fully and unconditionally
guaranteed on a senior unsecured basis by Jazz Pharmaceuticals plc. No subsidiary of Jazz Pharmaceuticals plc guaranteed the
Exchangeable Senior Notes. Subject to certain local law restrictions on payment of dividends, among other things, and potential negative
tax consequences, we are not aware of any significant restrictions on the ability of Jazz Pharmaceuticals plc to obtain funds from the Issuer
or Jazz Pharmaceuticals plc’s other subsidiaries by dividend or loan, or any legal or economic restrictions on the ability of the Issuer or
Jazz Pharmaceuticals plc’s other subsidiaries to transfer funds to Jazz Pharmaceuticals plc in the form of cash dividends, loans or
advances. There is no assurance that in the future such restrictions will not be adopted.

For the years ended December 31, 2021, 2020 and 2019, we recognized $89.9 million, $87.6 million and $62.5 million, respectively,

in interest expense, net related to the contractual coupon rate and the amortization of the debt discount and debt issuance costs on the
Exchangeable Senior Notes.

K
-
0
1
m
r
o
F

JAZZ PHARMACEUTICALS | 2021 Annual Report

F-33

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Scheduled maturities with respect to our long-term debt are as follows (in thousands):

Year Ending December 31,

2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2024 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2025 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2026 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Thereafter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Scheduled Long-Term
Debt Maturities

$

31,000
31,000
606,000
31,000
1,031,000
4,665,458

$6,395,458

13. Leases

We have noncancelable leases for our buildings and growing facilities and we are obligated to make payments under noncancelable

operating leases for automobiles used by our sales force.

The components of the lease expense for the years ended December 31, 2021, 2020 and 2019 were as follows (in thousands):

Lease Cost

Year Ended
December 31,

2021

2020

2019

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Operating lease cost
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Short-term lease cost
Variable lease cost
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sublease income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$23,869
5,540
10
—

$21,755
4,079
3
(224)

$23,087
2,465
5
(634)

Finance Lease Cost

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Amortization of leased asset
Interest on lease liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

324
295

—
—

—
—

Net lease cost

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$30,038

$25,613

$24,923

Supplemental balance sheet information related to operating and finance leases was as follows (in thousands):

Leases

Assets

Classification

Operating lease assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Operating lease assets
Finance lease assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Property, plant and equipment

Total lease assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

December 31,

2021

2020

$ 86,586
5,738

$129,169
—

$ 92,324

$129,169

Liabilities
Current

Operating lease liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Accrued liabilities
Finance lease liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Accrued liabilities

$ 15,357
406

$ 14,457
—

Non-current

Operating lease liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Operating lease liabilities, less current portion
Finance lease liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Other non-current liabilities

87,200
6,269

140,035
—

Total lease liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$109,232

$154,492

F-34

2021 Annual Report

| JAZZ PHARMACEUTICALS

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Lease Term and Discount Rate

Weighted-average remaining lease term (years) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Operating leases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Finance leases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Weighted-average discount rate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Operating leases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Finance leases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

December 31,

2021

2020

6.5
8.7
12.9 —

5.2% 5.3%
7.4% — %

Supplemental cash flow information related to operating and finance leases was as follows (in thousands):

Cash paid for amounts included in the measurement of lease liabilities:

. . . . . . . . . . . . . . . . . . . . . . . . .
Operating cash outflows from operating leases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Operating cash outflows from finance leases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Financing cash outflows from finance leases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Operating lease assets obtained in exchange for new operating lease liabilities (1) . . . . . . . . . . . . . . .
Finance lease assets obtained in exchange for new finance lease liabilities . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
De-recognition of operating lease asset on lease assignment
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
De-recognition of operating lease liability on lease assignment

Non-cash operating activities:

Year Ended
December 31,

2021

2020

2019

$24,847
625
324

$21,678
—
—

$ 17,066
—
—

$ 8,188
650
56,968
68,064

$ 1,763
—
—
—

$153,448
—
—
—

K
-
0
1
m
r
o
F

(1)

Includes the balances recognized on January 1, 2019 on adoption of ASU No. 2016-02.

Maturities of operating and finance lease liabilities were as follows (in thousands):

Year Ending December 31,

Operating
Leases

Finance
Leases

2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2024 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2025 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2026 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Thereafter

$ 20,373
19,426
20,996
14,565
12,741
34,560

$

876
872
872
872
872
6,135

Total lease payments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Less imputed interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$122,661
(20,104)

$10,499
(3,824)

Present value of lease liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$102,557

$ 6,675

14. Commitments and Contingencies

Indemnification

In the normal course of business, we enter into agreements that contain a variety of representations and warranties and provide for

general indemnification, including indemnification associated with product liability or infringement of intellectual property rights. Our
exposure under these agreements is unknown because it involves future claims that may be made but have not yet been made against us.
To date, we have not paid any claims or been required to defend any action related to these indemnification obligations.

We have agreed to indemnify our executive officers, directors and certain other employees for losses and costs incurred in
connection with certain events or occurrences, including advancing money to cover certain costs, subject to certain limitations. The
maximum potential amount of future payments we could be required to make under the indemnification obligations is unlimited; however,
we maintain insurance policies that may limit our exposure and may enable us to recover a portion of any future amounts paid. Assuming
the applicability of coverage, the willingness of the insurer to assume coverage, and subject to certain retention, loss limits and other policy

JAZZ PHARMACEUTICALS | 2021 Annual Report

F-35

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

provisions, we believe the fair value of these indemnification obligations is not significant. Accordingly, we did not recognize any liabilities
relating to these obligations as of December 31, 2021 and December 31, 2020. No assurances can be given that the covering insurers will
not attempt to dispute the validity, applicability, or amount of coverage without expensive litigation against these insurers, in which case we
may incur substantial liabilities as a result of these indemnification obligations.

Other Commitments

As of December 31, 2021, we had $73.2 million of noncancelable purchase commitments due within one year, primarily related to

agreements with third party manufacturers.

Legal Proceedings

We are involved in legal proceedings, including the following matters:

Xyrem Class Action

From June 2020 to October 2021, a number of lawsuits were filed on behalf of purported direct and indirect Xyrem purchasers,
alleging that the patent litigation settlement agreements we entered with generic drug manufacturers who had filed Abbreviated New Drug
Applications, or ANDA, violate state and federal antitrust and consumer protection laws, as follows:

On June 17, 2020, a class action lawsuit was filed in the United States District Court for the Northern District of Illinois by Blue Cross

and Blue Shield Association, or BCBS, against Jazz Pharmaceuticals plc, Jazz Pharmaceuticals, Inc., and Jazz Pharmaceuticals Ireland
Limited, or, collectively, the Company Defendants (hereinafter referred to as the BCBS Lawsuit). The BCBS Lawsuit also names Roxane
Laboratories, Inc., Hikma Pharmaceuticals USA Inc., Eurohealth (USA), Inc., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC,
Par Pharmaceuticals, Inc., Lupin Ltd., Lupin Pharmaceuticals Inc., and Lupin Inc., or, collectively, the BCBS Defendants.

On June 18 and June 23, 2020, respectively, two additional class action lawsuits were filed against the Company Defendants and the

BCBS Defendants: one by the New York State Teamsters Council Health and Hospital Fund in the United States District Court for the
Northern District of California, and another by the Government Employees Health Association Inc. in the United States District Court for the
Northern District of Illinois (hereinafter referred to as the GEHA Lawsuit).

On June 18, 2020, a class action lawsuit was filed in the United States District Court for the Northern District of California by the City

of Providence, Rhode Island, on behalf of itself and all others similarly situated, against Jazz Pharmaceuticals plc, and Roxane
Laboratories, Inc., West-Ward Pharmaceuticals Corp., Hikma Labs Inc., Hikma Pharmaceuticals USA Inc., and Hikma Pharmaceuticals plc,
or, collectively, the City of Providence Defendants.

On June 30, 2020, a class action lawsuit was filed in the United States District Court for the Northern District of Illinois by UFCW

Local 1500 Welfare Fund on behalf of itself and all others similarly situated, against Jazz Pharmaceuticals Ireland Ltd., Jazz
Pharmaceuticals, Inc., Roxane Laboratories, Inc., Hikma Pharmaceuticals plc, Eurohealth (USA), Inc. and West-Ward Pharmaceuticals
Corp., or collectively the UFCW Defendants (hereinafter referred to as the UFCW Lawsuit).

On July 13, 2020, the plaintiffs in the BCBS Lawsuit and the GEHA Lawsuit dismissed their complaints in the United States District
Court for the Northern District of Illinois and refiled their respective lawsuits in the United States District Court for the Northern District of
California. On July 14, 2020, the plaintiffs in the UFCW Lawsuit dismissed their complaint in the United States District Court for the
Northern District of Illinois and on July 15, 2020, refiled their lawsuit in the United States District Court for the Northern District of California.

On July 31, 2020, a class action lawsuit was filed in the United States District Court for the Southern District of New York by the A.F.
of L.-A.G.C. Building Trades Welfare Plan on behalf of itself and all others similarly situated, against Jazz Pharmaceuticals plc (hereinafter
referred to as the AFL Plan Lawsuit). The AFL Plan Lawsuit also names Roxane Laboratories Inc., West-Ward Pharmaceuticals Corp.,
Hikma Labs Inc., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Par Pharmaceuticals Inc., Lupin Ltd., Lupin Pharmaceuticals,
Inc., and Lupin Inc.

On August 14, 2020, an additional class action lawsuit was filed in the United States District Court for the Southern District of

New York by the Self-Insured Schools of California on behalf of itself and all others similarly situated, against the Company Defendants, as
well as Hikma Pharmaceuticals plc, Eurohealth (USA) Inc., Hikma Pharmaceuticals USA, Inc., West-Ward Pharmaceuticals Corp., Roxane

F-36

2021 Annual Report

| JAZZ PHARMACEUTICALS

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Laboratories, Inc., Amneal Pharmaceuticals LLC, Endo International, plc, Endo Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd.,
Lupin Pharmaceuticals Inc., Lupin Inc., Sun Pharmaceutical Industries Ltd., Sun Pharmaceutical Holdings USA, Inc., Sun Pharmaceutical
Industries, Inc., Ranbaxy Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Watson Laboratories, Inc., Wockhardt Ltd., Morton Grove
Pharmaceuticals, Inc., Wockhardt USA LLC, Mallinckrodt plc, and Mallinckrodt LLC (hereinafter referred to as the Self-Insured Schools
Lawsuit).

On September 16, 2020, an additional class action lawsuit was filed in the United States District Court for the Northern District of

California, by Ruth Hollman on behalf of herself and all others similarly situated, against the same defendants named in the Self-Insured
Schools Lawsuit.

In December 2020, the above cases were centralized and transferred to the United States District Court for the Northern District of

California, where the multidistrict litigation will proceed for the purpose of discovery and pre-trial proceedings.

On March 18, 2021, United Healthcare Services, Inc. filed a lawsuit in the United States District Court for the District of Minnesota
against the Company Defendants, Hikma Pharmaceuticals plc, Roxane Laboratories, Inc., Hikma Pharmaceuticals USA Inc., Eurohealth
(USA) Inc., Amneal Pharmaceuticals LLC, Par Pharmaceutical Inc., Lupin Ltd., and Lupin Pharmaceuticals, Inc., raising similar allegations,
or the UHS Lawsuit. On March 24, 2021, the U.S. Judicial Panel on Multidistrict Litigation conditionally transferred the UHS Lawsuit to the
United States District Court for the Northern District of California, where it was consolidated for discovery and pre-trial proceedings with the
other cases.

K
-
0
1
m
r
o
F

On August 13, 2021, the United States District Court for the Northern District of California granted in part and denied in part the

Company Defendants motion to dismiss the complaints in the cases referenced above.

On October 8, 2021, Humana Inc. filed a lawsuit in the United States District Court for the Northern District of California against the
Company Defendants, Hikma Pharmaceuticals plc, Hikma Pharmaceuticals USA Inc., Hikma Labs, Inc., Eurohealth (USA), Inc., Amneal
Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., and Lupin Inc, raising similar allegations.

On October 8, 2021, Molina Healthcare Inc. filed a lawsuit in the United States District Court for the Northern District of California
against the Company Defendants, Hikma Pharmaceuticals plc, Hikma Pharmaceuticals USA Inc., Hikma Labs, Inc., Eurohealth (USA),
Inc., Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., and Lupin Inc, raising similar
allegations.

On February 17, 2022, Health Care Service Corporation filed a lawsuit in the United States District Court for the Northern District of
California against the Company Defendants, Hikma Pharmaceuticals plc, Hikma Pharmaceuticals USA Inc., Hikma Labs, Inc., Eurohealth
(USA), Inc., Amneal Pharmaceuticals LLC, Par Pharmaceutical, Inc., Lupin Ltd., Lupin Pharmaceuticals, Inc., and Lupin Inc, raising similar
allegations.

The parties have submitted a proposed case schedule through briefing on class certification. A trial date will be set following a ruling

on class certification.

The plaintiffs in certain of these lawsuits are seeking to represent a class of direct purchasers of Xyrem, and the plaintiffs in the

remaining lawsuits are seeking to represent a class of indirect purchasers of Xyrem. Each of the lawsuits generally alleges violations of
U.S. federal and state antitrust, consumer protection, and unfair competition laws in connection with the Company Defendants’ conduct
related to Xyrem, including actions leading up to, and entering into, patent litigation settlement agreements with each of the other named
defendants. Each of the lawsuits seeks monetary damages, exemplary damages, equitable relief against the alleged unlawful conduct,
including disgorgement of profits and restitution, and injunctive relief. It is possible that additional lawsuits will be filed against the Company
Defendants making similar or related allegations. If the plaintiffs were to be successful in their claims, they may be entitled to injunctive
relief or we may be required to pay significant monetary damages, which could have a material adverse effect on our business, financial
condition, results of operations and growth prospects.

GW Acquisition Litigation

On March 15, 2021, GW filed a definitive proxy statement, or Proxy Statement, with the Securities and Exchange Commission in

connection with the GW Acquisition.

JAZZ PHARMACEUTICALS | 2021 Annual Report

F-37

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Since the filing of the Proxy Statement, Jazz Pharmaceuticals plc has been named in two lawsuits filed in state and federal courts in

New York on March 17, 2021 by purported GW shareholders in connection with the GW Acquisition. The first was filed in the United States
District Court for the Southern District of New York by James Farrell (hereinafter referred to as the Farrell Lawsuit) and an additional suit
was filed in New York state court by Brian Levy (hereinafter referred to as the Levy Lawsuit). In addition to Jazz Pharmaceuticals plc, Jazz
Pharmaceuticals U.K. Holdings Ltd., GW Pharmaceuticals plc, and the GW Board of Directors are named as defendants in the Farrell
Lawsuit. In the Levy Lawsuit, GW Pharmaceuticals plc, the GW Board of Directors, Centerview Partners LLC, and Goldman Sachs & Co.
LLC are named as defendants. In addition to the Farrell Lawsuit and the Levy Lawsuit, ten additional suits have been filed in New York,
California, and Pennsylvania federal courts by purported GW shareholders against GW Pharmaceuticals plc and its Board of Directors, but
which do not name any Jazz Pharmaceuticals parties (hereinafter referred to as the GW Litigation, and collectively with the Farrell Lawsuit
and the Levy Lawsuit, as the Transaction Litigation). In the Transaction Litigation, the plaintiffs allege that the Proxy Statement omitted
material information and contained misrepresentations, and that the individual members of the GW Board of Directors breached their
fiduciary duties, in violation of state and federal laws, including the Securities Exchange Act of 1934. The plaintiffs in the Transaction
Litigation sought various remedies, including injunctive relief to prevent the consummation of the GW Acquisition unless certain allegedly
material information was disclosed, or in the alternative, rescission or damages.

On April 14, 2021, GW filed a Form 8-K containing supplemental disclosures related to the GW Acquisition. Pursuant to a

memorandum of understanding between the parties, the Levy Lawsuit was dismissed on April 14, 2021.

On May 27, 2021, a class action lawsuit was filed in the United States District Court for the Southern District of California by plaintiff
Kurt Ziegler against GW and its former Directors asserting claims under Sections 14(a) and 20(a) of the Securities Exchange Act of 1934,
referred to as the Ziegler Lawsuit. The allegations in the Ziegler Lawsuit are similar to those in the previously dismissed Transaction
Litigation.

Patent Infringement Litigation

Avadel Patent Litigation

On May 13, 2021, we filed a patent infringement suit against Avadel Pharmaceuticals plc, or Avadel, and several of its corporate
affiliates in the United States District Court for the District of Delaware. The suit alleges that Avadel’s product candidate FT-218 will infringe
five of our patents related to controlled release formulations of oxybate and the safe and effective distribution of oxybate. The suit seeks an
injunction to prevent Avadel from launching a product that would infringe these patents, and an award of monetary damages if Avadel does
launch an infringing product. Avadel filed an answer to the complaint and counterclaims asserting that the patents are invalid or not
enforceable, and that its product, if approved, will not infringe our patents.

On August 4, 2021, we filed an additional patent infringement suit against Avadel in the United States District Court for the District of
Delaware. The second suit alleges that Avadel’s product candidate FT-218 will infringe a newly-issued patent related to sustained-release
formulations of oxybate. The suit seeks an injunction to prevent Avadel from launching a product that would infringe this patent, and an
award of monetary damages if Avadel does launch an infringing product. Avadel filed an answer to the complaint and counterclaims
asserting that the patents are invalid or not enforceable, and that its product, if approved, will not infringe our patents.

On November 10, 2021, we filed an additional patent infringement suit against Avadel in the United States District Court for the
District of Delaware. The third suit alleges that Avadel’s product candidate FT-218 will infringe a newly-issued patent related to sustained-
release formulations of oxybate. The suit seeks an injunction to prevent Avadel from launching a product that would infringe this patent,
and an award of monetary damages if Avadel does launch an infringing product. Avadel filed an answer to the complaint and counterclaims
asserting that the patents are invalid or not enforceable, and that its product, if approved, will not infringe our patents.

Canopy Patent Litigation

In December 2020, Canopy Growth Corporation filed a complaint against our subsidiary, GW, in the United States District Court for
the Western District of Texas, alleging infringement of its patent, U.S. Patent No. 10,870,632. Canopy claims that our extraction process
used to produce material used to produce Epidiolex infringes its patent. Canopy seeks a judgment that we have infringed their patent and
an award of monetary damages. In July 2021, we filed an answer to the amended complaint, and counterclaims seeking judgment that the
‘632 patent is invalid and that we have not infringed the patent. In October 2021, the United States District Court for the Western District of
Texas held a claim construction hearing regarding the disputed term of the ‘632 patent. In November 2021, the Court issued a claim

F-38

2021 Annual Report

| JAZZ PHARMACEUTICALS

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

construction order, which the Company views as generally favorable. On February 23, 2022, the parties filed a Joint Motion and Stipulation
to Enter Final Judgment in favor of GW. Pursuant to the stipulation, Canopy has the right to appeal the Court’s ruling on the disputed term.
On February 25, 2022, the Court granted the parties’ motion and entered final judgment in favor of GW.

Lupin Patent Litigation

In June 2021, we received notice from Lupin Inc., or Lupin, that it has filed with FDA an ANDA, for a generic version of Xywav. The
notice from Lupin included a “paragraph IV certification” with respect to ten of our patents listed in FDA’s Orange Book for Xywav on the
date of our receipt of the notice. The asserted patents relate generally to the composition and method of use of Xywav, and methods of
treatment when Xywav is administered concomitantly with certain other medications. A paragraph IV certification is a certification by a
generic applicant that alleges that patents covering the branded product are invalid, unenforceable, and/or will not be infringed by the
manufacture, use or sale of the generic product.

In July 2021, we filed a patent infringement suit against Lupin in the United States District Court for the District of New Jersey. The
complaint alleges that by filing its ANDA, Lupin has infringed ten of our Orange Book listed patents. We are seeking a permanent injunction
to prevent Lupin from introducing a generic version of Xywav that would infringe our patents. As a result of this lawsuit, we expect that a
stay of approval of up to 30 months will be imposed by FDA on Lupin’s ANDA. In June 2021, FDA recognized seven years of Orphan Drug
Exclusivity for Xywav through July 21, 2027. On October 4, 2021, Lupin filed an answer to the complaint and counterclaims asserting that
the patents are invalid or not enforceable, and that its product, if approved, will not infringe our patents.

K
-
0
1
m
r
o
F

Otsuka Patent Litigation

In October 2021, Otsuka Pharmaceutical Co., Ltd., or Otsuka, filed claims against GW Pharma Limited and GW Pharmaceuticals

Limited, or collectively, the GW Parties, in the English High Court, Patents Court. Otsuka alleges that under a now-expired Research
Collaboration and License Agreement between Otsuka and the GW Parties, Otsuka and the GW Parties jointly own certain patents and other
intellectual property, that Epidiolex is covered by that intellectual property, and that Otsuka is therefore due a royalty on net sales of Epidiolex.

In December 2021, we filed an application for an order declaring that the English High Court, Patents Court has no jurisdiction over

the dispute with Otsuka, or should not exercise its jurisdiction.

In January 2022, we filed a lawsuit against Otsuka in the Supreme Court of the State of New York, County of New York, seeking a

declaration that Otsuka is not entitled to any royalties on sales of Epidiolex under the Research Collaboration and License Agreement.

The Company vigorously enforces its intellectual property rights, but cannot predict the outcome of these matters.

From time to time we are involved in legal proceedings arising in the ordinary course of business. We believe there is no other litigation

pending that could have, individually or in the aggregate, a material adverse effect on our results of operations or financial condition.

15. Shareholders’ Equity

Share Repurchase Program

In November 2016, our board of directors authorized a share repurchase program and as of December 31, 2021 had authorized the

repurchase of up to $1.5 billion, exclusive of any brokerage commissions. Under this program, which has no expiration date, we may
repurchase ordinary shares from time to time on the open market. The timing and amount of repurchases will depend on a variety of
factors, including the price of our ordinary shares, alternative investment opportunities, restrictions under the amended credit agreement,
corporate and regulatory requirements and market conditions. The share repurchase program may be modified, suspended or discontinued
at any time without prior notice. In 2021, we did not repurchase any of our ordinary shares under the share repurchase program. In 2020,
we spent a total of $146.5 million to repurchase 1.2 million of our ordinary shares at an average total purchase price, including brokerage
commissions, of $121.98 per share. All ordinary shares repurchased were canceled. As of December 31, 2021, the remaining amount
authorized under the share repurchase program was $431.2 million.

JAZZ PHARMACEUTICALS | 2021 Annual Report

F-39

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Authorized But Unissued Ordinary Shares

We had reserved the following shares of authorized but unissued ordinary shares (in thousands):

2011 Equity Incentive Plan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2007 Employee Stock Purchase Plan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
GW Incentive Plans . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Amended and Restated 2007 Non-Employee Directors Stock Award Plan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2007 Equity Incentive Plan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

22,195
3,285
1,853
807
—

21,070
2,600
—
889
5

Total

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

28,140

24,564

December 31,
2020
2021

Dividends

In 2021 and 2020, we did not declare or pay cash dividends on our common equity. Under Irish law, dividends may only be paid, and

share repurchases and redemptions must generally be funded only out of, “distributable reserves.” In addition, the terms of our credit
agreement restrict our ability to make certain restricted payments, including dividends and other distributions by us in respect of our
ordinary shares, subject to, among other exceptions, (1) a general exception for dividends and restricted payments up to $30 million in the
aggregate and (2) an exception that allows for restricted payments, subject to a cap equal to the sum of (i) $100 million plus (ii) so long as
our secured leverage ratio (as defined in our credit agreement) does not exceed 3:1 after giving pro forma effect to the restricted payment,
a formula-based amount tied to our consolidated net income; provided that such cap applies only if our total leverage ratio (as defined in
our credit agreement) exceeds 2:1 after giving pro forma effect to the restricted payment. Any future determination as to the payment of
dividends will, subject to Irish legal requirements, be at the sole discretion of our board of directors and will depend on our consolidated
financial condition, results of operations, capital requirements, compliance with the terms our credit agreement or other future borrowing
arrangements, and other factors our board of directors deems relevant.

16. Comprehensive Income (Loss)

Comprehensive income (loss) includes net income (loss) and all changes in shareholders’ equity during a period, except for those

changes resulting from investments by shareholders or distributions to shareholders.

Accumulated Other Comprehensive Loss

The components of accumulated other comprehensive loss as of December 31, 2021 and 2020 were as follows (in thousands):

Net Unrealized
Loss From
Hedging
Activities

Foreign
Currency
Translation
Adjustments

Total
Accumulated
Other
Comprehensive
Loss

Balance at December 31, 2020 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other comprehensive income (loss) before reclassifications . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . .
Amounts reclassified from accumulated other comprehensive income (loss)

$(2,467)
(389)
2,728

$(131,885)
(268,347)

—

$(134,352)
(268,736)
2,728

Other comprehensive income (loss), net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2,339

(268,347)

(266,008)

Balance at December 31, 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ (128)

$(400,232)

$(400,360)

In 2021, other comprehensive loss reflects foreign currency translation adjustments, primarily due to the weakening of the sterling

and euro against the U.S. dollar.

17. Net Income (Loss) per Ordinary Share

Basic net income (loss) per ordinary share is based on the weighted-average number of ordinary shares outstanding. Diluted net
income (loss) per ordinary share is based on the weighted-average number of ordinary shares outstanding and potentially dilutive ordinary
shares outstanding.

F-40

2021 Annual Report

| JAZZ PHARMACEUTICALS

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Basic and diluted net income (loss) per ordinary share were computed as follows (in thousands, except per share amounts):

Year Ended December 31,

2021

2020

2019

Numerator:

Net income (loss) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$(329,668) $238,616

$523,367

Denominator:

Weighted-average ordinary shares used in per share calculations—basic . . . . . . . . . . . . . . . . .
Dilutive effect of employee equity incentive and purchase plans . . . . . . . . . . . . . . . . . . . . . . . . .

Weighted-average ordinary shares used in per share calculations—diluted . . . . . . . . . . . . . . . .

59,694
—

59,694

55,712
805

56,517

56,749
801

57,550

Net income (loss) per ordinary share :

Basic . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Diluted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

$

(5.52) $

(5.52) $

4.28

4.22

$

$

9.22

9.09

Potentially dilutive ordinary shares from our employee equity incentive and purchase plans and the Exchangeable Senior Notes are

determined by applying the treasury stock method to the assumed exercise of share options, the assumed vesting of outstanding restricted
stock units, or RSUs and PRSUs, the assumed issuance of ordinary shares under our employee stock purchase plan, or ESPP, and the
assumed issuance of ordinary shares upon exchange of the Exchangeable Senior Notes. The average share price of our ordinary shares in
2021 exceeded the effective exchange price per ordinary share of the 2026 Notes. However, the potential ordinary shares issuable upon
exchange were excluded from the calculation of diluted net loss per ordinary share because their effect would have been anti-dilutive. The
average price of our ordinary shares in 2021 did not exceed the effective exchange price per ordinary share of the 2021 Notes and 2024
Notes. The potential issue of ordinary shares issuable upon exchange of the Exchangeable Senior Notes had no effect on diluted net
income per ordinary share for 2020 and 2019 as the average price of our ordinary shares during those periods did not exceed the effective
exchange prices per ordinary share of the Exchangeable Senior Notes.

The following table represents the weighted-average ordinary shares that were excluded from the computation of diluted net income

(loss) per ordinary share for the years presented because including them would have an anti-dilutive effect (in thousands):

K
-
0
1
m
r
o
F

Year Ended December 31,

2021

2020

2019

Exchangeable Senior Notes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Employee equity incentive and purchase plans . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

9,725
3,927

8,077
4,780

5,504
5,000

18. Segment and Other Information

Our operating segment is reported in a manner consistent with the internal reporting provided to the chief operating decision maker,
or CODM. Our CODM has been identified as our chief executive officer. We have determined that we operate in one business segment,
which is the identification, development and commercialization of meaningful pharmaceutical products that address unmet medical needs.

The following table presents total long-lived assets by location (in thousands):

December 31,

2021

2020

Ireland . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
United Kingdom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
United States . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Italy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 65,478
176,778
76,290
16,698
8,179

$ 71,906
3,438
157,282
16,008
8,470

Total long-lived assets (1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$343,423

$257,104

(1)

Long-lived assets consist of property, plant and equipment and operating lease assets.

JAZZ PHARMACEUTICALS | 2021 Annual Report

F-41

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

19. Revenues

The following table presents a summary of total revenues (in thousands):

Year Ended December 31,

2021

2020

2019

Xyrem . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Xywav . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$1,265,830
535,297

$1,741,758
15,264

$1,642,525
—

Total Oxybate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Epidiolex/Epidyolex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sunosi
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Sativex . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total Neuroscience . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Zepzelca . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Rylaze . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Vyxeos . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Defitelio/defibrotide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Erwinaze/Erwinase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Total Oncology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Other

1,801,127
463,645
57,914
12,707

2,335,393
246,808
85,629
134,060
197,931
69,382

733,810
9,798

1,757,022
—
28,333
—

1,785,355
90,380
—
121,105
195,842
147,136

554,463
6,842

1,642,525
—
3,714
—

1,646,239
—
—
121,407
172,938
177,465

471,810
17,552

Product sales, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Royalties and contract revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

3,079,001
15,237

2,346,660
16,907

2,135,601
26,160

Total revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$3,094,238

$2,363,567

$2,161,761

The following table presents a summary of total revenues attributed to geographic sources (in thousands):

Year Ended December 31,

2021

2020

2019

United States . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Europe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
All other

$2,820,242
230,158
43,838

$2,144,541
175,208
43,818

$1,964,161
150,201
47,399

Total revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$3,094,238

$2,363,567

$2,161,761

The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our

total revenues:

ESSDS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
McKesson . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

60%
12%

74%
12%

76%
14%

Financing and payment

Our payment terms vary by the type and location of our customer but payment is generally required in a term ranging from 30 to 45

Year Ended December 31,

2021

2020

2019

days.

Contract Liabilities—Deferred Revenue

The deferred revenue balance as of December 31, 2021 primarily related to deferred upfront fees received from Nippon Shinyaku

Co., Ltd., or Nippon Shinyaku, in connection with two license, development and commercialization agreements granting Nippon Shinyaku

F-42

2021 Annual Report

| JAZZ PHARMACEUTICALS

K
-
0
1
m
r
o
F

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

exclusive rights to develop and commercialize each of Defitelio and Vyxeos in Japan. We recognized contract revenues of $2.8 million in
2021 relating to these upfront payments. The deferred revenue balances are being recognized over an average of four years representing
the period we expect to perform our research and developments obligations under each agreement.

The following table presents a reconciliation of our beginning and ending balances in contract liabilities from contracts with customers

for the year ended December 31, 2021 (in thousands):

Balance as of December 31, 2020 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Additions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Amount recognized within royalties and contract revenues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Contract
Liabilities

$ 4,861
483
(2,788)

Balance as of December 31 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 2,556

20. Share-Based Compensation

GW Incentive Plans

On May 5, 2021, Jazz Pharmaceuticals plc acquired the entire issued share capital of GW Pharmaceuticals plc. In connection with

the GW Acquisition, we assumed the GW Pharmaceuticals plc 2008 Long-Term Incentive Plan, GW Pharmaceuticals plc 2017 Long-Term
Incentive Plan and GW Pharmaceuticals plc 2020 Long-Term Incentive Plan, each as amended from time to time, together referred to as
the GW Incentive Plans. The terms of the GW Incentive Plans provide for the grant of stock options, stock appreciation rights, RSUs, other
stock awards, and performance awards that may be settled in cash, shares, or other property. Ordinary shares granted to employees in
exchange for GW ADS in connection with the GW Acquisition vest ratably over service periods of two years, while all post-acquisition
grants vest ratably over service periods of four years, and expire no more than 10 years after the date of grant. As of December 31, 2021,
a total of 1,864,475 of our ordinary shares had been authorized for issuance under the GW Incentive Plans.

2011 Equity Incentive Plan

On January 18, 2012, the businesses of Jazz Pharmaceuticals, Inc. and Azur Pharma were combined in a merger transaction, or the
Azur Merger. In connection with the Azur Merger, Jazz Pharmaceuticals, Inc.’s board of directors adopted the 2011 Equity Incentive Plan,
or the 2011 Plan, in October 2011 and its stockholders approved the 2011 Plan at the special meeting of the stockholders held in
December 2011 in connection with the Azur Merger. The 2011 Plan became effective immediately before the consummation of the Azur
Merger and was assumed and adopted by us upon the consummation of the Azur Merger. The terms of the 2011 Plan provide for the grant
of stock options, stock appreciation rights, RSUs, other stock awards, and performance awards that may be settled in cash, shares, or
other property. All outstanding grants under the 2011 Plan were granted to employees and vest ratably over service periods of four years
and expire no more than 10 years after the date of grant. As of December 31, 2021, a total of 32,065,082 of our ordinary shares had been
authorized for issuance under the 2011 Plan. In addition, the share reserve under the 2011 Plan will automatically increase on January 1 of
each year through January 1, 2022, by the least of (a) 4.5% of the total number of ordinary shares outstanding on December 31 of the
preceding calendar year, (b) 5,000,000 shares, or (c) such lesser number of ordinary shares as determined by our board of directors. On
January 1, 2022, the share reserve under the 2011 Plan automatically increased by 2,771,906 ordinary shares pursuant to this provision.

2007 Equity Incentive Plan

The 2007 Equity Incentive Plan, or the 2007 Plan, which was initially adopted by the Jazz Pharmaceuticals, Inc. board of directors
and approved by the Jazz Pharmaceuticals, Inc. stockholders in connection with its initial public offering, was continued and assumed by
us upon consummation of the Azur Merger. The 2007 Plan provided for the grant of stock options, RSUs, stock appreciation rights,
performance stock awards and other forms of equity compensation to employees, including officers, non-employee directors and
consultants. Prior to the consummation of the Azur Merger, all of the grants under the 2007 Plan were granted to employees and vest
ratably over service periods of three to five years and expire no more than 10 years after the date of grant. Effective as of the closing of the
Azur Merger on January 18, 2012, the number of shares reserved for issuance under the 2007 Plan was set to 1,000,000 ordinary shares.
The share reserve under the 2007 Plan will not automatically increase. Since the Azur Merger, all of the new grants under the 2007 Plan
were granted to non-employee directors, vest ratably over service periods of one to three years and expire no more than 10 years after the

JAZZ PHARMACEUTICALS | 2021 Annual Report

F-43

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

date of grant. The 2007 Plan expired in April 2017, and accordingly, no new grants can be awarded under the 2007 Plan. As of
December 31, 2021, the number of shares reserved represents issuable shares from options granted but not yet exercised under the 2007
Plan.

2007 Employee Stock Purchase Plan

In 2007, Jazz Pharmaceuticals, Inc.’s employees became eligible to participate in the ESPP. The ESPP was amended and restated

by Jazz Pharmaceuticals, Inc.’s board of directors in October 2011 and approved by its stockholders in December 2011. The amended and
restated ESPP became effective immediately prior to the effective time of the Azur Merger and was assumed by us upon the
consummation of the Azur Merger. The amended and restated ESPP allows our eligible employee participants (including employees of any
of a parent or subsidiary company if our board of directors designates such company as eligible to participate) to purchase our ordinary
shares at a discount of 15% through payroll deductions. The ESPP consists of a fixed offering period of 24 months with four purchase
periods within each offering period. The number of shares available for issuance under our ESPP during any six-month purchase period is
175,000 shares. As of December 31, 2021, a total of 6,105,282 of our ordinary shares had been authorized for issuance under the ESPP.
The share reserve under the ESPP will automatically increase on January 1 of each year through January 1, 2022, by the least of (a) 1.5%
of the total number of ordinary shares outstanding on December 31 of the preceding calendar year, (b) 1,000,000 shares, and (c) such
lesser number of ordinary shares as determined by our board of directors or a duly-authorized committee thereof. On January 1, 2022, the
share reserve under the ESPP automatically increased by 923,968 ordinary shares pursuant to this provision.

Amended and Restated 2007 Non-Employee Directors Stock Award Plan

The Amended and Restated 2007 Non-Employee Directors Stock Award Plan, or the 2007 Directors Award Plan, which was initially
adopted by the Jazz Pharmaceuticals, Inc. board of directors and approved by the Jazz Pharmaceuticals, Inc. stockholders in connection
with its initial public offering, was continued and assumed by us upon the consummation of the Azur Merger. Until October 2011, the 2007
Directors Award Plan provided for the automatic grant of stock options to purchase shares of Jazz Pharmaceuticals, Inc.’s common stock
to its non-employee directors initially at the time any individual first became a non-employee director, which vest over three years, and then
annually over their period of service on its board of directors, which vest over one year. On October 24, 2011, Jazz Pharmaceuticals, Inc.’s
board of directors amended the 2007 Directors Award Plan to eliminate all future initial and annual automatic grants so that future
automatic grants would not be made that would be subject to the excise tax imposed by Section 4985 of the Internal Revenue Code of
1986, as amended, or the Internal Revenue Code, in connection with the Azur Merger. Accordingly, all future stock option grants under the
2007 Directors Award Plan will be at the discretion of our board of directors. Since the Azur Merger, all of the new grants under the 2007
Directors Award Plan were granted to non-employee directors and vest ratably over service periods of one to three years and expire no
more than 10 years after the date of grant. In addition, the 2007 Directors Award Plan provides the source of shares to fund distributions
made prior to August 15, 2010 under the Directors Deferred Compensation Plan described below. In August 2016, our shareholders
approved our proposal to expand the types of stock awards that may be granted to our non-employee directors under the 2007 Directors
Award Plan and eliminate the final automatic share reserve increase under the 2007 Directors Award Plan that was scheduled to occur on
January 1, 2017. In July 2020, our shareholders approved our proposal to increase the number of ordinary shares authorized for issuance
under the 2007 Directors Award Plan by 500,000 shares. As of December 31, 2021, a total of 1,403,938 of our ordinary shares had been
authorized for issuance under the 2007 Directors Award Plan.

Amended and Restated Directors Deferred Compensation Plan

In May 2007, the Jazz Pharmaceuticals, Inc. board of directors adopted the Directors Deferred Compensation Plan, or the Directors

Deferred Plan, which was amended in December 2008 and was then amended and restated in August 2010, and which was continued and
assumed by us upon consummation of the Azur Merger. The Directors Deferred Plan allows each non-employee director to elect to defer
receipt of all or a portion of his or her annual retainer fees to a future date or dates. Amounts deferred under the Directors Deferred Plan
are credited as shares of Jazz Pharmaceuticals, Inc.’s common stock (or our ordinary shares following the Azur Merger) to a phantom
stock account, the number of which are based on the amount of the retainer fees deferred divided by the market value of Jazz
Pharmaceuticals, Inc.’s common stock (or our ordinary shares following the Azur Merger) on the first trading day of the first open window
period following the date the retainer fees are deemed earned. On the 10th business day following the day of separation from the board of
directors or the occurrence of a change in control, or as soon thereafter as practical once the non-employee director has provided the
necessary information for electronic deposit of the deferred shares, each non-employee director will receive (or commence receiving,
depending upon whether the director has elected to receive distributions from his or her phantom stock account in a lump sum or in

F-44

2021 Annual Report

| JAZZ PHARMACEUTICALS

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

installments over time) a distribution of his or her phantom stock account, in our ordinary shares (i) reserved under the 2007 Directors
Option Plan prior to August 15, 2010 and (ii) from a new reserve of 200,000 shares set up under the Directors Deferred Plan on
August 15, 2010. Since the consummation of the Azur Merger we have not permitted non-employee directors to defer any annual retainer
fees under the Directors Deferred Plan. On October 31, 2019, our board of directors approved the termination of the Directors Deferred
Plan, and all outstanding phantom stock was distributed to each applicable non-employee director on November 2, 2020. We recorded no
expense in 2021, 2020 and 2019 related to retainer fees earned and deferred.

Share-Based Compensation

The table below shows, for market strike price option grants, the weighted-average assumptions used in the Black-Scholes option

pricing model and the resulting weighted-average grant date fair value of market strike price option grants granted in each of the past
three years:

Grant date fair value . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Volatility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Expected term (years) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Range of risk-free rates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Expected dividend yield . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Year Ended December 31,

2021

2020

2019

$ 51.39

$ 34.68

$ 42.09

37%
4.5

33%
4.6
0.4-0.8% 0.2-1.6% 1.3-2.5%
— %

32%
4.5

— %

— %

K
-
0
1
m
r
o
F

We rely on a blend of the historical and implied volatilities of our own ordinary shares to determine expected volatility for share option

grants. In addition, we use a single volatility estimate for each share option grant. The weighted-average volatility is determined by
calculating the weighted average of volatilities for all share options granted in a given year.

The expected term of share option grants represents the weighted-average period the awards are expected to remain outstanding

and our estimates were based on historical exercise data. The risk-free interest rate assumption was based on zero coupon U.S. Treasury
instruments whose term was consistent with the expected term of our share option grants. The expected dividend yield assumption was
based on our history and expectation of dividend payouts.

Share-based compensation expense related to share options, RSUs, PRSUs and grants under our ESPP was as follows (in

thousands):

Year Ended December 31,

2021

2020

2019

Selling, general and administrative . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Research and development
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cost of product sales . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$135,285
43,758
9,963

$ 84,384
29,242
7,372

$ 78,697
25,229
6,637

Total share-based compensation expense, pre-tax . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Income tax benefit from share-based compensation expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

189,006
(33,958)

120,998
(12,838)

110,563
(15,712)

Total share-based compensation expense, net of tax . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$155,048

$108,160

$ 94,851

We recognized income tax benefits related to share option exercises of $9.3 million, $3.9 million and $5.1 million in 2021, 2020 and

2019, respectively.

JAZZ PHARMACEUTICALS | 2021 Annual Report

F-45

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Share Options

The following table summarizes information as of December 31, 2021 and activity during 2021 related to our share option plans:

Outstanding at January 1, 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Options granted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Options exercised . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Options forfeited . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Options expired . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Outstanding at December 31, 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Vested and expected to vest at December 31, 2021 . . . . . . . . . . . . . . . . . . . . . . .
Exercisable at December 31, 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Shares
Subject to
Outstanding
Options
(In thousands)

5,279
110
(1,041)
(137)
(90)

4,121

4,039
3,270

Weighted-
Average
Exercise
Price

$130.51
164.45
114.33
139.24
164.45

$134.48

$134.56
$135.06

Weighted-
Average
Remaining
Contractual
Term (Years)

Aggregate
Intrinsic
Value
(In thousands)

5.6

5.6
5.1

$30,696

$30,164
$26,248

Aggregate intrinsic value shown in the table above is equal to the difference between the exercise price of the underlying share
options and the fair value of our ordinary shares for share options that were in the money. The aggregate intrinsic value changes based on
the fair market value of our ordinary shares. The aggregate intrinsic value of share options exercised was $51.8 million, $26.4 million and
$26.2 million during 2021, 2020 and 2019, respectively. We issued new ordinary shares upon exercise of share options.

As of December 31, 2021, total compensation cost not yet recognized related to unvested share options was $29.2 million, which is

expected to be recognized over a weighted-average period of 1.8 years.

As of December 31, 2021, total compensation cost not yet recognized related to grants under the ESPP was $4.4 million, which is

expected to be recognized over a weighted-average period of 1.1 years.

Nominal Strike Price Options

During the second quarter of 2021, we issued nominal strike price options to replace certain unvested GW awards in connection with
the GW Acquisition with a weighted-average grant date fair value of $170.82. The fair value of nominal strike price options was determined
on the date of the grant based on the market price of our ordinary shares as of that date.

The following table summarizes information as of December 31, 2021 and activity during 2021 related to our nominal strike price

options:

Shares
Subject to
Outstanding
Options
(In thousands)

Weighted-
Average
Exercise
Price

Weighted-
Average
Remaining
Contractual
Term (Years)

Aggregate
Intrinsic
Value
(In thousands)

Outstanding at January 1, 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Options granted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Options exercised . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Options forfeited . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Outstanding at December 31, 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Vested and expected to vest at December 31, 2021 . . . . . . . . . . . . . . . . . . . . . . .
Exercisable at December 31, 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

—
124
(1)
(7)

116

110
22

$ —
0.02
0.02
0.02

$0.02

$0.02
$0.02

7.4

7.3
0.5

$14,803

$13,969
$ 2,846

As of December 31, 2021, total compensation cost not yet recognized related to unvested nominal strike price options was

$8.1 million, which is expected to be recognized over a weighted-average period of 1.1 years.

F-46

2021 Annual Report

| JAZZ PHARMACEUTICALS

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Restricted Stock Units

In 2021, we granted RSUs covering an equal number of our ordinary shares to employees with a weighted-average grant date fair
value of $168.10. The fair value of RSUs is determined on the date of grant based on the market price of our ordinary shares as of that
date. The fair value of the RSUs is recognized as an expense ratably over the vesting period of four years. In 2021, 692,000 RSUs were
released with 465,000 ordinary shares issued and 227,000 ordinary shares withheld for tax purposes. The total fair value of shares vested
was $109.2 million, $53.5 million and $52.0 million during 2021, 2020 and 2019, respectively.

As of December 31, 2021, total compensation cost not yet recognized related to unvested RSUs was $238.2 million, which is

expected to be recognized over a weighted-average period of 2.6 years.

The following table summarizes information as of December 31, 2021 and activity during 2021 related to our RSUs:

Outstanding at January 1, 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
RSUs granted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
RSUs released . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
RSUs forfeited . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Outstanding at December 31, 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Weighted-
Average
Grant-
Date
Fair Value

$125.07
168.10
133.40
148.12

$149.05

Number of
RSUs (In
thousands)

1,878
1,780
(692)
(335)

2,631

Weighted-
Average
Remaining
Contractual
Term (Years)

Aggregate
Intrinsic
Value
(In thousands)

K
-
0
1
m
r
o
F

1.4

$335,224

Performance-Based Restricted Stock Units

In May 2021, the Compensation & Management Development Committee of our board of directors approved awards of PRSU’s to
certain employees of the Company, subject to vesting on the achievement of certain commercial and pipeline performance criteria to be
assessed over a performance period from the date of the grant to December 31, 2023. Following the determination of the Company’s
achievement with respect to the performance criteria, the amount of shares awarded will be subject to adjustment based on the application
of a relative TSR modifier. The number of shares that may be earned ranges between 0% and 200% of the target number of PRSUs
granted based on the degree of achievement of the applicable performance metric and the application of the relative TSR modifier.

The table below shows the number of PRSUs granted covering an equal number of our ordinary shares and the weighted-average

grant date fair value of PRSUs granted:

Outstanding at January 1, 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
PRSUs granted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
PRSUs forfeited . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Outstanding at December 31, 2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Weighted-
Average
Grant-
Date
Fair Value

$ —
190.81
190.81

$190.81

Number of
PRSUs (In
thousands)

—
224
(10)

214

Weighted-
Average
Remaining
Contractual
Term (Years)

Aggregate
Intrinsic
Value
(In thousands)

2.0

$27,265

As of December 31, 2021, total compensation cost not yet recognized related to unvested PRSUs was $26.4 million, which is

expected to be recognized over a weighted-average period of 2.0 years.

As the PRSUs granted in May 2021 are subject to a market condition, the grant date fair value for such PRSUs was based on a
Monte Carlo simulation model. The Company evaluated the performance targets in the context of its current long-range financial plan and
its product candidate development pipeline and recognized compensation expense based on the probable number of awards that will
ultimately vest.

JAZZ PHARMACEUTICALS | 2021 Annual Report

F-47

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

21. Employee Benefit Plans

We maintain a qualified 401(k) savings plan, in which all U.S. based employees are eligible to participate, provided they meet the

requirements of the plan. We match certain employee contributions under the 401(k) savings plan and for the years ended December 31,
2021, 2020 and 2019 we recorded expense of $9.1 million, $6.3 million and $5.0 million, respectively, related to this plan.

We also operate a number of defined contribution retirement plans for certain non-U.S. based employees. Expenses related to
contributions to such plans for the years ended December 31, 2021, 2020 and 2019 were $11.4 million, $4.2 million and $3.2 million,
respectively.

The expense for employee benefit plans in 2021 included plans acquired in the GW Acquisition.

22. Income Taxes

The components of income (loss) before income tax expense (benefit) and equity in loss of investees were as follows (in thousands):

Year Ended December 31,

2021

2020

2019

Ireland . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
United Kingdom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
United States . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other

$ 97,557
(681,291)
221,185
249,711

$(102,328) $ (6,451)
3,304
317,728
139,721

3,836
372,910
677

Total

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$(112,838) $ 275,095

$454,302

The following table sets forth the details of income tax expense (benefit) (in thousands):

Year Ended December 31,

2021

2020

2019

Current

Ireland . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
United Kingdom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
United States . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 25,770
(924)
88,850
33,222

$ 19,437
166
110,896
39,955

$ 51,696
—
109,495
2,265

Total current tax expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

146,918

170,454

163,456

Deferred, exclusive of other components below

Ireland . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
United Kingdom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
United States . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(5,388)
(111,534)
(46,531)
(28,604)

(32,458)
679
(29,117)
(74,278)

(163,626)
1,353
(41,297)
(38,597)

Total deferred, exclusive of other components . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(192,057)

(135,174)

(242,167)

Deferred, change in tax rates

United Kingdom . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
United States . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

259,873
1,377
5

Total deferred, change in tax rates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

261,255

(1,155)
(371)
(237)

(1,763)

(52)
203
5,406

5,557

Total deferred tax expense (benefit) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

69,198

(136,937)

(236,610)

Total income tax expense (benefit) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 216,116

$ 33,517

$ (73,154)

Our income tax expense of $216.1 million and $33.5 million in 2021 and 2020, respectively, and our income tax benefit of
$73.2 million in 2019 related to tax arising on income in Ireland, the U.K., the U.S. and certain other foreign jurisdictions, certain
unrecognized tax benefits and various expenses not deductible for income tax purposes. Our income tax expense in 2021 included an

F-48

2021 Annual Report

| JAZZ PHARMACEUTICALS

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

expense of $259.9 million arising on the remeasurement of our U.K. net deferred tax liability, which arose primarily in relation to the GW
Acquisition, due to a change in the statutory tax rate in the U.K. following enactment of the U.K. Finance Act 2021. Our income tax benefit
in 2019 included a discrete tax benefit of $112.3 million resulting from an intra-entity intellectual property asset transfer.

The effective tax rates for 2021, 2020 and 2019 were (191.5)% , 12.2% and (16.1)%, respectively. The effective tax rate for 2021 was
lower than the Irish statutory rate of 12.5% primarily due to the impact of the remeasurement of our U.K. net deferred tax liability due to the
change in the statutory tax rate in the U.K. The effective tax rate for 2020 was lower than the Irish statutory rate of 12.5% primarily due to
the impact of originating tax credits and deductions on subsidiary equity, partially offset by income taxable at a rate higher than the Irish
statutory rate, the disallowance of certain interest deductions and a provision for a proposed settlement reached with the French taxing
authorities. The effective tax rate for 2019 was lower than the Irish statutory rate of 12.5% primarily due to the impact of the intra-entity
intellectual property asset transfer. The decrease in the effective tax rate in 2021 compared to 2020 was primarily due to the impact of the
U.K. statutory rate change. Excluding this impact, the increase in the benefit for income taxes in 2021 compared to 2020 resulted primarily
from the mix of pre-tax income and losses incurred across tax jurisdictions, deductions on subsidiary equity and the impacts recognized in
2020 of the disallowance of certain interest deductions and a provision for a proposed settlement reached with the French taxing
authorities. The increase in the effective tax rate in 2020 compared to 2019 was primarily due to the impact of the intra-entity intellectual
property asset transfer. Excluding this effect, the increase in the effective tax rate for 2020 compared to 2019 was primarily due to the
benefit recognized in 2019 from the application of the Italian patent box incentive regime 2015 through 2019 and the impacts recognized in
2020 of the disallowance of certain interest deductions and a provision for a proposed settlement reached with the French taxing
authorities.

K
-
0
1
m
r
o
F

The reconciliation between the statutory income tax rate applied to income before the income tax expense (benefit) and equity in loss

of investees and our effective income tax rate was as follows (in thousands):

Income tax expense/(benefit) at the statutory income tax rate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Change in tax rate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deduction on subsidiary equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Change in valuation allowance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Research and other tax credits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Non-deductible acquisition-related costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Non-deductible compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Financing costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Change in unrecognized tax benefits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Tax deficiencies/(excess tax benefits) from share-based compensation . . . . . . . . . . . . . . . . . . .
Foreign income tax rate differential . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Foreign derived intangible income benefit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Change in estimates . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Intra-entity transfer of intellectual property assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Patent box incentive benefit
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Year Ended December 31,

2021

2020

2019

$ (14,105) $ 34,387
(1,836)
(25,740)
6,074
(30,836)
—
8,604
7,132
16,309
5,274
16,126
—
(3,604)
—
—
1,627

261,663
(116,438)
81,280
(31,069)
20,929
19,914
14,418
(6,436)
(5,555)
(4,343)
(3,416)
(2,653)
—
—
1,927

$ 56,788
6,923
(23,450)
14,823
(39,776)
11,738
8,321
(7,615)
499
537
39,695
—
1,156
(112,274)
(31,642)
1,123

Reported income tax expense/(benefit) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ 216,116

$ 33,517

$ (73,154)

JAZZ PHARMACEUTICALS | 2021 Annual Report

F-49

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

Significant components of our net deferred tax assets/(liabilities) were as follows (in thousands):

December 31,

2021

2020

Deferred tax assets:

Tax credit carryforwards . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Operating loss carryforwards . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Intangible assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deduction on subsidiary equity carryforwards . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Indirect effects of unrecognized tax benefits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Share-based compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Lease liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other

$

284,155
265,156
189,959
84,509
78,514
46,876
37,289
15,865
65,224

$ 258,296
68,860
173,918
62,561
13,201
48,743
26,090
31,787
69,289

Total deferred tax assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Valuation allowance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

1,067,547
(154,255)

752,745
(77,342)

Deferred tax assets, net of valuation allowance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred tax liabilities:

913,292

675,403

Intangible assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Inventory . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Operating lease assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other

(1,652,297)
(181,742)
(12,657)
(56,034)

(448,310)

—
(26,316)
(76,258)

Total deferred tax liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

(1,902,730)

(550,884)

Net of deferred tax assets and (liabilities) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ (989,438) $ 124,519

The net change in valuation allowance was an increase of $76.9 million, $11.0 million and $5.1 million in 2021, 2020 and 2019,

respectively.

The following table summarizes the presentation of deferred tax assets and liabilities (in thousands):

December 31,

2021

2020

Deferred tax assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred tax liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$

311,103
(1,300,541)

$ 254,916
(130,397)

Net of deferred tax assets and (liabilities) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$ (989,438) $ 124,519

As of December 31, 2021, we had net operating losses, or NOL, carryforwards and tax credit carryforwards for U.S. federal income
tax purposes of approximately $81.6 million and $216.5 million, respectively, available to reduce future income subject to income taxes.
The U.S. federal NOL carryforwards will expire, if not utilized, in the tax years 2022 to 2036, and the U.S. federal tax credits will expire, if
not utilized, in the tax years 2022 to 2041. In addition, we had approximately $44.3 million of NOL carryforwards and $8.0 million of tax
credit carryforwards as of December 31, 2021 available to reduce future taxable income for U.S. state income tax purposes. The U.S. state
NOL carryforwards will expire, if not utilized, in the tax years 2022 to 2040. As of December 31, 2021, there were NOL and other
carryforwards for income tax purposes of approximately $864.9 million, $224.3 million, $133.5 million and $45.7 million available to reduce
future income subject to income taxes in the United Kingdom, Malta, Ireland and Luxembourg respectively. The NOLs and other
carryforwards generated in the United Kingdom, Malta, Ireland and Luxembourg have no expiration date. We also had foreign tax credit
carryforwards in Ireland, as of December 31, 2021, of $58.8 million, which may only be utilized against certain sources of income. The
foreign tax credit carryforwards have no expiration date.

Utilization of certain of our NOL and tax credit carryforwards in the U.S. is subject to an annual limitation due to the ownership change

limitations provided by Sections 382 and 383 of the Internal Revenue Code and similar state provisions. Such an annual limitation may

F-50

2021 Annual Report

| JAZZ PHARMACEUTICALS

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

result in the expiration of certain NOLs and tax credits before future utilization. In addition, as a result of the Azur Merger, until 2022 we are
subject to certain limitations under the Internal Revenue Code in relation to the utilization of U.S. NOLs to offset U.S. taxable income
resulting from certain transactions.

Valuation allowances require an assessment of both positive and negative evidence when determining whether it is more likely than

not that deferred tax assets are recoverable. Such assessment is required by tax paying component. Our valuation allowance was
$154.3 million and $77.3 million as of December 31, 2021 and 2020, respectively, for certain Irish, U.S. (federal and state) and foreign
deferred tax assets which we maintain until sufficient positive evidence exists to support reversal. During 2021, as part of the overall
change in valuation allowance, we recognized a net income tax expense of $81.3 million relating primarily to the creation of a valuation
allowance against certain deferred tax assets primarily associated with temporary differences related to foreign subsidiaries and foreign tax
credit carryforwards. During 2020, as part of the overall change in valuation allowance, we recognized a net income tax expense of
$6.2 million relating primarily to the creation of a valuation allowance against certain deferred tax assets primarily associated with
temporary differences related to foreign subsidiaries. During 2019, as part of the overall change in valuation allowance, we recognized a
net income tax expense of $6.3 million relating primarily to the creation of a valuation allowance of $15.7 million against certain deferred tax
assets primarily associated with foreign tax credits and temporary differences related to foreign subsidiaries, partially offset by the net
release of valuation allowances against certain deferred tax assets primarily associated with NOLs. We periodically evaluate the likelihood
of the realization of deferred tax assets and will adjust such amounts in light of changing facts and circumstances including, but not limited
to, future projections of taxable income, tax legislation, rulings by relevant taxing authorities, the progress of tax examinations and the
regulatory approval of products currently under development. Realization of the deferred tax assets is dependent on future taxable income.

K
-
0
1
m
r
o
F

No provision has been made for income tax on undistributed earnings of the Company’s foreign subsidiaries where such earnings are

considered indefinitely reinvested in the foreign operations. Temporary differences related to such earnings totaled approximately
$2.3 billion as of December 31, 2021. In the event of the distribution of those earnings in the form of dividends, a sale of the subsidiaries, or
certain other transactions, we may be liable for income taxes, subject to an adjustment, if any, for foreign tax credits. The Company
estimates that it would incur additional income taxes of up to approximately $113 million on repatriation of these unremitted earnings to
Ireland.

We only recognize the financial statement effects of a tax position when it is more likely than not, based on the technical merits, that
the position will be sustained upon examination. As a result, we have recorded an unrecognized tax benefit for certain tax benefits which
we judge may not be sustained upon examination.

A reconciliation of our gross unrecognized tax benefits follows (in thousands):

December 31,

2021

2020

2019

Balance at the beginning of the year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Increases related to current year tax positions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Increases related to prior year tax positions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Decreases related to prior year tax positions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Increases recognized through purchase accounting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Decreases related to settlements with taxing authorities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Lapse of the applicable statute of limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$146,557
26,675
211
(182)
5,916
(14,744)
(26,566)

$124,319
27,908
19,712
(213)
—
—
(25,169)

$118,213
27,552
761
(91)
—
—
(22,116)

Balance at the end of the year

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

$137,867

$146,557

$124,319

The unrecognized tax benefits were included in income taxes payable, other non-current liabilities and deferred tax assets, net, in our

consolidated balance sheets. Interest related to our unrecognized tax benefits is recorded in the income tax expense (benefit) in our
consolidated statements of income (loss). As of December 31, 2021 and 2020, our accrued interest and penalties related to income taxes
was $4.6 million and $11.3 million, respectively. Interest and penalties related to income taxes benefits recognized in the consolidated
statements of income (loss) were not significant. Included in the balance of unrecognized tax benefits were potential benefits of
$82.0 million and $93.0 million at December 31, 2021 and 2020, respectively, that, if recognized, would affect the effective tax rate on
income.

JAZZ PHARMACEUTICALS | 2021 Annual Report

F-51

JAZZ PHARMACEUTICALS PLC

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)

We file income tax returns in multiple tax jurisdictions, the most significant of which are Ireland the U.K. and the U.S. (both at the
federal level and in various state jurisdictions). For Ireland we are no longer subject to income tax examinations by taxing authorities for the
years prior to 2017. For the U.K. we are no longer subject to income tax examinations by taxing authorities for the years prior to 2018. The
U.S. jurisdictions generally have statute of limitations three to four years from the later of the return due date or the date when the return
was filed. However, in the U.S. (at the federal level and in most states), carryforwards that were generated in 2017 and earlier may still be
adjusted upon examination by the taxing authorities. During 2021, certain of our subsidiaries were under examination by the French taxing
authorities for the years ended December 31, 2012, 2013, 2015, 2016 and 2017. Due to the subjective nature of the transfer pricing issues
involved, the Company reached an agreement with the French taxing authorities to settle the examinations for all open years. The
Company paid incremental taxes, interest and penalties of $19.7 million, during 2021 to close all periods under examination. Certain of our
Italian subsidiaries are currently under examination by the Italian taxing authorities for the year ended December 31, 2017. Certain of our
Luxembourg subsidiaries are currently under examination by the Luxembourg taxing authorities for the years ended December 31, 2017
and 2018. Certain of our German subsidiaries are currently under examination by the German taxing authorities for the years ended
December 31, 2017, 2018 and 2019.

F-52

2021 Annual Report

| JAZZ PHARMACEUTICALS

Schedule II

Valuation and Qualifying Accounts
(In thousands)

Balance at
beginning
of period

Additions
charged to
costs and
expenses

Other
Additions

Deductions

Balance at
end of
period

For the year ended December 31, 2021
Allowance for doubtful accounts . . . . . . . . . . . . . . . . . . . . . . . . . . .
Allowance for sales discounts . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Allowance for chargebacks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred tax asset valuation allowance . . . . . . . . . . . . . . . . . . . . . .
For the year ended December 31, 2020
Allowance for doubtful accounts . . . . . . . . . . . . . . . . . . . . . . . . . . .
Allowance for sales discounts . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Allowance for chargebacks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred tax asset valuation allowance . . . . . . . . . . . . . . . . . . . . . .
For the year ended December 31, 2019
Allowance for doubtful accounts . . . . . . . . . . . . . . . . . . . . . . . . . . .
Allowance for sales discounts . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Allowance for chargebacks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred tax asset valuation allowance . . . . . . . . . . . . . . . . . . . . . .

(1)
(1)
(1)
(2)(3)(4)

(1)
(1)
(1)
(2)(3)(4)

(1)
(1)
(1)
(2)(3)

$

50
144
5,293
77,342

$

50
113
1,133
66,307

$

50
76
408
61,237

$

127
13,196
91,425
82,820

$

5
1,432
45,550
6,576

$

9
782
41,864
20,086

$ 771
1,243
1,322
9

$ —
—
—
4,961

$ —
—
—
357

$

(650) $

(12,457)
(86,651)
(5,916)

298
2,126
11,389
154,255

$

(5) $

(1,401)
(41,390)
(502)

$

(9) $

(745)
(41,139)
(15,373)

50
144
5,293
77,342

50
113
1,133
66,307

K
-
0
1
m
r
o
F

(1) Shown as a reduction of accounts receivable. Charges related to sales discounts and chargebacks are reflected as a reduction of

revenue.

(2) Additions to the deferred tax asset valuation allowance charged to costs and expenses relate to movements on certain Irish, U.S.

(federal and state) and other foreign deferred tax assets where we continue to maintain a valuation allowance until sufficient positive
evidence exists to support reversal.

(3) Other additions to the deferred tax asset valuation allowance relate to currency translation adjustments recorded directly in other

comprehensive income and, in 2019, additions resulting from the Cavion asset acquisition.

(4) Deductions from the deferred tax asset valuation allowance include movements relating to utilization of NOLs and tax credit

carryforwards, release in valuation allowance and other movements including adjustments following finalization of tax returns.

JAZZ PHARMACEUTICALS | 2021 Annual Report

F-53

[THIS PAGE INTENTIONALLY LEFT BLANK]

EXECUTIVE COMMITTEE
Bruce C. Cozadd
Chairperson and Chief Executive Officer
George Eliades, Ph.D.
Senior Vice President, Corporate Development and  
Chief Transformation Officer
Renée Galá
Executive Vice President and Chief Financial Officer
Robert Iannone, M.D., M.S.C.E.
Executive Vice President, Global Head of Research and Development
Finbar Larkin, Ph.D.
Senior Vice President, Technical Operations
Heidi Manna
Senior Vice President and Chief Human Resources Officer
John Miller
Senior Vice President, Global Product Strategy and Program Management
Neena M. Patil
Chief Legal Officer and Senior Vice President, Legal and Corporate Affairs
Samantha Pearce
Senior Vice President, Europe and International
Kim Sablich
Executive Vice President and General Manager, North America
Daniel N. Swisher, Jr.
President
Chris Tovey
Executive Vice President and Chief Operating Officer and  
Managing Director, Europe and International

COMPANY SECRETARY
Aislinn Doody

ORDINARY SHARES
Jazz Pharmaceuticals plc ordinary shares are traded on the Nasdaq 
Global Select Market under the symbol “JAZZ”

JAZZ PHARMACEUTICALS PLC CORPORATE HEADQUARTERS
Fifth Floor, Waterloo Exchange
Waterloo Road, Dublin 4, Ireland
+353 1 634 7800
+353 1 634 7850 fax
www.jazzpharmaceuticals.com

INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
KPMG, Dublin, Ireland

BOARD OF DIRECTORS
Jennifer E. Cook
Director, BridgeBio Pharma, Inc. and Denali Therapeutics, Inc.
Bruce C. Cozadd
Chairperson and Chief Executive Officer, Jazz Pharmaceuticals plc
Patrick G. Enright
Managing Director, Longitude Capital
Peter Gray
Chairperson, Teckro, Inc. and Abzena
Heather Ann McSharry
Director, International Airlines Group, S.A.
Seamus Mulligan
Director, Jazz Pharmaceuticals plc
Kenneth W. O’Keefe
Managing Director, Beecken Petty O’Keefe & Company
Anne O’Riordan
Group Director of Digital, Jardine Matheson Limited
Norbert G. Riedel, Ph.D.
Executive Chairperson, Aptinyx Inc.
Mark D. Smith, M.D.
Professor, University of California, San Francisco and Director,  
Teladoc Health, Inc. and Phreesia, Inc.
Catherine A. Sohn, Pharm.D.
Chairperson, BioEclipse Therapeutics Inc., and Director, Axcella Health Inc., 
Landec Corporation and Rubius Therapeutics
Rick E Winningham
Lead Independent Director, Jazz Pharmaceuticals plc and
Chairperson and Chief Executive Officer, Theravance Biopharma, Inc.

REGISTRAR AND TRANSFER AGENT
Computershare
www.computershare.com

Ireland 
+353 1 447 5566 
+353 1 447 5571 fax 
3100 Lake Drive 
Citywest Business Campus 
Dublin 24, Ireland D24 AK82

United States 
+1 781 575 2879 (outside U.S.) 
+1 877 373 6374 (inside U.S.) 
462 South 4th Street, Suite 1600 
Louisville, KY 40202 U.S.A. 

ANNUAL GENERAL MEETING
The annual general meeting of shareholders will be held at 9:45 a.m. local 
time on July 28, 2022 at the company’s corporate headquarters located 
at Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland.

FOR MORE INFORMATION
Information about Jazz Pharmaceuticals plc can be found on the Internet at www.jazzpharmaceuticals.com.  Inquiries regarding Jazz Pharmaceuticals plc and its 
activities may be directed to the Investor Relations Department at investorinfo@jazzpharmaceuticals.com or +353 1 634 7892 (Ireland) or + 650 496 2800 (U.S.). 
Communications concerning shares and transfer requirements, lost certiﬁcates or changes of address should be directed to the Transfer Agent.

CAUTION CONCERNING FORWARD-LOOKING STATEMENTS
This communication contains forward-looking statements and ﬁnancial targets, including, but not limited to, statements related to: the company’s expectation of 
sustainable growth and enhanced value as part of its Vision 2025; the ability of the company’s pipeline to produce sustainable growth; growing and diversifying the 
company’s revenue, investing in its pipeline of novel therapies, and delivering innovative therapies for patients; the company’s expectation of delivering at least ﬁve 
additional novel product approvals by the end of the decade; the company’s ability to realize the commercial potential of its products; planned or anticipated clinical 
trial events, including with respect to near-term pipeline opportunities; and other statements that are not historical facts. These forward-looking statements are 
based on the company’s current plans, objectives, estimates, expectations and intentions and inherently involve signiﬁcant risks and uncertainties. Actual results 
and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, 
without limitation, risks and uncertainties associated with: maintaining or increasing sales of and revenue from the company’s key marketed products; effectively 
launching and commercializing the company’s product candidates; the time-consuming and uncertain regulatory approval process; the costly and time-consuming 
pharmaceutical product development and the uncertainty of clinical success; regulatory initiatives and changes in tax laws; the sufficiency of the company’s cash 
ﬂows and capital resources to fund its debt service obligations, de-lever and meet its stated leverage targets; the company’s ability to achieve expected future 
ﬁnancial performance and results and the uncertainty of future tax, accounting and other provisions and estimates; the company’s ability to meet its projected long-
term goals and objectives, including as part of Vision 2025, in the time periods that the company anticipates, or at all, and the inherent uncertainty and signiﬁcant 
judgments and assumptions underlying the company’s long-term goals and objectives; and other risks and uncertainties affecting the company, including those 
described under the caption “Risk Factors” in Part I, Item 1A of the enclosed Annual Report on Form 10-K. Other risks and uncertainties of which the company is 
not currently aware may also affect the company’s forward-looking statements and may cause actual results and timing of events to differ materially from those 
anticipated. The forward-looking statements herein are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if they 
are subsequently made available by the company on its website or otherwise. The company undertakes no obligation to update or supplement any forward-looking 
statements to reﬂect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the 
forward-looking statements were made.

Fifth Floor, Waterloo Exchange
Waterloo Road, Dublin 4, Ireland
+353  1  634  7800

jazzpharmaceuticals.com

KELLEY
EPIDIOLEX® Patient

MEAGHAN
XYWAV® Patient

WILLOW
RYLAZE® Patient

BOBBY
EPIDIOLEX® Patient